Clustering O 0 0.00017588520131539553
of O 0 1.108621927414788e-05
missense O 0 0.002116312738507986
mutations O 0 0.0001911513099912554
in O 0 2.389546534686815e-05
the O 0 0.0007459031185135245
ataxia B-Disease 1 0.9995691180229187
- I-Disease 1 0.9939115047454834
telangiectasia I-Disease 1 0.9924827218055725
gene O 0 0.00011546052701305598
in O 0 1.1763578186219092e-05
a O 0 0.00017029793525580317
sporadic B-Disease 1 0.5475770831108093
T I-Disease 1 0.9984555244445801
- I-Disease 1 0.9695895910263062
cell I-Disease 1 0.779475212097168
leukaemia I-Disease 1 0.9968008995056152
. O 0 0.0002079062833217904

Ataxia B-Disease 1 0.9985082745552063
- I-Disease 1 0.9907998442649841
telangiectasia I-Disease 1 0.9957131147384644
( O 0 0.0012847938342019916
A B-Disease 1 0.9655516147613525
- I-Disease 1 0.9834657907485962
T I-Disease 1 0.9978532195091248
) O 0 2.480723878761637e-06
is O 0 1.7247549521925976e-06
a O 0 4.573175101540983e-05
recessive B-Disease 1 0.9652795195579529
multi I-Disease 1 0.9899773597717285
- I-Disease 1 0.9976375102996826
system I-Disease 1 0.9078495502471924
disorder I-Disease 1 0.9998785257339478
caused O 0 0.20786596834659576
by O 0 3.929310878447723e-06
mutations O 0 1.243440874532098e-05
in O 0 4.7648302370362217e-07
the O 0 1.058703105627501e-06
ATM O 0 9.501514432486147e-05
gene O 0 1.525547031633323e-05
at O 0 1.8582433767733164e-05
11q22 O 0 0.00128680351190269
- O 0 0.00047937515773810446
q23 O 0 0.0005500611150637269
( O 0 3.587775063351728e-05
ref O 0 0.004415386356413364
. O 0 1.9927406356146093e-06
3 O 0 7.584398190374486e-06
) O 0 8.107340363494586e-06
. O 0 1.2980931387573946e-05

The O 0 0.00030696214525960386
risk O 0 0.01587437279522419
of O 0 0.0001506262633483857
cancer B-Disease 1 0.9995286464691162
, O 0 6.35207979939878e-05
especially O 0 0.00011960211850237101
lymphoid B-Disease 0 0.4378402829170227
neoplasias I-Disease 0 0.15586219727993011
, O 0 1.0992877832904924e-05
is O 0 1.712881203275174e-05
substantially O 0 0.0031561164651066065
elevated O 1 0.8375810384750366
in O 0 0.00022703730792272836
A B-Disease 1 0.9986810088157654
- I-Disease 1 0.9995336532592773
T I-Disease 1 0.9998683929443359
patients O 1 0.849734365940094
and O 0 3.863969141093548e-06
has O 0 1.025740675686393e-05
long O 0 9.081711323233321e-05
been O 0 7.15569922249415e-06
associated O 0 5.091036291560158e-05
with O 0 0.0001222962891915813
chromosomal O 1 0.995144784450531
instability O 1 0.989566445350647
. O 0 0.0005841024103574455

By O 0 0.00013079761993139982
analysing O 0 0.0049699218943715096
tumour B-Disease 1 0.9980944991111755
DNA O 0 0.001870197942480445
from O 0 0.00019166161655448377
patients O 0 0.4243740737438202
with O 0 3.9470207411795855e-05
sporadic B-Disease 0 0.15827004611492157
T I-Disease 1 0.9982746839523315
- I-Disease 0 0.16044504940509796
cell I-Disease 0 0.014267180114984512
prolymphocytic I-Disease 1 0.9381600618362427
leukaemia I-Disease 1 0.9984075427055359
( O 0 0.00209561875090003
T B-Disease 1 0.9961787462234497
- I-Disease 0 0.005046230275183916
PLL I-Disease 0 0.05431881919503212
) O 0 2.955276158900233e-06
, O 0 7.956909939821344e-07
a O 0 5.879695891053416e-06
rare O 0 0.000662309059407562
clonal B-Disease 0 0.4722033143043518
malignancy I-Disease 1 0.9948471784591675
with O 0 1.998434754568734e-06
similarities O 0 7.94494462752482e-06
to O 0 1.399640268573421e-06
a O 0 0.00012921802408527583
mature B-Disease 0 0.03898502141237259
T I-Disease 1 0.9982272982597351
- I-Disease 0 0.21317842602729797
cell I-Disease 0 0.056318070739507675
leukaemia I-Disease 1 0.9978567957878113
seen O 0 0.00019838007574435323
in O 0 2.212036997661926e-05
A B-Disease 1 0.9694172739982605
- I-Disease 1 0.9810358285903931
T I-Disease 1 0.9978969097137451
, O 0 5.09158894601569e-07
we O 0 6.016178843992748e-08
demonstrate O 0 3.129289893877285e-07
a O 0 2.904970983763633e-07
high O 0 5.750392801928683e-07
frequency O 0 4.0757777242106386e-07
of O 0 3.156619641231373e-07
ATM O 0 0.0010637002997100353
mutations O 0 0.00032046870910562575
in O 0 0.00012223891098983586
T B-Disease 1 0.9940940737724304
- I-Disease 0 0.019049661234021187
PLL I-Disease 1 0.5275771021842957
. O 0 0.00021639377519022673

In O 0 1.3998210306453984e-05
marked O 0 3.966006261180155e-05
contrast O 0 6.617898634431185e-06
to O 0 3.487388084977283e-07
the O 0 1.4628905091740307e-06
ATM O 0 0.00019560028158593923
mutation O 0 4.7131874453043565e-05
pattern O 0 8.731652633287013e-05
in O 0 1.3185248462832533e-05
A B-Disease 1 0.9192607998847961
- I-Disease 1 0.9658421874046326
T I-Disease 1 0.997307300567627
, O 0 2.5877886855596444e-07
the O 0 8.89785098934226e-08
most O 0 5.0860752054404657e-08
frequent O 0 6.827007723586576e-07
nucleotide O 0 1.1326088724672445e-06
changes O 0 1.6960503899099422e-06
in O 0 1.7361948039251729e-06
this O 0 1.0372369615652133e-05
leukaemia B-Disease 1 0.997700035572052
were O 0 1.6948933989624493e-05
missense O 0 0.00363852153532207
mutations O 0 0.000964235223364085
. O 0 0.00012194053124403581

These O 0 2.370772108406527e-06
clustered O 0 1.766506647982169e-05
in O 0 5.15745682605484e-07
the O 0 3.1291585855797166e-07
region O 0 3.966052304349432e-07
corresponding O 0 1.9675184148582048e-07
to O 0 3.8344655450828213e-08
the O 0 1.7631106175031164e-07
kinase O 0 7.129086498025572e-06
domain O 0 1.0016022997660912e-06
, O 0 1.0140500705801969e-07
which O 0 6.078150960320272e-08
is O 0 9.320598337581032e-08
highly O 0 7.283256309165154e-07
conserved O 0 1.7610583427085658e-06
in O 0 1.4812600284130895e-06
ATM O 0 0.0006506062927655876
- O 0 4.000211265520193e-05
related O 0 1.7672110743660596e-06
proteins O 0 1.2203180403957958e-06
in O 0 9.473877184973389e-07
mouse O 0 5.5526932555949315e-05
, O 0 1.6466581200802466e-06
yeast O 0 3.837155600194819e-05
and O 0 2.532659436838003e-06
Drosophila O 0 6.514757842523977e-05
. O 0 5.4920314141782e-05

The O 0 1.6582962416578084e-05
resulting O 0 6.194737943587825e-05
amino O 0 4.725676990346983e-05
- O 0 0.0004950968432240188
acid O 0 0.00010244404256809503
substitutions O 0 4.102868388144998e-06
are O 0 2.576962572220509e-07
predicted O 0 1.3854907592758536e-05
to O 0 2.498640299108956e-07
interfere O 0 3.0809499094175408e-06
with O 0 8.538586371287238e-07
ATP O 0 0.0008463370031677186
binding O 0 3.22807773045497e-06
or O 0 1.8243188151245704e-06
substrate O 0 5.072968633612618e-05
recognition O 0 2.907206908275839e-05
. O 0 4.054072269354947e-05

Two O 0 7.548230769316433e-07
of O 0 1.798459038582223e-06
seventeen O 0 0.0004225499869789928
mutated O 0 0.24979130923748016
T B-Disease 1 0.9928103685379028
- I-Disease 0 0.001267560524865985
PLL I-Disease 0 0.007275742944329977
samples O 0 2.729350171648548e-06
had O 0 2.6684676868171664e-06
a O 0 4.2914280129480176e-06
previously O 0 3.295177157269791e-05
reported O 0 0.0011942539131268859
A B-Disease 1 0.9065417647361755
- I-Disease 1 0.9744861721992493
T I-Disease 1 0.9963240623474121
allele O 0 0.0002579734427854419
. O 0 5.18092347192578e-05

In O 0 2.8141979782958515e-05
contrast O 0 8.996781980386004e-05
, O 0 4.3866307350981515e-06
no O 0 3.042016714971396e-06
mutations O 0 1.2020705071336124e-05
were O 0 3.5583147450779506e-07
detected O 0 8.8249689724762e-06
in O 0 1.189506306786825e-07
the O 0 4.334928291882534e-07
p53 O 0 2.048218266281765e-05
gene O 0 6.039833351678681e-06
, O 0 1.063284685187682e-06
suggesting O 0 1.6139334547915496e-05
that O 0 1.3298511021275772e-06
this O 0 2.4910152205848135e-05
tumour B-Disease 1 0.9996596574783325
suppressor O 0 0.019327733665704727
is O 0 1.4663993397334707e-06
not O 0 6.645801704507903e-07
frequently O 0 5.9396606957307085e-06
altered O 0 9.931180102284998e-05
in O 0 5.2748378038813826e-06
this O 0 7.559278310509399e-05
leukaemia B-Disease 1 0.9982873797416687
. O 0 0.000168558704899624

Occasional O 0 0.0015428087208420038
missense O 0 0.0027729785069823265
mutations O 0 0.00011717739835148677
in O 0 3.3461953989899484e-06
ATM O 0 0.00015097035793587565
were O 0 5.680922186002135e-07
also O 0 7.5131191579203e-07
found O 0 3.3960166092583677e-06
in O 0 1.044650525727775e-05
tumour B-Disease 1 0.9994586110115051
DNA O 0 0.00012527871876955032
from O 0 1.5579096725559793e-05
patients O 0 0.026128988713026047
with O 0 1.3237888197181746e-05
B B-Disease 0 0.07576369494199753
- I-Disease 0 0.0038740031886845827
cell I-Disease 0 0.001179030747152865
non I-Disease 0 0.0007661569979973137
- I-Disease 1 0.8579420447349548
Hodgkins I-Disease 1 0.9991737008094788
lymphomas I-Disease 1 0.9891519546508789
( O 0 2.740146555879619e-05
B B-Disease 0 0.0008084387518465519
- I-Disease 0 4.590026946971193e-05
NHL I-Disease 0 9.586205123923719e-06
) O 0 2.8437813170967274e-07
and O 0 1.4871707776364929e-07
a O 0 5.0666899369389284e-06
B B-Disease 0 0.0005846638814546168
- I-Disease 0 0.00022518669720739126
NHL I-Disease 0 0.0002453133638482541
cell O 0 0.00035249386564828455
line O 0 7.730310608167201e-05
. O 0 4.619778337655589e-05

The O 0 4.8743740990175866e-06
evidence O 0 1.4433427395488252e-06
of O 0 2.1114429671342805e-07
a O 0 2.0117822714382783e-06
significant O 0 1.40473241572181e-06
proportion O 0 3.3733340387698263e-06
of O 0 1.1314914445392787e-06
loss O 0 0.00401600357145071
- O 0 5.63545836484991e-05
of O 0 4.091214691470668e-07
- O 0 5.406209675129503e-05
function O 0 7.586696142425353e-07
mutations O 0 3.2113555334944976e-06
and O 0 1.0759932678183759e-07
a O 0 4.3097423940707813e-07
complete O 0 1.4073606280362583e-06
absence O 0 2.452285798426601e-06
of O 0 6.008587405403887e-08
the O 0 2.8835464149779e-07
normal O 0 1.8064246205540258e-06
copy O 0 2.36455366575683e-06
of O 0 1.2846035701841174e-07
ATM O 0 4.501380317378789e-05
in O 0 2.3543127269931574e-07
the O 0 2.1455588239405188e-07
majority O 0 1.0111065193996183e-06
of O 0 4.6130030568747316e-06
mutated O 0 0.062351714819669724
tumours B-Disease 1 0.9973152279853821
establishes O 0 0.0006643421365879476
somatic O 0 0.00026437846827320755
inactivation O 0 0.0005474254721775651
of O 0 2.1525620752527175e-07
this O 0 3.8567938531741675e-07
gene O 0 5.264505489321891e-06
in O 0 8.730809213375323e-07
the O 0 4.471259671845473e-06
pathogenesis O 0 0.007520704064518213
of O 0 9.1265565060894e-06
sporadic B-Disease 0 0.21697545051574707
T I-Disease 1 0.9979845285415649
- I-Disease 0 0.012364262714982033
PLL I-Disease 0 0.06985993683338165
and O 0 1.370421387036913e-06
suggests O 0 7.336835551541299e-06
that O 0 9.60158217822027e-07
ATM O 0 9.317959484178573e-05
acts O 0 3.3351595902786357e-06
as O 0 8.85836016095709e-06
a O 0 0.0009964198106899858
tumour B-Disease 1 0.9987301230430603
suppressor O 0 0.315920889377594
. O 0 0.00022375637490767986

As O 0 6.371350536937825e-06
constitutional O 0 1.716907718218863e-05
DNA O 0 5.502820567926392e-05
was O 0 6.591885266971076e-06
not O 0 1.5817329312994843e-07
available O 0 1.9797300865320722e-07
, O 0 4.999779434911034e-07
a O 0 8.976893695944455e-06
putative O 0 0.0012930940138176084
hereditary O 1 0.9670146107673645
predisposition O 1 0.9890981912612915
to O 0 0.00038948116707615554
T B-Disease 1 0.9983559250831604
- I-Disease 0 0.024220803752541542
PLL I-Disease 0 0.13174401223659515
will O 0 1.220404101331951e-06
require O 0 3.6057433590030996e-06
further O 0 3.7973400139890146e-06
investigation O 0 9.051796951098368e-05
. O 0 9.25627591641387e-06
. O 0 3.790178743656725e-05

Myotonic B-Disease 1 0.9977378845214844
dystrophy I-Disease 1 0.9989727735519409
protein O 0 0.0003175218007527292
kinase O 0 0.00024341476091649383
is O 0 1.1586653272388503e-06
involved O 0 5.315511657499883e-07
in O 0 9.406431189518116e-08
the O 0 9.380649146351061e-08
modulation O 0 1.1046947747672675e-06
of O 0 1.4870218478790775e-07
the O 0 4.331979653215967e-06
Ca2 O 0 0.0020904974080622196
+ O 0 0.0015152510022744536
homeostasis O 0 0.09214449673891068
in O 0 0.00019238867389503866
skeletal O 1 0.9966802597045898
muscle O 1 0.9942693710327148
cells O 0 0.008717620745301247
. O 0 0.00022919158800505102

Myotonic B-Disease 1 0.9991039633750916
dystrophy I-Disease 1 0.999862551689148
( O 1 0.7907239198684692
DM B-Disease 1 0.9995853304862976
) O 0 4.03522644774057e-05
, O 0 4.256996362528298e-06
the O 0 6.059750376152806e-06
most O 0 4.906953472527675e-05
prevalent O 1 0.9924571514129639
muscular B-Disease 1 0.9999129772186279
disorder I-Disease 1 0.9999370574951172
in O 0 0.0007628320017829537
adults O 0 0.009327308274805546
, O 0 1.5163048374233767e-05
is O 0 1.2736465578200296e-05
caused O 0 0.00324118766002357
by O 0 2.175781901314622e-06
( O 0 1.4415336409001611e-05
CTG O 0 0.0022330202627927065
) O 0 3.6527408155961893e-06
n O 0 2.4494867830071598e-05
- O 0 1.4193312381394207e-05
repeat O 0 3.878285042446805e-06
expansion O 0 8.81479024883447e-07
in O 0 1.9280388841025342e-08
a O 0 9.52995407033086e-08
gene O 0 2.3357128497991653e-07
encoding O 0 1.3851595781488868e-07
a O 0 6.840251103312767e-07
protein O 0 6.9286743382690474e-06
kinase O 0 6.227967969607562e-05
( O 0 1.4866255696688313e-05
DM B-Disease 1 0.9892537593841553
protein O 0 2.164205398003105e-05
kinase O 0 5.841168240294792e-05
; O 0 3.1400538773596054e-06
DMPK O 0 0.0016187260625883937
) O 0 7.650313591511804e-07
and O 0 2.00712420905802e-07
involves O 0 4.669628197007114e-06
changes O 0 5.065260211267741e-06
in O 0 4.3172226469323505e-06
cytoarchitecture O 0 0.0018020442221313715
and O 0 1.2278415852051694e-05
ion O 0 0.0025783877354115248
homeostasis O 1 0.8473928570747375
. O 0 0.0003066699719056487

To O 0 2.4371570361836348e-06
obtain O 0 4.03819694838603e-06
clues O 0 7.579828434245428e-06
to O 0 4.073834816153976e-07
the O 0 7.82000995513954e-07
normal O 0 5.48863044969039e-06
biological O 0 4.4339858504827134e-06
role O 0 8.808748361843755e-07
of O 0 5.891033652005717e-07
DMPK O 0 0.0038792064879089594
in O 0 3.321092435726314e-06
cellular O 0 0.00013639444659929723
ion O 0 0.0006039476720616221
homeostasis O 0 0.12313340604305267
, O 0 2.148699195458903e-06
we O 0 2.0474570305850648e-07
have O 0 1.2409836358528992e-07
compared O 0 1.7513710872663069e-06
the O 0 1.002069552669127e-06
resting O 0 0.0005848566652275622
[ O 0 9.073886030819267e-05
Ca2 O 0 0.0006276877247728407
+ O 0 0.00030105747282505035
] O 0 3.226019180146977e-05
i O 0 5.514609711099183e-07
, O 0 2.858700298702388e-08
the O 0 3.300973361319848e-08
amplitude O 0 4.377949096578959e-07
and O 0 1.7899533588661143e-07
shape O 0 6.833529369032476e-06
of O 0 1.0751414265541825e-06
depolarization O 0 0.011079791933298111
- O 0 0.003328186459839344
induced O 0 0.006449459586292505
Ca2 O 0 0.0010763771133497357
+ O 0 0.0005825975676998496
transients O 0 0.0001602707925485447
, O 0 2.0100817721413478e-07
and O 0 4.3339277056020364e-08
the O 0 4.507990070123924e-08
content O 0 1.6206732311729866e-07
of O 0 3.0746932111469505e-07
ATP O 0 0.0022270968183875084
- O 0 4.8823407269082963e-05
driven O 0 1.0198570635111537e-05
ion O 0 7.011178968241438e-05
pumps O 0 0.0002082909777527675
in O 0 1.4578722584701609e-05
cultured O 0 0.0038636750541627407
skeletal O 1 0.9955630302429199
muscle O 1 0.6905477643013
cells O 0 3.385993113624863e-05
of O 0 1.1931798553632689e-06
wild O 0 0.0001313392713200301
- O 0 0.001164099550805986
type O 0 0.00014219641161616892
and O 0 4.064353106514318e-06
DMPK O 0 0.1628311723470688
[ O 0 0.0023147144820541143
- O 0 0.027924831956624985
/ O 0 0.005528808571398258
- O 0 0.0006864049355499446
] O 0 0.00023261448950506747
knockout O 0 0.0036880893167108297
mice O 0 0.0056263767182827
. O 0 7.63620701036416e-05

In O 0 0.00011190846998943016
vitro O 0 0.0008717547170817852
- O 0 0.0017613187665119767
differentiated O 0 0.0006572961574420333
DMPK O 0 0.30813920497894287
[ O 0 0.006457156501710415
- O 0 0.03912833705544472
/ O 0 0.003984910901635885
- O 0 0.0002241691545350477
] O 0 3.0311426598927937e-05
myotubes O 0 7.219806866487488e-05
exhibit O 0 4.4938651626580395e-06
a O 0 2.7694877644535154e-06
higher O 0 2.1330075469450094e-05
resting O 0 0.0013744666939601302
[ O 0 0.00028215241036377847
Ca2 O 0 0.0011204216862097383
+ O 0 0.0005613752291537821
] O 0 5.6596178183099255e-05
i O 0 3.0716996661794838e-06
than O 0 2.727921639689157e-07
do O 0 5.905990860810562e-07
wild O 0 9.138105269812513e-06
- O 0 0.0004573532205540687
type O 0 0.0001392630802001804
myotubes O 0 0.00041468336712569
because O 0 3.721244468124496e-07
of O 0 4.882571857933726e-08
an O 0 6.618894303755951e-07
altered O 0 5.1113929657731205e-06
open O 0 7.834700568309927e-07
probability O 0 1.3611872873298125e-07
of O 0 2.7480902531351603e-07
voltage O 0 0.00015824762522242963
- O 0 0.0002609217772260308
dependent O 0 2.424884951324202e-05
l O 0 0.003236618358641863
- O 0 0.00012594791769515723
type O 0 4.312485907576047e-05
Ca2 O 0 0.00011725439981091768
+ O 0 3.0204691938706674e-05
and O 0 1.3321498499863083e-06
Na O 0 0.001248732558451593
+ O 0 0.00010566889977781102
channels O 0 1.1761244422814343e-05
. O 0 2.035269972111564e-05

The O 0 6.24741951469332e-05
mutant O 0 0.0006291046738624573
myotubes O 0 0.0022511424031108618
exhibit O 0 3.69190784113016e-05
smaller O 0 5.1059896577498876e-06
and O 0 1.0712359426179319e-06
slower O 0 6.277924694586545e-05
Ca2 O 0 0.0002944410080090165
+ O 0 5.4966378229437396e-05
responses O 0 2.1754913177574053e-06
upon O 0 1.2684312196142855e-06
triggering O 0 0.00013299639977049083
by O 0 2.6432815047883196e-06
acetylcholine O 0 0.0073422593995928764
or O 0 9.500744454271626e-06
high O 0 7.95415326138027e-05
external O 0 0.00010950418800348416
K O 0 0.0028228729497641325
+ O 0 0.0014485897263512015
. O 0 4.3440290028229356e-05

In O 0 1.3540855434257537e-05
addition O 0 1.0792735338327475e-05
, O 0 1.1171099458806566e-06
we O 0 3.079238695136155e-07
observed O 0 5.212546625443792e-07
that O 0 1.0262949956540979e-07
these O 0 2.862353767341119e-07
Ca2 O 0 0.0004062807420268655
+ O 0 0.0005944736767560244
transients O 0 0.0011623313184827566
partially O 0 0.0001343982294201851
result O 0 2.261967438244028e-06
from O 0 2.638571459101513e-07
an O 0 1.7498807380889048e-07
influx O 0 2.239195282527362e-06
of O 0 1.298710259334257e-07
extracellular O 0 1.921081820910331e-05
Ca2 O 0 7.692315557505935e-05
+ O 0 1.4346927855513059e-05
through O 0 3.753364410385984e-07
the O 0 3.8254443097685e-06
l O 0 0.006663932465016842
- O 0 0.00021500578441191465
type O 0 9.405078162671998e-05
Ca2 O 0 0.00025287337484769523
+ O 0 0.00018211566202808172
channel O 0 3.4484990464989096e-05
. O 0 2.394398325122893e-05

Neither O 0 7.012421701801941e-05
the O 0 1.556466486363206e-06
content O 0 1.926089225889882e-06
nor O 0 3.698692808029591e-06
the O 0 2.403877203960292e-07
activity O 0 8.84736664374941e-07
of O 0 2.2379761048796354e-06
Na O 0 0.00761105353012681
+ O 0 0.00047768783406354487
/ O 0 0.00018816861847881228
K O 0 8.76848425832577e-05
+ O 0 0.00010993525211233646
ATPase O 0 0.00021760209347121418
and O 0 4.366504981589969e-06
sarcoplasmic O 0 0.02163884975016117
reticulum O 0 0.009343836456537247
Ca2 O 0 0.0022827181965112686
+ O 0 0.0020843062084168196
- O 0 0.0005465204594656825
ATPase O 0 0.00018185001681558788
are O 0 5.654534334098571e-07
affected O 0 2.1280458895489573e-05
by O 0 1.2020189387840219e-05
DMPK O 0 0.4453731179237366
absence O 0 0.00118543510325253
. O 0 0.00013395810674410313

In O 0 1.0568737707217224e-05
conclusion O 0 1.379646982968552e-05
, O 0 1.425819959877117e-06
our O 0 3.5211479598729056e-07
data O 0 9.296822440774122e-07
suggest O 0 5.618317572952947e-06
that O 0 1.2868441672253539e-06
DMPK O 0 0.002801331924274564
is O 0 8.474983701489691e-07
involved O 0 9.39979258873791e-07
in O 0 3.676543940400734e-07
modulating O 0 4.647315654437989e-05
the O 0 3.6359918453854334e-07
initial O 0 1.6574693972870591e-06
events O 0 3.2577096931163396e-07
of O 0 5.524495350073266e-07
excitation O 0 0.0003623896336648613
- O 0 0.0038430364802479744
contraction O 0 0.0028793741948902607
coupling O 0 0.0005163562018424273
in O 0 0.00016285982565023005
skeletal O 1 0.998609185218811
muscle O 1 0.9961104989051819
. O 0 0.00013778568245470524
. O 0 0.00012241902004461735

Constitutional O 0 0.002402879297733307
RB1 O 1 0.9852197170257568
- O 0 0.01089258212596178
gene O 0 0.00019652994524221867
mutations O 0 0.0005635811248794198
in O 0 5.8008343330584466e-05
patients O 1 0.5587304830551147
with O 0 6.438434502342716e-05
isolated O 0 0.008702605031430721
unilateral B-Disease 0 0.010851769708096981
retinoblastoma I-Disease 1 0.9922566413879395
. O 0 0.0003573100839275867

In O 0 5.6861583288991824e-05
most O 0 3.93030968552921e-05
patients O 0 0.12018237262964249
with O 0 2.1267151169013232e-05
isolated O 0 0.0017183109885081649
unilateral B-Disease 0 0.0030584954656660557
retinoblastoma I-Disease 1 0.9978162050247192
, O 0 0.00019637166406027973
tumor B-Disease 1 0.9951514005661011
development O 0 4.786400040757144e-06
is O 0 1.111455731006572e-06
initiated O 0 6.381274488376221e-06
by O 0 9.806889238461736e-07
somatic O 0 4.7684283345006406e-05
inactivation O 0 0.00023232816602103412
of O 0 1.258126758330036e-07
both O 0 2.1866414101623377e-07
alleles O 0 2.1543971797655104e-06
of O 0 6.775604788344936e-07
the O 0 7.826484943507239e-05
RB1 O 1 0.9937465190887451
gene O 0 0.0006157406023703516
. O 0 9.598986071068794e-05

However O 0 2.79523701465223e-05
, O 0 1.7873296656034654e-06
some O 0 2.395555611656164e-07
of O 0 6.487018708867254e-07
these O 0 5.426036295830272e-06
patients O 1 0.5811675190925598
can O 0 9.993544153985567e-06
transmit O 0 0.0018445265013724566
retinoblastoma B-Disease 1 0.9931280612945557
predisposition O 0 0.14385086297988892
to O 0 1.941432628882467e-06
their O 0 2.947077518911101e-06
offspring O 0 0.0005333541776053607
. O 0 0.00010986670531565323

To O 0 8.92233742888493e-07
determine O 0 4.861746560891334e-07
the O 0 3.5077547977380164e-07
frequency O 0 7.841921387807815e-07
and O 0 1.9580058108203957e-07
nature O 0 9.90332637229585e-07
of O 0 5.702623298020626e-07
constitutional O 0 0.00019469911057967693
RB1 O 1 0.9965611100196838
- O 0 0.0054980251006782055
gene O 0 8.656756108393893e-05
mutations O 0 0.00019081933714915067
in O 0 1.7584503439138643e-05
patients O 0 0.42815154790878296
with O 0 2.325812602066435e-05
isolated O 0 0.002728967694565654
unilateral B-Disease 0 0.002570354612544179
retinoblastoma I-Disease 1 0.9502376914024353
, O 0 2.2904146135260817e-06
we O 0 2.905115081830445e-07
analyzed O 0 4.845471266889945e-06
DNA O 0 2.096263415296562e-05
from O 0 1.3192845472076442e-05
peripheral O 1 0.7782190442085266
blood O 0 0.2628366947174072
and O 0 3.865417602355592e-05
from O 0 0.002888328395783901
tumor B-Disease 1 0.9989936947822571
tissue O 1 0.9864485859870911
. O 0 0.00033101782901212573

The O 0 7.485914920835057e-06
analysis O 0 8.670752322359476e-06
of O 0 1.6432712072855793e-05
tumors B-Disease 1 0.9987431168556213
from O 0 8.313905709655955e-06
54 O 0 5.279803735902533e-05
( O 0 1.9064982552663423e-06
71 O 0 6.615451638936065e-06
% O 0 3.3631599194450246e-07
) O 0 2.0867445016392594e-07
of O 0 2.305673660885077e-07
76 O 0 0.00024389749160036445
informative O 0 0.00011043160338886082
patients O 0 0.24723000824451447
showed O 0 0.00034634635085240006
loss O 0 0.00023370626149699092
of O 0 1.8415507838653866e-06
constitutional O 0 0.000320115388603881
heterozygosity O 1 0.8720604181289673
( O 0 0.0037609320133924484
LOH O 1 0.9964728951454163
) O 0 1.947810778801795e-05
at O 0 5.77332939428743e-05
intragenic O 0 0.004392171278595924
loci O 0 0.00040094711584970355
. O 0 0.00010315689723938704

Three O 0 1.047745445248438e-05
of O 0 2.2944326701690443e-05
13 O 0 0.0019516698084771633
uninformative O 1 0.9781109094619751
patients O 1 0.8826240301132202
had O 0 9.573480929248035e-05
constitutional O 0 0.00013384931662585586
deletions O 0 0.002042303094640374
. O 0 0.00012226666149217635

For O 0 8.029418495425489e-06
39 O 0 3.3922824513865635e-05
randomly O 0 1.5522211469942704e-05
selected O 0 8.104804874164984e-05
tumors B-Disease 1 0.9983482360839844
, O 0 4.453622022992931e-05
SSCP O 0 0.0734575167298317
, O 0 3.20968174492009e-05
hetero O 0 0.015271766111254692
- O 0 0.00047229809570126235
duplex O 0 0.00031472885166294873
analysis O 0 1.090941964321246e-06
, O 0 2.269079004690866e-07
sequencing O 0 1.4844405313851894e-06
, O 0 2.2100358876286919e-07
and O 0 2.3621863931566622e-07
Southern O 0 2.9275754513946595e-06
blot O 0 5.240376412984915e-05
analysis O 0 5.562081923926598e-07
were O 0 2.8257196049708e-07
used O 0 6.008335162732692e-07
to O 0 1.490268687120988e-06
identify O 0 4.178729795967229e-05
mutations O 0 0.0002722259669099003
. O 0 6.87275969539769e-05

Mutations O 0 0.00024281948572024703
were O 0 5.043598321208265e-06
detected O 0 4.283528687665239e-05
in O 0 6.772342544536514e-07
21 O 0 5.126551059220219e-06
( O 0 1.5519991620749352e-06
91 O 0 1.3933640730101615e-05
% O 0 1.2245615153005929e-06
) O 0 6.699177106384013e-07
of O 0 1.1265365174040198e-06
23 O 0 0.012575761415064335
tumors B-Disease 1 0.9994650483131409
with O 0 0.007683843374252319
LOH O 1 0.9979775547981262
. O 0 0.00022843913757242262

In O 0 6.982083505135961e-06
6 O 0 1.9207445802749135e-05
( O 0 2.5188116978824837e-06
38 O 0 4.085003183718072e-06
% O 0 1.113415123654704e-06
) O 0 5.365427000469936e-07
of O 0 2.0094657884328626e-06
16 O 0 0.002069132635369897
tumors B-Disease 1 0.9994893074035645
without O 0 0.0009710749727673829
LOH O 1 0.9982408285140991
, O 0 2.0114714516239474e-06
one O 0 1.296646473747387e-06
mutation O 0 3.751300391741097e-05
was O 0 3.1098265026230365e-05
detected O 0 2.4243947336799465e-05
, O 0 1.592157445884368e-07
and O 0 6.571746524741684e-08
in O 0 1.241031100107648e-07
9 O 0 1.0316101679563872e-06
( O 0 2.448840348279191e-07
56 O 0 4.89052240482124e-07
% O 0 1.997423879629423e-07
) O 0 1.2297302021124779e-07
of O 0 2.081263374975606e-07
the O 0 0.00012624601367861032
tumors B-Disease 1 0.999596893787384
without O 0 0.0013193708145990968
LOH O 1 0.9990807771682739
, O 0 2.18473519453255e-06
both O 0 1.0088141380037996e-06
mutations O 0 1.9757231711992063e-05
were O 0 2.7878702439920744e-06
found O 0 3.5503999242791906e-05
. O 0 5.670119571732357e-05

Thus O 0 9.04691933101276e-06
, O 0 7.519054179283557e-07
a O 0 3.6813719361816766e-07
total O 0 7.082344666287099e-08
of O 0 8.312918708952566e-08
45 O 0 2.913776825153036e-06
mutations O 0 1.0851750630536117e-05
were O 0 1.00686111181858e-06
identified O 0 2.0838917407672852e-05
in O 0 3.302226832602173e-05
tumors B-Disease 1 0.9988794922828674
of O 0 1.267827428819146e-05
36 O 0 0.008939568884670734
patients O 1 0.9797334671020508
. O 0 0.00025227712467312813

Thirty O 0 9.629211126593873e-05
- O 0 3.727880903170444e-05
nine O 0 4.653236658214155e-07
of O 0 9.899080311015496e-08
the O 0 1.2378364999676705e-06
mutations O 0 1.879887167888228e-05
- O 0 1.95591346709989e-05
including O 0 2.8244909344721236e-07
34 O 0 1.0437893251946662e-06
small O 0 7.517526796618768e-07
mutations O 0 5.229088856140152e-06
, O 0 5.200778332437039e-07
2 O 0 2.9201196412032004e-06
large O 0 4.8516722017666325e-06
structural O 0 0.004639759659767151
alterations O 0 0.001122727757319808
, O 0 1.592620492374408e-06
and O 0 1.7049682128345012e-06
hypermethylation O 0 0.02530769258737564
in O 0 3.092779661528766e-05
3 O 0 0.005481270141899586
tumors O 1 0.9997779726982117
- O 0 0.0005333782755769789
were O 0 3.232265726182959e-07
not O 0 2.1315985065939458e-07
detected O 0 8.121161044982728e-06
in O 0 1.7520046924346389e-07
the O 0 1.2538785085780546e-06
corresponding O 0 4.3013144022552297e-05
peripheral O 1 0.7453577518463135
blood O 1 0.7536969184875488
DNA O 0 0.002105980645865202
. O 0 0.000141809563501738

In O 0 1.598837843630463e-05
6 O 0 2.2257938326220028e-05
( O 0 3.0914634407963604e-06
17 O 0 1.8753198673948646e-06
% O 0 2.3436719231995085e-07
) O 0 4.2829459090398814e-08
of O 0 3.592568376120653e-08
the O 0 1.3831414662490715e-06
36 O 0 2.955875424959231e-05
patients O 0 0.003063134616240859
, O 0 7.134277097975428e-07
a O 0 4.178973085799953e-06
mutation O 0 9.257142664864659e-05
was O 0 2.0221950762788765e-05
detected O 0 2.32897527894238e-05
in O 0 1.6641645572690322e-07
constitutional O 0 1.2444744470485603e-06
DNA O 0 6.62825823383173e-06
, O 0 1.5364287264674203e-07
and O 0 4.290410871021777e-08
1 O 0 1.3531678177969297e-07
of O 0 1.8446808525141023e-08
these O 0 1.2611323541023012e-07
mutations O 0 7.518246547988383e-06
is O 0 3.142430387015338e-07
known O 0 1.3838143786415458e-06
to O 0 1.759321577310402e-07
be O 0 4.1028661712516623e-07
associated O 0 8.100771992758382e-06
with O 0 7.027167157502845e-06
reduced O 0 0.002274323720484972
expressivity O 1 0.61971515417099
. O 0 0.00030617680749855936

The O 0 5.15664851263864e-06
presence O 0 1.904928126350569e-06
of O 0 1.1734883997860379e-07
a O 0 3.264603492425522e-06
constitutional O 0 7.771960554237012e-06
mutation O 0 0.00013912864960730076
was O 0 1.2939723092131317e-05
not O 0 2.8185820610815426e-07
associated O 0 8.266574127446802e-07
with O 0 2.8828731046814937e-07
an O 0 1.1457333357611788e-06
early O 0 3.311279942863621e-05
age O 0 0.0006345305009745061
at O 0 0.0003095630672760308
treatment O 0 0.33473771810531616
. O 0 0.00019358290592208505

In O 0 5.9143701946595684e-05
1 O 0 0.00026624248130246997
patient O 0 0.04303446412086487
, O 0 2.407504325674381e-05
somatic O 0 0.0008355343597941101
mosaicism O 0 0.44826486706733704
was O 0 3.150005068164319e-05
demonstrated O 0 4.373022875370225e-06
by O 0 2.1128610683263105e-07
molecular O 0 1.787607516234857e-06
analysis O 0 2.6289717425243e-07
of O 0 1.1863885163165833e-07
DNA O 0 1.0663601642590947e-05
and O 0 7.98048347405711e-07
RNA O 0 5.983506343909539e-05
from O 0 4.699686905951239e-05
peripheral O 1 0.8716070652008057
blood O 1 0.7946103811264038
. O 0 0.0001510282454546541

In O 0 5.549988054553978e-05
2 O 0 0.00026534919743426144
patients O 0 0.0038446031976491213
without O 0 5.14060229761526e-06
a O 0 2.0566345483530313e-05
detectable O 0 0.003757472848519683
mutation O 0 0.00036082317819818854
in O 0 2.3636930563952774e-05
peripheral O 1 0.9453937411308289
blood O 1 0.9318920373916626
, O 0 4.3016712879762053e-05
mosaicism O 1 0.924574613571167
was O 0 0.00014692051627207547
suggested O 0 1.662948852754198e-05
because O 0 1.142937435361091e-06
1 O 0 8.550573511456605e-07
of O 0 3.7624172932737565e-07
the O 0 9.464989852858707e-05
patients O 1 0.9950354099273682
showed O 1 0.9685475826263428
multifocal O 1 0.9997249245643616
tumors B-Disease 1 0.9998239874839783
and O 0 4.181078111287206e-06
the O 0 1.0834188515218557e-06
other O 0 4.650406424389075e-07
later O 0 2.3382153813145123e-05
developed O 0 0.00030685242381878197
bilateral B-Disease 0 0.0018833006033673882
retinoblastoma I-Disease 1 0.9894993305206299
. O 0 0.0004206668527331203

In O 0 6.4261307670676615e-06
conclusion O 0 1.0064905836770777e-05
, O 0 6.680803039671446e-07
our O 0 2.853956004855718e-07
results O 0 1.3353883332456462e-06
emphasize O 0 2.714126594582922e-06
that O 0 2.3366375501154835e-07
the O 0 8.386238050661632e-07
manifestation O 0 0.00012075944687239826
and O 0 2.1554410523094703e-06
transmissibility O 0 0.001539893914014101
of O 0 2.8433764782676008e-06
retinoblastoma B-Disease 0 0.1709440052509308
depend O 0 1.7607426343602128e-06
on O 0 2.023916039206597e-07
the O 0 1.5850157808472431e-07
nature O 0 2.661950873061869e-07
of O 0 1.8925947031789292e-08
the O 0 1.657603831972665e-07
first O 0 4.3276421024529554e-07
mutation O 0 4.3547524910536595e-06
, O 0 6.642506633625089e-08
its O 0 3.732902342790112e-08
time O 0 1.0957283080870184e-07
in O 0 1.0820254203736113e-07
development O 0 4.5106565949026844e-07
, O 0 1.2169438434739277e-07
and O 0 4.341688608633376e-08
the O 0 4.5458520503416366e-08
number O 0 3.193072828366894e-08
and O 0 1.0197933875133458e-07
types O 0 1.3307023891684366e-06
of O 0 7.137333000173385e-07
cells O 0 0.00016376626444980502
that O 0 9.603761554899393e-07
are O 0 6.782690888940124e-07
affected O 0 5.074265573057346e-05
. O 0 7.041140634100884e-06
. O 0 2.963125916721765e-05

Hereditary B-Disease 1 0.9969431757926941
deficiency I-Disease 1 0.9993195533752441
of I-Disease 0 2.4136131742125144e-06
the I-Disease 0 4.458890089154011e-06
fifth I-Disease 0 1.112324207497295e-05
component I-Disease 0 5.074843102192972e-06
of I-Disease 0 5.447753892440232e-07
complement I-Disease 0 2.0312678316258825e-05
in O 0 1.4300115253718104e-05
man O 0 0.0008231228566728532
. O 0 9.240297367796302e-05

I O 0 0.010359054431319237
. O 0 0.0005562909063883126

Clinical O 0 0.020999042317271233
, O 0 0.00011453425395302474
immunochemical O 0 0.04285811260342598
, O 0 1.2237640476087108e-05
and O 0 5.4298357099469285e-06
family O 0 9.469522046856582e-05
studies O 0 7.512317097280174e-05
. O 0 7.415115396725014e-05

The O 0 7.094861757650506e-06
first O 0 5.648267233482329e-06
recognized O 0 1.5978455849108286e-05
human O 0 5.0359038141323254e-05
kindred O 0 0.0743420347571373
with O 0 0.0010612914338707924
hereditary B-Disease 1 0.9996329545974731
deficiency I-Disease 1 0.999893307685852
of I-Disease 0 4.6965178057689627e-07
the I-Disease 0 1.2847523294112762e-06
fifth I-Disease 0 8.554875421395991e-06
component I-Disease 0 1.990336158996797e-06
of I-Disease 0 2.696770309285057e-07
complement I-Disease 0 1.5993440683814697e-05
( O 0 3.325824945932254e-05
C5 O 0 0.042318057268857956
) O 0 6.5316230575263035e-06
is O 0 7.290988833119627e-06
described O 0 0.00015741601237095892
. O 0 7.45116631151177e-05

The O 0 3.9223305066116154e-05
proband O 0 0.001052000210620463
, O 0 2.172870381400571e-06
a O 0 5.667919140250888e-06
20 O 0 2.1180763724260032e-05
- O 0 0.0006420857389457524
year O 0 5.158659041626379e-05
- O 0 0.0008619828731752932
old O 0 0.0008153509115800261
black O 0 0.00132681371178478
female O 0 0.001874354900792241
with O 1 0.8994050621986389
systemic B-Disease 1 0.9999730587005615
lupus I-Disease 1 0.999985933303833
erythematosus I-Disease 1 0.9999649524688721
since O 0 0.021471096202731133
age O 0 0.00962582603096962
11 O 0 0.00017343545914627612
, O 0 2.9875958716729656e-05
lacked O 0 0.01226057019084692
serum O 1 0.9900208711624146
hemolytic O 1 0.9991118311882019
complement O 0 4.687521141022444e-05
activity O 0 1.589118255651556e-05
, O 0 6.783319349779049e-06
even O 0 2.8615904739126563e-05
during O 0 0.0005111604696139693
remission O 1 0.9000023007392883
. O 0 0.0001494451571488753

C5 O 1 0.8275133371353149
was O 0 0.002038985025137663
undetectable O 0 0.04259734973311424
in O 0 4.793187599716475e-06
her O 0 7.171041215769947e-05
serum O 0 0.004355037584900856
by O 0 2.3430243345501367e-06
both O 0 4.06678054787335e-06
immunodiffusion O 0 0.053931839764118195
and O 0 9.703200339572504e-05
hemolytic O 1 0.9983875751495361
assays O 0 0.001897830399684608
. O 0 0.00037055008579045534

Other O 0 1.1659757319648634e-06
complement O 0 8.793649612925947e-06
components O 0 4.7666071623098105e-06
were O 0 1.561128556204494e-06
normal O 0 3.3639720641076565e-05
during O 0 0.00018445448949933052
remission O 1 0.8676154017448425
of O 0 0.00022749319032300264
lupus O 1 0.9998099207878113
, O 0 4.4467469706432894e-05
but O 0 3.1455321732209995e-05
C1 O 1 0.8126554489135742
, O 0 1.4708666640217416e-05
C4 O 0 0.00829328503459692
, O 0 8.940573934523854e-06
C2 O 0 0.10021451115608215
, O 0 3.704930804815376e-06
and O 0 3.7544853057625005e-06
C3 O 1 0.6304070949554443
levels O 0 0.0006849457276985049
fell O 0 0.005598269868642092
during O 0 0.0005814479663968086
exacerbations O 1 0.9838874936103821
. O 0 0.00028916256269440055

A O 0 0.00030561568564735353
younger O 0 0.0003498469013720751
half O 0 9.70137698459439e-05
- O 0 0.0013746093027293682
sister O 0 0.0002316777827218175
, O 0 4.594387519318843e-06
who O 0 9.593843060429208e-06
had O 0 8.898667874746025e-05
no O 0 0.0004400370817165822
underlying O 1 0.996232807636261
disease O 1 0.9998668432235718
, O 0 5.1607996283564717e-05
was O 0 9.251759183825925e-05
also O 0 2.322561840628623e-06
found O 0 2.635272494444507e-06
to O 0 1.0364628906245343e-06
lack O 0 0.00012811711349058896
immunochemically O 0 0.12356863915920258
detectable O 0 0.09815414249897003
C5 O 1 0.6452683806419373
. O 0 9.371988562634215e-05

By O 0 0.0016196580836549401
hemolytic O 1 0.9977157115936279
assay O 0 0.001968547236174345
, O 0 2.9570992410299368e-05
she O 0 3.337218004162423e-05
exhibited O 0 3.988558455603197e-05
1 O 0 4.624521352525335e-06
- O 0 8.607602467236575e-06
2 O 0 2.263774945276964e-07
% O 0 7.119726319615438e-08
of O 0 4.2982577497241437e-08
the O 0 6.433204475797538e-07
normal O 0 3.929661397705786e-05
serum O 0 0.013259580358862877
C5 O 0 0.0035664429888129234
level O 0 2.5234207896573935e-06
and O 0 1.6615859976809588e-07
normal O 0 1.7209824818564812e-06
concentrations O 0 2.685926119738724e-06
of O 0 5.984145445836475e-08
other O 0 1.3799909481804207e-07
complement O 0 5.6997700994543266e-06
components O 0 4.158083174843341e-05
. O 0 5.897636947338469e-05

C5 O 0 0.1616850346326828
levels O 0 4.955960321240127e-05
of O 0 3.024871659818018e-07
other O 0 4.233226036376436e-07
family O 0 7.104950782377273e-06
members O 0 2.617738630306121e-07
were O 0 2.313929741148968e-07
either O 0 3.4143991456403455e-07
normal O 0 1.6657603509884211e-06
or O 0 5.010089694224007e-07
approximately O 0 8.217228355533734e-07
half O 0 3.6527408155961893e-06
- O 0 6.636334001086652e-05
normal O 0 3.3079775221267482e-06
, O 0 4.239116151438793e-07
consistent O 0 3.5077925986115588e-06
with O 0 5.657971996697597e-06
autosomal O 1 0.8938301205635071
codominant O 0 0.028074605390429497
inheritance O 0 0.0001484813983552158
of O 0 1.025355459205457e-06
the O 0 2.1460497009684332e-05
gene O 0 0.0011103678261861205
determining O 0 0.005459129344671965
C5 B-Disease 1 0.9991201758384705
deficiency I-Disease 1 0.9999080896377563
. O 0 0.0015225941315293312

Normal O 1 0.5870088934898376
hemolytic O 1 0.9989578723907471
titers O 1 0.8951799869537354
were O 0 1.00739980553044e-05
restored O 0 8.016554784262553e-05
to O 0 7.92835351148824e-07
both O 0 4.901854481431656e-06
homozygous O 0 0.0076778908260166645
C5 B-Disease 1 0.9983922839164734
- I-Disease 1 0.9949727058410645
deficient I-Disease 1 0.9984671473503113
( O 0 0.00015415744564961642
C5D B-Disease 1 0.9857030510902405
) O 0 1.9232742488384247e-05
sera O 0 0.0006379559636116028
by O 0 5.306683306116611e-07
addition O 0 9.726823009259533e-07
of O 0 1.0664816727512516e-06
highly O 0 0.00011243644985370338
purified O 0 0.0015704960096627474
human O 0 0.0003068781807087362
C5 O 1 0.9082465767860413
. O 0 0.000208512952667661

In O 0 3.179721534252167e-05
specific O 0 3.8805414078524336e-05
C5 O 1 0.7965808510780334
titrations O 0 0.1986294388771057
, O 0 6.5484132392157335e-06
however O 0 3.7385711948445532e-06
, O 0 8.181166322174249e-07
it O 0 3.2131308103089395e-07
was O 0 5.675859938492067e-06
noted O 0 1.9144310954288812e-06
that O 0 1.0832189190068675e-07
when O 0 3.016661196397763e-07
limited O 0 2.720104816944513e-07
amounts O 0 4.554895838282391e-07
of O 0 2.2537882671258558e-07
C5 O 0 0.001938684843480587
were O 0 2.1394045290890062e-07
assayed O 0 2.8323531751084374e-06
in O 0 1.1774411490250714e-07
the O 0 1.3662464937169716e-07
presence O 0 4.988867772226513e-07
of O 0 2.6513552597862144e-07
low O 0 4.810094469576143e-05
dilutions O 0 0.000427060091169551
of O 0 1.8525403220337466e-06
either O 0 0.0001074488100130111
C5D B-Disease 1 0.9967240691184998
serum O 0 0.08205808699131012
, O 0 1.2580143220475293e-06
curving O 0 4.3154810555279255e-05
rather O 0 5.817649935124791e-07
than O 0 5.251390007288137e-07
linear O 0 8.318434265675023e-05
dose O 0 0.04228594899177551
- O 0 0.00066686439095065
response O 0 5.919963768974412e-06
plots O 0 2.0954762476321775e-06
were O 0 3.547353628619021e-07
consistently O 0 3.410670387893333e-06
obtained O 0 1.6583453543717042e-06
, O 0 8.778833375799877e-07
suggesting O 0 1.0625158211041708e-05
some O 0 8.091791983133589e-07
inhibitory O 0 7.36234214855358e-05
effect O 0 8.932761556934565e-05
. O 0 4.09653403039556e-05

Further O 0 3.4461849281797186e-05
studies O 0 1.978298678295687e-05
suggested O 0 1.786172106221784e-05
that O 0 2.4287207907036645e-06
low O 0 7.103003008523956e-05
dilutions O 0 0.0009729318553581834
of O 0 8.152961527230218e-06
C5D B-Disease 1 0.996286153793335
serum O 0 0.046638812869787216
contain O 0 1.6097677871584892e-05
a O 0 9.41493362915935e-06
factor O 0 1.4827165614406113e-05
( O 0 3.9642818592255935e-06
or O 0 1.228260998686892e-06
factors O 0 1.8109127495335997e-06
) O 0 1.0233068223897135e-06
interfering O 0 2.7272137685940834e-06
at O 0 7.393098826469213e-07
some O 0 1.1994634974143992e-07
step O 0 2.244375536974985e-06
in O 0 1.2771660067301127e-06
the O 0 7.692270628467668e-06
hemolytic O 1 0.9988206028938293
assay O 0 7.272106449818239e-05
of O 0 3.1941349334374536e-06
C5 O 0 0.18602703511714935
, O 0 6.206039415701525e-07
rather O 0 3.362723930422362e-07
than O 0 3.107864188223175e-07
a O 0 4.794906999450177e-06
true O 0 4.317650382290594e-05
C5 O 0 0.1288587599992752
inhibitor O 0 0.008989025838673115
or O 0 5.4442512919194996e-05
inactivator O 0 0.020828906446695328
. O 0 9.598628093954176e-05

Of O 0 1.462980708311079e-05
clinical O 0 0.0008775200694799423
interest O 0 4.7884000196063425e-06
are O 0 2.4714807977943565e-07
( O 0 1.2587812534547993e-06
a O 0 8.800427053756721e-07
) O 0 3.8755462128392537e-07
the O 0 3.08860279574219e-07
documentation O 0 8.644373338029254e-06
of O 0 1.878288821899332e-05
membranous O 1 0.9987354874610901
glomerulonephritis B-Disease 1 0.9997355341911316
, O 0 0.42003482580184937
vasculitis B-Disease 1 0.9998859167098999
, O 0 0.02965838834643364
and O 0 0.1667262315750122
arthritis B-Disease 1 0.9999827146530151
in O 0 1.0693132935557514e-05
an O 0 5.2898699323122855e-06
individual O 0 5.058202987129334e-06
lacking O 0 0.0011851132148876786
C5 O 0 0.1968216598033905
( O 0 1.5371424524346367e-06
and O 0 1.4634805722835154e-07
its O 0 2.1035522479451174e-07
biologic O 0 0.00017414885223843157
functions O 0 5.001787144465197e-07
) O 0 7.142351137190417e-07
, O 0 3.6455682561609137e-07
and O 0 2.1578607345418277e-07
( O 0 1.066694267137791e-06
b O 0 3.469392822808004e-06
) O 0 2.284530324914158e-07
a O 0 8.147443963935075e-07
remarkable O 0 3.308685700176284e-05
propensity O 0 0.001066436874680221
to O 0 5.144932583789341e-05
bacterial B-Disease 1 0.9996769428253174
infections I-Disease 1 0.9997557997703552
in O 0 8.708235327503644e-06
the O 0 1.1873989933519624e-05
proband O 0 0.006491233129054308
, O 0 1.226216227223631e-06
even O 0 5.095134838484228e-07
during O 0 1.2456582680897554e-06
periods O 0 4.667437679017894e-06
of O 0 1.2068384194208193e-06
low O 0 0.0008811253355816007
- O 0 0.000472802174044773
dose O 0 0.00011498456296976656
or O 0 2.968495437016827e-06
alternate O 0 2.2646183424512856e-05
- O 0 0.001162234926596284
day O 0 8.527466707164422e-05
corticosteroid O 1 0.9665400385856628
therapy O 0 0.10973715782165527
. O 0 0.00019622305990196764

Other O 0 5.020065600547241e-06
observations O 0 1.0880537956836633e-05
indicate O 0 2.530456731619779e-05
that O 0 1.7797859754864476e-06
the O 0 7.661231393285561e-06
C5D B-Disease 1 0.7232969999313354
state O 0 1.9829888060485246e-06
is O 0 5.530135922526824e-07
compatible O 0 2.3633972432435257e-06
with O 0 3.536122790137597e-07
normal O 0 1.9730174244614318e-05
coagulation O 0 0.0009385970188304782
function O 0 9.303101364821487e-07
and O 0 2.0902379560538975e-07
the O 0 8.662742061460449e-07
capacity O 0 3.16787577503419e-06
to O 0 7.356554760917788e-07
mount O 0 0.00014628322969656438
a O 0 0.0003681111556943506
neutrophilic O 1 0.9891974329948425
leukocytosis O 1 0.9915181994438171
during O 1 0.5861556529998779
pyogenic B-Disease 1 0.9980224370956421
infection I-Disease 1 0.9989309906959534
. O 0 0.0001093006576411426
. O 0 0.00011345886014169082

Susceptibility O 1 0.8338705897331238
to O 0 0.028719430789351463
ankylosing B-Disease 1 0.999906063079834
spondylitis I-Disease 1 0.9999583959579468
in O 0 0.0006986177177168429
twins O 0 0.007392313797026873
: O 0 4.003341018687934e-06
the O 0 3.4741367471724516e-07
role O 0 4.1204881995327014e-07
of O 0 2.602668587314838e-07
genes O 0 1.0541801202634815e-05
, O 0 1.2907618838653434e-05
HLA O 1 0.9146118760108948
, O 0 1.6145655763466493e-06
and O 0 7.428259323205566e-07
the O 0 5.8253608585800976e-06
environment O 0 7.67096207709983e-05
. O 0 6.218780617928132e-05

OBJECTIVE O 0 2.047489761025645e-05
To O 0 5.817261126139783e-07
determine O 0 8.671098044032988e-07
the O 0 1.0572077826509485e-06
relative O 0 6.7721302912104875e-06
effects O 0 6.656312325503677e-05
of O 0 6.369640459524817e-07
genetic O 0 0.0003717346990015358
and O 0 4.001634806627408e-06
environmental O 0 0.00016741549188736826
factors O 0 2.7305522962706164e-05
in O 0 7.368565275100991e-05
susceptibility O 1 0.9704996943473816
to O 0 0.028566161170601845
ankylosing B-Disease 1 0.9999493360519409
spondylitis I-Disease 1 0.9999774694442749
( O 0 0.017835920676589012
AS B-Disease 0 0.014023489318788052
) O 0 9.161211346508935e-05
. O 0 8.565125608583912e-05

METHODS O 0 0.00014535455557052046
Twins O 0 0.0015600756742060184
with O 0 7.834050848032348e-06
AS B-Disease 0 5.905105354031548e-05
were O 0 6.761074473615736e-07
identified O 0 2.627818730616127e-06
from O 0 1.4520836657538894e-06
the O 0 6.671431947324891e-06
Royal O 0 0.0073130764067173
National O 0 0.1002606675028801
Hospital O 1 0.997819185256958
for O 0 0.08356492221355438
Rheumatic B-Disease 1 0.9999762773513794
Diseases I-Disease 1 0.9997901320457458
database O 0 0.0198576170951128
. O 0 0.0005755783640779555

Clinical O 0 0.009980686940252781
and O 0 3.326973455841653e-05
radiographic O 0 0.01766120083630085
examinations O 0 0.0001826657389756292
were O 0 2.4280770958284847e-06
performed O 0 1.0509708772588056e-05
to O 0 2.3187817532743793e-06
establish O 0 8.067968883551657e-05
diagnoses O 1 0.9664660096168518
, O 0 0.0003424997557885945
and O 0 0.005001729354262352
disease O 1 0.9999134540557861
severity O 1 0.996515154838562
was O 0 0.0001283089368371293
assessed O 0 7.676539098611102e-06
using O 0 3.3011721711773134e-07
a O 0 2.0519894405879313e-06
combination O 0 8.085875379038043e-06
of O 0 4.412845839851798e-07
validated O 0 2.790645339700859e-05
scoring O 0 9.631897228246089e-06
systems O 0 0.00041773365228436887
. O 0 5.068704194854945e-05

HLA O 0 0.2727462649345398
typing O 0 0.000566673930734396
for O 0 5.518017860595137e-05
HLA O 1 0.9662109613418579
- O 0 0.0015543929766863585
B27 O 0 0.0005884716520085931
, O 0 2.4780736566754058e-05
HLA O 1 0.7441257834434509
- O 0 0.00027139930170960724
B60 O 0 0.0001356733700959012
, O 0 1.8231361309517524e-06
and O 0 6.64335038891295e-06
HLA O 1 0.9920837879180908
- O 0 0.011721537448465824
DR1 O 0 0.29028695821762085
was O 0 5.963618605164811e-06
performed O 0 1.4212557744031074e-06
by O 0 6.264934881983208e-07
polymerase O 0 5.6275373935932294e-05
chain O 0 4.853675272897817e-05
reaction O 0 5.479148512677057e-06
with O 0 4.553141081942158e-07
sequence O 0 2.740510808507679e-06
- O 0 1.4301643204817083e-05
specific O 0 2.4144270582837635e-07
primers O 0 1.8810349502018653e-05
, O 0 1.5660701819797396e-06
and O 0 2.5511899366392754e-06
zygosity O 0 0.0012528437655419111
was O 0 2.6075327696162276e-05
assessed O 0 4.967477070749737e-05
using O 0 1.842954588937573e-05
microsatellite O 0 0.016546549275517464
markers O 0 0.0034310610499233007
. O 0 0.00018119542801287025

Genetic O 0 0.0003595934540499002
and O 0 2.833279950209544e-06
environmental O 0 1.4266157450038008e-05
variance O 0 2.125436594724306e-06
components O 0 5.15535066369921e-06
were O 0 5.104054139337677e-07
assessed O 0 6.841100002930034e-06
with O 0 3.0996000077720964e-07
the O 0 1.505260797785013e-06
program O 0 1.6114465324790217e-05
Mx O 0 0.0013114578323438764
, O 0 1.0450349208213083e-07
using O 0 4.912276452273545e-08
data O 0 1.1034548208499473e-07
from O 0 9.970860759267453e-08
this O 0 3.997882203066183e-08
and O 0 6.99988618180214e-08
previous O 0 7.063093221404415e-07
studies O 0 1.2779213420799351e-06
of O 0 1.0171112307943986e-06
twins O 0 0.0019342968007549644
with O 0 2.621678140712902e-05
AS B-Disease 0 0.0010327218333259225
. O 0 8.12109065009281e-05

RESULTS O 0 4.114505281904712e-05
Six O 0 2.5281299258494982e-06
of O 0 1.0153522680411697e-06
8 O 0 4.80300368508324e-05
monozygotic O 0 0.009169790893793106
( O 0 0.00014102959539741278
MZ O 1 0.9767325520515442
) O 0 2.1624065993819386e-05
twin O 0 0.0017371047288179398
pairs O 0 0.00022874603746458888
were O 0 0.00021069472131785005
disease O 1 0.9993734955787659
concordant O 0 0.059185322374105453
, O 0 5.109409357828554e-06
compared O 0 8.427138709521387e-06
with O 0 4.741015402487392e-07
4 O 0 8.44310193315323e-07
of O 0 2.1852069664873852e-07
15 O 0 9.230782779923175e-06
B27 O 0 0.000609791197348386
- O 0 6.596226012334228e-05
positive O 0 5.167917606740957e-06
dizygotic O 0 0.0009005131432786584
( O 0 2.3499984308728017e-05
DZ O 0 0.007548580411821604
) O 0 3.4709116789599648e-06
twin O 0 7.772161916363984e-05
pairs O 0 6.680581464024726e-06
( O 0 2.249009867227869e-06
27 O 0 2.5885465220198967e-06
% O 0 6.148555371510156e-07
) O 0 1.802300033659776e-07
and O 0 5.823156357109838e-08
4 O 0 2.6422782184454263e-07
of O 0 1.227241881451846e-07
32 O 0 1.0337184903619345e-05
DZ O 0 0.005255515221506357
twin O 0 8.686979708727449e-05
pairs O 0 5.549770321522374e-06
overall O 0 8.007747055671643e-06
( O 0 1.8199988289779867e-06
12 O 0 7.363124154835532e-07
. O 0 2.4269672849186463e-07
5 O 0 1.5399492667711456e-06
% O 0 1.4975618114476674e-06
) O 0 4.030432592116995e-06
. O 0 9.837737707130145e-06

Nonsignificant O 0 0.02317710593342781
increases O 0 0.0001345517230220139
in O 0 1.5553952152913553e-06
similarity O 0 5.153571237315191e-06
with O 0 1.1126180652354378e-06
regard O 0 3.045836820092518e-06
to O 0 2.2632921172771603e-06
age O 0 0.0055716256611049175
at O 0 0.14412997663021088
disease O 1 0.9998942613601685
onset O 1 0.9994714856147766
and O 0 1.0616897725412855e-06
all O 0 1.0002404593478786e-07
of O 0 2.2339011138683418e-06
the O 0 0.003466120222583413
disease O 1 0.9998393058776855
severity O 1 0.9936827421188354
scores O 0 0.00019335508113726974
assessed O 0 0.00013349507935345173
were O 0 5.012023848394165e-06
noted O 0 0.0004085061082150787
in O 0 0.0004510377475526184
disease O 1 0.9997037053108215
- O 1 0.8893941044807434
concordant O 1 0.9456037878990173
MZ O 1 0.9965468049049377
twins O 0 0.013746773824095726
compared O 0 0.00047224905574694276
with O 0 8.417902427027002e-05
concordant O 1 0.9479167461395264
DZ O 1 0.9886093139648438
twins O 0 0.08483600616455078
. O 0 0.00028355661197565496

HLA O 1 0.9877666234970093
- O 0 0.008354530669748783
B27 O 0 0.0006756599177606404
and O 0 2.755787591013359e-06
B60 O 0 0.00017170606588479131
were O 0 1.1635564760581474e-06
associated O 0 7.512112006224925e-06
with O 0 7.324734269786859e-06
the O 0 0.0005254766438156366
disease O 1 0.9997705817222595
in O 0 1.0868362551264e-05
probands O 0 0.0061836643144488335
, O 0 6.628407049902307e-07
and O 0 2.350512460225218e-07
the O 0 7.966415864757437e-07
rate O 0 1.4094792277319357e-05
of O 0 8.491337212035432e-06
disease O 1 0.9994951486587524
concordance O 0 0.004566058982163668
was O 0 0.0005586553597822785
significantly O 0 0.00021724718681070954
increased O 0 1.2262664313311689e-05
among O 0 4.909822109766537e-06
DZ O 0 0.14589878916740417
twin O 0 0.0003332536725793034
pairs O 0 8.78782338986639e-06
in O 0 5.786089332104893e-07
which O 0 3.559023866728239e-07
the O 0 5.2285204219515435e-06
co O 0 0.0011950823245570064
- O 0 0.000450001418357715
twin O 0 8.273421553894877e-05
was O 0 3.808099791058339e-06
positive O 0 6.413246751435508e-07
for O 0 1.7369487181895238e-07
both O 0 9.57357542574755e-07
B27 O 0 0.0008426776621490717
and O 0 2.8453638151404448e-05
DR1 O 1 0.9733484387397766
. O 0 0.00013096696056891233

Additive O 0 0.0014577818801626563
genetic O 0 0.0014718425227329135
effects O 0 0.0005601621815003455
were O 0 1.4822167031525169e-06
estimated O 0 3.152896852043341e-06
to O 0 1.3137936605289724e-07
contribute O 0 9.027846203935042e-07
97 O 0 2.3624327241122955e-06
% O 0 9.915482479527782e-08
of O 0 4.3276251915358444e-08
the O 0 5.58869942324236e-07
population O 0 1.042429516928678e-06
variance O 0 1.3532412594940979e-05
. O 0 3.7359350244514644e-05

CONCLUSION O 0 0.0008100761915557086
Susceptibility O 0 0.005169233772903681
to O 0 4.348333277448546e-06
AS B-Disease 0 7.044076482998207e-05
is O 0 2.207504849138786e-06
largely O 0 6.7840892370441e-06
genetically O 0 2.26113734242972e-05
determined O 0 2.938682882813737e-06
, O 0 4.920275387121364e-07
and O 0 2.489938708549744e-07
the O 0 1.7900591728903237e-06
environmental O 0 7.443404319928959e-05
trigger O 0 0.0005010140012018383
for O 0 7.768448085698765e-06
the O 0 0.0008288772660307586
disease O 1 0.9996811151504517
is O 0 8.84199544088915e-05
probably O 0 0.0007906021201051772
ubiquitous O 0 0.0034256295766681433
. O 0 7.132767495932057e-05

HLA O 1 0.9742974042892456
- O 0 0.0012779324315488338
B27 O 0 0.00012802027049474418
accounts O 0 7.252330078699742e-07
for O 0 9.922520405325486e-08
a O 0 5.17865998972411e-07
minority O 0 3.4674172866289155e-07
of O 0 7.51743485238876e-08
the O 0 1.399795110046398e-06
overall O 0 0.00015555607387796044
genetic O 0 0.0008760405471548438
susceptibility O 0 0.005209061317145824
to O 0 6.380623290169751e-06
AS B-Disease 0 0.0006647626869380474
. O 0 9.870557551039383e-05

Cell O 0 0.003840226447209716
cycle O 0 0.0020238100551068783
- O 0 0.0006353168282657862
dependent O 0 2.3738472009426914e-05
colocalization O 0 0.0002519509580451995
of O 0 2.364997953918646e-06
BARD1 O 0 0.013876131735742092
and O 0 3.1613208193448372e-06
BRCA1 O 0 0.00020822189981117845
proteins O 0 4.711617975772242e-07
in O 0 3.430457695685618e-07
discrete O 0 6.320562988548772e-06
nuclear O 0 0.00019829477241728455
domains O 0 0.00012536978465504944
. O 0 4.967259519617073e-05

Germ O 1 0.956557035446167
- O 0 0.0008484254940412939
line O 0 1.35586369651719e-05
mutations O 0 4.230318609188544e-06
of O 0 2.241544478920332e-07
the O 0 5.413626695371931e-06
BRCA1 O 0 0.011374951340258121
gene O 0 6.451575609389693e-05
predispose O 0 0.0005646090721711516
women O 0 1.075503860192839e-05
to O 0 5.030455668020295e-06
early O 0 0.0022980310022830963
- O 1 0.993412435054779
onset O 1 0.9996591806411743
breast B-Disease 1 0.9998113512992859
and I-Disease 1 0.9760484099388123
ovarian I-Disease 1 0.9999915361404419
cancer I-Disease 1 0.9999213218688965
by O 0 1.9221264665247872e-05
compromising O 0 0.0004517522465903312
the O 0 5.478229013533564e-06
genes O 0 2.619138831505552e-05
presumptive O 0 0.07250473648309708
function O 0 2.2434027414419688e-05
as O 0 3.145982191199437e-05
a O 0 0.0036092863883823156
tumor B-Disease 1 0.9980493783950806
suppressor O 0 0.3423687517642975
. O 0 0.0001211043490911834

Although O 0 1.7779670088202693e-05
the O 0 4.634460310626309e-06
biochemical O 0 8.900059765437618e-05
properties O 0 8.294945473608095e-06
of O 0 3.167168870277237e-06
BRCA1 O 0 0.1736348271369934
polypeptides O 0 9.858395060291514e-05
are O 0 3.983155067999178e-07
not O 0 5.734133878831926e-07
understood O 0 2.3428096938005183e-06
, O 0 9.517601995412406e-08
their O 0 2.995641068537225e-08
expression O 0 1.1953529792663176e-06
pattern O 0 1.5059319594001863e-05
and O 0 4.495416021654819e-07
subcellular O 0 1.3873206626158208e-05
localization O 0 5.241966209723614e-05
suggest O 0 6.744704933225876e-06
a O 0 2.1422906684165355e-06
role O 0 4.749731033371063e-06
in O 0 5.600177246378735e-06
cell O 0 0.0020785511005669832
- O 0 0.0007309730863198638
cycle O 0 0.00016124785179272294
regulation O 0 0.00018357283261138946
. O 0 3.768025999306701e-05

When O 0 0.0008234272827394307
resting O 0 0.05586962774395943
cells O 0 0.00027462586876936257
are O 0 1.3316189324541483e-06
induced O 0 0.0023621809668838978
to O 0 1.93133860193484e-06
proliferate O 0 0.00010372287943027914
, O 0 3.3388084830221487e-07
the O 0 4.6959266342128103e-07
steady O 0 4.357670695753768e-05
- O 0 9.594949915481266e-06
state O 0 2.119795965427329e-07
levels O 0 1.4248046227294253e-06
of O 0 3.349358053128526e-07
BRCA1 O 0 0.0008110610069707036
increase O 0 3.1418569506058702e-06
in O 0 8.668435498293547e-07
late O 0 4.161768811172806e-05
G1 O 0 0.003988908603787422
and O 0 1.4821189608937857e-07
reach O 0 3.458487469742977e-07
a O 0 5.90559125157597e-07
maximum O 0 1.913350615723175e-06
during O 0 2.5909799660439603e-05
S O 0 0.003219887614250183
phase O 0 0.00023387614055536687
. O 0 3.968730379710905e-05

Moreover O 0 0.00031924984068609774
, O 0 1.3548051356337965e-05
in O 0 8.858773981046397e-06
S O 0 0.0034795929677784443
phase O 0 0.00018991380056831986
cells O 0 0.00012004096788587049
, O 0 6.873653546790592e-06
BRCA1 O 0 0.0007328360225073993
polypeptides O 0 1.2840386261814274e-05
are O 0 1.8415281033412612e-07
hyperphosphorylated O 0 0.00012241178774274886
and O 0 4.520638867688831e-07
accumulate O 0 1.4246742466639262e-05
into O 0 3.746669960946747e-07
discrete O 0 1.363773026241688e-05
subnuclear O 0 0.008878829888999462
foci O 0 0.002171985572203994
termed O 0 0.00739730428904295
" O 0 0.0002244409843115136
BRCA1 O 0 0.07612795382738113
nuclear O 0 0.0011638019932433963
dots O 0 0.0020715168211609125
. O 0 6.855271203676239e-05

" O 0 0.0009036810370162129
BRCA1 O 0 0.2544473707675934
associates O 0 0.002692208392545581
in O 0 4.744927991851e-06
vivo O 0 4.971325324731879e-05
with O 0 2.1580224256467773e-06
a O 0 4.411769623402506e-05
structurally O 0 0.013352448120713234
related O 0 0.00019220109970774502
protein O 0 0.0005989267374388874
termed O 0 0.04247777536511421
BARD1 O 1 0.9388482570648193
. O 0 0.00032564467983320355

Here O 0 1.7172204024973325e-05
we O 0 7.137292072911805e-07
show O 0 1.1887752862094203e-06
that O 0 1.563224572009858e-07
the O 0 1.1949688314416562e-06
steady O 0 8.881492976797745e-05
- O 0 2.8267482775845565e-05
state O 0 8.565525604353752e-07
levels O 0 2.6117786546819843e-06
of O 0 7.381466957667726e-07
BARD1 O 0 0.03548017516732216
, O 0 1.7729284991219174e-06
unlike O 0 2.993995622091461e-06
those O 0 2.3861025510996114e-07
of O 0 1.10144628706621e-06
BRCA1 O 0 0.0690024197101593
, O 0 2.47699335886864e-06
remain O 0 1.1528533150340081e-06
relatively O 0 2.4022413072088966e-06
constant O 0 6.79630875310977e-06
during O 0 0.00011132138752145693
cell O 0 0.0037996177561581135
cycle O 0 0.005523777101188898
progression O 1 0.5474450588226318
. O 0 0.00017096813826356083

However O 0 0.0001247797772521153
, O 0 4.006957897217944e-05
immunostaining O 0 0.012659363448619843
revealed O 0 0.0004578365187626332
that O 0 9.497718565398827e-06
BARD1 O 0 0.015830013900995255
resides O 0 6.357788515742868e-05
within O 0 5.067888196208514e-06
BRCA1 O 0 0.004767867736518383
nuclear O 0 6.800609116908163e-05
dots O 0 6.530520477099344e-05
during O 0 8.343372428498697e-06
S O 0 0.00018651879508979619
phase O 0 2.638458681758493e-06
of O 0 1.2055471643179771e-07
the O 0 1.305129785578174e-06
cell O 0 8.020509267225862e-05
cycle O 0 3.109829776803963e-05
, O 0 6.4609696437401e-07
but O 0 2.450197769121587e-07
not O 0 1.553908219875666e-07
during O 0 3.4328734273003647e-06
the O 0 4.421381618158193e-06
G1 O 0 0.1438847780227661
phase O 0 0.00029172725044190884
. O 0 5.5319171224255115e-05

Nevertheless O 0 0.0006845173775218427
, O 0 3.338539318065159e-05
BARD1 O 0 0.011036046780645847
polypeptides O 0 4.866935341851786e-05
are O 0 2.715410971632082e-07
found O 0 4.986845851817634e-07
exclusively O 0 2.381419648145311e-07
in O 0 1.234145372563944e-07
the O 0 1.095914399229514e-07
nuclear O 0 6.591839110114961e-07
fractions O 0 1.2294300688608928e-07
of O 0 7.188662465296147e-08
both O 0 2.173481789213838e-06
G1 O 1 0.6323375105857849
- O 0 0.00024200059124268591
and O 0 3.7958589018671773e-06
S O 0 0.006419620011001825
- O 0 0.0001995966158574447
phase O 0 9.53434209804982e-05
cells O 0 0.00016999132640194148
. O 0 2.9445402105920948e-05

Therefore O 0 3.940649185096845e-05
, O 0 1.084126142814057e-05
progression O 0 0.0009121763869188726
to O 0 1.857860524978605e-06
S O 0 0.0006864634924568236
phase O 0 1.2191258065286092e-05
is O 0 3.4365774581601727e-07
accompanied O 0 1.3472294995153788e-06
by O 0 1.2723623399324424e-07
the O 0 1.7660219953086198e-07
aggregation O 0 8.183091267710552e-06
of O 0 5.384362680160848e-07
nuclear O 0 8.388444985030219e-05
BARD1 O 0 0.002346381777897477
polypeptides O 0 7.603254198329523e-05
into O 0 2.511797174520325e-05
BRCA1 O 0 0.019880026578903198
nuclear O 0 0.0006130905239842832
dots O 0 0.0009362703422084451
. O 0 4.1733223042683676e-05

This O 0 2.5252567866118625e-05
cell O 0 0.0006960664759390056
cycle O 0 0.0008742827922105789
- O 0 0.00031439989106729627
dependent O 0 1.0291340004187077e-05
colocalization O 0 0.00014386506518349051
of O 0 1.5042319319036324e-06
BARD1 O 0 0.024642236530780792
and O 0 5.9043181863671634e-06
BRCA1 O 0 0.0026479291263967752
indicates O 0 1.9527187760104425e-05
a O 0 2.3191357740870444e-06
role O 0 1.8042467218037928e-06
for O 0 2.229486881333287e-06
BARD1 O 0 0.026216741651296616
in O 0 3.785494118346833e-05
BRCA1 O 1 0.9479533433914185
- O 0 0.16083380579948425
mediated O 0 0.17067395150661469
tumor B-Disease 1 0.9962698221206665
suppression O 0 0.028364771977066994
. O 0 0.0003167478134855628

Ethnic O 0 1.0048782314697746e-05
differences O 0 2.5082907086471096e-05
in O 0 3.8030043469916563e-06
the O 0 1.509189769421937e-05
HFE O 0 0.12898899614810944
codon O 0 0.0001516489137429744
282 O 0 0.0006577367312274873
( O 0 0.00021168080274946988
Cys O 1 0.9625250697135925
/ O 0 0.03837509825825691
Tyr O 0 0.03111199103295803
) O 0 3.3848471503006294e-05
polymorphism O 0 0.00023712262918706983
. O 0 6.431795191019773e-05

Recent O 0 0.00016928948753047734
studies O 0 3.0802675610175356e-05
have O 0 4.296399310987908e-06
shown O 0 0.00010111750452779233
that O 0 0.00020706905343104154
hereditary B-Disease 1 0.9993984699249268
hemochromatosis I-Disease 1 0.9999784231185913
( O 1 0.6212770342826843
HH B-Disease 1 0.9996198415756226
) O 0 2.2819835066911764e-05
is O 0 1.9095625702902908e-06
likely O 0 2.245490804853034e-06
to O 0 3.4346311394983786e-07
be O 0 6.546769100168603e-07
caused O 0 0.00014278595335781574
by O 0 7.746770052108332e-07
homozygosity O 0 0.00014886402641423047
for O 0 3.977753237904835e-07
a O 0 6.908906016178662e-06
Cys282Tyr O 0 0.0009702325332909822
mutation O 0 2.4152010155376047e-05
in O 0 1.329588599219278e-06
the O 0 6.083769221731927e-06
HFE O 0 0.488026887178421
gene O 0 8.608023927081376e-05
located O 0 3.1239993404597044e-05
4 O 0 5.7954381190938875e-05
. O 0 3.880748772644438e-05

5 O 0 0.0003260818193666637
Mb O 0 0.006491196341812611
telomeric O 0 0.013845517300069332
to O 0 7.11313696228899e-05
HLA O 1 0.9883434176445007
- O 0 0.003995369654148817
A O 0 0.0001870293781394139
. O 0 4.975314368493855e-05

Population O 0 5.615189365926199e-06
studies O 0 1.5468275478269788e-06
of O 0 1.5856748802889342e-07
this O 0 3.206934593436017e-07
polymorphism O 0 6.873286110931076e-06
are O 0 4.856621416138296e-08
facilitated O 0 3.295678425274673e-06
by O 0 2.3941308313624177e-07
the O 0 2.994758574459411e-07
fact O 0 4.661177968046104e-07
that O 0 1.9887981750343897e-07
the O 0 1.100703912015888e-06
Cys282Tyr O 0 0.0006718458025716245
mutation O 0 5.3524392569670454e-05
creates O 0 4.344961416791193e-05
a O 0 4.441157216206193e-05
Rsal O 0 0.00892452523112297
restriction O 0 0.00017627555644139647
site O 0 0.00021074677351862192
. O 0 6.776572990929708e-05

We O 0 3.4470062928448897e-06
have O 0 3.935796542009484e-07
studied O 0 2.1996538634994067e-06
the O 0 1.5461166640307056e-06
codon O 0 4.073743912158534e-05
282 O 0 0.0003679651999846101
( O 0 0.0001111192541429773
Cys O 1 0.8125455975532532
/ O 0 0.0077956803143024445
Tyr O 0 0.003891534870490432
) O 0 1.2332294545558398e-06
polymorphism O 0 2.670448566277628e-06
in O 0 1.4395772041098098e-07
different O 0 6.271462638096637e-08
ethnic O 0 1.4041056601854507e-06
groups O 0 3.4035640510410303e-06
. O 0 5.026168219046667e-05

In O 0 6.255482276174007e-06
agreement O 0 3.7198929021542426e-06
with O 0 6.261948328756262e-07
previous O 0 2.9151888156775385e-06
observations O 0 4.546235231828177e-06
the O 0 1.0332916644983925e-05
Tyr O 0 0.05313592031598091
allele O 0 4.6838973503327e-05
appeared O 0 1.2207732652314007e-05
to O 0 3.524232283780293e-07
be O 0 5.016811996938486e-07
rare O 0 5.832835449837148e-05
or O 0 8.709007488505449e-06
absent O 0 0.00023133236391004175
in O 0 5.301859800965758e-06
Asiatic O 0 0.00473847147077322
( O 0 1.2766552572429646e-05
Indian O 0 1.5042340237414464e-05
, O 0 1.3380603149926174e-06
Chinese O 0 3.957743047067197e-06
) O 0 5.775085810455494e-06
populations O 0 1.1215849553991575e-05
. O 0 2.6484176487429067e-05

The O 0 2.9597408683912363e-06
highest O 0 7.653782631678041e-06
allele O 0 4.228402303851908e-06
frequency O 0 7.769505714350089e-07
( O 0 5.308009463078633e-07
7 O 0 4.956908128406212e-07
. O 0 8.014227148578357e-08
5 O 0 3.650626752005337e-07
% O 0 2.985636058383534e-07
) O 0 4.866598715125292e-07
was O 0 2.251067826364306e-06
found O 0 1.7909213738676044e-06
in O 0 2.77175490737136e-06
Swedes O 0 0.00016060979396570474
. O 0 3.0865448934491724e-05

Saamis O 0 0.006469763815402985
( O 0 2.6136251108255237e-05
2 O 0 9.257431884179823e-06
% O 0 3.4295881050638855e-06
) O 0 1.3018964182265336e-06
and O 0 4.7084785137485596e-07
Mordvinians O 0 0.00011032191105186939
( O 0 6.762010116290185e-07
1 O 0 2.858537584415899e-07
. O 0 5.961645399565896e-08
8 O 0 5.609899176306499e-07
% O 0 3.53247258999545e-07
) O 0 4.2358306018286385e-07
had O 0 1.529871042293962e-06
significantly O 0 2.658444600456278e-06
lower O 0 1.2643444051718689e-06
frequencies O 0 8.95367335829178e-08
of O 0 2.2468866234248708e-07
the O 0 8.209151019400451e-06
Tyr O 0 0.04548441246151924
allele O 0 0.00025628117145970464
. O 0 7.29959283489734e-05

Comparisons O 0 1.0782643585116602e-05
with O 0 7.999945523806673e-07
allele O 0 5.768431037722621e-06
frequencies O 0 6.003936050547054e-07
based O 0 1.5058883491292363e-06
on O 0 9.650138053984847e-06
prevalence O 0 0.05830864608287811
estimates O 0 4.081584120285697e-05
of O 0 1.813158087315969e-05
HH B-Disease 1 0.9990656971931458
showed O 0 0.00014805811224505305
some O 0 4.290198205580964e-07
disagreements O 0 9.543917258270085e-06
with O 0 5.525180313270539e-07
the O 0 1.9986482584499754e-06
RFLP O 0 0.0003018199058715254
data O 0 1.6944223943937686e-06
, O 0 2.510339299988118e-06
particularly O 0 7.621420081704855e-06
in O 0 6.745284281350905e-06
Finns O 0 0.0006569742690771818
. O 0 8.218559378292412e-05

The O 0 7.441083289450034e-05
newly O 0 0.0004730739747174084
described O 0 0.0010942083317786455
HFE O 1 0.9185837507247925
marker O 0 7.409488898701966e-05
provides O 0 2.408535920039867e-06
a O 0 1.5140734603846795e-06
new O 0 6.39959807813284e-07
approach O 0 4.987702482139866e-07
to O 0 9.393056643602904e-08
the O 0 5.220655339144287e-07
screening O 0 1.6730498828110285e-05
of O 0 2.810633532135398e-06
HH B-Disease 1 0.9979988932609558
as O 0 1.1767332352974336e-06
well O 0 2.1037489261743758e-07
as O 0 9.207636963992627e-08
studies O 0 1.365708470757454e-07
of O 0 4.165743661133092e-08
the O 0 5.497449251379294e-07
relationship O 0 9.424158633919433e-06
between O 0 3.4158395010308595e-06
the O 0 5.06774231325835e-05
HFE O 1 0.9939270615577698
Tyr O 1 0.6630518436431885
allele O 0 0.00013383361510932446
and O 0 6.174124791868962e-06
different O 0 2.556987601565197e-05
disorders O 1 0.9997715353965759
including O 0 0.2108669877052307
cancer B-Disease 1 0.9995204210281372

Autosomal B-Disease 1 0.9933723211288452
dominant I-Disease 1 0.9906685948371887
neurohypophyseal I-Disease 1 0.998314380645752
diabetes I-Disease 1 0.9999357461929321
insipidus I-Disease 1 0.9986538887023926
associated O 0 0.00015177229943219572
with O 0 2.6803172659128904e-06
a O 0 1.9103468730463646e-05
missense O 0 0.0001925793767441064
mutation O 0 2.437699913571123e-05
encoding O 0 2.6497287763049826e-05
Gly23 O 0 0.29096952080726624
- O 0 0.07185941934585571
- O 0 0.002332703210413456
> O 0 0.0007805656641721725
Val O 0 0.0018245531246066093
in O 0 3.537000884534791e-05
neurophysin O 0 0.03799997270107269
II O 1 0.86196368932724
. O 0 0.0002117445837939158

Autosomal B-Disease 1 0.9905412793159485
dominant I-Disease 1 0.9809622168540955
neurohypophyseal I-Disease 1 0.9968495965003967
diabetes I-Disease 1 0.999891996383667
insipidus I-Disease 1 0.9985978007316589
( O 0 0.0027324033435434103
ADNDI B-Disease 1 0.9857856631278992
) O 0 7.234824443003163e-05
is O 0 0.0001240716956090182
an O 0 0.12408081442117691
inherited B-Disease 1 0.9999227523803711
disease I-Disease 1 0.9999797344207764
caused O 1 0.996870219707489
by O 0 0.0007813374395482242
progressive O 1 0.9893980026245117
degeneration O 1 0.9994097948074341
of O 0 2.589331643321202e-06
the O 0 2.332017720618751e-05
magnocellular O 0 0.04527532681822777
neurons O 0 7.221150008263066e-05
of O 0 4.757474698635633e-07
the O 0 4.3342852222849615e-06
hypothalamus O 0 0.0005911423941142857
leading O 0 2.0632825908251107e-05
to O 0 1.1815777725132648e-06
decreased O 0 6.481735908892006e-05
ability O 0 5.791554258394171e-07
to O 0 9.071320050679788e-08
produce O 0 9.100864986066881e-07
the O 0 1.9728406641661422e-06
hormone O 0 0.0005838247016072273
arginine O 0 0.0001776512508513406
vasopressin O 0 0.0010920733911916614
( O 0 5.6289056374225765e-05
AVP O 0 0.05582226440310478
) O 0 3.350585757289082e-05
. O 0 2.811815829772968e-05

Affected O 0 0.0007654870278201997
individuals O 0 7.39134657123941e-06
are O 0 1.5490743408008711e-06
not O 0 4.996213192498544e-06
symptomatic O 1 0.9127250909805298
at O 0 6.602261419175193e-05
birth O 0 0.0010052198776975274
, O 0 6.5121489569719415e-06
but O 0 5.144658189237816e-06
usually O 0 0.00011905444989679381
develop O 0 0.3280561864376068
diabetes B-Disease 1 0.9998226761817932
insipidus I-Disease 1 0.9972692131996155
at O 0 0.00012845927267335355
1 O 0 0.00010118733189301565
- O 0 0.000506524636875838
6 O 0 3.1387786293635145e-05
yr O 0 0.002971596084535122
of O 0 2.671768015716225e-06
age O 0 0.000498174864333123
. O 0 6.686434790026397e-05

The O 0 1.700109351077117e-05
genetic O 0 9.694886102806777e-05
locus O 0 5.094970401842147e-05
of O 0 4.8031038204499055e-06
the O 0 0.001060863141901791
disease O 1 0.9994742274284363
is O 0 6.5077474573627114e-06
the O 0 2.4011691493797116e-05
AVP O 1 0.9545310735702515
- O 0 0.009677954018115997
neurophysin O 0 0.01452979538589716
II O 0 0.10652004182338715
( O 0 1.3930716704635415e-05
NPII O 0 0.004190859850496054
) O 0 3.331027073727455e-06
gene O 0 1.2882543160230853e-05
, O 0 8.287159971587243e-07
and O 0 9.841320434134104e-07
mutations O 0 3.77149845007807e-05
that O 0 6.3606476032873616e-06
cause O 0 0.02993795834481716
ADNDI B-Disease 1 0.8387326598167419
have O 0 1.116527414524171e-06
been O 0 6.345582050926168e-07
found O 0 4.3653707848534395e-07
in O 0 4.497967154293292e-08
both O 0 3.1020483959309786e-08
the O 0 1.5220534521631635e-07
signal O 0 1.4072170415602159e-06
peptide O 0 3.7255695133353584e-06
of O 0 1.4732155761976173e-07
the O 0 7.067971637297887e-06
prepro O 0 0.03621881827712059
- O 0 0.0051978575065732
AVP O 0 0.1370677649974823
- O 0 0.0004951261216774583
NPII O 0 0.0020676867570728064
precursor O 0 2.8903719794470817e-05
and O 0 9.506695164418488e-07
within O 0 4.81814686281723e-06
NPII O 0 0.17005985975265503
itself O 0 0.00032780016772449017
. O 0 0.00010150091839022934

An O 0 0.00018012431974057108
affected O 0 0.0012811730848625302
girl O 0 0.0016856533475220203
who O 0 5.89293813391123e-06
presented O 0 4.87823854200542e-06
at O 0 4.002646164735779e-06
9 O 0 6.211052550497698e-06
months O 0 1.7975022501559579e-06
of O 0 1.3939839504928386e-07
age O 0 3.363212090334855e-05
and O 0 8.807630820228951e-07
her O 0 4.1992196202045307e-05
similarly O 0 0.0002662033657543361
affected O 0 0.00012721407983917743
younger O 0 0.0002207833167631179
brother O 0 0.000146489663165994
and O 0 1.3691020512851537e-06
father O 0 3.217502307961695e-05
were O 0 2.5624521526879107e-07
all O 0 6.707833932750873e-08
found O 0 6.360037900776661e-07
to O 0 9.955734014965856e-08
have O 0 7.152132752707985e-08
a O 0 1.1422596344345948e-06
novel O 0 1.6037609384511597e-05
missense O 0 0.00019453711865935475
mutation O 0 6.543885683640838e-05
( O 0 1.775090458977502e-05
G1758 O 0 0.004362454637885094
- O 0 0.008804486133158207
- O 0 0.0010041026398539543
> O 0 0.0003022250602953136
T O 0 0.00044311684905551374
) O 0 3.081332522469893e-08
encoding O 0 3.301074258388326e-08
the O 0 4.2270531963595204e-08
amino O 0 1.1805190069935634e-06
acid O 0 8.498136594425887e-05
substitution O 0 7.974658365128562e-05
Gly23 O 0 0.02719409577548504
- O 0 0.0072886766865849495
- O 0 0.0007243002764880657
> O 0 0.00033430822077207267
Val O 0 0.0005578250274993479
within O 0 9.19338344829157e-06
NPII O 0 0.02694460190832615
. O 0 6.279355875449255e-05

The O 0 5.019046875531785e-05
mutation O 0 0.00032767080119811
was O 0 6.12233197898604e-05
confirmed O 0 2.095549825753551e-05
by O 0 1.896654794109054e-06
restriction O 0 3.72844297089614e-05
endonuclease O 0 0.0016786546912044287
analysis O 0 3.901090531144291e-05
. O 0 5.887808947591111e-05

A O 0 0.0013976822374388576
T1 O 1 0.9200682044029236
- O 0 0.0001445656962459907
weighted O 0 3.212204092051252e-06
magnetic O 0 8.405980224779341e-06
resonance O 0 1.3889210094930604e-05
imaging O 0 3.075224594795145e-05
of O 0 1.076816033673822e-06
the O 0 2.4288608983624727e-05
fathers O 0 0.0006387319881469011
pituitary O 1 0.9806542992591858
gland O 1 0.5148881673812866
demonstrates O 0 0.0002649626403581351
an O 0 6.56344709568657e-05
attenuated O 0 0.2770257890224457
posterior O 1 0.7814597487449646
pituitary O 1 0.988461971282959
bright O 0 0.17562134563922882
spot O 0 0.0013293592492118478
. O 0 0.00020266072533559054

This O 0 3.753988130483776e-05
mutation O 0 0.0004057686892338097
may O 0 7.1868371378513984e-06
be O 0 1.0029818753309883e-07
valuable O 0 4.0865822370506066e-07
for O 0 2.6944027808895044e-07
developing O 0 6.033052159182262e-06
models O 0 7.44821682019392e-06
of O 0 7.4894069257425144e-06
dominantly B-Disease 1 0.9951176643371582
inherited I-Disease 1 0.9994334578514099
neurodegeneration I-Disease 1 0.9998646974563599
, O 0 1.2017621884297114e-05
as O 0 5.725914888898842e-07
the O 0 3.862801349896472e-07
early O 0 4.300178261473775e-06
age O 0 2.1559204469667748e-05
of O 0 3.717537992997677e-06
onset O 1 0.9993315935134888
of O 0 0.00044251675717532635
symptoms O 1 0.9997201561927795
suggests O 0 0.0005779746570624411
that O 0 3.308738087071106e-06
this O 0 4.239579084241996e-06
mutation O 0 0.00043839961290359497
may O 0 1.6720865460229106e-05
be O 0 2.9778422572235286e-07
particularly O 0 1.4800808685322409e-06
deleterious O 0 3.5334040148882195e-05
to O 0 6.141089556876977e-07
the O 0 8.623994290246628e-06
magnocellular O 1 0.6212378144264221
neuron O 1 0.5341814756393433
. O 0 3.0564078770112246e-05
. O 0 5.18552988069132e-05

Frequent O 0 0.001726039918139577
inactivation O 0 0.016401194036006927
of O 0 0.0001026559475576505
PTEN O 1 0.987519383430481
/ O 1 0.7119699120521545
MMAC1 O 1 0.8161590099334717
in O 0 0.0015970150707289577
primary O 1 0.9898736476898193
prostate B-Disease 1 0.9999682903289795
cancer I-Disease 1 0.9998675584793091
. O 0 0.0016277985414490104

Sporadic B-Disease 1 0.9892669916152954
prostate I-Disease 1 0.9999319314956665
carcinoma I-Disease 1 0.9999635219573975
is O 0 5.057280577602796e-05
the O 0 5.897238679608563e-06
most O 0 5.08443508806522e-06
common O 0 0.00030624278588220477
male B-Disease 0 0.04458843171596527
cancer I-Disease 1 0.9994286894798279
in O 0 1.9558424355636816e-06
the O 0 1.5168005802479456e-06
Western O 0 5.050086201663362e-06
world O 0 1.6013351569199585e-06
, O 0 2.2863741833134554e-07
yet O 0 1.4269433279423538e-07
many O 0 9.97378624134626e-09
of O 0 2.7910941113873378e-08
the O 0 6.730979862368258e-07
major O 0 5.8378855101182126e-06
genetic O 0 1.899825656437315e-05
events O 0 4.937460289511364e-07
involved O 0 8.074555353232427e-07
in O 0 4.055607973896258e-07
the O 0 1.6487967968714656e-06
progression O 0 0.0009503816836513579
of O 0 7.226095135592914e-07
this O 0 1.9531435100361705e-05
often O 0 0.008860945701599121
fatal O 1 0.9998453855514526
cancer B-Disease 1 0.999826967716217
remain O 0 3.254559123888612e-05
to O 0 3.722234851011308e-06
be O 0 6.9915054154989775e-06
elucidated O 0 0.0028568748384714127
. O 0 8.275970321847126e-05

Numerous O 0 0.00042895323713310063
cytogenetic O 0 0.02474525198340416
and O 0 5.397328641265631e-05
allelotype O 0 0.012716648168861866
studies O 0 2.191608837165404e-05
have O 0 2.8955746529391035e-06
reported O 0 8.730196714168414e-05
frequent O 0 4.5208384108264e-05
loss O 0 0.00027758890064433217
of O 0 2.790280177578097e-06
heterozygosity O 0 0.040137261152267456
on O 0 5.175827391212806e-05
chromosomal O 0 0.3276926279067993
arm O 1 0.7640124559402466
10q O 0 0.09554590284824371
in O 0 0.0011198896681889892
sporadic B-Disease 1 0.9966949224472046
prostate I-Disease 1 0.9999796152114868
cancer I-Disease 1 0.9998797178268433
. O 0 0.002901808125898242

Deletion O 0 0.0010568508878350258
mapping O 0 0.0001284126192331314
studies O 0 1.3802445209876169e-05
have O 0 1.802375436454895e-06
unambiguously O 0 5.996662002871744e-05
identified O 0 3.2299160466209287e-06
a O 0 2.1516764263651567e-06
region O 0 8.657232797304459e-07
of O 0 3.6426419569579593e-07
chromosome O 0 0.00011505246220622212
10q23 O 0 0.00013487310206983238
to O 0 1.6625941157144553e-07
be O 0 1.5206184400540224e-07
the O 0 5.357937880035024e-07
minimal O 0 2.2655405700788833e-05
area O 0 6.797462447138969e-06
of O 0 3.560185405149241e-06
loss O 0 0.015895362943410873
. O 0 0.00014924164861440659

A O 0 0.0005817844066768885
new O 0 0.0004081923107150942
tumor B-Disease 1 0.9902626276016235
suppressor O 0 0.008661782369017601
gene O 0 0.00025231228210031986
, O 0 5.947671888861805e-05
PTEN O 1 0.9793602228164673
/ O 0 0.04274646192789078
MMAC1 O 0 0.09911616891622543
, O 0 9.367832717543934e-06
was O 0 7.977260247571394e-05
isolated O 0 0.00013809044321533293
recently O 0 1.6004365534172393e-05
at O 0 7.544941809101147e-07
this O 0 1.5901694894182583e-07
region O 0 4.3210104649915593e-07
of O 0 1.460654317497756e-07
chromosome O 0 9.437031985726207e-05
10q23 O 0 0.0001872011780506
and O 0 2.8974454835406505e-07
found O 0 4.0102705156641605e-07
to O 0 5.5309275381887346e-08
be O 0 1.6664196778037876e-07
inactivated O 0 1.1474106031528208e-05
by O 0 3.430061497056158e-07
mutation O 0 3.754388671950437e-05
in O 0 1.5938672731863335e-05
three O 0 0.011702921241521835
prostate B-Disease 1 0.9999784231185913
cancer I-Disease 1 0.9999326467514038
cell O 1 0.8428724408149719
lines O 0 0.0029558066744357347
. O 0 0.0002096730750054121

We O 0 0.00014489525347016752
screened O 0 0.004850051831454039
80 O 0 0.10579192638397217
prostate B-Disease 1 0.9998447895050049
tumors I-Disease 1 0.9992142915725708
by O 0 7.2030102273856755e-06
microsatellite O 0 0.002589602954685688
analysis O 0 4.456836904864758e-06
and O 0 1.5515996665271814e-06
found O 0 9.143596798821818e-06
chromosome O 0 0.00011452989565441385
10q23 O 0 0.0001913349551614374
to O 0 4.940531539432413e-07
be O 0 4.732441425403522e-07
deleted O 0 1.9012340999324806e-05
in O 0 2.546843234085827e-06
23 O 0 5.272870112094097e-05
cases O 0 7.52019404899329e-05
. O 0 4.208568498142995e-05

We O 0 1.7254328668059316e-06
then O 0 5.699274652215536e-07
proceeded O 0 5.424274718279776e-07
with O 0 2.5906773615247403e-08
sequence O 0 8.724602906795553e-08
analysis O 0 7.988328576402637e-08
of O 0 6.109858929903567e-08
the O 0 2.8565202683239477e-06
entire O 0 0.0002680457546375692
PTEN O 1 0.9672319293022156
/ O 0 0.009875640273094177
MMAC1 O 0 0.007680020295083523
coding O 0 0.00015366374282166362
region O 0 3.0755131774640176e-06
and O 0 8.653122449686634e-07
tested O 0 8.66061236592941e-06
for O 0 3.2469006328028627e-07
homozygous O 0 2.4571769245085306e-05
deletion O 0 8.127086766762659e-05
with O 0 2.3464367586711887e-06
new O 0 1.0441207450639922e-05
intragenic O 0 0.007436586078256369
markers O 0 9.832697833189741e-05
in O 0 8.447983077530807e-07
these O 0 3.3847825875454873e-07
23 O 0 9.942203178070486e-06
cases O 0 9.74119575403165e-06
with O 0 4.410970177559648e-06
10q23 O 0 0.003814193420112133
loss O 0 0.0014183077728375793
of O 0 2.160112671845127e-05
heterozygosity O 0 0.4074004888534546
. O 0 0.0003496623830869794

The O 0 2.1504579308384564e-06
identification O 0 7.678066253902216e-07
of O 0 1.1463144744539022e-07
the O 0 6.753496677447401e-07
second O 0 4.095812073501293e-06
mutational O 0 0.0005319047486409545
event O 0 6.124676019680919e-06
in O 0 7.538124009442981e-07
10 O 0 1.0834519343916327e-06
( O 0 1.4372139958140906e-06
43 O 0 7.394921794912079e-06
% O 0 1.1261916370131075e-05
) O 0 8.359913772437721e-05
tumors B-Disease 1 0.9979299306869507
establishes O 0 0.01842307485640049
PTEN O 1 0.9919047355651855
/ O 0 0.025886602699756622
MMAC1 O 0 0.0027508693747222424
as O 0 8.566390761188813e-07
a O 0 1.9649921796371927e-06
main O 0 3.7777551824547118e-06
inactivation O 0 0.00017965589358936995
target O 0 8.033026119846909e-07
of O 0 5.910650884288771e-07
10q O 0 0.004445724189281464
loss O 0 0.028077414259314537
in O 0 0.0003871667431667447
sporadic B-Disease 1 0.9966877102851868
prostate I-Disease 1 0.9999877214431763
cancer I-Disease 1 0.9999449253082275
. O 0 0.00041865577804856
. O 0 0.00018118333537131548

Risk O 0 0.011609639041125774
reversals O 0 0.0009680488728918135
in O 0 1.4168158486427274e-05
predictive O 0 0.00045332356239669025
testing O 0 0.004302677698433399
for O 0 0.007690273690968752
Huntington B-Disease 1 0.9996672868728638
disease I-Disease 1 0.999806821346283
. O 0 0.003993632737547159

The O 0 3.4991053325938992e-06
first O 0 2.4373173346248223e-06
predictive O 0 4.5108215999789536e-05
testing O 0 0.0004369547532405704
for O 0 0.0007747269701212645
Huntington B-Disease 1 0.9998165965080261
disease I-Disease 1 0.9999382495880127
( O 0 0.0002631432143971324
HD B-Disease 0 0.005026531871408224
) O 0 1.6415232266808744e-06
was O 0 1.302336045228003e-06
based O 0 6.555809051178585e-08
on O 0 6.190729351374102e-08
analysis O 0 1.7666705787178216e-07
of O 0 2.023854364097133e-07
linked O 0 0.00010603005648590624
polymorphic O 0 7.990690937731415e-05
DNA O 0 3.815481250057928e-05
markers O 0 2.7197102099307813e-05
to O 0 2.7981735684079467e-07
estimate O 0 2.553662852733396e-06
the O 0 2.916641221872851e-07
likelihood O 0 3.3153899039461976e-06
of O 0 2.2993978632257495e-07
inheriting O 0 0.0005727349198423326
the O 0 4.286622242943849e-06
mutation O 0 4.988241198589094e-05
for O 0 4.278196684026625e-06
HD B-Disease 0 0.004912393167614937
. O 0 5.493566641234793e-05

Limits O 0 5.219980721449247e-06
to O 0 2.909629301939276e-07
accuracy O 0 7.758858373563271e-07
included O 0 3.3268511856476835e-07
recombination O 0 3.83276983484393e-06
between O 0 4.956747261530836e-07
the O 0 8.99475139704009e-07
DNA O 0 1.569321466377005e-05
markers O 0 1.4067263691686094e-05
and O 0 2.385176571806369e-07
the O 0 1.143512008638936e-06
mutation O 0 4.5942881115479395e-05
, O 0 2.9557297693827422e-06
pedigree O 0 0.00110111222602427
structure O 0 4.772627289639786e-05
, O 0 4.6335483716575254e-07
and O 0 9.723366645175702e-08
whether O 0 1.987944955317289e-07
DNA O 0 3.3835540307336487e-06
samples O 0 8.99578083135566e-07
were O 0 2.6431905553181423e-07
available O 0 6.505883902718779e-07
from O 0 1.718194539535034e-06
family O 0 3.090220707235858e-05
members O 0 6.7258088165544905e-06
. O 0 4.72698338853661e-05

With O 0 3.0173914637998678e-06
direct O 0 1.4420246543522808e-06
tests O 0 3.829236447927542e-06
for O 0 4.232724961639178e-07
the O 0 2.9260124847496627e-06
HD B-Disease 0 0.0023092126939445734
mutation O 0 2.444527854095213e-05
, O 0 4.3214473066655046e-07
we O 0 1.1334792304751318e-07
have O 0 4.613389137375634e-08
assessed O 0 8.959153774412698e-07
the O 0 7.922157863049506e-08
accuracy O 0 2.551369391312619e-07
of O 0 1.44221829145863e-07
results O 0 1.5252863931891625e-06
obtained O 0 1.0420727676319075e-06
by O 0 5.146166586200707e-07
linkage O 0 4.9619764467934147e-05
approaches O 0 4.681341579271248e-06
when O 0 3.4785566640493926e-06
requested O 0 2.48908463618136e-06
to O 0 1.3604163484615128e-07
do O 0 1.2799810633623565e-07
so O 0 8.847959520608129e-08
by O 0 1.3198288684179715e-07
the O 0 8.903705293050734e-07
test O 0 9.595682058716193e-06
individuals O 0 3.752401880774414e-06
. O 0 3.051776729989797e-05

For O 0 2.9189945962571073e-06
six O 0 3.162023404001957e-06
such O 0 6.370211735884368e-07
individuals O 0 7.124669991753763e-07
, O 0 8.532506399205886e-07
there O 0 8.186629543160961e-07
was O 0 1.0215302609140053e-05
significant O 0 2.8807671696995385e-06
disparity O 0 0.00033997150603681803
between O 0 1.1456787660790724e-06
the O 0 7.499205366912065e-06
tests O 0 8.612105011707172e-05
. O 0 2.7013107683160342e-05

Three O 0 4.573683781927684e-06
went O 0 1.518617500551045e-05
from O 0 3.7819763747393154e-06
a O 0 4.034322773804888e-05
decreased O 0 0.0046242233365774155
risk O 0 0.0001824570499593392
to O 0 4.2603531369422853e-07
an O 0 2.906766212618095e-06
increased O 0 6.670640868833289e-05
risk O 0 0.000248435593675822
, O 0 2.694171712391835e-07
while O 0 2.6476106995687587e-07
in O 0 1.0089279811609231e-07
another O 0 6.164424917187716e-07
three O 0 4.796763732883846e-07
the O 0 1.3452688108372968e-05
risk O 0 0.0037953986320644617
was O 0 0.00023880817752797157
decreased O 0 0.003065092023462057
. O 0 4.7956807975424454e-05

Knowledge O 0 4.9231989578402136e-06
of O 0 5.06668186517345e-07
the O 0 2.7362721084500663e-06
potential O 0 5.310866981744766e-06
reasons O 0 1.129843894887017e-06
for O 0 7.750192310140847e-08
these O 0 4.714521750770473e-08
changes O 0 7.788497669025674e-07
in O 0 4.325966642682033e-07
results O 0 2.1629282400681404e-06
and O 0 3.842497733330674e-07
impact O 0 3.5585660498327343e-06
of O 0 1.986421125366178e-07
these O 0 1.8097351812684792e-06
risk O 0 0.0016074368031695485
reversals O 0 0.0006023908499628305
on O 0 5.784356744698016e-06
both O 0 1.1359654308762401e-05
patients O 0 0.1533852219581604
and O 0 6.623428134844289e-07
the O 0 2.156232540073688e-06
counseling O 0 6.803301221225411e-05
team O 0 1.1150642649226938e-06
can O 0 8.856723354710994e-08
assist O 0 1.9509526794081467e-07
in O 0 6.8304345290926e-08
the O 0 1.111763552330558e-07
development O 0 3.035233930859249e-07
of O 0 6.937813168406137e-08
strategies O 0 3.8546722862520255e-06
for O 0 7.269655384334328e-07
the O 0 6.266527634579688e-06
prevention O 0 0.015320951119065285
and O 0 5.768050641563605e-07
, O 0 3.449409007316717e-07
where O 0 2.6206058123534604e-07
necessary O 0 5.17239129749214e-07
, O 0 5.719857085750846e-07
management O 0 5.797262929263525e-06
of O 0 2.6888838533523085e-07
a O 0 4.131426976528019e-05
risk O 0 0.0009560224716551602
reversal O 0 0.00015961805183906108
in O 0 6.637567366851727e-07
any O 0 6.772548886146978e-07
predictive O 0 1.9300172425573692e-05
testing O 0 5.3619722166331485e-05
program O 0 2.6465670089237392e-05
. O 0 4.557200099952752e-06
. O 0 2.3006332412478514e-05

A O 0 9.998082532547414e-05
novel O 0 5.0553229812067e-05
common O 0 3.398966509848833e-05
missense O 0 0.00057413981994614
mutation O 0 0.00013057231262791902
G301C O 0 0.0002255812578368932
in O 0 1.9562173747544875e-06
the O 0 3.7208685625955695e-06
N O 0 0.0004976670606993139
- O 0 0.0006316027138382196
acetylgalactosamine O 0 0.001862799865193665
- O 0 0.0002641000901348889
6 O 0 3.811706119449809e-05
- O 0 0.0003541858750395477
sulfate O 0 0.0038219664711505175
sulfatase O 0 0.031107522547245026
gene O 0 7.952529995236546e-05
in O 0 3.427790215937421e-05
mucopolysaccharidosis B-Disease 0 0.4311516284942627
IVA I-Disease 1 0.9821747541427612
. O 0 0.00046214228495955467

Mucopolysaccharidosis B-Disease 1 0.7582325339317322
IVA I-Disease 1 0.9833812713623047
( O 0 0.0008500584517605603
MPS B-Disease 0 0.35210010409355164
IVA I-Disease 1 0.9972048401832581
) O 0 2.0373283405206166e-05
is O 0 8.005403287825175e-06
an O 0 0.00011478047963464633
autosomal B-Disease 1 0.9970598816871643
recessive I-Disease 1 0.9985455274581909
lysosomal I-Disease 1 0.9995720982551575
storage I-Disease 1 0.9995635151863098
disorder I-Disease 1 0.9999418258666992
caused O 1 0.9965115189552307
by O 0 0.00011679175804601982
a O 0 0.0032052656169980764
genetic B-Disease 1 0.979516327381134
defect I-Disease 1 0.9977648258209229
in O 0 6.51840673526749e-05
N O 0 0.0034144334495067596
- O 0 0.0020682085305452347
acetylgalactosamine O 0 0.0030018531251698732
- O 0 0.0005020815879106522
6 O 0 6.807740282965824e-05
- O 0 0.001573751913383603
sulfate O 0 0.06535246968269348
sulfatase O 1 0.5088778138160706
( O 0 0.00012469675857573748
GALNS O 0 0.0681634396314621
) O 0 3.937610381399281e-05
. O 0 5.6691897043492645e-05

In O 0 1.6830130334710702e-05
previous O 0 2.1439713236759417e-05
studies O 0 1.1326854291837662e-05
, O 0 1.5852816659389646e-06
we O 0 1.5422833143929893e-07
have O 0 7.134556767596223e-08
found O 0 2.6200413572041725e-07
two O 0 8.78305712603833e-08
common O 0 7.045063284749631e-06
mutations O 0 4.341250314610079e-05
in O 0 3.2650423236191273e-06
Caucasians O 0 0.0014267326332628727
and O 0 4.632736363419099e-06
Japanese O 0 0.00016870292893145233
, O 0 1.060633803717792e-05
respectively O 0 8.222352334996685e-05
. O 0 6.527693767566234e-05

To O 0 1.0045735507446807e-05
characterize O 0 0.00031234920606948435
the O 0 1.392220383422682e-05
mutational O 0 0.0012279920047149062
spectrum O 0 1.2997752492083237e-05
in O 0 3.8190802342796815e-07
various O 0 8.906323500923463e-08
ethnic O 0 4.904506454295188e-07
groups O 0 3.482389558939758e-07
, O 0 6.51895163628069e-07
mutations O 0 6.379857040883508e-06
in O 0 6.355720643114182e-07
the O 0 5.253260496829171e-06
GALNS O 0 0.006199916824698448
gene O 0 4.6732875489396974e-05
in O 0 1.1184670256625395e-05
Colombian O 0 0.0008461059769615531
MPS B-Disease 1 0.9821021556854248
IVA I-Disease 1 0.9995463490486145
patients O 1 0.988098680973053
were O 0 1.0159440535062458e-05
investigated O 0 0.00019814397091977298
, O 0 2.341532308491878e-06
and O 0 8.730484637453628e-07
genetic O 0 0.00011380646901670843
backgrounds O 0 5.948225862084655e-06
were O 0 1.2131966968809138e-06
extensively O 0 1.5103416444617324e-05
analyzed O 0 3.4309587135794573e-06
to O 0 2.47909156314563e-07
identify O 0 1.785031827239436e-06
racial O 0 4.416627689352026e-06
origin O 0 6.494731792372477e-07
, O 0 4.7558867777297564e-07
based O 0 2.9755315722468367e-07
on O 0 6.345933343254728e-07
mitochondrial O 0 2.106987994920928e-05
DNA O 0 2.8472341000451706e-05
( O 0 6.386565473803785e-06
mtDNA O 0 2.087949906126596e-05
) O 0 5.29969611307024e-06
lineages O 0 5.365737160900608e-05
. O 0 2.9276057830429636e-05

Three O 0 1.2914033504785039e-05
novel O 0 0.0001579002127982676
missense O 0 0.00407882547006011
mutations O 0 0.0005916347727179527
never O 0 8.400517253903672e-05
identified O 0 2.022924309130758e-05
previously O 0 5.012999281461816e-06
in O 0 4.0515334376323153e-07
other O 0 1.0166723285465196e-07
populations O 0 5.069417738923221e-07
and O 0 1.1823798473642455e-07
found O 0 6.339448646031087e-07
in O 0 1.1465102289776041e-07
16 O 0 5.245173611001519e-07
out O 0 4.20802059863945e-08
of O 0 1.4415252280741697e-07
19 O 0 1.0445668522152118e-05
Colombian O 0 4.1985505959019065e-05
MPS B-Disease 0 0.004150268156081438
IVA I-Disease 1 0.9792450666427612
unrelated O 0 0.00015491084195673466
alleles O 0 1.7161317373393103e-05
account O 0 3.2044506497186376e-06
for O 0 4.624309895007173e-06
84 O 0 0.0008854385814629495
. O 0 5.7443550758762285e-05

2 O 0 7.23512584954733e-06
% O 0 6.681860327262257e-07
of O 0 9.443336779213496e-08
the O 0 4.372437274469121e-07
alleles O 0 5.34906121174572e-06
in O 0 8.011046475076e-07
this O 0 1.0647640920069534e-06
study O 0 2.46854451688705e-05
. O 0 4.792659092345275e-05

The O 0 3.343583011883311e-05
G301C O 0 0.0005103724543005228
and O 0 3.6364569950819714e-06
S162F O 0 0.00025798522983677685
mutations O 0 2.8250882678548805e-05
account O 0 2.5060144253075123e-06
for O 0 2.460778205204406e-06
68 O 0 0.00028121002833358943
. O 0 5.970829806756228e-05

4 O 0 4.452967914403416e-05
% O 0 8.26248106022831e-06
and O 0 4.122141035622917e-06
10 O 0 2.560887332947459e-05
. O 0 3.133777136099525e-05

5 O 0 1.4977651517256163e-05
% O 0 2.5065019144676626e-06
of O 0 6.560950396305998e-07
mutations O 0 3.451064549153671e-05
, O 0 1.0205186526945909e-06
respectively O 0 2.0484544620558154e-06
, O 0 1.6866741248122707e-07
whereas O 0 5.535686113944394e-07
the O 0 2.391209932284255e-07
remaining O 0 7.88981026289548e-07
F69V O 0 0.003462092252448201
is O 0 4.859160185333167e-07
limited O 0 2.950830548797967e-07
to O 0 3.242434942762884e-08
a O 0 9.013315889205842e-07
single O 0 3.4331353617744753e-06
allele O 0 8.067653106991202e-05
. O 0 2.385818697803188e-05

The O 0 2.960555866593495e-05
skewed O 0 0.0003333130734972656
prevalence O 0 0.0030415288638323545
of O 0 2.0761597170348978e-06
G301C O 0 0.0006236138287931681
in O 0 2.508774059606367e-06
only O 0 2.1008509065723047e-06
Colombian O 0 0.00016393874830100685
patients O 0 0.0021014383528381586
and O 0 1.0717927807490923e-06
haplotype O 0 0.00015688090934418142
analysis O 0 9.684051747171907e-07
by O 0 5.94457958413841e-07
restriction O 0 5.9389076341176406e-06
fragment O 0 1.0294264939147979e-05
length O 0 8.745211744098924e-06
polymorphisms O 0 1.534822331450414e-05
in O 0 5.231525506133039e-07
the O 0 2.19748812924081e-06
GALNS O 0 0.008978297002613544
gene O 0 2.5035420549102128e-05
suggest O 0 7.743107744317967e-06
that O 0 1.6096856825242867e-06
G301C O 0 0.00020369637059047818
originated O 0 1.6897194655030034e-05
from O 0 2.537334921726142e-06
a O 0 2.030427276622504e-05
common O 0 3.481343446765095e-05
ancestor O 0 0.0002481427800375968
. O 0 0.00010298655979568139

Investigation O 0 3.091090184170753e-05
of O 0 6.710495199513389e-07
the O 0 3.8663797568005975e-06
genetic O 0 2.5535809982102364e-05
background O 0 3.076627990594716e-06
by O 0 2.403340602086246e-07
means O 0 2.1654304305229743e-07
of O 0 1.1839854607842426e-07
mtDNA O 0 1.0502514669497032e-05
lineages O 0 1.3002414561924525e-05
indicate O 0 6.1238174566824455e-06
that O 0 3.343597541061172e-07
all O 0 2.0654803734032612e-07
our O 0 3.404369181225775e-06
patients O 0 0.006491442210972309
are O 0 1.0330333566344052e-07
probably O 0 2.545136339904275e-06
of O 0 2.541943899814214e-07
native O 0 1.1195790648343973e-05
American O 0 6.808720354456455e-05
descent O 0 0.0017262027831748128

Low O 0 7.006405940046534e-05
frequency O 0 6.048687737347791e-06
of O 0 7.349398401856888e-06
BRCA1 O 0 0.014337994158267975
germline O 0 0.0028200021479278803
mutations O 0 0.0001253652444574982
in O 0 1.8781151084112935e-05
45 O 0 0.0020467813592404127
German O 1 0.9955487251281738
breast B-Disease 1 0.9998815059661865
/ I-Disease 1 0.9996699094772339
ovarian I-Disease 1 0.9999830722808838
cancer I-Disease 1 0.9999080896377563
families O 0 0.0031375447288155556
. O 0 0.0006732296897098422

In O 0 5.2636114560300484e-06
this O 0 1.5664347756683128e-06
study O 0 7.260174697876209e-06
we O 0 1.3030963827986852e-06
investigated O 0 0.00022952992003411055
45 O 0 0.0005067235906608403
German O 1 0.9845716953277588
breast B-Disease 1 0.9997987151145935
/ I-Disease 1 0.9995641112327576
ovarian I-Disease 1 0.9999806880950928
cancer I-Disease 1 0.9998444318771362
families O 0 3.4113742003683e-05
for O 0 1.3338940334506333e-05
germline O 0 0.028682822361588478
mutations O 0 8.401558443438262e-05
in O 0 5.152597623236943e-06
the O 0 4.2363564716652036e-05
BRCA1 O 0 0.13422147929668427
gene O 0 0.00045752761070616543
. O 0 0.00012008138583041728

We O 0 8.327148862008471e-06
identified O 0 8.19915203464916e-06
four O 0 6.0977149587415624e-06
germline O 0 0.0017632516101002693
mutations O 0 8.215574780479074e-05
in O 0 1.8296143025509082e-05
three O 0 0.0012115210993215442
breast B-Disease 1 0.9998764991760254
cancer I-Disease 1 0.9997105002403259
families O 0 2.5545894459355623e-05
and O 0 3.1737845347379334e-06
in O 0 6.510362436529249e-05
one O 0 0.043559737503528595
breast B-Disease 1 0.9999154806137085
- I-Disease 1 0.9998366832733154
ovarian I-Disease 1 0.9999890327453613
cancer I-Disease 1 0.9999663829803467
family O 0 0.0008295733714476228
. O 0 1.610519461792137e-06
among O 0 1.6494765020524937e-07
these O 0 6.219691073283684e-08
were O 0 2.691711245006445e-07
one O 0 1.5429275208589388e-06
frameshift O 0 0.002523509319871664
mutation O 0 1.5530829841736704e-05
, O 0 3.572762636849802e-07
one O 0 4.895412644145836e-07
nonsense O 0 5.6945744290715083e-05
mutation O 0 5.807555226056138e-06
, O 0 1.392329807003989e-07
one O 0 1.4079471100103547e-07
novel O 0 3.08783887703612e-06
splice O 0 5.408014476415701e-05
site O 0 1.1326746061968151e-05
mutation O 0 9.863138984655961e-06
, O 0 4.6146260501700453e-07
and O 0 4.3081561784674705e-07
one O 0 2.9317830012587365e-06
missense O 0 0.0007145061972551048
mutation O 0 0.0005138526321388781
. O 0 6.222933734534308e-05

The O 0 5.2837222028756514e-05
missense O 0 0.0019640333484858274
mutation O 0 0.0005597075214609504
was O 0 5.809099457110278e-05
also O 0 2.766249053820502e-06
found O 0 7.319601536437403e-06
in O 0 4.447597348189447e-06
2 O 0 4.279698623577133e-05
. O 0 4.675543095800094e-05

8 O 0 1.5150155377341434e-05
% O 0 1.212403162753617e-06
of O 0 2.037919415442957e-07
the O 0 1.0506955732125789e-06
general O 0 4.168719442532165e-06
population O 0 1.0924683238044963e-06
, O 0 7.356337050623551e-07
suggesting O 0 9.633807167119812e-06
that O 0 4.861616957896331e-07
it O 0 1.2664996802413953e-06
is O 0 1.204498767037876e-05
not O 0 7.93561339378357e-05
disease O 1 0.9989746809005737
associated O 0 0.0014259135350584984
. O 0 0.00017019876395352185

The O 0 2.2242700651986524e-05
average O 0 0.0002873848716262728
age O 0 0.001297195442020893
of O 0 0.000480093527585268
disease O 1 0.9999264478683472
onset O 1 0.9995595812797546
in O 0 5.603765384876169e-05
those O 0 7.969220860104542e-06
families O 0 8.05072340881452e-05
harbouring O 1 0.8165770769119263
causative O 0 0.015747763216495514
mutations O 0 0.00026622749282978475
was O 0 3.7800178688485175e-05
between O 0 1.2501587661972735e-05
32 O 0 0.00012429444177541882
. O 0 6.457182462327182e-05

3 O 0 0.00013968547864351422
and O 0 1.6811844034236856e-05
37 O 0 0.00021147906954865903
. O 0 8.952681673690677e-05

4 O 0 7.309037755476311e-05
years O 0 2.036823207163252e-05
, O 0 1.1833832331831218e-06
whereas O 0 3.00945407616382e-06
the O 0 1.3953407460576273e-06
family O 0 1.9271663404651918e-05
harbouring O 0 0.0018633753061294556
the O 0 3.7893807984801242e-06
missense O 0 0.00021412892965599895
mutation O 0 3.1867642974248156e-05
had O 0 2.9445770906022517e-06
an O 0 5.539763492379279e-07
average O 0 8.756895113037899e-06
age O 0 6.921449767105514e-06
of O 0 7.78370065290801e-07
onset O 1 0.9850637912750244
of O 0 8.543085641576909e-06
51 O 0 0.0006938111037015915
. O 0 9.021729783853516e-05

2 O 0 0.00042462479905225337
years O 0 0.0002556791005190462
. O 0 0.00014327175449579954

These O 0 3.9434339669242036e-06
findings O 0 2.8777532861568034e-05
show O 0 7.656132765987422e-06
that O 0 2.100732672261074e-06
BRCA1 O 0 0.0019095595926046371
is O 0 2.6893249014392495e-06
implicated O 0 8.643425098853186e-05
in O 0 4.779138293997676e-07
a O 0 2.0596633021341404e-06
small O 0 3.2421062314824667e-06
fraction O 0 3.0171038815751672e-05
of O 0 0.0006251336890272796
breast B-Disease 1 0.9999195337295532
/ I-Disease 1 0.9998520612716675
ovarian I-Disease 1 0.9999889135360718
cancer I-Disease 1 0.9999382495880127
families O 0 7.963654206832871e-05
suggesting O 0 9.666434925748035e-05
the O 0 1.0075191312353127e-06
involvement O 0 7.845954314689152e-06
of O 0 4.816640171156905e-07
another O 0 2.3600417989655398e-05
susceptibility O 0 0.002139152493327856
gene O 0 0.00015292108582798392
( O 0 0.00012008402700303122
s O 0 0.005687136668711901
) O 0 9.048680658452213e-05

Paternal O 0 0.09814872592687607
transmission O 1 0.824521541595459
of O 0 0.08566141873598099
congenital B-Disease 1 0.9999617338180542
myotonic I-Disease 1 0.9999047517776489
dystrophy I-Disease 1 0.9998965263366699
. O 0 0.22969408333301544

We O 0 3.034011388081126e-05
report O 0 5.587373016169295e-05
a O 0 2.519873305573128e-05
rare O 0 0.00029178342083469033
case O 0 0.00011513520439621061
of O 0 5.442346082418226e-05
paternally O 1 0.9931812882423401
transmitted O 1 0.9978328347206116
congenital B-Disease 1 0.999966025352478
myotonic I-Disease 1 0.9999439716339111
dystrophy I-Disease 1 0.9999666213989258
( O 1 0.9915760159492493
DM B-Disease 1 0.9996387958526611
) O 0 0.0009605985251255333
. O 0 0.0002518304099794477

The O 0 3.643229865701869e-05
proband O 0 0.001266268896870315
is O 0 4.871437340625562e-06
a O 0 1.2331599464232568e-05
23 O 0 3.7208028516033664e-05
year O 0 5.0603823183337227e-05
old O 0 0.0066746193915605545
, O 0 0.0003952193364966661
mentally B-Disease 1 0.9987789988517761
retarded I-Disease 1 0.9978650212287903
male O 0 0.49406903982162476
who O 1 0.9551858305931091
suffers O 1 0.9998688697814941
severe O 1 0.9998606443405151
muscular B-Disease 1 0.9998430013656616
weakness I-Disease 1 0.9987020492553711
. O 0 0.005499010905623436

He O 0 0.00028943471261300147
presented O 0 0.0011350688291713595
with O 0 0.005395286250859499
respiratory O 1 0.9998472929000854
and O 0 0.0001250313362106681
feeding O 0 0.010962596163153648
difficulties O 0 0.01760684885084629
at O 0 0.000702064426150173
birth O 0 0.01901051215827465
. O 0 0.00019950185378547758

His O 0 0.0004265763272996992
two O 0 0.0002351143048144877
sibs O 1 0.9909870028495789
suffer O 1 0.9934642910957336
from O 0 0.004385038278996944
childhood O 1 0.9958683252334595
onset O 1 0.9995348453521729
DM B-Disease 1 0.999423623085022
. O 0 0.003213847754523158

Their O 0 7.701702998019755e-06
late O 0 0.00013289751950651407
father O 0 7.252163049997762e-05
had O 0 2.7137539291288704e-06
the O 0 1.020469994728046e-06
adult O 0 1.654422885621898e-05
type O 0 0.00018775963690131903
of O 0 1.0510661923035514e-05
DM B-Disease 1 0.9997389912605286
, O 0 5.179151685297256e-06
with O 0 5.772652002633549e-06
onset O 1 0.9958481788635254
around O 0 8.648850780446082e-06
30 O 0 1.7535237930133007e-05
years O 0 3.9920218114275485e-05
. O 0 3.4762077120831236e-05

Only O 0 2.7156129362992942e-06
six O 0 1.8290642174179084e-06
other O 0 2.566627017586143e-07
cases O 0 2.3370437247649534e-06
of O 0 9.949646937457146e-07
paternal O 0 0.003995578736066818
transmission O 0 0.14171727001667023
of O 0 0.006390836555510759
congenital B-Disease 1 0.9999873638153076
DM I-Disease 1 0.9999293088912964
have O 0 0.000268731004325673
been O 0 0.00019285868620499969
reported O 0 0.0015345782740041614
recently O 0 0.0010215226793661714
. O 0 8.391837036469951e-05

We O 0 7.399478818115313e-06
review O 0 9.932469765772112e-06
the O 0 3.554567229002714e-06
sex O 0 3.7078134482726455e-05
related O 0 5.2653776947408915e-05
effects O 0 0.0005653187399730086
on O 0 3.709157317643985e-05
transmission O 0 0.16544519364833832
of O 0 0.00440624775364995
congenital B-Disease 1 0.9999533891677856
DM I-Disease 1 0.9996258020401001
. O 0 0.005680002737790346

Decreased O 0 0.010434248484671116
fertility O 0 0.00148995581548661
of O 0 1.5209360526569071e-06
males O 0 2.1432844732771628e-05
with O 0 1.798609082470648e-05
adult O 0 0.047290537506341934
onset O 1 0.9996931552886963
DM B-Disease 1 0.9998037219047546
and O 0 8.669048838783056e-06
contraction O 0 0.0003500943130347878
of O 0 3.3429756740588346e-07
the O 0 2.1086289052618667e-06
repeat O 0 6.578065949724987e-05
upon O 0 2.9249467843328603e-06
male O 0 1.903107659018133e-05
transmission O 0 0.00010773503890959546
contribute O 0 1.1452483477114583e-06
to O 0 5.6871346743037066e-08
the O 0 2.673123731256055e-07
almost O 0 1.10305450107262e-06
absent O 0 2.5971889044740237e-05
occurrence O 0 1.2290013728488702e-05
of O 0 1.8028621298071812e-06
paternal O 0 0.007177357561886311
transmission O 0 0.09844889491796494
of O 0 0.002939168829470873
congenital B-Disease 1 0.9999655485153198
DM I-Disease 1 0.9998173117637634
. O 0 0.00819668173789978

Also O 0 6.2833373704052065e-06
the O 0 1.4258472447181703e-06
fathers O 0 3.146033577650087e-06
of O 0 1.073299472409417e-06
the O 0 4.8926140152616426e-05
reported O 0 0.018850522115826607
congenitally O 1 0.9915879368782043
affected O 0 0.0007108488352969289
children O 0 4.662955325329676e-05
showed O 0 3.563000791473314e-05
, O 0 3.5471137493914284e-07
on O 0 4.907191737402172e-07
average O 0 7.753371392027475e-06
, O 0 1.9069384507020004e-06
shorter O 0 7.330998050747439e-05
CTG O 0 0.008230732753872871
repeat O 0 0.00040489662205800414
lengths O 0 0.00025257995002903044
and O 0 4.754099791171029e-06
hence O 0 0.00020188307098578662
less O 0 0.004987127147614956
severe O 1 0.9997028708457947
clinical O 1 0.9990239143371582
symptoms O 1 0.9995244741439819
than O 0 7.637492672074586e-06
the O 0 1.791316935850773e-05
mothers O 0 0.0003663549432530999
of O 0 4.859688033320708e-06
children O 0 0.005557435564696789
with O 1 0.7380101084709167
congenital B-Disease 1 0.9999750852584839
DM I-Disease 1 0.9998446702957153
. O 0 0.0052338563837111

We O 0 1.1858623111038469e-05
conclude O 0 4.941161387250759e-05
that O 0 3.938870577258058e-06
paternal O 0 0.0006737540243193507
transmission O 0 0.008245576173067093
of O 0 0.0016847027000039816
congenital B-Disease 1 0.9999833106994629
DM I-Disease 1 0.9999383687973022
is O 0 0.00021955318516120315
rare O 0 0.0004281041619833559
and O 0 1.5798167396496865e-06
preferentially O 0 1.7471538740210235e-05
occurs O 0 1.741013147693593e-05
with O 0 1.134601279773051e-05
onset O 1 0.996815025806427
of O 0 5.660092938342132e-05
DM B-Disease 1 0.9994897842407227
past O 0 1.2073680409230292e-05
30 O 0 1.0108035894518252e-05
years O 0 6.249447778827744e-06
in O 0 1.1031703479602584e-06
the O 0 2.6241675641358597e-06
father O 0 0.00013328903878573328
. O 0 1.2521108146756887e-05
. O 0 3.374913285369985e-05

The O 0 0.00011987098696408793
RB1 O 1 0.9142593145370483
gene O 0 0.00012335163773968816
mutation O 0 6.957807636354119e-05
in O 0 3.274915798101574e-06
a O 0 4.897495819022879e-05
child O 0 0.003492021933197975
with O 0 0.0009281500824727118
ectopic B-Disease 1 0.9953860640525818
intracranial I-Disease 1 0.9989328980445862
retinoblastoma I-Disease 1 0.9952072501182556
. O 0 0.0020544494036585093

The O 0 0.00023425661493092775
RB1 O 1 0.9573571085929871
gene O 0 0.0003173371951561421
mutation O 0 0.0002187726931879297
was O 0 5.907954982831143e-05
investigated O 0 4.802664625458419e-05
in O 0 1.9173235159541946e-06
a O 0 1.3369033695198596e-05
child O 0 0.0007026024395599961
with O 0 0.00017132959328591824
ectopic B-Disease 1 0.9947221279144287
intracranial I-Disease 1 0.9992280006408691
retinoblastoma I-Disease 1 0.5627294182777405
using O 0 2.867528110073181e-06
DNA O 0 1.4657583960797638e-05
obtained O 0 2.47122216023854e-06
from O 0 1.671825316407194e-06
both O 0 5.728678615923855e-07
the O 0 1.316097768722102e-05
pineal B-Disease 0 0.1617376059293747
and I-Disease 0 0.0002323359076399356
retinal I-Disease 1 0.9989129304885864
tumours I-Disease 1 0.9991683959960938
of O 0 1.1193527825525962e-05
the O 0 0.0007140140514820814
patient O 1 0.9672468900680542
. O 0 0.0003068495134357363

A O 0 0.00016999620129354298
nonsense O 0 0.00031194029725156724
mutation O 0 2.7511910957400687e-05
in O 0 1.5139087281568209e-06
exon O 0 6.788563769077882e-05
17 O 0 5.509056336450158e-06
( O 0 9.2651532668242e-07
codon O 0 2.8649476462305756e-06
556 O 0 1.2031749974994455e-05
) O 0 1.1844824854279068e-07
of O 0 9.704875481020281e-08
the O 0 4.8748947847343516e-06
RB1 O 1 0.9869023561477661
gene O 0 3.062575706280768e-05
was O 0 5.987182248645695e-06
found O 0 7.010888793956838e-07
to O 0 6.395656271251937e-08
be O 0 6.512314598694502e-08
present O 0 5.135655101184966e-07
homozygously O 0 0.00015177794557530433
in O 0 2.4897514094845974e-07
both O 0 3.42866826485988e-07
the O 0 1.4262729564507026e-05
retinal B-Disease 1 0.974722146987915
and I-Disease 0 1.558855001349002e-05
the I-Disease 0 0.0003796590317506343
pineal I-Disease 1 0.9898753762245178
tumours I-Disease 1 0.9985677003860474
. O 0 0.0006509654340334237

The O 0 6.7703158492804505e-06
same O 0 5.8817199715122115e-06
mutation O 0 6.0964248405070975e-05
was O 0 9.936221431416925e-06
present O 0 3.7166234960750444e-06
heterozygously O 0 0.00027981773018836975
in O 0 2.7088802312391635e-07
the O 0 3.7707798128394643e-07
DNA O 0 2.162169266739511e-06
from O 0 1.4178765184169606e-07
the O 0 1.8689124203774554e-07
constitutional O 0 1.9052968127653003e-06
cells O 0 5.481761945702601e-06
of O 0 2.8640496907428314e-07
the O 0 2.200272137997672e-05
patient O 0 0.1384565234184265
, O 0 3.649290192697663e-06
proving O 0 5.0526818085927516e-05
it O 0 1.3767729001301632e-07
to O 0 6.174032307626476e-08
be O 0 7.376394250968588e-08
of O 0 5.095465098747809e-07
germline O 0 0.0016554363537579775
origin O 0 1.4383409506990574e-05
. O 0 6.732245674356818e-05

The O 0 1.9497952962410636e-05
initial O 0 0.0001183210697490722
mutation O 0 0.00018106347124557942
was O 0 3.0514098398271017e-05
shown O 0 1.5105816828508978e-06
to O 0 2.3048954744808725e-07
have O 0 2.1033477537457657e-07
occurred O 0 4.145234470342984e-06
in O 0 4.269716669114132e-07
the O 0 2.7168277938471874e-06
paternally O 0 0.002699138130992651
derived O 0 0.00028764308081008494
RB1 O 1 0.9778642058372498
allele O 0 0.001275311573408544
. O 0 0.00011803315283032134

The O 0 1.7578051483724266e-05
mutation O 0 5.5014825193211436e-05
is O 0 5.431200520433777e-07
in O 0 1.7769067994777288e-07
an O 0 1.4596669473121437e-07
area O 0 1.7594456380720658e-07
of O 0 2.0370832132243777e-08
the O 0 2.414445532394893e-07
gene O 0 1.2667449027503608e-06
that O 0 4.199032943574821e-08
encodes O 0 5.682460937350697e-07
the O 0 2.1377587700044387e-07
protein O 0 6.056318397895666e-06
- O 0 2.511840284569189e-05
binding O 0 1.105651790567208e-06
region O 0 2.7476185096020345e-06
known O 0 2.1660471247741953e-06
as O 0 7.434076678691781e-07
the O 0 4.594124675350031e-06
pocket O 0 0.0020723629277199507
region O 0 6.308934189291904e-06
and O 0 7.849178587093775e-07
has O 0 2.676256144695799e-06
been O 0 2.031581061601173e-06
detected O 0 3.245701373089105e-05
in O 0 2.677655288607639e-07
other O 0 2.0734815109335614e-07
cases O 0 7.724977876932826e-06
of O 0 4.197758244117722e-06
retinoblastoma B-Disease 1 0.9955188035964966
. O 0 4.501968214754015e-05
. O 0 8.568246994400397e-05

Low O 0 0.00020913696789648384
levels O 0 1.7372914953739382e-05
of O 0 1.0897316542468616e-06
beta O 0 0.0002592642849776894
hexosaminidase O 0 0.001520334044471383
A O 0 2.7935157049796544e-05
in O 0 7.264607575052651e-06
healthy O 0 0.00031475198920816183
individuals O 0 2.5987596927734558e-06
with O 0 9.652267908677459e-05
apparent O 1 0.9919307827949524
deficiency O 1 0.9996997117996216
of O 0 1.7857112197816605e-06
this O 0 7.966546036186628e-06
enzyme O 0 0.001392060425132513
. O 0 9.81882112682797e-05

Appreciable O 0 0.0020408311393111944
beta O 0 0.0008287160890176892
hexosaminidase O 0 0.0031495762523263693
A O 0 4.675663512898609e-05
( O 0 7.5620669122145046e-06
hex O 0 5.6315264373552054e-05
A O 0 7.931597792776302e-06
) O 0 1.0763540103653213e-06
activity O 0 1.731174961605575e-06
has O 0 2.208665137004573e-06
been O 0 4.524543783190893e-06
detected O 0 0.00010902429494308308
in O 0 1.640254231460858e-05
cultured O 0 0.028394710272550583
skin O 1 0.9980214834213257
fibroblasts O 1 0.501263439655304
and O 0 0.009805756621062756
melanoma B-Disease 1 0.9999146461486816
tissue O 1 0.992091178894043
from O 0 0.00010884189396165311
healthy O 0 0.007454601116478443
individuals O 0 6.523543106595753e-06
previously O 0 0.00016979740757960826
reported O 0 0.0010290630161762238
as O 0 2.082528590108268e-05
having O 0 0.0021826354786753654
deficiency B-Disease 1 0.9996569156646729
of I-Disease 0 1.0827722007888951e-06
hex I-Disease 0 0.00027857886743731797
A I-Disease 0 1.504850933997659e-05
activity O 0 2.9203090434748447e-06
indistinguishable O 0 1.3321954611456022e-05
from O 0 1.0621789670040016e-06
that O 0 5.929123290115967e-07
of O 0 5.360898740036646e-06
patients O 1 0.9950418472290039
with O 1 0.6994619369506836
Tay B-Disease 1 0.9998780488967896
- I-Disease 1 0.9994903802871704
Sachs I-Disease 1 0.9996522665023804
disease I-Disease 1 0.999763548374176
( O 0 0.0036913021467626095
TSD B-Disease 1 0.9957616925239563
) O 0 0.00015945741324685514
. O 0 8.630478259874508e-05

Identification O 0 1.9247090676799417e-05
and O 0 2.0002539713459555e-06
quantitation O 0 0.00023369200062006712
of O 0 1.2671412150666583e-06
hex O 0 0.00025314767844974995
A O 0 3.0413755666813813e-05
, O 0 2.389104338362813e-06
amounting O 0 1.8937371351057664e-05
to O 0 9.963624734155019e-07
3 O 0 2.861306711565703e-05
. O 0 2.027049231401179e-05

5 O 0 0.00012466359476093203
% O 0 0.00012414991215337068
- O 0 0.0016045384109020233
6 O 0 8.964744483819231e-05
. O 0 2.3578551918035373e-05

9 O 0 2.284526635776274e-05
% O 0 9.785709380594199e-07
of O 0 1.6332286634224147e-07
total O 0 2.5489014205959393e-06
beta O 0 9.920986485667527e-05
hexosaminidase O 0 0.000982922501862049
activity O 0 5.168306870473316e-06
, O 0 7.371041874648654e-07
has O 0 5.677466674569587e-07
been O 0 1.7792689277484897e-07
obtained O 0 6.812582569182268e-07
by O 0 1.984252548936638e-06
cellulose O 0 0.006008529104292393
acetate O 0 0.005870317108929157
gel O 0 0.007224030792713165
electrophoresis O 0 0.0010089412098750472
, O 0 1.857805546023883e-05
DEAE O 0 0.017520427703857422
- O 0 0.00041579807293601334
cellulose O 0 0.0008646477945148945
ion O 0 0.0002236117870779708
- O 0 0.00011315224401187152
exchange O 0 1.1581314538489096e-05
chromatography O 0 0.0009094002889469266
, O 0 1.2880578651675023e-05
radial O 0 0.005373676773160696
immunodiffusion O 0 0.018370816484093666
, O 0 1.0022348760685418e-05
and O 0 1.0882405149459373e-05
radioimmunoassay O 0 0.007715451996773481
. O 0 8.902402623789385e-05

Previous O 0 0.00019669566245283931
family O 0 0.0002059985708910972
studies O 0 2.7377172955311835e-05
suggested O 0 3.5594552173279226e-05
that O 0 5.505555691343034e-07
these O 0 2.923104318597325e-07
individuals O 0 1.5615603388141608e-06
may O 0 1.1081789125455543e-05
be O 0 3.648883080131782e-07
compound O 0 2.9274158805492334e-05
heterozygotes O 0 7.31012478354387e-05
for O 0 1.4737777576101507e-07
the O 0 6.693500154142384e-07
common O 0 1.0119098988070618e-05
mutant O 0 0.0005208202637732029
TSD B-Disease 1 0.9121290445327759
gene O 0 1.537866955914069e-05
and O 0 7.144653864088468e-07
a O 0 1.1560987331904471e-05
rare O 0 0.00019813772814814
( O 0 1.0942994776996784e-05
allelic O 0 0.0005674635758623481
) O 0 1.2407614121912047e-05
mutant O 0 0.00021428537729661912
gene O 0 0.0002142485900549218
. O 0 9.698028588900343e-05

Thus O 0 1.7205300537170842e-05
, O 0 1.559179395371757e-06
the O 0 1.7423418512407807e-06
postulated O 0 3.632482184912078e-05
rate O 0 2.335939643671736e-05
mutant O 0 7.105855911504477e-05
gene O 0 1.2619649169209879e-05
appears O 0 3.4427616810717154e-06
to O 0 3.3569939716926456e-08
code O 0 1.2723307918349747e-07
for O 0 2.0661337529759294e-08
the O 0 5.7443365619747055e-08
expression O 0 1.558449440608456e-07
of O 0 4.412862253388994e-08
low O 0 5.35755634700763e-06
amounts O 0 1.8172584077547072e-06
of O 0 8.335629786415666e-07
hex O 0 0.0003596589667722583
A O 0 0.00011361877841409296
. O 0 4.570942837744951e-05

Heterozygotes O 0 0.001963775372132659
for O 0 3.3424382763769245e-06
the O 0 6.750091415597126e-06
rare O 0 0.0011540788691490889
mutant O 0 0.0007670500781387091
may O 0 1.7699449017527513e-05
be O 0 5.580683932748798e-07
indistinguishable O 0 2.323684202565346e-05
from O 0 2.2376325432560407e-06
heterozygotes O 0 0.0001867756072897464
for O 0 6.921785598024144e-07
the O 0 4.622929736797232e-06
common O 0 0.00027555692940950394
TSD B-Disease 1 0.9856293797492981
mutant O 0 0.0033481253776699305
. O 0 0.0001729510840959847

However O 0 4.007316965726204e-05
, O 0 2.953180000986322e-06
direct O 0 1.8219647017758689e-06
visualization O 0 4.8234105634037405e-05
and O 0 1.260840463146451e-06
quantitation O 0 0.00016792136011645198
of O 0 9.834452612267341e-07
hex O 0 9.698362555354834e-05
A O 0 6.138259777799249e-06
by O 0 4.751081519316358e-07
the O 0 6.950659212634491e-07
methods O 0 2.6255868306179764e-06
described O 0 0.00017449124425183982
may O 0 5.637296271743253e-05
prevent O 0 0.00011419651855248958
false O 0 0.00011390450526960194
- O 0 0.0008314718143083155
positive O 0 2.1639600163325667e-05
prenatal O 0 0.42650553584098816
diagnosis O 1 0.9544177651405334
of O 0 1.3368650797929149e-05
TSD B-Disease 1 0.9964466691017151
in O 0 3.8941099774092436e-05
fetuses O 0 0.001623793737962842
having O 0 6.7330224737816025e-06
the O 0 2.5079823444684735e-06
incomplete O 0 0.0003277929499745369
hex B-Disease 0 0.006958597339689732
A I-Disease 0 0.019715644419193268
deficiency I-Disease 1 0.999512791633606
of O 0 5.60325815968099e-07
the O 0 6.046172984497389e-06
type O 0 0.00103197677526623
described O 0 3.0239016268751584e-05
in O 0 6.210871106304694e-07
the O 0 1.3275196124595823e-06
four O 0 5.502167368831579e-06
healthy O 0 0.0014162752777338028
individuals O 0 6.99082956998609e-05

The O 0 0.0011047922307625413
tumor B-Disease 1 0.9887536764144897
suppressor O 0 0.028031092137098312
gene O 0 0.0008152039954438806
Smad4 O 0 0.3140237331390381
/ O 0 0.01322217471897602
Dpc4 O 0 0.0012141497572883964
is O 0 1.1775190387197654e-06
required O 0 1.7021121720972587e-06
for O 0 1.0651276625139872e-06
gastrulation O 0 0.004143858328461647
and O 0 1.1178741488038213e-06
later O 0 4.749214895127807e-06
for O 0 1.4445930673900875e-06
anterior O 0 0.008739437907934189
development O 0 2.413829406577861e-06
of O 0 8.77438083080051e-07
the O 0 2.5220680981874466e-05
mouse O 0 0.0017210105434060097
embryo O 0 0.0008916732622310519
. O 0 8.056814112933353e-05

Mutations O 0 0.0001627765886951238
in O 0 1.0514952009543777e-05
the O 0 4.462380093173124e-05
SMAD4 O 1 0.9851463437080383
/ O 1 0.8052771687507629
DPC4 O 1 0.9897013902664185
tumor B-Disease 1 0.9954752326011658
suppressor O 0 0.0021977247670292854
gene O 0 1.4049874152988195e-05
, O 0 5.056785994383972e-07
a O 0 7.97548466380249e-07
key O 0 1.6460379583804752e-06
signal O 0 9.257996680389624e-06
transducer O 0 6.832076905993745e-05
in O 0 1.0183883887293632e-06
most O 0 1.8900154827861115e-06
TGFbeta O 0 0.07461626827716827
- O 0 0.0012826027814298868
related O 0 1.4764304069103673e-05
pathways O 0 3.45222360920161e-05
, O 0 3.440558202782995e-07
are O 0 3.983997842738063e-08
involved O 0 5.055252927377296e-07
in O 0 6.329275947791757e-07
50 O 0 2.6680556857172633e-06
% O 0 4.583473128150217e-06
of O 0 7.468096009688452e-05
pancreatic B-Disease 1 0.9997325539588928
cancers I-Disease 1 0.9993199110031128
. O 0 0.0011667963117361069

Homozygous O 0 0.007471870165318251
Smad4 O 0 0.39354631304740906
mutant O 0 0.06478182971477509
mice O 1 0.8986148238182068
die O 0 0.29244908690452576
before O 0 2.233706254628487e-05
day O 0 3.7405658076750115e-05
7 O 0 6.605642556678504e-05
. O 0 6.211461732164025e-05

5 O 0 6.276548083405942e-05
of O 0 1.4171671864460222e-05
embryogenesis O 0 0.008980123326182365
. O 0 0.00033100522705353796

Mutant O 0 0.0005735482554882765
embryos O 0 6.4354513597209e-05
have O 0 3.0421067549468717e-06
reduced O 0 4.798860027221963e-05
size O 0 1.5961413737386465e-05
, O 0 2.8594529339898145e-06
fail O 0 5.100171620142646e-05
to O 0 8.378795541830186e-07
gastrulate O 0 0.0003691074380185455
or O 0 2.0272475467209006e-06
express O 0 9.891991794575006e-06
a O 0 8.83034044818487e-06
mesodermal O 0 0.002812872175127268
marker O 0 0.0004237478133291006
, O 0 3.1538831990474137e-06
and O 0 2.3355755729426164e-06
show O 0 3.713195837917738e-05
abnormal O 0 0.013969633728265762
visceral O 0 0.016924550756812096
endoderm O 1 0.6391817331314087
development O 0 0.00039217169978655875
. O 0 0.00024316423514392227

Growth B-Disease 1 0.9846668243408203
retardation I-Disease 1 0.996393620967865
of O 0 1.2708585018117446e-05
the O 0 0.00032893719617277384
Smad4 O 1 0.9877279996871948
- O 1 0.8034876585006714
deficient O 1 0.610542893409729
embryos O 0 1.6259897165582515e-05
results O 0 6.9513162088696845e-06
from O 0 5.044641966378549e-06
reduced O 0 0.0004594283236656338
cell O 0 0.0015001225983723998
proliferation O 0 0.0004962170496582985
rather O 0 1.0970223911499488e-06
than O 0 1.7890505432660575e-06
increased O 0 6.005657996865921e-05
apoptosis O 0 0.00137905974406749
. O 0 6.286707503022626e-05

Aggregation O 0 0.00026379458722658455
of O 0 1.8851636923500337e-05
mutant O 0 0.0013916462194174528
Smad4 O 0 0.06932622939348221
ES O 0 0.0028788214549422264
cells O 0 2.817780477926135e-05
with O 0 2.450293777656043e-06
wild O 0 5.633695764117874e-05
- O 0 0.0007997958455234766
type O 0 0.00019432726548984647
tetraploid O 0 0.000899820530321449
morulae O 0 0.01267772726714611
rescues O 0 0.004055099096149206
the O 0 0.00019656369113363326
gastrulation B-Disease 1 0.984514057636261
defect I-Disease 1 0.9872499108314514
. O 0 0.0005644073244184256

These O 0 4.976734999218024e-06
results O 0 3.623804877861403e-05
indicate O 0 5.03070950799156e-05
that O 0 2.8712306630040985e-06
Smad4 O 0 0.0011105388402938843
is O 0 1.1615541097853566e-06
initially O 0 1.5181507251327275e-06
required O 0 2.2802771582064452e-07
for O 0 5.5314227864755594e-08
the O 0 1.0792984284080376e-07
differentiation O 0 1.3530016076401807e-06
of O 0 1.339974176062242e-07
the O 0 1.9241945210524136e-06
visceral O 0 0.0009618908516131341
endoderm O 0 0.006356612779200077
and O 0 8.747444439904939e-07
that O 0 5.072290605312446e-07
the O 0 6.332141310849693e-06
gastrulation B-Disease 1 0.746842086315155
defect I-Disease 1 0.5025421380996704
in O 0 2.5368535716552287e-06
the O 0 8.54567679198226e-06
epiblast O 0 0.2921956777572632
is O 0 2.880654619730194e-06
secondary O 0 1.990166856558062e-05
and O 0 3.214128355466528e-06
non O 0 7.787095819367096e-05
- O 0 0.0010451647685840726
cell O 0 0.00019213184714317322
autonomous O 0 2.1476405891007744e-05
. O 0 6.931900134077296e-05

Rescued O 0 0.026858709752559662
embryos O 0 0.0018910050857812166
show O 0 0.002705543301999569
severe O 1 0.9975566864013672
anterior O 1 0.9915443658828735
truncations O 0 0.061827708035707474
, O 0 2.9011112928856164e-05
indicating O 0 5.8629379054764286e-05
a O 0 2.1849684799235547e-06
second O 0 8.447386790066957e-07
important O 0 2.351902423924912e-07
role O 0 1.0320441106159706e-06
for O 0 1.2549600114653003e-06
Smad4 O 0 0.005159011110663414
in O 0 2.7301306545268744e-05
anterior O 1 0.9045182466506958
patterning O 0 0.06286529451608658
during O 0 0.0011503953719511628
embryogenesis O 0 0.10093120485544205
. O 0 0.0002473429776728153

Prevalence O 0 0.016068512573838234
of O 0 1.5664403690607287e-05
p16 O 0 0.0017855791375041008
and O 0 2.4693217710591853e-05
CDK4 O 0 0.08011050522327423
germline O 0 0.017433032393455505
mutations O 0 0.00039359359652735293
in O 0 7.099359936546534e-05
48 O 0 0.24143479764461517
melanoma B-Disease 1 0.9998661279678345
- O 1 0.9802951216697693
prone O 1 0.5685058236122131
families O 0 2.8834725526394323e-05
in O 0 1.5334380805143155e-05
France O 0 0.00025620032101869583
. O 0 9.446045442018658e-05

The O 0 0.0005610109656117857
French O 0 0.035035304725170135
Familial B-Disease 1 0.995478093624115
Melanoma I-Disease 1 0.9996196031570435
Study O 0 0.0020456151105463505
Group O 0 0.00036346877459436655
. O 0 0.00015874241944402456

Germline O 0 0.017679302021861076
mutations O 0 9.068176586879417e-05
in O 0 2.0669594960054383e-06
the O 0 3.2902357816055883e-06
p16 O 0 0.0005695883301086724
and O 0 5.006668288842775e-06
CDK4 O 0 0.010701317340135574
genes O 0 7.690862730669323e-06
have O 0 5.602488499789615e-07
been O 0 7.793780127940408e-07
reported O 0 2.5378819827892585e-06
in O 0 1.260266628833051e-07
a O 0 1.1350297199896886e-06
subset O 0 7.688408004469238e-06
of O 0 2.5988887500716373e-05
melanoma B-Disease 1 0.9998816251754761
pedigrees O 0 0.010657111182808876
, O 0 6.082829258957645e-06
but O 0 1.5323562365665566e-06
their O 0 1.5295238426915603e-06
prevalence O 0 0.09658022969961166
is O 0 2.0907193629682297e-06
not O 0 6.792069484617969e-07
well O 0 1.189083718600159e-06
known O 0 2.1044215827714652e-05
. O 0 4.795461427420378e-05

We O 0 5.702939688490005e-06
searched O 0 1.8569517123978585e-05
for O 0 7.212697141767421e-07
such O 0 1.9545502709661378e-06
germline O 0 0.0014308063546195626
mutations O 0 6.571727863047272e-05
in O 0 1.0560213922872208e-05
48 O 0 0.0008141723228618503
French O 0 0.40963223576545715
melanoma B-Disease 1 0.9998435974121094
- O 1 0.7561519145965576
prone O 0 0.01694503054022789
families O 0 1.7307096413787804e-06
selected O 0 2.8556439701787895e-07
according O 0 2.3183297059858887e-07
to O 0 8.28477553227458e-08
two O 0 1.1191910687102791e-07
major O 0 2.0377417513373075e-06
criteria O 0 1.3192743608669844e-06
families O 0 4.524753762780165e-07
with O 0 1.9589658961649548e-07
at O 0 1.3007819461563486e-06
least O 0 2.3566083484638511e-07
three O 0 2.327514465605418e-07
affected O 0 3.4258157484146068e-06
members O 0 3.13417615416256e-07
( O 0 1.4452366485784296e-06
n O 0 7.891835593909491e-06
= O 0 9.458762178837787e-06
20 O 0 5.627388190987404e-07
) O 0 2.7581225481299043e-07
or O 0 1.4981918639023206e-07
families O 0 1.1234664754056212e-07
with O 0 1.529838868918887e-07
two O 0 3.0003988626958744e-07
affected O 0 4.849165179621195e-06
members O 0 9.661325606202809e-08
, O 0 9.387378696601445e-08
one O 0 2.799181686441443e-08
of O 0 2.4668839415653565e-08
them O 0 1.1103416852620285e-07
affected O 0 2.243594281026162e-06
before O 0 3.525253760017222e-07
the O 0 1.2262275106422749e-07
age O 0 1.196555103888386e-06
of O 0 5.97827067849721e-08
50 O 0 1.0281617051077774e-06
( O 0 7.902793299763289e-07
n O 0 5.405532192526152e-06
= O 0 8.701502338226419e-06
28 O 0 1.9109597815258894e-06
) O 0 2.1275488393257547e-07
, O 0 5.03146360131268e-08
and O 0 3.243752288994983e-08
one O 0 7.221618147923436e-08
additional O 0 1.2875120773969684e-06
minor O 0 0.0008510025800205767
criterion O 0 0.0028228138107806444
. O 0 0.00010453889262862504

Sixteen O 0 5.573392991209403e-05
different O 0 5.986229098198237e-06
p16 O 0 0.004241592716425657
germline O 0 0.009452322497963905
mutations O 0 4.6816821850370616e-05
were O 0 7.254917022692098e-07
found O 0 2.4936725822044536e-06
in O 0 5.023025551054161e-07
21 O 0 2.333273641852429e-06
families O 0 4.4372879415277566e-07
, O 0 2.2473152228030813e-07
while O 0 2.4461607495140925e-07
one O 0 7.702392963437887e-07
germline O 0 0.0006398090627044439
mutation O 0 4.1179162508342415e-05
, O 0 1.8370637917541899e-06
Arg24His O 0 0.0013327134074643254
, O 0 1.585794393577089e-06
was O 0 2.1419131371658295e-05
detected O 0 2.590105214039795e-05
in O 0 5.925364234826702e-07
the O 0 4.629560862667859e-06
CDK4 O 0 0.037582773715257645
gene O 0 0.00021352057228796184
. O 0 6.681386730633676e-05

The O 0 1.020411559693457e-06
frequency O 0 7.743690275674453e-07
of O 0 6.212043786035792e-07
p16 O 0 0.00017274869605898857
gene O 0 1.2197770047350787e-05
mutation O 0 4.54743167210836e-06
in O 0 1.1611294326030475e-07
our O 0 6.620460624162661e-08
sample O 0 3.243425226173713e-07
( O 0 5.046697992838745e-07
44 O 0 1.3581418443209259e-06
% O 0 5.729946224164451e-07
) O 0 4.224784504458512e-07
is O 0 1.1034505575935327e-07
among O 0 7.193148121587001e-08
the O 0 2.1577865538802143e-07
highest O 0 1.1714522770489566e-05
rates O 0 1.3090303582430352e-05
yet O 0 2.5295889827248175e-06
reported O 0 4.499903752730461e-06
and O 0 1.4510590062855044e-07
the O 0 9.696268534753472e-07
CDK4 O 0 0.00123007467482239
mutation O 0 3.1499214401264908e-06
is O 0 7.91836640701149e-08
the O 0 1.0284976781349542e-07
second O 0 1.0786887969516101e-06
mutation O 0 2.911035880970303e-05
detected O 0 2.7888228942174464e-05
in O 0 5.437725576484809e-07
this O 0 8.591205187258311e-07
gene O 0 3.6859626561636105e-05
worldwide O 0 3.575520167942159e-05
. O 0 3.7697442166972905e-05

In O 0 1.4317650311568286e-05
summary O 0 4.092129893251695e-05
, O 0 2.181397803724394e-06
our O 0 4.4841419821750605e-07
results O 0 2.1167750219319714e-06
show O 0 1.5321721775762853e-06
frequent O 0 2.399217009951826e-06
involvement O 0 1.6786488004072453e-06
of O 0 1.3385744068727945e-07
the O 0 4.350527433416573e-06
p16 O 0 0.0012417264515534043
gene O 0 0.00015136878937482834
in O 0 7.004736107774079e-05
familial B-Disease 1 0.9990761280059814
melanoma I-Disease 1 0.9998925924301147
and O 0 4.041263309773058e-06
confirm O 0 6.010392098687589e-06
the O 0 2.1648111214744858e-07
role O 0 3.857831245568377e-07
of O 0 1.0532532712659304e-07
the O 0 2.7074206627730746e-06
CDK4 O 0 0.006229558028280735
gene O 0 3.614427623688243e-05
as O 0 7.67564597481396e-06
a O 0 0.0038741356693208218
melanoma B-Disease 1 0.9998756647109985
- O 0 0.12422897666692734
predisposing O 0 0.004308939911425114
gene O 0 0.00017789346748031676
. O 0 1.4346298485179432e-05
. O 0 4.92422295792494e-05

Progression O 0 0.0017020620871335268
of O 0 7.922564691398293e-06
somatic O 0 0.0009454028913751245
CTG O 0 0.028360966593027115
repeat O 0 0.00033170965616591275
length O 0 3.07679692923557e-05
heterogeneity O 0 8.986364264274016e-05
in O 0 3.242712182327523e-06
the O 0 3.7031139072496444e-05
blood O 1 0.6919302344322205
cells O 0 0.0041883052326738834
of O 0 0.002754969522356987
myotonic B-Disease 1 0.9998596906661987
dystrophy I-Disease 1 0.9999650716781616
patients O 1 0.998305082321167
. O 0 0.003910842817276716

The O 0 1.5484611139982007e-05
genetic O 0 8.891254401532933e-05
basis O 0 1.1999240086879581e-05
of O 0 0.0009832142386585474
myotonic B-Disease 1 0.9999064207077026
dystrophy I-Disease 1 0.9999637603759766
( O 1 0.6997838616371155
DM B-Disease 1 0.999735414981842
) O 0 5.524555490410421e-06
is O 0 4.329474734277028e-07
the O 0 2.3405402771459194e-07
expansion O 0 2.810475507430965e-06
of O 0 2.480893783740612e-07
an O 0 6.762275461369427e-06
unstable O 0 0.16342926025390625
CTG O 0 0.027920223772525787
repeat O 0 8.19756678538397e-05
in O 0 4.4633557649831346e-07
the O 0 3.953092857500451e-07
34 O 0 3.3870182960527018e-06
UTR O 0 4.926383189740591e-05
of O 0 3.412390583434899e-07
the O 0 8.850928679748904e-06
DM B-Disease 1 0.9885115623474121
protein O 0 1.844889084168244e-05
kinase O 0 4.709525819635019e-05
gene O 0 1.307424645347055e-05
on O 0 6.106484761403408e-06
chromosome O 0 0.0002058750542346388
19 O 0 0.00011398643982829526
. O 0 6.860319263068959e-05

One O 0 6.809827937104274e-07
of O 0 1.1741667549358681e-07
the O 0 6.244296173463226e-07
principal O 0 1.927950734170736e-06
features O 0 1.1931047083635349e-06
of O 0 5.685463975169114e-07
the O 0 6.374872464220971e-05
DM B-Disease 1 0.9995299577713013
mutation O 0 7.271170761669055e-05
is O 0 7.474469612134271e-07
an O 0 7.029776156741718e-07
extraordinarily O 0 5.113154475111514e-05
high O 0 6.140706318547018e-06
level O 0 1.2055960496581974e-06
of O 0 5.514020813279785e-07
somatic O 0 0.0004483363009057939
mosaicism O 1 0.5496875047683716
, O 0 2.2670078578812536e-06
due O 0 6.349932391458424e-06
to O 0 3.1049731319399143e-07
an O 0 8.229886248045659e-07
extremely O 0 1.822818558139261e-05
high O 0 5.777140358986799e-06
degree O 0 2.9476930194505258e-06
of O 0 1.161890850198688e-06
somatic O 0 0.00018220757192466408
instability O 0 0.0001435555168427527
both O 0 2.8730937629006803e-07
within O 0 3.8992880035948474e-07
and O 0 4.4141842181488755e-07
between O 0 1.855625896496349e-06
different O 0 4.0638183236296754e-06
tissues O 0 0.00989565346390009
. O 0 0.00014643701433669776

This O 0 8.394399628741667e-05
instability O 0 0.00555813405662775
appears O 0 6.366275920299813e-05
to O 0 5.175174351279566e-07
be O 0 3.378017083832674e-07
biased O 0 1.8866137452278053e-06
towards O 0 3.0432511266553774e-07
further O 0 5.712116148970381e-07
expansion O 0 1.1449819794506766e-06
and O 0 3.650410107525204e-08
continuous O 0 5.300457246448786e-07
throughout O 0 1.3598094028566265e-07
the O 0 1.147310797477985e-07
life O 0 2.5816902393671626e-07
of O 0 3.639891232865011e-08
an O 0 4.317357138461375e-07
individual O 0 4.048126811539987e-07
, O 0 4.6935269892856013e-07
features O 0 1.2972562899449258e-06
that O 0 1.7185766409966163e-07
could O 0 3.1457736326956365e-07
be O 0 8.545334395648752e-08
associated O 0 6.709944955218816e-07
with O 0 1.9903083625649742e-07
the O 0 1.0089709121530177e-06
progressive O 0 0.0006852392107248306
nature O 0 1.2663627785514109e-05
of O 0 7.220547558972612e-06
the O 0 0.0069228122010827065
disease O 1 0.9995500445365906
. O 0 0.0005551615613512695

Although O 0 2.8597190976142883e-05
increasing O 0 1.2912013517052401e-05
measured O 0 2.0838260752498172e-05
allele O 0 5.232606781646609e-05
size O 0 7.221452688099816e-05
between O 0 4.826465738005936e-05
patients O 0 0.4669109582901001
clearly O 0 1.4980566447775345e-05
correlates O 0 2.3141572455642745e-05
with O 0 1.6756226841607713e-06
an O 0 9.316951036453247e-06
increased O 0 0.0004180519899819046
severity O 1 0.5172279477119446
of O 0 1.9169603547197767e-05
symptoms O 1 0.9992944002151489
and O 0 1.4093941445025848e-06
an O 0 1.4183243592924555e-06
earlier O 0 1.7842790839495137e-05
age O 0 5.180483276490122e-05
of O 0 2.602708264021203e-06
onset O 1 0.9992086291313171
, O 0 2.05843184630794e-06
this O 0 2.1015512174926698e-07
correlation O 0 2.4925050183810527e-06
is O 0 2.1021163831846934e-07
not O 0 6.5935935822381e-08
precise O 0 2.602862139156059e-07
and O 0 2.4307149715241394e-07
measured O 0 2.2671308670396684e-06
allele O 0 1.2628786862478592e-05
length O 0 8.911103577702306e-06
cannot O 0 8.195284522116708e-07
be O 0 4.095148753435751e-08
used O 0 5.17524298970784e-08
as O 0 4.232587968999724e-08
an O 0 1.0946462936090029e-07
accurate O 0 1.097268182093103e-06
predictor O 0 2.7878548280568793e-05
of O 0 4.7580144268977165e-07
age O 0 0.0002229048404842615
of O 0 3.0000896003912203e-05
onset O 1 0.9984985589981079
. O 0 0.0007460723281838

In O 0 3.865682629111689e-06
order O 0 1.100889676308725e-06
to O 0 4.910332904728421e-07
further O 0 1.6513351965841139e-06
characterize O 0 3.605865640565753e-05
the O 0 3.122414454992395e-06
dynamics O 0 0.00032787956297397614
of O 0 5.258954843156971e-05
DM B-Disease 1 0.9988216757774353
CTG O 1 0.8555365800857544
repeat O 0 0.009318720549345016
somatic O 0 0.0016059076879173517
instability O 0 0.0021283573005348444
, O 0 1.5033314184620394e-06
we O 0 1.3082123473395768e-07
have O 0 5.3572932756651426e-08
studied O 0 9.675577530288137e-07
repeat O 0 1.0108430615218822e-05
length O 0 3.0699804938194575e-06
changes O 0 1.0716159977164352e-06
over O 0 1.0623167554513202e-06
time O 0 4.2864094211836345e-06
in O 0 5.967089600744657e-05
111 O 1 0.92462158203125
myotonic B-Disease 1 0.9998435974121094
dystrophy I-Disease 1 0.9999794960021973
patients O 1 0.9976245760917664
with O 0 6.90859742462635e-05
varying O 0 0.0009148656390607357
clinical O 1 0.9367991089820862
severity O 1 0.987999439239502
and O 0 2.2816680939286016e-05
CTG O 0 0.26126185059547424
repeat O 0 0.000167894599144347
size O 0 1.821349655983795e-06
over O 0 1.5613771608968818e-07
time O 0 6.855114520476491e-08
intervals O 0 6.998523645052046e-07
of O 0 2.930358391495247e-07
1 O 0 2.5357736376463436e-05
- O 0 0.00020589095947798342
7 O 0 1.3591312381322496e-05
years O 0 1.799206256691832e-05
. O 0 2.5750616259756498e-05

We O 0 5.506177785719046e-06
have O 0 9.224931432072481e-07
found O 0 1.221626803271647e-06
a O 0 9.919065178110031e-07
direct O 0 8.04642070306727e-07
progression O 0 7.732404628768563e-05
of O 0 1.3906047513501107e-07
the O 0 8.306196832563728e-07
size O 0 5.169144969841e-06
heterogeneity O 0 1.635664921195712e-05
over O 0 4.3300363472553727e-07
time O 0 6.54073460282234e-07
related O 0 2.2344827357301256e-06
to O 0 2.4119509589581867e-07
initial O 0 1.983147558348719e-05
CTG O 0 0.010189362801611423
repeat O 0 6.97467548889108e-05
size O 0 2.3086604414856993e-06
and O 0 9.987954285861633e-08
the O 0 1.1150722656338985e-07
time O 0 1.5870425329467253e-07
interval O 0 1.7306368818026385e-06
and O 0 2.0206933015742834e-07
always O 0 5.145454906596569e-07
biased O 0 2.1158161871426273e-06
towards O 0 7.323933459701948e-07
further O 0 3.456667627688148e-06
expansion O 0 8.979152335086837e-05
. O 0 4.136978532187641e-05

Attempts O 0 1.2059343134751543e-05
to O 0 9.672274927652325e-07
mathematically O 0 8.933763638196979e-06
model O 0 6.745734481228283e-06
the O 0 2.8734823445120128e-06
dynamics O 0 0.0002683282655198127
have O 0 1.399939264956629e-06
proved O 0 1.7349451809423044e-05
only O 0 8.288844242088089e-07
partially O 0 0.00010109667346114293
successful O 0 6.890264558023773e-06
suggesting O 0 1.1060556971642654e-05
that O 0 1.616998872577824e-07
individual O 0 1.784472232202461e-07
specific O 0 1.0760512623164686e-06
genetic O 0 0.0003492599062155932
and O 0 1.4313691281131469e-05
/ O 0 0.03760038688778877
or O 0 5.652955678669969e-06
environmental O 0 1.1681556316034403e-05
factors O 0 5.801250608783448e-07
also O 0 1.3823196809426008e-07
play O 0 7.076322106058797e-08
a O 0 7.576032317047066e-07
role O 0 2.4565176772739505e-06
in O 0 3.716375431395136e-06
somatic O 0 0.000628510199021548
mosaicism O 1 0.7570532560348511
. O 0 2.4306171326315962e-05
. O 0 4.6947279770392925e-05

Aspartylglucosaminuria B-Disease 1 0.9101669192314148
among O 0 9.800197585718706e-05
Palestinian O 0 0.0004979939549230039
Arabs O 0 0.00040343825821764767
. O 0 0.00021548332006204873

Aspartylglucosaminuria B-Disease 1 0.9733933210372925
( O 0 0.004500400274991989
AGU B-Disease 1 0.9952184557914734
) O 0 3.593151632230729e-05
is O 0 7.406193162751151e-06
a O 0 7.673785876249894e-05
rare O 0 0.16695785522460938
disorder B-Disease 1 0.9995025396347046
of I-Disease 0 2.5767471015569754e-05
glycoprotein I-Disease 1 0.9947918057441711
metabolism I-Disease 1 0.8745604157447815
caused O 0 0.15930694341659546
by O 0 1.3531935110222548e-05
the O 0 0.0001991612953133881
deficiency B-Disease 1 0.9994810223579407
of I-Disease 0 1.6550117152291932e-06
the I-Disease 0 4.0613893361296505e-05
lysosomal I-Disease 1 0.9617144465446472
enzyme I-Disease 0 0.001982091460376978
aspartylglucosaminidase I-Disease 0 0.12370291352272034
( O 0 0.00018280497170053422
AGA O 1 0.501846969127655
) O 0 4.45138466602657e-05
. O 0 6.755647336831316e-05

AGU B-Disease 1 0.9951130747795105
is O 0 0.0006272344035096467
inherited O 1 0.8571847677230835
as O 0 2.9018890927545726e-05
an O 0 0.0001413579739164561
autosomal O 1 0.9988610744476318
recessive O 1 0.9987450838088989
trait O 0 0.051134221255779266
and O 0 1.8381292647973169e-06
occurs O 0 9.54372535488801e-06
with O 0 5.251640686765313e-07
a O 0 2.115810275427066e-06
high O 0 4.443082616489846e-06
frequency O 0 6.060959094611462e-07
in O 0 2.7287492798677704e-07
Finland O 0 1.5208431705104886e-06
because O 0 4.802082003152464e-07
of O 0 2.9197917683632113e-07
a O 0 3.733242556336336e-05
founder O 0 0.0007091998704709113
effect O 0 0.0001236497046193108
. O 0 5.1384013204369694e-05

While O 0 9.676800982560962e-05
very O 0 5.785018947790377e-05
few O 0 0.00018434689263813198
patients O 1 0.7705832719802856
with O 0 0.0006558644818142056
AGU B-Disease 1 0.9992114305496216
have O 0 4.790628736373037e-06
been O 0 5.019184300181223e-06
reported O 0 3.543739876477048e-05
from O 0 3.1968138500815257e-06
non O 0 2.1223062503850088e-05
- O 0 0.00010314676183043048
Finnish O 0 4.194988650851883e-05
origin O 0 1.9320166302350117e-06
, O 0 9.614275768399239e-06
we O 0 7.702335278736427e-05
diagnosed O 1 0.9997335076332092
the O 0 0.0009724351111799479
disorder O 1 0.9998200535774231
in O 0 6.25150787527673e-05
8 O 0 0.0016232870984822512
patients O 0 0.18139240145683289
originating O 0 1.5530444215983152e-05
from O 0 3.7479958336916752e-06
3 O 0 1.3914771443523932e-05
unrelated O 0 0.00012440707359928638
families O 0 1.567391109347227e-06
, O 0 2.8010916253151663e-07
all O 0 3.8604582641710294e-08
Palestinian O 0 2.5238659873139113e-06
Arabs O 0 1.411504626958049e-06
from O 0 2.3071739008173608e-07
the O 0 4.3938644012087025e-07
region O 0 1.615751671124599e-06
of O 0 1.2090259815522586e-06
Jerusalem O 0 0.0001715473335934803
. O 0 5.359221904654987e-05

The O 0 0.00023744978534523398
clinical O 1 0.842683732509613
diagnosis O 1 0.9977774024009705
of O 0 0.00020138650143053383
AGU B-Disease 1 0.999582827091217
is O 0 2.40263034356758e-05
often O 0 4.303230525692925e-06
difficult O 0 6.136088359198766e-06
, O 0 3.351038628807146e-07
in O 0 1.5343377413046255e-07
particular O 0 1.58408184347536e-07
early O 0 6.723550427523151e-07
in O 0 1.4324722030778503e-07
the O 0 4.930966497340705e-07
course O 0 8.090919436654076e-06
of O 0 9.086218142329017e-07
the O 0 0.0006346275331452489
disease O 1 0.9998044371604919
, O 0 1.027942175824137e-06
and O 0 1.542798031550774e-07
most O 0 1.0571679354143271e-07
of O 0 4.311493739805883e-07
the O 0 0.00016097408661153167
patients O 1 0.9957629442214966
are O 0 3.69071785826236e-05
diagnosed O 1 0.9998301267623901
after O 0 5.4002273827791214e-05
the O 0 1.833926944527775e-06
age O 0 1.8258249838254414e-05
of O 0 1.1380494697732502e-06
5 O 0 3.6852597986580804e-05
years O 0 5.0983137043658644e-05
. O 0 3.198046761099249e-05

However O 0 7.306277984753251e-05
, O 0 1.357528890366666e-05
since O 0 2.8252443371457048e-05
these O 0 3.773423713937518e-06
patients O 0 0.09051129966974258
excrete O 0 0.0005079630645923316
early O 0 5.750284344685497e-06
large O 0 1.0208125331701012e-06
amounts O 0 1.7344751768177957e-06
of O 0 6.637984597546165e-07
aspartylglucosamine O 0 0.006795001216232777
in O 0 4.761954642162891e-06
urine O 0 0.0001847812091000378
, O 0 2.2165843347465852e-06
biochemical O 0 7.245809683809057e-05
screening O 0 2.1639682017848827e-05
is O 0 8.285721833090065e-07
easy O 0 4.416556294017937e-06
by O 0 3.208187536074547e-06
urine O 0 0.00039973939419724047
chromatography O 0 0.011025445535779
. O 0 1.7485708667663857e-05
. O 0 5.2691004384541884e-05

Detection O 0 0.0001519556244602427
of O 0 3.5316845696797827e-06
heterozygous O 0 0.00013578622019849718
carriers O 0 0.00013259032857604325
of O 0 6.771368589397753e-06
the O 0 0.0016952211735770106
ataxia B-Disease 1 0.9996991157531738
- I-Disease 1 0.993599534034729
telangiectasia I-Disease 1 0.9940695762634277
( O 0 1.7837906852946617e-05
ATM O 0 0.00014417005877476186
) O 0 1.5789643157404498e-06
gene O 0 5.18232400281704e-06
by O 0 2.422638999632909e-06
G2 O 0 0.3158915042877197
phase O 0 0.00025325873866677284
chromosomal O 0 0.011415071785449982
radiosensitivity O 0 0.03808434307575226
of O 0 8.115995296975598e-05
peripheral O 1 0.996025562286377
blood O 1 0.9976335763931274
lymphocytes O 1 0.981584370136261
. O 0 0.00037816030089743435

In O 0 0.004202184267342091
ataxia B-Disease 1 0.999054491519928
- I-Disease 1 0.993664026260376
telangiectasia I-Disease 1 0.9974453449249268
( O 0 0.0018734345212578773
A B-Disease 1 0.9972057938575745
- I-Disease 1 0.9983668923377991
T I-Disease 1 0.9994992017745972
) O 0 4.9258054787060246e-05
patients O 0 0.004111074842512608
, O 0 7.220157272058714e-07
mutations O 0 1.7761980188879534e-06
in O 0 1.410193846140828e-07
a O 0 6.257136533349694e-07
single O 0 7.663325618523231e-07
gene O 0 4.270573754183715e-06
, O 0 7.080695922923042e-07
ATM O 0 9.570952533977106e-05
, O 0 1.178474008156627e-06
result O 0 8.709422218089458e-06
in O 0 1.129878182837274e-05
an O 0 0.004917229991406202
autosomal B-Disease 1 0.9999072551727295
recessive I-Disease 1 0.9999504089355469
syndrome I-Disease 1 0.9999954700469971
that O 0 3.9988040953176096e-05
embraces O 0 0.00012548999802675098
a O 0 5.714236522180727e-06
variety O 0 2.4677531200723024e-06
of O 0 1.8695324115469703e-06
clinical O 0 0.004925300367176533
features O 0 8.446487481705844e-05
and O 0 1.0029750228568446e-05
manifests O 0 0.014438898302614689
extreme O 0 0.002311429474502802
radiosensitivity O 0 0.02630859985947609
and O 0 2.5316548999398947e-06
a O 0 9.994506399380043e-06
strong O 0 4.3624237150652334e-05
pre O 0 0.007535959128290415
- O 0 0.002601619577035308
disposition O 0 0.0005183850298635662
to O 0 3.52451934304554e-05
malignancy B-Disease 1 0.9929649829864502
. O 0 0.00015456073742825538

Heterozygotes O 0 0.0010726903565227985
for O 0 2.874748588510556e-06
the O 0 7.870625267969444e-06
ATM O 0 0.0006751520559191704
gene O 0 1.8640685084392317e-05
have O 0 5.163106493455416e-07
no O 0 1.4738143363501877e-06
clinical O 0 3.119536631857045e-05
expression O 0 2.3749789761495776e-06
of O 0 6.5548174461582676e-06
A B-Disease 1 0.998190701007843
- I-Disease 1 0.9982011318206787
T I-Disease 1 0.9994649291038513
but O 0 1.736006379360333e-05
may O 0 0.00015506261843256652
be O 0 6.503461918327957e-05
cancer B-Disease 1 0.9993351101875305
prone O 0 0.01597675122320652
with O 0 1.877689101092983e-06
a O 0 1.5075356714078225e-05
moderate O 0 0.0002955634845420718
increase O 0 7.658994945813902e-06
in O 0 1.493380182182591e-06
in O 0 3.4198649245809065e-06
vitro O 0 0.0002811939921230078
radiosensitivity O 0 0.019879480823874474
. O 0 0.0001047639234457165

We O 0 7.094090506143402e-06
performed O 0 1.0908443982771132e-05
a O 0 1.8758866644930094e-05
blind O 0 0.0005834302864968777
chromosomal O 0 0.0001973620237549767
analysis O 0 8.01184887677664e-06
on O 0 1.802067163225729e-05
G2 O 1 0.9805246591567993
- O 0 0.0005622386233881116
phase O 0 0.00011419118527555838
lymphocytes O 0 0.0010782004101201892
from O 0 2.9185910079831956e-06
7 O 0 1.4379665117303375e-05
unrelated O 0 0.001302351476624608
A B-Disease 1 0.9976027607917786
- I-Disease 1 0.9987077713012695
T I-Disease 1 0.9996299743652344
patients O 0 0.15422788262367249
, O 0 1.7809983319239109e-06
13 O 0 1.242383586941287e-05
obligate O 0 0.00020346578094176948
A B-Disease 1 0.8051059246063232
- I-Disease 1 0.9902752637863159
T I-Disease 1 0.9985501170158386
heterozygotes O 0 0.0018145518843084574
( O 0 5.419840817921795e-06
parents O 0 3.2036837183113676e-06
of O 0 4.5939052029098093e-07
the O 0 4.335887933848426e-05
patients O 0 0.2141943871974945
) O 0 2.5288411507062847e-06
, O 0 4.3179127828807395e-07
and O 0 2.1268063221668854e-07
14 O 0 1.1614389450187446e-06
normal O 0 1.910466153276502e-06
controls O 0 2.8053982532583177e-06
following O 0 5.482462711370317e-06
X O 0 0.00021308472787495703
- O 0 4.398281089379452e-05
irradiation O 0 5.9336371123208664e-06
with O 0 4.265670838776714e-07
1 O 0 6.355130608426407e-06
Gy O 0 0.00029483341495506465
in O 0 1.363172259516432e-07
order O 0 9.063415973287192e-08
to O 0 5.557215132512283e-08
evaluate O 0 5.384583232626028e-07
this O 0 1.2295660667405173e-07
cytogenetic O 0 4.434927541296929e-05
method O 0 2.313305316192782e-07
as O 0 3.1369810926662467e-07
a O 0 8.239703106482921e-07
tool O 0 2.7663966193358647e-06
for O 0 2.986814990890707e-07
detection O 0 2.6663701646612026e-05
of O 0 3.214692242181627e-06
ATM O 0 0.029119886457920074
carriers O 0 0.001992303878068924
. O 0 6.693784962408245e-05

Both O 0 0.0002795598702505231
A B-Disease 1 0.9824586510658264
- I-Disease 1 0.9952026605606079
T I-Disease 1 0.998068630695343
homozygotes O 0 0.021528085693717003
and O 0 1.0135401680599898e-05
heterozygotes O 0 0.004775142762809992
showed O 0 0.0003160196356475353
significantly O 0 6.863846647320315e-05
increased O 0 1.0245802513964009e-05
levels O 0 2.2664029529551044e-05
of O 0 8.010824785742443e-06
radiation O 1 0.9851663708686829
- O 0 0.28012168407440186
induced O 1 0.8924326300621033
chromatid O 1 0.9914855360984802
damage O 0 0.41176673769950867
relative O 0 8.04736373538617e-06
to O 0 2.3521269554294122e-07
that O 0 2.7489187459650566e-07
of O 0 3.6440385997593694e-07
normal O 0 6.723430124111474e-05
controls O 0 0.0001351346872979775
. O 0 5.4278447350952774e-05

These O 0 2.193356976931682e-06
results O 0 5.606322702078614e-06
show O 0 3.707765927174478e-06
that O 0 4.4690887079923414e-07
the O 0 3.912872671207879e-06
G2 O 1 0.7299060821533203
- O 0 0.00018409831682220101
phase O 0 3.5125740396324545e-05
chromosomal O 0 0.0005226657376624644
radiosensitivity O 0 0.001355447224341333
assay O 0 1.61396437761141e-05
can O 0 1.696747773394236e-07
be O 0 2.664078380121282e-08
used O 0 5.3601453942064836e-08
for O 0 4.832071098803681e-08
the O 0 4.2188378301943885e-07
detection O 0 1.4622664821217768e-05
of O 0 5.651661922456697e-06
A B-Disease 1 0.9923495054244995
- I-Disease 1 0.9934571385383606
T I-Disease 1 0.9970308542251587
heterozygotes O 0 0.016049150377511978
. O 0 0.00013740074064116925

In O 0 1.0860933798539918e-05
combination O 0 6.36672557448037e-05
with O 0 3.127444870187901e-06
molecular O 0 6.027334165992215e-05
genetic O 0 7.985342381289229e-05
analyses O 0 9.14859447220806e-06
, O 0 7.988555239535344e-07
this O 0 5.868704420208815e-07
test O 0 4.292459379939828e-06
may O 0 8.257331955974223e-07
be O 0 1.2737167764953483e-08
of O 0 1.1427241375372432e-08
value O 0 6.473614178048592e-08
in O 0 2.2135922961297183e-07
studies O 0 6.828225309618574e-07
of O 0 7.599180094075564e-07
familial B-Disease 1 0.8096607327461243
and I-Disease 0 2.7861275157192722e-05
sporadic I-Disease 0 0.03833809494972229
cancers I-Disease 1 0.9962478280067444
aimed O 0 1.8159962564823218e-05
at O 0 2.4519581529602874e-06
determination O 0 6.949996418370574e-07
of O 0 5.937645397580127e-08
the O 0 3.8192766282918456e-07
potential O 0 1.54665633544937e-06
involvement O 0 4.720240212918725e-06
of O 0 1.0790117812575772e-06
ATM O 0 0.005506913177669048
mutations O 0 0.0005323069053702056
in O 0 0.0002295747835887596
tumor B-Disease 1 0.9993112087249756
risk O 0 0.03286401554942131
or O 0 2.3307771698455326e-05
development O 0 4.4698674173559994e-05
. O 0 1.4310769984149374e-05
. O 0 4.706391700892709e-05

Ataxia B-Disease 1 0.9991384744644165
- I-Disease 1 0.9963964819908142
telangiectasia I-Disease 1 0.9960454106330872
: O 0 1.705411159491632e-05
identification O 0 3.0757712465856457e-06
and O 0 4.431477407251805e-07
detection O 0 8.292493475892115e-06
of O 0 6.963763325984473e-07
founder O 0 0.0008704623905941844
- O 0 0.0002260546898469329
effect O 0 3.4054016850859625e-06
mutations O 0 2.7213889097765787e-06
in O 0 1.870734820386133e-07
the O 0 7.869010687500122e-07
ATM O 0 8.581722795497626e-05
gene O 0 7.340992397075752e-06
in O 0 1.0241454901915858e-06
ethnic O 0 4.092942162969848e-06
populations O 0 4.5046483137412e-05
. O 0 6.36569966445677e-05

To O 0 1.6279971077892696e-06
facilitate O 0 1.9867557057295926e-06
the O 0 6.974191251174489e-07
evaluation O 0 4.8134256758203264e-06
of O 0 1.1172421636729268e-06
ATM O 0 0.0014076721854507923
heterozygotes O 0 0.0006198359187692404
for O 0 2.444062602080521e-06
susceptibility O 0 0.0013359013246372342
to O 0 2.8354368168947985e-06
other O 0 2.2672093109576963e-05
diseases O 1 0.9996139407157898
, O 0 1.4024518350197468e-05
such O 0 2.3856389816501178e-05
as O 0 0.11773822456598282
breast B-Disease 1 0.9999642372131348
cancer I-Disease 1 0.9999094009399414
, O 0 3.8535949897777755e-06
we O 0 1.74061341340348e-07
have O 0 8.08684106345936e-08
attempted O 0 8.316184221257572e-07
to O 0 6.464532731342842e-08
define O 0 4.814591534341162e-07
the O 0 2.2467922633495618e-07
most O 0 2.0781810405878787e-07
common O 0 1.3006604149268242e-06
mutations O 0 3.6098272175877355e-06
and O 0 1.0688361840038851e-07
their O 0 1.1520209852733387e-07
frequencies O 0 2.4539747300877934e-06
in O 0 6.153548747533932e-05
ataxia B-Disease 1 0.9994943141937256
- I-Disease 1 0.994473397731781
telangiectasia I-Disease 1 0.9976435303688049
( O 0 0.0004250681377016008
A B-Disease 1 0.986440122127533
- I-Disease 1 0.9928606152534485
T I-Disease 1 0.9985004663467407
) O 0 6.090752776799491e-06
homozygotes O 0 0.00039313462912105024
from O 0 1.7336864175376832e-06
10 O 0 2.2650888240605127e-06
ethnic O 0 3.646896630016272e-06
populations O 0 3.290902895969339e-05
. O 0 4.212993735563941e-05

Both O 0 8.268535566458013e-06
genomic O 0 0.00011470717436168343
mutations O 0 3.968715463997796e-05
and O 0 7.327762432396412e-07
their O 0 3.8598554397140106e-07
effects O 0 6.693707837257534e-05
on O 0 2.3771112864778843e-06
cDNA O 0 8.345679816557094e-05
were O 0 1.1926978004339617e-05
characterized O 0 0.005595976486802101
. O 0 9.36879005166702e-05

Protein O 0 0.00024022288562264293
- O 0 0.0002764988166745752
truncation O 0 7.047396502457559e-05
testing O 0 4.391846687212819e-06
of O 0 1.0970855157665937e-07
the O 0 5.626186521112686e-07
entire O 0 5.563754712056834e-06
ATM O 0 0.00010743476013885811
cDNA O 0 3.967156226281077e-05
detected O 0 5.666093420586549e-05
92 O 0 1.897853690024931e-05
( O 0 1.661704800426378e-06
66 O 0 7.3063438321696594e-06
% O 0 8.170202931978565e-07
) O 0 9.57038992055459e-07
truncating O 0 8.237161819124594e-05
mutations O 0 1.1632219866442028e-05
in O 0 7.620007522746164e-07
140 O 0 1.2640413842746057e-05
mutant O 0 0.00015654513845220208
alleles O 0 9.712522296467796e-05
screened O 0 0.0005191608797758818
. O 0 8.113605144899338e-05

The O 0 3.469028160907328e-05
haplotyping O 0 0.005899480078369379
of O 0 1.104748389479937e-05
patients O 0 0.46190187335014343
with O 0 6.271944130276097e-06
identical O 0 0.00026797212194651365
mutations O 0 0.00026088792947120965
indicates O 0 4.641770283342339e-05
that O 0 8.102202997406494e-08
almost O 0 7.684088387804877e-08
all O 0 4.935800212990671e-09
of O 0 1.5542010345370727e-08
these O 0 1.934511040246889e-08
represent O 0 1.4399974190837384e-07
common O 0 3.91330922866473e-06
ancestry O 0 9.20415641303407e-06
and O 0 5.820602382300422e-07
that O 0 5.245053671387723e-07
very O 0 3.0463511393463705e-06
few O 0 8.19588422018569e-06
spontaneously O 0 0.00037917104782536626
recurring O 0 0.00525261415168643
ATM O 0 0.026228493079543114
mutations O 0 0.00037673325277864933
exist O 0 2.9607394026243128e-05
. O 0 4.975176489097066e-05

Assays O 0 0.00013220917026046664
requiring O 0 7.872565038269386e-05
minimal O 0 3.2839056075317785e-05
amounts O 0 1.9853448520734673e-06
of O 0 3.31479100168508e-07
genomic O 0 4.257448381395079e-05
DNA O 0 3.0517359846271574e-05
were O 0 5.58448505216802e-07
designed O 0 3.8974653762124944e-06
to O 0 1.1858862336566744e-07
allow O 0 7.963658958942688e-07
rapid O 0 8.534568041795865e-05
screening O 0 1.0945708709186874e-05
for O 0 3.94488267829729e-07
common O 0 7.868666216381826e-06
ethnic O 0 1.3157989997125696e-05
mutations O 0 0.0007714986568316817
. O 0 0.00011137439287267625

These O 0 4.352772066340549e-06
rapid O 0 0.0003159175394102931
assays O 0 5.0134636694565415e-05
detected O 0 0.00014901868416927755
mutations O 0 1.0636006663844455e-05
in O 0 8.212998068302113e-07
76 O 0 1.6951295037870295e-05
% O 0 4.3942122829321306e-07
of O 0 3.284663421254663e-07
Costa O 0 5.7859513617586344e-05
Rican O 0 0.00014738536265213042
patients O 0 0.007512763142585754
( O 0 3.495579903756152e-06
3 O 0 1.3411943200480891e-06
) O 0 4.1581793652767374e-07
, O 0 9.398684142070124e-08
50 O 0 1.4419266847198742e-07
% O 0 1.7651413486419187e-07
of O 0 2.7835295668410254e-07
Norwegian O 0 0.00040785159217193723
patients O 0 0.006716235540807247
( O 0 3.5056455089943483e-06
1 O 0 1.2654987813220941e-06
) O 0 3.326178443785466e-07
, O 0 9.549787449714131e-08
25 O 0 2.1101406844081794e-07
% O 0 2.7236742994318774e-07
of O 0 5.104872116135084e-07
Polish O 0 0.04155973345041275
patients O 0 0.09483421593904495
( O 0 4.119672667002305e-06
4 O 0 2.9498612548195524e-06
) O 0 4.653476253224653e-07
, O 0 7.810605495706113e-08
and O 0 3.675842208394897e-08
14 O 0 3.667985026822862e-07
% O 0 2.481596652614826e-07
of O 0 4.6250940499703574e-07
Italian O 0 0.004194511100649834
patients O 0 0.09085392951965332
( O 0 6.769063475076109e-06
1 O 0 2.30367209042015e-06
) O 0 8.014133641154331e-07
, O 0 1.3406004484295408e-07
as O 0 1.2711713281987613e-07
well O 0 1.8019855474449287e-07
as O 0 5.534387810257613e-07
in O 0 2.2804388208896853e-06
patients O 0 0.0011192274978384376
of O 0 2.464415956637822e-06
Amish O 0 0.006693526171147823
/ O 0 0.008984634652733803
Mennonite O 0 0.00035195579403080046
and O 0 5.385361873777583e-06
Irish O 0 0.00022113052546046674
English O 0 5.709201650461182e-05
backgrounds O 0 0.00013063942606095225
. O 0 0.00011429859296185896

Additional O 0 3.680061854538508e-05
mutations O 0 6.112771370681003e-05
were O 0 8.618992524134228e-07
observed O 0 4.6155423660820816e-06
in O 0 1.5529052461715764e-06
Japanese O 0 3.0319059078465216e-05
, O 0 1.7982052895604284e-06
Utah O 0 1.9226908989367075e-05
Mormon O 0 8.736533345654607e-06
, O 0 2.053093339782208e-06
and O 0 2.478902842995012e-06
African O 0 8.815777255222201e-05
American O 0 0.00028274054056964815
patients O 1 0.7786266207695007
. O 0 0.00021067584748379886

These O 0 1.201114628202049e-06
assays O 0 8.91652780410368e-06
should O 0 7.457758215423382e-07
facilitate O 0 1.8953384142150753e-06
screening O 0 2.1087851564516313e-05
for O 0 4.615216312231496e-06
A B-Disease 1 0.890365719795227
- I-Disease 1 0.9921846985816956
T I-Disease 1 0.9982984662055969
heterozygotes O 0 0.00026856883778236806
in O 0 7.439452929247636e-07
the O 0 1.2189641438453691e-06
populations O 0 3.3232279292860767e-06
studied O 0 1.2131689800298773e-05
. O 0 6.148095508251572e-06
. O 0 3.0463303119177e-05

The O 0 0.0005071055493317544
von B-Disease 1 0.6903979778289795
Hippel I-Disease 1 0.9738513827323914
- I-Disease 1 0.9511118531227112
Lindau I-Disease 1 0.9919873476028442
tumor I-Disease 1 0.9960734844207764
suppressor O 0 0.002871778095141053
gene O 0 1.3658879652211908e-05
is O 0 5.151734967512311e-07
required O 0 6.586956260434818e-07
for O 0 3.9305825794144766e-07
cell O 0 0.00018483864550944418
cycle O 0 0.00010385768109699711
exit O 0 0.0001593361230334267
upon O 0 3.5767203371506184e-05
serum O 0 0.03369831293821335
withdrawal O 0 0.0007980467635206878
. O 0 8.505903679179028e-05

The O 0 3.713418482220732e-05
inactivation O 0 0.0008434492629021406
of O 0 3.7095167044753907e-06
the O 0 5.3800013120053336e-05
von B-Disease 1 0.7142738103866577
Hippel I-Disease 1 0.9753491282463074
- I-Disease 0 0.3915698826313019
Lindau I-Disease 1 0.947698175907135
( I-Disease 0 0.000855816702824086
VHL I-Disease 1 0.9935746788978577
) I-Disease 0 0.0007095642504282296
tumor I-Disease 1 0.9954694509506226
suppressor O 0 0.4152415096759796
gene O 0 0.0026578432880342007
predisposes O 1 0.6847322583198547
affected O 0 0.0001301995653193444
individuals O 0 2.8116012344980845e-06
to O 0 2.6850630092667416e-06
the O 0 0.00019425184291321784
human O 1 0.8240177035331726
VHL B-Disease 1 0.9998700618743896
cancer I-Disease 1 0.9999738931655884
syndrome I-Disease 1 0.9999793767929077
and O 0 5.3724899771623313e-05
is O 0 2.7073301680502482e-05
associated O 0 0.00011469393939478323
with O 0 0.00015693684690631926
sporadic B-Disease 1 0.9890047907829285
renal I-Disease 1 0.9999241828918457
cell I-Disease 1 0.998336672782898
carcinomas I-Disease 1 0.9997732043266296
( O 0 0.20088188350200653
RCC B-Disease 1 0.9993994235992432
) O 0 0.0003415365645196289
and O 0 9.681471419753507e-05
brain B-Disease 1 0.991678774356842
hemangioblastomas I-Disease 1 0.5294687747955322
. O 0 0.00029858291964046657

VHL O 1 0.9650033116340637
- O 0 0.007451679091900587
negative O 0 0.00017024550470523536
786 O 0 0.04557173326611519
- O 0 0.004849458113312721
0 O 0 0.00012262324162293226
RCC B-Disease 1 0.9930930137634277
cells O 0 5.999842323944904e-05
are O 0 8.656259069539374e-07
tumorigenic O 0 0.002047951566055417
in O 0 2.0644753021770157e-05
nude O 0 0.0223222766071558
mice O 0 0.001155645470134914
which O 0 9.404033676219115e-07
is O 0 1.0753916512840078e-06
suppressed O 0 1.7456768546253443e-05
by O 0 4.7383434775838396e-07
the O 0 1.5559916164420429e-06
reintroduction O 0 0.00023937852529343218
of O 0 1.8427823306410573e-05
VHL B-Disease 1 0.9918849468231201
. O 0 0.0003445515176281333

Remarkably O 0 0.0031505662482231855
, O 0 5.4752363212173805e-06
this O 0 6.341432481349329e-07
occurs O 0 4.592337063513696e-06
without O 0 8.976533081295202e-07
affecting O 0 6.240133188839536e-06
the O 0 9.214187457473599e-07
growth O 0 1.6628666344331577e-05
rate O 0 3.612582304413081e-06
and O 0 2.7330568741490424e-07
cell O 0 3.0802701076027006e-05
cycle O 0 2.0594610759872012e-05
profile O 0 3.485776232992066e-06
of O 0 1.368941013879521e-07
these O 0 4.7264424551940465e-07
cells O 0 5.3865824156673625e-05
in O 0 4.394603365653893e-06
culture O 0 5.0042970542563125e-05
. O 0 5.4889223974896595e-05

The O 0 9.427885379409418e-05
786 O 0 0.013391387648880482
- O 0 0.0007670149207115173
0 O 0 1.91653634828981e-05
cell O 0 0.00016653268539812416
line O 0 3.1332809157902375e-05
, O 0 2.845367589543457e-06
like O 0 1.1525209629326127e-05
many O 0 1.0497277799004223e-05
cancer B-Disease 1 0.9995115995407104
cells O 0 0.0002639681624714285
, O 0 2.075094926112797e-06
fails O 0 1.8435874153510667e-05
to O 0 1.9495725211982062e-07
exit O 0 1.8750532035483047e-05
the O 0 1.828860149544198e-06
cell O 0 0.00012381521810311824
cycle O 0 5.633045657305047e-05
upon O 0 1.956618689291645e-05
serum O 0 0.047664135694503784
withdrawal O 0 0.0006254560430534184
. O 0 8.665303903399035e-05

Here O 0 2.557975494710263e-05
, O 0 1.8551498897068086e-06
it O 0 2.4104608087327506e-07
is O 0 2.176791582542137e-07
shown O 0 3.0200232004062855e-07
that O 0 3.529592973450235e-08
reintroduction O 0 2.913821390393423e-06
of O 0 7.943037871882552e-08
the O 0 1.5163130910877953e-06
wild O 0 6.293426122283563e-05
- O 0 0.001468365779146552
type O 0 0.00043926050420850515
VHL B-Disease 1 0.5747490525245667
gene O 0 1.9471030100248754e-05
restores O 0 5.807542765978724e-05
the O 0 6.912616186127707e-07
ability O 0 6.119439149188111e-06
of O 0 1.0036801540991291e-05
VHL O 1 0.9964175224304199
- O 1 0.8663561940193176
negative O 0 0.013773667626082897
RCC B-Disease 1 0.9995923638343811
cancer I-Disease 1 0.9990083575248718
cells O 0 6.497337744804099e-05
to O 0 5.679243031408987e-07
exit O 0 2.060458791675046e-05
the O 0 1.3034841686021537e-06
cell O 0 8.14413942862302e-05
cycle O 0 2.2667640223517083e-05
and O 0 1.1077361250499962e-06
enter O 0 2.837205283867661e-05
G0 O 1 0.7309032082557678
/ O 0 0.0037955620791763067
quiescence O 0 0.002212032675743103
in O 0 2.426770151942037e-05
low O 0 0.0031910736579447985
serum O 0 0.10171028971672058
. O 0 0.00015259698557201773

Both O 0 0.00018994331185240299
VHL O 1 0.9821893572807312
- O 0 0.003219667123630643
positive O 0 2.486671473889146e-05
and O 0 3.625765020842664e-05
VHL O 1 0.9931414723396301
- O 0 0.009395216591656208
negative O 0 0.0001718012208584696
RCC B-Disease 1 0.9962480664253235
cells O 0 5.7618952268967405e-05
exit O 0 3.621296855271794e-05
the O 0 2.2447973151429323e-06
cell O 0 7.395498687401414e-05
cycle O 0 3.8776270230300725e-05
by O 0 2.1617013317154488e-06
contact O 0 4.081840961589478e-05
inhibition O 0 0.0005945111042819917
. O 0 8.581117435824126e-05

The O 0 9.697881614556536e-05
cyclin O 0 0.007919742725789547
- O 0 0.0001804249477572739
dependent O 0 2.9760336474282667e-05
kinase O 0 0.0001851981651270762
inhibitor O 0 0.0006028520874679089
, O 0 7.464065674867015e-06
p27 O 0 0.0015621270285919309
, O 0 1.891277634058497e-06
accumulates O 0 0.00011415709741413593
upon O 0 4.4727648855769075e-06
serum O 0 0.011974929831922054
withdrawal O 0 1.9417069779592566e-05
, O 0 1.9377982596324728e-07
only O 0 2.659164266560765e-08
in O 0 7.15282908458903e-08
the O 0 1.907078939211715e-07
presence O 0 1.041603695739468e-06
of O 0 1.1626779041762347e-06
VHL B-Disease 1 0.991174042224884
, O 0 7.325211868192127e-07
as O 0 1.9078500201885618e-07
a O 0 5.903913233851199e-07
result O 0 4.174246441834839e-07
of O 0 5.606840502991872e-08
the O 0 5.396483970798727e-07
stabilization O 0 1.931578663061373e-05
of O 0 2.8402496354829054e-07
the O 0 3.0599371712014545e-06
protein O 0 7.136727072065696e-05
. O 0 3.691816164064221e-05

We O 0 4.342196007200982e-06
propose O 0 1.857136157923378e-05
that O 0 4.46904635964529e-07
the O 0 1.3460685295285657e-06
loss O 0 5.8733741752803326e-05
of O 0 1.2247191989445128e-06
wild O 0 0.000176126035512425
- O 0 0.004403065424412489
type O 0 0.0011220178566873074
VHL B-Disease 1 0.8766527771949768
gene O 0 1.5578949387418106e-05
results O 0 2.1054881926829694e-06
in O 0 3.227737579436507e-07
a O 0 1.515711687716248e-06
specific O 0 2.6199163585260976e-06
cellular O 0 0.0025680596008896828
defect O 1 0.8763133883476257
in O 0 3.398807530174963e-05
serum O 1 0.7209659814834595
- O 0 0.0009015669347718358
dependent O 0 1.1691575309669133e-05
growth O 0 2.0971112462575547e-05
control O 0 6.581878551514819e-06
, O 0 1.1462295788078336e-06
which O 0 9.867992503131973e-07
may O 0 4.837137385038659e-05
initiate O 0 0.000714929134119302
tumor B-Disease 1 0.9960860013961792
formation O 0 0.005240156315267086
. O 0 0.00011356927279848605

This O 0 1.3462904462357983e-05
is O 0 1.4285434190242086e-05
corrected O 0 0.0002561436267569661
by O 0 3.207173051578138e-07
the O 0 4.3167599983462424e-07
reintroduction O 0 3.710123564815149e-05
of O 0 1.3237485063655186e-06
wild O 0 0.00017775209562387317
- O 0 0.019049670547246933
type O 0 0.022419840097427368
VHL B-Disease 1 0.9949506521224976
, O 0 3.4255652280990034e-05
implicating O 0 0.3802603483200073
VHL B-Disease 1 0.9642102718353271
as O 0 1.7674705077297403e-06
the O 0 3.0939468160795514e-06
first O 0 2.9652601369889453e-05
tumor B-Disease 1 0.9927349090576172
suppressor O 0 0.0004912890144623816
involved O 0 9.702993111204705e-07
in O 0 1.593944034539163e-07
the O 0 1.8705850379774347e-07
regulation O 0 1.9839762899209745e-06
of O 0 3.2991110288094205e-07
cell O 0 0.00019643439736682922
cycle O 0 7.473396544810385e-05
exit O 0 7.171041215769947e-05
, O 0 3.776393953103252e-07
which O 0 7.926072242980808e-08
is O 0 1.882004738718024e-07
consistent O 0 4.5475260890270874e-07
with O 0 1.0475054779135462e-07
its O 0 4.2625885043889866e-07
gatekeeper O 0 0.00022661710681859404
function O 0 2.506028749849065e-06
in O 0 4.812691258848645e-06
the O 0 0.00036393996560946107
kidney O 1 0.9996570348739624
. O 0 5.988170232740231e-05
. O 0 6.082198160584085e-05

Piebaldism B-Disease 1 0.9783072471618652
with O 0 0.0069636995904147625
deafness B-Disease 1 0.9997007846832275
: O 0 6.936390127521008e-05
molecular O 0 8.170735964085907e-05
evidence O 0 2.101369682350196e-05
for O 0 6.66904088575393e-06
an O 0 0.00030785400304012
expanded O 0 0.40097281336784363
syndrome O 1 0.9997972846031189
. O 0 0.0006445318576879799

In O 0 1.3169968042348046e-05
a O 0 1.4240685231925454e-05
South O 0 2.094788578688167e-05
African O 0 1.8023283701040782e-05
girl O 0 0.00028305340674705803
of O 0 6.684768322884338e-06
Xhosa O 1 0.8733183741569519
stock O 0 0.011208873242139816
with O 0 0.0010715582175180316
severe O 1 0.9988724589347839
piebaldism B-Disease 1 0.9921465516090393
and O 0 0.003050306113436818
profound O 1 0.9967922568321228
congenital O 1 0.9999885559082031
sensorineural B-Disease 1 0.9999610185623169
deafness I-Disease 1 0.9999725818634033
we O 0 2.14282645174535e-05
identified O 0 1.2906732081319205e-05
a O 0 2.8155511699878844e-06
novel O 0 5.7275710787507705e-06
missense O 0 3.4325337765039876e-05
substitution O 0 2.6673735646909336e-06
at O 0 1.4323127288662363e-06
a O 0 8.739439181226771e-07
highly O 0 1.2265929854038404e-06
conserved O 0 1.5053325341796153e-06
residue O 0 5.037925802753307e-06
in O 0 1.1521099452238559e-07
the O 0 2.433642407595471e-07
intracellular O 0 9.598756150808185e-06
kinase O 0 3.968908458773512e-06
domain O 0 5.451516926768818e-07
of O 0 2.0403035705385264e-07
the O 0 8.321624591189902e-06
KIT O 0 0.4147147536277771
proto O 0 0.2849411070346832
- O 0 0.004343534354120493
oncogene O 0 0.004768981132656336
, O 0 1.3859109458280727e-05
R796G O 0 0.0010923217050731182
. O 0 9.249192225979641e-05

Though O 0 0.0015825785230845213
auditory B-Disease 0 0.13760797679424286
anomalies I-Disease 0 0.07046059519052505
have O 0 6.461447355832206e-06
been O 0 3.6013684621138964e-06
observed O 0 6.911608124937629e-06
in O 0 4.98620784128434e-06
mice O 0 0.0008110381895676255
with O 0 5.901148597331485e-06
dominant O 0 0.0008879521628841758
white O 0 0.018739115446805954
spotting O 0 0.17992886900901794
( O 0 0.00013790871889796108
W O 1 0.9372552633285522
) O 0 2.292562612637994e-06
due O 0 2.3131973648560233e-05
to O 0 4.9551294978300575e-06
KIT O 1 0.8011927008628845
mutations O 0 0.0017078014789149165
, O 0 0.00035495657357387245
deafness B-Disease 1 0.9998475313186646
is O 0 9.715367923490703e-06
not O 0 1.4571817246178398e-06
typical O 0 0.00014469685265794396
in O 0 1.130615419242531e-05
human O 0 8.909843018045649e-05
piebaldism B-Disease 0 0.12390249222517014
. O 0 0.00016293949738610536

Thus O 0 1.7850705262389965e-05
, O 0 2.9888090011809254e-06
the O 0 3.1089127787709003e-06
occurrence O 0 0.00017574656521901488
of O 0 8.529368642484769e-05
sensorineural B-Disease 1 0.999833345413208
deafness I-Disease 1 0.9999613761901855
in O 0 7.93113504187204e-05
this O 0 2.0019022485939786e-05
patient O 0 0.040598299354314804
extends O 0 4.938118581776507e-05
considerably O 0 1.7185982869705185e-05
the O 0 2.0474237771850312e-07
phenotypic O 0 6.650989689660491e-06
range O 0 1.058769612427568e-06
of O 0 7.833983204363903e-07
piebaldism B-Disease 0 0.0029361406341195107
due O 0 4.6021061280043796e-05
to O 0 1.9148255887557752e-06
KIT O 0 0.05939707159996033
gene O 0 5.0089241995010525e-05
mutation O 0 3.6375153285916895e-05
in O 0 1.4395664038602263e-06
humans O 0 1.2225264981680084e-05
and O 0 2.989290578625514e-06
tightens O 0 0.005719026084989309
the O 0 3.951011422032025e-06
clinical O 0 0.00018817544332705438
similarity O 0 2.1741705495514907e-05
between O 0 1.3495323401002679e-05
piebaldism B-Disease 0 0.0037080293986946344
and O 0 5.05700313624402e-07
the O 0 3.490955293727893e-07
various O 0 5.021138917982171e-07
forms O 0 0.00017811244470067322
of O 0 0.005192815791815519
Waardenburg B-Disease 1 0.9998910427093506
syndrome I-Disease 1 0.9999641180038452
. O 0 0.0006520519964396954
. O 0 0.00038111567846499383

Cycloheximide O 0 0.003547914093360305
facilitates O 0 6.921998283360153e-05
the O 0 1.5497481626880472e-06
identification O 0 1.8700512782743317e-06
of O 0 8.592172662247322e-07
aberrant O 0 0.0002679049503058195
transcripts O 0 3.0051582143642008e-05
resulting O 0 1.99187397811329e-05
from O 0 1.5168945992627414e-06
a O 0 3.850409939332167e-06
novel O 0 1.765800880093593e-05
splice O 0 0.0002591777592897415
- O 0 0.0001614276843611151
site O 0 8.805483048490714e-06
mutation O 0 1.0152883987757377e-05
in O 0 1.5692907027187175e-06
COL17A1 O 0 0.010326826013624668
in O 0 4.665269898396218e-06
a O 0 0.0001253003574674949
patient O 0 0.15572579205036163
with O 0 0.00029922235989943147
generalized O 1 0.9833074808120728
atrophic B-Disease 1 0.998984158039093
benign I-Disease 1 0.9991508722305298
epidermolysis I-Disease 1 0.997815728187561
bullosa I-Disease 1 0.9943153262138367
. O 0 0.007304450962692499

Patients O 1 0.979017972946167
with O 0 0.0029687422793358564
generalized O 1 0.9878305792808533
atrophic B-Disease 1 0.9992817044258118
benign I-Disease 1 0.999464213848114
epidermolysis I-Disease 1 0.9989562034606934
bullosa I-Disease 1 0.9981179237365723
often O 0 0.00027130640228278935
show O 0 8.177626295946538e-05
decreased O 0 0.0005695741274394095
expression O 0 7.850976544432342e-06
of O 0 7.507527698180638e-06
type O 1 0.7751147150993347
XVII O 1 0.9983035326004028
collagen O 1 0.8672559857368469
, O 0 1.8434062667438411e-06
a O 0 5.369208338379394e-06
transmembrane O 0 0.00022375487606041133
hemidesmosomal O 0 0.0002341704093851149
protein O 0 6.914218374731718e-06
encoded O 0 2.895086026910576e-06
by O 0 2.180168667109683e-05
COL17A1 O 0 0.08680600672960281
. O 0 0.00015678504132665694

This O 0 8.629935109638609e-06
report O 0 1.2253079148649704e-05
documents O 0 2.899053470173385e-06
a O 0 7.683584954065736e-06
novel O 0 2.2099331545177847e-05
splice O 0 0.0003833672381006181
- O 0 0.0001415775768691674
site O 0 6.227155608939938e-06
mutation O 0 1.0151828064408619e-05
in O 0 1.6454306432933663e-06
COL17A1 O 0 0.012684391811490059
in O 0 3.412248361200909e-06
a O 0 0.00015183468349277973
patient O 0 0.36398956179618835
with O 0 0.0005019734380766749
generalized O 1 0.9932025074958801
atrophic B-Disease 1 0.9995597004890442
benign I-Disease 1 0.9996392726898193
epidermolysis I-Disease 1 0.9994150400161743
bullosa I-Disease 1 0.9986144304275513
, O 0 2.9180118872318417e-05
and O 0 2.081421143884654e-06
applies O 0 3.6109840948483907e-06
a O 0 1.871446556833689e-06
new O 0 1.0100502549903467e-06
methodology O 0 1.711680397420423e-06
to O 0 1.666492863705571e-07
define O 0 1.5773990753586986e-06
and O 0 3.722117583038198e-07
characterize O 0 3.423863381613046e-05
the O 0 1.1828867627627915e-06
resulting O 0 3.4722586860880256e-05
mRNA O 0 4.668280598707497e-05
splice O 0 0.0006375107332132757
variants O 0 0.0002683533530216664
. O 0 7.44734425097704e-05

Mutational O 0 0.0016375202685594559
analysis O 0 1.1376999282219913e-05
of O 0 4.27319764639833e-06
COL17A1 O 0 0.115125872194767
identified O 0 8.56906408444047e-05
a O 0 0.00010738047421909869
maternally O 0 0.012899265624582767
inherited O 1 0.958294153213501
G O 0 0.1142023354768753
- O 0 0.0016245176084339619
to O 0 4.0930049181042705e-06
- O 0 0.0025273868814110756
T O 0 0.02266060933470726
transversion O 0 8.217454160330817e-05
at O 0 9.319805371887924e-07
the O 0 5.102107252241694e-07
- O 0 6.5182689468201715e-06
1 O 0 1.7736410029556282e-07
position O 0 8.17190368707088e-08
of O 0 2.3968217988112883e-07
exon O 0 0.0003061076276935637
32 O 0 5.125349707668647e-05
. O 0 3.297952935099602e-05

This O 0 1.8372902559349313e-05
acceptor O 0 0.00034112943103536963
splice O 0 0.0006392449722625315
- O 0 0.00024398750974796712
site O 0 8.230881576309912e-06
mutation O 0 4.696688847616315e-06
led O 0 6.421337275241967e-07
to O 0 6.438433075572902e-08
the O 0 1.900238117968911e-07
formation O 0 3.618168193497695e-06
of O 0 2.7087119747193356e-07
aberrant O 0 0.00017113365174736828
transcripts O 0 1.6672314814059064e-05
present O 0 3.7541451547440374e-06
at O 0 2.4835671865730546e-05
extremely O 0 0.00021898515115026385
low O 0 0.0004657044482883066
levels O 0 0.00021817900415044278
. O 0 3.5949433367932215e-05

Based O 0 9.563068488205317e-06
on O 0 1.8684540918911807e-06
our O 0 1.6546993037991342e-06
recent O 0 6.775961537641706e-06
finding O 0 7.090980034263339e-06
that O 0 5.324661287886556e-06
cycloheximide O 0 0.00994216650724411
stabilized O 0 0.0080310283228755
mutant O 0 0.00015004341548774391
COL17A1 O 0 0.003029561135917902
transcripts O 0 1.947697273863014e-05
in O 0 1.8953672906718566e-06
keratinocytes O 0 0.00020007259445264935
homozygous O 0 9.281449820264243e-06
for O 0 3.788210563016037e-07
a O 0 1.506538137618918e-05
frameshift O 0 0.015206354670226574
mutation O 0 3.234305768273771e-05
, O 0 3.8031242866054527e-07
the O 0 3.337675025250064e-07
effects O 0 4.023562269139802e-06
of O 0 1.196546719484104e-07
the O 0 3.7841232369828504e-06
splice O 0 0.00036277229082770646
- O 0 5.943295036558993e-05
site O 0 2.504829353711102e-06
mutation O 0 1.6187004803214222e-06
on O 0 2.2296073609595624e-07
splicing O 0 3.8002199289621785e-06
of O 0 6.501592224594788e-07
COL17A1 O 0 0.0033805654384195805
transcripts O 0 1.6504378436366096e-05
were O 0 3.587426817830419e-07
determined O 0 7.27475935491384e-07
using O 0 5.239663778411341e-07
reverse O 0 4.4723576138494536e-05
transcriptase O 0 0.000326771754771471
polymerase O 0 6.28294437774457e-05
chain O 0 2.780351678666193e-05
reaction O 0 1.833103283388482e-06
of O 0 4.1838990938458664e-08
total O 0 4.707082155164244e-07
RNA O 0 8.445360435871407e-06
from O 0 1.8432692741043866e-06
keratinocytes O 0 0.00012828655599150807
incubated O 0 1.688485463091638e-05
for O 0 8.871979275681952e-07
2 O 0 2.9226239348645322e-05
. O 0 4.304930189391598e-05

5 O 0 8.122198050841689e-05
h O 0 0.00010469542030477896
in O 0 8.960470267993514e-07
the O 0 6.669674803561065e-07
presence O 0 1.8146122329198988e-06
or O 0 8.96390645266365e-07
absence O 0 5.905055786570301e-06
of O 0 8.335876486853522e-07
10 O 0 1.3855158613296226e-05
microg O 0 0.0033628400415182114
cycloheximide O 0 0.0019129542633891106
per O 0 2.732073699007742e-05
ml O 0 0.006138109602034092
. O 0 7.537058263551444e-05

Using O 0 5.126062205818016e-06
this O 0 1.0640007985784905e-06
approach O 0 4.311347311158897e-06
, O 0 1.2381754004309187e-06
an O 0 5.868005246156827e-06
abnormally O 0 0.012635206803679466
spliced O 0 0.0002863147237803787
transcript O 0 0.0015677716583013535
was O 0 5.4728134273318574e-05
identified O 0 1.3376686638366664e-06
that O 0 7.028422288613001e-08
contains O 0 1.0363785207800902e-07
an O 0 7.641732224783482e-08
extra O 0 3.616839308051567e-07
264 O 0 2.4296775791299297e-06
bases O 0 1.9062042611039942e-07
upstream O 0 2.0606908037734684e-06
from O 0 5.196102961235738e-07
exon O 0 2.8766036848537624e-05
32 O 0 2.0069417132617673e-06
, O 0 4.6390047714339744e-07
resulting O 0 6.733773716405267e-06
in O 0 9.706056971481303e-07
a O 0 1.1302661732770503e-05
premature O 0 0.0033352074678987265
termination O 0 0.00045269180554896593
codon O 0 3.333693530294113e-05
27 O 0 2.239253808511421e-05
bp O 0 0.00010201559780398384
downstream O 0 9.763629350345582e-06
from O 0 1.7355026784571237e-06
the O 0 6.029543328622822e-06
cryptic O 0 0.0007468149997293949
splice O 0 0.0014860823284834623
site O 0 0.0003284483391325921
. O 0 0.00012117388541810215

Three O 0 2.274960479553556e-06
other O 0 1.1019747034879401e-06
splice O 0 0.00014145141176413745
variants O 0 1.5761836039018817e-05
, O 0 3.6963726302019495e-07
including O 0 7.087236042480072e-08
one O 0 8.338804491359042e-08
derived O 0 2.249000488063757e-07
from O 0 1.10333068903401e-07
the O 0 2.048120961717359e-07
skipping O 0 5.540336587728234e-06
of O 0 2.729607899709663e-07
exon O 0 0.00012776356015820056
32 O 0 6.330571522994433e-06
, O 0 5.135321998750442e-07
were O 0 4.1991529542428907e-07
also O 0 2.394857574472553e-06
identified O 0 2.0207955458317883e-05
. O 0 2.3292328478419222e-05

These O 0 2.869336412913981e-06
results O 0 9.293877155869268e-06
indicate O 0 8.341877219208982e-06
the O 0 1.6157484878931427e-06
usefulness O 0 2.2346652258420363e-05
of O 0 2.0584241156029748e-06
cycloheximide O 0 0.35063180327415466
treatment O 0 0.002863120287656784
in O 0 1.2838680731874774e-06
evaluating O 0 5.685660198651021e-06
the O 0 1.0395286835773732e-06
abnormal O 0 6.065966954338364e-05
processing O 0 5.917983685321815e-07
of O 0 8.665545436770117e-08
mRNA O 0 1.3308393818078912e-06
due O 0 3.9315186768362764e-06
to O 0 2.967893806271604e-07
splice O 0 0.0001374442654196173
- O 0 0.00022614290355704725
site O 0 1.4127667782304343e-05
mutations O 0 1.8696820916375145e-05
, O 0 1.7613372165214969e-06
because O 0 4.976459422323387e-06
( O 0 4.119232471566647e-06
i O 0 2.9210661978140706e-06
) O 0 5.363704644878453e-07
aberrant O 0 2.3195882022264414e-05
splicing O 0 4.815547072212212e-06
often O 0 1.340515268566378e-06
generates O 0 6.037932962499326e-06
a O 0 1.0657541679393034e-05
premature O 0 0.005692849867045879
termination O 0 0.0006623330409638584
codon O 0 6.0144782764837146e-05
, O 0 4.168027771811467e-06
( O 0 6.226603090908611e-06
ii O 0 0.0004068602283950895
) O 0 1.2107370821468066e-06
transcripts O 0 1.0441804079164285e-05
with O 0 3.628728563853656e-06
premature O 0 0.007451588287949562
termination O 0 0.0016585126286372542
codons O 0 2.5711011403473094e-05
can O 0 7.544898608102812e-07
occur O 0 3.0147220968501642e-06
at O 0 1.3246930393506773e-05
low O 0 0.0002466572041157633
or O 0 3.251884845667519e-05
undetectable O 0 0.15311531722545624
levels O 0 3.1013329135021195e-05
due O 0 1.0954543540719897e-05
to O 0 7.021815804364451e-07
nonsense O 0 6.818447582190856e-05
- O 0 1.3350788321986329e-05
mediated O 0 7.971462764544412e-06
mRNA O 0 2.7933792807743885e-06
decay O 0 2.5179155272780918e-05
, O 0 1.0573328381724423e-06
and O 0 6.682395792267926e-07
( O 0 4.436494236870203e-06
iii O 0 0.0002992155496031046
) O 0 2.7633751642497373e-07
the O 0 1.7208400038271066e-07
levels O 0 9.511510370430187e-07
of O 0 2.910327623339981e-08
these O 0 8.854898680965562e-08
transcripts O 0 6.817718258389505e-06
can O 0 2.9844858318028855e-07
be O 0 1.9926635275169247e-07
increased O 0 5.158517524250783e-06
by O 0 4.84918791698874e-06
cycloheximide O 0 0.00864277221262455
. O 0 7.062378426780924e-05

A O 0 9.351222979603335e-05
deletion O 0 0.0005974865052849054
mutation O 0 0.00012588802201207727
in O 0 6.382023457263131e-06
COL17A1 O 0 0.011569234542548656
in O 0 2.196044533775421e-06
five O 0 4.688047283707419e-06
Austrian O 0 0.0010688718175515532
families O 0 1.4320082300400827e-05
with O 0 0.00011278748570475727
generalized O 1 0.9820193648338318
atrophic B-Disease 1 0.9992632269859314
benign I-Disease 1 0.9991363883018494
epidermolysis I-Disease 1 0.9978653788566589
bullosa I-Disease 1 0.9892820119857788
represents O 0 3.8378657336579636e-05
propagation O 0 1.0267331163049676e-05
of O 0 1.023663116939133e-06
an O 0 8.608694770373404e-06
ancestral O 0 0.0007143355906009674
allele O 0 0.0004953956231474876
. O 0 9.17839424801059e-05

Patients O 1 0.9719537496566772
with O 0 0.00285396259278059
generalized O 1 0.9867562055587769
atrophic B-Disease 1 0.9990124702453613
benign I-Disease 1 0.9991673231124878
epidermolysis I-Disease 1 0.9985215067863464
bullosa I-Disease 1 0.9974532723426819
, O 0 3.291109896963462e-05
a O 0 1.704500573396217e-05
usually O 0 1.744709697959479e-05
nonlethal O 0 0.00022566085681319237
form O 0 2.5104371161432937e-05
of O 0 5.610256630461663e-05
junctional B-Disease 1 0.996006429195404
epidermolysis I-Disease 1 0.9976029992103577
bullosa I-Disease 1 0.995253324508667
, O 0 4.513462772592902e-05
have O 0 1.059558053384535e-05
generalized O 0 0.0027749487198889256
blistering B-Disease 1 0.9650161862373352
, O 0 0.007377475034445524
nail B-Disease 1 0.9988321661949158
dystrophy I-Disease 1 0.9997574687004089
, O 0 0.17113026976585388
patchy B-Disease 1 0.9988964796066284
alopecia I-Disease 1 0.9998525381088257
, O 0 0.0019478794420138001
and O 0 0.0021883626468479633
dental B-Disease 1 0.999204695224762
abnormalities I-Disease 1 0.9986781477928162
. O 0 0.001143370638601482

Skin B-Disease 1 0.999028205871582
fragility I-Disease 1 0.9950864911079407
in O 0 2.4777404178166762e-05
most O 0 8.214696208597161e-06
cases O 0 2.8294023650232702e-05
is O 0 2.5602689674997237e-06
due O 0 6.145416136860149e-06
to O 0 2.0651297916174371e-07
mutations O 0 2.1932648905931273e-06
in O 0 1.5148143006626924e-07
the O 0 4.6698636424480355e-07
gene O 0 9.761747605807614e-06
encoding O 0 3.3502219594083726e-05
type O 0 0.23575250804424286
XVII O 1 0.9978479146957397
collagen O 1 0.9941406846046448
( O 0 0.00030745682306587696
COL17A1 O 0 0.2641755938529968
) O 0 6.914780533406883e-05
. O 0 7.364159682765603e-05

Recently O 0 0.0014077076921239495
, O 0 1.566013270348776e-05
we O 0 3.113838374702027e-06
reported O 0 2.5267625460401177e-05
five O 0 5.56323448108742e-06
Austrian O 0 0.001221013837493956
families O 0 3.414980892557651e-05
with O 0 0.00012084802438039333
generalized O 1 0.981752872467041
atrophic B-Disease 1 0.9993293285369873
benign I-Disease 1 0.9993932247161865
epidermolysis I-Disease 1 0.9992707371711731
bullosa I-Disease 1 0.9985302686691284
who O 0 6.17966361460276e-05
share O 0 1.0863989700737875e-05
the O 0 6.7759033299807925e-06
same O 0 3.2962518162094057e-05
COL17A1 O 1 0.7138592600822449
mutation O 0 0.002581943990662694
. O 0 9.957304428098723e-05

Affected O 0 0.00041490598232485354
individuals O 0 2.8960439522052184e-06
in O 0 8.735406140658597e-07
three O 0 3.3620437989156926e-07
families O 0 1.721489752526395e-06
are O 0 1.3794330300243018e-07
homozygous O 0 7.996231033757795e-06
for O 0 1.5910508182059857e-06
4003delTC O 0 0.0008388449205085635
, O 0 1.8858671637644875e-06
whereas O 0 2.305054522366845e-06
those O 0 1.9159018904701952e-07
in O 0 3.1836171388022194e-07
two O 0 3.2507489322597394e-07
others O 0 2.0496579509199364e-06
are O 0 9.450234870200802e-07
compound O 0 0.0007862504571676254
heterozygotes O 0 0.017701979726552963
. O 0 0.00016881671035662293

To O 0 2.0609659259207547e-06
determine O 0 1.683127607066126e-06
if O 0 7.545662015218113e-07
the O 0 3.504197536585707e-07
occurrence O 0 1.1028074368368834e-05
of O 0 9.010479971038876e-07
4003delTC O 0 0.0013080548960715532
in O 0 7.799141030773171e-07
these O 0 2.3697137407907576e-07
unrelated O 0 4.831384285353124e-05
families O 0 2.133527459591278e-06
signifies O 0 1.6300278730341233e-05
propagation O 0 1.0006351658375934e-06
of O 0 7.940326440802892e-08
an O 0 1.100808844967105e-06
ancestral O 0 2.9957098377053626e-05
allele O 0 1.1116507266706321e-05
or O 0 1.305802015849622e-06
a O 0 9.977526133297943e-06
mutational O 0 0.0065258340910077095
hot O 0 0.00020829516870435327
spot O 0 2.7250373022980057e-05
, O 0 1.4615936834161403e-06
haplotypes O 0 4.120315861655399e-05
were O 0 2.5056701247194724e-07
determined O 0 1.2759777519022464e-06
for O 0 2.066063444772226e-07
polymorphisms O 0 1.4087803720030934e-05
both O 0 2.7242819555794995e-07
within O 0 1.0285883718097466e-06
and O 0 7.143801212805556e-06
flanking O 0 0.02011469565331936
COL17A1 O 1 0.8925458192825317
. O 0 0.00034648572909645736

Five O 0 8.788004925008863e-05
intragenic O 0 0.0058049364015460014
polymorphisms O 0 0.00011389190331101418
were O 0 6.227508038136875e-07
chosen O 0 8.036596454985556e-07
based O 0 6.557716574207006e-07
on O 0 1.6963317648333032e-06
their O 0 2.001339680646197e-06
informativeness O 0 0.009730308316648006
. O 0 6.190203566802666e-05

One O 0 1.803185227799986e-06
of O 0 4.0945795376501337e-07
these O 0 5.068702648713952e-07
, O 0 1.4306035609479295e-06
not O 0 5.229440489529225e-07
previously O 0 7.499870662286412e-06
reported O 0 3.211751391063444e-05
, O 0 7.157993877626723e-07
was O 0 5.821728791488567e-06
2988 O 0 0.00013247659080661833
A O 0 6.449036391131813e-06
or O 0 1.666720095272467e-06
C O 0 2.3197761038318276e-05
that O 0 1.5138755316002062e-07
introduces O 0 2.5893389192788163e-06
a O 0 7.021066039669677e-07
new O 0 9.149372317551752e-07
restriction O 0 6.182898232509615e-06
site O 0 6.718776148773031e-06
for O 0 2.966851297969697e-06
Eco0109 O 0 0.0018869198393076658
I O 0 0.0005542748840525746
. O 0 3.640451905084774e-05

All O 0 1.032167233461223e-06
the O 0 3.872527486237232e-06
4003delTC O 0 0.0003612097061704844
alleles O 0 1.1713272215274628e-05
showed O 0 7.580146302643698e-06
the O 0 4.4644454533226963e-07
same O 0 7.25383813460212e-07
haplotype O 0 7.422974886139855e-05
for O 0 1.4403104842131143e-07
these O 0 1.907104234533108e-07
five O 0 3.2584975997451693e-06
polymorphic O 0 0.0011890047462657094
markers O 0 0.0034643784165382385
. O 0 0.000124715908896178

Fourteen O 0 0.00033759011421352625
microsatellite O 0 0.005098328460007906
polymorphisms O 0 0.0001523522805655375
were O 0 6.544465804836364e-07
selected O 0 2.563911607467162e-07
based O 0 2.7565869231693796e-07
on O 0 2.7072141506323533e-07
their O 0 2.576153974587214e-07
high O 0 4.402960621519014e-05
heterozygosity O 0 0.0002601626329123974
and O 0 2.5365363853779854e-07
their O 0 1.1123257337430914e-07
location O 0 1.5947908877933514e-06
within O 0 3.7335260003601434e-06
10q23 O 0 0.002807810204103589
- O 0 0.0015076352283358574
q25 O 0 0.0010798218427225947
near O 0 0.000497694534715265
COL17A1 O 0 0.07353723794221878
. O 0 0.00018139247549697757

Three O 0 8.077397069428116e-06
families O 0 8.147116204781923e-06
shared O 0 1.342574705631705e-05
microsatellite O 0 0.005317544564604759
polymorphisms O 0 0.0003311661712359637
covering O 0 7.561066740890965e-05
at O 0 8.333767254953273e-06
most O 0 1.6093541717054904e-06
19 O 0 2.5856332285911776e-05
cM O 0 0.0014870896702632308
, O 0 9.092364052776247e-07
whereas O 0 2.1932860363449436e-06
the O 0 1.8567432391591865e-07
others O 0 3.5052002544944116e-07
shared O 0 3.1421728863278986e-07
smaller O 0 1.3449406424115296e-06
regions O 0 7.229900234051456e-07
consistent O 0 3.0790758955845376e-06
with O 0 1.4332499631564133e-06
cross O 0 8.50523792905733e-05
- O 0 4.341978637967259e-05
over O 0 1.8681497238048905e-07
events O 0 2.600509958483599e-07
during O 0 1.179384639726777e-06
passage O 0 6.116400754763163e-07
of O 0 5.310140593905999e-08
this O 0 1.5710246259459382e-07
mutation O 0 4.302090019336902e-06
through O 0 3.0476888923658407e-07
several O 0 8.729393812245689e-07
generations O 0 7.855241710785776e-05
. O 0 6.270792800933123e-05

These O 0 4.179826191830216e-06
results O 0 1.8032189473160543e-05
indicate O 0 1.836850424297154e-05
that O 0 1.7203179822899983e-06
4003delTC O 0 0.00014828234270680696
occurs O 0 3.699737135320902e-06
on O 0 3.3960313317038526e-07
a O 0 2.2089327558205696e-06
single O 0 4.49316257800092e-06
ancestral O 0 9.460648288950324e-05
allele O 0 0.00012568352394737303
. O 0 1.2219004929647781e-05
. O 0 4.0382827137364075e-05

The O 0 0.0001615254586795345
haptoglobin O 0 0.041738905012607574
- O 0 0.0020079128444194794
gene O 0 0.00011147754412377253
deletion O 0 0.000598111015278846
responsible O 0 8.011145109776407e-05
for O 0 4.4892483856529e-05
anhaptoglobinemia B-Disease 0 0.11068101227283478
. O 0 0.0001857885654317215

We O 0 7.252251180034364e-06
have O 0 6.777653425160679e-07
found O 0 9.470770123698458e-07
an O 0 5.422076583272428e-07
allelic O 0 3.270239176345058e-05
deletion O 0 2.025169123953674e-05
of O 0 4.1533996864018263e-07
the O 0 5.134825642016949e-06
haptoglobin O 0 0.0032065424602478743
( O 0 7.836008990125265e-06
Hp O 0 4.501753574004397e-05
) O 0 4.4792182052333374e-07
gene O 0 1.4457397128353477e-06
from O 0 2.1114389880949602e-07
an O 0 2.8501099791355955e-07
individual O 0 7.830763593119627e-07
with O 0 1.2657929801207501e-05
anhaptoglobinemia B-Disease 0 0.04909246787428856
. O 0 0.00011171655933139846

The O 0 2.962052712973673e-05
Hp O 0 0.0005203092005103827
gene O 0 3.1052481062943116e-05
cluster O 0 1.6752481315052137e-05
consists O 0 5.540429128814139e-07
of O 0 2.618916994379106e-07
coding O 0 2.9620046916534193e-05
regions O 0 4.018225467916636e-07
of O 0 1.2728212084311963e-07
the O 0 1.6550353620914393e-06
alpha O 0 1.5190331396297552e-05
chain O 0 3.809656482189894e-05
and O 0 4.563505058285955e-07
beta O 0 2.7365871574147604e-05
chain O 0 9.133356797974557e-06
of O 0 1.595836067735945e-07
the O 0 2.0626196146622533e-06
haptoglobin O 0 0.0010403962805867195
gene O 0 1.8587201338959858e-05
( O 0 3.366838882357115e-06
Hp O 0 2.9985851142555475e-05
) O 0 1.6562955806875834e-07
and O 0 1.9973356302216416e-08
of O 0 2.258878950556209e-08
the O 0 3.5482503335515503e-07
alpha O 0 6.268302968237549e-06
chain O 0 1.5371542758657597e-05
and O 0 3.6850914852948335e-07
beta O 0 2.951011083496269e-05
chain O 0 1.4086164810578339e-05
of O 0 3.623854922807368e-07
the O 0 9.713394319987856e-06
haptoglobin O 0 0.018705878406763077
- O 0 0.0004016883613076061
related O 0 1.507052638771711e-05
gene O 0 3.382717113709077e-05
( O 0 1.2550445717351977e-05
Hpr O 0 0.005080870818346739
) O 0 3.507645487843547e-06
, O 0 8.183740760614455e-07
in O 0 5.807339107377629e-07
tandem O 0 2.8077614842914045e-05
from O 0 8.352619147444784e-07
the O 0 1.7638922145124525e-06
5 O 0 1.5119411727937404e-05
side O 0 8.390861330553889e-05
. O 0 4.3251755414530635e-05

Southern O 0 0.00019934137526433915
blot O 0 0.001340361195616424
and O 0 7.24618075764738e-06
PCR O 0 0.00019461836200207472
analyses O 0 1.8791790353134274e-05
have O 0 1.1345266557327705e-06
indicated O 0 5.144770966580836e-06
that O 0 8.595009859391212e-08
the O 0 1.0712690823311277e-07
individual O 0 9.084565988359827e-08
with O 0 5.487507905854727e-07
anhaptoglobinemia B-Disease 0 0.00125933310482651
was O 0 3.192350504832575e-06
homozygous O 0 1.6623198462184519e-06
for O 0 4.5055834618779045e-08
the O 0 2.8592029366336646e-07
gene O 0 6.3627348936279304e-06
deletion O 0 2.382835555181373e-05
and O 0 1.3961526690309256e-07
that O 0 1.103749482922467e-07
the O 0 7.367900707322406e-07
gene O 0 1.3001349543628749e-05
deletion O 0 9.081953612621874e-05
was O 0 7.344396180997137e-06
included O 0 6.861079100417555e-07
at O 0 1.5695750334998593e-06
least O 0 2.2445692593464628e-07
from O 0 4.3789722781184537e-07
the O 0 1.1013138419002644e-06
promoter O 0 0.0002158012066502124
region O 0 2.3225795757753076e-06
of O 0 3.9309722410507675e-07
Hp O 0 0.00011045823339372873
to O 0 1.4588976000595721e-06
Hpr O 0 0.0014474273193627596
alpha O 0 7.967153578647412e-06
but O 0 4.2799410948646255e-07
not O 0 9.966449709963854e-08
to O 0 5.330319368113123e-07
Hpr O 0 0.0018129822565242648
beta O 0 0.00019405600323807448
( O 0 2.7674081138684414e-05
Hpdel O 0 0.002934488467872143
) O 0 2.4004022634471767e-05
. O 0 3.059049049625173e-05

In O 0 1.3686340025742538e-05
addition O 0 5.512435564014595e-06
, O 0 1.3060075616522226e-06
we O 0 1.1501306573791226e-07
found O 0 4.041900751872163e-07
seven O 0 2.1827806051533116e-07
individuals O 0 2.439679462895583e-07
with O 0 1.1694726254063426e-06
hypohaptoglobinemia B-Disease 0 0.0015878190752118826
in O 0 7.715523224760545e-07
three O 0 4.2015403778350446e-07
families O 0 8.866135203788872e-07
, O 0 1.2471602417463146e-07
and O 0 5.360247001817697e-08
the O 0 1.5549873921827384e-07
genotypes O 0 8.152727787091862e-06
of O 0 3.541893534020346e-08
six O 0 1.5428040001097543e-07
of O 0 6.218053982820493e-08
the O 0 5.36101481429796e-07
seven O 0 9.720915841171518e-07
individuals O 0 5.18630088208738e-07
were O 0 2.276539703416347e-07
found O 0 1.2158642448412138e-06
to O 0 6.300417112470313e-07
be O 0 6.0259676502028015e-06
Hp2 O 0 0.020123889669775963
/ O 0 0.016323445364832878
Hpdel O 0 0.01236442569643259
. O 0 0.00012637018517125398

The O 0 4.5331940782489255e-05
phenotypes O 0 0.0004907516413368285
and O 0 5.3735011533717625e-06
genotypes O 0 0.00013870553812012076
in O 0 3.665645351702551e-07
one O 0 7.588962347426786e-08
of O 0 3.471512854957837e-08
these O 0 3.454781349887526e-08
three O 0 2.954375588615221e-07
families O 0 2.0148004296061117e-06
showed O 0 1.9226488802814856e-05
the O 0 7.220597808554885e-07
father O 0 9.03043746802723e-06
to O 0 3.118570646165608e-07
be O 0 8.121045311781927e-07
hypohaptoglobinemic B-Disease 0 0.0006185857928358018
( O 0 9.300226338382345e-06
Hp2 O 0 0.0003620702482294291
) O 0 3.289235337433638e-06
and O 0 2.945293317679898e-06
Hp2 O 0 0.00894745159894228
/ O 0 0.0023550917394459248
Hpdel O 0 0.0006331100012175739
, O 0 9.912001814882387e-07
the O 0 8.449256370113289e-07
mother O 0 2.7664476874633692e-05
to O 0 3.8606725638601347e-07
be O 0 7.092834266586578e-07
Hp2 O 0 0.0005226030480116606
- O 0 2.68613948719576e-05
1 O 0 1.0962066880892962e-06
and O 0 1.07859000308963e-06
Hp1 O 0 0.0027100059669464827
/ O 0 0.0003825418243650347
Hp2 O 0 0.00014202334568835795
, O 0 8.671083406852631e-08
one O 0 1.041450836680724e-08
of O 0 1.1960055168458439e-08
the O 0 2.2888306716595253e-07
two O 0 1.1117403175830987e-07
children O 0 1.6778436702225008e-06
to O 0 2.302621595617893e-07
be O 0 6.657447784164106e-07
hypohaptoglobinemic B-Disease 0 0.00023785945086274296
( O 0 5.3156200010562316e-06
Hp2 O 0 0.0003894481051247567
) O 0 1.7173231299238978e-06
and O 0 1.5616616337865707e-06
Hp2 O 0 0.01100665982812643
/ O 0 0.0032270902302116156
Hpdel O 0 0.0008500852272845805
, O 0 4.3641554725581955e-07
and O 0 1.3023841916037782e-07
the O 0 2.485561481080367e-07
other O 0 1.666105049480393e-07
child O 0 1.72078944160603e-05
to O 0 3.5324185887475323e-07
be O 0 9.73745045484975e-07
Hp1 O 0 0.0005037598893977702
and O 0 6.765306807210436e-06
Hp1 O 0 0.04808778688311577
/ O 0 0.007134552579373121
Hpdel O 0 0.0014699040912091732
, O 0 1.4988834209361812e-06
showing O 0 6.410931291611632e-06
an O 0 8.907340429686883e-07
anomalous O 0 7.301067671505734e-05
inheritance O 0 3.644877506303601e-05
of O 0 2.2171889213495888e-06
Hp O 0 0.008344336412847042
phenotypes O 0 0.000512454193085432
in O 0 2.9671823540411424e-06
the O 0 6.09756989433663e-06
child O 0 0.00042739894706755877
with O 0 2.7988940928480588e-05
Hp1 O 0 0.19329236447811127
. O 0 0.00011109308252343908

The O 0 0.0001941616937983781
Hp2 O 1 0.5598017573356628
/ O 0 0.129257470369339
Hpdel O 0 0.008822443895041943
individuals O 0 4.506083314481657e-06
had O 0 8.490066647937056e-06
an O 0 1.2579747590280022e-06
extremely O 0 1.762447936926037e-05
low O 0 1.0533460226724856e-05
level O 0 1.80060430921003e-06
of O 0 5.793399395770393e-07
Hp O 0 0.00015152084233704954
( O 0 6.290124474617187e-06
mean O 0 1.7540474800625816e-05
+ O 0 0.00014385957911144942
/ O 0 0.00014699058374390006
- O 0 2.417597352177836e-05
SD O 0 5.7673201808938757e-05
= O 0 7.1415665843233e-06
0 O 0 6.600727715522225e-07
. O 0 7.552766874141525e-07
049 O 0 0.0007660292321816087
+ O 0 0.00013194997154641896
/ O 0 9.613467409508303e-05
- O 0 7.736604857200291e-06
0 O 0 6.147816407064965e-07
. O 0 6.865660679977736e-07
043 O 0 0.00022085510136093944
mg O 0 0.0005424144328571856
/ O 0 0.00016401568427681923
ml O 0 8.51463628350757e-05
; O 0 8.619912819085584e-07
n O 0 4.244992396706948e-06
= O 0 8.120170605252497e-06
6 O 0 1.1914515880562249e-06
) O 0 2.4290790179293253e-07
, O 0 5.632447042103195e-08
compared O 0 3.680227393942914e-07
with O 0 4.8480512049309255e-08
the O 0 1.2712442298834503e-07
level O 0 1.09977520423854e-06
( O 0 3.153526506594062e-07
1 O 0 2.3114661473755405e-07
. O 0 1.3711949975458992e-07
64 O 0 5.3972125897416845e-06
+ O 0 4.3958738388027996e-05
/ O 0 1.9521081412676722e-05
- O 0 3.867419309244724e-06
1 O 0 4.3162495444448723e-07
. O 0 4.5551738026006205e-07
07 O 0 7.743272726656869e-05
mg O 0 0.0004434988659340888
/ O 0 9.701358794700354e-05
ml O 0 6.018242129357532e-05
) O 0 2.4736974069128337e-07
obtained O 0 5.994959337840555e-07
from O 0 1.5691769021941582e-06
52 O 0 2.6629904823494144e-05
healthy O 0 0.0001571157918078825
volunteers O 0 3.433315941947512e-05
having O 0 5.929013423155993e-05
phenotype O 0 0.003071506740525365
Hp2 O 0 0.0025477742310613394
, O 0 1.82875726295606e-06
whereas O 0 5.4860192904016e-06
the O 0 2.543435357438284e-06
serum O 0 0.0036358917132019997
Hp O 0 4.822720802621916e-05
level O 0 9.079859637495247e-07
of O 0 7.363139076232983e-08
an O 0 3.3411592426091374e-07
individual O 0 7.69557175317459e-07
with O 0 5.885367500013672e-06
Hp1 O 0 0.16300347447395325
/ O 0 0.005533771123737097
Hpdel O 0 0.004171751439571381
was O 0 7.480476779164746e-05
0 O 0 2.092219074256718e-05
. O 0 3.20255130645819e-05

50 O 0 0.00034360153949819505
mg O 0 0.07437367737293243
/ O 0 0.018894173204898834
ml O 0 0.0013429340906441212
, O 0 7.38186145099462e-07
which O 0 1.5254116192409128e-07
was O 0 3.6667606195806e-07
approximately O 0 7.699229342961189e-08
half O 0 8.28610282610498e-08
the O 0 5.8736883801202566e-08
level O 0 3.820041740709712e-07
of O 0 1.0298266062136463e-07
Hp O 0 4.4356213038554415e-05
in O 0 1.3092299013806041e-06
control O 0 1.5005645764176734e-05
sera O 0 0.0005373055464588106
from O 0 1.136844389293401e-06
the O 0 3.837696567643434e-06
Hp1 O 0 0.0011942362179979682
phenotype O 0 0.00024947550264187157
( O 0 2.9607062970171683e-06
1 O 0 1.334227363258833e-06
. O 0 4.200082344141265e-07
26 O 0 5.14048952027224e-06
+ O 0 5.020874959882349e-05
/ O 0 3.294661655672826e-05
- O 0 2.437066314087133e-06
0 O 0 2.0646729126383434e-07
. O 0 8.858851430204595e-08
33 O 0 2.4864937131496845e-06
mg O 0 0.00016906832752283663
/ O 0 8.558748959330842e-05
ml O 0 6.042607856215909e-05
; O 0 1.0513560937397415e-06
n O 0 6.820280304964399e-06
= O 0 6.136199317552382e-06
9 O 0 1.2285386219446082e-06
) O 0 1.395686552996267e-07
, O 0 1.0177976861314164e-07
showing O 0 2.6932980290439446e-06
a O 0 5.864715603820514e-06
gene O 0 0.00016498297918587923
- O 0 0.0008810372091829777
dosage O 0 0.0009979944443330169
effect O 0 7.786895730532706e-05
. O 0 4.1998326196335256e-05

The O 0 7.3839064498315565e-06
other O 0 1.3953301731817191e-06
allele O 0 3.8399233744712546e-05
( O 0 7.371664196398342e-06
Hp2 O 0 0.0002586707123555243
) O 0 4.809644451597705e-07
of O 0 8.452627042743188e-08
individuals O 0 8.417768526669533e-07
with O 0 7.937189366202801e-06
Hp2 O 1 0.8500167727470398
/ O 0 0.07787377387285233
Hpdel O 0 0.01084515918046236
was O 0 3.8398207834688947e-05
found O 0 1.942792096087942e-06
to O 0 1.212564626484891e-07
have O 0 9.576893233997907e-08
, O 0 4.5751921362580106e-08
in O 0 3.2896597446097076e-08
all O 0 1.5214562054666203e-08
exons O 0 3.2578668651694898e-06
, O 0 2.903641700413573e-07
no O 0 6.459848691520165e-07
mutation O 0 5.241890903562307e-06
, O 0 2.1872108391107759e-07
by O 0 4.4619085315389384e-07
DNA O 0 2.5256758817704394e-05
sequencing O 0 4.338948929216713e-05
. O 0 3.411318903090432e-05

On O 0 1.703819066278811e-06
the O 0 3.139848274713586e-07
basis O 0 9.067306905308214e-08
of O 0 6.787291795262718e-08
the O 0 4.0960441083370824e-07
present O 0 1.6935241546889301e-06
study O 0 1.9285005237179575e-06
, O 0 2.5085344645958685e-07
the O 0 2.6974726097250823e-07
mechanism O 0 2.00986460185959e-06
of O 0 4.171214698089898e-07
anhaptoglobinemia B-Disease 0 0.0004515475011430681
and O 0 2.5747641529960674e-07
the O 0 2.5173272888423526e-07
mechanism O 0 1.953788114406052e-06
of O 0 2.213089942415536e-07
anomalous O 0 0.00016962103836704046
inheritance O 0 0.0001661589922150597
of O 0 7.179192380135646e-06
Hp O 0 0.01542440801858902
phenotypes O 0 0.0020425645634531975
were O 0 6.324983132799389e-06
well O 0 7.349678980972385e-06
explained O 0 0.0001749150105752051
. O 0 6.760848918929696e-05

However O 0 2.431493703625165e-05
, O 0 2.8857330107712187e-06
the O 0 1.6272085758828325e-06
mechanism O 0 2.2184280169312842e-05
of O 0 6.953524007258238e-06
hypohaptoglobinemia B-Disease 0 0.13703930377960205
remains O 0 0.0008347760303877294
unknown O 0 0.0010029284749180079

ATM O 0 0.00624798284843564
mutations O 0 0.00033937228727154434
and O 0 2.2546133550349623e-05
phenotypes O 0 0.04195578768849373
in O 0 0.00747233722358942
ataxia B-Disease 1 0.999847412109375
- I-Disease 1 0.9983779191970825
telangiectasia I-Disease 1 0.9985820055007935
families O 0 1.3243937246443238e-05
in O 0 1.2381693750285194e-06
the O 0 1.7319744074484333e-06
British O 0 2.000451786443591e-05
Isles O 0 1.7354930605506524e-05
: O 0 8.162360813912528e-07
expression O 0 2.3594623144163052e-07
of O 0 1.2245446612269006e-07
mutant O 0 3.204766471753828e-05
ATM O 0 0.0001402108755428344
and O 0 1.0024997436630656e-06
the O 0 8.721757694729604e-06
risk O 0 0.00493761757388711
of O 0 0.0005417430074885488
leukemia B-Disease 1 0.9999638795852661
, O 1 0.9492812752723694
lymphoma B-Disease 1 0.999988317489624
, O 0 0.00937429815530777
and O 0 0.1685745269060135
breast B-Disease 1 0.9998350143432617
cancer I-Disease 1 0.9995409250259399
. O 0 0.0011386253172531724

We O 0 5.82322809350444e-06
report O 0 3.039178182007163e-06
the O 0 3.7691907550652104e-07
spectrum O 0 4.165492555330275e-06
of O 0 5.114939654049522e-07
59 O 0 9.17514698812738e-05
ATM O 0 0.0004656203091144562
mutations O 0 5.834499097545631e-05
observed O 0 5.347459591575898e-05
in O 0 0.00033587979851290584
ataxia B-Disease 1 0.9995021820068359
- I-Disease 1 0.9950083494186401
telangiectasia I-Disease 1 0.9970717430114746
( O 0 0.0009288130677305162
A B-Disease 1 0.9960746765136719
- I-Disease 1 0.9978875517845154
T I-Disease 1 0.9993270635604858
) O 0 7.045399979688227e-05
patients O 0 0.005546238739043474
in O 0 2.2619865376327652e-06
the O 0 7.439300588885089e-06
British O 0 0.00021054570970591158
Isles O 0 0.0005842337850481272
. O 0 6.845191091997549e-05

Of O 0 7.981480848684441e-06
51 O 0 0.00018142725457437336
ATM O 0 0.002249889774248004
mutations O 0 6.860528810648248e-05
identified O 0 4.248633558745496e-06
in O 0 5.864391141585656e-07
families O 0 4.933412469654286e-07
native O 0 5.372631903810543e-07
to O 0 1.3101676188398415e-07
the O 0 8.907425126380986e-07
British O 0 2.1437301256810315e-05
Isles O 0 3.1584513635607436e-05
, O 0 1.3097782129989355e-06
11 O 0 3.849976565106772e-06
were O 0 5.561699936151854e-07
founder O 0 4.6027955249883235e-05
mutations O 0 9.588199645804707e-06
, O 0 2.454507921356708e-07
and O 0 6.567198340690084e-08
2 O 0 1.7489696801931132e-07
of O 0 3.679468818518217e-08
these O 0 1.260206659026153e-07
11 O 0 5.480517756950576e-06
conferred O 0 0.00015019616694189608
a O 0 8.409374277107418e-05
milder O 0 0.14796261489391327
clinical O 0 0.010962146334350109
phenotype O 0 0.0012060606386512518
with O 0 1.7592153653822606e-06
respect O 0 1.4868504649712122e-06
to O 0 1.9347896795807173e-06
both O 0 3.6579349398380145e-05
cerebellar B-Disease 1 0.9990018010139465
degeneration I-Disease 1 0.9996914863586426
and O 0 8.511113264830783e-05
cellular O 0 0.006649919785559177
features O 0 0.00041033283923752606
. O 0 0.00014728507085237652

We O 0 1.001531654765131e-05
report O 0 7.522563919337699e-06
, O 0 6.947438464521838e-07
in O 0 6.108391517045675e-07
two O 0 3.0923479243938345e-06
A B-Disease 0 0.38339048624038696
- I-Disease 1 0.9046396017074585
T I-Disease 1 0.9942792654037476
families O 0 8.931941124501463e-07
, O 0 1.8449311767199106e-07
an O 0 6.853728109490476e-07
ATM O 0 6.010608558426611e-05
mutation O 0 2.1196627130848356e-05
( O 0 5.78033677811618e-06
7271T O 0 0.000892617623321712
- O 0 0.00150050048250705
- O 0 0.00026604963932186365
> O 0 0.0002127812331309542
G O 0 0.00017385583487339318
) O 0 8.581886845604458e-07
that O 0 2.5893638166962774e-07
may O 0 1.0449167575643514e-06
be O 0 1.0781975845475245e-07
associated O 0 8.652395990793593e-07
with O 0 2.6668320174394466e-07
an O 0 2.073581526929047e-06
increased O 0 0.00011287861707387492
risk O 0 0.004561577457934618
of O 0 0.0004377193981781602
breast B-Disease 1 0.9999213218688965
cancer I-Disease 1 0.9998328685760498
in O 0 7.1053163992473856e-06
both O 0 4.086818535142811e-06
homozygotes O 0 0.02638958767056465
and O 0 5.146115654497407e-06
heterozygotes O 0 0.005071450024843216
( O 0 1.9112470909021795e-05
relative O 0 5.214654083829373e-05
risk O 0 0.0005249534733593464
12 O 0 3.7153902212594403e-06
. O 0 9.268352414437686e-07
7 O 0 3.7060760860185837e-06
; O 0 2.6646632704796502e-06
P O 0 0.00099457788746804
= O 0 5.123907612869516e-05
. O 0 2.178127942897845e-06
0025 O 0 0.005199796054512262
) O 0 1.0564025387793663e-06
, O 0 2.871954052352521e-07
although O 0 2.5074007226066897e-07
there O 0 1.5314549273170996e-07
is O 0 3.7891788906563306e-07
a O 0 7.048000043141656e-06
less O 0 0.00010187968291575089
severe O 1 0.9992695450782776
A B-Disease 1 0.9990739822387695
- I-Disease 1 0.9988773465156555
T I-Disease 1 0.9995019435882568
phenotype O 0 0.00021084024047013372
in O 0 1.6023327020775469e-07
terms O 0 1.3712747204408515e-07
of O 0 8.801251993872938e-08
the O 0 1.832783482313971e-06
degree O 0 3.1512427085544914e-05
of O 0 7.07364160916768e-05
cerebellar B-Disease 1 0.9991230368614197
degeneration I-Disease 1 0.9997184872627258
. O 0 0.005108099430799484

This O 0 1.5904675819911063e-05
mutation O 0 0.00015863000589888543
( O 0 4.604349669534713e-05
7271T O 0 0.002615242963656783
- O 0 0.0017664472106844187
- O 0 0.0002351367293158546
> O 0 0.00012102065375074744
G O 0 5.21613510500174e-05
) O 0 2.2539646238328714e-07
also O 0 3.1198968741819044e-08
allows O 0 3.6202894904135974e-08
expression O 0 7.296564064063205e-08
of O 0 3.7341060021844896e-08
full O 0 1.6153602473423234e-06
- O 0 6.790530278522056e-06
length O 0 1.4590854107154883e-06
ATM O 0 1.0422067134641111e-05
protein O 0 8.914333875509328e-07
at O 0 5.576847570409882e-07
a O 0 1.5663450767533504e-06
level O 0 2.7571836653805804e-06
comparable O 0 5.77325772610493e-06
with O 0 3.691011158934998e-07
that O 0 1.0165022104047239e-06
in O 0 6.073589247534983e-06
unaffected O 0 0.002960803685709834
individuals O 0 1.5697285562055185e-05
. O 0 7.764236215734854e-05

In O 0 1.5912050002953038e-05
addition O 0 9.734500054037198e-06
, O 0 1.7988913896260783e-06
we O 0 2.2888306716595253e-07
have O 0 1.943020322414668e-07
studied O 0 6.539676178363152e-06
18 O 0 0.00010776422277558595
A B-Disease 1 0.9936042428016663
- I-Disease 1 0.9984765648841858
T I-Disease 1 0.9997014403343201
patients O 0 0.0768994465470314
, O 0 1.048634430844686e-06
in O 0 5.232263902144041e-07
15 O 0 2.455936737533193e-06
families O 0 2.928717549366411e-06
, O 0 5.757373855885817e-06
who O 0 0.00020623144519049674
developed O 1 0.9000852108001709
leukemia B-Disease 1 0.9999476671218872
, O 1 0.8738420009613037
lymphoma B-Disease 1 0.9999723434448242
, O 0 0.0029399681370705366
preleukemic O 1 0.9930623173713684
T O 1 0.9982210993766785
- O 1 0.5217731595039368
cell O 0 0.010613753460347652
proliferation O 0 0.13099129498004913
, O 0 0.00015439311391673982
or O 0 0.20405259728431702
Hodgkin B-Disease 1 0.9999599456787109
lymphoma I-Disease 1 0.9999856948852539
, O 0 3.943423507735133e-05
mostly O 0 1.4057151929591782e-05
in O 0 3.667187411338091e-05
childhood O 1 0.6656002402305603
. O 0 0.00032354966970160604

A O 0 3.927556099370122e-05
wide O 0 1.055795746651711e-05
variety O 0 1.8247363868795219e-06
of O 0 9.826924269873416e-07
ATM O 0 0.0013549852883443236
mutation O 0 9.31317190406844e-05
types O 0 1.2291057828406338e-05
, O 0 8.915516218621633e-07
including O 0 1.4199578117768397e-06
missense O 0 0.00037124031223356724
mutations O 0 4.962354796589352e-05
and O 0 1.6449928352813004e-06
in O 0 3.882162673107814e-06
- O 0 0.00040305504808202386
frame O 0 0.00015526592324022204
deletions O 0 3.1457511795451865e-05
, O 0 9.628219004298444e-07
were O 0 4.964420554642857e-07
seen O 0 1.0952099728456233e-05
in O 0 2.296606680829427e-06
these O 0 5.719830824091332e-06
patients O 1 0.8075469732284546
. O 0 0.0001240131532540545

We O 0 6.619994564971421e-06
also O 0 1.3098418776280596e-06
show O 0 4.1906199044206005e-07
that O 0 6.083602244189024e-08
25 O 0 2.2055426995848393e-07
% O 0 6.628180670986694e-08
of O 0 5.16773681624727e-08
all O 0 8.678766789671499e-07
A B-Disease 1 0.9850142598152161
- I-Disease 1 0.9984766840934753
T I-Disease 1 0.999665379524231
patients O 0 0.02591055817902088
carried O 0 5.208831680647563e-06
in O 0 3.0641715511592338e-06
- O 0 0.0001405897201038897
frame O 0 4.2212457628920674e-05
deletions O 0 2.286697599629406e-05
or O 0 5.021684046369046e-06
missense O 0 0.000486751610878855
mutations O 0 3.0229963158490136e-05
, O 0 2.963837459901697e-07
many O 0 3.170219287085274e-08
of O 0 6.649770512012765e-08
which O 0 3.2141423389475676e-07
were O 0 3.277997961959045e-07
also O 0 4.0331292439077515e-07
associated O 0 6.316540179795993e-07
with O 0 1.037044867757686e-07
expression O 0 4.6762718852733087e-07
of O 0 4.1250649474022794e-07
mutant O 0 0.00019174587214365602
ATM O 0 0.0009856222895905375
protein O 0 0.00012947357026860118
. O 0 5.6823802879080176e-05

The O 0 0.00016047892859205604
DMPK O 0 0.13850580155849457
gene O 0 0.0004851682751905173
of O 0 0.00045498640974983573
severely O 1 0.9982936978340149
affected O 1 0.995468020439148
myotonic B-Disease 1 0.9999109506607056
dystrophy I-Disease 1 0.9999797344207764
patients O 1 0.9986585378646851
is O 0 0.00037589395651593804
hypermethylated O 0 0.12794525921344757
proximal O 0 0.0068899900652468204
to O 0 5.124234576214803e-06
the O 0 1.1099632502009626e-05
largely O 0 6.957389996387064e-05
expanded O 0 0.00021879917767364532
CTG O 0 0.11055868864059448
repeat O 0 0.004818070214241743
. O 0 0.00012647446419578046

Using O 0 2.288287942064926e-05
methylation O 0 0.00023991413763724267
- O 0 0.00031822946039028466
sensitive O 0 9.730035344546195e-06
restriction O 0 1.1400383300497197e-05
enzymes O 0 6.207807928149123e-06
, O 0 6.728425319124653e-07
we O 0 1.7231488413926854e-07
characterized O 0 1.0195438335358631e-05
the O 0 2.311880678007583e-07
methylation O 0 2.823009253916098e-06
pattern O 0 7.990407539182343e-06
on O 0 2.9346878704927803e-07
the O 0 2.6901534511125647e-07
5 O 0 6.509725949399581e-07
side O 0 6.626145250265836e-07
of O 0 8.75328893812366e-08
the O 0 3.0485948627756443e-06
CTG O 0 0.004504473879933357
repeat O 0 3.140035551041365e-05
in O 0 6.546288204845041e-07
the O 0 1.9500762391544413e-06
DMPK O 0 0.0013990845764055848
gene O 0 4.432015884958673e-06
of O 0 2.6680478981688793e-07
normal O 0 1.9536651961971074e-05
individuals O 0 9.992600098485127e-07
and O 0 2.328627488168422e-06
of O 0 2.1982947146170773e-05
patients O 1 0.9981399774551392
affected O 0 0.2499309778213501
with O 0 0.39705318212509155
myotonic B-Disease 1 0.9999492168426514
dystrophy I-Disease 1 0.9999567270278931
, O 0 6.585126538993791e-05
showing O 0 7.928964623715729e-05
expansions O 0 3.073658808716573e-05
of O 0 5.175431283532816e-07
the O 0 1.1082423043262679e-05
repetitive O 0 0.008142592385411263
sequence O 0 0.00010953928722301498
. O 0 0.00010802081669680774

The O 0 1.7223554095835425e-05
gene O 0 3.557762465788983e-05
segment O 0 3.282881880295463e-05
analyzed O 0 5.446945579024032e-06
corresponds O 0 2.73785667559423e-06
to O 0 5.202757620281773e-07
the O 0 2.4681557988515124e-06
genomic O 0 0.00012225894897710532
SacI O 0 0.005927808582782745
- O 0 0.00032434461172670126
HindIII O 0 0.00024039542768150568
fragment O 0 2.310044874320738e-05
carrying O 0 6.506332283606753e-06
exons O 0 4.398062810651027e-05
11 O 0 5.462786430143751e-05
- O 0 0.0002834341721609235
15 O 0 8.965830602392089e-06
. O 0 1.1556951903912704e-05

There O 0 8.176429219020065e-06
is O 0 1.6099804724944988e-06
constitutive O 0 2.418090844003018e-05
methylation O 0 1.0255030247208197e-05
in O 0 1.4569162658517598e-06
intron O 0 0.0008743393700569868
12 O 0 4.2568622120597865e-06
at O 0 1.5753395246065338e-06
restriction O 0 1.8993608819073415e-06
sites O 0 1.5346010684424982e-07
of O 0 2.5402886194569874e-07
SacII O 0 0.0006328279268927872
and O 0 2.0685529307229444e-06
HhaI O 0 0.00041204679291695356
, O 0 1.1462263955763774e-06
localized O 0 4.195428846287541e-05
1 O 0 4.38536790170474e-06
, O 0 1.0703249699872686e-06
159 O 0 1.5186579730652738e-05
- O 0 1.208683806908084e-05
1 O 0 5.546646661969135e-07
, O 0 1.6777464395545394e-07
232 O 0 4.759380317409523e-06
bp O 0 1.151434571511345e-05
upstream O 0 9.912379255183623e-07
of O 0 1.1162320134872061e-07
the O 0 3.4505253552197246e-06
CTG O 0 0.012228776700794697
repeat O 0 0.00023512034385930747
, O 0 1.5773567838550662e-06
whereas O 0 3.2148516311281128e-06
most O 0 3.561499113402533e-07
, O 0 4.4664301412922214e-07
if O 0 2.1132278504865099e-07
not O 0 1.3472492454980056e-08
all O 0 4.6037089695971645e-09
, O 0 1.857861953169504e-08
of O 0 8.223326020129207e-09
the O 0 8.828775577285342e-08
other O 0 4.219891636125794e-08
sites O 0 2.4108655338750395e-07
of O 0 2.675235464266734e-07
SacII O 0 0.002183993114158511
, O 0 5.283396603772417e-06
HhaI O 0 0.0008580130524933338
, O 0 1.545320515106141e-06
and O 0 8.5599396015823e-07
HpaII O 0 0.00034442279138602316
in O 0 4.383493319437548e-07
this O 0 3.147145264392748e-07
region O 0 2.5291401470894925e-06
are O 0 1.8456492512086697e-07
unmethylated O 0 0.0002594245015643537
, O 0 1.0120519391421112e-06
in O 0 8.456841555926076e-07
normal O 0 5.398741905082716e-06
individuals O 0 3.2493167623215413e-07
and O 0 1.5597370861542004e-07
most O 0 1.6387923551519634e-07
of O 0 1.0014122153734206e-06
the O 0 0.00017682468751445413
patients O 1 0.9515558481216431
. O 0 0.00016967214469332248

In O 0 5.815963504574029e-06
a O 0 2.7818759917863645e-06
number O 0 4.5711624352406943e-07
of O 0 1.5571006315440172e-06
young O 0 0.0007882496574893594
and O 0 0.0003143270732834935
severely O 1 0.9984616041183472
affected O 0 0.4728332757949829
patients O 1 0.967520534992218
, O 0 2.2790691218688153e-06
however O 0 3.610894054872915e-07
, O 0 1.2228537116243388e-07
complete O 0 3.1944927059157635e-07
methylation O 0 6.51275627205905e-07
of O 0 1.968666651919193e-08
these O 0 4.8184684686702894e-08
restriction O 0 2.853204023267608e-06
sites O 0 4.961410127179988e-07
was O 0 1.7282028466070187e-06
found O 0 9.996031167247565e-07
in O 0 3.870367777381034e-07
the O 0 4.049511517223436e-06
mutated O 0 0.00042653337004594505
allele O 0 0.000167094636708498
. O 0 6.311822653515264e-05

In O 0 3.4698496165219694e-06
most O 0 8.017626669243327e-07
of O 0 6.114149755376275e-07
these O 0 3.84941131414962e-06
patients O 0 0.2607528865337372
, O 0 4.112670012546005e-06
the O 0 8.622136192570906e-06
onset O 1 0.995893120765686
of O 0 4.4644395529758185e-05
the O 0 0.30921292304992676
disease O 1 0.999931812286377
was O 1 0.9972879886627197
congenital O 1 0.9998972415924072
. O 0 0.007186122238636017

Preliminary O 0 7.437891326844692e-05
in O 0 1.5883850210229866e-05
vivo O 0 0.00027172680711373687
footprinting O 0 0.009155250154435635
data O 0 1.6869361161298002e-06
gave O 0 1.8145049125450896e-06
evidence O 0 1.1333230531818117e-06
for O 0 3.021581846951449e-07
protein O 0 1.2204728591314051e-05
- O 0 5.144637907505967e-05
DNA O 0 5.5132186389528215e-06
contact O 0 2.0500940536294365e-06
in O 0 3.7431269106491527e-07
normal O 0 5.994174898660276e-06
genes O 0 2.741904154390795e-06
at O 0 2.400180392214679e-06
an O 0 1.956681899173418e-06
Sp1 O 0 0.004161079879850149
consensus O 0 1.515997951173631e-06
binding O 0 1.0446100304761785e-06
site O 0 1.9541719211702002e-06
upstream O 0 1.7561343383931671e-06
of O 0 1.6264733915249963e-07
the O 0 1.8009287714448874e-06
CTG O 0 0.003442265558987856
repeat O 0 2.1654255760950036e-05
and O 0 8.6218555850337e-08
for O 0 5.965900129467627e-08
a O 0 5.24002359725273e-07
significant O 0 6.007888373460446e-07
reduction O 0 4.2396436583658215e-06
of O 0 3.3482209005342156e-08
this O 0 8.733975676022965e-08
interaction O 0 5.257764428279188e-07
in O 0 5.166534720046911e-07
cells O 0 4.48210766990087e-06
with O 0 8.020663244678872e-07
a O 0 1.9207849618396722e-05
hypermethylated O 0 0.025306666269898415
DMPK O 1 0.5577168464660645
gene O 0 0.00018948709475807846
. O 0 1.0732383998401929e-05
. O 0 4.127371357753873e-05

The O 0 0.001441141706891358
hemochromatosis B-Disease 1 0.9983091354370117
gene O 0 0.00023524549033027142
product O 0 2.8390513762133196e-05
complexes O 0 3.584703881642781e-05
with O 0 6.333248734335939e-07
the O 0 3.7326574329199502e-06
transferrin O 0 0.02372625842690468
receptor O 0 5.8211717259837314e-05
and O 0 1.137196818490338e-06
lowers O 0 0.0002538948319852352
its O 0 1.9693112562890747e-07
affinity O 0 3.054732587770559e-06
for O 0 2.385119728387508e-07
ligand O 0 2.2522557628690265e-05
binding O 0 6.354570359690115e-05
. O 0 5.40124747203663e-05

We O 0 1.887606777017936e-05
recently O 0 4.2941544961649925e-05
reported O 0 7.669016667932738e-06
the O 0 2.1325502075342229e-07
positional O 0 3.492687710604514e-06
cloning O 0 2.0246875465090852e-06
of O 0 1.381236529596208e-07
a O 0 6.0339498304529116e-06
candidate O 0 1.957805761776399e-05
gene O 0 0.00019882735796272755
for O 0 0.0003447963099461049
hereditary B-Disease 1 0.9993209838867188
hemochromatosis I-Disease 1 0.9999256134033203
called O 1 0.7402349710464478
HFE O 1 0.9939363598823547
. O 0 0.0012483734171837568

The O 0 2.1715573893743567e-05
gene O 0 3.979584653279744e-05
product O 0 8.124570740619674e-06
, O 0 5.74775583572773e-07
a O 0 5.308024810801726e-07
member O 0 3.2653926496095664e-07
of O 0 1.2923524650432228e-07
the O 0 2.6733380309451604e-06
major O 0 0.00015428289771080017
histocompatibility O 1 0.988497793674469
complex O 0 0.0005417926586233079
class O 0 0.0009744545677676797
I O 0 0.001432988909073174
- O 0 0.00030348796281032264
like O 0 2.524253659430542e-06
family O 0 6.19183219896513e-06
, O 0 7.608207965859037e-07
was O 0 1.6564596307944157e-06
found O 0 3.2984061704155465e-07
to O 0 3.3872165516868336e-08
have O 0 4.648898865866613e-08
a O 0 1.4783965980313951e-06
mutation O 0 1.902476287796162e-05
, O 0 8.463744052278344e-06
Cys O 0 0.03763178735971451
- O 0 0.0007168578449636698
282 O 0 0.0005331107531674206
- O 0 0.0017202161252498627
- O 0 0.0006204148521646857
> O 0 0.00035907741403207183
Tyr O 0 0.0016981579829007387
( O 0 4.3767613533418626e-06
C282Y O 0 6.38907658867538e-05
) O 0 6.237404477360542e-07
, O 0 1.8394113965314318e-07
in O 0 2.555908906742843e-07
85 O 0 3.251457201258745e-06
% O 0 8.975985110737383e-07
of O 0 1.019999103846203e-06
patient O 0 0.030199192464351654
chromosomes O 0 0.00024762374232523143
. O 0 9.27689325180836e-05

This O 0 8.743410035094712e-06
mutation O 0 8.322671783389524e-05
eliminates O 0 9.045557089848444e-05
the O 0 1.3095896065351553e-06
ability O 0 3.2555715279158903e-06
of O 0 1.7842131683210027e-06
HFE O 0 0.21638372540473938
to O 0 1.402660245730658e-06
associate O 0 1.2993292330065742e-05
with O 0 1.0909795491897967e-05
beta2 O 0 0.10472285747528076
- O 0 0.004465919919312
microglobulin O 0 0.0030339821241796017
( O 0 1.1695345165207982e-05
beta2m O 0 0.0010050078853964806
) O 0 4.549027835309971e-06
and O 0 3.3748722216841998e-06
prevents O 0 0.0006187013350427151
cell O 0 0.0037169908173382282
- O 0 0.0010712203802540898
surface O 0 9.899260476231575e-05
expression O 0 4.212258500047028e-05
. O 0 4.7058711061254144e-05

A O 0 5.884463098482229e-05
second O 0 1.9434131900197826e-05
mutation O 0 8.361340587725863e-05
that O 0 1.222469336426002e-06
has O 0 1.747683768371644e-06
no O 0 2.205787723141839e-06
effect O 0 5.924849574512336e-06
on O 0 3.6318997445050627e-06
beta2m O 0 0.006886003538966179
association O 0 0.00021243843366391957
, O 0 5.347479600459337e-06
H63D O 0 0.01602402701973915
, O 0 1.6441271100120503e-06
was O 0 2.9689456368942047e-06
found O 0 5.007529466638516e-07
in O 0 6.203850233532648e-08
eight O 0 8.837839970965433e-08
out O 0 5.099645861150748e-08
of O 0 1.0324581012355338e-07
nine O 0 1.0981079867633525e-05
patients O 0 0.0025734747759997845
heterozygous O 0 7.051381544442847e-06
for O 0 5.902579118810536e-07
the O 0 8.95109315024456e-06
C282Y O 0 0.0021677962504327297
mutant O 0 0.0007637510425411165
. O 0 0.00011528681352501735

In O 0 1.0879998626478482e-05
this O 0 3.2558507427893346e-06
report O 0 6.614391622861149e-06
, O 0 5.611418600892648e-07
we O 0 1.6352296938748623e-07
demonstrate O 0 1.5006842204456916e-06
in O 0 1.736168201205146e-06
cultured O 0 0.00010354943515267223
293 O 0 0.0005666453507728875
cells O 0 0.0003406380710657686
overexpressing O 0 0.014901561662554741
wild O 0 0.0001711517688818276
- O 0 0.0013837325386703014
type O 0 0.000162491574883461
or O 0 5.459093699755613e-06
mutant O 0 0.00012983137276023626
HFE O 0 0.032964494079351425
proteins O 0 7.518810321016645e-07
that O 0 1.1535578892107878e-07
both O 0 1.3562038247982855e-07
the O 0 8.212567195187148e-07
wild O 0 2.0698609660030343e-05
- O 0 0.0005671170074492693
type O 0 6.996484444243833e-05
and O 0 2.297826995345531e-06
H63D O 0 0.04246518760919571
HFE O 0 0.1194676011800766
proteins O 0 5.5691325542284176e-06
form O 0 1.2888417586509604e-05
stable O 0 0.0003708147560246289
complexes O 0 6.987843516981229e-05
with O 0 1.3533812079913332e-06
the O 0 1.3133218999428209e-05
transferrin O 0 0.22741304337978363
receptor O 0 0.0006404442247003317
( O 0 7.665265729883686e-05
TfR O 0 0.38392797112464905
) O 0 3.5521989047992975e-05
. O 0 4.863975482294336e-05

The O 0 4.752906897920184e-05
C282Y O 0 0.0018480406142771244
mutation O 0 0.00021313756587915123
nearly O 0 1.739476647344418e-05
completely O 0 7.015184382908046e-05
prevents O 0 6.96320494171232e-05
the O 0 1.7250380324185244e-06
association O 0 7.556566743005533e-06
of O 0 2.2568725910332432e-07
the O 0 2.0637212401197758e-06
mutant O 0 0.00013422968913801014
HFE O 0 0.05431973189115524
protein O 0 2.0516885342658497e-05
with O 0 7.177426141424803e-06
the O 0 6.179993943078443e-05
TfR O 1 0.948324978351593
. O 0 0.0001465602108510211

Studies O 0 0.00010134609328815714
on O 0 5.3282492444850504e-05
cell O 0 0.0031346268951892853
- O 0 0.0007533955504186451
associated O 0 2.5559860659996048e-05
transferrin O 0 0.001461653271690011
at O 0 4.128915861656424e-06
37 O 0 4.8750994210422505e-06
degrees O 0 3.3863368571473984e-06
C O 0 7.534923497587442e-05
suggest O 0 2.2570327473658836e-06
that O 0 4.556912074349384e-07
the O 0 1.7869052726382506e-06
overexpressed O 0 0.0009076080750674009
wild O 0 5.422882532002404e-05
- O 0 0.0005211638635955751
type O 0 0.00013204650895204395
HFE O 0 0.027129003778100014
protein O 0 1.4884528354741633e-05
decreases O 0 2.2332525986712426e-05
the O 0 5.52983976831456e-07
affinity O 0 2.6871637146541616e-06
of O 0 3.321639212572336e-07
the O 0 7.502289008698426e-06
TfR O 0 0.20415541529655457
for O 0 2.0727449737023562e-05
transferrin O 0 0.29848939180374146
. O 0 7.826051296433434e-05

The O 0 0.00015700841322541237
overexpressed O 0 0.03116544708609581
H63D O 0 0.10999299585819244
protein O 0 8.86218695086427e-05
does O 0 3.3439623621234205e-06
not O 0 2.5044755602721125e-07
have O 0 5.1508209253370296e-08
this O 0 6.75929641147377e-08
effect O 0 5.484222356244572e-07
, O 0 4.811240827962138e-08
providing O 0 9.396639910619342e-08
the O 0 4.34511839841889e-08
first O 0 6.926454432232276e-08
direct O 0 6.70995774498806e-08
evidence O 0 3.3132425869553117e-07
for O 0 1.5418302723446686e-07
a O 0 1.491941020503873e-06
functional O 0 5.723366484744474e-06
consequence O 0 2.0772369680344127e-05
of O 0 8.911231930142094e-07
the O 0 2.8797105187550187e-05
H63D O 1 0.6057705879211426
mutation O 0 0.00166447798255831
. O 0 0.00010885154915740713

Addition O 0 2.7893067453987896e-05
of O 0 8.015464118216187e-06
soluble O 0 0.020391102880239487
wild O 0 0.0009840102866292
- O 0 0.10046111792325974
type O 0 0.05185679346323013
HFE O 1 0.9941874742507935
/ O 0 0.02761584147810936
beta2m O 0 0.006357431877404451
heterodimers O 0 0.003821977414190769
to O 0 4.783246822626097e-06
cultured O 0 0.0003390139900147915
cells O 0 6.991215923335403e-05
also O 0 1.601553435648384e-06
decreased O 0 5.099520058138296e-05
the O 0 6.637187084379548e-07
apparent O 0 1.748512477206532e-05
affinity O 0 1.672464804869378e-06
of O 0 1.9367156767202687e-07
the O 0 2.3412487735186005e-06
TfR O 0 0.0034101090859621763
for O 0 1.2230729851125943e-07
its O 0 3.0394747341233597e-07
ligand O 0 8.87157420947915e-06
under O 0 1.3964316167403013e-05
steady O 0 0.0003705885901581496
- O 0 0.00016814356786198914
state O 0 1.5262658052961342e-06
conditions O 0 1.4983023902459536e-05
, O 0 2.783768593417335e-07
both O 0 1.384472767540501e-07
in O 0 1.794159175005916e-06
293 O 0 0.00033854146022349596
cells O 0 4.766727943206206e-05
and O 0 2.718323003136902e-06
in O 0 2.3023276298772544e-05
HeLa O 0 0.23295657336711884
cells O 0 0.0006465251208283007
. O 0 0.00010051147546619177

Furthermore O 0 3.987885429523885e-05
, O 0 2.34891513173352e-06
at O 0 3.141958814012469e-06
4 O 0 1.4049549008632312e-06
degrees O 0 1.8171405145039898e-06
C O 0 3.960095637012273e-05
, O 0 3.5216518767811067e-07
the O 0 3.423669170388166e-07
added O 0 2.892855945901829e-06
soluble O 0 0.00010444592771818861
complex O 0 1.2067350326105952e-05
of O 0 5.658587269863347e-06
HFE O 1 0.9960653185844421
/ O 0 0.01361124124377966
beta2m O 0 0.0009706643759272993
inhibited O 0 3.776670928345993e-05
binding O 0 2.1237349301372888e-06
of O 0 1.5141903304538573e-06
transferrin O 0 0.004831624682992697
to O 0 7.196645583462669e-06
HeLa O 0 0.029456166550517082
cell O 0 0.0013513884041458368
TfR O 0 0.03570842370390892
in O 0 2.8588367513293633e-06
a O 0 2.526822754589375e-05
concentration O 0 0.0017934665083885193
- O 0 0.0004776127461809665
dependent O 0 2.309670344402548e-05
manner O 0 4.116180934943259e-05
. O 0 6.209062848938629e-05

Scatchard O 0 0.00044470347347669303
plots O 0 6.731641860824311e-06
of O 0 1.9422570574079145e-07
these O 0 1.7718961942136957e-07
data O 0 1.218810666614445e-06
indicate O 0 2.467670810801792e-06
that O 0 2.2437517088746972e-07
the O 0 8.575701144764025e-07
added O 0 1.431336386303883e-05
heterodimer O 0 0.0033759484067559242
substantially O 0 0.0002249405806651339
reduced O 0 9.286062777391635e-06
the O 0 5.542690928450611e-07
affinity O 0 7.41987923902343e-06
of O 0 2.9124432785465615e-06
TfR O 1 0.7913106083869934
for O 0 2.8619999284273945e-05
transferrin O 0 0.3699290156364441
. O 0 0.00013755688269156963

These O 0 4.972844635631191e-06
results O 0 7.986125638126396e-06
establish O 0 3.850101620628266e-06
a O 0 5.432653324533021e-06
molecular O 0 2.9441162041621283e-05
link O 0 7.834190910216421e-05
between O 0 7.891715540608857e-06
HFE O 0 0.32089176774024963
and O 0 4.15117455077052e-07
a O 0 1.063398258338566e-06
key O 0 1.2266280009498587e-06
protein O 0 2.386922687946935e-06
involved O 0 1.9750543742702575e-06
in O 0 3.1586482691636775e-06
iron O 1 0.5986146926879883
transport O 0 0.00014731301052961498
, O 0 1.937633442139486e-06
the O 0 5.056967893324327e-06
TfR O 0 0.207816481590271
, O 0 9.094080724025844e-07
and O 0 2.3050317565775913e-07
raise O 0 2.1904306777287275e-06
the O 0 4.2711744185908174e-07
possibility O 0 4.175172762188595e-06
that O 0 5.303834882397496e-07
alterations O 0 4.687293039751239e-05
in O 0 4.2065201455443457e-07
this O 0 4.851580115428078e-07
regulatory O 0 4.309858923079446e-05
mechanism O 0 1.1830924449895974e-05
may O 0 2.1487933281605365e-06
play O 0 1.2514827574250376e-07
a O 0 9.054083420778625e-07
role O 0 1.6168613683475996e-06
in O 0 1.119699732043955e-06
the O 0 9.757373845786788e-06
pathogenesis O 1 0.9224002957344055
of O 0 0.0006633514421992004
hereditary B-Disease 1 0.9998857975006104
hemochromatosis I-Disease 1 0.9999845027923584
. O 0 0.002141334814950824
. O 0 0.0003251396701671183

Genomic O 0 0.00020677191787399352
organization O 0 1.8426786482450552e-05
of O 0 1.960415829671547e-06
the O 0 7.143754191929474e-05
UBE3A O 1 0.8860943913459778
/ O 0 0.021755794063210487
E6 O 0 0.1487613320350647
- O 0 0.0027580340392887592
AP O 0 0.00018632379942573607
gene O 0 1.375060310238041e-05
and O 0 1.7523533415442216e-06
related O 0 7.340812589973211e-05
pseudogenes O 0 0.0014017898356541991
. O 0 0.00010619265958666801

The O 0 8.056083606788889e-05
UBE3A O 0 0.004276469815522432
gene O 0 2.5090610506595112e-05
encodes O 0 1.0587075848889071e-05
the O 0 8.852077371557243e-06
E6 O 0 0.005699918605387211
- O 0 0.0002591175143606961
AP O 0 6.361651321640238e-05
ubiquitin O 0 0.00012993242125958204
- O 0 4.92594663228374e-05
protein O 0 5.3692797337134834e-06
ligase O 0 8.132094808388501e-05
and O 0 9.499888733444095e-07
has O 0 4.111905127501814e-06
recently O 0 2.0411614968907088e-05
been O 0 8.719700304027356e-07
shown O 0 1.2432218454705435e-06
to O 0 4.880728283751523e-07
be O 0 4.510184680839302e-06
mutated O 0 0.03393937274813652
in O 0 0.26941922307014465
Angelman B-Disease 1 0.9999755620956421
syndrome I-Disease 1 0.9999967813491821
patients O 1 0.9992345571517944
who O 0 0.0028181683737784624
lack O 0 0.00659542391076684
15q11 O 0 0.2824136018753052
- O 0 0.00852455198764801
q13 O 0 0.000921452883630991
deletions O 0 0.00014938903041183949
or O 0 2.5923342036549002e-05
chromosome O 0 0.00047156165237538517
15 O 0 0.00020220402802806348
paternal O 0 0.044125091284513474
uniparental B-Disease 1 0.9807074666023254
disomy I-Disease 1 0.5405663847923279
. O 0 0.000530279241502285

Previous O 0 0.0001864149671746418
UBE3A O 0 0.004288578871637583
cDNA O 0 5.2646195399574935e-05
analysis O 0 5.750821401306894e-06
has O 0 2.1492894575203536e-06
shown O 0 1.9209658148611197e-06
a O 0 2.446574171699467e-06
coding O 0 2.0195433535263874e-05
region O 0 6.467591333603195e-07
of O 0 1.2230729851125943e-07
approximately O 0 4.170484771748306e-06
2 O 0 2.6116813387488946e-05
. O 0 2.7636659069685265e-05

6 O 0 0.00010809046943904832
kb O 0 0.0003953648265451193
and O 0 1.6034470036174753e-06
a O 0 9.502248758508358e-06
3 O 0 1.6338019122486003e-05
- O 0 0.00026200717547908425
untranslated O 0 0.00012734577467199415
region O 0 3.999738510174211e-06
( O 0 1.4657044857813162e-06
UTR O 0 8.461700053885579e-05
) O 0 3.02018463571585e-07
of O 0 3.467833948889165e-07
< O 0 0.00018334035121370107
50 O 0 3.352219664520817e-06
bp O 0 3.6899506085319445e-05
, O 0 1.8371497390035074e-07
whereas O 0 8.943327429733472e-07
Northern O 0 2.3792628667251847e-07
analysis O 0 3.311211571599415e-07
has O 0 3.371895331838459e-07
indicated O 0 1.6888741356524406e-06
mRNA O 0 4.3895838075513893e-07
sizes O 0 3.621284463406482e-07
of O 0 2.404142946943466e-07
5 O 0 1.5587895177304745e-05
- O 0 9.49682216742076e-05
8 O 0 1.467074343963759e-05
kb O 0 0.0004134687769692391
. O 0 2.3211303414427675e-05

We O 0 4.073658601555508e-06
have O 0 4.5154510530664993e-07
analyzed O 0 1.3744551097261137e-06
additional O 0 7.701754043409892e-07
cDNA O 0 1.5205316231003962e-05
clones O 0 3.207509143976495e-05
and O 0 1.458722209690677e-07
provide O 0 3.3612809602345806e-07
evidence O 0 4.2915567632917373e-07
for O 0 9.760938723957224e-08
an O 0 3.0221238489502866e-07
additional O 0 1.7461427432863275e-06
0 O 0 1.8684093447518535e-05
. O 0 1.8881215510191396e-05

5 O 0 5.217513535171747e-05
kb O 0 0.00012846234312746674
of O 0 2.385070274613099e-06
5 O 0 5.5019077990436926e-05
- O 0 0.00020631028746720403
UTR O 0 0.00018159582396037877
and O 0 8.556764896638924e-07
> O 0 2.6140611225855537e-05
2 O 0 3.276721372458269e-06
kb O 0 3.968583041569218e-05
of O 0 8.235468840211979e-07
3 O 0 8.635764243081212e-05
- O 0 0.002338299760594964
UTR O 0 0.005742653738707304
. O 0 4.635179357137531e-05

We O 0 4.977465778210899e-06
have O 0 4.334407606165769e-07
established O 0 4.786285785485234e-07
the O 0 4.436331835222518e-07
genomic O 0 8.043650268518832e-06
organization O 0 1.0941073469439289e-06
of O 0 4.208530413052358e-07
UBE3A O 0 0.002452764194458723
and O 0 1.885493645659153e-07
the O 0 2.9246461963339243e-07
sequence O 0 1.280671426684421e-06
of O 0 3.146411700072349e-06
intron O 1 0.72278892993927
- O 0 0.005654516629874706
exon O 0 0.0013958353083580732
borders O 0 6.728195876348764e-05
. O 0 9.314379713032395e-05

We O 0 7.714317689533345e-06
have O 0 3.71961959899636e-07
also O 0 2.8934690021742426e-07
mapped O 0 2.02992509912292e-06
two O 0 1.431543665830759e-07
highly O 0 5.78839080844773e-06
homologous O 0 4.8088062612805516e-05
processed O 0 1.9407518266234547e-05
pseudogenes O 0 0.00019178169895894825
, O 0 1.076872013072716e-05
UBE3AP1 O 0 0.013503745198249817
and O 0 3.62156151823001e-06
UBE3AP2 O 0 0.002478416310623288
, O 0 3.1239284226103337e-07
to O 0 7.78355442321299e-08
chromosomes O 0 1.2046776873830822e-06
2 O 0 1.1301241329420009e-06
and O 0 3.580051100016135e-07
21 O 0 2.337901833016076e-06
, O 0 3.7405501984721923e-07
respectively O 0 1.107352773033199e-06
, O 0 2.644052869982261e-07
and O 0 1.5114751761302614e-07
determined O 0 1.1241603488088003e-06
their O 0 3.0315484877974086e-07
genomic O 0 7.35184657969512e-05
organization O 0 3.7722973502241075e-05
. O 0 4.8518009862164035e-05

These O 0 2.7290975594951306e-06
results O 0 3.7483105188584886e-06
will O 0 1.1221815299222726e-07
form O 0 2.6794816676556366e-07
the O 0 5.8611984599110656e-08
basis O 0 2.979747470988059e-08
for O 0 4.2148883494519396e-08
studies O 0 4.640464794647414e-07
of O 0 1.772950923850658e-07
mutation O 0 2.421409408270847e-05
and O 0 2.0946251879649935e-06
imprinting O 0 0.00020547675376292318
of O 0 2.832787504303269e-05
UBE3A O 1 0.9452422261238098
. O 0 0.00023716514988336712

Mutation O 0 0.0004609192837961018
spectrum O 0 0.00019786340999417007
and O 0 2.006864633585792e-05
genotype O 0 0.005802482832223177
- O 0 0.00860687717795372
phenotype O 0 0.0029721034225076437
analyses O 0 0.00019782870367635041
in O 0 0.0012862012954428792
Cowden B-Disease 1 0.9987760186195374
disease I-Disease 1 0.9996503591537476
and O 0 0.002223839983344078
Bannayan B-Disease 1 0.9971609115600586
- I-Disease 1 0.9986590147018433
Zonana I-Disease 1 0.998950183391571
syndrome I-Disease 1 0.9999065399169922
, O 0 0.00020243723702151328
two O 0 0.00022874756541568786
hamartoma B-Disease 1 0.9975711703300476
syndromes I-Disease 1 0.9970239996910095
with O 0 0.002264457754790783
germline O 1 0.9831864833831787
PTEN O 1 0.9857958555221558
mutation O 0 0.01292092353105545
. O 0 0.000353389565134421

The O 0 0.00307108904235065
tumour B-Disease 1 0.9969839453697205
suppressor O 0 0.3355599045753479
gene O 0 0.0021310709416866302
PTEN O 1 0.5111401677131653
, O 0 3.7653785511793103e-06
which O 0 1.5554160199826583e-06
maps O 0 6.947598194528837e-06
to O 0 7.17356670065783e-06
10q23 O 0 0.0016716676764190197
. O 0 0.00011032327165594324

3 O 0 1.0481002391315997e-05
and O 0 3.6355760357764666e-07
encodes O 0 1.326397068623919e-06
a O 0 9.58076270762831e-07
403 O 0 4.887519025942311e-06
amino O 0 1.2904314417028218e-06
acid O 0 3.184798697475344e-05
dual O 0 8.726666237635072e-06
specificity O 0 1.0994408512488008e-05
phosphatase O 0 0.001084473798982799
( O 0 2.026319862125092e-06
protein O 0 6.994266186666209e-06
tyrosine O 0 6.057273640180938e-05
phosphatase O 0 0.008849503472447395
; O 0 1.4573663065675646e-05
PTPase O 0 0.0013390252133831382
) O 0 3.8412958929257e-06
, O 0 1.3887694194636424e-06
was O 0 5.246351520327153e-06
shown O 0 1.7482822158854106e-06
recently O 0 3.396055262783193e-06
to O 0 4.4002131716069925e-08
play O 0 8.863820966098501e-08
a O 0 1.0800887366713141e-06
broad O 0 2.2332653315970674e-05
role O 0 8.791705113253556e-06
in O 0 1.5704788893344812e-05
human O 0 0.0009037430281750858
malignancy B-Disease 1 0.9977333545684814
. O 0 0.00027337425854057074

Somatic O 0 0.0062174201011657715
PTEN O 0 0.4135638475418091
deletions O 0 0.0001285052130697295
and O 0 2.99041698781366e-06
mutations O 0 1.4333239050756674e-05
were O 0 6.084611641199444e-07
observed O 0 9.760407920111902e-06
in O 0 1.080070433090441e-05
sporadic B-Disease 0 0.1584690660238266
breast I-Disease 1 0.9996200799942017
, I-Disease 0 0.0023519794922322035
brain I-Disease 1 0.9991668462753296
, I-Disease 0 0.08915230631828308
prostate I-Disease 1 0.9999346733093262
and I-Disease 1 0.9107476472854614
kidney I-Disease 1 0.9999829530715942
cancer I-Disease 1 0.9999234676361084
cell O 0 0.16218028962612152
lines O 0 6.115826545283198e-05
and O 0 9.79092760644562e-07
in O 0 1.0705944077926688e-06
several O 0 2.8754011509590782e-06
primary O 0 0.0005964305601082742
tumours B-Disease 1 0.9989948868751526
such O 0 4.188357343082316e-05
as O 0 0.00805324874818325
endometrial B-Disease 1 0.9995183944702148
carcinomas I-Disease 1 0.9999305009841919
, O 1 0.9981260895729065
malignant B-Disease 1 0.9999933242797852
melanoma I-Disease 1 0.9999936819076538
and O 1 0.9968457818031311
thyroid B-Disease 1 0.9999723434448242
tumours I-Disease 1 0.999727189540863
. O 0 0.006199215073138475

In O 0 1.5160548173298594e-05
addition O 0 2.3470285668736324e-05
, O 0 2.424593549221754e-05
PTEN O 0 0.1873224824666977
was O 0 2.0392935766722076e-05
identified O 0 3.3902724680956453e-06
as O 0 3.695181192142627e-07
the O 0 7.808749842297402e-07
susceptibility O 0 0.00021641029161401093
gene O 0 2.4731394660193473e-05
for O 0 3.7880547552049393e-06
two O 0 0.00023073980992194265
hamartoma B-Disease 1 0.998798131942749
syndromes I-Disease 1 0.9998036026954651
Cowden B-Disease 1 0.999657392501831
disease I-Disease 1 0.9997918009757996
( O 0 0.0012448882916942239
CD B-Disease 0 0.005626443773508072
; O 0 9.563352796249092e-05
MIM O 0 0.1559293419122696
158350 O 0 0.0022087753750383854
) O 0 1.527261883893516e-05
and O 0 1.132335455622524e-05
Bannayan B-Disease 0 0.02946237102150917
- I-Disease 0 0.005406135693192482
Zonana I-Disease 0 0.18236415088176727
( I-Disease 0 2.5403653125977144e-05
BZS I-Disease 0 0.006218866910785437
) I-Disease 0 9.995965228881687e-06
or I-Disease 0 3.2327112421626225e-05
Ruvalcaba I-Disease 1 0.8034932613372803
- I-Disease 0 0.177892804145813
Riley I-Disease 0 0.15547066926956177
- I-Disease 1 0.9522433876991272
Smith I-Disease 1 0.8171749114990234
syndrome I-Disease 1 0.9996764659881592
( O 0 0.001108565367758274
MIM O 1 0.9175843000411987
153480 O 0 0.026339154690504074
) O 0 5.028829400544055e-05
. O 0 5.36024417669978e-05

Constitutive O 0 0.0008467335137538612
DNA O 0 8.505773439537734e-05
from O 0 8.869391422194894e-06
37 O 0 2.8083641154807992e-05
CD B-Disease 0 5.3023781219962984e-05
families O 0 1.957663698703982e-06
and O 0 6.198829964887409e-07
seven O 0 9.608611435396597e-06
BZS B-Disease 0 0.06063905730843544
families O 0 1.1823999557236675e-05
was O 0 2.6846104447031394e-05
screened O 0 6.226803816389292e-05
for O 0 1.2748642802762333e-05
germline O 0 0.13236795365810394
PTEN O 1 0.9634922742843628
mutations O 0 0.002594117308035493
. O 0 0.0001464005617890507

PTEN O 1 0.8446950912475586
mutations O 0 0.00022215080389287323
were O 0 1.981499281100696e-06
identified O 0 3.4890754250227474e-06
in O 0 4.3970334218101925e-07
30 O 0 5.075116291664017e-07
of O 0 1.170276462403308e-07
37 O 0 4.643356987799052e-06
( O 0 1.4840921949144104e-06
81 O 0 1.0444483450555708e-05
% O 0 6.082453865019488e-07
) O 0 8.820525749797525e-07
CD B-Disease 0 8.033500307647046e-06
families O 0 9.682592008175561e-07
, O 0 2.9774531640214263e-07
including O 0 3.994414896624221e-07
missense O 0 5.8739682572195306e-05
and O 0 1.3945771115686512e-06
nonsense O 0 5.388190402300097e-05
point O 0 2.2752294626116054e-06
mutations O 0 1.0798912626341917e-05
, O 0 8.769186479185009e-07
deletions O 0 1.1519739018694963e-05
, O 0 6.376636179084016e-07
insertions O 0 1.0675973499019165e-05
, O 0 7.39463587251521e-07
a O 0 4.3915410969930235e-06
deletion O 0 0.000731608597561717
/ O 0 0.0006294894847087562
insertion O 0 3.419500353629701e-05
and O 0 4.5349156607699115e-06
splice O 0 0.00045224622590467334
site O 0 0.00018857237591873854
mutations O 0 0.00036860068212263286
. O 0 6.525845674332231e-05

These O 0 7.898634976299945e-06
mutations O 0 5.249179230304435e-05
were O 0 5.08517359776306e-07
scattered O 0 1.0579570925983717e-06
over O 0 2.467096180680528e-07
the O 0 2.502513041235943e-07
entire O 0 1.9968460946984123e-06
length O 0 3.394883151486283e-06
of O 0 9.1182585038041e-07
PTEN O 0 0.13768436014652252
, O 0 3.217122923615534e-07
with O 0 7.889556741247361e-08
the O 0 8.768477499643268e-08
exception O 0 2.2961241086250084e-07
of O 0 1.407586758261914e-08
the O 0 1.5137456443881092e-07
first O 0 2.766423392586148e-07
, O 0 3.46086295621717e-07
fourth O 0 2.080399099213537e-06
and O 0 1.2006611314063775e-06
last O 0 2.0405328541528434e-05
exons O 0 0.00015632719441782683
. O 0 5.400892041507177e-05

A O 0 0.00019183638505637646
hot O 0 0.00019851478282362223
spot O 0 2.7249958293396048e-05
for O 0 4.213315605738899e-06
PTEN O 0 0.07300019264221191
mutation O 0 4.3233856558799744e-05
in O 0 1.057075678545516e-06
CD B-Disease 0 4.8094618250615895e-05
was O 0 5.3910962378722616e-06
identified O 0 1.01449950307142e-06
in O 0 2.517430459647585e-07
exon O 0 3.05643116007559e-05
5 O 0 6.970932986405387e-07
that O 0 6.802520147175528e-08
contains O 0 2.0063778549683775e-07
the O 0 8.260741992671683e-07
PTPase O 0 0.00031516244052909315
core O 0 9.393472282681614e-06
motif O 0 1.742568019835744e-05
, O 0 1.9473613122045208e-07
with O 0 9.408530132759552e-08
13 O 0 3.396770011931949e-07
of O 0 3.429995487636006e-08
30 O 0 1.2502092658905894e-06
( O 0 3.6504664535641496e-07
43 O 0 6.384796620295674e-07
% O 0 2.993185432842438e-07
) O 0 3.223249507300352e-07
CD B-Disease 0 1.0196770745096728e-05
mutations O 0 6.0080596995248925e-06
identified O 0 2.727695346038672e-06
in O 0 8.887213880370837e-07
this O 0 3.5534317248675507e-06
exon O 0 0.0013838406885042787
. O 0 6.858343840576708e-05

Seven O 0 4.639965936803492e-06
of O 0 1.0340194194213836e-06
30 O 0 7.150426426960621e-06
( O 0 2.5461438326601638e-06
23 O 0 1.8559337604528992e-06
% O 0 4.3309159991622437e-07
) O 0 1.5545928988558444e-07
were O 0 2.2783330777542687e-08
within O 0 2.395943532462752e-08
the O 0 1.8808384538715472e-07
core O 0 4.6187828957044985e-06
motif O 0 2.184553704864811e-05
, O 0 2.7148777803631674e-07
the O 0 1.674819287700302e-07
majority O 0 4.3761585288848437e-07
( O 0 2.44767278445579e-07
five O 0 3.3227728124529676e-08
of O 0 2.315598024438259e-08
seven O 0 4.577177605824545e-07
) O 0 1.7464462587213347e-07
of O 0 3.0632723024837105e-08
which O 0 2.2076049788211094e-07
were O 0 4.035468634810968e-07
missense O 0 0.00011509458272485062
mutations O 0 2.8550102797453292e-05
, O 0 1.3912496115153772e-06
possibly O 0 7.3499736572557595e-06
pointing O 0 5.2748378038813826e-06
to O 0 9.813038559514098e-08
the O 0 2.1117955384397646e-07
functional O 0 2.588516963442089e-06
significance O 0 9.673491376815946e-07
of O 0 5.231216277934436e-07
this O 0 4.970933787262766e-06
region O 0 7.240926788654178e-05
. O 0 4.708358392235823e-05

Germline O 0 0.37610384821891785
PTEN O 1 0.7152792811393738
mutations O 0 0.00018220320635009557
were O 0 1.0594635568850208e-06
identified O 0 1.441616177544347e-06
in O 0 7.754213982025249e-08
four O 0 4.4586503378241105e-08
of O 0 5.3115691400762444e-08
seven O 0 1.2184074194010464e-06
( O 0 2.4123703497025417e-06
57 O 0 1.2639207852771506e-05
% O 0 5.274273917166283e-06
) O 0 7.438470220222371e-06
BZS B-Disease 0 0.010500439442694187
families O 0 1.7958016542252153e-05
studied O 0 8.472768968204036e-05
. O 0 7.338586146943271e-05

Interestingly O 0 0.0009193298756144941
, O 0 4.1730709199327976e-06
none O 0 1.1079484920628602e-06
of O 0 8.266386686273108e-08
these O 0 3.250150371059135e-07
mutations O 0 1.845114275056403e-05
was O 0 7.779776751704048e-06
observed O 0 2.0737932118208846e-06
in O 0 4.215411308905459e-07
the O 0 2.6353352495789295e-06
PTPase O 0 0.002925837179645896
core O 0 0.00011629699292825535
motif O 0 0.0013883922947570682
. O 0 8.840797818265855e-05

It O 0 4.365359927760437e-06
is O 0 8.854287898429902e-07
also O 0 4.926764063384326e-07
worthy O 0 1.8535123444962665e-06
of O 0 1.4933416991880222e-07
note O 0 2.58824297816318e-06
that O 0 1.2961353945684095e-07
a O 0 5.433941510091245e-07
single O 0 8.725332349968085e-07
nonsense O 0 1.4232322428142652e-05
point O 0 2.0670856883953093e-06
mutation O 0 1.251523553946754e-05
, O 0 1.0509832009120146e-06
R233X O 0 0.00014098550309427083
, O 0 9.207766424879082e-07
was O 0 2.34370827456587e-06
observed O 0 4.787294187735824e-07
in O 0 1.785146253041603e-07
the O 0 5.07091669987858e-07
germline O 0 0.00012989004608243704
DNA O 0 4.5952638174640015e-06
from O 0 4.931878834213421e-07
two O 0 3.861423465423286e-07
unrelated O 0 0.0001554631016915664
CD B-Disease 0 0.00011791279393946752
families O 0 3.466561565801385e-06
and O 0 2.496280330888112e-06
one O 0 1.1104089935543016e-05
BZS B-Disease 0 0.3929612934589386
family O 0 0.00034127337858080864
. O 0 7.228838512673974e-05

Genotype O 0 0.05569160357117653
- O 0 0.028256958350539207
phenotype O 0 0.0013292593648657203
studies O 0 4.874997102888301e-06
were O 0 3.0371103321158444e-07
not O 0 6.960504350672636e-08
performed O 0 4.917714022667496e-07
on O 0 1.0172503550620604e-07
this O 0 1.3253384167910554e-07
small O 0 5.164781100575055e-07
group O 0 1.5990475503713242e-06
of O 0 3.886400918418076e-06
BZS B-Disease 0 0.2667345404624939
families O 0 8.507964230375364e-05
. O 0 0.00013059171033091843

However O 0 7.204346911748871e-05
, O 0 2.811236663546879e-05
genotype O 0 0.000765142438467592
- O 0 0.0007078787311911583
phenotype O 0 9.208524716086686e-05
analysis O 0 3.226670969525003e-06
inthe O 0 0.00031600758666172624
group O 0 1.5163767557169194e-06
of O 0 4.50719937816757e-07
CD B-Disease 0 0.00015371519839391112
families O 0 3.232954668419552e-06
revealed O 0 2.082254650304094e-05
two O 0 2.0888592189294286e-07
possible O 0 7.242369974846952e-07
associations O 0 8.108725069178035e-07
worthy O 0 1.7647756749283872e-06
of O 0 2.0449395776722668e-07
follow O 0 4.520687980402727e-06
- O 0 5.4524974984815344e-05
up O 0 5.170640520191228e-07
in O 0 4.220439393520792e-07
independent O 0 2.010667913054931e-06
analyses O 0 3.3816009818110615e-05
. O 0 3.5022152587771416e-05

The O 0 7.054623893054668e-06
first O 0 6.4841078710742295e-06
was O 0 2.345238499401603e-05
an O 0 3.750033783944673e-06
association O 0 5.777740807388909e-05
noted O 0 3.9045785342750605e-06
in O 0 1.9833356645904132e-07
the O 0 2.455196295159112e-07
group O 0 4.7506463829449785e-07
of O 0 3.7861445889575407e-07
CD B-Disease 0 0.0007704216404817998
families O 0 7.811453542672098e-05
with O 0 0.033479392528533936
breast B-Disease 1 0.9998984336853027
disease I-Disease 1 0.9998317956924438
. O 0 0.0021592355333268642

A O 0 7.138830551411957e-05
correlation O 0 2.3215641704155132e-05
was O 0 2.0934745407430455e-05
observed O 0 2.0882605440419866e-06
between O 0 1.1003354529748322e-06
the O 0 2.5902947982103797e-06
presence O 0 1.1108199942100327e-05
/ O 0 0.00015512680693063885
absence O 0 3.79622451873729e-06
of O 0 2.654750801411865e-07
a O 0 2.5028284653672017e-05
PTEN O 0 0.06129295006394386
mutation O 0 1.8281318261870183e-05
and O 0 3.5078417681688734e-07
the O 0 2.0779918941116193e-06
type O 0 0.0004855518345721066
of O 0 2.6583520593703724e-05
breast O 1 0.999110996723175
involvement O 0 0.012481861747801304
( O 0 0.0010659188264980912
unaffected O 0 0.4162788987159729
versus O 0 0.43126899003982544
benign O 1 0.99764484167099
versus O 1 0.9941774606704712
malignant O 1 0.9996339082717896
) O 0 0.0008860717061907053
. O 0 0.00027188699459657073

Specifically O 0 3.360954360687174e-05
and O 0 2.028686594712781e-06
more O 0 3.1720460924589133e-07
directly O 0 2.22622338696965e-06
, O 0 1.291788407797867e-06
an O 0 1.7650112340561463e-06
association O 0 0.0001237098331330344
was O 0 5.932658041274408e-06
also O 0 3.098819831848232e-07
observed O 0 3.93623935224241e-07
between O 0 1.424197080268641e-07
the O 0 2.3664141224344348e-07
presence O 0 7.938529620332702e-07
of O 0 4.544048977095372e-07
a O 0 0.00035528602893464267
PTEN O 1 0.9867454171180725
mutation O 0 0.0840882956981659
and O 0 0.06889638304710388
malignant B-Disease 1 0.9999635219573975
breast I-Disease 1 0.9999645948410034
disease I-Disease 1 0.9998685121536255
. O 0 0.005389705765992403

Secondly O 0 0.003865617560222745
, O 0 1.6429672541562468e-05
there O 0 4.44008355771075e-06
appeared O 0 1.1786823961301707e-05
to O 0 1.7729104229147197e-07
be O 0 1.4870090581098339e-07
an O 0 8.372556976610213e-07
interdependent O 0 0.00011915689538000152
association O 0 4.130293382331729e-05
between O 0 3.0031064852664713e-06
mutations O 0 2.097743345075287e-05
upstream O 0 7.155931143643102e-06
and O 0 2.3218920830458956e-07
within O 0 2.29546287755511e-07
the O 0 1.5723196611361345e-06
PTPase O 0 0.0004891185672022402
core O 0 1.737016464176122e-05
motif O 0 3.3786553103709593e-05
, O 0 4.655065310998907e-07
the O 0 2.0656104027239053e-07
core O 0 2.141257255061646e-06
motif O 0 6.032943019818049e-06
containing O 0 6.031667112438299e-07
the O 0 1.7939146346179768e-07
majority O 0 4.7279661430366104e-07
of O 0 5.595514949163771e-07
missense O 0 0.0006035995320416987
mutations O 0 4.4961812818655744e-05
, O 0 7.166430009419855e-07
and O 0 1.235139137634178e-07
the O 0 4.4232695017853985e-07
involvement O 0 4.399174031277653e-06
of O 0 2.4820488420118636e-07
all O 0 8.504366064698843e-07
major O 0 0.0002502695133443922
organ O 1 0.8493605852127075
systems O 0 0.0032651813235133886
( O 0 8.011695899767801e-05
central O 0 0.0004883117508143187
nervous O 1 0.971983015537262
system O 0 0.00785265676677227
, O 0 0.003858694341033697
thyroid O 1 0.9997699856758118
, O 0 0.05504300817847252
breast O 1 0.9997307658195496
, O 0 0.06823728233575821
skin O 1 0.9995802044868469
and O 0 0.04223322868347168
gastrointestinal O 1 0.9998012185096741
tract O 1 0.9989902377128601
) O 0 0.001467847847379744
. O 0 0.00040706852450966835

However O 0 4.009186159237288e-05
, O 0 1.6917597349674907e-06
these O 0 1.0257040372607662e-07
observations O 0 5.151803179614944e-07
would O 0 3.527897547428438e-07
need O 0 3.0184051524884126e-07
to O 0 8.328392908651949e-08
be O 0 9.142449641785788e-08
confirmed O 0 8.671891578160285e-07
by O 0 7.508808153033897e-08
studying O 0 5.204901185607014e-07
a O 0 4.572696923332842e-07
larger O 0 4.065994403390505e-07
number O 0 6.98530797649255e-08
of O 0 3.2979059483295714e-07
CD B-Disease 0 0.0002928527828771621
families O 0 1.7765672964742407e-05
. O 0 5.046662408858538e-05

Molecular O 0 0.0644799992442131
defects O 1 0.9959142804145813
leading O 0 6.040383595973253e-05
to O 0 1.9740186871786136e-06
human O 0 1.7943397324415855e-05
complement B-Disease 0 0.0002600217703729868
component I-Disease 0 0.1713913083076477
C6 I-Disease 1 0.9996558427810669
deficiency I-Disease 1 0.9999105930328369
in O 0 9.391706953465473e-06
an O 0 7.994507541297935e-06
African O 0 0.00013099719944875687
- O 0 0.0015585421351715922
American O 0 1.8950377125293016e-05
family O 0 0.00010984564869431779
. O 0 3.8532682083314285e-05

Complement B-Disease 0 0.004127047955989838
component I-Disease 1 0.7280454635620117
C6 I-Disease 1 0.9993234872817993
deficiency I-Disease 1 0.9998871088027954
( O 0 0.001053050858899951
C6D B-Disease 1 0.919707715511322
) O 0 9.440084249945357e-05
was O 0 0.00423201359808445
diagnosed O 1 0.9989884495735168
in O 0 2.080984586427803e-06
a O 0 9.416378816240467e-06
16 O 0 3.8530331949004903e-05
- O 0 0.0004114943149033934
year O 0 1.6401245375163853e-05
- O 0 0.00011173594975844026
old O 0 4.077619450981729e-05
African O 0 1.7856866179499775e-05
- O 0 7.555905176559463e-05
American O 0 6.09280959906755e-06
male O 0 9.074925037566572e-05
with O 0 0.0010663686553016305
meningococcal B-Disease 1 0.9995476603507996
meningitis I-Disease 1 0.9995195865631104
. O 0 0.0016225436702370644

The O 0 0.0009761276305653155
patients O 1 0.7665480971336365
father O 0 0.0003026806516572833
and O 0 2.6520228857407346e-06
two O 0 1.8914741986009176e-06
brothers O 0 0.00020622966985683888
also O 0 5.225434961175779e-06
had O 0 2.8545015084091574e-05
C6D B-Disease 0 0.019045883789658546
, O 0 6.739509785802511e-07
but O 0 1.876946669199242e-07
gave O 0 1.2601011576407473e-06
no O 0 6.912991921126377e-07
history O 0 3.3819733289419673e-06
of O 0 1.5215238818200305e-05
meningitis B-Disease 1 0.9997298121452332
or O 0 0.00019889845862053335
other O 0 5.723866343032569e-05
neisserial B-Disease 1 0.9896122813224792
infection I-Disease 1 0.9967795014381409
. O 0 0.00048808459541760385

By O 0 5.524091648112517e-06
using O 0 4.38754295828403e-06
exon O 0 0.0002156798291252926
- O 0 2.6690360755310394e-05
specific O 0 7.066461762406107e-07
polymerase O 0 5.286343366606161e-05
chain O 0 0.00011919666576432064
reaction O 0 2.6976194931194186e-05
( O 0 3.7569168398476904e-06
PCR O 0 4.862593050347641e-05
) O 0 3.867021405312698e-06
/ O 0 4.7678506234660745e-05
single O 0 1.7002026879708865e-06
- O 0 1.6166275599971414e-05
strand O 0 3.67849065696646e-06
conformation O 0 3.010524778801482e-06
polymorphism O 0 1.7355324644086068e-06
as O 0 7.335817997500271e-08
a O 0 4.0469456052960595e-07
screening O 0 1.3407197911874391e-06
step O 0 2.516077017844509e-07
and O 0 1.8379518351707702e-08
nucleotide O 0 8.683827701361224e-08
sequencing O 0 1.1286984857861171e-07
of O 0 3.246209345775242e-08
target O 0 6.612459060306719e-07
exons O 0 5.691839305654867e-06
, O 0 3.7128361896066053e-07
we O 0 9.860450234100426e-08
determined O 0 3.2638735092405113e-07
that O 0 1.1838115909768021e-07
the O 0 5.617217198050639e-07
proband O 0 0.000326720328303054
was O 0 4.3068966988357715e-06
a O 0 1.954473873411189e-06
compound O 0 2.2359718059306033e-05
heterozygote O 0 5.56825143576134e-05
for O 0 4.905629111817689e-07
two O 0 3.74625915355864e-06
C6 O 1 0.975054919719696
gene O 0 0.00041390571277588606
mutations O 0 0.0004946492263115942
. O 0 0.0001094660910894163

The O 0 6.278790806391044e-06
first O 0 2.623516820676741e-06
, O 0 1.7436251482649823e-06
1195delC O 0 5.454509300761856e-05
located O 0 1.8865129050027463e-06
in O 0 5.699600365005608e-07
exon O 0 3.6936406104359776e-05
7 O 0 3.097823309872183e-06
, O 0 2.1321068288671086e-07
is O 0 1.2535157623005944e-07
a O 0 4.679974949794996e-07
novel O 0 3.0173882805684116e-06
mutation O 0 5.284979124553502e-06
, O 0 1.1470985583628135e-07
while O 0 8.860625655415788e-08
the O 0 1.0398078842399627e-07
second O 0 6.117054454080062e-07
, O 0 3.944562934066198e-07
1936delG O 0 3.135612860205583e-05
in O 0 4.728430553768703e-07
exon O 0 5.0055528845405206e-05
12 O 0 4.1422940739721525e-06
, O 0 8.854980819705816e-07
has O 0 8.510036764164397e-07
been O 0 5.319081424204342e-07
described O 0 4.9305290303891525e-06
before O 0 1.6866080159161356e-06
to O 0 8.537813300790731e-07
cause O 0 0.0007868463872000575
C6D B-Disease 0 0.02545296400785446
in O 0 3.3489409361209255e-06
an O 0 6.065190518711461e-06
unrelated O 0 0.0007317099953070283
African O 0 0.00015864649321883917
- O 0 0.0004848938842769712
American O 0 5.597331437456887e-06
individual O 0 2.267518084408948e-06
. O 0 2.8253469281480648e-05

Both O 0 2.0085150026716292e-05
mutations O 0 0.0002080345875583589
result O 0 8.332034485647455e-05
in O 0 2.4399905669270083e-05
premature O 0 0.179729625582695
termination O 0 0.003990913275629282
codons O 0 0.00020539959950838238
and O 0 1.937801789608784e-05
C6 O 1 0.6830984950065613
null O 0 0.0002707843959797174
alleles O 0 0.0003284909762442112
. O 0 0.0001247749023605138

Allele O 0 0.00068246218143031
- O 0 0.00020479902741499245
specific O 0 3.3897554203576874e-06
PCR O 0 0.00014801816723775119
indicated O 0 2.6684509066399187e-05
that O 0 5.579667003985378e-07
the O 0 1.901136783999391e-06
probands O 0 0.00025751712382771075
two O 0 1.4205064644556842e-06
brothers O 0 0.0001227891625603661
also O 0 5.269201665214496e-06
inherited O 0 0.007679198868572712
the O 0 4.134652954235207e-06
1195delC O 0 0.000879156228620559
mutation O 0 1.8581937183625996e-05
from O 0 5.140902885614196e-07
their O 0 3.20197159453528e-07
heterozygous O 0 1.4957341591070872e-05
mother O 0 4.114866169402376e-05
and O 0 2.2143608191527164e-07
the O 0 6.116482609286322e-07
1936delG O 0 0.00021725504484493285
mutation O 0 1.3465511074173264e-05
from O 0 8.336584187418339e-07
their O 0 5.723993012907158e-07
homozygous O 0 0.00012043653259752318
father O 0 0.0003382859576959163
. O 0 1.9734390662051737e-05
. O 0 5.776897523901425e-05

PAX6 O 1 0.8985375165939331
mutations O 0 0.006722689606249332
reviewed O 0 0.00200590118765831
. O 0 0.0002953302173409611

Mutations O 0 0.0008412415045313537
in O 0 2.9203894882812165e-05
PAX6 O 0 0.3146321177482605
are O 0 1.1928293588425731e-06
responsible O 0 9.160127774521243e-06
for O 0 2.1217913399596e-06
human O 0 9.057684655999765e-05
aniridia B-Disease 1 0.9678923487663269
and O 0 1.5688716530348756e-06
have O 0 2.957453943963628e-07
also O 0 9.295793574892741e-07
been O 0 1.0682059610189754e-06
found O 0 8.775386959314346e-06
in O 0 2.034759563684929e-05
patients O 1 0.7982503175735474
with O 0 0.0002872829500120133
Peters B-Disease 1 0.9988082647323608
anomaly I-Disease 1 0.9987057447433472
, O 0 0.0021997487638145685
with O 1 0.9147916436195374
congenital B-Disease 1 0.9999943971633911
cataracts I-Disease 1 0.9999781847000122
, O 0 0.0005780959618277848
with O 0 0.002103168750181794
autosomal B-Disease 1 0.9991808533668518
dominant I-Disease 1 0.9701484441757202
keratitis I-Disease 1 0.9984481334686279
, O 0 6.634069723077118e-05
and O 0 1.1871588867506944e-05
with O 0 0.0002710290136747062
isolated B-Disease 1 0.8607910871505737
foveal I-Disease 1 0.9972074627876282
hypoplasia I-Disease 1 0.9988864064216614
. O 0 0.004292917903512716

No O 0 2.5347339033032767e-05
locus O 0 3.948029552702792e-05
other O 0 5.610722837445792e-07
than O 0 2.035092848018394e-06
chromosome O 0 0.0002157205599360168
11p13 O 0 0.001612985972315073
has O 0 7.4412305366422515e-06
been O 0 3.7789047837577527e-06
implicated O 0 0.0006010333308950067
in O 0 1.8549304513726383e-05
aniridia B-Disease 1 0.8877125978469849
, O 0 5.611928827420343e-06
and O 0 3.0476617212116253e-06
PAX6 O 0 0.15584449470043182
is O 0 1.3911845826442004e-06
clearly O 0 2.674804363778094e-06
the O 0 9.039744099936797e-07
major O 0 9.649365892983042e-06
, O 0 5.708118919756089e-07
if O 0 3.886457307089586e-07
not O 0 7.921341449446118e-08
only O 0 9.043230164706983e-08
, O 0 5.185895588510903e-07
gene O 0 2.4171502445824444e-05
responsible O 0 3.9581394958077e-05
. O 0 4.8575690016150475e-05

Twenty O 0 0.00011367262777639553
- O 0 0.00011833834287244827
eight O 0 1.881395974123734e-06
percent O 0 2.9115547022229293e-06
of O 0 7.624449267495947e-07
identified O 0 7.757796993246302e-05
PAX6 O 0 0.10976427793502808
mutations O 0 0.000130075219203718
are O 0 2.831694246197003e-06
C O 0 0.011899661272764206
- O 0 0.010249322280287743
T O 0 0.015102975070476532
changes O 0 2.403992311883485e-06
at O 0 5.604633315670071e-06
CpG O 0 0.0001495343749411404
dinucleotides O 0 0.000520121306180954
, O 0 7.468399303434126e-07
20 O 0 6.618320185225457e-07
% O 0 1.6033018823691236e-07
are O 0 2.620880401593695e-08
splicing O 0 2.794783540593926e-06
errors O 0 9.134236279351171e-06
, O 0 1.6483788556342915e-07
and O 0 2.5490727750820952e-08
more O 0 2.0995514660171466e-08
than O 0 7.260385359586508e-08
30 O 0 5.945215093561274e-07
% O 0 5.365427000469936e-07
are O 0 7.694692527593361e-08
deletion O 0 4.1658233385533094e-05
or O 0 2.954450337711023e-06
insertion O 0 0.00010982911771861836
events O 0 2.4932491214713082e-05
. O 0 9.93325375020504e-05

There O 0 1.1770962373702787e-05
is O 0 6.796100933570415e-06
a O 0 3.586358798202127e-05
noticeably O 0 0.0037777619436383247
elevated O 0 0.004806797485798597
level O 0 1.8957723568746587e-06
of O 0 1.5626820015768317e-07
mutation O 0 6.025703441991936e-06
in O 0 1.8062128503970598e-07
the O 0 2.7208494657315896e-07
paired O 0 6.13731162957265e-06
domain O 0 1.1794701322287438e-06
compared O 0 1.2071641322108917e-06
with O 0 1.5523026775099424e-07
the O 0 2.037157571521675e-07
rest O 0 5.819159127895546e-07
of O 0 1.2354264811165194e-07
the O 0 5.547573891817592e-06
gene O 0 0.00011855224875034764
. O 0 3.892063978128135e-05

Increased O 0 7.339979492826387e-05
mutation O 0 2.88686223939294e-05
in O 0 4.775620823238569e-07
the O 0 1.0107344223797554e-06
homeodomain O 0 0.0011062334524467587
is O 0 5.8748526043928e-07
accounted O 0 1.212637926073512e-06
for O 0 1.0167712360953374e-07
by O 0 4.1528687688696664e-07
the O 0 3.516440756357042e-06
hypermutable O 0 0.0007307828636839986
CpG O 0 0.0004234421066939831
dinucleotide O 0 0.0003226370026823133
in O 0 4.764507593790768e-06
codon O 0 7.486736285500228e-05
240 O 0 6.80839002598077e-05
. O 0 5.10069694428239e-05

Very O 0 1.1175330655532889e-05
nearly O 0 7.662443749723025e-06
all O 0 5.577081765295588e-07
mutations O 0 2.3821403374313377e-05
appear O 0 9.81298308033729e-06
to O 0 9.983713198380428e-07
cause O 0 0.0005407241987995803
loss O 0 3.3430344046792015e-05
of O 0 5.477082964944202e-08
function O 0 2.071540450288012e-07
of O 0 8.180636967836108e-08
the O 0 7.749171118121012e-07
mutant O 0 2.4647879399708472e-05
allele O 0 7.642221135029104e-06
, O 0 2.1680817496871896e-07
and O 0 4.964467947843332e-08
more O 0 1.7520038753104927e-08
than O 0 4.326205527149796e-08
80 O 0 3.7786705320286273e-07
% O 0 1.1862730531220222e-07
of O 0 1.6951402415088523e-07
exonic O 0 0.00029876030748710036
substitutions O 0 8.105037522909697e-06
result O 0 8.989847628981806e-06
in O 0 3.6155502129986417e-06
nonsense O 0 0.0004050927236676216
codons O 0 0.00031159253558143973
. O 0 8.17362597445026e-05

In O 0 9.553223208058625e-06
a O 0 1.0511823347769678e-05
gene O 0 8.925979273044504e-06
with O 0 6.496404125755362e-07
such O 0 9.87657813311671e-07
extraordinarily O 0 0.00017667353677097708
high O 0 7.976641427376308e-06
sequence O 0 2.2727529085386777e-06
conservation O 0 5.1918800636485685e-06
throughout O 0 8.094447139228578e-07
evolution O 0 1.8284503084942116e-06
, O 0 7.625482112416648e-07
there O 0 3.4294140505153337e-07
are O 0 2.6195516511506867e-07
presumed O 0 8.187847561202943e-05
undiscovered O 0 0.0007244293810799718
missense O 0 0.0006857135449536145
mutations O 0 5.3140101954340935e-05
, O 0 6.980805551393132e-07
these O 0 5.100676858660336e-08
are O 0 5.2877737743983744e-08
hypothesized O 0 4.532364982878789e-06
to O 0 1.0526869687055296e-07
exist O 0 3.3085254358411476e-07
in O 0 7.74904549416533e-07
as O 0 4.609841198544018e-06
- O 0 0.00041831706766970456
yet O 0 1.6063602743088268e-05
unidentified O 0 0.0003431763034313917
phenotypes O 0 0.0008239115122705698
. O 0 2.436619070067536e-05
. O 0 5.584262544289231e-05

Genetic O 0 0.0007776509155519307
heterogeneity O 0 0.00038055796176195145
and O 0 5.901908480154816e-06
penetrance O 0 0.0013194996863603592
analysis O 0 2.2091664959589252e-06
of O 0 6.905743816787435e-07
the O 0 2.5418023142265156e-05
BRCA1 O 0 0.024786457419395447
and O 0 1.6012701962608844e-05
BRCA2 O 0 0.017313839867711067
genes O 0 0.0004906520480290055
in O 0 0.012718234211206436
breast B-Disease 1 0.9997931122779846
cancer I-Disease 1 0.9997450709342957
families O 0 0.0007179031381383538
. O 0 0.0003267069405410439

The O 1 0.742426872253418
Breast B-Disease 1 0.9997003078460693
Cancer I-Disease 1 0.9995214939117432
Linkage O 0 0.34182053804397583
Consortium O 0 0.007628581020981073
. O 0 0.00033707841066643596

The O 0 8.286122465506196e-06
contribution O 0 1.2694777979049832e-05
of O 0 4.679730409407057e-06
BRCA1 O 0 0.09014344960451126
and O 0 4.458785770111717e-05
BRCA2 O 1 0.8995060324668884
to O 0 0.0038625227753072977
inherited B-Disease 1 0.9999070167541504
breast I-Disease 1 0.9999673366546631
cancer I-Disease 1 0.9999641180038452
was O 0 0.0033189873211085796
assessed O 0 8.962454012362286e-05
by O 0 2.157059498131275e-06
linkage O 0 0.00010663772263797
and O 0 5.748906346525473e-07
mutation O 0 9.626138307794463e-06
analysis O 0 9.436609502699866e-07
in O 0 9.285019473281864e-07
237 O 0 4.006824019597843e-05
families O 0 5.868419066246133e-07
, O 0 5.127863289544621e-08
each O 0 1.0981864306813804e-08
with O 0 8.826738451261917e-08
at O 0 5.387983605942281e-07
least O 0 1.5312825496494042e-07
four O 0 3.19020614369947e-07
cases O 0 3.0938026611693203e-05
of O 0 0.00013317533012013882
breast B-Disease 1 0.999893307685852
cancer I-Disease 1 0.9996269941329956
, O 0 4.499461738305399e-06
collected O 0 2.720522161325789e-06
by O 0 2.8786207622033544e-05
the O 0 0.020879389718174934
Breast B-Disease 1 0.999882698059082
Cancer I-Disease 1 0.9997616410255432
Linkage O 0 0.4524235427379608
Consortium O 0 0.006200545933097601
. O 0 0.00017396760813426226

Families O 0 2.674805000424385e-05
were O 0 1.210099867421377e-06
included O 0 1.1483423350000521e-06
without O 0 5.218609544499486e-07
regard O 0 4.946471676703368e-07
to O 0 1.1728327820037521e-07
the O 0 1.0401604413345922e-06
occurrence O 0 6.353576463880017e-05
of O 0 5.576439434662461e-05
ovarian B-Disease 1 0.9998942613601685
or I-Disease 0 0.0005553234950639307
other I-Disease 0 0.00011102372081950307
cancers I-Disease 1 0.9986053109169006
. O 0 0.0003149702097289264

Overall O 0 0.0456852987408638
, O 0 0.006016043946146965
disease O 1 0.999683141708374
was O 0 0.0008542116265743971
linked O 0 0.00021837008534930646
to O 0 1.3626073496197932e-06
BRCA1 O 0 0.0006130229448899627
in O 0 3.3613835626056243e-07
an O 0 3.92041869190507e-07
estimated O 0 2.6410541522636777e-06
52 O 0 1.5679233911214396e-06
% O 0 1.6821570625324966e-07
of O 0 7.051975359217977e-08
families O 0 5.082492862129584e-07
, O 0 2.9788677124997776e-07
to O 0 1.592512717252248e-07
BRCA2 O 0 7.830314279999584e-05
in O 0 1.534776714606778e-07
32 O 0 8.179777069017291e-07
% O 0 1.8965593540087866e-07
of O 0 1.2387984327233426e-07
families O 0 1.0651247066562064e-06
, O 0 1.9873193934927258e-07
and O 0 6.839729849161813e-08
to O 0 7.816164071527965e-08
neither O 0 1.4807571915298468e-06
gene O 0 1.4854855407975265e-06
in O 0 1.5812382514468482e-07
16 O 0 7.055519404275401e-07
% O 0 3.9148554265011626e-07
( O 0 3.900016736224643e-07
95 O 0 6.565763897015131e-07
% O 0 3.2532392424400314e-07
confidence O 0 4.116569925827207e-06
interval O 0 1.4242789802665357e-05
[ O 0 7.74882864789106e-05
CI O 0 0.016637347638607025
] O 0 1.7358835975755937e-05
6 O 0 2.137026058335323e-06
% O 0 1.3538070788854384e-06
- O 0 1.687825351837091e-05
28 O 0 1.5194050320133101e-06
% O 0 6.787925599383016e-07
) O 0 7.368561227849568e-07
, O 0 6.479814942395024e-07
suggesting O 0 2.524953379179351e-05
other O 0 2.478508349668118e-06
predisposition O 0 0.05860744044184685
genes O 0 0.00011442531103966758
. O 0 6.778356328140944e-05

The O 0 9.134401807386894e-06
majority O 0 8.282480848720297e-06
( O 0 6.457086328737205e-06
81 O 0 2.073069117614068e-05
% O 0 9.827655276239966e-07
) O 0 7.990399240043189e-07
of O 0 1.7889479977384326e-06
the O 0 0.007401528302580118
breast B-Disease 1 0.9999198913574219
- I-Disease 1 0.9998593330383301
ovarian I-Disease 1 0.9999909400939941
cancer I-Disease 1 0.9999419450759888
families O 0 5.129794226377271e-05
were O 0 2.109489741997095e-06
due O 0 6.249659782042727e-05
to O 0 3.7451659409271087e-06
BRCA1 O 0 0.00685403635725379
, O 0 6.138500907582056e-07
with O 0 4.893134359917894e-07
most O 0 2.628575828111934e-07
others O 0 7.293098178706714e-07
( O 0 1.1274028111074585e-06
14 O 0 1.2791346080121002e-06
% O 0 1.2321102076384705e-06
) O 0 1.4381997743839747e-06
due O 0 1.3413947272056248e-05
to O 0 8.417355275014415e-06
BRCA2 O 0 0.009470063261687756
. O 0 9.118000889429823e-05

Conversely O 0 0.00041719485307112336
, O 0 3.1203126127365977e-06
the O 0 5.065928689873544e-07
majority O 0 6.054182790649065e-07
of O 0 2.5082090360228904e-07
families O 0 2.770488890746492e-06
with O 0 5.586607130680932e-06
male B-Disease 0 0.0002518604160286486
and I-Disease 0 6.56555057503283e-05
female I-Disease 1 0.9185556173324585
breast I-Disease 1 0.9998824596405029
cancer I-Disease 1 0.9997617602348328
were O 0 5.731193596147932e-06
due O 0 0.00010752474918263033
to O 0 7.563531198684359e-06
BRCA2 O 0 0.006407265085726976
( O 0 1.2500705452112015e-05
76 O 0 0.00014002220996189862
% O 0 8.340174645127263e-06
) O 0 1.4855967492621858e-05
. O 0 3.292695328127593e-05

The O 0 1.2425613931554835e-05
largest O 0 2.4368793674511835e-05
proportion O 0 1.0375585588917602e-05
( O 0 2.2709502900397638e-06
67 O 0 6.50546371616656e-06
% O 0 4.314722730214271e-07
) O 0 1.7452475731261075e-07
of O 0 9.873812700789131e-08
families O 0 1.0861831469810568e-06
due O 0 2.5775377707759617e-06
to O 0 8.876848056615927e-08
other O 0 6.438457944568654e-08
genes O 0 1.6101340634122607e-06
was O 0 4.7987496145651676e-06
found O 0 8.87816668182495e-07
in O 0 1.418144250919795e-07
families O 0 1.6558122695187194e-07
with O 0 1.6048561235493253e-07
four O 0 3.0713550813743495e-07
or O 0 1.0706148714234587e-06
five O 0 9.631296506995568e-07
cases O 0 2.043150016106665e-05
of O 0 2.1671528884326108e-05
female O 1 0.9535555243492126
breast B-Disease 1 0.9998360872268677
cancer I-Disease 1 0.9995619654655457
only O 0 2.2006981453159824e-05
. O 0 9.847110050031915e-05

These O 0 8.028032425499987e-06
estimates O 0 5.720051558455452e-05
were O 0 2.106138936142088e-06
not O 0 2.050774583040038e-06
substantially O 0 0.00013741751899942756
affected O 0 4.149133928876836e-06
either O 0 4.538124471764604e-07
by O 0 2.1447772269311827e-07
changing O 0 2.167832690247451e-06
the O 0 1.2788456160706119e-06
assumed O 0 5.9035286540165544e-05
penetrance O 0 0.004699623677879572
model O 0 1.902581425383687e-05
for O 0 2.1388468667282723e-06
BRCA1 O 0 0.0037139158230274916
or O 0 1.4193932429407141e-06
by O 0 4.679180278799322e-07
including O 0 6.952927265047038e-07
or O 0 5.636935384245589e-06
excluding O 0 5.8540215832181275e-05
BRCA1 O 0 0.02631319686770439
mutation O 0 0.00017740295152179897
data O 0 2.3633796445210464e-05
. O 0 5.706653973902576e-05

Among O 0 2.6848741981666535e-05
those O 0 6.076660156395519e-06
families O 0 8.320537017425522e-05
with O 0 0.005437200888991356
disease O 1 0.9998393058776855
due O 0 0.0011018203804269433
to O 0 9.380858500662725e-06
BRCA1 O 0 0.0737648531794548
that O 0 5.833010732203547e-07
were O 0 4.736089351808914e-07
tested O 0 2.6708967197919264e-06
by O 0 2.642539520536502e-08
one O 0 1.5904964456581183e-08
of O 0 1.516024639158786e-08
the O 0 3.5040568491240265e-07
standard O 0 6.76067656968371e-06
screening O 0 4.60459932583035e-06
methods O 0 7.155024945859623e-07
, O 0 1.5599706557622994e-06
mutations O 0 8.496474038111046e-06
were O 0 4.619773505964986e-07
detected O 0 6.206280886544846e-06
in O 0 6.449704414990265e-08
the O 0 1.4482829158168897e-07
coding O 0 2.25741814574576e-06
sequence O 0 2.811843273775594e-07
or O 0 5.124920221533102e-07
splice O 0 7.885193554102443e-06
sites O 0 1.3235006690592854e-07
in O 0 8.851807820065005e-08
an O 0 1.9037298670809832e-07
estimated O 0 2.2007197912898846e-06
63 O 0 5.569392214965774e-06
% O 0 5.847664397151675e-07
( O 0 7.58896817387722e-07
95 O 0 2.080938884319039e-06
% O 0 2.3416303065459942e-06
CI O 0 0.008883656933903694
51 O 0 1.0727289009082597e-05
% O 0 5.456085546029499e-06
- O 0 5.179693107493222e-05
77 O 0 1.2395101293805055e-05
% O 0 3.7750578485429287e-06
) O 0 8.492163942719344e-06
. O 0 2.5998604542110115e-05

The O 0 2.2728765543433838e-05
estimated O 0 3.7651523598469794e-05
sensitivity O 0 5.0955877668457106e-05
was O 0 4.747259026771644e-06
identical O 0 1.938119339683908e-06
for O 0 8.613488944320125e-08
direct O 0 3.356271065513283e-07
sequencing O 0 1.8146640741178999e-06
and O 0 3.0379069926311786e-07
other O 0 3.490143001272372e-07
techniques O 0 1.9709395928657614e-05
. O 0 4.3227173591731116e-05

The O 0 4.4606054871110246e-05
penetrance O 0 0.007216657977551222
of O 0 1.5847566828597337e-05
BRCA2 O 0 0.04086625576019287
was O 0 1.931553015310783e-05
estimated O 0 3.5536315863282653e-06
by O 0 4.3052239107055357e-07
maximizing O 0 4.547817752609262e-06
the O 0 1.6167226704055793e-06
LOD O 0 0.0015259876381605864
score O 0 2.0151080661889864e-06
in O 0 6.9164739215921145e-06
BRCA2 O 0 0.0403628870844841
- O 0 0.0009191003628075123
mutation O 0 3.065298733417876e-05
families O 0 1.699807171462453e-06
, O 0 2.4001704446163785e-07
over O 0 1.9124534844650043e-07
all O 0 1.1061119664645958e-07
possible O 0 3.317034725114354e-06
penetrance O 0 0.0036522767040878534
functions O 0 1.3965142898086924e-05
. O 0 6.288589793257415e-05

The O 0 5.4700161854270846e-05
estimated O 0 0.0002089635527227074
cumulative O 0 0.002480326918885112
risk O 0 0.03437190130352974
of O 0 0.00040062598418444395
breast B-Disease 1 0.9998276233673096
cancer I-Disease 1 0.998907208442688
reached O 0 1.867775063146837e-05
28 O 0 6.0602010307775345e-06
% O 0 9.003299510368379e-07
( O 0 7.331236133722996e-07
95 O 0 1.6998573073578882e-06
% O 0 1.3917684782427386e-06
CI O 0 0.0033962393645197153
9 O 0 1.8924881715065567e-06
% O 0 7.135495252441615e-07
- O 0 4.261045432940591e-06
44 O 0 5.291083766678639e-07
% O 0 1.4453024732574704e-07
) O 0 9.59415231704952e-08
by O 0 7.834478310542181e-08
age O 0 2.6291522772226017e-06
50 O 0 4.7535152702948835e-07
years O 0 6.939267791494785e-07
and O 0 1.2744087030114315e-07
84 O 0 2.8046893021382857e-06
% O 0 5.05817524754093e-07
( O 0 4.847477725888893e-07
95 O 0 1.2715208868030459e-06
% O 0 1.4018257843417814e-06
CI O 0 0.0030719595961272717
43 O 0 4.431719844433246e-06
% O 0 1.3261061440061894e-06
- O 0 7.330730568355648e-06
95 O 0 1.024202219923609e-06
% O 0 3.234350174352585e-07
) O 0 3.2869698429749405e-07
by O 0 6.967091508158774e-07
age O 0 3.38374957209453e-05
70 O 0 2.4161547116818838e-05
years O 0 5.0348040531389415e-05
. O 0 3.0734478059457615e-05

The O 0 0.0023872037418186665
corresponding O 1 0.9907615780830383
ovarian B-Disease 1 0.9999879598617554
cancer I-Disease 1 0.9999713897705078
risks O 1 0.9221511483192444
were O 0 1.9813327526208013e-05
0 O 0 9.889305511023849e-05
. O 0 5.1519586122594774e-05

4 O 0 2.0216706616338342e-05
% O 0 5.763658009527717e-06
( O 0 3.3230442113563186e-06
95 O 0 4.740856638818514e-06
% O 0 3.4313645755901234e-06
CI O 0 0.00280526140704751
0 O 0 1.7086746311179013e-06
% O 0 1.0426383596495725e-06
- O 0 4.484065811993787e-06
1 O 0 2.3297263851418393e-07
% O 0 1.4458402119998937e-07
) O 0 9.96844633505134e-08
by O 0 8.949558605308994e-08
age O 0 1.531297129986342e-06
50 O 0 3.1391655852530675e-07
years O 0 3.3865970294755243e-07
and O 0 6.786554251902999e-08
27 O 0 1.068562596628908e-06
% O 0 1.681258936514496e-07
( O 0 1.8542164070822764e-07
95 O 0 6.649947863479611e-07
% O 0 7.150788974286115e-07
CI O 0 0.0010073133744299412
0 O 0 7.465764610969927e-07
% O 0 6.636465741394204e-07
- O 0 6.854787443444366e-06
47 O 0 8.641238764539594e-07
% O 0 3.186229378115968e-07
) O 0 2.53968323704612e-07
by O 0 3.3583268077563844e-07
age O 0 2.4540669983252883e-05
70 O 0 1.6919962945394218e-05
years O 0 2.7621901608654298e-05
. O 0 2.629131449793931e-05

The O 0 0.00014241108146961778
lifetime O 0 0.06498584151268005
risk O 0 0.28447574377059937
of O 0 0.0039044285658746958
breast B-Disease 1 0.9999243021011353
cancer I-Disease 1 0.9998206496238708
appears O 0 0.0006971153197810054
similar O 0 5.055849214841146e-06
to O 0 8.459995797238662e-07
the O 0 1.0230717634840403e-05
risk O 0 0.0012797936797142029
in O 0 1.5179976799117867e-05
BRCA1 O 1 0.8851358890533447
carriers O 0 0.0007441991474479437
, O 0 8.585553814555169e-07
but O 0 2.63429484448352e-07
there O 0 1.5774095629694784e-07
was O 0 1.0103199201694224e-06
some O 0 5.586419504766127e-08
suggestion O 0 2.3328532279265346e-06
of O 0 3.3739408422661654e-07
a O 0 3.350969200255349e-05
lower O 0 0.00190540193580091
risk O 0 0.0014356106985360384
in O 0 1.5366955267381854e-05
BRCA2 O 0 0.06430474668741226
carriers O 0 0.0006864863680675626
< O 0 0.00047741926391609013
50 O 0 2.366270564380102e-06
years O 0 2.337409341635066e-06
of O 0 1.145971737059881e-06
age O 0 0.0007078149355947971
. O 0 7.466273382306099e-05

Eye B-Disease 1 0.9671987891197205
movement I-Disease 0 0.0018144670175388455
abnormalities I-Disease 1 0.9700998067855835
correlate O 0 0.00021558362641371787
with O 0 2.2222478946787305e-05
genotype O 0 0.005393410567194223
in O 0 0.00026520073879510164
autosomal O 1 0.9980853796005249
dominant O 1 0.9943528175354004
cerebellar B-Disease 1 0.999626636505127
ataxia I-Disease 1 0.9997521042823792
type I-Disease 1 0.9985270500183105
I I-Disease 1 0.7476097345352173
. O 0 0.0004675232048612088

We O 0 3.104034476564266e-05
compared O 0 0.0002801161608658731
horizontal O 0 0.003193574259057641
eye O 0 0.04401983320713043
movements O 0 2.7861644412041642e-05
( O 0 2.945424785139039e-05
visually O 0 0.0002843129332177341
guided O 0 0.00012231750588398427
saccades O 0 0.02788947895169258
, O 0 1.1325428204145283e-05
antisaccades O 0 0.001022796262986958
, O 0 1.1676137319227564e-06
and O 0 3.3322936587865115e-07
smooth O 0 2.67435098066926e-05
pursuit O 0 1.7304195353062823e-05
) O 0 1.0980450042552548e-06
in O 0 3.8195315710254363e-07
control O 0 1.396617449245241e-06
subjects O 0 3.484971784928348e-06
( O 0 2.8848223792010685e-06
n O 0 1.4357002328324597e-05
= O 0 1.9323377273394726e-05
14 O 0 2.4842775019351393e-06
) O 0 1.2313385013840161e-06
and O 0 6.012639914843021e-07
patients O 0 0.0001824171922635287
with O 0 1.1546574540943766e-07
three O 0 1.4468581355231436e-07
forms O 0 3.6741150779562304e-06
of O 0 8.00938141765073e-06
autosomal O 1 0.9971055388450623
dominant O 1 0.6658453941345215
cerebellar B-Disease 1 0.9988631010055542
ataxias I-Disease 1 0.9955980181694031
type I-Disease 1 0.9876595139503479
I I-Disease 0 0.28396159410476685
spinocerebellar B-Disease 1 0.9966740608215332
ataxias I-Disease 0 0.005363441538065672
1 I-Disease 0 5.323331151885213e-06
and I-Disease 0 4.0731666217652673e-07
2 I-Disease 0 2.0894317458441947e-06
( O 0 2.0660372683778405e-06
SCA1 B-Disease 0 0.0003715043712873012
, O 0 5.498949349203031e-07
n O 0 8.10979963716818e-06
= O 0 1.103111389966216e-05
11 O 0 1.238163463312958e-06
; O 0 8.20793957245769e-07
SCA2 B-Disease 0 0.00023828462872188538
, O 0 6.414923063857714e-07
n O 0 3.8569151001865976e-06
= O 0 8.05956733529456e-06
10 O 0 6.460354029513837e-07
) O 0 7.736367706456804e-07
and O 0 2.2236242784856586e-06
SCA3 B-Disease 1 0.8663350343704224
/ O 0 0.008395564742386341
Machado B-Disease 0 0.004327078815549612
- I-Disease 0 0.015289817936718464
Joseph I-Disease 0 0.005076897796243429
disease I-Disease 1 0.9989069700241089
( O 0 0.00011325100058456883
MJD B-Disease 1 0.957459568977356
) O 0 5.863625119673088e-06
( O 0 5.815758413518779e-06
n O 0 2.346594374103006e-05
= O 0 4.5450589823303744e-05
16 O 0 6.059206953068497e-06
) O 0 4.302914476284059e-06
. O 0 1.507640536146937e-05

In O 0 6.735925126122311e-05
SCA1 B-Disease 0 0.009379359893500805
, O 0 1.0867315722862259e-05
saccade O 0 0.0002964979503303766
amplitude O 0 5.268286258797161e-05
was O 0 0.000155416113557294
significantly O 0 0.00015262115630321205
increased O 0 1.0901248970185407e-05
, O 0 2.7101821160613326e-06
resulting O 0 7.415921572828665e-05
in O 0 2.423410114715807e-05
hypermetria B-Disease 0 0.055065445601940155
. O 0 9.319950186181813e-05

The O 0 2.5499355615465902e-05
smooth O 0 0.0003123432397842407
pursuit O 0 0.0002532413345761597
gain O 0 0.00017626008775550872
was O 0 0.0006344207213260233
decreased O 0 0.006197134964168072
. O 0 9.53878989093937e-05

In O 0 0.00012902115122415125
SCA2 B-Disease 0 0.014805355109274387
, O 0 1.6339015928679146e-05
saccade O 0 0.0005747922114096582
velocity O 0 0.0001336428540525958
was O 0 0.0011053101625293493
markedly O 0 0.024907279759645462
decreased O 0 0.007606146391481161
. O 0 7.190948963398114e-05

The O 0 6.330619271466276e-06
percentage O 0 8.712704584468156e-06
of O 0 7.396455430352944e-07
errors O 0 7.370392268057913e-05
in O 0 1.0898213076870888e-05
antisaccades O 0 0.03596413880586624
was O 0 0.00011647024075500667
greatly O 0 5.623427568934858e-05
increased O 0 6.3303118622570764e-06
and O 0 5.870607537872274e-07
was O 0 2.2724843802279793e-05
significantly O 0 5.802748637506738e-05
correlated O 0 2.901955485867802e-05
with O 0 1.0110397852258757e-05
age O 0 0.020631922408938408
at O 0 0.45464637875556946
disease O 1 0.9997816681861877
onset O 1 0.9987249970436096
. O 0 0.001975164981558919

In O 0 4.766920937981922e-06
addition O 0 3.7317106489354046e-06
, O 0 5.449624609354942e-07
a O 0 1.1605310419326997e-06
correlation O 0 1.935494765348267e-06
between O 0 8.195002578759158e-07
smooth O 0 7.426607771776617e-05
pursuit O 0 2.164543911931105e-05
gain O 0 2.247770453323028e-06
and O 0 1.0559266172549542e-07
the O 0 1.3479231597557373e-07
number O 0 1.7396325802110368e-07
of O 0 1.912733978315373e-06
trinucleotide O 1 0.9311767220497131
repeats O 0 0.0019259974360466003
was O 0 0.00032280280720442533
found O 0 6.466043851105496e-05
. O 0 3.743981142179109e-05

In O 0 0.0004192963824607432
SCA3 B-Disease 1 0.9872640371322632
, O 0 0.000238220309256576
gaze B-Disease 0 0.07159329950809479
- I-Disease 0 0.03496337682008743
evoked I-Disease 0 0.009447537362575531
nystagmus I-Disease 1 0.6368576288223267
was O 0 7.763502799207345e-05
often O 0 2.585297352197813e-06
present O 0 1.6516327150384313e-06
as O 0 2.694916702239425e-06
was O 0 3.185020250384696e-05
saccade O 0 0.000679739227052778
hypometria O 0 0.0006775428773835301
and O 0 1.8860055206459947e-06
smooth O 0 9.274213516619056e-05
pursuit O 0 0.00018867327889893204
gain O 0 0.00013715439126826823
was O 0 0.0012605170486494899
markedly O 0 0.049158040434122086
decreased O 0 0.010958652012050152
. O 0 8.789857383817434e-05

Three O 0 1.005931062536547e-05
major O 0 2.604014298412949e-05
criteria O 0 6.202245003805729e-06
, O 0 1.6341491573257372e-06
saccade O 0 5.8980531321140006e-05
amplitude O 0 4.477566108107567e-06
, O 0 1.2906222082165186e-06
saccade O 0 6.042723180144094e-05
velocity O 0 5.924922788835829e-06
, O 0 9.288474416280224e-07
and O 0 2.628906656809704e-07
presence O 0 2.204496695412672e-06
of O 0 2.0869226773356786e-06
gaze B-Disease 0 0.01851678267121315
- I-Disease 0 0.005349896848201752
evoked I-Disease 0 0.0032800412736833096
nystagmus I-Disease 0 0.006292179226875305
, O 0 6.480705110334384e-07
permitted O 0 5.973814154458523e-07
the O 0 3.2551324125051906e-07
correct O 0 4.515650743996957e-06
assignment O 0 1.3926102155892295e-06
of O 0 3.9292853415417994e-08
90 O 0 3.258238052694651e-07
% O 0 1.2513133640368324e-07
of O 0 4.98161725204227e-08
the O 0 9.91610477285576e-07
SCA1 B-Disease 0 0.0008227002108469605
, O 0 1.880164148815311e-07
90 O 0 2.15838554140646e-07
% O 0 8.137654106121772e-08
of O 0 3.917364566063952e-08
the O 0 1.2451558859538636e-06
SCA2 B-Disease 0 0.0026205957401543856
, O 0 3.8935542079343577e-07
and O 0 9.350460317136822e-08
93 O 0 1.9299836822028738e-06
% O 0 2.4687670929779415e-07
of O 0 1.6712708372779161e-07
the O 0 1.9167995560565032e-05
patients O 0 0.07217240333557129
with O 0 2.4796339857857674e-05
SCA3 B-Disease 1 0.9902353882789612
to O 0 1.7259528704016702e-06
their O 0 1.7052658449756564e-06
genetically O 0 0.0003032158419955522
confirmed O 0 0.0007899769698269665
patient O 0 0.01914162002503872
group O 0 4.081156021129573e-06
and O 0 6.082267987039813e-07
, O 0 1.0812987056851853e-06
therefore O 0 1.7231799347428023e-06
, O 0 1.869797983999888e-06
may O 0 1.27286702991114e-05
help O 0 7.986872333276551e-06
orient O 0 0.0003609549312386662
diagnoses O 0 0.004577643238008022
of O 0 4.564106802718015e-06
SCA1 B-Disease 1 0.7015654444694519
, O 0 1.652300670684781e-05
SCA2 B-Disease 0 0.030087070539593697
, O 0 4.839851044380339e-06
and O 0 2.8931292490597116e-06
SCA3 B-Disease 0 0.36011990904808044
at O 0 9.306898391514551e-06
early O 0 8.267289558716584e-06
clinical O 0 0.0001542790705570951
stages O 0 2.4965898774098605e-05
of O 0 4.349656137492275e-06
the O 0 0.005254081916064024
diseases O 1 0.9997194409370422
. O 0 0.00010522567754378542
. O 0 9.939516894519329e-05

Genetic O 0 0.00010195132199442014
basis O 0 2.8543718144646846e-06
and O 0 3.6525491395877907e-06
molecular O 0 0.00029181066201999784
mechanism O 0 0.0045087928883731365
for O 0 0.021241076290607452
idiopathic B-Disease 1 0.9999551773071289
ventricular I-Disease 1 0.9997052550315857
fibrillation I-Disease 1 0.9998181462287903
. O 0 0.03334588184952736

Ventricular B-Disease 1 0.9966114163398743
fibrillation I-Disease 1 0.9987564086914062
causes O 0 0.05684342235326767
more O 0 2.4783023491181666e-06
than O 0 2.0435097667359514e-06
300 O 0 9.142279850493651e-06
, O 0 3.532095661284984e-06
000 O 0 3.16748846671544e-05
sudden O 0 0.003980647306889296
deaths O 0 6.587010284420103e-05
each O 0 3.389686185073515e-07
year O 0 4.897784037893871e-06
in O 0 1.2411782108756597e-06
the O 0 4.9194582061318215e-06
USA O 0 0.00017819464846979827
alone O 0 0.00010712100629461929
. O 0 3.584676596801728e-05

In O 0 3.4842939840018516e-06
approximately O 0 3.6980686672904994e-06
5 O 0 8.974787306215148e-06
- O 0 1.3750747712037992e-05
12 O 0 5.235978051132406e-07
% O 0 1.0680719242373016e-07
of O 0 5.6671783710271484e-08
these O 0 1.492071959319219e-07
cases O 0 8.861891728884075e-06
, O 0 6.41658687072777e-07
there O 0 4.2270855260539975e-07
are O 0 2.685414131065045e-07
no O 0 1.0933366866083816e-05
demonstrable O 1 0.6943438053131104
cardiac O 1 0.998566210269928
or O 0 0.00078058015787974
non O 0 0.04095160961151123
- O 1 0.9973267316818237
cardiac O 1 0.999091386795044
causes O 0 0.0006401994614861906
to O 0 1.6711177863726334e-07
account O 0 2.9063232886983315e-07
for O 0 1.149445338910482e-07
the O 0 5.909174092266767e-07
episode O 0 1.532442547613755e-05
, O 0 5.307437049850705e-07
which O 0 2.9706347959290724e-07
is O 0 1.0068112032968202e-06
therefore O 0 6.722795205860166e-06
classified O 0 0.005725618917495012
as O 0 0.00493317237123847
idiopathic B-Disease 1 0.9999340772628784
ventricular I-Disease 1 0.9996535778045654
fibrillation I-Disease 1 0.9999030828475952
( O 0 0.446310430765152
IVF B-Disease 1 0.996645987033844
) O 0 0.00033834241912700236
. O 0 0.0001209164984175004

A O 0 9.024458267958835e-05
distinct O 0 1.7105259757954627e-05
group O 0 3.324680437799543e-05
of O 0 5.7649012887850404e-05
IVF B-Disease 1 0.9993265867233276
patients O 1 0.9963562488555908
has O 0 1.5477968190680258e-05
been O 0 1.7484787804278312e-06
found O 0 7.814932700966892e-07
to O 0 8.472302681639121e-08
present O 0 5.641714437842893e-07
with O 0 6.105537977418862e-07
a O 0 2.5144885512418114e-05
characteristic O 0 0.0010570393642410636
electrocardiographic O 1 0.6307608485221863
pattern O 0 0.020256610587239265
. O 0 0.00020642699382733554

Because O 0 7.0227188189164735e-06
of O 0 1.9749421653614263e-07
the O 0 9.797055326998816e-07
small O 0 1.0950593605230097e-06
size O 0 1.323508627137926e-06
of O 0 1.1997255455753475e-07
most O 0 6.749298790964531e-07
pedigrees O 0 3.3925087336683646e-05
and O 0 4.266354096671421e-07
the O 0 3.1207830488710897e-06
high O 0 0.000317837082548067
incidence O 0 0.31296828389167786
of O 0 7.807365363987628e-06
sudden B-Disease 1 0.9441922307014465
death I-Disease 0 0.0014004276599735022
, O 0 1.2596771057360456e-06
however O 0 9.98324708234577e-07
, O 0 5.286392479320057e-07
molecular O 0 5.717332896892913e-06
genetic O 0 1.8797760276356712e-05
studies O 0 2.169652816519374e-06
of O 0 2.8286847282288363e-06
IVF B-Disease 1 0.9959134459495544
have O 0 1.850476223808073e-06
not O 0 1.0127278073923662e-06
yet O 0 4.791651917912532e-06
been O 0 2.6070356398122385e-06
done O 0 1.6228774256887846e-05
. O 0 2.2036592781660147e-05

Because O 0 0.027689984068274498
IVF B-Disease 1 0.9925141930580139
causes O 1 0.9925883412361145
cardiac O 1 0.9990789890289307
rhythm O 1 0.956433117389679
disturbance O 1 0.9810642004013062
, O 0 2.471765037626028e-05
we O 0 3.4471113394829445e-06
investigated O 0 6.531379767693579e-05
whether O 0 5.097451776236994e-06
malfunction O 0 0.0034344051964581013
of O 0 5.663233650921029e-07
ion O 0 0.00014118431136012077
channels O 0 2.128102642018348e-05
could O 0 2.7145430067321286e-05
cause O 0 0.0029901734087616205
the O 0 3.680595546029508e-05
disorder O 1 0.9991069436073303
by O 0 1.7507732081867289e-06
studying O 0 7.447669759130804e-06
mutations O 0 1.4774333067180123e-05
in O 0 2.0325924197095446e-06
the O 0 1.4342441318149213e-05
cardiac O 1 0.9873877167701721
sodium O 0 0.0006219607312232256
channel O 0 0.00015472499944735318
gene O 0 0.00032789300894364715
SCN5A O 0 0.10859609395265579
. O 0 0.000245274743065238

We O 0 4.394209554448025e-06
have O 0 5.162033289707324e-07
now O 0 8.415256047555886e-07
identified O 0 1.3361858464122633e-06
a O 0 1.416117243024928e-06
missense O 0 0.00011224982881685719
mutation O 0 1.796677133825142e-05
, O 0 5.623676315735793e-07
a O 0 7.548031589976745e-06
splice O 0 0.0009101128089241683
- O 0 0.0009652821463532746
donor O 0 7.14581910870038e-05
mutation O 0 1.616559711692389e-05
, O 0 4.076741788594518e-07
and O 0 3.1069635042513255e-07
a O 0 5.285104634822346e-06
frameshift O 0 0.0022704428993165493
mutation O 0 1.1614140930760186e-05
in O 0 2.260974412138239e-07
the O 0 7.662470693503565e-07
coding O 0 2.9169268600526266e-05
region O 0 1.572235760249896e-06
of O 0 6.804790473324829e-07
SCN5A O 0 0.018305325880646706
in O 0 5.275385774439201e-06
three O 0 2.1546748030232266e-05
IVF B-Disease 1 0.9780799150466919
families O 0 6.188858242239803e-05
. O 0 5.633276668959297e-05

We O 0 1.7083699503928074e-06
show O 0 9.493494985690631e-07
that O 0 1.1263845323128407e-07
sodium O 0 2.124747652487713e-06
channels O 0 2.9916100174887106e-07
with O 0 1.8050900507660117e-07
the O 0 1.208911839967186e-06
missense O 0 0.000383578531909734
mutation O 0 0.0001374721759930253
recover O 0 0.0013838986633345485
from O 0 6.566485808434663e-06
inactivation O 0 0.005459531210362911
more O 0 5.63131834496744e-07
rapidly O 0 3.472808384685777e-05
than O 0 2.740092952535633e-07
normal O 0 2.4553089588152943e-06
and O 0 1.8690228387185925e-07
that O 0 2.5612283138798375e-07
the O 0 1.7821537312556757e-06
frameshift O 0 0.004031393676996231
mutation O 0 8.004242408787832e-05
causes O 0 0.00010407389345346019
the O 0 7.249702207445807e-07
sodium O 0 1.620091097720433e-05
channel O 0 2.231671714980621e-06
to O 0 2.214014500623307e-07
be O 0 5.173407657821372e-07
non O 0 1.0566378477960825e-05
- O 0 0.00014618101704400033
functional O 0 3.959661262342706e-05
. O 0 2.5543555238982663e-05

Our O 0 1.7804884919314645e-05
results O 0 1.9846800569212064e-05
indicate O 0 1.1739260116883088e-05
that O 0 1.2846383015130414e-06
mutations O 0 2.322443287994247e-05
in O 0 8.363942470168695e-06
cardiac O 1 0.9326037168502808
ion O 0 0.0010857218876481056
- O 0 0.00010788730287458748
channel O 0 3.0455319119937485e-06
genes O 0 6.00056466737442e-07
contribute O 0 6.485788048848917e-07
to O 0 1.1756571183241249e-07
the O 0 1.436043817193422e-06
risk O 0 6.864795432193205e-05
of O 0 2.489794496796094e-06
developing O 0 0.0007874704315327108
IVF B-Disease 1 0.9908719658851624
. O 0 3.261748861405067e-05
. O 0 6.944630877114832e-05

Molecular O 0 0.0005178170977160335
heterogeneity O 0 0.0009361646953038871
in O 0 5.533773946808651e-05
mucopolysaccharidosis B-Disease 0 0.08799915760755539
IVA I-Disease 1 0.8955881595611572
in O 0 3.869633019348839e-06
Australia O 0 1.29039210605697e-06
and O 0 3.408871123156132e-07
Northern O 0 1.493146555731073e-06
Ireland O 0 2.3825286916689947e-06
: O 0 7.320148824874195e-07
nine O 0 6.642949870183656e-07
novel O 0 5.273454462439986e-06
mutations O 0 1.4237589311960619e-05
including O 0 1.9029979512197315e-06
T312S O 0 0.0005100612179376185
, O 0 7.670922741453978e-07
a O 0 2.388544089626521e-06
common O 0 6.779296654713107e-06
allele O 0 2.359281097596977e-05
that O 0 3.247509312132024e-06
confers O 0 0.0024441212881356478
a O 0 0.001367960125207901
mild O 1 0.9958339929580688
phenotype O 1 0.5545295476913452
. O 0 0.00035671479417942464

Mucopolysaccharidosis B-Disease 1 0.725411057472229
IVA I-Disease 1 0.9806500673294067
( O 0 0.0013461194466799498
MPS B-Disease 1 0.6736057996749878
IVA I-Disease 1 0.997062623500824
) O 0 3.0611503461841494e-05
is O 0 9.448159289604519e-06
an O 0 7.872317655710503e-05
autosomal B-Disease 1 0.9971776008605957
recessive I-Disease 1 0.9991907477378845
lysosomal I-Disease 1 0.9997232556343079
storage I-Disease 1 0.9994334578514099
disorder I-Disease 1 0.9999147653579712
caused O 1 0.9945741295814514
by O 0 9.001999569591135e-05
a O 0 0.0010533491149544716
genetic B-Disease 1 0.9366540312767029
defect I-Disease 1 0.9978498220443726
in O 0 2.6638743293005973e-05
N O 0 0.0024587041698396206
- O 0 0.001002493198029697
acetylgalactosamine O 0 0.0019162337994202971
- O 0 0.0003786866436712444
6 O 0 8.210694068111479e-05
- O 0 0.0010464834049344063
sulfate O 0 0.08958113938570023
sulfatase O 0 0.35995686054229736
( O 0 6.356734229484573e-05
GALNS O 0 0.04699823260307312
) O 0 3.1975647289073095e-05
. O 0 3.956796717830002e-05

Previous O 0 2.8969228878850117e-05
studies O 0 1.7585911336936988e-05
of O 0 5.5699501899653114e-06
patients O 0 0.08551450073719025
from O 0 6.5004774114640895e-06
a O 0 4.0536313463235274e-05
British O 0 0.0006861573201604187
- O 0 0.0007751848897896707
Irish O 0 1.2663760571740568e-05
population O 0 3.2366520485993533e-07
showed O 0 2.8882523110951297e-06
that O 0 9.804114853295687e-08
the O 0 5.445468218567839e-07
I113F O 0 7.03718833392486e-05
mutation O 0 5.9038052313553635e-06
is O 0 1.2828236606310384e-07
the O 0 1.4104145407145552e-07
most O 0 9.208813622763046e-08
common O 0 1.4269653547671624e-06
single O 0 6.44267402094556e-06
mutation O 0 0.0001706612529233098
among O 0 4.4643969886237755e-05
MPS B-Disease 1 0.9906427264213562
IVA I-Disease 1 0.9997840523719788
patients O 1 0.9886012673377991
and O 0 2.0399374989210628e-05
produces O 0 0.0015488112112507224
a O 0 0.00933579821139574
severe O 1 0.9990968704223633
clinical O 1 0.9819031953811646
phenotype O 1 0.9476451277732849
. O 0 0.0007840314065106213

We O 0 5.625314315693686e-06
studied O 0 1.1831330994027667e-05
mutations O 0 1.5583376807626337e-05
in O 0 1.140808535637916e-06
the O 0 2.4159298845916055e-06
GALNS O 0 0.00448566023260355
gene O 0 1.4059150089451578e-05
from O 0 2.8643821678997483e-06
23 O 0 1.949317447724752e-05
additional O 0 1.850347689469345e-05
MPS B-Disease 1 0.695965588092804
IVA I-Disease 1 0.99937903881073
patients O 0 0.457149863243103
( O 0 5.122128641232848e-06
15 O 0 1.5962973520800006e-06
from O 0 5.193279548620922e-07
Australia O 0 3.7291383137016965e-07
, O 0 1.1818082867876001e-07
8 O 0 3.779413191296044e-07
from O 0 1.3246283003809367e-07
Northern O 0 5.908869979975861e-07
Ireland O 0 9.233909850081545e-07
) O 0 4.4427207512853784e-07
, O 0 1.05617232293298e-07
with O 0 1.273608063456777e-07
various O 0 7.043881851132028e-07
clinical O 0 0.04965580999851227
phenotypes O 1 0.8103486895561218
( O 0 0.006398862227797508
severe O 1 0.9993767142295837
, O 0 2.693729766178876e-05
16 O 0 4.958229692419991e-05
cases O 0 2.0309968022047542e-05
; O 0 2.834431143128313e-06
intermediate O 0 6.413745722966269e-05
, O 0 1.968495553228422e-06
4 O 0 1.4514297618006822e-05
cases O 0 6.664778629783541e-05
; O 0 5.637651338474825e-05
mild O 1 0.986788272857666
, O 0 8.899172826204449e-06
3 O 0 3.264670885982923e-05
cases O 0 8.366236579604447e-05
) O 0 2.1236020984360948e-05
. O 0 4.079256905242801e-05

We O 0 5.039420557295671e-06
found O 0 5.195337507757358e-06
two O 0 4.5951756533213484e-07
common O 0 5.8914606597681995e-06
mutations O 0 8.054442332650069e-06
that O 0 8.869215406548392e-08
together O 0 1.4008993787228974e-07
accounted O 0 6.054564209989621e-07
for O 0 5.140221404076328e-08
32 O 0 3.2388874160460546e-07
% O 0 7.657693856799597e-08
of O 0 3.486555755216614e-08
the O 0 5.565520382333489e-07
44 O 0 8.869485100149177e-06
unrelated O 0 5.6742632295936346e-05
alleles O 0 2.371670416323468e-05
in O 0 4.088674359081779e-06
these O 0 7.014104994595982e-06
patients O 1 0.9595826268196106
. O 0 0.00015373966016341

One O 0 3.3228666325157974e-06
is O 0 2.276570739923045e-06
the O 0 2.536280135245761e-06
T312S O 0 0.0002703286299947649
mutation O 0 2.8399936127243564e-05
, O 0 7.345435619754426e-07
a O 0 2.646386292326497e-06
novel O 0 1.6610470993327908e-05
mutation O 0 5.607015918940306e-05
found O 0 1.3006978406338021e-05
exclusively O 0 2.9197462936281227e-05
in O 0 0.00011881775571964681
milder O 1 0.987334132194519
patients O 1 0.9927088022232056
. O 0 0.0005090968334116042

The O 0 6.723993919877103e-06
other O 0 6.650823252130067e-07
is O 0 1.5024871800051187e-06
the O 0 1.950691739693866e-06
previously O 0 1.5820927728782408e-05
described O 0 0.00013154330372344702
I113F O 0 0.0004730361106339842
that O 0 4.589071977534331e-06
produces O 0 0.0002589903015177697
a O 0 0.002399678807705641
severe O 1 0.99831223487854
phenotype O 1 0.9269289970397949
. O 0 0.0005604302859865129

The O 0 4.689260822487995e-05
I113F O 0 0.0008442275575362146
and O 0 7.656256457266863e-06
T312S O 0 0.0005128964548930526
mutations O 0 2.0487848814809695e-05
accounted O 0 4.178829385637073e-06
for O 0 3.301773858765955e-07
8 O 0 2.812572120092227e-06
( O 0 7.36873630557966e-07
18 O 0 8.313249963975977e-07
% O 0 3.381607598385017e-07
) O 0 1.3460399372888787e-07
and O 0 2.547808897190862e-08
6 O 0 7.046179462122382e-07
( O 0 2.052806280516961e-07
14 O 0 1.7627374404582952e-07
% O 0 1.1730140414556445e-07
) O 0 6.208514236050178e-08
of O 0 5.600149677320587e-08
44 O 0 4.786294994119089e-06
unrelated O 0 8.204550249502063e-05
alleles O 0 3.025955447810702e-05
, O 0 4.347503818280529e-06
respectively O 0 4.5832777686882764e-05
. O 0 6.623139779549092e-05

The O 0 2.3563019567518495e-05
relatively O 0 5.622242679237388e-05
high O 0 0.00014007270510774106
residual O 0 0.0017757572932168841
GALNS O 0 0.0404263436794281
activity O 0 9.7129041023436e-06
seen O 0 5.405047431850107e-06
when O 0 6.209129992384987e-07
the O 0 4.0018039726419374e-07
T312S O 0 4.5399163354886696e-05
mutant O 0 1.1788104529841803e-05
cDNA O 0 8.38694722915534e-06
is O 0 1.8302438320461079e-06
overexpressed O 0 0.0001175128563772887
in O 0 8.719542847757111e-07
mutant O 0 3.641302464529872e-05
cells O 0 8.081202395260334e-06
provides O 0 5.250799404166173e-07
an O 0 3.839259363758174e-07
explanation O 0 2.637334091559751e-06
for O 0 6.823948979217676e-07
the O 0 2.897486774600111e-05
mild O 1 0.9982190728187561
phenotype O 1 0.7491356134414673
in O 0 8.811206498648971e-05
patients O 0 0.34329646825790405
with O 0 7.363851182162762e-06
this O 0 8.13782935438212e-06
mutation O 0 0.0009190670680254698
. O 0 7.45514698792249e-05

The O 0 2.177108171963482e-06
distribution O 0 8.118041137095133e-07
and O 0 9.056694239006902e-08
relative O 0 3.589028096939728e-07
frequencies O 0 8.160222364494985e-08
of O 0 5.4089799306211717e-08
the O 0 1.0183359790971735e-06
I113F O 0 0.000108347725472413
and O 0 1.2548355243779952e-06
T312S O 0 0.00020083443087060004
mutations O 0 8.399040780204814e-06
in O 0 5.147599608790188e-07
Australia O 0 4.669115298838733e-07
corresponded O 0 2.179962848458672e-06
to O 0 6.628610549341829e-08
those O 0 1.0839256958661281e-07
observed O 0 1.4032756325832452e-06
in O 0 6.702219366161444e-07
Northern O 0 1.875863631539687e-06
Ireland O 0 2.0837092051806394e-06
and O 0 1.3681892596650869e-07
are O 0 1.0741186606821884e-08
unique O 0 7.523717471258351e-08
to O 0 3.1999135785554245e-08
these O 0 1.6385103052130034e-08
two O 0 1.2738412635826535e-07
populations O 0 1.2994428288948257e-06
, O 0 8.094177132988989e-07
suggesting O 0 8.684880413056817e-06
that O 0 1.469088033445587e-07
both O 0 3.321157748814585e-07
mutations O 0 1.4430301234824583e-05
were O 0 5.107569904794218e-07
probably O 0 3.5917273635277525e-06
introduced O 0 1.0191200772169395e-06
to O 0 6.324509627120278e-08
Australia O 0 3.12207589558966e-07
by O 0 2.0078766738151899e-07
Irish O 0 6.865903287689434e-06
migrants O 0 7.384600166915334e-07
during O 0 2.262687758047832e-06
the O 0 1.0532970691201626e-06
19th O 0 3.7941681512165815e-05
century O 0 5.924067954765633e-05
. O 0 3.275795097579248e-05

Haplotype O 0 0.00042652388219721615
analysis O 0 4.54017799711437e-06
using O 0 2.5030526558111887e-06
6 O 0 1.7851776647148654e-05
RFLPs O 0 0.00030904647428542376
provides O 0 1.0493326954019722e-06
additional O 0 2.85443491065962e-07
data O 0 4.6579964418924646e-07
that O 0 2.3685771566306357e-07
the O 0 1.041240238919272e-06
I113F O 0 0.00018449300841894
mutation O 0 2.9079557862132788e-05
originated O 0 6.258846497075865e-06
from O 0 2.0278896499803523e-06
a O 0 6.797941750846803e-06
common O 0 3.832197398878634e-05
ancestor O 0 0.0002954099327325821
. O 0 9.700692316982895e-05

The O 0 5.431524641608121e-06
other O 0 1.0593624892862863e-06
9 O 0 2.007971124839969e-05
novel O 0 2.0151954231550917e-05
mutations O 0 2.5206372811226174e-05
identified O 0 3.749490133486688e-06
in O 0 7.068510967656039e-07
these O 0 6.141651738289511e-07
23 O 0 0.00026811062707565725
patients O 0 0.005332258064299822
were O 0 9.90134694234257e-08
each O 0 3.395314962517659e-08
limited O 0 2.79299598560101e-07
to O 0 8.233766379817098e-08
a O 0 1.688634256424848e-06
single O 0 6.173059318825835e-06
family O 0 4.762166281579994e-05
. O 0 4.2864950955845416e-05

These O 0 2.417891209915979e-06
data O 0 2.687432697712211e-06
provide O 0 1.5463673435078817e-06
further O 0 1.3849378319719108e-06
evidence O 0 3.098656407019007e-06
for O 0 1.2355695844235015e-06
extensive O 0 0.00011823626118712127
allelic O 0 0.004104343708604574
heterogeneity O 0 0.0019066790118813515
in O 0 6.602298526559025e-05
MPS B-Disease 0 0.2347671091556549
IVA I-Disease 1 0.9965194463729858
in O 0 8.572186197852716e-05
British O 0 0.00635816715657711
- O 1 0.5358592867851257
Irish O 0 0.005099305417388678
patients O 0 0.06491120904684067
and O 0 5.932301974098664e-07
provide O 0 4.816235446014616e-07
evidence O 0 1.354009782517096e-06
for O 0 1.1580307557323977e-07
their O 0 1.962222881957132e-07
transmission O 0 3.8121859688544646e-05
to O 0 2.382746231432975e-07
Australia O 0 1.3332937669474632e-06
by O 0 1.2811868828066508e-06
British O 0 0.00014997534162830561
- O 0 0.0003406491014175117
Irish O 0 4.091474329470657e-05
migrants O 0 1.2152487215644214e-05
. O 0 4.524207270151237e-06
. O 0 2.2272673959378153e-05

Identification O 0 1.3974788089399226e-05
of O 0 2.5430304049223196e-06
constitutional O 0 0.0002161611628253013
WT1 O 1 0.9840050935745239
mutations O 0 0.0008820468210615218
, O 0 2.0841222067247145e-05
in O 0 4.9647973355604336e-05
patients O 1 0.9315279722213745
with O 0 0.0007871185662224889
isolated O 1 0.9814597368240356
diffuse B-Disease 1 0.9988514184951782
mesangial I-Disease 1 0.9999147653579712
sclerosis I-Disease 1 0.9999784231185913
, O 0 1.358634926873492e-05
and O 0 6.319481258287851e-07
analysis O 0 9.073929732039687e-07
of O 0 1.5250872138494742e-06
genotype O 0 0.015481924638152122
/ O 0 0.020321564748883247
phenotype O 0 0.00016120236250571907
correlations O 0 5.267402684694389e-06
by O 0 2.6218259563393076e-07
use O 0 1.7270215835196723e-07
of O 0 2.8424389597603295e-07
a O 0 3.4095461160177365e-05
computerized O 0 0.002821166068315506
mutation O 0 0.00045393104664981365
database O 0 0.00017288430535700172
. O 0 7.144333358155563e-05

Constitutional O 0 4.445114973350428e-05
mutations O 0 1.990597775147762e-05
of O 0 9.032814887177665e-07
the O 0 9.734165359986946e-06
WT1 O 0 0.02193770371377468
gene O 0 6.216931978997309e-06
, O 0 5.141231440575211e-07
encoding O 0 2.259772372781299e-06
a O 0 4.13624475186225e-05
zinc O 1 0.6796364188194275
- O 0 0.0012197745963931084
finger O 0 0.00033728545531630516
transcription O 0 5.281903577269986e-05
factor O 0 3.395914245629683e-05
involved O 0 4.651865310734138e-05
in O 0 0.0003222895902581513
renal O 1 0.9997918009757996
and O 0 6.90494998707436e-05
gonadal O 1 0.9614872336387634
development O 0 2.793563726299908e-05
, O 0 1.7703080175124342e-06
are O 0 1.8782967003971862e-07
found O 0 3.0562771371478448e-06
in O 0 2.6478958261577645e-06
most O 0 8.52397715789266e-06
patients O 1 0.7993425130844116
with O 0 0.0008891128236427903
Denys B-Disease 1 0.9958374500274658
- I-Disease 1 0.9981650710105896
Drash I-Disease 1 0.9984955787658691
syndrome I-Disease 1 0.9999364614486694
( O 0 0.03094734437763691
DDS B-Disease 1 0.9992578625679016
) O 0 0.00010186656436417252
, O 0 3.41919730999507e-05
or O 0 0.0008767269318923354
diffuse B-Disease 1 0.9922651052474976
mesangial I-Disease 1 0.9995238780975342
sclerosis I-Disease 1 0.9999586343765259
( O 0 0.210261732339859
DMS B-Disease 1 0.9980125427246094
) O 0 6.22271400061436e-05
associated O 0 4.902870568912476e-05
with O 0 3.3276908652624115e-05
pseudohermaphroditism B-Disease 1 0.9898831248283386
and O 0 0.00016365558258257806
/ O 1 0.7602253556251526
or O 0 0.0018444184679538012
Wilms B-Disease 1 0.9992146492004395
tumor I-Disease 1 0.9989985823631287
( O 0 0.0013666871236637235
WT B-Disease 1 0.9923271536827087
) O 0 5.9175974456593394e-05
. O 0 7.254070806084201e-05

Most O 0 0.0001097690110327676
mutations O 0 0.0033924358431249857
in O 0 0.002054495271295309
DDS B-Disease 1 0.9995926022529602
patients O 1 0.9889482259750366
lie O 0 0.0001840944605646655
in O 0 3.488529955575359e-06
exon O 0 0.0001870181440608576
8 O 0 6.657970061496599e-06
or O 0 1.5250842579916934e-06
exon O 0 3.4463490010239184e-05
9 O 0 2.9800883112329757e-06
, O 0 4.880919277638895e-07
encoding O 0 5.103351668367395e-06
zinc O 0 0.006965262815356255
finger O 0 0.0007827130611985922
2 O 0 1.197054280055454e-05
or O 0 1.265409173356602e-05
zinc O 0 0.07216943055391312
finger O 0 0.0005696328007616103
3 O 0 3.487372168820002e-06
, O 0 2.671105505669402e-07
respectively O 0 5.817771580041153e-07
, O 0 9.926780109026367e-08
with O 0 1.433932084182743e-07
a O 0 2.626037485242705e-06
hot O 0 4.184452700428665e-05
spot O 0 8.63755849422887e-06
( O 0 3.977726009907201e-06
R394W O 0 5.909691026317887e-05
) O 0 1.2049304132233374e-06
in O 0 1.6460647884741775e-06
exon O 0 0.0002745245292317122
9 O 0 8.048858580878004e-05
. O 0 4.261275171302259e-05

We O 0 4.100075784663204e-06
analyzed O 0 4.651019025914138e-06
a O 0 1.3208380096330075e-06
series O 0 6.702756536469678e-07
of O 0 1.081393520507845e-06
24 O 0 0.0001445556408725679
patients O 0 0.027234023436903954
, O 0 1.7927669659911771e-06
10 O 0 2.8404358545230934e-06
with O 0 1.0948172530333977e-05
isolated B-Disease 0 0.0030699127819389105
DMS I-Disease 1 0.996040940284729
( O 0 0.00012217459152452648
IDMS B-Disease 1 0.9887579083442688
) O 0 4.404203082231106e-06
, O 0 1.5574316876154626e-06
10 O 0 1.8900767599916435e-06
with O 0 1.1024572813767008e-05
DDS B-Disease 1 0.9984756112098694
, O 0 1.2909176803077571e-06
and O 0 4.827271595786442e-07
4 O 0 7.087836365826661e-06
with O 0 5.0828861276386306e-05
urogenital B-Disease 1 0.9985477328300476
abnormalities I-Disease 1 0.9989820122718811
and O 0 0.00037113239523023367
/ O 1 0.8589757084846497
or O 0 0.00028851567185483873
WT B-Disease 1 0.9877179861068726
. O 0 0.00022046398953534663

We O 0 4.304219692130573e-05
report O 0 0.00019278311810921878
WT1 O 0 0.026641808450222015
heterozygous O 0 0.00018460773571860045
mutations O 0 8.289365359814838e-05
in O 0 9.92096738627879e-06
16 O 0 0.00047954145702533424
patients O 0 0.05926661938428879
, O 0 1.9097265067102853e-06
4 O 0 2.7623525511444313e-06
of O 0 5.965559353171557e-07
whom O 0 2.906153713411186e-05
presented O 0 0.0001065665710484609
with O 0 0.00023538975801784545
IDMS B-Disease 1 0.9930328130722046
. O 0 0.00039085326716303825

One O 0 1.0192405170528218e-05
male O 0 3.801527418545447e-05
and O 0 2.7980024697171757e-06
two O 0 1.0961012776533607e-05
female O 0 0.014346184208989143
IDMS B-Disease 1 0.9986761212348938
patients O 1 0.9819485545158386
with O 0 0.0006898717838339508
WT1 O 1 0.9938070178031921
mutations O 0 0.055754177272319794
underwent O 1 0.9975476861000061
normal O 0 0.014430745504796505
puberty O 1 0.9704160094261169
. O 0 0.00034223159309476614

Two O 0 2.200618473580107e-05
mutations O 0 0.00048366968985646963
associated O 0 0.00015233717567753047
with O 0 6.9192930823192e-05
IDMS B-Disease 1 0.9949612617492676
are O 0 1.8025201597993146e-07
different O 0 8.750083679842646e-08
from O 0 3.1180343285086565e-06
those O 0 3.391786094653071e-06
described O 0 0.0023253685794770718
in O 0 0.0021476999390870333
DDS B-Disease 1 0.9996459484100342
patients O 1 0.9957576394081116
. O 0 0.0004622445849236101

No O 0 0.000463980803033337
WT1 O 1 0.7765297889709473
mutations O 0 0.00015052191156428307
were O 0 2.635669488881831e-06
detected O 0 3.2177416869672015e-05
in O 0 3.4248023439431563e-07
the O 0 8.15489897831867e-07
six O 0 7.935313078633044e-06
other O 0 2.2784368411521427e-05
IDMS B-Disease 1 0.9992444515228271
patients O 1 0.9821131825447083
, O 0 1.2404502740537282e-05
suggesting O 0 0.00017345348896924406
genetic O 0 0.00012910016812384129
heterogeneity O 0 0.0003419015556573868
of O 0 2.871078504540492e-05
this O 0 0.007552549708634615
disease O 1 0.9995874762535095
. O 0 0.0008318510954268277

We O 0 4.7726454795338213e-05
analyzed O 0 0.0002902012784034014
genotype O 0 0.00399621669203043
/ O 0 0.01313081942498684
phenotype O 0 0.0005425356794148684
correlations O 0 2.4787261281744577e-05
, O 0 3.387714855307422e-07
on O 0 4.3098655311268885e-08
the O 0 2.231327655977111e-08
basis O 0 7.4246515602283125e-09
of O 0 1.8799269696501142e-08
the O 0 1.507803801814589e-07
constitution O 0 3.172306435317296e-07
of O 0 1.162481240157831e-07
a O 0 1.0605771421978716e-05
WT1 O 0 0.019877679646015167
mutation O 0 6.7271307671035174e-06
database O 0 2.463541704855743e-06
of O 0 1.5326163520512637e-06
84 O 0 0.0027036641258746386
germ O 1 0.9924207329750061
- O 0 0.0007573553593829274
line O 0 1.5109610103536397e-05
mutations O 0 6.7451424001774285e-06
, O 0 1.0700090058435308e-07
to O 0 5.25449550536905e-08
compare O 0 8.225806595874019e-07
the O 0 6.256993145825618e-08
distribution O 0 2.373076597450563e-07
and O 0 2.0913188336635358e-07
type O 0 1.5034208445285913e-05
of O 0 4.3591225562522595e-07
mutations O 0 3.678342909552157e-05
, O 0 4.5475431420527457e-07
according O 0 3.8722731687812484e-07
to O 0 1.286847606252195e-07
the O 0 1.5651893363610725e-06
different O 0 5.814028099848656e-06
symptoms O 1 0.998120129108429
. O 0 0.00043116824235767126

This O 0 8.74677971296478e-06
demonstrated O 0 2.6316098228562623e-05
( O 0 3.5328839658177458e-06
1 O 0 2.2850583718536654e-06
) O 0 5.001734848519845e-07
the O 0 3.9668694284955563e-07
association O 0 7.289973382285098e-06
between O 0 4.262653305886488e-07
mutations O 0 4.445222657523118e-06
in O 0 2.0816126777845056e-07
exons O 0 6.2867779888620134e-06
8 O 0 2.627052253956208e-06
and O 0 3.7768691640849283e-07
9 O 0 4.473242370295338e-06
and O 0 1.923994659591699e-06
DMS B-Disease 1 0.7131543159484863
; O 0 1.7580915709913825e-06
( O 0 2.1334137727535563e-06
2 O 0 3.28001010529988e-06
) O 0 1.8442326563672395e-06
among O 0 2.5224005639756797e-06
patients O 0 0.00410348828881979
with O 0 9.406389835930895e-06
DMS B-Disease 1 0.9945037364959717
, O 0 4.5356756572800805e-07
a O 0 2.9775327448078315e-07
higher O 0 2.3252624714587e-07
frequency O 0 8.57770032780536e-08
of O 0 9.649833287994625e-08
exon O 0 6.205403769854456e-05
8 O 0 5.74760315430467e-06
mutations O 0 9.664920071372762e-06
among O 0 6.612660854443675e-07
46 O 0 2.0329031030996703e-05
, O 0 1.2995658835279755e-05
XY O 1 0.8205052018165588
patients O 0 0.0111799081787467
with O 0 4.017193532490637e-06
female O 0 0.00010500926873646677
phenotype O 0 0.0007307654013857245
than O 0 1.530408098915359e-06
among O 0 3.873775767715415e-06
46 O 0 0.00011579749116208404
, O 0 5.430386227089912e-05
XY O 1 0.9805154800415039
patients O 0 0.04075761139392853
with O 0 2.324509750906145e-06
sexual O 0 3.4032964322250336e-05
ambiguity O 0 9.031103400047868e-05
or O 0 5.176533159101382e-05
male O 0 0.0004486146499402821
phenotype O 0 0.0044743362814188
; O 0 3.5406351344136056e-06
and O 0 5.41283839083917e-07
( O 0 1.9223675735702273e-06
3 O 0 9.854045401880285e-07
) O 0 4.286370085537783e-07
statistically O 0 6.034670718690904e-07
significant O 0 4.725604298982944e-07
evidence O 0 1.537025127618108e-06
that O 0 3.3543417998771474e-07
mutations O 0 3.2313855626853183e-06
in O 0 1.5858957169712085e-07
exons O 0 6.133671831776155e-06
8 O 0 1.8535175740908016e-06
and O 0 1.595162046896803e-07
9 O 0 1.271216547138465e-06
preferentially O 0 1.6267972569039557e-06
affect O 0 3.860657784571231e-07
amino O 0 3.5374452522773936e-07
acids O 0 6.848135853942949e-07
with O 0 1.0666774130640988e-07
different O 0 5.769800992538876e-08
functions O 0 1.0770359040179756e-06
. O 0 6.0342258620949e-06
. O 0 2.8563883461174555e-05

The O 0 9.527944348519668e-05
185delAG O 0 0.016121627762913704
BRCA1 O 0 0.015117119066417217
mutation O 0 0.00010500706412130967
originated O 0 7.683657713641878e-06
before O 0 1.021975663206831e-06
the O 0 2.0427313529580715e-07
dispersion O 0 2.297634182468755e-06
of O 0 1.111557921262829e-07
Jews O 0 7.509817123718676e-07
in O 0 2.631264237606956e-07
the O 0 5.741608788412123e-07
diaspora O 0 2.941113962151576e-06
and O 0 2.545084782923368e-07
is O 0 5.35532194589905e-07
not O 0 4.020318442599091e-07
limited O 0 2.2498379621538334e-06
to O 0 3.1523045436188113e-06
Ashkenazim O 0 0.0014934421051293612
. O 0 7.896835450083017e-05

The O 0 4.3521598854567856e-05
185delAG O 0 0.0019600370433181524
mutation O 0 0.00012723532563541085
in O 0 1.865439844550565e-05
BRCA1 O 0 0.0411108173429966
is O 0 8.236912435677368e-06
detected O 0 0.00015708566934335977
in O 0 2.1860128072148655e-06
Ashkenazi O 0 0.00011588310007937253
Jews O 0 2.915800450864481e-06
both O 0 1.8082878341374453e-06
in O 0 0.00012294817133806646
familial B-Disease 1 0.9989585876464844
breast I-Disease 1 0.9999188184738159
and I-Disease 1 0.997774064540863
ovarian I-Disease 1 0.9999964237213135
cancer I-Disease 1 0.9999711513519287
and O 0 1.4642955648014322e-05
in O 0 5.549457910092315e-06
the O 0 4.814913154405076e-06
general O 0 3.095207648584619e-05
population O 0 1.3685086742043495e-05
. O 0 6.136518641142175e-05

All O 0 1.5438266927958466e-05
tested O 0 0.0007392216939479113
Ashkenazi O 0 0.001592929009348154
mutation O 0 0.0001321718591498211
carriers O 0 2.307471186213661e-05
share O 0 5.163884111425432e-07
the O 0 3.1533429023511417e-07
same O 0 1.2729854006465757e-06
allelic O 0 0.0002178326976718381
pattern O 0 0.00013466467498801649
at O 0 2.205699092883151e-05
the O 0 2.518177279853262e-05
BRCA1 O 0 0.018468625843524933
locus O 0 0.0005108574987389147
. O 0 0.00011478310625534505

Our O 0 7.523317435698118e-06
previous O 0 1.013522796711186e-05
study O 0 9.599726581654977e-06
showed O 0 3.294536145403981e-05
that O 0 4.919018010696163e-07
this O 0 7.778045869599737e-07
Ashkenazi O 0 0.0002414852351648733
mutation O 0 4.3484098569024354e-05
also O 0 9.483387088948803e-07
occurs O 0 7.45993838791037e-06
in O 0 8.111308602565259e-07
Iraqi O 0 3.0543451430276036e-06
Jews O 0 7.346514507844404e-07
with O 0 4.6132399234011245e-07
a O 0 3.888476840074873e-06
similar O 0 3.1924708309816197e-05
allelic O 0 0.009252644143998623
pattern O 0 0.012303931638598442
. O 0 0.00028125697281211615

We O 0 3.296152954135323e-06
extended O 0 4.060227183799725e-06
our O 0 1.7848262245934166e-07
analysis O 0 2.2004793720498128e-07
to O 0 9.378519649771988e-08
other O 0 1.572867063259764e-07
non O 0 6.5896479100047145e-06
- O 0 3.1240080716088414e-05
Ashkenazi O 0 9.822897482081316e-06
subsets O 0 9.846380635281093e-07
354 O 0 3.062950327148428e-06
of O 0 2.5881590204335225e-07
Moroccan O 0 1.0412033589091152e-05
origin O 0 5.704135901396512e-07
, O 0 8.482398925480084e-07
200 O 0 1.7227509943040786e-06
Yemenites O 0 0.00023271144891623408
and O 0 7.684483307457413e-07
150 O 0 5.658694590238156e-06
Iranian O 0 1.114837868954055e-05
Jews O 0 1.0118847967532929e-05
. O 0 4.933703530696221e-05

Heteroduplex O 0 0.002695073839277029
analysis O 0 9.089727427635808e-06
complemented O 0 1.4691830074298196e-05
by O 0 3.118778693078639e-07
direct O 0 5.602894361800281e-07
DNA O 0 7.368157184828306e-06
sequencing O 0 4.8349102144129574e-06
of O 0 3.2197976906900294e-06
abnormally O 0 0.24314112961292267
migrating O 0 3.656002809293568e-05
bands O 0 2.387687527516391e-05
were O 0 5.329324721969897e-06
employed O 0 5.665720163960941e-05
. O 0 3.2653497328283265e-05

Four O 0 1.5036727063488797e-06
of O 0 5.375625278247753e-07
Moroccan O 0 1.2904578397865407e-05
origin O 0 8.673455340613145e-07
( O 0 1.7097405589083792e-06
1 O 0 7.572528488708485e-07
. O 0 1.1600027249869527e-07
1 O 0 5.921754677729041e-07
% O 0 4.25375986878862e-07
) O 0 2.204054112553422e-07
and O 0 5.681529557932663e-08
none O 0 3.5674887044478965e-07
of O 0 8.932283890317194e-08
the O 0 1.5727845266155782e-06
Yemenites O 0 0.0010416682343930006
or O 0 9.223278425452008e-07
Iranians O 0 9.176847015623935e-07
was O 0 1.7991537788475398e-06
a O 0 1.4084924941926147e-06
carrier O 0 7.581751560792327e-06
of O 0 1.39280928124208e-07
the O 0 5.210769813857041e-06
185delAG O 0 0.0032421748619526625
mutation O 0 0.0005813193274661899
. O 0 6.3526131270919e-05

BRCA1 O 0 0.12989473342895508
allelic O 0 0.0027833154890686274
patterns O 0 4.05441242037341e-05
were O 0 7.270417654581252e-07
determined O 0 1.445069869987492e-06
for O 0 6.986520162399756e-08
four O 0 5.1129990907838874e-08
of O 0 4.578046386427559e-08
these O 0 5.616644926931258e-08
individuals O 0 5.506432998458877e-08
and O 0 4.3779532887811e-08
for O 0 8.211652868794772e-08
12 O 0 7.611220098624472e-07
additional O 0 8.072553328020149e-07
non O 0 1.3961840522824787e-05
- O 0 0.0004403526254463941
Ashkenazi O 0 0.0003079167800024152
185delAG O 0 0.0012830084888264537
mutation O 0 0.00041633748332969844
carriers O 0 0.0015145499492064118
who O 0 0.0006984666106291115
had O 1 0.5501183867454529
breast B-Disease 1 0.999830961227417
/ I-Disease 1 0.9995280504226685
ovarian I-Disease 1 0.9999713897705078
cancer I-Disease 1 0.9999114274978638
. O 0 0.0022698098327964544

Six O 0 9.584688814356923e-05
non O 0 0.00034791629877872765
- O 0 0.0032910595182329416
Ashkenazi O 0 0.00010792938701342791
individuals O 0 4.29817561098389e-07
shared O 0 8.009060366021004e-07
the O 0 1.4115382782620145e-06
common O 0 3.109948374913074e-05
Ashkenazi O 0 0.0019271621713414788
haplotype O 0 0.004462301265448332
, O 0 1.2781822533725062e-06
four O 0 4.4601304693969723e-07
had O 0 4.715093382401392e-06
a O 0 4.5901128942205105e-06
closely O 0 6.5838685259222984e-06
related O 0 3.520337486406788e-05
pattern O 0 0.00016585949924774468
, O 0 9.089147283702914e-07
and O 0 1.5839216871427197e-07
the O 0 4.971195721736876e-07
rest O 0 1.718927137517312e-06
( O 0 1.2689056347880978e-06
n O 0 7.45660918255453e-06
= O 0 1.1528815775818657e-05
6 O 0 9.784757821762469e-07
) O 0 3.1065130201568536e-07
displayed O 0 2.1556611500272993e-06
a O 0 2.763464635791024e-06
distinct O 0 1.825730942073278e-05
BRCA1 O 0 0.025652704760432243
allelic O 0 0.010328177362680435
pattern O 0 0.010436675511300564
. O 0 0.00025923538487404585

We O 0 3.989510332758073e-06
conclude O 0 1.4947031559131574e-05
that O 0 6.876905445096781e-07
the O 0 3.7064930893393466e-06
185delAG O 0 0.0031475694850087166
BRCA1 O 0 0.008654099889099598
mutation O 0 6.144594954093918e-05
occurs O 0 1.1648759937088471e-05
in O 0 8.144235152940382e-07
some O 0 7.63281605031807e-07
non O 0 6.818629481131211e-05
- O 0 0.0016963700763881207
Ashkenazi O 0 0.00015738974616397172
populations O 0 2.734172312557348e-06
at O 0 5.5612504183955025e-06
rates O 0 1.2623632756003644e-05
comparable O 0 9.851886716205627e-06
with O 0 5.098318638374622e-07
that O 0 8.218403877435776e-07
of O 0 3.941598606616026e-06
Ashkenazim O 0 0.00966737698763609
. O 0 8.978330151876435e-05

The O 0 5.032298304286087e-06
majority O 0 2.914374363172101e-06
of O 0 1.022467017719464e-06
Jewish O 0 3.3986681955866516e-05
185delAG O 0 0.029096277430653572
mutation O 0 0.0014219126896932721
carriers O 0 0.0002909123431891203
have O 0 6.506467116196291e-07
a O 0 4.237558187014656e-06
common O 0 1.9927898392779753e-05
allelic O 0 0.0027925437316298485
pattern O 0 0.0009079098817892373
, O 0 3.563687641872093e-06
supporting O 0 5.2660866458609235e-06
the O 0 3.0278927170002135e-06
founder O 0 0.00011439737863838673
effect O 0 7.936530892038718e-06
notion O 0 6.730049790348858e-06
, O 0 7.79755680468952e-07
but O 0 2.9209948593234003e-07
dating O 0 2.276596887895721e-06
the O 0 1.895969745646653e-07
mutations O 0 1.484065364820708e-06
origin O 0 7.286411118911928e-08
to O 0 6.259774920636119e-08
an O 0 2.458424717133312e-07
earlier O 0 3.2584914606559323e-06
date O 0 2.2160390926728724e-06
than O 0 7.034215059320559e-07
currently O 0 5.639209575747373e-06
estimated O 0 3.247342101531103e-05
. O 0 3.9802071114536375e-05

However O 0 2.1715946786571294e-05
, O 0 1.3738471125179785e-06
the O 0 4.3776108782367373e-07
different O 0 3.201178060407983e-07
allelic O 0 0.00017784837109502405
pattern O 0 7.174570782808587e-05
at O 0 7.761501365166623e-06
the O 0 7.881997589720413e-06
BRCA1 O 0 0.003660887945443392
locus O 0 3.179654959239997e-05
even O 0 9.343120837002061e-07
in O 0 1.9822995511731278e-07
some O 0 2.7570786187425256e-07
Jewish O 0 1.2103238987037912e-05
mutation O 0 0.0003155734739266336
carriers O 0 0.0005049189203418791
, O 0 2.325536115677096e-06
might O 0 3.2030850434239255e-06
suggest O 0 2.233496388726053e-06
that O 0 1.9258783368059085e-07
the O 0 1.2986549791094149e-06
mutation O 0 5.7111348723992705e-05
arose O 0 3.44909421983175e-05
independently O 0 5.681150923919631e-06
. O 0 1.137695653596893e-05
. O 0 4.5328739361139014e-05

Crystal O 0 0.004433543886989355
structure O 0 4.828482633456588e-05
of O 0 4.579567303153453e-06
the O 0 0.00040624322718940675
hemochromatosis B-Disease 1 0.9995954632759094
protein O 0 0.001075725187547505
HFE O 1 0.9200498461723328
and O 0 3.568958959476731e-07
characterization O 0 4.735403308586683e-06
of O 0 8.806507878489356e-08
its O 0 3.818533969024429e-07
interaction O 0 1.5086309304024326e-06
with O 0 1.1899892342626117e-05
transferrin O 0 0.15486937761306763
receptor O 0 0.0016020790208131075
. O 0 5.835761839989573e-05

HFE O 1 0.8028606176376343
is O 0 2.470233266649302e-05
an O 0 5.474457429954782e-05
MHC O 0 0.4653477072715759
- O 0 0.00034937544842250645
related O 0 6.452044544857927e-06
protein O 0 3.575456048565684e-06
that O 0 5.164027356840961e-07
is O 0 1.4265435765992152e-06
mutated O 0 5.009258529753424e-05
in O 0 3.931072569685057e-06
the O 0 0.0002169565559597686
iron B-Disease 1 0.9990418553352356
- I-Disease 1 0.9990347623825073
overload I-Disease 1 0.9996663331985474
disease I-Disease 1 0.9999219179153442
hereditary B-Disease 1 0.9998151659965515
hemochromatosis I-Disease 1 0.9999518394470215
. O 0 0.0314047746360302

HFE O 0 0.14123284816741943
binds O 0 0.00016455940203741193
to O 0 7.845603249734268e-06
transferrin O 0 0.01023169606924057
receptor O 0 0.00038320315070450306
( O 0 3.065819328185171e-05
TfR O 0 0.011658411473035812
) O 0 1.9529347810021136e-06
and O 0 8.206969255297736e-07
reduces O 0 2.9605587769765407e-05
its O 0 7.010079912106448e-07
affinity O 0 1.235804029420251e-05
for O 0 3.817553988483269e-06
iron O 1 0.9476902484893799
- O 0 0.001201863749884069
loaded O 0 7.674415974179283e-05
transferrin O 0 0.008257032372057438
, O 0 2.60069591604406e-05
implicating O 0 0.06944818794727325
HFE O 1 0.9796419143676758
in O 0 0.00018981529865413904
iron O 1 0.9927430152893066
metabolism O 0 0.18296527862548828
. O 0 0.00029115405050106347

The O 0 9.007915650727227e-05
2 O 0 0.0002060384431388229
. O 0 0.00011369681305950508

6 O 0 0.00014458886289503425
A O 0 9.180626511806622e-05
crystal O 0 0.0023603837471455336
structure O 0 5.392051025410183e-05
of O 0 3.415722176214331e-06
HFE O 1 0.9699940085411072
reveals O 0 8.548497135052457e-05
the O 0 2.398194510533358e-06
locations O 0 4.167550741840387e-06
of O 0 1.9013446944882162e-05
hemochromatosis B-Disease 1 0.9998494386672974
mutations O 0 0.0013678251998499036
and O 0 1.2840398994740099e-05
a O 0 0.00033677005558274686
patch O 1 0.9895771741867065
of O 0 4.800571332452819e-06
histidines O 0 0.08301442116498947
that O 0 1.5475179679924622e-06
could O 0 9.472973943047691e-07
be O 0 1.478519209285878e-07
involved O 0 1.5019242027847213e-06
in O 0 3.847539574053371e-06
pH O 0 0.024402271956205368
- O 0 0.000460270355688408
dependent O 0 1.3692972061107866e-05
interactions O 0 2.842779394995887e-05
. O 0 3.894284236594103e-05

We O 0 1.382209848088678e-05
also O 0 4.9421000767324585e-06
demonstrate O 0 1.6389658412663266e-05
that O 0 9.60692523221951e-06
soluble O 0 0.05855874717235565
TfR O 1 0.896609365940094
and O 0 1.289761348743923e-05
HFE O 1 0.9076342582702637
bind O 0 2.4598473828518763e-05
tightly O 0 7.844218089303467e-06
at O 0 1.5003809039626503e-06
the O 0 2.685508775357448e-07
basic O 0 1.5230247072395287e-06
pH O 0 4.182309930911288e-05
of O 0 1.8185050976171624e-07
the O 0 2.145531425412628e-06
cell O 0 0.0002725193917285651
surface O 0 4.02360237785615e-05
, O 0 5.090122385809082e-07
but O 0 1.2627040746338025e-07
not O 0 2.402592791383995e-08
at O 0 4.2224687035741226e-07
the O 0 9.380646019963024e-07
acidic O 0 0.0004009702242910862
pH O 0 0.00029743564664386213
of O 0 2.938632633231464e-06
intracellular O 0 0.0016315309330821037
vesicles O 0 0.011656619608402252
. O 0 0.00018658408953342587

TfR O 1 0.9241688847541809
HFE O 1 0.7779905200004578
stoichiometry O 0 0.0009853565134108067
( O 0 2.895378929679282e-05
2 O 0 7.624517365911743e-06
1 O 0 3.7624206470354693e-06
) O 0 1.2473689139369526e-06
differs O 0 9.301361387770157e-06
from O 0 6.969085916352924e-06
TfR O 0 0.04713085666298866
transferrin O 0 0.005715812090784311
stoichiometry O 0 0.00011863899999298155
( O 0 3.971854312112555e-06
2 O 0 2.115443066941225e-06
2 O 0 1.741898245199991e-06
) O 0 3.0878842949277896e-07
, O 0 9.779257226227855e-08
implying O 0 9.728020131660742e-07
a O 0 6.587383438727556e-08
different O 0 4.936892672446902e-09
mode O 0 3.361880658303562e-07
of O 0 2.937004950354094e-08
binding O 0 4.305324182496406e-06
for O 0 3.056256673517055e-06
HFE O 1 0.8894469141960144
and O 0 6.023715741321212e-06
transferrin O 0 0.025614745914936066
to O 0 4.544717739918269e-06
TfR O 0 0.4995719790458679
, O 0 1.6790937706900877e-06
consistent O 0 3.136800387437688e-06
with O 0 4.602447347679117e-07
our O 0 6.170195092636277e-07
demonstration O 0 1.371534563077148e-05
that O 0 2.8759441192960367e-06
HFE O 0 0.46889907121658325
, O 0 1.607665944902692e-05
transferrin O 0 0.014608129858970642
, O 0 2.5028759864653694e-06
and O 0 2.0832003428949974e-06
TfR O 0 0.0310030747205019
form O 0 1.1421362614782993e-05
a O 0 3.676151391118765e-05
ternary O 0 0.004108607769012451
complex O 0 0.002139932243153453
. O 0 0.00021961198945064098

Identification O 0 4.931521289108787e-06
of O 0 3.74753454934762e-07
three O 0 7.887004471740511e-07
novel O 0 1.6266536476905458e-05
mutations O 0 7.597197054565186e-06
and O 0 2.3100403723219642e-07
a O 0 5.670951281899761e-07
high O 0 1.4363780564963236e-06
frequency O 0 1.1266401855891672e-07
of O 0 7.388997147472764e-08
the O 0 1.6556969058001414e-06
Arg778Leu O 0 0.002233008621260524
mutation O 0 0.00013834942365065217
in O 0 3.490188828436658e-05
Korean O 0 0.45304641127586365
patients O 1 0.99210125207901
with O 0 0.001840062439441681
Wilson B-Disease 1 0.9942856431007385
disease I-Disease 1 0.999309778213501
. O 0 0.000715263478923589

Four O 0 9.842979488894343e-05
mutations O 0 0.001229286310262978
- O 0 0.00405702693387866
- O 0 0.0003655405016615987
R778L O 0 0.0001824970677262172
, O 0 3.1574734293826623e-06
A874V O 0 0.00011271458060946316
, O 0 1.6623927194814314e-06
L1083F O 0 5.410119047155604e-05
, O 0 1.1908177839359269e-06
and O 0 1.895370814963826e-06
2304delC O 0 0.000899206439498812
- O 0 0.0002461732074152678
- O 0 1.0020504305430222e-05
in O 0 3.5505723872120143e-07
the O 0 1.186188683277578e-06
copper O 0 0.0010047992691397667
- O 0 2.5834668122115545e-05
transporting O 0 9.883618076855782e-06
enzyme O 0 1.776882345438935e-05
, O 0 3.1607207802153425e-06
P O 0 0.0012135225115343928
- O 0 0.00014039280358701944
type O 0 6.949035741854459e-05
ATPase O 0 0.00024795354693196714
( O 0 8.376283403777052e-06
ATP7B O 0 0.0018651686841621995
) O 0 1.1314299399600714e-06
, O 0 3.4756678246594674e-07
were O 0 2.6874431569012813e-07
identified O 0 7.174579423008254e-06
in O 0 1.1661198186629917e-05
Korean O 1 0.534165620803833
Patients O 1 0.990446925163269
with O 0 0.0033405341673642397
Wilson B-Disease 1 0.9943796992301941
disease I-Disease 1 0.9996084570884705
. O 0 0.0011112906504422426

Arg778Leu O 0 0.023451581597328186
, O 0 1.4882795767334756e-05
the O 0 4.222567440592684e-06
most O 0 1.6201059906961746e-06
frequently O 0 1.0166593710891902e-05
reported O 0 1.8111484678229317e-05
mutation O 0 2.8774584279744886e-06
of O 0 6.233075566797197e-08
this O 0 4.0183405758398294e-07
enzyme O 0 3.2317217119270936e-05
, O 0 8.965513416114845e-07
was O 0 3.526414275256684e-06
found O 0 3.300848163689807e-07
in O 0 8.430326658981357e-08
six O 0 1.4280610116657044e-07
of O 0 2.3164844265011197e-07
eight O 0 1.8740931409411132e-05
unrelated O 0 0.0215863399207592
patients O 0 0.040057964622974396
studied O 0 4.276470917830011e-06
, O 0 3.682172291519237e-07
an O 0 1.2026993090330507e-07
allele O 0 2.6995464850188e-06
frequency O 0 7.99739041212888e-07
of O 0 8.645286015962483e-07
37 O 0 8.484832505928352e-05
. O 0 4.23739074904006e-05

5 O 0 5.09779856656678e-05
% O 0 1.082499966287287e-05
, O 0 1.4154853715808713e-06
which O 0 7.079358965711435e-07
is O 0 9.292017466577818e-07
considerably O 0 2.6810668714460917e-05
higher O 0 1.5895373053353978e-06
than O 0 1.1497599672338765e-07
those O 0 1.4701194572808163e-07
in O 0 4.281173744402622e-07
other O 0 8.93217929842649e-07
Asian O 0 9.443443559575826e-05
populations O 0 5.511276322067715e-05
. O 0 3.753300916287117e-05

The O 0 3.927415491489228e-06
novel O 0 7.759296750009526e-06
single O 0 1.7440208921470912e-06
nucleotide O 0 8.381030056625605e-06
deletion O 0 0.0001513149618403986
, O 0 2.2860458557261154e-06
2304delC O 0 0.00043891873792745173
, O 0 1.9032992213396938e-06
was O 0 7.74349882703973e-06
found O 0 4.553667622531066e-06
in O 0 2.4929711344157113e-06
one O 0 1.292002070840681e-05
patient O 0 0.11264527589082718
. O 0 7.75436419644393e-05

Since O 0 3.616603498812765e-05
a O 0 7.634733265149407e-06
mutation O 0 2.2749607524019666e-05
at O 0 5.82463871978689e-06
cDNA O 0 2.35091065405868e-05
nucleotide O 0 5.1787454140139744e-05
2302 O 0 0.019115030765533447
( O 0 1.7404936443199404e-05
2302insC O 0 0.0006837609689682722
) O 0 6.055388894310454e-06
had O 0 6.002887857903261e-06
been O 0 1.6530872244402417e-06
previously O 0 4.140635155636119e-06
described O 0 1.0719578313000966e-05
, O 0 1.8814161251157202e-07
this O 0 5.977939565582346e-08
region O 0 3.822366636541119e-07
of O 0 1.2179398822809162e-07
the O 0 5.978139142825967e-06
ATP7B O 1 0.9139241576194763
gene O 0 0.00041376688750460744
may O 0 5.0980757805518806e-05
be O 0 2.239645709778415e-06
susceptible O 0 0.0019545243121683598
to O 0 4.7921089390001725e-06
gene O 0 0.000683767138980329
rearrangements O 0 0.22555285692214966
causing O 1 0.9942681789398193
Wilson B-Disease 1 0.9947062134742737
disease I-Disease 1 0.9993463158607483
. O 0 0.0012076537823304534

Disruption O 0 0.0003281421959400177
of O 0 1.359012458124198e-06
splicing O 0 3.549367465893738e-05
regulated O 0 1.6514406524947844e-05
by O 0 2.195793285864056e-06
a O 0 2.7110612791148014e-05
CUG O 0 0.037477292120456696
- O 0 0.00023765521473251283
binding O 0 3.192650183336809e-05
protein O 0 0.0003034697729162872
in O 0 0.0008786253165453672
myotonic B-Disease 1 0.9992218017578125
dystrophy I-Disease 1 0.9997180104255676
. O 0 0.004034301731735468

Myotonic B-Disease 1 0.998755693435669
dystrophy I-Disease 1 0.9997617602348328
( O 1 0.9663477540016174
DM B-Disease 1 0.999502420425415
) O 0 0.0001614032225916162
is O 0 1.8051545339403674e-05
caused O 0 0.0006256503402255476
by O 0 2.0971915546397213e-06
a O 0 1.1409964827180374e-05
CTG O 0 0.0019068316323682666
expansion O 0 9.32006150833331e-06
in O 0 4.609255483956076e-07
the O 0 7.13448855549359e-07
3 O 0 4.350469680503011e-06
untranslated O 0 9.838372352533042e-05
region O 0 1.6144239225468482e-06
of O 0 9.284364637096587e-07
the O 0 0.0001139060259447433
DM B-Disease 1 0.9987645149230957
gene O 0 0.0008076140657067299
. O 0 8.148014603648335e-05

One O 0 2.2065067241783254e-05
model O 0 0.0001823498896555975
of O 0 0.00015791768964845687
DM B-Disease 1 0.9995902180671692
pathogenesis O 1 0.9921040534973145
suggests O 0 0.00010569389996817335
that O 0 1.9543695088941604e-06
RNAs O 0 5.6657423556316644e-05
from O 0 2.7625424081634264e-07
the O 0 1.3799028408811864e-07
expanded O 0 1.2964287634531502e-06
allele O 0 1.4077110108701163e-06
create O 0 3.5466334225020546e-07
a O 0 1.7625554846745217e-06
gain O 0 8.374973731406499e-06
- O 0 1.759819315338973e-05
of O 0 2.1721132270613452e-07
- O 0 2.360419966862537e-05
function O 0 4.4042013769285404e-07
mutation O 0 1.7116267372330185e-06
by O 0 9.834905512207115e-08
the O 0 2.1240212788598e-07
inappropriate O 0 1.494098114562803e-06
binding O 0 2.4507141915819375e-07
of O 0 4.118970764466212e-08
proteins O 0 4.5764750211674254e-07
to O 0 2.176482212234987e-07
the O 0 4.255993644619593e-06
CUG O 0 0.034906160086393356
repeats O 0 0.001055047265253961
. O 0 6.126829975983128e-05

Data O 0 3.141131310258061e-05
presented O 0 3.781077975872904e-05
here O 0 6.745696282450808e-06
indicate O 0 4.5686006160394754e-06
that O 0 1.7207514702022308e-07
the O 0 6.019616307639808e-07
conserved O 0 7.684067895752378e-06
heterogeneous O 0 0.00013518611376639456
nuclear O 0 0.0006748008891008794
ribonucleoprotein O 1 0.5805988311767578
, O 0 1.3420729374047369e-05
CUG O 0 0.0020855769980698824
- O 0 1.778024852683302e-05
binding O 0 2.357908442718326e-06
protein O 0 7.649440703971777e-06
( O 0 1.3515531463781372e-05
CUG O 0 0.045043837279081345
- O 0 0.0010837202426046133
BP O 0 0.0008001945680007339
) O 0 1.4119030993242632e-06
, O 0 6.793754323553003e-07
may O 0 1.756087385729188e-06
mediate O 0 1.645458905841224e-05
the O 0 3.737231054401491e-06
trans O 0 0.0006858663982711732
- O 0 0.0001039943381329067
dominant O 0 5.007236723031383e-06
effect O 0 1.2161564200141584e-06
of O 0 1.0553144846880969e-07
the O 0 3.4855502235586755e-06
RNA O 0 0.00020195895922370255
. O 0 3.71267888112925e-05

CUG O 1 0.949191153049469
- O 0 0.16108262538909912
BP O 0 0.011338738724589348
was O 0 2.8478803869802505e-05
found O 0 1.6486852700836607e-06
to O 0 1.9624961566933052e-07
bind O 0 3.6854573863820406e-06
to O 0 3.6039963902112504e-07
the O 0 5.0575658860907424e-06
human O 0 0.0003996563609689474
cardiac O 1 0.9986864924430847
troponin O 1 0.9982728958129883
T O 1 0.993218719959259
( O 0 1.9202794646844268e-05
cTNT O 0 0.00033483674633316696
) O 0 3.1565703011438018e-06
pre O 0 0.00010259359987685457
- O 0 3.284406557213515e-05
messenger O 0 7.257253400894115e-06
RNA O 0 2.3612703898834297e-06
and O 0 9.352689289698901e-08
regulate O 0 2.23342817662342e-06
its O 0 4.947236220687046e-07
alternative O 0 5.616051566903479e-06
splicing O 0 0.0001317876303801313
. O 0 7.742940942989662e-05

Splicing O 0 0.00020062850671820343
of O 0 1.9279494154034182e-05
cTNT O 0 0.018542364239692688
was O 0 0.0013433004496619105
disrupted O 0 0.023518888279795647
in O 0 0.0014320715563371778
DM B-Disease 1 0.9995587468147278
striated O 1 0.9965493679046631
muscle O 1 0.9809765219688416
and O 0 6.763707460777368e-06
in O 0 6.012317953718593e-06
normal O 0 0.0001747929782141
cells O 0 0.0001088550707208924
expressing O 0 1.725614129099995e-05
transcripts O 0 2.3971148038981482e-05
that O 0 2.5212727905454813e-06
contain O 0 8.078277460299432e-05
CUG O 0 0.33304181694984436
repeats O 0 0.0034531429409980774
. O 0 9.66323641478084e-05

Altered O 0 0.00013774287072010338
expression O 0 5.389163561630994e-06
of O 0 9.849122761806939e-07
genes O 0 1.664618139329832e-05
regulated O 0 0.0001402652997057885
posttranscriptionally O 0 0.006913502234965563
by O 0 5.694015635526739e-05
CUG O 1 0.9263713955879211
- O 0 0.03966178745031357
BP O 0 0.0036065676249563694
therefore O 0 1.1086356607847847e-05
may O 0 2.4810909962980077e-05
contribute O 0 3.071074388572015e-05
to O 0 5.4056174121797085e-05
DM B-Disease 1 0.9991409778594971
pathogenesis O 1 0.9905393123626709
. O 0 7.32339613023214e-05
. O 0 0.00011541254207259044

Identification O 0 5.479713308886858e-06
of O 0 7.274086897268717e-07
a O 0 8.728055945539381e-06
novel O 0 3.528652814566158e-05
nonsense O 0 0.0001570587046444416
mutation O 0 9.290013622376136e-06
and O 0 2.490760664386471e-07
a O 0 1.4973362567616277e-06
missense O 0 2.5214185370714404e-05
substitution O 0 2.4130790734488983e-06
in O 0 8.40357870401931e-07
the O 0 6.070433300919831e-06
vasopressin O 0 0.0010280228452757
- O 0 0.0007932281587272882
neurophysin O 0 0.0015431451611220837
II O 0 0.0019284640438854694
gene O 0 4.226676992402645e-06
in O 0 2.6867002134167706e-07
two O 0 4.079690256730828e-07
Spanish O 0 2.7698506528395228e-05
kindreds O 0 0.002783192554488778
with O 0 0.0003432456578593701
familial B-Disease 1 0.9983540773391724
neurohypophyseal I-Disease 1 0.9989967942237854
diabetes I-Disease 1 0.9999212026596069
insipidus I-Disease 1 0.9983996748924255
. O 0 0.005708418320864439

Familial B-Disease 1 0.9911346435546875
neurohypophyseal I-Disease 1 0.9978140592575073
diabetes I-Disease 1 0.9999222755432129
insipidus I-Disease 1 0.998790442943573
( O 0 0.013795746490359306
FNDI B-Disease 1 0.9971043467521667
) O 0 2.8932039640494622e-05
is O 0 1.3762752132606693e-05
an O 0 0.0001294508547289297
autosomal B-Disease 1 0.9990476965904236
dominant I-Disease 1 0.9987745881080627
disease I-Disease 1 0.9999383687973022
caused O 1 0.9990707635879517
by O 0 0.13804952800273895
deficiency O 1 0.9999419450759888
in O 0 1.1032829206669703e-05
the O 0 2.141555887646973e-05
antidiuretic O 0 0.05459070950746536
hormone O 0 0.004004784859716892
arginine O 0 0.0002808143326546997
vasopressin O 0 0.0004099596990272403
( O 0 1.0885582014452666e-05
AVP O 0 0.0008728875545784831
) O 0 2.5886674848152325e-07
encoded O 0 1.8344501029332605e-07
by O 0 4.187004662981053e-07
the O 0 6.711264632031089e-06
AVP O 0 0.13324691355228424
- O 0 0.0025181833188980818
neurophysin O 0 0.004605688154697418
II O 0 0.025492912158370018
( O 0 5.5476546549471095e-05
AVP O 0 0.16540363430976868
- O 0 0.0007995832129381597
NPII O 0 0.001394215738400817
) O 0 1.4963854937377619e-06
gene O 0 8.786013495409861e-06
on O 0 4.132343292440055e-06
chromosome O 0 0.0004713688977062702
20p13 O 0 0.002554763574153185
. O 0 8.558218542020768e-05

In O 0 1.3216520528658293e-05
this O 0 1.4718352758791298e-06
study O 0 4.437247298483271e-06
, O 0 5.763201329500589e-07
we O 0 1.071058548518522e-07
analyzed O 0 8.778507094575616e-07
two O 0 8.47673220505385e-08
families O 0 7.97648112893512e-07
with O 0 1.418578563061601e-06
FNDI B-Disease 0 0.011246469803154469
using O 0 3.9755042280376074e-07
direct O 0 7.438374041157658e-07
automated O 0 1.2699328181042802e-05
fluorescent O 0 4.269597047823481e-05
, O 0 4.3857093601218367e-07
solid O 0 3.938446297979681e-06
phase O 0 6.077581474528415e-06
, O 0 4.405478648550343e-07
single O 0 1.3545626416089362e-06
- O 0 1.2369087016850244e-05
stranded O 0 1.6720055100449827e-06
DNA O 0 6.94726622896269e-07
sequencing O 0 7.213880053313915e-07
of O 0 7.104030714799592e-07
PCR O 0 0.0004230640479363501
- O 0 0.0005964157171547413
amplified O 0 0.0005028521991334856
AVP O 0 0.09292034059762955
- O 0 0.002679569413885474
NPII O 0 0.011344796046614647
DNA O 0 0.0004942434024997056
. O 0 0.00012536572467070073

In O 0 2.681524165382143e-06
one O 0 3.742513001725456e-07
of O 0 2.585334470950329e-07
the O 0 3.498611704344512e-06
families O 0 6.990144811425125e-06
, O 0 3.413879085201188e-06
affected O 0 8.200841875805054e-06
individuals O 0 5.189308467379306e-07
presented O 0 3.596326678234618e-06
a O 0 3.3294390959781595e-06
novel O 0 1.413816698914161e-05
nonsense O 0 5.866674109711312e-05
mutation O 0 6.435059276554966e-06
in O 0 3.4948791949318547e-07
exon O 0 9.938476978277322e-06
3 O 0 2.550016802160826e-07
of O 0 2.0224605989938027e-08
the O 0 2.3208471588986868e-07
gene O 0 2.0817010408791248e-06
, O 0 9.559117586377397e-08
consisting O 0 2.56454740110712e-07
in O 0 3.74231319710816e-07
a O 0 5.042751581640914e-06
G O 0 0.00011210402590222657
to O 0 7.37138634576695e-07
T O 0 0.0020569886546581984
transition O 0 2.412591129541397e-06
at O 0 2.2339224869938334e-06
nucleotide O 0 1.4077731066208798e-05
2101 O 0 0.002374620409682393
, O 0 5.3889806395091e-07
which O 0 8.428220610312565e-08
produces O 0 9.46876411944686e-07
a O 0 7.063766815917916e-07
stop O 0 1.64554671755468e-06
signal O 0 2.734756662903237e-06
in O 0 6.959959364394308e-07
codon O 0 1.1873400580952875e-05
82 O 0 4.615868238033727e-05
( O 0 1.9765731849474832e-05
Glu O 0 0.008007390424609184
) O 0 4.092802100785775e-06
of O 0 4.394775260152528e-06
NPII O 0 0.12108413130044937
. O 0 0.0001223653380293399

The O 0 0.0001428156392648816
premature O 0 0.1460055708885193
termination O 0 0.001385416486300528
eliminates O 0 9.704782860353589e-05
part O 0 7.715780725447985e-07
of O 0 2.3675247007304279e-07
the O 0 5.573845101025654e-06
C O 0 0.0015331768663600087
- O 0 0.00016122001397889107
terminal O 0 4.157274815952405e-05
domain O 0 4.541449527550867e-07
of O 0 2.9067447826491843e-07
NPII O 0 0.001752388314343989
, O 0 1.867479824113616e-07
including O 0 6.960065945804672e-08
a O 0 4.039064549488103e-07
cysteine O 0 3.168386683682911e-06
residue O 0 1.1115745110146236e-05
in O 0 4.772588226842345e-07
position O 0 1.2533583912954782e-06
85 O 0 4.6925611059123185e-06
, O 0 2.2875518368437042e-07
which O 0 1.4666521508388541e-07
could O 0 3.4091118550350075e-07
be O 0 4.075761594890537e-08
involved O 0 2.2835369861695654e-07
in O 0 1.1179728431898184e-07
the O 0 5.443469035526505e-07
correct O 0 3.876994378515519e-05
folding O 0 0.00034131944994442165
of O 0 1.3157989542378346e-06
the O 0 6.465093611041084e-05
prohormone O 1 0.8075593113899231
. O 0 0.0001778862060746178

In O 0 4.165055543126073e-06
the O 0 1.508153331997164e-06
second O 0 4.467228336579865e-06
family O 0 3.6644780720962444e-06
, O 0 2.673669428077119e-07
a O 0 8.875846333467052e-07
G279A O 0 1.5466885088244453e-05
substitution O 0 1.2742607395921368e-06
at O 0 1.1858788866447867e-06
position O 0 1.2788503909177962e-06
- O 0 4.029771389468806e-06
1 O 0 8.995113631726781e-08
of O 0 1.502139745923614e-08
the O 0 2.1463262100951397e-07
signal O 0 4.286544026399497e-06
peptide O 0 1.4462967556028161e-05
was O 0 2.5930828542186646e-06
observed O 0 1.8760442799248267e-06
in O 0 5.042262500865036e-07
all O 0 5.613987354990968e-07
affected O 0 5.808805508422665e-05
individuals O 0 1.0899314474954735e-05
. O 0 7.668827311135828e-05

This O 0 1.4350102901516948e-05
missense O 0 0.0006545593496412039
mutation O 0 0.00011077162344008684
, O 0 3.237403916500625e-06
which O 0 5.922668606217485e-06
replaces O 0 0.00714208884164691
Ala O 0 0.20625287294387817
with O 0 2.5082403226406313e-05
Thr O 1 0.871891975402832
, O 0 3.1809629490453517e-06
is O 0 2.5215565528924344e-06
frequent O 0 8.747212268644944e-05
among O 0 0.00012361409608274698
FNDI B-Disease 1 0.9997245669364929
patients O 1 0.992305338382721
and O 0 2.1554185423156014e-06
is O 0 9.167138159682509e-07
thought O 0 9.46892726005899e-07
to O 0 1.1311705350181e-07
reduce O 0 2.6123766474484e-06
the O 0 1.478550188949157e-07
efficiency O 0 1.5572148868159275e-06
of O 0 3.6724651408803766e-07
cleavage O 0 0.0010286320466548204
by O 0 3.7144054658710957e-06
signal O 0 9.27529254113324e-05
peptidases O 0 0.0012269738363102078
. O 0 1.7630345610086806e-05
. O 0 4.997982978238724e-05

Genetic O 0 0.0012848918559029698
heterogeneity O 0 0.0014884566189721227
of O 0 0.00022885248472448438
Saethre B-Disease 1 0.9939255118370056
- I-Disease 1 0.9984613656997681
Chotzen I-Disease 1 0.9987543821334839
syndrome I-Disease 1 0.9999465942382812
, O 0 3.072407344006933e-05
due O 0 7.9772224125918e-05
to O 0 2.7734417926694732e-06
TWIST O 0 0.00092845200560987
and O 0 1.1571907634788658e-05
FGFR O 1 0.7575019001960754
mutations O 0 0.001015629037283361
. O 0 8.364130917470902e-05

Thirty O 0 0.00046669275616295636
- O 0 0.0010427376255393028
two O 0 5.779334060207475e-06
unrelated O 0 0.0033020705450326204
patients O 0 0.02323199063539505
with O 0 1.998217612708686e-06
features O 0 2.115741153829731e-05
of O 0 2.9159060431993566e-05
Saethre B-Disease 1 0.9977722764015198
- I-Disease 1 0.998823344707489
Chotzen I-Disease 1 0.9990923404693604
syndrome I-Disease 1 0.9999549388885498
, O 0 9.699379916128237e-06
a O 0 6.302999099716544e-05
common O 0 0.0012024673633277416
autosomal B-Disease 1 0.9983142614364624
dominant I-Disease 1 0.9031676054000854
condition I-Disease 1 0.9983826875686646
of O 0 0.0006086502107791603
craniosynostosis B-Disease 1 0.9997280240058899
and O 0 0.013783731497824192
limb B-Disease 1 0.9994010925292969
anomalies I-Disease 1 0.9862828850746155
, O 0 5.750344371335814e-06
were O 0 1.8931560816781712e-06
screened O 0 1.3413065062195528e-05
for O 0 5.246594696473039e-07
mutations O 0 1.9375911506358534e-05
in O 0 3.044025106646586e-06
TWIST O 0 0.0018360826652497053
, O 0 2.024404238909483e-05
FGFR2 O 0 0.12815289199352264
, O 0 1.004470050247619e-05
and O 0 1.0865129297599196e-05
FGFR3 O 0 0.17116430401802063
. O 0 8.064253779593855e-05

Nine O 0 4.399031968205236e-05
novel O 0 4.224854274070822e-05
and O 0 2.4900580228859326e-06
three O 0 7.221876330731902e-06
recurrent O 1 0.7888106107711792
TWIST O 0 0.020305868238210678
mutations O 0 0.000121601129649207
were O 0 1.5119220506676356e-06
found O 0 4.744398211187217e-06
in O 0 1.8449645722284913e-06
12 O 0 1.0782757271954324e-05
families O 0 1.940196489158552e-05
. O 0 4.4656917452812195e-05

Seven O 0 3.350218685227446e-05
families O 0 7.267899036378367e-06
were O 0 6.36557160760276e-07
found O 0 1.5383831168946926e-06
to O 0 1.4043237683836196e-07
have O 0 2.1133890015789802e-07
the O 0 1.6574679193581687e-06
FGFR3 O 0 0.009988571517169476
P250R O 0 0.0006776964874006808
mutation O 0 5.5093532864702865e-05
, O 0 6.857553103145619e-07
and O 0 1.2353346789950592e-07
one O 0 1.2880482813670824e-07
individual O 0 2.9505770271498477e-07
was O 0 3.795717702814727e-06
found O 0 4.922922585137712e-07
to O 0 9.488564245430098e-08
have O 0 1.3330200943073578e-07
an O 0 1.1388605116735562e-06
FGFR2 O 0 0.008102105930447578
VV269 O 0 0.002906089648604393
- O 0 0.0005912246997468174
270 O 0 6.239322101464495e-05
deletion O 0 0.0006940772873349488
. O 0 6.893686077091843e-05

To O 0 2.335591261726222e-06
date O 0 3.983124315709574e-06
, O 0 5.771407245447335e-07
our O 0 2.697467493817385e-07
detection O 0 8.615790648036636e-06
rate O 0 2.431448592687957e-06
for O 0 3.5615875049188617e-07
TWIST O 0 0.00014114018995314837
or O 0 5.644627435685834e-06
FGFR O 0 0.004148788284510374
mutations O 0 1.2085823072993662e-05
is O 0 6.909320973136346e-07
68 O 0 1.1340322089381516e-05
% O 0 9.472440751778777e-07
in O 0 1.2599462024809327e-06
our O 0 1.6281961507047527e-05
Saethre B-Disease 1 0.9796318411827087
- I-Disease 1 0.9972255229949951
Chotzen I-Disease 1 0.9985174536705017
syndrome I-Disease 1 0.9999830722808838
patients O 1 0.9966273903846741
, O 0 5.212360065343091e-06
including O 0 2.572223820607178e-06
our O 0 3.087727236561477e-06
five O 0 8.524929580744356e-05
patients O 1 0.585603654384613
elsewhere O 0 8.11742793302983e-05
reported O 0 0.00012467906344681978
with O 0 1.4172618648444768e-05
TWIST O 0 0.017418652772903442
mutations O 0 0.0019195863278582692
. O 0 9.153474820777774e-05

More O 0 1.3999713246448664e-06
than O 0 5.345178237803339e-07
35 O 0 1.4442391602642601e-06
different O 0 1.5262526176229585e-07
TWIST O 0 0.00044548456207849085
mutations O 0 1.6671694538672455e-05
are O 0 9.464109496093442e-08
now O 0 1.8105070012097713e-06
known O 0 1.3601223827208742e-06
in O 0 2.363978097719155e-07
the O 0 1.5473158327949932e-06
literature O 0 1.9690232875291258e-05
. O 0 2.530562960600946e-05

The O 0 9.422073162568267e-06
most O 0 9.909316531775403e-07
common O 0 4.948433343088254e-06
phenotypic O 0 3.08665657939855e-05
features O 0 1.0060538443212863e-05
, O 0 6.512749450848787e-07
present O 0 6.597329615942726e-07
in O 0 1.5632633676432306e-07
more O 0 2.0705797965092643e-08
than O 0 4.0714027704780165e-08
a O 0 4.095860504094162e-07
third O 0 5.376952572078153e-07
of O 0 3.548412621512398e-07
our O 0 7.874605216784403e-06
patients O 0 0.005424298346042633
with O 0 5.842252448928775e-06
TWIST O 0 0.004927534610033035
mutations O 0 0.00010149483568966389
, O 0 1.5573544942526496e-06
are O 0 4.7238830802598386e-07
coronal B-Disease 0 0.002639072248712182
synostosis I-Disease 0 0.013731233775615692
, O 0 2.27907148655504e-05
brachycephaly B-Disease 0 0.020954515784978867
, O 0 8.031951438169926e-05
low B-Disease 0 0.08883670717477798
frontal I-Disease 1 0.9982926249504089
hairline I-Disease 1 0.999834418296814
, O 0 0.005229794420301914
facial B-Disease 1 0.9981865286827087
asymmetry I-Disease 1 0.9802780747413635
, O 0 0.006167936604470015
ptosis B-Disease 1 0.9988508224487305
, O 0 0.0005232425173744559
hypertelorism B-Disease 1 0.9926376342773438
, O 0 2.9260263545438647e-05
broad B-Disease 0 0.000816708488855511
great I-Disease 0 0.0009029850480146706
toes I-Disease 0 0.0690462663769722
, O 0 1.1935376278415788e-05
and O 0 1.47927885336685e-05
clinodactyly B-Disease 0 0.012931715697050095
. O 0 0.0001821693585952744

Significant O 0 0.0001948489953065291
intra O 0 0.003422874491661787
- O 0 0.0008301909547299147
and O 0 3.5734583434532396e-06
interfamilial O 0 0.0005845580599270761
phenotypic O 0 7.411248225253075e-05
variability O 0 0.00011129857739433646
is O 0 8.056886713347922e-07
present O 0 1.0065529068015167e-06
for O 0 3.4015062055914314e-07
either O 0 5.250070444162702e-06
TWIST O 0 0.0028485911898314953
mutations O 0 0.0005271913832984865
or O 0 0.0001566384598845616
FGFR O 1 0.9540987610816956
mutations O 0 0.002179606119170785
. O 0 0.00010868393292184919

The O 0 1.473860174883157e-05
overlap O 0 3.0243052606238052e-05
in O 0 4.820504273084225e-06
clinical O 0 0.0001715515973046422
features O 0 2.7217731712880777e-06
and O 0 3.309629619252519e-07
the O 0 4.6472985104628606e-07
presence O 0 1.2432478797563817e-06
, O 0 1.7334701851723366e-07
in O 0 4.974078393615855e-08
the O 0 7.09439049728644e-08
same O 0 1.1007913514049505e-07
genes O 0 2.304429500554761e-07
, O 0 3.409657267638977e-08
of O 0 2.633221463099744e-08
mutations O 0 1.2424774240571423e-06
for O 0 5.619141418833351e-08
more O 0 4.187827329360516e-08
than O 0 3.8553523040718574e-07
one O 0 3.7952290767861996e-06
craniosynostotic B-Disease 0 0.4615814685821533
condition I-Disease 1 0.9463179707527161
- O 0 0.00020874790789093822
such O 0 5.135116225574166e-07
as O 0 6.136369393061614e-06
Saethre B-Disease 0 0.011856566183269024
- I-Disease 0 0.0012005502358078957
Chotzen I-Disease 0 0.0014568106271326542
, I-Disease 0 6.580616627616109e-06
Crouzon I-Disease 0 0.00409664586186409
, I-Disease 0 2.4201557607739232e-05
and I-Disease 0 6.459263386204839e-05
Pfeiffer I-Disease 1 0.9976707100868225
syndromes I-Disease 1 0.9988813996315002
- O 0 0.0015606008237227798
support O 0 2.374036739638541e-06
the O 0 1.3412109183263965e-06
hypothesis O 0 1.307928414462367e-05
that O 0 1.1334786904626526e-06
TWIST O 0 0.00018470370559953153
and O 0 1.7915637045007315e-06
FGFRs O 0 0.00022608145081903785
are O 0 5.0778655946714935e-08
components O 0 1.5655818685900158e-07
of O 0 2.6359300520084616e-08
the O 0 1.780205849399863e-07
same O 0 2.8084289738217194e-07
molecular O 0 7.042054221528815e-06
pathway O 0 9.844044143392239e-06
involved O 0 9.096613666770281e-07
in O 0 2.1471534239481116e-07
the O 0 8.78144589933072e-07
modulation O 0 2.3580259949085303e-05
of O 0 1.1747435564757325e-05
craniofacial O 1 0.9992200136184692
and O 0 0.00026142873684875667
limb O 1 0.9965193271636963
development O 0 0.00011675156565615907
in O 0 1.951557169377338e-05
humans O 0 0.00010032129648607224
. O 0 1.8098346117767505e-05
. O 0 5.7609497162047774e-05

Mutation O 0 0.0004620436520781368
analysis O 0 4.811465987586416e-05
of O 0 0.00013456339365802705
UBE3A O 1 0.9904724359512329
in O 1 0.9892759323120117
Angelman B-Disease 1 0.999945878982544
syndrome I-Disease 1 0.9999942779541016
patients O 1 0.9989320635795593
. O 0 0.0056638168171048164

Angelman B-Disease 1 0.9998819828033447
syndrome I-Disease 1 0.9999773502349854
( O 0 0.012675502337515354
AS B-Disease 0 0.009918813593685627
) O 0 2.565529393905308e-05
is O 0 1.3776368177786935e-05
caused O 0 0.0007689371705055237
by O 0 6.401119662768906e-06
chromosome O 0 0.00043408683268353343
15q11 O 0 0.002066184999421239
- O 0 0.00021549586381297559
q13 O 0 8.29738492029719e-05
deletions O 0 8.923655514081474e-06
of O 0 4.486922478008637e-07
maternal O 0 0.00033197636366821826
origin O 0 2.090294856316177e-06
, O 0 3.5177115478290943e-06
by O 0 8.869365956343245e-06
paternal O 0 0.006597127299755812
uniparental B-Disease 1 0.9884639382362366
disomy I-Disease 1 0.8912737369537354
( O 0 0.000900990329682827
UPD B-Disease 1 0.9933038353919983
) O 0 7.562630344182253e-06
15 O 0 4.891473508905619e-06
, O 0 1.3335048834051122e-06
by O 0 5.504025466507301e-06
imprinting O 0 0.0551864318549633
defects O 1 0.9981698989868164
, O 0 2.146245606127195e-06
and O 0 3.81677153882265e-07
by O 0 1.4642612313764403e-06
mutations O 0 1.8391920093563385e-05
in O 0 1.5854297998885158e-06
the O 0 1.3937149560661055e-05
UBE3A O 0 0.3687344193458557
gene O 0 0.000601750158239156
. O 0 0.00012308785517234355

UBE3A O 0 0.008627302013337612
encodes O 0 4.199255636194721e-05
a O 0 2.6050323867821135e-05
ubiquitin O 0 0.0006466813501901925
- O 0 0.0001539720396976918
protein O 0 9.286045496992301e-06
ligase O 0 0.00020505637803580612
and O 0 4.260476998751983e-06
shows O 0 8.55327452882193e-05
brain O 1 0.857235848903656
- O 0 0.00046880313311703503
specific O 0 1.4148552509141155e-05
imprinting O 0 0.002408490050584078
. O 0 9.147924720309675e-05

Here O 0 6.887233030283824e-05
we O 0 8.69149971549632e-06
describe O 0 6.57818527542986e-05
UBE3A O 0 0.04929426684975624
coding O 0 0.0022625548299402
- O 0 0.0020657444838434458
region O 0 2.6129046091227792e-05
mutations O 0 4.325348709244281e-05
detected O 0 6.380651029758155e-05
by O 0 2.2728636395186186e-06
SSCP O 0 0.0021008604671806097
analysis O 0 2.918092604886624e-06
in O 0 2.169582558053662e-06
13 O 0 2.8880573154310696e-05
AS B-Disease 0 0.00013799422595184296
individuals O 0 2.1012817796872696e-06
or O 0 9.939263691194355e-06
families O 0 3.338539318065159e-05
. O 0 5.565176979871467e-05

Two O 0 2.6100335617229575e-06
identical O 0 2.6860498110181652e-05
de O 0 5.331949796527624e-05
novo O 0 6.998900789767504e-05
5 O 0 1.3125305486028083e-05
- O 0 0.00011501603876240551
bp O 0 7.449439726769924e-05
duplications O 0 2.0720175598398782e-05
in O 0 1.2622143685803167e-06
exon O 0 0.0001243862061528489
16 O 0 1.26603918033652e-05
were O 0 3.449097448537941e-06
found O 0 3.982196722063236e-05
. O 0 4.868918040301651e-05

Among O 0 5.031290129409172e-06
the O 0 1.0306857802788727e-06
other O 0 3.356540219101589e-07
11 O 0 1.9356848497409374e-06
unique O 0 1.8647052684173104e-06
mutations O 0 1.038306891132379e-05
, O 0 5.775216891379387e-07
8 O 0 1.4785304074393935e-06
were O 0 2.121069968552547e-07
small O 0 5.758443535341939e-07
deletions O 0 9.674114153312985e-06
or O 0 1.8236960386275314e-06
insertions O 0 7.706639735260978e-05
predicted O 0 0.00020397586922626942
to O 0 2.269785454700468e-06
cause O 0 0.0016897699097171426
frameshifts O 0 0.004133359994739294
, O 0 1.4335780633700779e-06
1 O 0 1.3132915910318843e-06
was O 0 8.821367032396665e-07
a O 0 3.6043468298885273e-07
mutation O 0 1.1170716334163444e-06
to O 0 3.3392026921319484e-08
a O 0 3.8725610806977784e-07
stop O 0 1.6549895462958375e-06
codon O 0 2.1226514945738018e-06
, O 0 1.545008103676082e-07
1 O 0 4.6929719133004255e-07
was O 0 9.074847753254289e-07
a O 0 1.3373612546274671e-06
missense O 0 5.238073936197907e-05
mutation O 0 1.2755805983033497e-05
, O 0 3.607180190101644e-07
and O 0 2.989151823840075e-07
1 O 0 1.9264234651927836e-06
was O 0 5.956672794127371e-06
predicted O 0 1.5923858882160857e-05
to O 0 1.8119372668934375e-07
cause O 0 1.0155478776141535e-05
insertion O 0 3.615322611949523e-06
of O 0 9.895154562400421e-08
an O 0 1.3533579021896003e-06
isoleucine O 0 0.0003619602939579636
in O 0 3.7387314932857407e-07
the O 0 3.2833418117661495e-07
hect O 0 3.329195533297025e-05
domain O 0 3.5606433357315836e-07
of O 0 6.195336510472771e-08
the O 0 1.3689322031495976e-06
UBE3A O 0 0.00446364376693964
protein O 0 5.3119915719435085e-06
, O 0 1.910712512653845e-07
which O 0 4.83360125258514e-08
functions O 0 7.679341251787264e-08
in O 0 6.016420002197265e-07
E2 O 0 0.0003893872199114412
binding O 0 2.9987791094754357e-06
and O 0 6.976107442824286e-07
ubiquitin O 0 0.0001304197357967496
transfer O 0 1.7193082385347225e-05
. O 0 4.2227718950016424e-05

Eight O 0 3.794530584855238e-06
of O 0 7.036469469312578e-07
the O 0 8.815178262011614e-06
cases O 0 5.4834021284477785e-05
were O 0 7.619930329383351e-06
familial O 0 0.3163643777370453
, O 0 4.498509042605292e-06
and O 0 5.117672685628349e-07
five O 0 2.406081648587133e-06
were O 0 3.569990667529055e-06
sporadic O 0 0.0004987840075045824
. O 0 0.00010056015889858827

In O 0 2.662904080352746e-05
two O 0 1.6207448425120674e-05
familial O 1 0.9298130869865417
cases O 0 0.00011755914601963013
and O 0 2.542572019592626e-06
one O 0 2.513137133064447e-06
sporadic O 0 0.00020203928579576313
case O 0 0.0001204808650072664
, O 0 7.942074262246024e-06
mosaicism O 0 0.016202788800001144
for O 0 7.120233021851163e-06
UBE3A O 1 0.6107062101364136
mutations O 0 0.00023115133808460087
was O 0 5.353327651391737e-05
detected O 0 5.95458950556349e-05
in O 0 4.077838582361437e-07
the O 0 4.3507662894626264e-07
mother O 0 1.3090640095470008e-05
of O 0 1.687047443965639e-07
three O 0 1.1965985322603956e-06
AS B-Disease 0 0.00020194162789266557
sons O 0 0.0001331255625700578
, O 0 5.20223181865731e-07
in O 0 2.3547259786482755e-07
the O 0 9.29028090013162e-07
maternal O 0 0.00014888674195390195
grandfather O 0 1.4954018297430594e-05
of O 0 5.4780237235263485e-08
two O 0 2.1085051571390068e-07
AS B-Disease 0 5.722634796256898e-06
first O 0 7.811617024344741e-07
cousins O 0 1.2987370610062499e-05
, O 0 2.7869933205693087e-07
and O 0 1.1222542894984144e-07
in O 0 2.668505771907803e-07
the O 0 7.467273235306493e-07
mother O 0 2.0837009287788533e-05
of O 0 3.53612961134786e-07
an O 0 1.1101305972260889e-05
AS B-Disease 0 0.0015989670064300299
daughter O 0 0.011334547773003578
. O 0 9.945878991857171e-05

The O 0 1.938575906024198e-06
frequencies O 0 1.20731840524968e-06
with O 0 8.732083074391994e-07
which O 0 5.116559691487055e-07
we O 0 5.778864533567685e-07
detected O 0 1.4897819710313343e-05
mutations O 0 2.246675194328418e-06
were O 0 1.5744969061870506e-07
5 O 0 8.182149144886353e-07
( O 0 2.9767829801130574e-07
14 O 0 3.745923038422916e-07
% O 0 1.462119172401799e-07
) O 0 5.720391982322326e-08
of O 0 2.7499927668372948e-08
35 O 0 8.127026376314461e-07
in O 0 3.819400546944962e-07
sporadic O 0 1.5461075236089528e-05
cases O 0 4.37455400970066e-06
and O 0 2.7869455720974656e-07
8 O 0 1.5184548374236329e-06
( O 0 5.127129725224222e-07
80 O 0 5.24060340012511e-07
% O 0 1.23681061836578e-07
) O 0 8.039657473091211e-08
of O 0 6.084367498715437e-08
10 O 0 1.8787567341860267e-06
in O 0 5.205539309827145e-06
familial O 1 0.8474393486976624
cases O 0 0.000575282727368176
. O 0 3.300730895716697e-05
. O 0 5.0480586651246995e-05

The O 0 0.00134626857470721
hemochromatosis B-Disease 1 0.9980605244636536
845 O 1 0.6727068424224854
G O 0 0.4258778691291809
- O 0 0.006166861392557621
- O 0 0.00016274167865049094
> O 0 2.2018948584445752e-05
A O 0 1.8228996623292915e-06
and O 0 3.814660942680348e-07
187 O 0 2.3371698262053542e-05
C O 0 0.00036544029717333615
- O 0 0.00026787404203787446
- O 0 7.339531293837354e-05
> O 0 6.747555016772822e-05
G O 0 0.00017406568804290146
mutations O 0 2.7527577913133428e-05
: O 0 1.0096860933117568e-05
prevalence O 0 0.0067680589854717255
in O 0 4.974884177499916e-06
non O 0 0.000245303992414847
- O 0 0.005848080851137638
Caucasian O 0 0.0029159910045564175
populations O 0 8.745911327423528e-05
. O 0 5.067601887276396e-05

Hemochromatosis B-Disease 1 0.9978131055831909
, O 0 0.001005530939437449
the O 0 0.030549079179763794
inherited B-Disease 1 0.9997782111167908
disorder I-Disease 1 0.9998821020126343
of I-Disease 0 9.85549995675683e-05
iron I-Disease 1 0.9992338418960571
metabolism I-Disease 1 0.8251156210899353
, O 0 1.879919545899611e-05
leads O 0 0.00020020484225824475
, O 0 2.037464400928002e-05
if O 0 4.9368423788109794e-05
untreated O 1 0.990712583065033
, O 0 5.661852810590062e-06
to O 0 7.230834853544366e-06
progressive O 1 0.6255964636802673
iron B-Disease 1 0.9990869760513306
overload I-Disease 1 0.9983214735984802
and O 0 0.0005397694767452776
premature B-Disease 1 0.9874316453933716
death I-Disease 0 0.052539434283971786
. O 0 0.00021810850012116134

The O 0 0.0017208157805725932
hemochromatosis B-Disease 1 0.9982507824897766
gene O 0 0.0031618254724889994
, O 0 0.0002853853802662343
HFE O 1 0.9935478568077087
, O 0 3.865926555590704e-05
recently O 0 0.0002915834484156221
has O 0 3.0263915959949372e-06
been O 0 8.809176961221965e-07
identified O 0 1.7176932942675194e-06
, O 0 1.3909867391248554e-07
and O 0 6.385003104014686e-08
characterization O 0 2.9420452847261913e-06
of O 0 1.2856087039381237e-07
this O 0 7.160759309954301e-07
gene O 0 2.3419219360221177e-05
has O 0 1.1951774467888754e-06
shown O 0 4.948576020069595e-07
that O 0 4.2019330237508257e-08
it O 0 1.796386150942908e-08
contains O 0 9.324190841653035e-08
two O 0 4.677146137055388e-08
mutations O 0 1.5954177570165484e-06
that O 0 5.798219504526969e-08
result O 0 3.9652428540648543e-07
in O 0 6.998070034569537e-08
amino O 0 7.683560170335113e-07
acid O 0 2.2004694983479567e-05
substitutions O 0 3.194119699401199e-06
- O 0 1.1514938705659006e-05
cDNA O 0 6.2082694967102725e-06
nucleotides O 0 2.0452473108889535e-05
845 O 0 0.0007980570080690086
G O 0 0.0019822141621261835
- O 0 0.000537783547770232
- O 0 8.629218791611493e-05
> O 0 3.247983113396913e-05
A O 0 5.5012546908983495e-06
( O 0 2.7100090846943203e-06
C282Y O 0 2.7008471079170704e-05
) O 0 5.414593715613591e-07
and O 0 2.616390588627837e-07
187 O 0 1.7812410078477114e-05
C O 0 0.0002528748591430485
- O 0 0.0004106711712665856
- O 0 0.0001362700277240947
> O 0 0.00014202823513187468
G O 0 0.00034876581048592925
( O 0 1.3508431948139332e-05
H63D O 0 0.004461540374904871
) O 0 1.6561421944061294e-05
. O 0 2.4387994926655665e-05

Although O 0 0.07613683491945267
hemochromatosis B-Disease 1 0.9992838501930237
is O 0 3.791440758504905e-05
common O 0 6.809869955759495e-05
in O 0 1.1985311175521929e-05
Caucasians O 0 0.0017234422266483307
, O 0 3.6559993077389663e-06
affecting O 0 5.708161916118115e-05
> O 0 0.000957854965236038
= O 0 8.7132299086079e-05
1 O 0 5.058665919932537e-06
/ O 0 3.981379995821044e-05
300 O 0 2.4502281803506776e-07
individuals O 0 2.0486321972157384e-08
of O 0 3.608886700590119e-08
northern O 0 6.613064442717587e-07
European O 0 1.0804266139530228e-06
origin O 0 3.7303973954294634e-07
, O 0 5.862596026418032e-07
it O 0 2.768967704014358e-07
has O 0 8.630573802292929e-07
not O 0 1.3391692732511729e-07
been O 0 3.5579211044023396e-07
recognized O 0 8.087564538072911e-07
in O 0 2.7258411705588514e-07
other O 0 6.358727659971919e-07
populations O 0 2.8358312192722224e-05
. O 0 4.0922313928604126e-05

The O 0 6.055596259102458e-06
present O 0 3.744123205251526e-06
study O 0 2.6287689252058044e-06
used O 0 1.2030587868139264e-06
PCR O 0 4.042968794237822e-05
and O 0 9.940267773345113e-07
restriction O 0 1.2619744666153565e-05
- O 0 2.3243068426381797e-05
enzyme O 0 3.037677288375562e-06
digestion O 0 7.630183063156437e-06
to O 0 3.1416806933748376e-08
analyze O 0 1.3628006456656294e-07
the O 0 2.472743965142854e-08
frequency O 0 7.224249287673956e-08
of O 0 3.7671131991601214e-08
the O 0 1.6915822698138072e-06
845 O 0 0.0016014688881114125
G O 0 0.0033041667193174362
- O 0 0.00038111460162326694
- O 0 3.056652712984942e-05
> O 0 7.436335181409959e-06
A O 0 1.0437237278893008e-06
and O 0 2.5987745289057784e-07
187 O 0 1.0824752280313987e-05
C O 0 0.00022459725732915103
- O 0 0.00020886796119157225
- O 0 4.3859792640432715e-05
> O 0 4.551985693979077e-05
G O 0 3.799744081334211e-05
mutations O 0 1.0208894309471361e-05
in O 0 2.6109917143912753e-06
HLA O 0 0.05019453540444374
- O 0 1.3758841305389069e-05
typed O 0 2.3466157017537626e-06
samples O 0 6.887827339596697e-07
from O 0 1.2668282352024107e-06
non O 0 3.637040572357364e-05
- O 0 0.0010280909482389688
Caucasian O 0 0.00034795646206475794
populations O 0 2.160221583835664e-06
, O 0 5.304826231622428e-07
comprising O 0 3.032652557521942e-06
Australian O 0 2.6593867005431093e-05
Aboriginal O 0 3.3510841603856534e-05
, O 0 2.4336311525985366e-06
Chinese O 0 3.0385813261091243e-06
, O 0 2.1110413399583194e-06
and O 0 3.2473976716573816e-06
Pacific O 0 0.0003508346853777766
Islanders O 0 0.00035559842945076525
. O 0 7.436862506438047e-05

Results O 0 0.00014643352187704295
showed O 0 5.52755591343157e-05
that O 0 1.247675868398801e-06
the O 0 6.2484227782988455e-06
845 O 0 0.0030452869832515717
G O 0 0.01982230506837368
- O 0 0.0031841753516346216
- O 0 0.00018473874661140144
> O 0 2.8039432436344214e-05
A O 0 3.966895292251138e-06
mutation O 0 3.871035460178973e-06
was O 0 1.0055675829789834e-06
present O 0 2.9478601959453954e-07
in O 0 6.894570958593249e-08
these O 0 1.7553018594185232e-08
populations O 0 2.5261462610615126e-07
( O 0 1.508879847733624e-07
allele O 0 2.832961740750761e-07
frequency O 0 1.218569707361894e-07
0 O 0 2.3698470386079862e-07
. O 0 1.0020315954761827e-07
32 O 0 5.467667847369739e-07
% O 0 3.925877365418273e-07
) O 0 3.696562771438039e-07
, O 0 9.868258388223694e-08
and O 0 1.2278927385978022e-07
, O 0 4.7548164161526074e-07
furthermore O 0 2.140920287274639e-06
, O 0 3.366137661942048e-07
it O 0 1.4559077499143314e-07
was O 0 1.7920848449648474e-06
always O 0 6.045499958418077e-07
seen O 0 1.1493229976622388e-06
in O 0 2.1388149207268725e-07
conjunction O 0 8.057876584643964e-06
with O 0 1.3619910532725044e-05
HLA O 1 0.99482262134552
haplotypes O 0 0.001385894836857915
common O 0 1.6999505533021875e-05
in O 0 5.198336111789104e-06
Caucasians O 0 0.0009853715309873223
, O 0 2.0158518054813612e-06
suggesting O 0 2.6111958504770882e-05
that O 0 2.451168029438122e-06
845 O 0 0.004810974467545748
G O 0 0.10023700445890427
- O 0 0.039083126932382584
- O 0 0.0010473212460055947
> O 0 0.0003416381368879229
A O 0 2.3134996808948927e-05
may O 0 5.267222149996087e-06
have O 0 1.7358490822516615e-07
been O 0 1.4288947625118453e-07
introduced O 0 3.258157050822774e-07
into O 0 1.5992519308838382e-07
these O 0 1.1750786654829426e-07
populations O 0 4.2093074625881854e-06
by O 0 1.0410265531390905e-05
Caucasian O 0 0.011603414081037045
admixture O 0 0.038819536566734314
. O 0 0.0004417139571160078

187 O 0 0.0006077610305510461
C O 0 0.0039465539157390594
- O 0 0.0022497633472085
- O 0 0.00028258422389626503
> O 0 0.00014088900934439152
G O 0 9.599360782885924e-05
was O 0 1.4612647873946116e-06
present O 0 2.2297709278973343e-07
at O 0 3.2365841207138146e-07
an O 0 1.277399519494793e-07
allele O 0 1.0795038178912364e-06
frequency O 0 3.0595822408940876e-07
of O 0 4.696701410011883e-07
2 O 0 2.425544153084047e-05
. O 0 2.6751520636025816e-05

68 O 0 0.00015304448606912047
% O 0 4.222446932544699e-06
in O 0 5.92561832490901e-07
the O 0 5.543029146792833e-07
two O 0 4.334655443472002e-07
populations O 0 3.18792081088759e-06
analyzed O 0 8.010168130567763e-06
( O 0 3.5233083508501295e-06
Australian O 0 1.5089982298377436e-05
Aboriginal O 0 1.5950075976434164e-05
and O 0 2.2093856841820525e-06
Chinese O 0 2.5444847778999247e-05
) O 0 1.8099828594131395e-05
. O 0 3.414310049265623e-05

In O 0 8.568902558181435e-06
the O 0 2.9999291655258276e-06
Australian O 0 1.6613070329185575e-05
Aboriginal O 0 1.3258154467621353e-05
samples O 0 2.0897527974739205e-06
, O 0 1.271324435947463e-06
187 O 0 3.221235965611413e-05
C O 0 0.0005778292543254793
- O 0 0.0009732363396324217
- O 0 0.0001867665268946439
> O 0 8.862491085892543e-05
G O 0 0.00011601953156059608
was O 0 3.2795969673315994e-06
found O 0 5.31309922280343e-07
to O 0 5.923268631136125e-08
be O 0 9.752489660286301e-08
associated O 0 2.3272621092473855e-06
with O 0 5.780932497145841e-06
HLA O 1 0.9881526827812195
haplotypes O 0 0.0013708246406167746
common O 0 3.053890395676717e-05
in O 0 1.3917346223024651e-05
Caucasians O 0 0.005229318048804998
, O 0 5.897908522456419e-06
suggesting O 0 5.781362051493488e-05
that O 0 3.4599949572111655e-07
it O 0 5.512769689630659e-07
was O 0 4.526921657088678e-06
introduced O 0 3.882229520968394e-06
by O 0 1.907105684040289e-06
recent O 0 4.624397843144834e-05
admixture O 0 0.006992415990680456
. O 0 0.00012230678112246096

In O 0 8.068966053542681e-06
the O 0 1.941147502293461e-06
Chinese O 0 4.07970810556435e-06
samples O 0 2.9763561997242505e-06
analyzed O 0 4.544622242974583e-06
, O 0 1.3853778000338934e-06
187 O 0 2.6124886062461883e-05
C O 0 0.00040969165274873376
- O 0 0.00048248740495182574
- O 0 0.00011070528853451833
> O 0 9.108128870138898e-05
G O 0 0.00012764630082529038
was O 0 4.28593511969666e-06
present O 0 1.0948400586130447e-06
in O 0 7.701760864620155e-07
association O 0 1.1276348232058808e-05
with O 0 1.5472846826014575e-07
a O 0 8.862237450557586e-07
wide O 0 1.6993565168377245e-06
variety O 0 1.6084612752820249e-06
of O 0 2.8092481443309225e-06
HLA O 1 0.9950581789016724
haplotypes O 0 0.0008805693360045552
, O 0 2.382383172516711e-06
showing O 0 9.71361714618979e-06
this O 0 4.415683179104235e-07
mutation O 0 1.2882887858722825e-05
to O 0 2.498044580079295e-07
be O 0 4.2856714799199835e-07
widespread O 0 1.3183084774937015e-05
and O 0 5.234300033407635e-07
likely O 0 2.5253516469092574e-06
to O 0 2.2834325363874086e-07
predate O 0 3.980161272920668e-05
the O 0 3.394538907741662e-07
more O 0 2.3797349513188237e-07
genetically O 0 2.268585012643598e-05
restricted O 0 1.862164026533719e-05
845 O 0 0.006944246124476194
G O 0 0.16332633793354034
- O 0 0.010537405498325825
- O 0 0.0005196915590204298
> O 0 0.00016245283768512309
A O 0 5.229443922871724e-05
mutation O 0 0.0001723720779409632
. O 0 4.6933582780184224e-05

Genotype O 0 0.03505650535225868
- O 0 0.02655756287276745
phenotype O 0 0.005513633135706186
correlations O 0 0.0013685862068086863
in O 0 0.001523758633993566
attenuated B-Disease 1 0.9921633005142212
adenomatous I-Disease 1 0.9994572997093201
polyposis I-Disease 1 0.9996209144592285
coli I-Disease 1 0.9987396597862244
. O 0 0.004578149877488613

Germ O 1 0.9545323848724365
- O 0 0.001465806388296187
line O 0 4.6484859922202304e-05
mutations O 0 9.521316314931028e-06
of O 0 1.135313368649804e-06
the O 0 0.00010487327381270006
tumor B-Disease 1 0.9979378581047058
suppressor O 0 0.19510015845298767
APC O 0 0.03151394799351692
are O 0 4.776691639563069e-06
implicated O 0 0.0036278781481087208
in O 0 0.00042021271656267345
attenuated B-Disease 1 0.9954586029052734
adenomatous I-Disease 1 0.9997298121452332
polyposis I-Disease 1 0.9997065663337708
coli I-Disease 1 0.9994679093360901
( O 0 0.024101316928863525
AAPC B-Disease 1 0.9962431192398071
) O 0 2.693950773391407e-05
, O 0 5.038040853833081e-06
a O 0 2.9265422199387103e-05
variant O 0 0.023715853691101074
of O 0 0.00024790747556835413
familial B-Disease 1 0.9994646906852722
adenomatous I-Disease 1 0.9996695518493652
polyposis I-Disease 1 0.9998433589935303
( O 1 0.6349604725837708
FAP B-Disease 1 0.9948953986167908
) O 0 0.00040175233152695
. O 0 0.0002212327963206917

AAPC B-Disease 1 0.9870907068252563
is O 0 1.8013266526395455e-05
recognized O 0 4.493903816182865e-06
by O 0 5.988496241116081e-07
the O 0 9.939527672031545e-07
occurrence O 0 1.914550557557959e-05
of O 0 1.8432410797686316e-06
< O 0 0.008851520717144012
100 O 0 3.578944961191155e-05
colonic B-Disease 1 0.984085202217102
adenomas I-Disease 1 0.5277957916259766
and O 0 2.197814865212422e-06
a O 0 2.0182495063636452e-05
later O 0 0.0002963914012070745
onset O 1 0.9985023736953735
of O 1 0.5585839152336121
colorectal B-Disease 1 0.9999948740005493
cancer I-Disease 1 0.9999531507492065
( O 0 0.0003874214889947325
age O 0 0.0036204347852617502
> O 0 0.008440629579126835
40 O 0 1.614176835573744e-05
years O 0 2.0763338397955522e-05
) O 0 9.900390978145879e-06
. O 0 3.0362056349986233e-05

The O 0 4.656362762034405e-06
aim O 0 3.6700459986604983e-06
of O 0 1.7677373875812918e-07
this O 0 6.975953965593362e-07
study O 0 5.103536295791855e-06
was O 0 4.4981188693782315e-06
to O 0 1.3913397651776904e-06
assess O 0 8.220973541028798e-05
genotype O 0 0.0009821404237300158
- O 0 0.0023764341603964567
phenotype O 0 0.0008000961970537901
correlations O 0 0.00032446705154143274
in O 0 0.00023705234343651682
AAPC B-Disease 1 0.9956772923469543
families O 0 0.0003913853142876178
. O 0 0.00020472638425417244

By O 0 1.5359672033810057e-05
protein O 0 3.878011557389982e-05
- O 0 0.00015246245311573148
truncation O 0 5.6912907894002274e-05
test O 0 1.0423846106277779e-05
( O 0 3.872733941534534e-06
PTT O 0 2.3991755369934253e-05
) O 0 5.216201088842354e-07
assay O 0 2.9331702080526156e-06
, O 0 1.01727756884884e-07
the O 0 1.480669453712835e-07
entire O 0 2.478846226949827e-06
coding O 0 7.880780685809441e-06
region O 0 2.7881418418473913e-07
of O 0 3.543934212757449e-08
the O 0 1.6496130683663068e-06
APC B-Disease 0 0.003295290283858776
gene O 0 3.1905408832244575e-05
was O 0 2.6550556867732666e-05
screened O 0 2.7055599275627173e-05
in O 0 2.2064293716539396e-06
affected O 0 1.1469883247627877e-05
individuals O 0 1.0837040917976992e-06
from O 0 1.5126305697776843e-05
11 O 0 0.0007139997323974967
AAPC B-Disease 1 0.9980979561805725
kindreds O 0 0.007102357689291239
, O 0 2.631590632518055e-06
and O 0 3.856039825222979e-07
their O 0 4.15645075690918e-07
phenotypic O 0 6.331578333629295e-05
differences O 0 7.216676021926105e-05
were O 0 3.1607356504537165e-05
examined O 0 0.0036192017141729593
. O 0 0.0001376403379254043

Five O 0 5.8721645473269746e-05
novel O 0 0.0009959033923223615
germ O 1 0.9813436269760132
- O 0 0.005920653697103262
line O 0 0.00015759517555125058
APC B-Disease 0 0.00511668948456645
mutations O 0 3.0263248845585622e-05
were O 0 9.147069022219512e-07
identified O 0 3.5261589346191613e-06
in O 0 1.2603138657141244e-06
seven O 0 2.478102032910101e-05
kindreds O 0 0.008681819774210453
. O 0 0.00016320726717822254

Mutations O 0 0.00016483126091770828
were O 0 1.5471358665308799e-06
located O 0 1.6795967212601681e-06
in O 0 2.441904882743984e-07
three O 0 4.7657117363542056e-08
different O 0 1.9324163602618682e-08
regions O 0 1.3339585791527497e-07
of O 0 1.0052725230025317e-07
the O 0 2.7192616016691318e-06
APC B-Disease 0 0.001147777191363275
gene O 0 7.677065696043428e-06
( O 0 8.981465384749754e-07
1 O 0 5.083748533252219e-07
) O 0 1.6712037620436604e-07
at O 0 2.615956589124835e-07
the O 0 1.0504525960186584e-07
5 O 0 3.6244492207515577e-07
end O 0 7.043344680823793e-07
spanning O 0 2.7962419153482188e-06
exons O 0 4.88599516756949e-06
4 O 0 1.7890469052872504e-06
and O 0 1.7009537600642943e-07
5 O 0 7.938643307170423e-07
, O 0 1.9415588781157567e-07
( O 0 2.758183086370991e-07
2 O 0 2.0084492291516653e-07
) O 0 6.732186363933579e-08
within O 0 7.593320816567939e-08
exon O 0 1.7056079741450958e-05
9 O 0 2.2715025806974154e-06
, O 0 1.4232561795779475e-07
and O 0 6.009274500229367e-08
( O 0 1.7205051960900164e-07
3 O 0 1.6902521338124643e-07
) O 0 6.377785410904835e-08
at O 0 1.0269608452517787e-07
the O 0 1.4117144075953547e-07
3 O 0 7.88628994996543e-07
distal O 0 6.753922207280993e-05
end O 0 2.4126877633534605e-06
of O 0 5.580167226071353e-07
the O 0 7.930992978799623e-06
gene O 0 0.00013480316556524485
. O 0 5.4242635087575763e-05

Variability O 0 0.0004819449968636036
in O 0 2.868559249691316e-06
the O 0 3.2191899208555697e-06
number O 0 5.196427537157433e-06
of O 0 0.0004843619535677135
colorectal B-Disease 1 0.9999887943267822
adenomas I-Disease 1 0.9997846484184265
was O 0 0.0012667224509641528
most O 0 3.6737299069500295e-06
apparent O 0 0.00025547679979354143
in O 0 6.690991654068057e-07
individuals O 0 5.147432489138737e-07
with O 0 1.2586286857185769e-06
mutations O 0 2.5187295250361785e-05
in O 0 8.406769325119967e-07
region O 0 4.593038283928763e-06
1 O 0 5.49655578652164e-06
, O 0 2.040001163550187e-06
and O 0 9.538730409985874e-06
upper O 1 0.9873130917549133
- O 1 0.9950674772262573
gastrointestinal O 1 0.998927652835846
manifestations O 0 0.017060967162251472
were O 0 1.2329730452620424e-05
more O 0 2.799630783556495e-05
severe O 1 0.9987220168113708
in O 0 1.2889659046777524e-05
them O 0 6.529181973746745e-06
. O 0 6.717687210766599e-05

In O 0 5.787043846794404e-06
individuals O 0 1.659446411395038e-06
with O 0 1.8463020978742861e-06
mutations O 0 2.117579606419895e-05
in O 0 6.164078172332665e-07
either O 0 2.124431603078847e-06
region O 0 3.2616253520245664e-06
2 O 0 2.1520888822124107e-06
or O 0 6.692038709843473e-07
region O 0 1.0428242376292474e-06
3 O 0 6.698793981740891e-07
, O 0 6.589255718836284e-08
the O 0 1.2174267283171503e-07
average O 0 9.424602467333898e-07
number O 0 8.539533524754006e-08
of O 0 1.1871824199261027e-06
adenomas B-Disease 1 0.7893052101135254
tended O 0 1.834880640672054e-05
to O 0 2.505278189346427e-07
be O 0 5.778114768872911e-07
lower O 0 1.4856688721920364e-05
than O 0 8.642848570161732e-08
those O 0 7.445216709811575e-08
in O 0 1.1738735139488199e-07
individuals O 0 1.286942108436051e-07
with O 0 4.646593936286081e-07
mutations O 0 1.0889299119298812e-05
in O 0 3.552174518972606e-07
region O 0 1.422104560333537e-06
1 O 0 1.2955845249962294e-06
, O 0 3.4875677101808833e-07
although O 0 1.218644456457696e-06
age O 0 0.00014002232637722045
at O 0 0.00035848518018610775
diagnosis O 1 0.9969326257705688
was O 0 0.00021471157378982753
similar O 0 7.259801350301132e-05
. O 0 5.611937012872659e-05

In O 0 3.5954199120169505e-05
all O 0 1.9163662727805786e-05
AAPC B-Disease 1 0.9922412633895874
kindreds O 0 0.0030292286537587643
, O 0 7.916334652691148e-06
a O 0 1.20492150017526e-05
predominance O 0 0.00041035766480490565
of O 0 2.274652615597006e-05
right O 0 0.14327241480350494
- O 1 0.9954562187194824
sided O 1 0.9979667663574219
colorectal B-Disease 1 0.9999285936355591
adenomas I-Disease 1 0.9992045760154724
and O 0 0.03867805749177933
rectal B-Disease 1 0.9992861151695251
polyp I-Disease 1 0.9989232420921326
sparing O 0 0.03757186233997345
was O 0 0.0011967163300141692
observed O 0 0.00017674666014499962
. O 0 8.592974336352199e-05

No O 0 0.004020946566015482
desmoid B-Disease 1 0.9907863140106201
tumors I-Disease 1 0.9992170333862305
were O 0 6.805647899454925e-06
found O 0 1.1042459846066777e-05
in O 0 4.216165507386904e-06
these O 0 4.217343757773051e-06
kindreds O 0 0.007871774956583977
. O 0 0.0002090837515424937

Our O 0 1.0796420610859059e-05
data O 0 1.1935012480535079e-05
suggest O 0 2.8484753784141503e-05
that O 0 1.825020149226475e-06
, O 0 5.394007075665286e-06
in O 0 1.7603731976123527e-05
AAPC B-Disease 1 0.9949839115142822
families O 0 3.469862804195145e-06
, O 0 2.093561732863236e-07
the O 0 2.0205257555971912e-07
location O 0 4.6224880634326837e-07
of O 0 3.019608527665696e-07
the O 0 1.4182542145135812e-05
APC B-Disease 0 0.17727304995059967
mutation O 0 0.0015495088882744312
may O 0 0.0001081817172234878
partially O 0 0.00029009641730226576
predict O 0 3.44242034771014e-05
specific O 0 3.5107109397358727e-06
phenotypic O 0 0.00019395224808249623
expression O 0 0.00014212254609446973
. O 0 0.0001356922584818676

This O 0 4.444201749720378e-06
should O 0 8.61202465785027e-07
help O 0 6.363641773532436e-07
in O 0 1.0375256209727013e-07
the O 0 1.7954995712443633e-07
design O 0 4.141504177823663e-06
of O 0 1.6576559573877603e-06
tailored O 0 0.0024339095689356327
clinical O 0 0.11327313631772995
- O 0 0.00919333752244711
management O 0 7.348741200985387e-05
protocols O 0 9.994611900765449e-06
in O 0 4.896654672847944e-07
this O 0 5.321917910805496e-07
subset O 0 1.5915416952339e-05
of O 0 5.138028791407123e-05
FAP B-Disease 1 0.9984549283981323
patients O 1 0.9949215054512024
. O 0 5.4171458032215014e-05
. O 0 8.973930380307138e-05

Wilms B-Disease 1 0.994269609451294
' I-Disease 0 0.028620518743991852
tumor I-Disease 1 0.948789656162262
1 O 0 2.2266132873483002e-05
and O 0 4.192549567960668e-06
Dax O 0 0.0019872947596013546
- O 0 2.0491854229476303e-05
1 O 0 8.483959845762001e-07
modulate O 0 8.185245860659052e-06
the O 0 1.3120222774887225e-06
orphan O 0 0.0023332214914262295
nuclear O 0 9.810576011659577e-05
receptor O 0 0.00022686761803925037
SF O 0 0.2189618945121765
- O 0 2.82757082459284e-05
1 O 0 4.3681609440682223e-07
in O 0 2.3811040250620863e-07
sex O 0 5.195763606025139e-06
- O 0 1.6896548913791776e-05
specific O 0 8.387949606003531e-07
gene O 0 2.0459730876609683e-05
expression O 0 1.6190377209568396e-05
. O 0 3.941442628274672e-05

Products O 0 6.92095491103828e-05
of O 0 1.2028124729113188e-05
steroidogenic O 0 0.31836798787117004
factor O 0 6.602708890568465e-05
1 O 0 3.9502105209976435e-05
( O 0 4.6992387069622055e-05
SF O 0 0.2655424475669861
- O 0 8.666626672493294e-05
1 O 0 2.490523456799565e-06
) O 0 1.828575932449894e-06
and O 0 1.082974995370023e-05
Wilms B-Disease 1 0.9982945322990417
tumor I-Disease 1 0.997112512588501
1 O 0 3.1659357773605734e-05
( O 0 2.5916371669154614e-05
WT1 O 0 0.022176388651132584
) O 0 8.571809075874626e-07
genes O 0 3.937463191050483e-07
are O 0 1.5160940947112067e-08
essential O 0 1.6459942742130806e-07
for O 0 2.231996489854282e-07
mammalian O 0 4.194500434095971e-05
gonadogenesis O 0 0.001260243821889162
prior O 0 7.786442438373342e-06
to O 0 9.091210699807561e-07
sexual O 0 3.385673699085601e-05
differentiation O 0 0.0005160941509529948
. O 0 9.107746882364154e-05

In O 0 3.9024522266117856e-05
males O 0 0.00010242703865515068
, O 0 3.837847543763928e-05
SF O 1 0.7468085289001465
- O 0 9.203846275340766e-05
1 O 0 2.8529784685815684e-06
participates O 0 5.613197117781965e-06
in O 0 3.477968846254953e-07
sexual O 0 2.166063950426178e-06
development O 0 1.084103132598102e-06
by O 0 6.0560023484868e-07
regulating O 0 1.2503614925662987e-05
expression O 0 9.72908651419857e-07
of O 0 4.179385086899856e-07
the O 0 1.954675099113956e-05
polypeptide O 0 0.012281110510230064
hormone O 0 0.14498712122440338
Mullerian O 0 0.27451053261756897
inhibiting O 0 0.004872173070907593
substance O 0 0.024208510294556618
( O 0 0.000339239340974018
MIS O 0 0.12417186796665192
) O 0 5.689738827641122e-05
. O 0 5.8741810789797455e-05

Here O 0 3.643209129222669e-05
, O 0 4.021033873868873e-06
we O 0 7.327503794840595e-07
show O 0 4.526593784248689e-06
that O 0 5.1779175009869505e-06
WT1 O 0 0.1609940379858017
- O 0 0.0008519640541635454
KTS O 0 0.011650100350379944
isoforms O 0 7.4231347753084265e-06
associate O 0 1.6556083210161887e-05
and O 0 2.173855136788916e-06
synergize O 0 0.0009055626578629017
with O 0 3.88439220841974e-05
SF O 1 0.9823351502418518
- O 0 0.000136997812660411
1 O 0 1.2031689493596787e-06
to O 0 2.1570049568708782e-07
promote O 0 5.046532805863535e-06
MIS O 0 0.0046759420074522495
expression O 0 2.9187967811594717e-05
. O 0 3.20285398629494e-05

In O 0 2.7057558327214792e-05
contrast O 0 0.00011722533963620663
, O 0 2.710559783736244e-05
WT1 O 0 0.4312698543071747
missense O 0 0.0017867661081254482
mutations O 0 0.00012058476568199694
, O 0 2.4350429157493636e-06
associated O 0 1.1657150025712326e-05
with O 0 6.474629572039703e-06
male B-Disease 0 0.0008447309373877943
pseudohermaphroditism I-Disease 1 0.9930911064147949
in O 0 0.000949700188357383
Denys B-Disease 1 0.9949416518211365
- I-Disease 1 0.9984139204025269
Drash I-Disease 1 0.9984311461448669
syndrome I-Disease 1 0.9999234676361084
, O 0 4.494753375183791e-05
fail O 0 0.0002314733574166894
to O 0 3.1997203677747166e-06
synergize O 0 0.004787011072039604
with O 0 0.00010354637197451666
SF O 1 0.9934578537940979
- O 0 0.002047054236754775
1 O 0 2.1108295186422765e-05
. O 0 1.4113811630522832e-05

Additionally O 0 0.00010152260074391961
, O 0 7.709581041126512e-06
the O 0 1.7455386114306748e-05
X O 0 0.004473648499697447
- O 0 0.001452593132853508
linked O 0 8.64556132000871e-05
, O 0 1.8678341575650848e-06
candidate O 0 1.2471174159145448e-05
dosage O 0 0.0009746128343977034
- O 0 0.0002110125933540985
sensitive O 0 1.2746138963848352e-05
sex O 0 4.043200169689953e-05
- O 0 0.0002529703197069466
reversal O 0 0.00016146263806149364
gene O 0 2.2539747078553773e-05
, O 0 4.765920948557323e-06
Dax O 0 0.003968074452131987
- O 0 4.989201624994166e-05
1 O 0 1.7820211724028923e-06
, O 0 7.418687459903595e-07
antagonizes O 0 0.00012182047066744417
synergy O 0 7.188281597336754e-05
between O 0 1.728015013213735e-05
SF O 1 0.9627232551574707
- O 0 0.00015554879792034626
1 O 0 2.785300466712215e-06
and O 0 1.179353262159566e-06
WT1 O 0 0.01534771267324686
, O 0 4.0424174585496075e-07
most O 0 8.178484023346755e-08
likely O 0 2.035807824540825e-07
through O 0 2.4781595442391335e-08
a O 0 2.0572667835949687e-07
direct O 0 1.9789752059296006e-07
interaction O 0 1.4154137488731067e-06
with O 0 2.310011950612534e-05
SF O 1 0.9928210377693176
- O 0 0.001066270167939365
1 O 0 1.9733994122361764e-05
. O 0 2.024414061452262e-05

We O 0 1.0385465429862961e-05
propose O 0 5.892684930586256e-05
that O 0 1.0882219612540212e-05
WT1 O 0 0.019168587401509285
and O 0 6.949334419914521e-06
Dax O 0 0.05749335139989853
- O 0 0.00012884422903880477
1 O 0 2.246516714876634e-06
functionally O 0 1.0465250852575991e-05
oppose O 0 1.0913936421275139e-06
each O 0 3.868971987230907e-08
other O 0 8.350980351679027e-08
in O 0 1.3780461358692264e-06
testis O 0 0.00045725383097305894
development O 0 5.012162546336185e-06
by O 0 6.01268538957811e-06
modulating O 0 0.007474044803529978
SF O 1 0.9875677824020386
- O 0 0.000871624331921339
1 O 0 2.2739171981811523e-05
- O 0 0.000246513809543103
mediated O 0 0.00025635716156102717
transactivation O 0 0.0037853389512747526
. O 0 2.0757041056640446e-05
. O 0 5.0160604587290436e-05

A O 0 0.000769506674259901
mouse O 0 0.002992793219164014
model O 0 0.0006925568450242281
for O 0 0.0012609113473445177
Prader B-Disease 1 0.9993301630020142
- I-Disease 1 0.9988222718238831
Willi I-Disease 1 0.9995456337928772
syndrome I-Disease 1 0.9998483657836914
imprinting O 1 0.9695237874984741
- O 1 0.598646879196167
centre O 0 0.0017749631078913808
mutations O 0 0.0019364660838618875
. O 0 0.0002746842510532588

Imprinting O 0 0.0006411244976334274
in O 0 9.347976629214827e-06
the O 0 1.2975412573723588e-05
15q11 O 0 0.005184391047805548
- O 0 0.0005218531005084515
q13 O 0 0.00015042217273730785
region O 0 3.5029452192247845e-06
involves O 0 6.354785000439733e-06
an O 0 3.4177487577835564e-06
imprinting O 0 0.0003809046756941825
centre O 0 8.268097008112818e-05
( O 0 2.2992360754869878e-05
IC O 0 0.0018050693906843662
) O 0 9.74993895397347e-07
, O 0 1.6945728020800743e-07
mapping O 0 8.331361982527596e-07
in O 0 9.48847329595992e-08
part O 0 2.6374948447482893e-07
to O 0 6.362245841273761e-08
the O 0 4.840474616685242e-07
promoter O 0 4.802444891538471e-05
and O 0 3.2421198170595744e-07
first O 0 1.2490854714997113e-06
exon O 0 9.85510487225838e-05
of O 0 8.773939043749124e-06
SNRPN O 1 0.7002953290939331
. O 0 0.00010915078019024804

Deletion O 0 0.0002868885640054941
of O 0 3.799125352088595e-06
this O 0 1.5637895558029413e-05
IC O 0 0.012450415641069412
abolishes O 0 0.0011700874892994761
local O 0 3.0196797524695285e-06
paternally O 0 0.00022549608547706157
derived O 0 4.873114448855631e-06
gene O 0 1.0836858564289287e-05
expression O 0 5.233080173638882e-06
and O 0 5.105230229673907e-06
results O 0 0.0003436457773204893
in O 0 0.0035331472754478455
Prader B-Disease 1 0.999734103679657
- I-Disease 1 0.99949049949646
Willi I-Disease 1 0.9997883439064026
syndrome I-Disease 1 0.9999638795852661
( O 1 0.8590549230575562
PWS B-Disease 1 0.9993665814399719
) O 0 0.000604270666372031
. O 0 0.00021207676036283374

We O 0 4.0497434383723885e-06
have O 0 4.141186309425393e-07
created O 0 1.1838426416943548e-06
two O 0 5.348890681489138e-07
deletion O 0 0.00026711737154982984
mutations O 0 0.00011032317706849426
in O 0 9.56523945205845e-06
mice O 0 0.002290588105097413
to O 0 3.912439751729835e-06
understand O 0 0.00011633060785243288
PWS B-Disease 1 0.9988270401954651
and O 0 5.648368528454739e-07
the O 0 3.253071554354392e-07
mechanism O 0 2.8994211334065767e-06
of O 0 6.652713295807189e-07
this O 0 1.4882625691825524e-05
IC O 0 0.16034813225269318
. O 0 0.00016495908494107425

Mice O 0 0.07392223924398422
harbouring O 0 0.01788620837032795
an O 0 2.9729821108048782e-05
intragenic O 0 0.012053596787154675
deletion O 0 0.0021220145281404257
in O 0 1.2905094990856014e-05
Snrpn O 0 0.015019198879599571
are O 0 1.407328454661183e-06
phenotypically O 0 0.0021319410298019648
normal O 0 2.5143712264252827e-05
, O 0 2.1282803572830744e-06
suggesting O 0 1.813260132621508e-05
that O 0 4.1879474110828596e-07
mutations O 0 5.439538199425442e-06
of O 0 7.656670959477196e-07
SNRPN O 0 0.06805314868688583
are O 0 3.050009240723739e-07
not O 0 3.8324265005940106e-07
sufficient O 0 7.0679307100363076e-06
to O 0 1.0980881597788539e-05
induce O 0 0.011849502101540565
PWS B-Disease 1 0.9957648515701294
. O 0 0.0003442957531660795

Mice O 0 0.0013681275304406881
with O 0 2.5298641048721038e-06
a O 0 8.165177860064432e-06
larger O 0 5.641451934934594e-06
deletion O 0 0.0001425843220204115
involving O 0 1.0730910616985057e-05
both O 0 3.079393081861781e-06
Snrpn O 0 0.005680097732692957
and O 0 5.022186996939126e-06
the O 0 3.138509055133909e-05
putative O 0 0.17577224969863892
PWS O 1 0.9988646507263184
- O 0 0.11010255664587021
IC O 0 0.011349310167133808
lack O 0 1.470528786740033e-05
expression O 0 1.5489738416363252e-06
of O 0 2.639955880567868e-07
the O 0 4.659214482671814e-06
imprinted O 0 0.0007203013519756496
genes O 0 2.1578394807875156e-05
Zfp127 O 0 0.0013951229630038142
( O 0 8.89556667971192e-06
mouse O 0 4.269849887350574e-05
homologue O 0 8.72407981660217e-05
of O 0 1.6193165492950357e-06
ZNF127 O 0 0.16049787402153015
) O 0 9.285247870138846e-06
, O 0 7.001113772275858e-06
Ndn O 0 0.020225297659635544
and O 0 2.762010126389214e-06
Ipw O 0 0.002706917468458414
, O 0 1.9929839254473336e-06
and O 0 8.999230090012134e-07
manifest O 0 4.8405243433080614e-05
several O 0 4.008506039099302e-06
phenotypes O 0 0.004671625792980194
common O 0 0.000629108923021704
to O 0 0.0008690295508131385
PWS B-Disease 1 0.9995115995407104
infants O 1 0.9927586317062378
. O 0 0.0005712498095817864

These O 0 1.7411956605428713e-06
data O 0 3.0673818400828168e-06
demonstrate O 0 1.6754117950767977e-06
that O 0 1.3342511806513357e-07
both O 0 3.3241740027278865e-08
the O 0 6.454504131170324e-08
position O 0 1.480771203432596e-07
of O 0 7.543762592376879e-08
the O 0 1.8382099824520992e-06
IC O 0 0.001363586401566863
and O 0 1.9112374616270245e-07
its O 0 1.2242165325915266e-07
role O 0 3.120314033822069e-07
in O 0 7.90363898772739e-08
the O 0 6.500314952972985e-08
coordinate O 0 2.913466516929475e-07
expression O 0 2.422906106858136e-07
of O 0 9.63195958547658e-08
genes O 0 1.201019472318876e-06
is O 0 3.7090916293891496e-07
conserved O 0 1.3500539353117347e-06
between O 0 2.9222419470897876e-06
mouse O 0 0.0003256344352848828
and O 0 7.011068987594626e-07
human O 0 1.1940654758291203e-06
, O 0 7.603058520544437e-07
and O 0 1.895228507464708e-07
indicate O 0 1.7282554836128838e-06
that O 0 9.639513365300445e-08
the O 0 4.814288558918633e-07
mouse O 0 1.1004173757100943e-05
is O 0 1.209148763336998e-07
a O 0 4.76917591640813e-07
suitable O 0 4.197465841571102e-06
model O 0 5.342830718291225e-06
system O 0 3.7684749258914962e-06
in O 0 1.339981849923788e-07
which O 0 4.9005972613258564e-08
to O 0 5.634015565192385e-08
investigate O 0 7.498044851672603e-07
the O 0 2.5726899366418365e-07
molecular O 0 3.3773385439417325e-06
mechanisms O 0 1.5078081787578412e-06
of O 0 2.444626261421945e-07
imprinting O 0 8.658068691147491e-05
in O 0 5.661203203999321e-07
this O 0 2.6466261715540895e-07
region O 0 8.542919545106997e-07
of O 0 7.72115598124401e-08
the O 0 2.3180698462965665e-06
genome O 0 6.549849058501422e-05
. O 0 8.116609024000354e-06
. O 0 3.194529199390672e-05

Mutations O 0 2.992289410030935e-05
of O 0 7.647053053005948e-07
the O 0 6.96126062393887e-06
ATM O 0 0.0009860335849225521
gene O 0 0.0001591338950674981
detected O 0 0.0004752033855766058
in O 0 5.24583701917436e-05
Japanese O 1 0.7567798495292664
ataxia B-Disease 1 0.9998908042907715
- I-Disease 1 0.9995933175086975
telangiectasia I-Disease 1 0.999609649181366
patients O 1 0.993427038192749
: O 0 2.092067734338343e-05
possible O 0 6.354366178129567e-06
preponderance O 0 0.00019456978770904243
of O 0 2.3258147052729328e-07
the O 0 1.501569045103679e-06
two O 0 3.391320433365763e-06
founder O 0 0.0007075162138789892
mutations O 0 0.00024368944286834449
4612del165 O 0 0.001142907771281898
and O 0 2.4148808734025806e-05
7883del5 O 0 0.007235900033265352
. O 0 0.00013794739788863808

The O 0 5.080463597550988e-05
ATM O 0 0.0011863088002428412
( O 0 0.0001221794809680432
A O 1 0.6153520345687866
- O 1 0.9082412719726562
T O 1 0.9969831109046936
, O 0 2.0544605376926484e-06
mutated O 0 3.002393714268692e-05
) O 0 9.4828982355466e-07
gene O 0 3.8924986256461125e-06
on O 0 1.3886304941479466e-06
human O 0 2.7495279937284067e-05
chromosome O 0 0.0012744039995595813
11q22 O 0 0.005980936344712973
. O 0 0.00017721121548675

3 O 0 9.596742893336341e-05
has O 0 1.311592131969519e-05
recently O 0 5.419982335297391e-05
been O 0 8.332983156833507e-07
identified O 0 7.713338163739536e-07
as O 0 8.998769374102267e-08
the O 0 1.648831613465518e-07
gene O 0 2.2975091269472614e-06
responsible O 0 8.668683335599781e-07
for O 0 8.694830171407375e-07
the O 0 2.5217144866473973e-05
human O 0 0.03184002265334129
recessive B-Disease 1 0.9997056126594543
disease I-Disease 1 0.9999779462814331
ataxia B-Disease 1 0.9999568462371826
- I-Disease 1 0.9994763731956482
telangiectasia I-Disease 1 0.9992111921310425
( O 0 0.006505788769572973
A B-Disease 1 0.9974881410598755
- I-Disease 1 0.9977667331695557
T I-Disease 1 0.9982158541679382
) O 0 2.8968841434107162e-05
. O 0 4.161804463365115e-05

In O 0 5.261282694846159e-06
order O 0 8.345278388333099e-07
to O 0 1.781985901061489e-07
define O 0 1.3079207974442397e-06
the O 0 1.209487322739733e-06
types O 0 1.9848806914524175e-05
of O 0 8.36899780551903e-05
disease O 1 0.9998373985290527
- O 0 0.3634423315525055
causing O 0 0.006415399722754955
ATM O 0 0.0007374531123787165
mutations O 0 3.5890552680939436e-05
in O 0 5.053222139395075e-06
Japanese O 0 0.005534584634006023
A B-Disease 1 0.9986764788627625
- I-Disease 1 0.9994762539863586
T I-Disease 1 0.9998089671134949
patients O 0 0.06835436820983887
as O 0 6.614924927816901e-07
well O 0 2.6565388111521315e-07
as O 0 1.5999597735572024e-07
to O 0 7.666696433261677e-08
look O 0 9.925887525241706e-07
for O 0 1.7928063300587382e-07
possible O 0 3.205281927876058e-06
mutational O 0 0.002485323464497924
hotspots O 0 6.736747309332713e-05
, O 0 1.791271529327787e-06
reverse O 0 3.850689245155081e-05
- O 0 9.538275662634987e-06
transcribed O 0 2.73828231911466e-06
RNA O 0 3.3599394555494655e-06
derived O 0 7.248160045492114e-07
from O 0 1.7977046127271024e-06
ten O 0 7.649418876098935e-06
patients O 0 0.002946124877780676
belonging O 0 5.055709607404424e-06
to O 0 2.8450534728108323e-07
eight O 0 5.147971023689024e-06
unrelated O 0 0.0007034030859358609
Japanese O 0 0.00796495657414198
A B-Disease 1 0.9961095452308655
- I-Disease 1 0.9966421127319336
T I-Disease 1 0.9985589385032654
families O 0 3.553418082447024e-06
was O 0 4.1532193790772e-06
analyzed O 0 2.222443526989082e-06
for O 0 1.5446325107859593e-07
mutations O 0 2.030204086622689e-06
by O 0 1.82549044325242e-07
the O 0 8.28482939141395e-07
restriction O 0 1.671799509495031e-05
endonuclease O 0 0.000775062246248126
fingerprinting O 0 8.044544665608555e-05
method O 0 1.3293361917021684e-05
. O 0 4.254380110069178e-05

As O 0 5.168049028725363e-05
has O 0 1.5712894310127012e-05
been O 0 4.583324880513828e-06
reported O 0 2.982349724334199e-05
by O 0 1.093018568099069e-06
others O 0 2.120132876370917e-06
, O 0 1.1180190995219164e-06
mutations O 0 7.715045285294764e-06
that O 0 2.6427269972373324e-07
lead O 0 2.855294496839633e-06
to O 0 6.762867883480794e-07
exon O 0 0.0001607216545380652
skipping O 0 0.00014008526341058314
or O 0 6.764455520169577e-06
premature O 0 0.0028792035300284624
protein O 0 2.0019842850160785e-05
truncation O 0 0.00012638355838134885
were O 0 9.121493462771468e-07
also O 0 8.234126198658487e-07
predominant O 0 9.044383659784216e-06
in O 0 2.615881840029033e-06
our O 0 7.297534921235638e-06
mutants O 0 0.00041226542089134455
. O 0 6.222476804396138e-05

Six O 0 6.36150343780173e-06
different O 0 6.344783400891174e-07
mutations O 0 1.899722519738134e-05
were O 0 3.6960483384973486e-07
identified O 0 1.159041175924358e-06
on O 0 2.026662571097404e-07
12 O 0 3.492340283628437e-07
of O 0 5.442811001898917e-08
the O 0 8.962452398009191e-07
16 O 0 1.769047048583161e-05
alleles O 0 5.964428055449389e-05
examined O 0 0.0007993874023668468
. O 0 8.110959606710821e-05

Four O 0 6.2578392316936515e-06
were O 0 1.6521794350410346e-06
deletions O 0 2.8551026844070293e-05
involving O 0 7.756958439131267e-06
a O 0 8.6371637735283e-06
loss O 0 4.436255767359398e-05
of O 0 1.4692729166654317e-07
a O 0 1.054431777447462e-06
single O 0 1.095414518204052e-06
exon O 0 3.913177351932973e-05
exon O 0 3.718649168149568e-05
7 O 0 2.3689030967943836e-06
, O 0 3.4965194117830833e-07
exon O 0 1.192358922708081e-05
16 O 0 1.4765338391953264e-06
, O 0 3.9340886814898113e-07
exon O 0 2.1237134205875918e-05
33 O 0 5.9644376051437575e-06
or O 0 1.7345596461382229e-06
exon O 0 0.0002418432995909825
35 O 0 4.488811828196049e-05
. O 0 3.134647340630181e-05

The O 0 1.4885407836118247e-05
others O 0 4.066156179760583e-06
were O 0 5.78466540446243e-07
minute O 0 2.3235388653120026e-06
deletions O 0 1.8519418517826125e-05
, O 0 8.301921070597018e-07
4649delA O 0 6.096720971981995e-05
in O 0 1.231724922945432e-06
exon O 0 7.528415153501555e-05
33 O 0 7.716730578977149e-06
and O 0 1.3783746908302419e-06
7883del5 O 0 0.00010321474837837741
in O 0 5.115923613630002e-06
exon O 0 0.0006130066467449069
55 O 0 0.0001343323674518615
. O 0 6.0744940128643066e-05

The O 0 6.826501339673996e-05
mutations O 0 0.00030166833312250674
4612del165 O 0 0.0009017543052323163
and O 0 4.626052032108419e-06
7883del5 O 0 0.0004077260091435164
were O 0 9.197541999128589e-07
found O 0 1.1021733143934398e-06
in O 0 1.411091261616093e-07
more O 0 3.9201001555966286e-08
than O 0 8.175427268497515e-08
two O 0 1.0707317699143459e-07
unrelated O 0 4.277054904378019e-05
families O 0 1.2200853234389797e-06
; O 0 6.018520366524172e-07
44 O 0 1.2509356110967929e-06
% O 0 3.850369694191613e-07
( O 0 2.859977428215643e-07
7 O 0 2.1533463723244495e-07
of O 0 2.2779941488693112e-08
16 O 0 3.2369422342526377e-07
) O 0 3.7643619776872583e-08
of O 0 7.871786777968737e-09
the O 0 1.6857285345395212e-07
mutant O 0 4.518032710620901e-06
alleles O 0 1.6709454939700663e-06
had O 0 5.498026212080731e-07
one O 0 4.040142442818251e-08
of O 0 3.469116549581486e-08
the O 0 6.399768608389422e-07
two O 0 1.3825031146552647e-06
mutations O 0 0.00011289906979072839
. O 0 5.839062578161247e-05

The O 0 4.6072134864516556e-05
4612del165 O 0 0.0012416058452799916
mutations O 0 4.6104036300675943e-05
in O 0 5.089268029223604e-07
three O 0 8.825896458120042e-08
different O 0 5.5585829272786214e-08
families O 0 6.069114988349611e-07
were O 0 9.466022987680844e-08
all O 0 3.662978542706696e-08
ascribed O 0 3.550159590304247e-06
to O 0 1.0309802433994264e-07
the O 0 7.574211053906765e-07
same O 0 2.1361485778470524e-05
T O 1 0.9884372353553772
- O 0 0.0004450902924872935
- O 0 2.5349758288939483e-05
> O 0 3.827623004326597e-06
A O 0 2.705446320305782e-07
substitution O 0 2.804837038183905e-07
at O 0 4.1035002595890546e-07
the O 0 3.281513727415586e-07
splice O 0 3.590691994759254e-05
donor O 0 2.699706601561047e-05
site O 0 1.057281951943878e-05
in O 0 3.906131496478338e-06
intron O 0 0.011812468990683556
33 O 0 0.00016746738401707262
. O 0 8.459424134343863e-05

Microsatellite O 0 0.004649328999221325
genotyping O 0 0.00048729105037637055
around O 0 4.683556653617416e-06
the O 0 3.972555077780271e-06
ATM O 0 0.000362844904884696
locus O 0 4.3767126044258475e-05
also O 0 2.0605825739039574e-06
indicated O 0 9.041778866958339e-06
that O 0 2.670265075721545e-07
a O 0 2.847346195267164e-06
common O 0 1.0662930435501039e-05
haplotype O 0 0.0014615884283557534
was O 0 2.3162488105299417e-06
shared O 0 1.9402281736802252e-07
by O 0 1.29931237324854e-07
the O 0 3.5167317946616095e-07
mutant O 0 1.4820180695096496e-05
alleles O 0 4.567785708786687e-06
in O 0 9.76177375378029e-07
both O 0 2.6885709303314798e-06
mutations O 0 0.0003665780241135508
. O 0 6.311780452961102e-05

This O 0 1.1272682058915962e-05
suggests O 0 3.273515176260844e-05
that O 0 3.5219272831454873e-07
these O 0 1.2329689980106195e-07
two O 0 9.009775681079191e-07
founder O 0 0.0006604275549761951
mutations O 0 0.00029898827779106796
may O 0 1.475903900427511e-05
be O 0 3.3951150157918164e-07
predominant O 0 8.034504389797803e-06
among O 0 1.75186391970783e-06
Japanese O 0 0.0001022294454742223
ATM O 0 0.001764565473422408
mutant O 0 0.0005688726669177413
alleles O 0 0.0003245577390771359
. O 0 0.00014211874804459512

W474C O 0 0.0007965648546814919
amino O 0 3.965802170569077e-05
acid O 0 0.000540013425052166
substitution O 0 3.874536560033448e-05
affects O 0 5.931823397986591e-05
early O 0 1.1125267747047474e-06
processing O 0 6.275291752899648e-07
of O 0 4.004644083011044e-08
the O 0 2.5588306584722886e-07
alpha O 0 3.084539457631763e-06
- O 0 1.5141340554691851e-06
subunit O 0 3.360351286119112e-07
of O 0 1.935873683578393e-07
beta O 0 0.00016547832638025284
- O 0 9.917438728734851e-05
hexosaminidase O 0 0.00012728954607155174
A O 0 3.2887990073504625e-06
and O 0 2.7982642336610297e-07
is O 0 7.274537665580283e-07
associated O 0 1.3471688362187706e-05
with O 0 1.9010818505194038e-05
subacute O 1 0.9946565628051758
G B-Disease 0 0.45416805148124695
( I-Disease 0 0.0004760673618875444
M2 I-Disease 1 0.7198541164398193
) I-Disease 0 6.492276588687673e-05
gangliosidosis I-Disease 0 0.009203789755702019
. O 0 9.598179894965142e-05

Mutations O 0 0.00014588565682061017
in O 0 3.538586042850511e-06
the O 0 6.797838068450801e-06
HEXA O 0 0.01839750073850155
gene O 0 3.808074552580365e-06
, O 0 1.1031875146727543e-07
encoding O 0 2.817071731442411e-07
the O 0 1.7799715124056092e-07
alpha O 0 2.1403627670224523e-06
- O 0 1.8014321767623187e-06
subunit O 0 3.513567037316534e-07
of O 0 1.9066278866830544e-07
beta O 0 0.00011026870197383687
- O 0 8.960538980318233e-05
hexosaminidase O 0 0.00010669051698641852
A O 0 3.2397508675785502e-06
( O 0 1.3165696373107494e-06
Hex O 0 1.283092478843173e-05
A O 0 4.407875621836865e-06
) O 0 5.186627163311641e-07
, O 0 1.2601128673850326e-07
that O 0 1.3328471482054738e-07
abolish O 0 6.45097406959394e-06
Hex O 0 2.499605579941999e-05
A O 0 2.2059599359636195e-05
enzyme O 0 0.0002211766695836559
activity O 0 0.0003619059280026704
cause O 1 0.9911133646965027
Tay B-Disease 1 0.9994920492172241
- I-Disease 1 0.9982638955116272
Sachs I-Disease 1 0.9993374943733215
disease I-Disease 1 0.9996305704116821
( O 0 0.0010821573669090867
TSD B-Disease 1 0.9948528409004211
) O 0 1.5840660125832073e-05
, O 0 4.653366431739414e-06
the O 0 2.161897464247886e-05
fatal O 1 0.995240330696106
infantile B-Disease 1 0.9688566327095032
form I-Disease 0 1.1866540262417402e-05
of I-Disease 0 5.091907951282337e-06
G I-Disease 0 0.05191505700349808
( I-Disease 0 6.689477595500648e-05
M2 I-Disease 0 0.05226162075996399
) I-Disease 0 1.208740195579594e-05
gangliosidosis I-Disease 0 0.0018341934774070978
, I-Disease 0 7.654140063095838e-06
Type I-Disease 0 0.00030629857792519033
1 I-Disease 0 3.8166057493072e-05
. O 0 3.245756670366973e-05

Less O 0 0.007471317891031504
severe O 1 0.9981811046600342
, O 0 0.0022262914571911097
subacute O 1 0.9969164133071899
( O 0 0.03545217216014862
juvenile O 1 0.998714804649353
- O 1 0.9955838322639465
onset O 1 0.9987364411354065
) O 0 0.00028737750835716724
and O 0 0.0005382056697271764
chronic O 1 0.9998965263366699
( O 0 0.000912889838218689
adult O 0 0.028532665222883224
- O 1 0.9771883487701416
onset O 1 0.9983477592468262
) O 0 1.0926403774647042e-05
variants O 0 1.6717644029995427e-05
are O 0 3.921454378996714e-07
characterized O 0 0.00017454584303777665
by O 0 7.301059667952359e-07
a O 0 1.0224251127510797e-05
broad O 0 9.930507803801447e-05
spectrum O 0 6.944312917767093e-05
of O 0 7.4863505687972065e-06
clinical O 0 0.21252907812595367
manifestations O 0 0.00587697746232152
and O 0 1.6373284097426222e-06
are O 0 1.8837143045402627e-07
associated O 0 4.750936113850912e-06
with O 0 1.0354197002016008e-06
residual O 0 0.00016503286315128207
levels O 0 6.9954667196725495e-06
of O 0 4.3782625880339765e-07
Hex O 0 7.064492820063606e-05
A O 0 2.3916982172522694e-05
enzyme O 0 9.880303696263582e-05
activity O 0 3.654549436760135e-05
. O 0 3.3809817978180945e-05

We O 0 1.3823970220983028e-05
identified O 0 4.929057467961684e-05
a O 0 5.140126813785173e-05
1422 O 0 0.33193665742874146
G O 0 0.025817425921559334
- O 0 0.0018832836067304015
- O 0 0.00011604386236285791
> O 0 3.308209124952555e-05
C O 0 9.40601239562966e-06
( O 0 3.853087946481537e-07
amino O 0 9.231338822246471e-07
acid O 0 4.505155447986908e-05
W474C O 0 2.772966581687797e-05
) O 0 1.8541456370257947e-07
substitution O 0 3.091458324888663e-07
in O 0 4.318637181199847e-08
the O 0 4.8742251124167524e-08
first O 0 4.901382411048871e-08
position O 0 5.819425652475729e-08
of O 0 8.106593440970755e-08
exon O 0 2.043526001216378e-05
13 O 0 1.655357323215867e-06
of O 0 7.406831628031796e-07
HEXA O 0 0.004824171774089336
of O 0 3.575864866434131e-07
a O 0 1.3486445823218673e-05
non O 0 2.375962503720075e-05
- O 0 0.00020620529539883137
Jewish O 0 1.274076657864498e-05
proband O 0 0.0024448330514132977
who O 0 1.7672327885520644e-05
manifested O 0 0.0004938835627399385
a O 0 0.00017590333300177008
subacute O 1 0.9928830862045288
variant O 0 0.011140257120132446
of O 0 1.0107312846230343e-05
G B-Disease 0 0.21801240742206573
( I-Disease 0 0.00021213560830801725
M2 I-Disease 1 0.6176846027374268
) I-Disease 0 4.880143751506694e-05
gangliosidosis I-Disease 0 0.010103459469974041
. O 0 0.00010453919821884483

On O 0 5.099810095998691e-06
the O 0 2.4816445147735067e-06
second O 0 2.0846629922743887e-05
maternally O 0 0.004759013187140226
inherited O 0 0.25101566314697266
allele O 0 4.7362878831336275e-05
, O 0 1.626180051061965e-06
we O 0 4.4210344185557915e-07
identified O 0 5.465110007207841e-06
the O 0 1.550933848193381e-05
common O 0 0.040836021304130554
infantile O 1 0.999755322933197
disease O 1 0.9998868703842163
- O 1 0.9171346426010132
causing O 0 0.08109088987112045
4 O 0 0.00012013246305286884
- O 0 0.0006319998647086322
bp O 0 0.00010246688907500356
insertion O 0 3.7809662899235263e-05
, O 0 5.824783329444472e-06
+ O 0 0.0005626568454317749
TATC O 0 0.012849151156842709
1278 O 0 0.011698641814291477
, O 0 3.56047735294851e-06
in O 0 2.6031948436866514e-06
exon O 0 0.0004939713981002569
11 O 0 9.851112554315478e-05
. O 0 3.8178764953045174e-05

Pulse O 0 0.011532166041433811
- O 0 0.0007204492576420307
chase O 0 0.00011381418153177947
analysis O 0 3.1219319680531044e-06
using O 0 6.481721356976777e-06
proband O 0 0.003957899287343025
fibroblasts O 0 0.0008894559578038752
revealed O 0 7.19682066119276e-05
that O 0 5.024003257858567e-07
the O 0 1.0268173582517193e-06
W474C O 0 0.0001275275571970269
- O 0 1.1136243301734794e-05
containing O 0 1.32410320929921e-06
alpha O 0 1.0413463314762339e-05
- O 0 7.600537628604798e-06
subunit O 0 3.4389943266432965e-06
precursor O 0 3.7404442991828546e-05
was O 0 3.335006795168738e-06
normally O 0 1.3452844314087997e-06
synthesized O 0 5.438821972347796e-06
, O 0 5.136213303558179e-07
but O 0 1.4753386778920685e-07
not O 0 9.958582580793518e-08
phosphorylated O 0 3.1012848467071308e-06
or O 0 6.423045988412923e-07
secreted O 0 3.887809725711122e-06
, O 0 2.1508876102416252e-07
and O 0 1.6509683575804956e-07
the O 0 1.101151042348647e-06
mature O 0 6.282081449171528e-05
lysosomal O 0 0.010561136528849602
alpha O 0 8.011962927412242e-05
- O 0 5.5768970923963934e-05
subunit O 0 1.0552965250099078e-05
was O 0 2.0345323719084263e-05
not O 0 2.167561888199998e-06
detected O 0 0.00024311993911396712
. O 0 3.582749195629731e-05

When O 0 3.989418109995313e-05
the O 0 1.0341651432099752e-05
W474C O 0 0.0004189887549728155
- O 0 3.936735447496176e-05
containing O 0 2.2144590730022173e-06
alpha O 0 9.949013474397361e-06
- O 0 1.1235173587920144e-05
subunit O 0 4.3658433241944294e-06
was O 0 1.6083868104033172e-05
transiently O 0 0.0010883253999054432
co O 0 0.00018472129886504263
- O 0 1.0301512702426407e-05
expressed O 0 3.4922007330351335e-07
with O 0 1.2325246245836752e-07
the O 0 4.1390225646864565e-07
beta O 0 1.1458490007498767e-05
- O 0 2.4156533982022665e-06
subunit O 0 3.4680257954278204e-07
to O 0 5.105047407027996e-08
produce O 0 3.991353594301472e-07
Hex O 0 1.262111709365854e-05
A O 0 5.427692485682201e-06
( O 0 4.238071142026456e-06
alphabeta O 0 0.00019153536413796246
) O 0 4.068433099746471e-06
in O 0 4.682730377680855e-06
COS O 0 0.3736337721347809
- O 0 0.00019805555348284543
7 O 0 6.038134415575769e-06
cells O 0 5.4490292313857935e-06
, O 0 1.1811671640771237e-07
the O 0 1.6753432419136516e-07
mature O 0 4.245445779815782e-06
alpha O 0 4.936951427225722e-06
- O 0 3.5005207337235333e-06
subunit O 0 8.73235819653928e-07
was O 0 1.7152052578239818e-06
present O 0 5.082720235805027e-07
, O 0 1.8998794359958993e-07
but O 0 7.819847525070145e-08
its O 0 1.330893582007775e-07
level O 0 1.9918818452424603e-06
was O 0 1.7118779851443833e-06
much O 0 6.569985657733923e-07
lower O 0 4.789719696418615e-06
than O 0 5.5081873284734684e-08
that O 0 4.459951341573287e-08
from O 0 1.5932479868752125e-07
normal O 0 9.481541951572581e-07
alpha O 0 4.858010925090639e-06
- O 0 5.925216555624502e-06
subunit O 0 2.161101292585954e-06
transfections O 0 0.00019229423196520656
, O 0 5.107423817207746e-07
although O 0 4.151079338043928e-07
higher O 0 1.3133192169334507e-06
than O 0 1.8541881274813932e-07
in O 0 2.5511747026030207e-07
those O 0 3.612412911024876e-07
cells O 0 1.0689462214941159e-05
transfected O 0 5.451587639981881e-05
with O 0 1.4985889151830634e-07
an O 0 4.238929989242024e-07
alpha O 0 7.339753665291937e-06
- O 0 1.4319835827336647e-05
subunit O 0 4.525199528870871e-06
associated O 0 2.362608938710764e-05
with O 0 5.363137825042941e-05
infantile O 1 0.9952709078788757
TSD B-Disease 1 0.9920433163642883
. O 0 0.0007378263399004936

Furthermore O 0 5.534080628422089e-05
, O 0 1.3905453215556918e-06
the O 0 7.802466939210717e-07
precursor O 0 8.74568650033325e-06
level O 0 5.278543540043756e-07
of O 0 6.028963639437279e-08
the O 0 7.119983251868689e-07
W474C O 0 4.2409235902596265e-05
alpha O 0 7.79761921876343e-06
- O 0 5.501464329427108e-06
subunit O 0 1.420293756382307e-06
was O 0 1.5455268567166058e-06
found O 0 4.396157180508453e-07
to O 0 1.09193123876139e-07
accumulate O 0 9.164216862700414e-06
in O 0 1.4001460613144445e-07
comparison O 0 4.173378727045929e-07
to O 0 3.152984362486677e-08
the O 0 1.3429294654088153e-07
normal O 0 3.280998726040707e-06
alpha O 0 8.847502613207325e-06
- O 0 1.4121136700850911e-05
subunit O 0 6.826104254287202e-06
precursor O 0 0.00011763809015974402
levels O 0 7.605677092215046e-05
. O 0 2.731291897362098e-05

We O 0 8.233723747252952e-06
conclude O 0 2.3475657144444995e-05
that O 0 1.1184457662238856e-06
the O 0 6.975029009481659e-06
1422 O 0 0.43261489272117615
G O 0 0.02788090892136097
- O 0 0.0025243544951081276
- O 0 0.0001751414965838194
> O 0 0.00010325816401746124
C O 0 5.293163121677935e-05
mutation O 0 5.944120403000852e-06
is O 0 3.138058275453659e-07
the O 0 4.1572755549168505e-07
cause O 0 2.091760325129144e-05
of O 0 1.1940985586988972e-06
Hex B-Disease 0 0.0010756195988506079
A I-Disease 0 0.006780825089663267
enzyme I-Disease 1 0.9922516942024231
deficiency I-Disease 1 0.9998420476913452
in O 0 1.800709833332803e-05
the O 0 6.346050213323906e-05
proband O 0 0.07581982761621475
. O 0 0.00010287584882462397

The O 0 4.1105595300905406e-05
resulting O 0 0.00021088407083880156
W474C O 0 0.00043624831596389413
substitution O 0 2.5542874936945736e-05
clearly O 0 9.738186236063484e-06
interferes O 0 2.091872192977462e-05
with O 0 5.656734742842673e-07
alpha O 0 7.779747647873592e-06
- O 0 5.971324299025582e-06
subunit O 0 1.7930850617631222e-06
processing O 0 2.0591151042026468e-06
, O 0 3.6344562204249087e-07
but O 0 2.195796184878418e-07
because O 0 2.4664046804900863e-07
the O 0 1.0453938159571408e-07
base O 0 7.546438496319752e-07
substitution O 0 3.2255018140858738e-06
falls O 0 8.713528950465843e-05
at O 0 4.385420595554024e-07
the O 0 5.212909215401851e-08
first O 0 5.4485234102230606e-08
position O 0 9.900327313516755e-08
of O 0 8.268973061831275e-08
exon O 0 6.249695434235036e-05
13 O 0 5.0842409109463915e-06
, O 0 9.089216632673924e-07
aberrant O 0 6.597339961444959e-05
splicing O 0 2.4077107809716836e-05
may O 0 9.788176612346433e-06
also O 0 8.171473382390104e-07
contribute O 0 1.4402188526219106e-06
to O 0 8.148027177412587e-07
Hex B-Disease 0 0.0007449123077094555
A I-Disease 0 0.019747093319892883
deficiency I-Disease 1 0.9997261166572571
in O 0 4.026421720482176e-06
this O 0 4.947310571878916e-06
proband O 0 0.013509221374988556
. O 0 1.7980690245167352e-05
. O 0 5.654730921378359e-05

Two O 0 2.4555582058383152e-05
frequent O 0 0.000795291387476027
missense O 0 0.03008897788822651
mutations O 0 0.02247346192598343
in O 0 0.01347745768725872
Pendred B-Disease 1 0.9992451667785645
syndrome I-Disease 1 0.9999594688415527
. O 0 0.005705658812075853

Pendred B-Disease 1 0.998855710029602
syndrome I-Disease 1 0.99994957447052
is O 0 0.021740132942795753
an O 1 0.9042475819587708
autosomal B-Disease 1 0.9998975992202759
recessive I-Disease 1 0.9999648332595825
disorder I-Disease 1 0.9999940395355225
characterized O 1 0.9986328482627869
by O 0 0.009458954446017742
early O 1 0.9800052642822266
childhood O 1 0.9996298551559448
deafness B-Disease 1 0.9999758005142212
and O 1 0.9776694178581238
goiter B-Disease 1 0.9998732805252075
. O 0 0.005557841621339321

A O 0 3.55244628735818e-05
century O 0 1.4431677300308365e-05
after O 0 6.779264822398545e-06
its O 0 8.326223337462579e-07
recognition O 0 5.06943524669623e-06
as O 0 1.5336048818426207e-05
a O 0 0.018058184534311295
syndrome O 1 0.999896764755249
by O 0 3.147873212583363e-05
Vaughan O 0 0.005510088987648487
Pendred O 0 0.11433905363082886
, O 0 2.2922980861039832e-05
the O 0 0.00020320131443440914
disease O 1 0.9994619488716125
gene O 0 0.0009847418405115604
( O 0 0.0001762165775289759
PDS O 1 0.898871898651123
) O 0 4.5087567741575185e-06
was O 0 7.717010703345295e-06
mapped O 0 1.0319977263861801e-05
to O 0 1.2404362905726884e-06
chromosome O 0 0.0003548790991771966
7q22 O 0 0.01115134172141552
- O 0 0.004766976460814476
q31 O 0 0.002158955903723836
. O 0 7.594841008540243e-05

1 O 0 5.706267256755382e-05
and O 0 7.586040283058537e-06
, O 0 6.370457867888035e-06
recently O 0 3.055078923352994e-05
, O 0 3.5724460190067475e-07
found O 0 2.506377541067195e-07
to O 0 3.951923588374484e-08
encode O 0 9.48023114233365e-07
a O 0 1.2349898497632239e-05
putative O 0 0.0016309400089085102
sulfate O 1 0.9682108759880066
transporter O 1 0.6010727286338806
. O 0 0.00023270081146620214

We O 0 4.3211234697082546e-06
performed O 0 3.997076873929473e-06
mutation O 0 3.701293508129311e-06
analysis O 0 4.639155122276861e-07
of O 0 3.8506561850226717e-07
the O 0 1.3264932931633666e-05
PDS B-Disease 1 0.9388884902000427
gene O 0 0.00019845215138047934
in O 0 2.6706506105256267e-05
patients O 0 0.03901232033967972
from O 0 1.0621864930726588e-05
14 O 0 4.3596202885964885e-05
Pendred B-Disease 0 0.004942338448017836
families O 0 3.3627507036726456e-06
originating O 0 3.961394668294815e-06
from O 0 5.730077532462019e-07
seven O 0 6.586126914953638e-07
countries O 0 1.2511581815033423e-07
and O 0 4.1050424215427483e-07
identified O 0 5.599760697805323e-06
all O 0 1.0232590739178704e-06
mutations O 0 0.0002055167278740555
. O 0 6.890846270835027e-05

The O 0 1.476233228459023e-05
mutations O 0 1.8553302652435377e-05
include O 0 1.1867725788761163e-06
three O 0 3.997692488155735e-07
single O 0 2.336615807507769e-06
base O 0 2.704739017644897e-06
deletions O 0 7.199336323537864e-06
, O 0 3.319751726849063e-07
one O 0 3.0659847993774747e-07
splice O 0 4.1350336687173694e-05
site O 0 9.02466126717627e-06
mutation O 0 1.2739345038426109e-05
and O 0 1.3045835203229217e-06
10 O 0 1.3992658750794362e-05
missense O 0 0.0009038402349688113
mutations O 0 0.0003105791111011058
. O 0 3.6756078770849854e-05

One O 0 2.1431822460726835e-05
missense O 0 0.0008844933472573757
mutation O 0 0.00020839607168454677
( O 0 2.141655932064168e-05
L236P O 0 0.0002538549015298486
) O 0 2.3221941773954313e-06
was O 0 2.767204250631039e-06
found O 0 4.669689417369227e-07
in O 0 9.337235695738855e-08
a O 0 7.534551969001768e-07
homozygous O 0 2.3704646991973277e-06
state O 0 2.9732933626291924e-07
in O 0 2.3508799529281532e-07
two O 0 3.053926889151626e-07
consanguineous O 0 0.0010509103303775191
families O 0 1.6040022501329076e-06
and O 0 1.6862495044733805e-07
in O 0 1.9142837004437752e-07
a O 0 9.840568964136764e-07
heterozygous O 0 1.8057303350360598e-06
state O 0 1.7289512754814496e-07
in O 0 1.393001838323471e-07
five O 0 4.913504199066665e-07
additional O 0 3.9607371036254335e-06
non O 0 0.00012095073907403275
- O 0 0.002472545253112912
consanguineous O 0 0.004285956732928753
families O 0 4.7076398914214224e-05
. O 0 9.444262832403183e-05

Another O 0 0.00011616453411988914
missense O 0 0.0015851333737373352
mutation O 0 0.0001853646244853735
( O 0 1.655148844292853e-05
T416P O 0 0.00032214829116128385
) O 0 2.9102416192472447e-06
was O 0 3.113223783657304e-06
found O 0 4.4424200495996047e-07
in O 0 1.657388821740824e-07
a O 0 8.566399287701643e-07
homozygous O 0 3.9897959140944295e-06
state O 0 2.885125525153853e-07
in O 0 1.7937384200195083e-07
one O 0 2.0275248857615225e-07
family O 0 1.5802205552972737e-06
and O 0 1.1876133498844865e-07
in O 0 1.471682224973847e-07
a O 0 8.832217304188816e-07
heterozygous O 0 2.0038587535964325e-06
state O 0 4.4990744640927005e-07
in O 0 5.541111249840469e-07
four O 0 2.514781726858928e-06
families O 0 2.2286145394900814e-05
. O 0 5.7234348787460476e-05

Pendred B-Disease 1 0.9737257957458496
patients O 0 0.4876089096069336
in O 0 1.420597436663229e-05
three O 0 1.0359162843087688e-05
non O 0 0.0005235166172496974
- O 0 0.003612010506913066
consanguineous O 0 0.003737242892384529
families O 0 3.2040472888184013e-06
were O 0 4.1279770357505186e-07
shown O 0 9.412279382559063e-07
to O 0 1.3174974355933955e-07
be O 0 3.5366085171517625e-07
compound O 0 4.95890126330778e-05
heterozygotes O 0 0.0002976659743580967
for O 0 3.0477285690722056e-06
L236P O 0 0.0008850045269355178
and O 0 1.1003964573319536e-05
T416P O 0 0.0026665711775422096
. O 0 8.707780216354877e-05

In O 0 6.12345547779114e-06
total O 0 2.0255470190022606e-06
, O 0 8.406208280575811e-07
one O 0 2.0735940609029058e-07
or O 0 1.9394808248307527e-07
both O 0 2.5086103860871845e-08
of O 0 2.5307608453317698e-08
these O 0 9.251382948605169e-08
mutations O 0 2.7633591344056185e-06
were O 0 1.0326787247549873e-07
found O 0 2.746633356309758e-07
in O 0 8.072848345364037e-08
nine O 0 1.705937933138557e-07
of O 0 1.2111824787552905e-07
the O 0 1.6953258636931423e-06
14 O 0 8.67405287863221e-06
families O 0 6.354694050969556e-06
analyzed O 0 6.309361924650148e-05
. O 0 3.879550058627501e-05

The O 0 2.2957526653044624e-06
identification O 0 1.6012709238566458e-06
of O 0 1.7997820123127894e-07
two O 0 9.033504397848446e-07
frequent O 0 0.0002621221065055579
PDS B-Disease 1 0.8897029757499695
mutations O 0 1.1148930752824526e-05
will O 0 1.6785865852853021e-07
facilitate O 0 6.933459530955588e-07
the O 0 3.6799785902985604e-06
molecular O 0 0.0030731982551515102
diagnosis O 1 0.9979277849197388
of O 0 0.005960568320006132
Pendred B-Disease 1 0.9996703863143921
syndrome I-Disease 1 0.9999749660491943
. O 0 0.007369608618319035

Insertional O 0 0.007037639617919922
mutation O 0 0.00010312021186109632
by O 0 6.916329311934533e-06
transposable O 0 0.0005312187131494284
element O 0 1.8504393665352836e-05
, O 0 6.312545338005293e-06
L1 O 0 0.0017076570075005293
, O 0 1.363010142085841e-06
in O 0 1.3075666629447369e-06
the O 0 1.3367197425395716e-05
DMD B-Disease 1 0.997498095035553
gene O 0 6.387187750078738e-05
results O 0 2.5094890588661656e-05
in O 0 5.148299169377424e-05
X B-Disease 1 0.9598260521888733
- I-Disease 1 0.9933561086654663
linked I-Disease 1 0.9807270765304565
dilated I-Disease 1 0.9977351427078247
cardiomyopathy I-Disease 1 0.9998449087142944
. O 0 0.0029442161321640015

X B-Disease 1 0.9547297358512878
- I-Disease 1 0.980878472328186
linked I-Disease 1 0.9822156429290771
dilated I-Disease 1 0.9980892539024353
cardiomyopathy I-Disease 1 0.9998762607574463
( O 0 0.0019094524905085564
XLDCM B-Disease 1 0.7648040652275085
) O 0 9.928681720339227e-06
is O 0 1.8702813804338803e-06
a O 0 8.582846930949017e-06
clinical O 0 0.0005970180500298738
phenotype O 0 0.0005799049395136535
of O 0 2.1036034922872204e-06
dystrophinopathy B-Disease 0 0.2180609256029129
which O 0 5.8224895838066e-06
is O 0 1.255415645573521e-05
characterized O 0 0.0022782515734434128
by O 0 4.2586787458276376e-05
preferential O 0 0.1023607924580574
myocardial B-Disease 1 0.9996647834777832
involvement I-Disease 0 0.0014133420772850513
without O 0 1.2025830073980615e-05
any O 0 6.859973382233875e-06
overt O 0 0.0014924994902685285
clinical O 0 0.22509634494781494
signs O 1 0.5749493837356567
of O 0 0.0030322542879730463
skeletal B-Disease 1 0.9998297691345215
myopathy I-Disease 1 0.9998874664306641
. O 0 0.021903852000832558

To O 0 3.1258882700058166e-06
date O 0 6.042229870217852e-06
, O 0 1.2765547126036836e-06
several O 0 1.276983311981894e-06
mutations O 0 4.603326669894159e-05
in O 0 2.4852351998561062e-05
the O 0 0.002363581443205476
Duchenne B-Disease 1 0.9989297986030579
muscular I-Disease 1 0.9996633529663086
dystrophy I-Disease 1 0.9997610449790955
gene O 1 0.7545734643936157
, O 0 0.009716635569930077
DMD O 1 0.9996433258056641
, O 0 1.6125826732604764e-05
have O 0 1.334848548140144e-06
been O 0 3.856848707073368e-06
identified O 0 2.2518068362842314e-05
in O 0 1.5773972336319275e-05
patients O 0 0.11962433159351349
with O 0 9.573389434081037e-06
XLDCM B-Disease 1 0.832078754901886
, O 0 1.1795826821980882e-06
but O 0 2.0335373562829773e-07
a O 0 8.185505180335895e-07
pathogenic O 0 4.809745860256953e-06
correlation O 0 5.885316909370886e-07
of O 0 1.5363612249075231e-07
these O 0 1.0614315897328197e-06
cardiospecific O 0 0.014332246035337448
mutations O 0 0.00029163743602111936
in O 0 5.2390976634342223e-05
DMD O 1 0.9989989399909973
with O 0 8.940616680774838e-06
the O 0 8.142089063767344e-05
XLDCM B-Disease 1 0.9935488104820251
phenotype O 0 0.1432112455368042
has O 0 2.2181697204359807e-05
remained O 0 3.0449857149505988e-05
to O 0 1.0219347359452513e-06
be O 0 1.8826057157639298e-06
elucidated O 0 0.0009400226990692317
. O 0 4.393107883515768e-05

We O 0 6.765010311937658e-06
report O 0 3.792193410845357e-06
here O 0 2.673123731256055e-07
the O 0 6.533390006779882e-08
identification O 0 8.701916698328205e-08
of O 0 2.6798360863722337e-08
a O 0 6.428653591683542e-07
unique O 0 8.795275334705366e-07
de O 0 6.630160896747839e-06
novo O 0 1.3565931112680119e-05
L1 O 0 0.00014135029050521553
insertion O 0 1.1121003808511887e-05
in O 0 1.4909495575921028e-06
the O 0 6.269163804972777e-06
muscle O 0 0.00765360938385129
exon O 0 0.0003677436034195125
1 O 0 1.5015766621218063e-05
in O 0 1.4735650438524317e-05
DMD O 1 0.9985949397087097
in O 0 6.331488748401171e-06
three O 0 1.7304708308074623e-05
XLDCM B-Disease 1 0.9970288872718811
patients O 0 0.052656762301921844
from O 0 2.279890850331867e-06
two O 0 1.7282424096265459e-06
unrelated O 0 0.0009191985009238124
Japanese O 0 0.0005565835162997246
families O 0 7.248899055412039e-05
. O 0 8.010350575204939e-05

The O 0 9.80148706730688e-06
insertion O 0 8.353625889867544e-05
was O 0 1.4804826605541166e-05
a O 0 5.511325980478432e-06
5 O 0 1.2075443009962328e-05
- O 0 7.135474879760295e-05
truncated O 0 1.4779758203076199e-05
form O 0 5.219142167334212e-07
of O 0 2.2010418376794405e-07
human O 0 4.833517778024543e-06
L1 O 0 0.0004923557862639427
inversely O 0 1.4023101357452106e-05
integrated O 0 8.97263907972956e-06
in O 0 3.739187945939193e-07
the O 0 1.4552097127307206e-06
5 O 0 1.6077918189694174e-05
- O 0 0.00012053487444063649
untranslated O 0 7.069574348861352e-05
region O 0 1.4503301599688712e-06
in O 0 3.719527228440711e-07
the O 0 2.3318743842537515e-06
muscle O 0 0.0073880222626030445
exon O 0 0.0003271962923463434
1 O 0 5.515121756616281e-06
, O 0 6.244320047699148e-07
which O 0 1.6500995059232082e-07
affected O 0 7.135767532417958e-07
the O 0 1.226321160174848e-07
transcription O 0 2.8331448902463308e-06
or O 0 2.559572465088422e-07
the O 0 1.745568738442671e-07
stability O 0 1.248628223038395e-06
of O 0 2.463971213728655e-07
the O 0 7.922617442090996e-06
muscle O 0 0.006324605084955692
form O 0 3.7689567307097604e-06
of O 0 1.847123030529474e-06
dystrophin O 0 0.3744191527366638
transcripts O 0 5.6107375712599605e-05
but O 0 7.948946176838945e-07
not O 0 9.426133829038008e-08
that O 0 4.1320486587892447e-08
of O 0 1.0484269097332799e-07
the O 0 8.350122698175255e-06
brain O 1 0.8986422419548035
or O 0 5.5957556469365954e-05
Purkinje O 1 0.8652849793434143
cell O 0 0.0011889140587300062
form O 0 1.18148809633567e-05
, O 0 3.142600235150894e-06
probably O 0 1.0333942555007525e-05
due O 0 2.466840214765398e-06
to O 0 5.978931483241468e-08
its O 0 1.0196144017982078e-07
unique O 0 6.289299108175328e-07
site O 0 3.002278845087858e-06
of O 0 5.723752565245377e-07
integration O 0 5.5946347856661305e-05
. O 0 5.4915180953685194e-05

We O 0 7.745633411104791e-06
speculate O 0 1.1556566278159153e-05
that O 0 5.993364027290227e-08
this O 0 4.384822460679061e-08
insertion O 0 1.8982290157509851e-06
of O 0 7.192022621893557e-08
an O 0 8.521519703208469e-07
L1 O 0 0.0007810604874975979
sequence O 0 8.164975952240638e-06
in O 0 2.9986736990395002e-05
DMD O 1 0.999462902545929
is O 0 1.3785087276119157e-06
responsible O 0 9.911981351251598e-07
for O 0 2.726027759081262e-08
some O 0 8.974477161416416e-09
of O 0 2.16045457079872e-08
the O 0 2.479100942309742e-07
population O 0 2.702034862522851e-07
of O 0 1.1454952755229897e-06
Japanese O 0 0.00727748591452837
patients O 1 0.5463215112686157
with O 0 7.167582225520164e-05
XLDCM B-Disease 1 0.9534964561462402
. O 0 3.9111888327170163e-05
. O 0 7.71737759350799e-05

Severe O 1 0.9962478280067444
early O 1 0.9037714600563049
- O 1 0.9984329342842102
onset O 1 0.9997414946556091
obesity B-Disease 1 0.9998565912246704
, O 0 0.36324864625930786
adrenal B-Disease 1 0.9993652701377869
insufficiency I-Disease 1 0.9996353387832642
and O 0 0.008169510401785374
red O 1 0.9984821677207947
hair O 1 0.9991154074668884
pigmentation O 1 0.9981386661529541
caused O 1 0.9657216668128967
by O 0 0.00033003598218783736
POMC O 1 0.994536280632019
mutations O 0 0.0009646413382142782
in O 0 2.1129302695044316e-05
humans O 0 0.00020354046137072146
. O 0 7.998946966836229e-05

Sequential O 0 4.640938277589157e-05
cleavage O 0 0.00016746755864005536
of O 0 4.635970753952279e-07
the O 0 2.623076625241083e-06
precursor O 0 0.00011459326196927577
protein O 0 4.154722046223469e-05
pre O 0 0.0013283162843436003
- O 0 0.0010062045184895396
pro O 0 0.0002568479685578495
- O 0 0.0004350649251136929
opiomelanocortin O 0 0.0008286877418868244
( O 0 1.6928257537074387e-05
POMC O 0 0.008708828128874302
) O 0 1.2289839332879637e-06
generates O 0 3.819061475951457e-06
the O 0 5.041943495598389e-06
melanocortin O 0 0.00695662060752511
peptides O 0 0.00011629299115156755
adrenocorticotrophin O 0 0.004617070313543081
( O 0 6.68751890771091e-05
ACTH O 0 0.021876269951462746
) O 0 1.640534173930064e-05
, O 0 2.3969523681444116e-05
melanocyte O 0 0.1958737075328827
- O 0 0.0015250941505655646
stimulating O 0 0.0006495511624962091
hormones O 0 0.0004909585113637149
( O 0 4.4601591071113944e-05
MSH O 0 0.4659211039543152
) O 0 1.957096401383751e-06
alpha O 0 4.2400843085488304e-06
, O 0 4.8785040007715e-07
beta O 0 7.367026228166651e-06
and O 0 1.3117679031893204e-07
gamma O 0 2.875063955798396e-06
as O 0 1.1405013822241017e-07
well O 0 6.24854976649658e-08
as O 0 1.9080285085237847e-07
the O 0 1.4135265473669278e-06
opioid O 0 0.0006419175770133734
- O 0 0.00013615521311294287
receptor O 0 2.6406878532725386e-05
ligand O 0 7.272543734870851e-05
beta O 0 0.002171846106648445
- O 0 0.005358752328902483
endorphin O 0 0.0732356384396553
. O 0 6.54195828246884e-05

While O 0 1.782836625352502e-05
a O 0 1.1083216122642625e-05
few O 0 7.5376306085672695e-06
cases O 0 2.2257725504459813e-05
of O 0 2.142503763025161e-05
isolated O 1 0.9648501873016357
ACTH B-Disease 1 0.9991587400436401
deficiency I-Disease 1 0.999883770942688
have O 0 1.2000739843642805e-05
been O 0 2.8839509468525648e-05
reported O 0 0.0007664315635338426
( O 0 0.00011014249321306124
OMIM O 1 0.9882568717002869
201400 O 0 0.002364274114370346
) O 0 7.651351552340202e-06
, O 0 3.925917553715408e-06
an O 0 0.00012118047015974298
inherited O 1 0.9977793097496033
POMC O 1 0.9992963075637817
defect O 1 0.9986203908920288
has O 0 3.77548931282945e-05
not O 0 2.016211283262237e-06
been O 0 3.901001491612988e-06
described O 0 4.4086442358093336e-05
so O 0 3.3269634513999335e-06
far O 0 1.1789791642513592e-05
. O 0 2.3874870748841204e-05

Recent O 0 0.00020611114450730383
studies O 0 2.0022782337036915e-05
in O 0 6.1329815252975095e-06
animal O 0 5.678783418261446e-05
models O 0 1.4250847016228363e-05
elucidated O 0 7.077257032506168e-05
a O 0 1.5119552472242503e-06
central O 0 1.8973277065015282e-06
role O 0 6.019703278070665e-07
of O 0 3.605151448482502e-07
alpha O 0 0.00020487108849920332
- O 0 0.002247793832793832
MSH O 0 0.29474523663520813
in O 0 2.3979055185918696e-07
the O 0 2.0802433198241488e-07
regulation O 0 2.2546082618646324e-06
of O 0 1.9198434131340036e-07
food O 0 1.1034963790734764e-05
intake O 0 2.3293463527807035e-05
by O 0 2.6346290837864217e-07
activation O 0 5.900940323044779e-06
of O 0 7.2276526452697e-07
the O 0 2.3476084606954828e-05
brain O 1 0.5511849522590637
melanocortin O 0 0.14559045433998108
- O 0 0.00043841006117872894
4 O 0 1.9679213437484577e-05
- O 0 0.00010038474283646792
receptor O 0 3.191374707967043e-05
( O 0 1.0199260941590182e-05
MC4 O 0 0.15795719623565674
- O 0 0.0004787179932463914
R O 0 0.000300716666970402
; O 0 3.9984993236430455e-06
refs O 0 8.934089419199154e-05
3 O 0 4.2374608710815664e-06
- O 0 1.0583977200440131e-05
5 O 0 5.054905614088057e-07
) O 0 1.1332199534308529e-07
and O 0 2.364338058669091e-08
the O 0 1.641277549424558e-07
linkage O 0 2.453695014992263e-05
of O 0 1.4584301197828609e-06
human O 0 0.00017562411085236818
obesity B-Disease 1 0.9983211159706116
to O 0 8.045998356465134e-07
chromosome O 0 1.7308586393482983e-05
2 O 0 8.172447678589378e-07
in O 0 1.5427099242515396e-07
close O 0 8.411436738242628e-07
proximity O 0 6.829274639130745e-07
to O 0 1.7393755058492388e-07
the O 0 1.2479174529289594e-06
POMC O 0 0.07372776418924332
locus O 0 2.088602923322469e-05
, O 0 6.306440241132805e-07
led O 0 7.696496595599456e-07
to O 0 5.409020786828478e-08
the O 0 1.5897389005203877e-07
proposal O 0 1.2786114211849053e-06
of O 0 1.4554967719959677e-07
an O 0 2.1921275674685603e-06
association O 0 8.949967741500586e-05
of O 0 8.334927770192735e-06
POMC O 1 0.9950956106185913
with O 0 0.0004101089434698224
human O 0 0.02890915423631668
obesity B-Disease 1 0.9989643096923828
. O 0 0.0005732651334255934

The O 0 4.922452717437409e-06
dual O 0 1.1155249012517743e-05
role O 0 2.6857928787649143e-06
of O 0 2.347034069316578e-06
alpha O 0 0.0007389681413769722
- O 0 0.016730107367038727
MSH O 1 0.9324613809585571
in O 0 4.388438355817925e-06
regulating O 0 0.00012496435374487191
food O 0 9.547106310492381e-05
intake O 0 0.0006578790489584208
and O 0 6.907113856868818e-06
influencing O 0 0.0006002371083013713
hair O 1 0.9947792291641235
pigmentation O 1 0.88956218957901
predicts O 0 0.0016834400594234467
that O 0 1.6691664086465607e-06
the O 0 5.539507128560217e-06
phenotype O 0 0.0017433788161724806
associated O 0 1.831572808441706e-05
with O 0 4.477271886571543e-06
a O 0 0.0005416975473053753
defect O 1 0.9944907426834106
in O 0 3.763565473491326e-05
POMC O 1 0.9852280616760254
function O 0 2.2316771719488315e-05
would O 0 7.781958629493602e-06
include O 0 0.00016568372666370124
obesity B-Disease 1 0.9991161227226257
, O 0 3.490378730930388e-05
alteration O 0 0.017500748857855797
in O 0 0.00033142490428872406
pigmentation O 1 0.9950637221336365
and O 0 0.006862740032374859
ACTH B-Disease 1 0.9983397722244263
deficiency I-Disease 1 0.999579131603241
. O 0 0.0017128068720921874

The O 0 9.937984032148961e-06
observation O 0 5.783126471214928e-05
of O 0 3.1158228921412956e-06
these O 0 1.025030724122189e-05
symptoms O 1 0.9981551766395569
in O 0 6.240091352083255e-06
two O 0 3.0748092285648454e-06
probands O 0 0.04626813903450966
prompted O 0 6.465803016908467e-05
us O 0 1.7868575241664075e-06
to O 0 5.9228280946399536e-08
search O 0 3.3046654834834044e-07
for O 0 2.763828490515152e-07
mutations O 0 9.051424967765342e-06
within O 0 9.70248493104009e-07
their O 0 4.868929408985423e-06
POMC O 1 0.914700448513031
genes O 0 0.00014591196668334305
. O 0 7.552951137768105e-05

Patient O 0 0.05055651813745499
1 O 0 6.113354174885899e-05
was O 0 2.0667959688580595e-05
found O 0 9.982484243664658e-07
to O 0 6.39012043279763e-08
be O 0 8.750617297437202e-08
a O 0 1.0198745030720602e-06
compound O 0 1.1592795999604277e-05
heterozygote O 0 2.8090311388950795e-05
for O 0 1.0928459914794075e-07
two O 0 1.6967705107617803e-07
mutations O 0 7.43932150726323e-06
in O 0 8.610678037257458e-07
exon O 0 0.00010866008960874751
3 O 0 7.371270839939825e-06
( O 0 7.422427188430447e-06
G7013T O 0 0.0001843565551098436
, O 0 2.612894832054735e-06
C7133delta O 0 0.0003790048067457974
) O 0 9.491376431469689e-07
which O 0 9.007011669837084e-08
interfere O 0 4.505068034177384e-07
with O 0 3.214386623540122e-08
appropriate O 0 1.3279877464356105e-07
synthesis O 0 2.0696954834420467e-06
of O 0 1.111886149374186e-06
ACTH O 0 0.04352397099137306
and O 0 1.880633135442622e-05
alpha O 0 0.0009353759232908487
- O 0 0.03310750797390938
MSH O 1 0.9672988653182983
. O 0 9.307578147854656e-05

Patient O 0 0.011091615073382854
2 O 0 3.151684722979553e-05
was O 0 1.1692914085870143e-05
homozygous O 0 4.75718843517825e-06
for O 0 2.030715791079274e-07
a O 0 2.8997887966397684e-06
mutation O 0 1.0129139809578191e-05
in O 0 7.933935535220371e-07
exon O 0 8.305886149173602e-05
2 O 0 7.669937986065634e-06
( O 0 5.2003592827531975e-06
C3804A O 0 0.00011329216795274988
) O 0 2.216717575720395e-06
which O 0 4.108060238650069e-06
abolishes O 0 0.00932274479418993
POMC O 1 0.6990369558334351
translation O 0 0.0003137315216008574
. O 0 0.00024685790413059294

These O 0 2.434441285004141e-06
findings O 0 3.177024836986675e-06
represent O 0 1.335778989641767e-07
the O 0 1.3139739962753083e-07
first O 0 2.2160340051868843e-07
examples O 0 5.101903184367984e-07
of O 0 3.1775081765772484e-07
a O 0 0.0002909958129748702
genetic B-Disease 1 0.8583933711051941
defect I-Disease 1 0.9972388744354248
within O 0 2.9156474283809075e-06
the O 0 1.6103635061881505e-05
POMC O 1 0.9352350831031799
gene O 0 1.2579778740473557e-05
and O 0 5.366906634662882e-07
define O 0 5.710406639991561e-06
a O 0 3.648702477221377e-05
new O 0 0.0007813664269633591
monogenic B-Disease 1 0.9980915188789368
endocrine I-Disease 1 0.9995492100715637
disorder I-Disease 1 0.9998134970664978
resulting O 0 0.18908202648162842
in O 0 0.0006554744904860854
early O 1 0.7066448926925659
- O 1 0.9986757636070251
onset O 1 0.9996411800384521
obesity B-Disease 1 0.9998134970664978
, O 0 0.19778499007225037
adrenal B-Disease 1 0.9994847774505615
insufficiency I-Disease 1 0.999710738658905
and O 0 0.019295334815979004
red O 1 0.9979590177536011
hair O 1 0.9982873797416687
pigmentation O 1 0.9907564520835876
. O 0 6.580356421181932e-05
. O 0 0.0001410209952155128

A O 0 0.00018012466898653656
European O 0 8.631226955913007e-05
multicenter O 0 0.009034872986376286
study O 0 4.563468974083662e-05
of O 0 3.0185141440597363e-05
phenylalanine B-Disease 1 0.9945587515830994
hydroxylase I-Disease 1 0.9978119134902954
deficiency I-Disease 1 0.9999632835388184
: O 0 5.04393465234898e-05
classification O 0 0.0001623391726752743
of O 0 4.769885890709702e-07
105 O 0 1.5298977814381942e-05
mutations O 0 7.995286068762653e-06
and O 0 2.533379017677362e-07
a O 0 1.1774382073781453e-06
general O 0 2.3447612420568475e-06
system O 0 5.545346994040301e-06
for O 0 1.0011868880610564e-06
genotype O 0 0.00036205604556016624
- O 0 7.236273813759908e-05
based O 0 1.748682279867353e-06
prediction O 0 6.295490311458707e-05
of O 0 9.917401257553138e-06
metabolic O 1 0.9890390634536743
phenotype O 1 0.5351725816726685
. O 0 0.00037923434865660965

Phenylketonuria B-Disease 1 0.9936309456825256
( O 0 0.009650600142776966
PKU B-Disease 1 0.9970777034759521
) O 0 0.00023625021276529878
and O 0 0.00016247530584223568
mild B-Disease 1 0.9980300068855286
hyperphenylalaninemia I-Disease 1 0.9978731870651245
( O 0 0.03769669681787491
MHP B-Disease 1 0.999294638633728
) O 0 4.733009700430557e-05
are O 0 1.0863978786801454e-05
allelic B-Disease 1 0.9894658327102661
disorders I-Disease 1 0.9998225569725037
caused O 1 0.7095715999603271
by O 0 3.8849925658723805e-06
mutations O 0 1.2234151654411107e-05
in O 0 2.8085469239158556e-07
the O 0 6.033278054928815e-07
gene O 0 7.658674803678878e-06
encoding O 0 1.149305171566084e-05
phenylalanine O 0 0.003141185734421015
hydroxylase O 0 0.07182586938142776
( O 0 0.0038199354894459248
PAH O 1 0.9983861446380615
) O 0 7.602536061313003e-05
. O 0 7.075070607243106e-05

Previous O 0 9.40485333558172e-05
studies O 0 2.4879595002857968e-05
have O 0 1.4680476851935964e-06
suggested O 0 5.9528224483074155e-06
that O 0 3.457801369677327e-07
the O 0 1.1385054676793516e-06
highly O 0 1.9805884221568704e-05
variable O 0 0.00012669921852648258
metabolic O 1 0.9803155064582825
phenotypes O 0 0.3786250948905945
of O 0 0.09160257875919342
PAH B-Disease 1 0.9999200105667114
deficiency I-Disease 1 0.999862790107727
correlate O 0 0.18136554956436157
with O 0 0.06761831045150757
PAH O 1 0.9995947480201721
genotypes O 0 0.2574220597743988
. O 0 0.0002565405739005655

We O 0 1.4946589544706512e-05
identified O 0 2.1287683921400458e-05
both O 0 6.0771235439460725e-06
causative O 0 0.0020628783386200666
mutations O 0 0.000577667320612818
in O 0 0.00010929263953585178
686 O 1 0.9850279092788696
patients O 1 0.6912565231323242
from O 0 1.045045064529404e-05
seven O 0 1.3332275557331741e-05
European O 0 3.05258872685954e-05
centers O 0 0.00010439405014039949
. O 0 7.697590626776218e-05

On O 0 1.5198442042674287e-06
the O 0 1.9816870633349026e-07
basis O 0 4.3951636996553134e-08
of O 0 4.7128583702260585e-08
the O 0 3.5411309795563284e-07
phenotypic O 0 1.8553302652435377e-05
characteristics O 0 9.400372618983965e-06
of O 0 2.310049922016333e-06
297 O 0 0.00842707883566618
functionally O 1 0.5256319046020508
hemizygous O 1 0.9878502488136292
patients O 0 0.2644749581813812
, O 0 6.93781203153776e-07
105 O 0 1.5948578493407695e-06
of O 0 1.261923898709938e-07
the O 0 8.563376923120813e-07
mutations O 0 4.513532530836528e-06
were O 0 6.113950945518809e-08
assigned O 0 1.5231408667659707e-07
to O 0 1.118985704096076e-08
one O 0 1.5221065297055247e-08
of O 0 3.084472410819217e-08
four O 0 2.75617423994845e-07
arbitrary O 0 4.678387085732538e-06
phenotype O 0 0.002735776361078024
categories O 0 0.00010959132487187162
. O 0 6.138825119705871e-05

We O 0 6.7762075559585355e-06
proposed O 0 1.2221009455970488e-05
and O 0 8.836649385557394e-07
tested O 0 1.0156766620639246e-05
a O 0 4.878866661783832e-07
simple O 0 5.384202950153849e-07
model O 0 8.723493465367937e-07
for O 0 1.022367968062099e-07
correlation O 0 2.854469585145125e-06
between O 0 2.5372237359988503e-06
genotype O 0 8.951315976446494e-05
and O 0 1.168849280475115e-06
phenotypic O 0 0.00013399131421465427
outcome O 0 0.0002732809807639569
. O 0 0.00013804607442580163

The O 0 2.168970058846753e-05
observed O 0 3.980776455136947e-05
phenotype O 0 0.0004485462268348783
matched O 0 2.6180950953857973e-05
the O 0 4.3360796553315595e-06
predicted O 0 0.00038001348730176687
phenotype O 0 0.00022262871789280325
in O 0 1.3968053735879948e-06
79 O 0 2.2473275748779997e-05
% O 0 3.298557089692622e-07
of O 0 9.44582296824592e-08
the O 0 1.2490854714997113e-06
cases O 0 6.061125532141887e-06
, O 0 2.8177004196550115e-07
and O 0 4.144061449551373e-08
in O 0 3.998667708060566e-08
only O 0 3.167571804851832e-08
5 O 0 3.068529679239873e-07
of O 0 2.802040341975953e-07
184 O 0 0.0002900233957916498
patients O 0 0.010870672762393951
was O 0 4.616717433236772e-06
the O 0 3.385931961474853e-07
observed O 0 2.156154550903011e-06
phenotype O 0 4.346104833530262e-05
more O 0 7.701976301177638e-08
than O 0 1.1104030761543981e-07
one O 0 2.9093183684381074e-07
category O 0 3.935461791115813e-06
away O 0 8.373251603188692e-07
from O 0 1.041582891048165e-06
that O 0 8.071714319157763e-07
expected O 0 1.5424922821694054e-05
. O 0 2.897961894632317e-05

Among O 0 6.001640031172428e-06
the O 0 1.746389216350508e-06
seven O 0 3.919232767657377e-06
contributing O 0 2.123395461239852e-05
centers O 0 3.449492396612186e-06
, O 0 2.1706617303607345e-07
the O 0 2.9675200607925944e-07
proportion O 0 4.076448931300547e-06
of O 0 2.959910489153117e-06
patients O 1 0.5005077719688416
for O 0 7.93794640685519e-07
whom O 0 7.061543783493107e-06
the O 0 2.383769697189564e-06
observed O 0 2.883896195271518e-05
phenotype O 0 0.0015455635730177164
did O 0 2.225641992481542e-06
not O 0 9.517346910570268e-08
match O 0 3.8778605926381715e-07
the O 0 3.820886718131078e-07
predicted O 0 3.787689274759032e-05
phenotype O 0 5.360596696846187e-05
was O 0 2.7918479190702783e-06
4 O 0 1.2308254326853785e-06
% O 0 1.8230596197099658e-06
- O 0 1.245074781763833e-05
23 O 0 1.5012138874226366e-06
% O 0 1.3967867289466085e-06
( O 0 5.521679213416064e-06
P O 0 0.0013995328918099403
< O 0 0.0003346978919580579
. O 0 2.591300471976865e-06
0001 O 0 0.002920308616012335
) O 0 1.4470639371211291e-06
, O 0 6.311976221695659e-07
suggesting O 0 3.1383174246002454e-06
that O 0 1.102651125961529e-07
differences O 0 3.54775636424165e-07
in O 0 1.2584723663167097e-07
methods O 0 1.279383212704488e-07
used O 0 2.4561754230489896e-07
for O 0 2.864628640963929e-07
mutation O 0 4.0849248762242496e-05
detection O 0 0.00023182606673799455
or O 0 3.831276626442559e-05
phenotype O 0 0.16025298833847046
classification O 0 0.09179680794477463
may O 0 9.06829063751502e-06
account O 0 2.999208561504929e-07
for O 0 6.484773251713705e-08
a O 0 4.992223239241866e-07
considerable O 0 1.7023329519361141e-06
proportion O 0 3.0978144422988407e-06
of O 0 3.1452386792807374e-06
genotype O 0 0.05557272210717201
- O 0 0.16887545585632324
phenotype O 0 0.006921757012605667
inconsistencies O 0 0.003977952525019646
. O 0 0.00017930234025698155

Our O 0 4.8699043873057235e-06
data O 0 5.818132194690406e-06
indicate O 0 2.4034919988480397e-05
that O 0 3.7992415400367463e-06
the O 0 0.0001765889610396698
PAH O 1 0.9991762042045593
- O 0 0.0014360578497871757
mutation O 0 2.9347844247240573e-05
genotype O 0 1.6725713066989556e-05
is O 0 1.7250167161364516e-07
the O 0 2.4228785377999884e-07
main O 0 1.7855425085144816e-06
determinant O 0 1.9159844669047743e-05
of O 0 3.227329671062762e-06
metabolic O 1 0.9886279702186584
phenotype O 0 0.32248300313949585
in O 0 7.280488352989778e-05
most O 0 0.0003768519381992519
patients O 1 0.9975595474243164
with O 1 0.9852951765060425
PAH B-Disease 1 0.9999057054519653
deficiency I-Disease 1 0.9998353719711304
. O 0 0.0025823726318776608

In O 0 6.578658940270543e-06
the O 0 2.745491428868263e-06
present O 0 3.958014985983027e-06
study O 0 5.047909780842019e-06
, O 0 7.842459694984427e-07
the O 0 7.471526828339847e-07
classification O 0 0.00023504483397118747
of O 0 4.8792485358717386e-06
105 O 0 0.0171820055693388
PAH O 1 0.9996178150177002
mutations O 0 9.880172001430765e-05
may O 0 2.077611497952603e-06
allow O 0 1.7960785214654607e-07
the O 0 1.9525793959473958e-07
prediction O 0 4.374950094643282e-06
of O 0 9.15810502988279e-08
the O 0 1.2854164879172458e-06
biochemical O 0 0.00018239060591440648
phenotype O 0 0.00042678171303123236
in O 0 2.577754003141308e-06
> O 0 0.00022395125415641814
10 O 0 1.8542301631896407e-06
, O 0 1.1132982535855263e-06
000 O 0 1.0184838174609467e-05
genotypes O 0 0.000154794062837027
, O 0 6.328937729449535e-07
which O 0 4.797403789780219e-07
may O 0 9.195507004733372e-07
be O 0 2.5529994118755894e-08
useful O 0 1.1843694380786474e-07
for O 0 6.877037606045633e-08
the O 0 9.671407497080509e-07
management O 0 2.9660943255294114e-05
of O 0 2.7099313228973188e-06
hyperphenylalaninemia B-Disease 1 0.9945942759513855
in O 0 0.00021433750225696713
newborns O 1 0.8648511171340942
. O 0 0.0001527496933704242

Somatic O 0 0.00044767887447960675
instability O 0 0.0001715515973046422
of O 0 1.3208366453909548e-06
the O 0 1.1947639904974494e-05
CTG O 0 0.06784064322710037
repeat O 0 0.0005420663510449231
in O 0 1.0689197551982943e-05
mice O 0 0.0009230240248143673
transgenic O 0 0.0001775489654392004
for O 0 1.010377673082985e-05
the O 0 0.0027130492962896824
myotonic B-Disease 1 0.9998540878295898
dystrophy I-Disease 1 0.9999583959579468
region O 0 0.002221982227638364
is O 0 2.69009979092516e-05
age O 0 0.00031593709718436003
dependent O 0 1.3163162293494679e-05
but O 0 5.978008630336262e-07
not O 0 1.883292100046674e-07
correlated O 0 2.5149545308522647e-06
to O 0 7.846995231375331e-08
the O 0 4.362366041732457e-07
relative O 0 7.848499080864713e-06
intertissue O 0 0.0011635387782007456
transcription O 0 0.00025174711481668055
levels O 0 0.0004117585194762796
and O 0 3.973274942836724e-05
proliferative O 1 0.9890791773796082
capacities O 0 0.0013103268574923277
. O 0 0.00014609962818212807

A O 0 0.000322978594340384
( O 0 9.713679901324213e-05
CTG O 0 0.00537382485345006
) O 0 9.030937690113205e-06
nexpansion O 0 0.00017843200475908816
in O 0 7.09374035068322e-07
the O 0 2.13862244891061e-06
3 O 0 2.3678056095377542e-05
- O 0 0.00018167428788729012
untranslated O 0 0.00010689754708437249
region O 0 4.262793481757399e-06
( O 0 1.0303488124918658e-06
UTR O 0 4.911639916826971e-05
) O 0 1.0899670144226548e-07
of O 0 6.289143072990555e-08
the O 0 3.347108304296853e-06
DM O 1 0.9903095364570618
protein O 0 1.3482896065397654e-05
kinase O 0 6.417299300665036e-05
gene O 0 3.568421379895881e-05
( O 0 1.1843918400700204e-05
DMPK O 0 0.003545497078448534
) O 0 3.9124734030338e-06
is O 0 2.5619028747314587e-06
responsible O 0 2.4382832634728402e-05
for O 0 0.00011758526670746505
causing O 1 0.9959288239479065
myotonic B-Disease 1 0.9998382329940796
dystrophy I-Disease 1 0.9999274015426636
( O 1 0.9720298647880554
DM B-Disease 1 0.999535322189331
) O 0 0.0006178253679536283
. O 0 0.00015906196495052427

Major O 0 0.0018964414484798908
instability O 0 0.0041046300902962685
, O 0 3.3356559470121283e-06
with O 0 8.303085223815287e-07
very O 0 9.883880238703568e-07
large O 0 1.5405912563437596e-06
expansions O 0 1.6114634490804747e-05
between O 0 1.0038207847173908e-06
generations O 0 4.5876195144956e-06
and O 0 4.46168741063957e-07
high O 0 8.050526048464235e-06
levels O 0 3.3817862004070776e-06
of O 0 4.779853952641133e-07
somatic O 0 0.0003655885811895132
mosaicism O 0 0.348640114068985
, O 0 4.983165126759559e-06
is O 0 6.427993866964243e-06
observed O 0 3.882377495756373e-05
in O 0 5.546438478631899e-05
patients O 1 0.8297709822654724
. O 0 0.00021995819406583905

There O 0 5.640301424136851e-06
is O 0 1.4463396382780047e-06
a O 0 1.9063475065195234e-06
good O 0 1.4510439996229252e-06
correlation O 0 2.0801392111025052e-06
between O 0 1.5324089872592594e-06
repeat O 0 6.981369369896129e-05
size O 0 6.206008492881665e-06
( O 0 1.0191006367676891e-06
at O 0 1.0260127965011634e-06
least O 0 5.866779133611999e-07
in O 0 1.8716071963353897e-06
leucocytes O 0 0.0021783155389130116
) O 0 6.561315331055084e-06
, O 0 7.70949282014044e-06
clinical O 0 0.006745718419551849
severity O 0 0.48506835103034973
and O 0 8.828840691421647e-06
age O 0 0.00038842009962536395
of O 0 4.7962021199055016e-05
onset O 1 0.9982907176017761
. O 0 0.0013965439284220338

The O 0 0.0006169419502839446
trinucleotide O 1 0.9818341135978699
repeat O 0 0.013035990297794342
instability O 0 0.001781525439582765
mechanisms O 0 8.632544631836936e-05
involved O 0 8.157655975082889e-05
in O 0 0.00031540743657387793
DM B-Disease 1 0.9996311664581299
and O 0 8.759167030802928e-06
other O 0 9.09170375962276e-06
human O 0 0.005451587960124016
genetic B-Disease 1 0.9992079138755798
diseases I-Disease 1 0.9999345541000366
are O 0 1.1387397535145283e-05
unknown O 0 0.0005279809702187777
. O 0 0.00017004756955429912

We O 0 1.4593550986319315e-05
studied O 0 5.6867334933485836e-05
somatic O 0 0.0002192293613916263
instability O 0 0.00023872121528256685
by O 0 2.600326524770935e-06
measuring O 0 6.699698133161291e-05
the O 0 1.1512314813444391e-05
CTG O 0 0.03534028306603432
repeat O 0 0.0001537401112727821
length O 0 1.0613178346829955e-05
at O 0 2.51737333201163e-06
several O 0 3.8783784361839935e-07
ages O 0 4.836123025597772e-06
in O 0 2.727601895458065e-07
various O 0 2.5586379592823505e-07
tissues O 0 6.736355135217309e-05
of O 0 2.361590077271103e-06
transgenic O 0 0.0015601313207298517
mice O 0 0.0003888061619363725
carrying O 0 4.952294602844631e-06
a O 0 8.008533768588677e-06
( O 0 9.002886145026423e-06
CTG O 0 0.002477629343047738
) O 0 4.191833795630373e-06
55expansion O 0 0.0001849028340075165
surrounded O 0 1.6918447727221064e-05
by O 0 5.467678079185134e-07
45 O 0 2.003925601457013e-06
kb O 0 3.229700814699754e-05
of O 0 4.5564948436549457e-07
the O 0 9.761860383150633e-06
human O 0 0.0003071805404033512
DM B-Disease 1 0.9992450475692749
region O 0 1.5028587768028956e-05
, O 0 8.286322668027424e-07
using O 0 1.3048087339484482e-06
small O 0 1.8267533960170113e-05
- O 0 0.0006271202000789344
pool O 0 0.0002753080043476075
PCR O 0 0.0006005231407471001
. O 0 5.630742452922277e-05

These O 0 3.5333265259396285e-05
mice O 0 0.005457739345729351
have O 0 1.5071784673637012e-06
been O 0 8.604439472037484e-07
shown O 0 5.654016490552749e-07
to O 0 1.0426577290445493e-07
reproduce O 0 3.0138166948745493e-06
the O 0 3.832035417872248e-07
intergenerational O 0 5.349699131329544e-05
and O 0 6.788313839933835e-07
somatic O 0 2.475851033523213e-05
instability O 0 1.668483491812367e-05
of O 0 1.9354786218173103e-07
the O 0 3.4624154068296775e-06
55 O 0 0.00012631801655516028
CTG O 0 0.06162463128566742
repeat O 0 0.0005541132413782179
suggesting O 0 3.0568684451282024e-05
that O 0 3.5288394428789616e-07
surrounding O 0 3.084930767727201e-06
sequences O 0 6.647170494034071e-07
and O 0 2.573941344508057e-07
the O 0 1.2489997516240692e-06
chromatin O 0 0.00022359174909070134
environment O 0 1.0109182767337188e-05
are O 0 1.4270291615048336e-07
involved O 0 4.255465682945214e-06
in O 0 1.388589953421615e-05
instability O 0 0.0019548211712390184
mechanisms O 0 0.0002388755965512246
. O 0 0.0001122389076044783

As O 0 7.105310032784473e-06
observed O 0 3.896123871527379e-06
in O 0 3.812068030129012e-07
some O 0 4.471834103014771e-08
of O 0 1.4524407276894635e-07
the O 0 7.015341907390393e-06
tissues O 0 0.004961279686540365
of O 0 0.0007854769937694073
DM B-Disease 1 0.9999740123748779
patients O 1 0.9978083968162537
, O 0 3.847601874440443e-06
there O 0 7.41994711006555e-07
is O 0 6.186044174683047e-07
a O 0 2.8464692150009796e-06
tendency O 0 1.78158916241955e-05
for O 0 4.2120316834370897e-07
repeat O 0 6.197125185281038e-05
length O 0 1.3000232684134971e-05
and O 0 1.2899724879389396e-06
somatic O 0 9.532242256682366e-05
mosaicism O 0 0.005474267527461052
to O 0 3.247826612096105e-07
increase O 0 8.740323096390057e-07
with O 0 1.9279255525361805e-07
the O 0 1.9239912774082768e-07
age O 0 4.7515072765236255e-06
of O 0 6.142647634987952e-07
the O 0 1.3887198292650282e-05
mouse O 0 0.0024625174701213837
. O 0 5.025022619520314e-05

Furthermore O 0 0.00015080851153470576
, O 0 3.142860805382952e-06
we O 0 2.994298711200827e-07
observed O 0 1.5231685210892465e-06
no O 0 2.5928974878297595e-07
correlation O 0 4.907313382318534e-07
between O 0 2.6355738214078883e-07
the O 0 1.039788458001567e-06
somatic O 0 5.322251672623679e-05
mutation O 0 7.092086889315397e-05
rate O 0 4.784142583957873e-05
and O 0 2.0267283616703935e-05
tissue O 1 0.909565806388855
proliferation O 0 0.07866858690977097
capacity O 0 0.00012578268069773912
. O 0 6.167624815134332e-05

The O 0 2.3882408640929498e-05
somatic O 0 0.0003606663376558572
mutation O 0 0.0002074192016152665
rates O 0 3.15585893986281e-05
in O 0 5.679519290424651e-07
different O 0 2.7652151857182616e-07
tissues O 0 0.0002794730244204402
were O 0 5.077236551187525e-07
also O 0 4.0483664065504854e-07
not O 0 8.006129803561635e-08
correlated O 0 9.917296210915083e-07
to O 0 4.424450494866505e-08
the O 0 2.2554095835403132e-07
relative O 0 1.1413709216867574e-05
inter O 0 0.0007713347440585494
- O 0 0.0021612709388136864
tissue O 0 0.00039539008866995573
difference O 0 1.044032387653715e-06
in O 0 2.3404666649184946e-07
transcriptional O 0 1.0144298357772641e-05
levels O 0 1.3701221632800298e-06
of O 0 3.878651355648799e-08
the O 0 2.1102634661929187e-07
three O 0 3.546413154253969e-07
genes O 0 2.231810185548966e-06
( O 0 3.6164638004265726e-06
DMAHP O 0 0.004501614253968
, O 0 3.723271674971329e-06
DMPK O 0 0.0021262820810079575
and O 0 1.17466015581158e-06
59 O 0 2.6683745090849698e-05
) O 0 1.194054107145348e-06
surrounding O 0 5.783181677543325e-06
the O 0 5.795554898213595e-06
repeat O 0 0.0007415422587655485
. O 0 8.721623999008443e-06
. O 0 3.289914093329571e-05

A O 0 0.00013098308409098536
novel O 0 0.00012307331780903041
missense O 0 0.003080903785303235
mutation O 0 0.0008427451248280704
in O 0 5.325048914528452e-05
patients O 0 0.2232750654220581
from O 0 2.2343647287925705e-05
a O 0 0.0006881219451315701
retinoblastoma B-Disease 1 0.9953393936157227
pedigree O 0 0.04331348463892937
showing O 0 8.905782306101173e-05
only O 0 3.4497127217036905e-06
mild O 0 0.08263342827558517
expression O 0 8.193586836569011e-06
of O 0 4.922461812384427e-06
the O 0 0.0009544874774292111
tumor B-Disease 1 0.9985373020172119
phenotype O 0 0.338142067193985
. O 0 0.00026586803141981363

We O 0 2.7304513423587196e-06
have O 0 2.2205570360256388e-07
used O 0 3.1961809554559295e-07
single O 0 5.895518597753835e-07
strand O 0 7.065935733407969e-06
conformation O 0 6.107801709731575e-06
polymorphism O 0 1.5964495787557098e-06
analysis O 0 1.507763585095745e-07
to O 0 5.8062983754325614e-08
study O 0 2.7933955948356015e-07
the O 0 8.931483108653993e-08
27 O 0 8.982723898043332e-07
exons O 0 1.0552677167652291e-06
of O 0 1.55494589648697e-07
the O 0 7.743705282337032e-06
RB1 O 1 0.9715607166290283
gene O 0 1.092863385565579e-05
in O 0 6.616180598939536e-07
individuals O 0 4.927196641801856e-07
from O 0 1.3539955716623808e-06
a O 0 1.6138057617354207e-05
family O 0 8.756310126045719e-05
showing O 0 0.00034876781865023077
mild O 0 0.33391430974006653
expression O 0 5.8997197811549995e-06
of O 0 1.9507531305862358e-06
the O 0 0.00016780082660261542
retinoblastoma B-Disease 1 0.9905283451080322
phenotype O 0 0.3244156539440155
. O 0 0.0004102506791241467

In O 0 2.4824850697768852e-05
this O 0 1.0109530194313265e-05
family O 0 0.00025943294167518616
affected O 0 0.00033868919126689434
individuals O 0 3.088879748247564e-05
developed O 0 0.018540332093834877
unilateral B-Disease 1 0.7140538692474365
tumors I-Disease 1 0.9998237490653992
and O 0 4.227600584272295e-06
, O 0 8.417142112193687e-07
as O 0 3.135037047741207e-07
a O 0 7.299361186596798e-07
result O 0 8.811041993794788e-07
of O 0 1.598901206989467e-07
linkage O 0 0.00010628049494698644
analysis O 0 2.597082357169711e-06
, O 0 7.3476744546496775e-06
unaffected O 0 0.004028167575597763
mutation O 0 0.0004641577252186835
carriers O 0 0.0001144785710494034
were O 0 4.689884747222095e-07
also O 0 5.639982418870204e-07
identified O 0 1.5730845461803256e-06
within O 0 4.057155251757649e-07
the O 0 7.252022896864219e-06
pedigree O 0 0.007608616258949041
. O 0 6.474526890087873e-05

A O 0 4.639796679839492e-05
single O 0 5.958615929557709e-06
band O 0 1.848581996455323e-05
shift O 0 8.282409908133559e-06
using O 0 3.379993586349883e-06
SSCP O 0 0.0046252659521996975
was O 0 1.4451372408075258e-05
identified O 0 3.084504442085745e-06
in O 0 5.845791406500211e-07
exon O 0 7.960055518196896e-05
21 O 0 2.9589591576950625e-06
which O 0 1.708155110691223e-07
resulted O 0 2.447355882395641e-06
in O 0 2.5241186563107476e-07
a O 0 1.1616804158620653e-06
missense O 0 2.2527176042785868e-05
mutation O 0 5.325326583260903e-06
converting O 0 5.329045052349102e-06
a O 0 7.413136336253956e-05
cys O 1 0.8175824880599976
- O 0 0.0042533958330750465
- O 0 0.00022433206322602928
> O 0 5.573536691372283e-05
arg O 0 2.9028324206592515e-05
at O 0 3.978576614827034e-07
nucleotide O 0 7.70101962643821e-07
position O 0 6.254046525100421e-07
28 O 0 2.938775423899642e-06
in O 0 4.736848211450706e-07
the O 0 2.6928023544314783e-06
exon O 0 0.0006941960309632123
. O 0 7.868120883358642e-05

The O 0 5.854451592313126e-05
mutation O 0 0.0002649098460096866
destroyed O 0 0.00020925843273289502
an O 0 7.879638360464014e-06
NdeI O 0 0.0012462278828024864
restriction O 0 5.9893238358199596e-05
enzyme O 0 0.00015917790005914867
site O 0 9.834132652031258e-05
. O 0 5.447279181680642e-05

Analysis O 0 4.340241957834223e-06
of O 0 7.915676292213902e-07
all O 0 4.2581922343742917e-07
family O 0 6.713312814099481e-06
members O 0 6.695581191706879e-07
demonstrated O 0 3.033546136066434e-06
that O 0 4.2915240783258923e-07
the O 0 2.109930392180104e-06
missense O 0 0.00039807925350032747
mutation O 0 0.0005888183368369937
co O 0 0.008726914413273335
- O 0 0.006980272941291332
segregated O 0 0.0010022659553214908
with O 0 0.00029757802258245647
patients O 1 0.997177243232727
with O 0 0.013197405263781548
tumors B-Disease 1 0.9998626708984375
or O 0 0.00010439613834023476
who O 0 7.063698831188958e-06
, O 0 5.270123892842093e-07
as O 0 1.629491634957958e-07
a O 0 5.048970024290611e-07
result O 0 1.1791350971179781e-06
of O 0 2.49315633027436e-07
linkage O 0 9.001055877888575e-05
analysis O 0 3.8119151213322766e-06
had O 0 7.494536475860514e-06
been O 0 1.321248646490858e-06
predicted O 0 5.7342440413776785e-06
to O 0 1.039617458786779e-07
carry O 0 1.076442345038231e-06
the O 0 3.9199990169436205e-06
predisposing O 0 0.0014038593508303165
mutation O 0 0.0006523205083794892
. O 0 9.20817328733392e-05

These O 0 6.856487289041979e-07
observations O 0 1.2282667967156158e-06
point O 0 9.928727422447992e-07
to O 0 1.5460355484719912e-07
another O 0 6.49738922220422e-07
region O 0 4.7533021074741555e-07
of O 0 1.2989977449251455e-07
the O 0 6.102031420596177e-06
RB1 O 1 0.9253896474838257
gene O 0 1.2778709788108245e-05
where O 0 8.141781222548161e-07
mutations O 0 2.772413154161768e-06
only O 0 6.106841254904793e-08
modify O 0 1.569393816680531e-06
the O 0 1.0962259011648712e-07
function O 0 1.2648300184991967e-07
of O 0 3.0797753680644746e-08
the O 0 7.765505642964854e-07
gene O 0 4.854453891312005e-06
and O 0 3.078519057453377e-07
raise O 0 1.8178548089053947e-06
important O 0 1.0850219922531323e-07
questions O 0 5.824611548632674e-07
for O 0 4.593164533162053e-07
genetic O 0 0.00013122998643666506
counseling O 0 0.000132814166136086
in O 0 1.3240110092738178e-06
families O 0 1.4016145541972946e-06
with O 0 8.701699130142515e-07
these O 0 1.2855709883297095e-06
distinctive O 0 0.0009386863675899804
phenotypes O 0 0.008946982212364674
. O 0 4.304030881030485e-05
. O 0 0.00010819781164173037

Maternal B-Disease 0 0.36100560426712036
disomy I-Disease 1 0.9586054682731628
and O 0 0.06750591099262238
Prader B-Disease 1 0.999727189540863
- I-Disease 1 0.999448835849762
Willi I-Disease 1 0.9998316764831543
syndrome I-Disease 1 0.9999072551727295
consistent O 0 0.0002713095163926482
with O 0 2.300536652910523e-05
gamete O 0 0.013677442446351051
complementation O 0 0.2793791592121124
in O 0 1.7398247109667864e-06
a O 0 3.4868669445131673e-06
case O 0 3.818649929598905e-06
of O 0 6.716667257933295e-07
familial O 0 0.1159137561917305
translocation O 0 0.0026727260556071997
( O 0 8.021199391805567e-06
3 O 0 4.339533916208893e-06
; O 0 7.717944185969827e-07
15 O 0 1.6976556480585714e-06
) O 0 1.0706006605687435e-06
( O 0 1.8056133512800443e-06
p25 O 0 0.0004208721802569926
; O 0 2.0372831386339385e-06
q11 O 0 5.321069329511374e-05
. O 0 1.0606950127112214e-06
2 O 0 5.387385499489028e-06
) O 0 4.165492555330275e-06
. O 0 1.2064093425578903e-05

Maternal B-Disease 1 0.5155735611915588
uniparental I-Disease 1 0.9792977571487427
disomy I-Disease 1 0.8141599297523499
( I-Disease 0 0.0012658551568165421
UPD I-Disease 1 0.9935665726661682
) I-Disease 0 5.178371793590486e-06
for I-Disease 0 5.348768468138587e-07
chromosome I-Disease 0 3.0242477805586532e-05
15 I-Disease 0 1.176282239612192e-06
is O 0 1.8740847451681475e-07
responsible O 0 3.3481384775768674e-07
for O 0 3.9407535012969674e-08
an O 0 1.7920986294939212e-07
estimated O 0 1.1447887118265498e-06
30 O 0 4.1374437387275975e-07
% O 0 2.305566084714883e-07
of O 0 3.498460898754274e-07
cases O 0 9.283981489716098e-05
of O 0 0.00040047973743639886
Prader B-Disease 1 0.9998751878738403
- I-Disease 1 0.9996664524078369
Willi I-Disease 1 0.9998378753662109
syndrome I-Disease 1 0.9999657869338989
( O 1 0.9176898002624512
PWS B-Disease 1 0.9994552731513977
) O 0 0.0006967069348320365
. O 0 0.00017500261310487986

We O 0 5.1553997764131054e-06
report O 0 3.1362649224320194e-06
on O 0 4.111589362310042e-07
an O 0 4.941252313983568e-07
unusual O 0 3.901221134583466e-06
case O 0 5.046763817517785e-06
of O 0 1.394202286064683e-06
maternal B-Disease 0 0.0050709787756204605
disomy I-Disease 0 0.037191830575466156
15 I-Disease 0 6.499711889773607e-05
in O 0 6.578140892088413e-05
PWS B-Disease 1 0.9992916584014893
that O 0 1.2015052561764605e-06
is O 0 4.76606629717935e-07
most O 0 1.8258873524246155e-07
consistent O 0 1.7733291315380484e-06
with O 0 6.894557031955628e-07
adjacent O 0 2.2606158381677233e-05
- O 0 5.724668881157413e-05
1 O 0 1.0129703014172264e-06
segregation O 0 1.0191725777985994e-05
of O 0 1.2637353563604847e-07
a O 0 1.1092976819782052e-05
paternal O 0 0.0008728053071536124
t O 0 0.007493630982935429
( O 0 1.5402739563796786e-06
3 O 0 1.380965386488242e-06
; O 0 4.578426455736917e-07
15 O 0 8.573346121920622e-07
) O 0 7.585097705486987e-07
( O 0 1.1328507980579161e-06
p25 O 0 0.0002303384244441986
; O 0 1.0660199905032641e-06
q11 O 0 3.3405300200683996e-05
. O 0 1.6308783301610674e-07
2 O 0 3.8051993556109664e-07
) O 0 1.259870145986497e-07
with O 0 1.4595556763197237e-07
simultaneous O 0 1.6426522506662877e-06
maternal O 0 0.0005288782413117588
meiotic O 0 0.02114992029964924
nondisjunction O 0 0.005010645836591721
for O 0 7.003250175330322e-06
chromosome O 0 0.000475002103485167
15 O 0 5.9865196817554533e-05
. O 0 5.173626050236635e-05

The O 0 0.0001650659105507657
patient O 0 0.03680083900690079
( O 0 8.706586231710389e-05
J O 0 0.08305323123931885
. O 0 1.6830890672281384e-06
B O 0 2.7945759939029813e-05
. O 0 1.9329957012814702e-07
) O 0 1.6954037107552722e-07
, O 0 9.851615345723985e-08
a O 0 2.540579544074717e-06
17 O 0 2.0328217942733318e-05
- O 0 0.00019016058649867773
year O 0 1.4445942724705674e-05
- O 0 0.00045595283154398203
old O 0 0.00020656915148720145
white O 0 0.0004373785632196814
male O 0 7.916778122307733e-05
with O 0 0.00016434912686236203
PWS B-Disease 1 0.9997411370277405
, O 0 1.3444120668282267e-05
was O 0 1.2955219972354826e-05
found O 0 6.896582362969639e-07
to O 0 6.9139687752795e-08
have O 0 6.468676616577795e-08
47 O 0 7.489896916013095e-07
chromosomes O 0 6.407035471056588e-07
with O 0 3.899819489561196e-07
a O 0 1.0599846063996665e-05
supernumerary O 0 0.004231852479279041
, O 0 4.413710030348739e-06
paternal O 0 0.00044098839862272143
der O 0 0.0025556094478815794
( O 0 1.072868599294452e-06
15 O 0 4.876206389781146e-07
) O 0 4.236997952489219e-08
consisting O 0 4.641872664024049e-08
of O 0 3.5941447151799366e-08
the O 0 8.060675327214994e-07
short O 0 2.857897743524518e-05
arm O 0 0.00048488005995750427
and O 0 4.169202441062225e-07
the O 0 2.5930187348421896e-06
proximal O 0 0.01104784570634365
long O 0 0.0008689251844771206
arm O 0 0.0010960705112665892
of O 0 1.1672351547531434e-06
chromosome O 0 0.00018284942780155689
15 O 0 5.622407115879469e-06
, O 0 2.3126644919102546e-06
and O 0 2.8199742700962815e-06
distal O 0 0.08245068788528442
chromosome O 0 0.14445054531097412
arm O 1 0.9608063697814941
3p O 1 0.9691420793533325
. O 0 0.0004021193308290094

The O 0 0.00019023657660000026
t O 0 0.03412582352757454
( O 0 7.617656592628919e-06
3 O 0 2.5304432256234577e-06
; O 0 6.052687808733026e-07
15 O 0 6.16354952853726e-07
) O 0 2.987988807490183e-07
was O 0 5.998287520014856e-07
present O 0 1.3047647939856688e-07
in O 0 5.995856611207273e-08
the O 0 1.148519430671513e-07
balanced O 0 1.9794179024756886e-06
state O 0 7.777512109896634e-07
in O 0 1.6560790072617237e-06
the O 0 2.939498153864406e-05
patients O 0 0.23848459124565125
father O 0 0.00011824719695141539
and O 0 2.219120460722479e-06
a O 0 4.8853777116164565e-05
sister O 0 0.001033283770084381
. O 0 8.329126285389066e-05

Fluorescent O 0 0.0004787705256603658
in O 0 6.278413820837159e-06
situ O 0 0.00019464120850898325
hybridization O 0 6.433549970097374e-06
analysis O 0 3.936673692805925e-06
demonstrated O 0 2.1995736460667104e-05
that O 0 2.917945266744937e-06
the O 0 6.187258259160444e-05
PWS B-Disease 1 0.9984961748123169
critical O 0 9.240570943802595e-05
region O 0 1.0656993254087865e-05
resided O 0 3.084249692619778e-05
on O 0 4.304074252559076e-07
the O 0 4.717800550224638e-07
derivative O 0 1.7754933651303872e-05
chromosome O 0 2.2601931050303392e-05
3 O 0 1.7788985360311926e-06
and O 0 1.5418216037232924e-07
that O 0 8.306785304057485e-08
there O 0 1.829483124993203e-07
was O 0 1.57176202719711e-06
no O 0 5.645654255204136e-07
deletion O 0 9.523141670797486e-06
of O 0 5.750694072048645e-07
the O 0 6.137899617897347e-05
PWS B-Disease 1 0.9989379048347473
region O 0 3.4196366414107615e-06
on O 0 2.7419645221016253e-07
the O 0 2.3566533968732983e-07
normal O 0 3.5231471429142402e-06
pair O 0 2.5480094336671755e-06
of O 0 7.271485742421646e-07
15s O 0 0.0015005847672000527
present O 0 2.0090492398594506e-05
in O 0 4.479314520722255e-05
J O 1 0.9376978874206543
. O 0 7.575377821922302e-05

B O 0 0.034038543701171875
. O 0 0.0012031960068270564

Methylation O 0 3.1725852750241756e-05
analysis O 0 2.7719029276340734e-06
at O 0 4.690864898293512e-06
exon O 0 3.799497790168971e-05
alpha O 0 2.8912920697621303e-06
of O 0 9.24064238461142e-08
the O 0 1.3861535990145057e-06
small O 0 1.075641284842277e-05
nuclear O 0 0.00041957167559303343
ribonucleoprotein O 0 0.35068830847740173
- O 0 0.00021715006732847542
associated O 0 8.687447916599922e-06
polypeptide O 0 0.0001381920010317117
N O 0 7.104595715645701e-05
( O 0 5.037176379119046e-06
SNRPN O 0 0.0015530982054769993
) O 0 1.1554168395377928e-06
gene O 0 5.8880846154352184e-06
showed O 0 5.536428034247365e-06
a O 0 1.1198886795682483e-06
pattern O 0 9.973511623684317e-06
characteristic O 0 2.8500494408945087e-06
of O 0 6.766545368463994e-08
only O 0 2.624047397148388e-07
the O 0 1.6611280670986162e-06
maternal O 0 0.0005659460439346731
chromosome O 0 0.00011187539348611608
15 O 0 2.1161380573175848e-05
in O 0 1.770692688296549e-05
J O 1 0.8887067437171936
. O 0 6.382622814271599e-05

B O 0 0.03326547518372536
. O 0 0.0007466648239642382

Maternal B-Disease 0 0.06001509726047516
disomy I-Disease 0 0.14173199236392975
was O 0 0.00023883550602477044
confirmed O 0 3.370532067492604e-05
by O 0 1.8413084035273641e-06
polymerase O 0 0.00010975990880979225
chain O 0 7.116176857380196e-05
reaction O 0 3.842376372631406e-06
analysis O 0 4.500249985994742e-07
of O 0 4.9698871862347e-07
microsatellite O 0 0.00045416218927130103
repeats O 0 5.675551437889226e-05
at O 0 2.5900208129314706e-06
the O 0 1.8599666873342358e-06
gamma O 0 7.046569226076826e-05
- O 0 6.389491318259388e-05
aminobutyric O 0 0.00014668982475996017
acid O 0 5.2298331866040826e-05
receptor O 0 3.0506300390698016e-05
beta3 O 0 0.00012656470062211156
subunit O 0 1.9378332581254654e-05
( O 0 1.8033995729638264e-05
GABRB3 O 0 0.006735169794410467
) O 0 1.6824244085000828e-05
locus O 0 0.0002869708987418562
. O 0 4.9844176828628406e-05

A O 0 0.00026947297737933695
niece O 0 0.006560289300978184
( O 0 3.4460859751561657e-05
B O 0 0.0004115066840313375
. O 0 1.668025674916862e-06
B O 0 2.0756051526404917e-05
. O 0 7.770604071311027e-08
) O 0 3.862822595124271e-08
with O 0 3.473168419532158e-08
45 O 0 1.6808485270303208e-07
chromosomes O 0 1.9608312129548722e-07
and O 0 3.9092363124382246e-08
the O 0 1.0353392099204939e-07
derivative O 0 4.29367082688259e-06
3 O 0 8.306942049784993e-07
but O 0 1.6459503626720107e-07
without O 0 1.9137836204663472e-07
the O 0 1.9502399482007604e-06
der O 0 0.0006579912733286619
( O 0 8.691464472576627e-07
15 O 0 5.951432626716269e-07
) O 0 3.7510352512981626e-07
demonstrated O 0 2.5896699753502617e-06
a O 0 3.6500732676358894e-06
phenotype O 0 0.00018310239829588681
consistent O 0 3.2848715818545315e-06
with O 0 6.256862548070785e-07
that O 0 9.102054718823638e-07
reported O 0 9.654327186581213e-06
for O 0 4.7074323106244265e-07
haploinsufficiency O 0 0.0003191582509316504
of O 0 1.3444149544739048e-06
distal O 0 0.06274185329675674
3 O 0 0.0006192127475515008
p O 0 0.015229250304400921
. O 0 9.555184078635648e-05

Uniparental B-Disease 1 0.9892212152481079
disomy I-Disease 1 0.9795140027999878
associated O 0 0.0005828258581459522
with O 0 3.7995483580743894e-05
unbalanced O 0 0.015112909488379955
segregation O 0 0.0011508535826578736
of O 0 4.829527370020514e-06
non O 0 0.00037764690932817757
- O 0 0.004834165330976248
Robertsonian O 0 0.006445643957704306
translocations O 0 0.00047766504576429725
has O 0 1.1276983059360646e-05
been O 0 1.0154007213714067e-05
reported O 0 9.801095438888296e-05
previously O 0 1.3879505786462687e-05
but O 0 1.5231191810016753e-06
has O 0 5.657598194375169e-07
not O 0 8.43310985487733e-08
, O 0 3.944303017533457e-08
to O 0 1.6663332047528456e-08
our O 0 4.0288767877427745e-08
knowledge O 0 2.63263473243569e-07
, O 0 3.0959486707615724e-07
been O 0 3.2180497555600596e-07
observed O 0 1.0171160056415829e-06
in O 0 5.044272484155954e-07
a O 0 9.160739864455536e-06
case O 0 4.364288179203868e-05
of O 0 5.0967773859156296e-05
PWS B-Disease 1 0.9979313611984253
. O 0 0.0006555145373567939

Furthermore O 0 0.0004303563910070807
, O 0 1.25515352920047e-05
our O 0 2.4200251118600136e-06
findings O 0 8.658076694700867e-06
are O 0 8.269004325711649e-08
best O 0 5.041098916080955e-07
interpreted O 0 1.3712840427615447e-06
as O 0 8.150117309924099e-07
true O 0 8.158156560966745e-06
gamete O 0 0.001426219241693616
complementation O 0 0.34910014271736145
resulting O 0 0.0020239371806383133
in O 0 0.00012945517664775252
maternal B-Disease 1 0.9216701984405518
UPD I-Disease 1 0.9956426620483398
15 I-Disease 0 0.0006965482025407255
and O 0 0.0005161490407772362
PWS B-Disease 1 0.9908283948898315

Schwartz B-Disease 1 0.9330474734306335
- I-Disease 1 0.9908305406570435
Jampel I-Disease 1 0.9951491951942444
syndrome I-Disease 1 0.999771773815155
type I-Disease 0 0.04301706701517105
2 I-Disease 0 0.0004672037612181157
and O 0 0.0002388967841397971
Stuve B-Disease 1 0.9944256544113159
- I-Disease 1 0.9975646734237671
Wiedemann I-Disease 1 0.9989123344421387
syndrome I-Disease 1 0.9999123811721802
: O 0 3.944980926462449e-05
a O 0 1.043936481437413e-05
case O 0 2.0985777155146934e-05
for O 0 1.449054025215446e-06
" O 0 1.4165793800202664e-05
lumping O 0 0.0009795257356017828
" O 0 3.8599027902819216e-05
. O 0 2.4151619072654285e-05

Recent O 0 7.066332182148471e-05
studies O 0 8.928082934289705e-06
demonstrated O 0 4.5663014134333935e-06
the O 0 5.962191949038242e-07
existence O 0 1.5370778783108108e-06
of O 0 2.5097261868722853e-07
a O 0 7.2348084358964115e-06
genetically O 0 1.908868034661282e-05
distinct O 0 2.0298400613683043e-06
, O 0 8.356643093065941e-07
usually O 0 1.066959725903871e-06
lethal O 0 8.187657840608153e-06
form O 0 8.497045200783759e-07
of O 0 1.132376723944617e-06
the O 0 0.00013739877613261342
Schwartz B-Disease 1 0.7118143439292908
- I-Disease 1 0.9866417646408081
Jampel I-Disease 1 0.9956613183021545
syndrome I-Disease 1 0.999852180480957
( O 0 0.013012843206524849
SJS B-Disease 1 0.9964473843574524
) O 0 1.3033091818215325e-05
of O 0 1.8807442756951787e-05
myotonia B-Disease 1 0.9984934329986572
and O 0 0.010619299486279488
skeletal B-Disease 1 0.9996609687805176
dysplasia I-Disease 1 0.9998619556427002
, O 0 6.0512575146276504e-05
which O 0 6.6140764829469845e-06
we O 0 6.106473392719636e-06
called O 0 0.0005615772679448128
SJS B-Disease 1 0.9940049052238464
type I-Disease 0 0.0008772576111368835
2 I-Disease 0 5.786657493445091e-05
. O 0 4.211616032989696e-05

This O 0 0.0014919961104169488
disorder O 1 0.9990252256393433
is O 0 1.2465799954952672e-05
reminiscent O 0 0.00032957218354567885
of O 0 4.9021673476090655e-06
another O 0 0.00047730733058415353
rare O 0 0.13394315540790558
condition O 1 0.9744426012039185
, O 0 3.069929516641423e-05
the O 0 0.00024620845215395093
Stuve B-Disease 1 0.9941902160644531
- I-Disease 1 0.9974738955497742
Wiedemann I-Disease 1 0.9983239769935608
syndrome I-Disease 1 0.999919056892395
( O 0 0.001140702050179243
SWS B-Disease 1 0.992742657661438
) O 0 5.125172719999682e-06
, O 0 5.900389510316018e-07
which O 0 2.763480608791724e-07
comprises O 0 3.73375769413542e-06
campomelia B-Disease 0 0.0016889707185328007
at O 0 4.4639891711995006e-05
birth O 0 0.0026399572379887104
with O 0 0.001289739040657878
skeletal B-Disease 1 0.9995357990264893
dysplasia I-Disease 1 0.999882698059082
, O 0 0.0032593279611319304
contractures B-Disease 1 0.9973471164703369
, O 0 1.4444951375480741e-05
and O 0 5.999716904625529e-06
early B-Disease 0 0.00021425246086437255
death I-Disease 0 0.004846674390137196
. O 0 0.0001302868768107146

To O 0 3.951256076106802e-06
test O 0 7.463432666554581e-06
for O 0 7.42387555874302e-07
possible O 0 5.262718332232907e-06
nosologic O 0 0.0034841822925955057
identity O 0 1.3460939953802153e-05
between O 0 1.7637274140724912e-05
these O 0 5.50524091522675e-05
disorders O 1 0.9998067021369934
, O 0 4.273099420970539e-06
we O 0 2.657587856447208e-07
reviewed O 0 9.328314831691387e-07
the O 0 1.3871000703602476e-07
literature O 0 2.3523152492543886e-07
and O 0 6.884583569899405e-08
obtained O 0 4.125879513594555e-07
a O 0 1.2019155519737978e-06
follow O 0 1.2264899851288646e-06
- O 0 4.7906792133289855e-06
up O 0 7.035772142671703e-08
of O 0 1.1088597595687588e-08
the O 0 1.1910159969374945e-07
only O 0 1.3700250178771967e-07
two O 0 8.868527743288723e-07
surviving O 0 0.01578306406736374
patients O 0 0.06666512787342072
, O 0 1.0413406243969803e-06
one O 0 1.1103104498033645e-06
with O 0 2.8112686777603813e-05
SJS B-Disease 1 0.9961643218994141
type I-Disease 0 8.759683259995654e-05
2 I-Disease 0 1.8918025261882576e-06
at O 0 2.008619048865512e-06
age O 0 6.698335710098036e-06
10 O 0 5.098216320220672e-07
years O 0 6.484550567620317e-07
and O 0 1.0381055659536287e-07
another O 0 9.569395160724525e-07
with O 0 5.071045507065719e-06
SWS B-Disease 1 0.9336539506912231
at O 0 2.5751085559022613e-05
age O 0 0.0002382873499300331
7 O 0 4.061416620970704e-05
years O 0 5.515508382814005e-05
. O 0 3.63639228453394e-05

Patients O 1 0.9865533709526062
reported O 0 0.001438483945094049
as O 0 1.7469341401010752e-05
having O 0 0.00018104362243320793
either O 0 0.0018606262747198343
neonatal O 1 0.9994413256645203
SJS B-Disease 1 0.9986911416053772
or O 0 0.00027080095605924726
SWS B-Disease 1 0.8684234023094177
presented O 0 1.5166925550147425e-05
a O 0 4.946442913933424e-06
combination O 0 3.091334656346589e-05
of O 0 2.405615987299825e-06
a O 0 0.0026515077333897352
severe O 1 0.9992509484291077
, O 0 0.003095504827797413
prenatal O 1 0.9978862404823303
- O 1 0.9991130232810974
onset O 1 0.99978107213974
neuromuscular B-Disease 1 0.9999392032623291
disorder I-Disease 1 0.9999364614486694
( O 0 0.37924113869667053
with O 1 0.8711978197097778
congenital B-Disease 1 0.9999790191650391
joint I-Disease 1 0.9987165927886963
contractures I-Disease 1 0.9997416138648987
, O 1 0.9702595472335815
respiratory O 1 0.999911904335022
and O 0 0.0003465951303951442
feeding O 0 0.0466262511909008
difficulties O 0 0.12151627242565155
, O 0 3.9865815779194236e-05
tendency O 0 0.0013517835177481174
to O 0 2.2346672267303802e-05
hyperthermia B-Disease 1 0.9980442523956299
, O 0 8.338520274264738e-06
and O 0 2.2560902834811714e-06
frequent O 0 8.443637489108369e-05
death O 0 0.0006963848718442023
in O 0 8.97097106644651e-06
infancy O 0 0.010348589159548283
) O 0 2.906474946939852e-06
with O 0 1.401289750901924e-06
a O 0 2.024290370172821e-05
distinct O 0 0.00018585004727356136
campomelic B-Disease 1 0.9798837900161743
- I-Disease 1 0.9732977747917175
metaphyseal I-Disease 1 0.9782472252845764
skeletal I-Disease 1 0.9973394274711609
dysplasia I-Disease 1 0.9991598129272461
. O 0 0.0030976522248238325

The O 0 4.6556078814319335e-06
similarity O 0 8.756360330153257e-06
of O 0 1.1346412520651938e-06
the O 0 2.2292480934993364e-05
clinical O 0 0.0018702949164435267
and O 0 9.061071068572346e-06
radiographic O 0 0.4107302725315094
findings O 0 0.00013453567225951701
is O 0 3.031978394574253e-06
so O 0 2.536449528633966e-06
extensive O 0 8.00370835349895e-05
that O 0 1.045712997438386e-05
these O 0 2.367588967899792e-05
disorders O 1 0.9997385144233704
appear O 0 2.6652716769604012e-05
to O 0 2.644042638166866e-07
be O 0 3.0806748441136733e-07
a O 0 1.8030167439064826e-06
single O 0 4.8375577534898184e-06
entity O 0 7.200520485639572e-05
. O 0 4.800594615517184e-05

The O 0 1.3879054677090608e-05
follow O 0 2.04071584448684e-05
- O 0 4.897500912193209e-05
up O 0 7.615350909873086e-07
observation O 0 1.5054158666316653e-06
of O 0 4.9966907056386844e-08
an O 0 3.5968267297903367e-07
identical O 0 2.2828280634712428e-06
and O 0 3.4020121120192925e-07
unique O 0 2.4968564957816852e-06
pattern O 0 0.00017482198018115014
of O 0 4.186177102383226e-05
progressive O 1 0.9983383417129517
bone B-Disease 1 0.9999045133590698
dysplasia I-Disease 1 0.9998787641525269
in O 0 2.152547131117899e-05
the O 0 1.3123903045197949e-05
two O 0 1.2485669685702305e-05
patients O 0 0.3242684304714203
( O 0 7.544937489001313e-06
one O 0 2.04927505365049e-06
with O 0 5.753247023676522e-05
SJS B-Disease 1 0.9976192116737366
type I-Disease 0 0.00017075517098419368
2 I-Disease 0 3.6557030398398638e-06
, O 0 4.535636719538161e-07
one O 0 1.6370209721117135e-07
with O 0 2.659367510204902e-06
SWS B-Disease 1 0.8694286942481995
) O 0 3.4752806641336065e-06
surviving O 0 0.00014858407666906714
beyond O 0 1.990949022001587e-05
infancy O 0 0.002125375671312213
adds O 0 2.9575334338005632e-05
to O 0 1.0788888005208719e-07
the O 0 2.1429515584259207e-07
evidence O 0 1.1668100796669023e-06
in O 0 2.7361809884496324e-07
favor O 0 9.44249677559128e-07
of O 0 5.956820814390085e-07
identity O 0 5.0366616051178426e-05
. O 0 5.839853474753909e-05

The O 0 3.434138125157915e-05
hypothesis O 0 0.00016661097470205277
that O 0 5.3743609896628186e-05
SWS B-Disease 1 0.985872209072113
and O 0 0.00012722246174234897
SJS B-Disease 1 0.9973819851875305
type I-Disease 0 0.0002742820361163467
2 I-Disease 0 3.161697804898722e-06
are O 0 1.0483729795396357e-07
the O 0 2.3724298898741836e-06
same O 0 6.480172305600718e-05
disorder O 1 0.999663233757019
should O 0 7.52533821923862e-07
be O 0 1.2463041798582708e-07
testable O 0 2.0607262740668375e-06
by O 0 4.427870123890898e-07
molecular O 0 1.441452513972763e-05
methods O 0 5.209785740589723e-06
. O 0 9.323528502136469e-06
. O 0 3.8693746319040656e-05

A O 0 0.0009356692899018526
mouse O 0 0.0017334265867248178
model O 0 0.000572808610741049
of O 0 0.0010880137560889125
severe O 1 0.9997856020927429
von B-Disease 1 0.9998747110366821
Willebrand I-Disease 1 0.9999368190765381
disease I-Disease 1 0.9999849796295166
: O 1 0.9902955293655396
defects O 1 0.9995003938674927
in O 0 0.007494446821510792
hemostasis O 1 0.9988521337509155
and O 0 0.08248867094516754
thrombosis B-Disease 1 0.9996157884597778
. O 0 0.0017628754721954465

von B-Disease 1 0.96368408203125
Willebrand I-Disease 1 0.9877036809921265
factor I-Disease 0 0.007480209693312645
( I-Disease 0 0.005288322456181049
vWf I-Disease 1 0.9887576699256897
) I-Disease 1 0.7989639043807983
deficiency I-Disease 1 0.9998950958251953
causes O 1 0.9991042017936707
severe O 1 0.9999226331710815
von B-Disease 1 0.9999208450317383
Willebrand I-Disease 1 0.9999411106109619
disease I-Disease 1 0.9999711513519287
in O 0 0.002808520570397377
humans O 0 0.0050296476110816
. O 0 0.0004263755108695477

We O 0 1.7565531607033336e-06
generated O 0 1.9439783045527292e-06
a O 0 9.073955880012363e-06
mouse O 0 6.621144711971283e-05
model O 0 6.2571943999500945e-06
for O 0 1.4453510175371775e-06
this O 0 1.4206705600372516e-05
disease O 1 0.9979565143585205
by O 0 2.0138975287409266e-06
using O 0 5.889241492695874e-06
gene O 0 8.189065556507558e-05
targeting O 0 6.950122769922018e-05
. O 0 6.71379457344301e-05

vWf B-Disease 1 0.9713860154151917
- I-Disease 1 0.991712212562561
deficient I-Disease 1 0.9954877495765686
mice O 0 0.032385919243097305
appeared O 0 0.00010660947009455413
normal O 0 4.013037687400356e-05
at O 0 2.0768842659890652e-05
birth O 0 0.0001810905960155651
; O 0 1.2283921932976227e-06
they O 0 1.375667864067509e-07
were O 0 2.6910336714536243e-07
viable O 0 6.550974376295926e-06
and O 0 2.415063590888167e-06
fertile O 0 0.00031492969719693065
. O 0 8.02318609203212e-05

Neither O 0 0.004615391604602337
vWf O 0 0.2077724039554596
nor O 0 0.0041657970286905766
vWf O 0 0.2940775752067566
propolypeptide O 0 0.43500497937202454
( O 0 0.0015213910955935717
von B-Disease 1 0.9758934378623962
Willebrand I-Disease 1 0.9978106617927551
antigen O 1 0.978549063205719
II O 0 0.4913026988506317
) O 0 2.5498300146864494e-06
were O 0 7.52247558466479e-07
detectable O 0 5.4373773309635e-05
in O 0 1.2071906212440808e-06
plasma O 0 0.00016082667571026832
, O 0 4.177108166913968e-06
platelets O 0 0.0017620600992813706
, O 0 2.6822965537576238e-06
or O 0 5.049922037869692e-06
endothelial O 0 0.00406464422121644
cells O 0 3.980549081461504e-06
of O 0 1.5557512256236805e-07
the O 0 6.8498611653922126e-06
homozygous O 0 0.00048472199705429375
mutant O 0 0.004500275943428278
mice O 0 0.01925855129957199
. O 0 0.00011438701767474413

The O 0 0.00015810674813110381
mutant O 0 0.01310998946428299
mice O 1 0.7720693945884705
exhibited O 0 0.17872865498065948
defects O 1 0.9984155893325806
in O 0 7.948586426209658e-05
hemostasis O 1 0.9893398880958557
with O 0 1.4795342394791078e-05
a O 0 0.00046507848310284317
highly O 0 0.0177142471075058
prolonged O 1 0.9987420439720154
bleeding O 1 0.9996021389961243
time O 0 1.3573476280726027e-05
and O 0 1.0186062354478054e-05
spontaneous O 0 0.0018805041909217834
bleeding O 1 0.9981592297554016
events O 0 1.448668513148732e-06
in O 0 3.7662871932298003e-07
approximately O 0 7.459800031028863e-07
10 O 0 1.04898151676025e-06
% O 0 1.9820699890260585e-06
of O 0 4.631270257959841e-06
neonates O 1 0.552014946937561
. O 0 0.0002717035240493715

As O 0 9.694237633084413e-06
in O 0 7.144747996790102e-06
the O 0 4.1976498323492706e-05
human O 0 0.004079677630215883
disease O 1 0.9995110034942627
, O 0 3.1033705454319715e-06
the O 0 3.2133316381077748e-06
factor O 0 2.560206121415831e-05
VIII O 0 0.05926898121833801
level O 0 1.1709072168741841e-05
in O 0 6.640061656071339e-07
these O 0 4.002682203463337e-07
mice O 0 0.0008099994738586247
was O 0 9.982189112633932e-06
reduced O 0 6.339186256809626e-06
strongly O 0 1.076847865988384e-06
as O 0 1.354841288048192e-07
a O 0 2.52851805271348e-07
result O 0 4.061126901433454e-07
of O 0 8.120846217707367e-08
the O 0 1.0140090580534888e-06
lack O 0 1.4424288565351162e-05
of O 0 9.376514071846032e-07
protection O 0 0.00025208553415723145
provided O 0 1.851392698881682e-05
by O 0 3.639896385720931e-05
vWf O 0 0.06898470968008041
. O 0 0.00010033747093984857

Defective O 1 0.9957725405693054
thrombosis B-Disease 1 0.9992468357086182
in O 0 0.0002505892189219594
mutant O 0 0.020706430077552795
mice O 0 0.041753124445676804
was O 0 4.007882671430707e-05
also O 0 1.208397748087009e-06
evident O 0 6.190143722051289e-06
in O 0 1.9544536655757838e-07
an O 0 4.744615580420941e-07
in O 0 1.8077722643283778e-06
vivo O 0 5.727747702621855e-05
model O 0 2.895083525800146e-05
of O 0 0.0001059099959093146
vascular B-Disease 1 0.9998648166656494
injury I-Disease 1 0.9981593489646912
. O 0 0.0010087807895615697

In O 0 9.118161869992036e-06
this O 0 1.7893371477839537e-06
model O 0 1.2604709809238557e-05
, O 0 1.954801746251178e-06
the O 0 4.025554062536685e-06
exteriorized O 0 0.002088369568809867
mesentery O 0 0.010797003284096718
was O 0 0.00013341353042051196
superfused O 0 0.002254482125863433
with O 0 1.6490768757648766e-05
ferric O 1 0.9940170049667358
chloride O 0 0.01020838599652052
and O 0 2.173583425246761e-06
the O 0 2.0020745523652295e-06
accumulation O 0 0.0006088753580115736
of O 0 7.731021469226107e-06
fluorescently O 1 0.8418872952461243
labeled O 0 0.09205567091703415
platelets O 0 0.14484648406505585
was O 0 5.2330957259982824e-05
observed O 0 1.7339960322715342e-05
by O 0 1.1657017239485867e-05
intravital O 0 0.006622447166591883
microscopy O 0 0.0010198714444413781
. O 0 0.00022982730297371745

We O 0 1.2087783034075983e-05
conclude O 0 5.348984996089712e-05
that O 0 1.6656714478813228e-06
these O 0 1.3324777228262974e-06
mice O 0 0.0022841589525341988
very O 0 3.3207983506144956e-05
closely O 0 0.0005099588888697326
mimic O 1 0.9927082657814026
severe O 1 0.9996213912963867
human O 1 0.9932942986488342
von B-Disease 1 0.9998986721038818
Willebrand I-Disease 1 0.9999744892120361
disease I-Disease 1 0.9999793767929077
and O 0 3.226289845770225e-05
will O 0 8.426603699263069e-07
be O 0 1.0139882533621858e-07
very O 0 1.1486376649827434e-07
useful O 0 1.3765340156624006e-07
for O 0 1.1176338432505872e-07
investigating O 0 3.605203346523922e-06
the O 0 3.505668075831636e-07
role O 0 7.783218052281882e-07
of O 0 8.111881015793188e-07
vWf O 0 0.002928704023361206
in O 0 4.628894203051459e-06
normal O 0 0.0001476988400099799
physiology O 0 0.006067581474781036
and O 0 1.9614197299233638e-05
in O 0 0.0009361383272334933
disease O 1 0.9998055100440979
models O 0 0.0005469099851325154
. O 0 1.9076142052654177e-05
. O 0 5.222133040660992e-05

Oral O 0 0.018430165946483612
contraceptives O 0 0.024558600038290024
and O 0 8.925477231969126e-06
the O 0 5.731485362048261e-05
risk O 0 0.046436771750450134
of O 0 0.0021905715111643076
hereditary B-Disease 1 0.9997214674949646
ovarian I-Disease 1 0.9999916553497314
cancer I-Disease 1 0.9999339580535889
. O 0 0.0076093655079603195

Hereditary B-Disease 1 0.9977438449859619
Ovarian I-Disease 1 0.9998891353607178
Cancer I-Disease 1 0.999626874923706
Clinical O 1 0.8045459389686584
Study O 0 0.0009233868331648409
Group O 0 0.000266056478722021
. O 0 0.0002132847293978557

BACKGROUND O 0 0.0009069995139725506
Women O 0 1.8166112567996606e-05
with O 0 2.0084139578102622e-06
mutations O 0 2.051095725619234e-05
in O 0 5.954906896477041e-07
either O 0 1.2088703442714177e-06
the O 0 3.27713996739476e-06
BRCA1 O 0 0.0018169820541515946
or O 0 2.7437613425718155e-06
the O 0 3.9574410948262084e-06
BRCA2 O 0 0.001426145900040865
gene O 0 8.434221854258794e-06
have O 0 6.566465344803873e-07
a O 0 8.068942406680435e-06
high O 0 0.00042117040720768273
lifetime O 0 0.034638725221157074
risk O 0 0.4244358241558075
of O 0 0.008361779153347015
ovarian B-Disease 1 0.9999779462814331
cancer I-Disease 1 0.9998124241828918
. O 0 0.003492519957944751

Oral O 0 0.1622411459684372
contraceptives O 1 0.936819314956665
protect O 0 0.27678704261779785
against O 1 0.9937257170677185
ovarian B-Disease 1 0.9999814033508301
cancer I-Disease 1 0.9999215602874756
in O 0 5.972322105662897e-05
general O 0 5.3119536460144445e-05
, O 0 4.663655545300571e-06
but O 0 7.104654287104495e-07
it O 0 2.1153692841835436e-07
is O 0 3.0293000463643693e-07
not O 0 8.697636388887986e-08
known O 0 1.045336375682382e-06
whether O 0 4.305375682633894e-07
they O 0 1.4093347999732941e-07
also O 0 4.84048371163226e-07
protect O 0 3.8825774026918225e-06
against O 0 1.1631976121861953e-05
hereditary B-Disease 1 0.6996930837631226
forms I-Disease 0 0.002246270189061761
of I-Disease 1 0.6276566982269287
ovarian I-Disease 1 0.9999915361404419
cancer I-Disease 1 0.9999353885650635
. O 0 0.004730638582259417

METHODS O 0 2.5103268853854388e-05
We O 0 5.351428626454435e-06
enrolled O 0 0.0001078790592146106
207 O 0 0.0018150320975109935
women O 0 0.00020466666319407523
with O 0 0.005590375512838364
hereditary B-Disease 1 0.9997255206108093
ovarian I-Disease 1 0.9999932050704956
cancer I-Disease 1 0.9999117851257324
and O 0 3.978337190346792e-06
161 O 0 1.1062571502407081e-05
of O 0 1.2671397087160585e-07
their O 0 1.7562838650064805e-07
sisters O 0 8.435130439465865e-06
as O 0 3.51033833112524e-07
controls O 0 1.9220983631385025e-06
in O 0 5.208486300034565e-07
a O 0 1.6158246580744162e-05
case O 0 0.00036686708335764706
- O 0 0.0005287842941470444
control O 0 2.0185461835353635e-05
study O 0 3.705127164721489e-05
. O 0 4.764409823110327e-05

All O 0 6.668283731414704e-06
the O 0 3.8079131627455354e-05
patients O 0 0.0035429848358035088
carried O 0 7.004773124208441e-06
a O 0 1.0830029168573674e-05
pathogenic O 0 0.00011603214807109907
mutation O 0 3.118727181572467e-05
in O 0 2.0206657609378453e-06
either O 0 1.2797380804840941e-05
BRCA1 O 0 0.0034860570449382067
( O 0 7.765774171275552e-06
179 O 0 4.634657670976594e-05
women O 0 4.9874442993314005e-06
) O 0 1.9129820429952815e-06
or O 0 9.86693976301467e-06
BRCA2 O 0 0.0024262811057269573
( O 0 8.185151273210067e-06
28 O 0 2.659528581716586e-05
women O 0 1.2797222552762832e-05
) O 0 1.0673133147065528e-05
. O 0 4.1545121348463e-05

The O 0 2.4811384719214402e-05
control O 0 5.3655934607377276e-05
women O 0 1.0703376574383583e-05
were O 0 6.041212259333406e-07
enrolled O 0 6.697332992189331e-06
regardless O 0 1.1081060620199423e-06
of O 0 2.310890891976669e-07
whether O 0 2.367046818108065e-06
or O 0 1.5592031559208408e-06
not O 0 2.7401296165407985e-07
they O 0 1.9094483150183805e-07
had O 0 3.8482476156787015e-06
either O 0 8.539070222468581e-06
mutation O 0 0.0002432340115774423
. O 0 4.81131901324261e-05

Lifetime O 0 0.0010827024234458804
histories O 0 0.00011406494013499469
of O 0 5.629349743685452e-06
oral O 0 0.2623631954193115
- O 0 0.03305857628583908
contraceptive O 0 0.0014923426788300276
use O 0 7.115231710486114e-07
were O 0 2.973361290514731e-07
obtained O 0 1.0043178235719097e-06
by O 0 5.249357286629674e-07
interview O 0 9.006734217109624e-06
or O 0 2.477404166256747e-07
by O 0 9.729173200412333e-08
written O 0 3.5782764484793006e-07
questionnaire O 0 1.4004272998136003e-05
and O 0 7.809888415977184e-07
were O 0 1.027144548970682e-06
compared O 0 6.204670353326946e-05
between O 0 5.1878203521482646e-05
patients O 1 0.7432903051376343
and O 0 2.335455292268307e-06
control O 0 3.543544153217226e-05
women O 0 5.223711013968568e-06
, O 0 8.666013968650077e-07
after O 0 7.154743798309937e-06
adjustment O 0 2.376950578764081e-05
for O 0 3.037845885955903e-07
year O 0 1.7025651004587417e-06
of O 0 3.8046115946599457e-07
birth O 0 0.00020946406584698707
and O 0 6.440769539040048e-06
parity O 0 0.0024260724894702435
. O 0 7.890452252468094e-05

RESULTS O 0 0.00021658431796822697
The O 0 1.8131755496142432e-05
adjusted O 0 0.0004542098322417587
odds O 0 0.0034671644680202007
ratio O 0 0.002754796529188752
for O 0 0.2268896996974945
ovarian B-Disease 1 0.9999915361404419
cancer I-Disease 1 0.9999707937240601
associated O 0 0.00016364309703931212
with O 0 6.598738764296286e-07
any O 0 1.437042271845712e-07
past O 0 1.8540325186222617e-07
use O 0 1.5343758263952623e-07
of O 0 4.930458885610278e-07
oral O 0 0.013349218294024467
contraceptives O 0 0.03512756526470184
was O 0 0.0002959796693176031
0 O 0 6.437218689825386e-05
. O 0 3.5363198549021035e-05

5 O 0 3.3915544918272644e-05
( O 0 5.638478342007147e-06
95 O 0 3.4813842830772046e-06
percent O 0 2.367710521866684e-06
confidence O 0 1.824315290832601e-06
interval O 0 1.6621136182948248e-06
, O 0 1.6794608370673814e-07
0 O 0 1.5084856386238243e-07
. O 0 3.0273238138534e-08
3 O 0 9.190231509137448e-08
to O 0 1.326420306924092e-08
0 O 0 2.457913694797753e-07
. O 0 1.563898592849e-07
8 O 0 1.7241728755834629e-06
) O 0 1.739018330226827e-06
. O 0 7.427341188304126e-06

The O 0 0.0001798540324671194
risk O 0 0.01556115411221981
decreased O 0 0.0005844031111337245
with O 0 9.914837164615165e-07
increasing O 0 2.935171096396516e-06
duration O 0 4.686075953941327e-06
of O 0 1.1706068647754364e-07
use O 0 8.886060527402151e-07
( O 0 4.905880814476404e-06
P O 0 0.00017559800471644849
for O 0 6.316082590274164e-07
trend O 0 1.4312326129584108e-05
, O 0 5.790438422081934e-07
< O 0 3.345821824041195e-05
0 O 0 5.825077664667333e-07
. O 0 3.1706002801001887e-07
001 O 0 3.661313894554041e-05
) O 0 1.720072049238297e-07
; O 0 4.881016835156515e-08
use O 0 1.4868412279156473e-08
for O 0 2.321364611646004e-08
six O 0 1.8635694232216338e-07
or O 0 1.8059235173950583e-07
more O 0 4.822384980229799e-08
years O 0 1.553411834720464e-06
was O 0 3.307810175101622e-06
associated O 0 4.7190201257762965e-07
with O 0 1.892957897098313e-07
a O 0 2.569732714619022e-06
60 O 0 5.940091341471998e-06
percent O 0 3.8117934309411794e-05
reduction O 0 0.0010302533628419042
in O 0 2.545479583204724e-05
risk O 0 0.006050372030586004
. O 0 7.244040170917287e-05

Oral O 0 0.13230326771736145
- O 0 0.08977336436510086
contraceptive O 0 0.021709321066737175
use O 0 6.854296225355938e-05
protected O 0 0.2668655514717102
against O 1 0.9838657975196838
ovarian B-Disease 1 0.999988317489624
cancer I-Disease 1 0.9998793601989746
both O 0 1.8776855768010137e-06
for O 0 8.347984703505062e-07
carriers O 0 1.0444314284541178e-05
of O 0 2.984773459502321e-07
the O 0 6.591131295863306e-06
BRCA1 O 0 0.006917084567248821
mutation O 0 5.675048305420205e-05
( O 0 4.143692876823479e-06
odds O 0 3.949573510908522e-05
ratio O 0 2.896082833103719e-06
, O 0 2.9204295515228296e-07
0 O 0 4.5311099938771804e-07
. O 0 1.2588529330059828e-07
5 O 0 3.180182091000461e-07
; O 0 1.7992947221046052e-07
95 O 0 5.065957111582975e-07
percent O 0 6.950248803150316e-07
confidence O 0 7.95341975390329e-07
interval O 0 3.7069844438519794e-07
, O 0 6.925120743517255e-08
0 O 0 1.1525121834665697e-07
. O 0 2.7347299536018e-08
3 O 0 6.954545739290552e-08
to O 0 1.6487081921923163e-08
0 O 0 1.7997786017076578e-07
. O 0 5.205219011372719e-08
9 O 0 2.355938875098218e-07
) O 0 6.116085415897032e-08
and O 0 2.0217894913798773e-08
for O 0 4.529209363113296e-08
carriers O 0 1.9073386283707805e-06
of O 0 5.8847451356314195e-08
the O 0 2.6066031750815455e-06
BRCA2 O 0 0.0015030232025310397
mutation O 0 3.393453880562447e-05
( O 0 4.321845153754111e-06
odds O 0 5.77400169277098e-05
ratio O 0 3.6318790535005974e-06
, O 0 3.342456125210447e-07
0 O 0 2.6575827405395103e-07
. O 0 8.252696659383219e-08
4 O 0 4.1947743056880427e-07
; O 0 1.6718797724024625e-07
95 O 0 5.122213337926951e-07
percent O 0 4.850747359341767e-07
confidence O 0 6.507348189188633e-07
interval O 0 1.0159740213566693e-06
, O 0 1.6083340881323238e-07
0 O 0 1.7402913954356336e-07
. O 0 4.690528498940694e-08
2 O 0 6.727835000219784e-08
to O 0 2.884409333603344e-08
1 O 0 5.37185314897215e-07
. O 0 2.3894500600363244e-07
1 O 0 1.228871497005457e-06
) O 0 2.2488382001029095e-06
. O 0 7.935940629977267e-06

CONCLUSIONS O 0 0.0013090076390653849
Oral O 0 0.05833800882101059
- O 0 0.05642221122980118
contraceptive O 0 0.007911264896392822
use O 0 6.86354633216979e-06
may O 0 3.058366564800963e-05
reduce O 0 0.0001305364421568811
the O 0 2.109147135342937e-05
risk O 0 0.0637190043926239
of O 0 0.006394186057150364
ovarian B-Disease 1 0.9999910593032837
cancer I-Disease 1 0.9999374151229858
in O 0 1.3019364814681467e-05
women O 0 1.1169171557412483e-05
with O 0 3.4916486129077384e-06
pathogenic O 0 0.00018283739336766303
mutations O 0 2.779731403279584e-05
in O 0 2.3484558369091246e-06
the O 0 1.4532012755807955e-05
BRCA1 O 0 0.07527085393667221
or O 0 0.00025330291828140616
BRCA2 O 0 0.0851656123995781
gene O 0 0.004015606828033924

A O 0 0.0004299865395296365
Japanese O 0 0.0007411953993141651
family O 0 0.0001453147706342861
with O 0 7.508327689720318e-05
adrenoleukodystrophy B-Disease 1 0.9981814622879028
with O 0 2.9084133075230056e-06
a O 0 1.149112267739838e-05
codon O 0 4.0563270886195824e-05
291 O 0 0.00012222540681250393
deletion O 0 0.0002789663849398494
: O 0 6.67647964291973e-06
a O 0 1.9856985090882517e-05
clinical O 0 0.0010505178943276405
, O 0 1.0276020475430414e-05
biochemical O 0 0.000721837452147156
, O 0 1.7534001017338596e-05
pathological O 0 0.09252059459686279
, O 0 1.3656625924340915e-05
and O 0 7.991977327037603e-06
genetic O 0 0.0013987201964482665
report O 0 0.00033005609293468297
. O 0 0.0001066100739990361

We O 0 1.7798671251512133e-05
report O 0 2.566831244621426e-05
a O 0 3.0016408345545642e-05
Japanese O 0 0.00021928601199761033
family O 0 0.0002657631121110171
with O 0 0.0009864356834441423
adrenoleukodystrophy B-Disease 1 0.9997153878211975
( O 0 0.05107450857758522
ALD B-Disease 1 0.9995543360710144
) O 0 2.651084741955856e-06
with O 0 3.046404515316681e-07
a O 0 5.770081088485313e-07
three O 0 1.312811690468152e-07
base O 0 1.5729600590930204e-06
pair O 0 4.8192127906077076e-06
deletion O 0 0.00011015351628884673
( O 0 1.1137688488815911e-05
delGAG O 0 0.0004971793387085199
291 O 0 5.6352651881752536e-05
) O 0 1.6962218296612264e-06
in O 0 1.8018720311374636e-06
the O 0 3.947370714740828e-05
ALD B-Disease 1 0.9992932081222534
gene O 0 0.0011522482382133603
. O 0 0.00011523515422595665

A O 0 6.276307976804674e-05
variety O 0 9.131031220022123e-06
of O 0 2.6952170628646854e-06
phenotypes O 0 0.0004486823745537549
were O 0 2.063221700154827e-06
observed O 0 7.683409421588294e-06
within O 0 1.215887436956109e-06
this O 0 3.468333943601465e-06
family O 0 0.00014450437447521836
. O 0 9.549155947752297e-05

While O 0 2.7405987566453405e-05
the O 0 2.6394216547487304e-05
proband O 0 0.023081809282302856
( O 0 8.899270324036479e-05
patient O 0 0.004978921730071306
1 O 0 2.1936788471066393e-05
) O 0 3.7751874515379313e-06
was O 0 1.5072782844072208e-05
classified O 0 1.2423503903846722e-05
as O 0 3.206705230240914e-07
having O 0 1.2200689525343478e-06
a O 0 2.9999121125001693e-06
rare O 0 4.4191256165504456e-05
intermediate O 0 8.721342601347715e-05
type O 0 0.00016178490477614105
of O 0 3.5089701668766793e-06
adult O 0 0.002989930333569646
cerebral O 1 0.9985564351081848
and O 0 0.00043832603842020035
cerebello O 1 0.9961013793945312
- O 1 0.9940217137336731
brain O 1 0.9870610237121582
stem O 0 0.0010146013228222728
forms O 0 1.2523317309387494e-05
, O 0 4.649879429052817e-06
his O 0 1.7547768948134035e-05
younger O 0 0.000280244363239035
brother O 0 0.0004905075184069574
( O 0 4.285257455194369e-05
patient O 0 0.002800628775730729
2 O 0 9.627488907426596e-06
) O 0 1.5397921515614144e-06
and O 0 1.494394609835581e-06
nephew O 0 0.002554256934672594
( O 0 3.470053707133047e-05
patient O 0 0.0022330041974782944
3 O 0 1.105598948925035e-05
) O 0 4.002539299108321e-06
had O 0 2.3264135961653665e-05
a O 0 0.0003217904013581574
childhood O 1 0.9924249649047852
ALD B-Disease 1 0.9994174242019653
type O 1 0.8631175756454468
. O 0 0.0005284111830405891

Another O 0 0.00022793959942646325
nephew O 0 0.00936761312186718
( O 0 7.950967119541019e-05
patient O 0 0.0018535531125962734
4 O 0 6.804584245401202e-06
) O 0 9.264816753784544e-07
of O 0 7.348406256824092e-07
patient O 0 0.006747378967702389
1 O 0 1.658340624999255e-05
was O 0 3.1736748496768996e-05
classified O 0 2.1565783754340373e-05
as O 0 7.052519208627928e-07
having O 0 3.3388766951247817e-06
an O 0 6.3501138356514275e-06
adolescent O 0 0.015582900494337082
form O 0 0.00011455457570264116
. O 0 0.00010182918776990846

The O 0 2.8707992896670476e-05
tau O 0 0.0003164625377394259
level O 0 1.5316027202061377e-05
in O 0 1.9631586383184185e-06
the O 0 1.3355665032577235e-05
cerebrospinal O 1 0.611574113368988
fluid O 0 0.049782875925302505
( O 0 0.0003981493064202368
CSF O 1 0.9014284014701843
) O 0 6.272452992561739e-06
in O 0 4.243089733790839e-06
patient O 0 0.0012375772930681705
1 O 0 5.793073796667159e-06
was O 0 5.344492365111364e-06
as O 0 3.4929431080854556e-07
high O 0 3.176003929183935e-06
as O 0 2.4865786940608814e-07
that O 0 7.5212625461063e-07
of O 0 7.273120445461245e-06
patients O 1 0.9953763484954834
with O 1 0.9092770218849182
Alzheimers B-Disease 1 0.9999740123748779
disease I-Disease 1 0.9999116659164429
( O 0 0.0015105315251275897
AD B-Disease 0 0.007495333906263113
) O 0 5.48635252926033e-05
. O 0 4.170521424384788e-05

His O 0 0.00035148748429492116
brain O 0 0.01986626535654068
magnetic O 0 8.652067481307313e-05
resonance O 0 0.00024288917484227568
image O 0 0.0012117605656385422
( O 0 0.00013983994722366333
MRI O 0 0.3757055997848511
) O 0 4.153303962084465e-05
showed O 0 0.0011952115455642343
abnormalities B-Disease 1 0.7688776850700378
in I-Disease 0 2.195167326135561e-06
the I-Disease 0 6.018823569320375e-06
bilateral I-Disease 0 0.0006901421002112329
cerebellar I-Disease 1 0.9970878958702087
hemispheres I-Disease 0 0.005070439539849758
and O 0 0.0005508656031452119
brain O 1 0.9985698461532593
stem O 0 0.05664515867829323
, O 0 2.76584796665702e-06
but O 0 5.629417501040734e-07
not O 0 1.8738363394277258e-07
in O 0 8.734731409276719e-07
the O 0 5.114154191687703e-05
cerebral O 1 0.999524712562561
white O 0 0.021141506731510162
matter O 0 4.685897692979779e-06
, O 0 7.50852109376865e-07
where O 0 8.259088417617022e-07
marked O 0 1.2436519682523794e-05
reductions O 0 1.2893457096652128e-05
of O 0 3.085897049004416e-07
the O 0 7.264164742082357e-05
cerebral O 1 0.9991959929466248
blood O 0 0.4054153859615326
flow O 0 5.481483822222799e-05
and O 0 3.241314743718249e-06
oxygen O 0 0.0010369705269113183
metabolism O 0 0.000517312902957201
were O 0 8.973707963377819e-07
clearly O 0 3.984229806519579e-06
demonstrated O 0 4.107836957700783e-06
by O 0 1.3124703173161834e-06
positron O 0 0.000397721363697201
emission O 0 8.972278737928718e-05
tomography O 0 0.00028536852914839983
( O 0 6.787179154343903e-05
PET O 0 0.007476142607629299
) O 0 2.8848697184002958e-05
. O 0 3.201995787094347e-05

In O 0 0.00035559094976633787
patients O 0 0.03459155187010765
2 O 0 1.1323160833853763e-05
and O 0 1.2389749599606148e-06
3 O 0 2.820399231495685e-06
, O 0 7.548209168817266e-07
the O 0 1.5085446420926019e-06
autopsy O 0 0.0014936903025954962
findings O 0 0.00015407000319100916
showed O 0 0.0011537555838003755
massive O 0 0.18559865653514862
demyelination B-Disease 1 0.9982689619064331
of I-Disease 0 1.2014378626190592e-05
the I-Disease 0 0.0016945161623880267
cerebral I-Disease 1 0.9992792010307312
white I-Disease 0 0.013823950663208961
matter I-Disease 0 4.313156750868075e-06
with O 0 1.309745698563347e-06
sparing O 0 1.6688079995219596e-05
of O 0 7.881282613197982e-07
the O 0 3.417795596760698e-05
U O 1 0.8270837068557739
- O 0 0.013470366597175598
fibers O 0 0.0009728734148666263
, O 0 4.4086391426390037e-07
compatible O 0 1.5639524235666613e-06
with O 0 5.068721975476365e-07
the O 0 2.27144846576266e-06
findings O 0 3.905083940480836e-05
of O 0 2.7962365493294783e-05
childhood O 1 0.994788408279419
ALD B-Disease 1 0.9993212223052979
. O 0 0.0016582885291427374

Oleic O 0 0.036941684782505035
and O 0 7.872219430282712e-05
erucic O 0 0.12535357475280762
acids O 0 0.00010816491703735664
( O 0 3.656662011053413e-05
Lorenzos O 0 0.0021097592543810606
Oil O 0 1.981831701414194e-05
) O 0 1.1756609410440433e-06
were O 0 5.399330689215276e-07
administered O 0 8.49094067234546e-06
to O 0 1.4003105661686277e-06
patients O 0 0.0015670859720557928
1 O 0 1.8091624269800377e-06
and O 0 2.3289132400350354e-07
4 O 0 2.3372576833935454e-06
, O 0 2.915940342518297e-07
but O 0 4.890121090284083e-07
sufficient O 0 3.97170288124471e-06
effectiveness O 0 5.069090912002139e-05
was O 0 7.867818567319773e-06
not O 0 5.134851903676463e-07
obtained O 0 9.807416063267738e-06
. O 0 2.509517980797682e-05

The O 0 2.0375868189148605e-05
findings O 0 2.9342330890358426e-05
in O 0 1.252406150342722e-06
this O 0 1.035834543472447e-06
family O 0 9.831856914388482e-06
suggest O 0 5.327170129021397e-06
that O 0 3.5822642985294806e-07
delGAG291 O 0 6.70965964673087e-05
is O 0 1.8731591922005464e-07
part O 0 1.6863572227521217e-07
of O 0 9.876863771296485e-08
the O 0 3.364088343005278e-06
cause O 0 0.0006113495910540223
of O 0 4.618549155566143e-06
Japanese O 0 0.07282095402479172
ALD B-Disease 1 0.9990935325622559
with O 0 2.4084136384772137e-05
phenotypic O 0 0.0007976836641319096
variations O 0 0.0007268507033586502
. O 0 0.00036668110988102853

Moreover O 0 0.00026029240689240396
, O 0 3.1079018754098797e-06
although O 0 8.375145057470945e-07
the O 0 3.103534425008547e-07
scale O 0 1.4661867453469313e-06
of O 0 8.223031500165234e-08
the O 0 7.111764830369793e-07
study O 0 2.3562854494230123e-06
is O 0 4.5235111656438676e-07
limited O 0 1.0520221849219524e-06
, O 0 2.625183412874321e-07
there O 0 9.46983291782999e-08
is O 0 2.2043231240331806e-07
a O 0 1.606162072675943e-06
possibility O 0 1.241843438037904e-05
that O 0 2.1532737264351454e-06
PET O 0 0.001247730222530663
can O 0 2.8413542167982087e-06
detect O 0 0.000256733619607985
an O 0 3.3076514228014275e-05
insidious B-Disease 1 0.9853761792182922
lesion I-Disease 1 0.9987350106239319
which O 0 2.9589873520308174e-06
is O 0 5.067453457741067e-06
undetectable O 0 0.0022998005151748657
by O 0 1.0453214827066404e-06
computed O 0 2.902757842093706e-05
tomogram O 0 0.008203902281820774
( O 0 9.539281018078327e-05
CT O 0 0.16809844970703125
) O 0 3.0110502393654315e-06
or O 0 2.103262659147731e-06
MRI O 0 0.0005054952926002443
analysis O 0 5.455708560475614e-07
, O 0 1.0928187776926279e-07
and O 0 3.453279262544129e-08
that O 0 4.106091111566457e-08
the O 0 8.139796392470089e-08
higher O 0 3.7651130924132303e-07
level O 0 4.290165520615119e-07
of O 0 5.4919794933994126e-08
tau O 0 3.4854921977967024e-05
reflects O 0 1.1390701502023148e-06
the O 0 1.2234136193001177e-07
process O 0 7.579088787679211e-07
of O 0 3.7881595744693186e-06
neuronal B-Disease 1 0.6267350316047668
degeneration I-Disease 1 0.9996101260185242
in O 0 0.01917974278330803
ALD B-Disease 1 0.9995688796043396
. O 0 0.0010179242817685008

Lorenzos O 0 0.023241210728883743
Oil O 0 6.37746270513162e-05
should O 0 6.932811515980575e-07
be O 0 7.699566850760675e-08
given O 0 1.234023017104846e-07
in O 0 8.775521820325594e-08
the O 0 2.4352209493372357e-07
early O 0 6.369006314344006e-06
stage O 0 0.00011761722998926416
. O 0 4.466329301067162e-06
. O 0 1.608380625839345e-05

Nonsense O 0 0.0008101471466943622
mutation O 0 6.60660007270053e-05
in O 0 2.2961883132666117e-06
exon O 0 4.858310057898052e-05
4 O 0 2.606116140668746e-06
of O 0 2.866549948521424e-07
human O 0 5.470058567880187e-06
complement O 0 2.8575599571922794e-05
C9 O 0 0.28162896633148193
gene O 0 2.1047910195193253e-05
is O 0 1.2863191614087555e-06
the O 0 2.1670969090337167e-06
major O 0 4.153751797275618e-05
cause O 0 0.0002990680804941803
of O 0 4.346766218077391e-06
Japanese O 0 0.007122072856873274
complement B-Disease 0 0.06451607495546341
C9 I-Disease 1 0.9984772801399231
deficiency I-Disease 1 0.9996918439865112
. O 0 0.000907765468582511

Deficiency B-Disease 1 0.9971990585327148
of I-Disease 0 2.002147084567696e-06
the I-Disease 0 2.8318750082689803e-06
ninth I-Disease 0 4.377217555884272e-05
component I-Disease 0 4.719119715446141e-06
of I-Disease 0 2.816351809542539e-07
human I-Disease 0 3.4549902920844033e-06
complement I-Disease 0 1.3533781384467147e-05
( O 0 1.5185276424745098e-05
C9 O 0 0.18416433036327362
) O 0 4.386320142657496e-07
is O 0 8.590241407091526e-08
the O 0 2.913488970079925e-07
most O 0 6.849480769233196e-07
common O 0 0.00011449778685346246
complement B-Disease 1 0.927760660648346
deficiency I-Disease 1 0.9999678134918213
in O 0 1.2760076970153023e-05
Japan O 0 0.00012186300591565669
but O 0 1.4859460861771367e-06
is O 0 1.453222353120509e-06
rare O 0 3.267651845817454e-05
in O 0 6.73124873173947e-07
other O 0 3.681996645354957e-07
countries O 0 1.8300728470421745e-06
. O 0 4.874265141552314e-05

We O 0 3.1565161862090463e-06
studied O 0 1.4142857480692328e-06
the O 0 4.617597539890994e-07
molecular O 0 3.2779810226202244e-06
basis O 0 9.674663488112856e-07
of O 0 3.159216794301756e-05
C9 B-Disease 1 0.9987989664077759
deficiency I-Disease 1 0.99969482421875
in O 0 1.6883856005733833e-05
four O 0 4.8215581045951694e-05
Japanese O 0 0.3246953785419464
C9 B-Disease 1 0.9990113973617554
- I-Disease 1 0.9986593723297119
deficient I-Disease 1 0.9993070363998413
patients O 1 0.9972073435783386
who O 0 0.002277717227116227
had O 0 0.0906723290681839
suffered O 1 0.9993225336074829
from O 0 0.16776388883590698
meningococcal B-Disease 1 0.9997920393943787
meningitis I-Disease 1 0.9996908903121948
. O 0 0.0028384672477841377

Direct O 0 5.353669621399604e-06
sequencing O 0 6.565785042766947e-06
of O 0 1.208677872455155e-06
amplified O 0 0.0003291573957540095
C9 O 0 0.007244805805385113
cDNA O 0 2.215772110503167e-05
and O 0 1.2597503200595384e-06
DNA O 0 1.7401798686478287e-05
revealed O 0 2.3173726731329225e-05
a O 0 4.211130544717889e-06
nonsense O 0 2.308655166416429e-05
substitution O 0 8.65775473357644e-06
( O 0 1.0395423487352673e-05
CGA O 0 0.003707048250362277
- O 0 0.0014237738214433193
- O 0 0.00017570218187756836
> O 0 9.533068805467337e-05
TGA O 0 0.000561543507501483
) O 0 2.7502190391714976e-07
at O 0 3.532711900788854e-07
codon O 0 7.951978773235169e-07
95 O 0 4.972333158548281e-07
in O 0 8.675252161083336e-08
exon O 0 8.021237590583041e-06
4 O 0 6.396668936758942e-07
in O 0 1.4094382549956208e-07
the O 0 1.087980763259111e-06
four O 0 2.0775698430952616e-05
C9 B-Disease 1 0.995201587677002
- I-Disease 1 0.8908593654632568
deficient I-Disease 1 0.9406338930130005
individuals O 0 2.59623793681385e-05
. O 0 7.957960769999772e-05

An O 0 2.0145114831393585e-05
allele O 0 0.00011932176857953891
- O 0 5.54390499019064e-05
specific O 0 1.616365011614107e-06
polymerase O 0 0.00017785227100830525
chain O 0 0.000802151276730001
reaction O 0 0.00016560651420149952
system O 0 4.2957766709150746e-05
designed O 0 1.1698925845848862e-05
to O 0 3.7834954014215327e-07
detect O 0 1.3134359505784232e-05
exclusively O 0 1.311337598508544e-07
only O 0 2.5699231187559235e-08
one O 0 3.617687482915244e-08
of O 0 2.227551476607914e-08
the O 0 2.546857160723448e-07
normal O 0 2.8736740205204114e-06
and O 0 4.595815710217721e-07
mutant O 0 1.9272214558441192e-05
alleles O 0 8.515171430190094e-06
indicated O 0 1.192037234432064e-05
that O 0 7.311052030445353e-08
all O 0 2.1188697019169922e-08
the O 0 5.080491405351495e-07
four O 0 2.8435554213501746e-06
patients O 0 0.0017671955283731222
were O 0 3.066037379539921e-07
homozygous O 0 1.616577833374322e-06
for O 0 5.279046888517769e-08
the O 0 2.1994303267547366e-07
mutation O 0 5.3467456382350065e-06
in O 0 4.025536100016325e-07
exon O 0 2.9735829230048694e-05
4 O 0 1.6777910332166357e-06
and O 0 1.0377235071246105e-07
that O 0 5.4554490702685143e-08
the O 0 2.2467237670298346e-07
parents O 0 8.72095654358418e-07
of O 0 5.159030820323096e-07
patient O 0 0.006146478001028299
2 O 0 1.5622526916558854e-05
were O 0 5.326240625436185e-06
heterozygous O 0 0.00012081010936526582
. O 0 4.4460899516707286e-05

The O 0 7.828031812096015e-06
common O 0 1.0485171515028924e-05
mutation O 0 1.78831960511161e-05
at O 0 2.850234295692644e-06
codon O 0 5.94712537349551e-06
95 O 0 2.9728159915975993e-06
in O 0 7.792167480147327e-07
exon O 0 5.8827521570492536e-05
4 O 0 4.4252537918509915e-06
might O 0 1.146153067566047e-06
be O 0 1.1826030998918213e-07
responsible O 0 1.5506648196605965e-06
for O 0 7.025419677120226e-07
most O 0 1.4983880646468606e-05
Japanese O 0 0.17875021696090698
C9 B-Disease 1 0.9988377690315247
deficiency I-Disease 1 0.9997605681419373
. O 0 0.0002118398988386616
. O 0 0.00018116259889211506

BRCA1 O 0 0.004082484170794487
required O 0 1.1566048669919837e-05
for O 0 5.620740012091119e-06
transcription O 0 0.0012244052486494184
- O 0 0.014580913819372654
coupled O 0 0.001918373629450798
repair O 0 0.25994154810905457
of O 0 1.5463936506421305e-05
oxidative O 1 0.9240179061889648
DNA O 0 0.10818056017160416
damage O 1 0.9772697687149048
. O 0 0.00026544660795480013

The O 0 0.017352264374494553
breast B-Disease 1 0.9988837838172913
and I-Disease 1 0.7559268474578857
ovarian I-Disease 1 0.9999551773071289
cancer I-Disease 1 0.9997609257698059
susceptibility O 0 0.43931135535240173
gene O 0 0.0005687245866283774
BRCA1 O 0 0.0024277858901768923
encodes O 0 1.895567220344674e-05
a O 0 6.974502321099862e-05
zinc O 0 0.08594988286495209
finger O 0 0.0004143455298617482
protein O 0 5.747482646256685e-06
of O 0 9.849433126873919e-07
unknown O 0 4.7942081437213346e-05
function O 0 4.474149318411946e-05
. O 0 8.462386176688597e-05

Association O 0 6.0675003624055535e-05
of O 0 4.1853917309708777e-07
the O 0 3.1033853247208754e-06
BRCA1 O 0 0.00042860087705776095
protein O 0 2.1414939510577824e-06
with O 0 3.584215448881878e-07
the O 0 1.8695698145165807e-06
DNA O 0 0.00010156792268389836
repair O 0 0.20152166485786438
protein O 0 8.095913653960451e-05
Rad51 O 0 0.008486021310091019
and O 0 2.719863800848543e-07
changes O 0 4.2081651940861775e-07
in O 0 4.8245194506080225e-08
the O 0 4.4747093141950245e-08
phosphorylation O 0 2.2042054581561388e-07
and O 0 1.1190224569190832e-07
cellular O 0 4.6581394599343184e-06
localization O 0 2.5253998501284514e-06
of O 0 7.394073264777035e-08
the O 0 5.146382022758189e-07
protein O 0 1.0168688277190086e-05
after O 0 2.330559254914988e-05
exposure O 0 0.00037939558387733996
to O 0 1.4585331200578366e-06
DNA O 0 0.00036464829463511705
- O 0 0.001790813752450049
damaging O 0 0.0003209851565770805
agents O 0 2.3021348170004785e-06
are O 0 2.011864808082464e-08
consistent O 0 3.858191917061049e-07
with O 0 1.7982620192924514e-07
a O 0 9.39726476190117e-07
role O 0 2.1281789486238267e-06
for O 0 1.5049020021251636e-06
BRCA1 O 0 0.016461780294775963
in O 0 1.3571419003710616e-05
DNA O 0 0.00450532790273428
repair O 1 0.9870327711105347
. O 0 0.00032301488681696355

Here O 0 3.5563069104682654e-05
, O 0 3.562579649951658e-06
it O 0 7.312557386285334e-07
is O 0 1.212843812936626e-06
shown O 0 4.659565547626698e-06
that O 0 2.1103410290379543e-06
mouse O 0 0.0006233702879399061
embryonic O 0 0.0022588432766497135
stem O 0 0.03210257366299629
cells O 0 0.005883070174604654
deficient B-Disease 1 0.9924969673156738
in I-Disease 0 1.6681986380717717e-05
BRCA1 I-Disease 0 0.04205583781003952
are O 0 1.448704438189452e-06
defective O 0 0.04991469904780388
in O 0 6.582127412002592e-07
the O 0 5.633047521769186e-07
ability O 0 4.967319000570569e-07
to O 0 1.053436164966115e-07
carry O 0 4.762049741202645e-07
out O 0 1.0432081580802333e-06
transcription O 0 0.00011014249321306124
- O 0 0.0010759163415059447
coupled O 0 0.0004596057115122676
repair O 0 0.02190433256328106
of O 0 6.017768100718968e-06
oxidative O 1 0.8593074083328247
DNA O 0 0.3064187169075012
damage O 1 0.9620988368988037
, O 0 5.738768777518999e-06
and O 0 1.4731188002770068e-06
are O 0 4.1076151546803885e-07
hypersensitive O 0 0.0024375037755817175
to O 0 4.572628313326277e-06
ionizing O 0 0.006971330847591162
radiation O 0 0.00590981962159276
and O 0 8.079669896687847e-06
hydrogen O 0 0.0003905656631104648
peroxide O 0 0.0249802079051733
. O 0 0.0001191715564345941

These O 0 5.665163371304516e-06
results O 0 1.3790708180749789e-05
suggest O 0 1.9671126210596412e-05
that O 0 4.48236414740677e-06
BRCA1 O 0 0.008814449422061443
participates O 0 5.4828691645525396e-05
, O 0 1.420797730133927e-06
directly O 0 1.574195152898028e-06
or O 0 1.8822645415639272e-06
indirectly O 0 6.581407433259301e-06
, O 0 6.106154728513502e-07
in O 0 8.904996207093063e-07
transcription O 0 0.00021453233784995973
- O 0 0.0017586002359166741
coupled O 0 0.0004927695845253766
repair O 0 0.04349523410201073
of O 0 6.00130761085893e-06
oxidative O 1 0.6271642446517944
DNA O 0 0.10295028984546661
damage O 1 0.9838893413543701
. O 0 5.444952330435626e-05
. O 0 8.302568312501535e-05

Truncation O 0 0.0028790116775780916
mutations O 0 9.109901293413714e-05
in O 0 2.6700713533500675e-06
the O 0 5.220877028477844e-06
transactivation O 0 0.0014482904225587845
region O 0 1.608368256711401e-05
of O 0 2.9518030260078376e-06
PAX6 O 1 0.7207743525505066
result O 0 6.0430287703638896e-05
in O 0 1.1643161997199059e-05
dominant O 0 0.0018869127379730344
- O 0 0.004895844496786594
negative O 0 6.0764930822188035e-05
mutants O 0 0.0006289812154136598
. O 0 7.892845314927399e-05

PAX6 O 0 0.03921743854880333
is O 0 4.626608188118553e-06
a O 0 4.863722097070422e-06
transcription O 0 1.9978397176600993e-05
factor O 0 2.1583248326351168e-06
with O 0 1.918606074013951e-07
two O 0 1.5022592947389057e-07
DNA O 0 2.92996883217711e-05
- O 0 2.4333634428330697e-05
binding O 0 1.6524362536074477e-06
domains O 0 6.335547823255183e-06
( O 0 3.5639729958347743e-06
paired O 0 5.032230546930805e-05
box O 0 0.00010629255120875314
and O 0 2.3397753921017284e-06
homeobox O 0 0.0015458307461813092
) O 0 7.472738161595771e-07
and O 0 1.6927685919654323e-07
a O 0 2.115620645781746e-06
proline O 0 0.00011485986033221707
- O 0 4.9549355026101694e-05
serine O 0 4.208628524793312e-05
- O 0 4.362007894087583e-05
threonine O 0 2.4524901164113544e-05
( O 0 1.0027760254160967e-05
PST O 0 0.0024040788412094116
) O 0 7.927280421426985e-06
- O 0 6.015218241373077e-05
rich O 0 7.389443908323301e-06
transactivation O 0 0.0005927158636040986
domain O 0 9.33796472963877e-05
. O 0 6.726181163685396e-05

PAX6 O 1 0.9408493638038635
regulates O 0 0.1945987343788147
eye O 1 0.5565229058265686
development O 0 5.850137313245796e-05
in O 0 5.730789325752994e-06
animals O 0 1.0279431080562063e-05
ranging O 0 2.04553798539564e-05
from O 0 7.269014986377442e-06
jellyfish O 0 7.485450623789802e-05
to O 0 4.009635574675485e-07
Drosophila O 0 7.682147952436935e-06
to O 0 1.3381012422541971e-06
humans O 0 4.0351493225898594e-05
. O 0 4.491933941608295e-05

Heterozygous O 0 0.0005276468582451344
mutations O 0 0.00012263657117728144
in O 0 3.3001474548655096e-06
the O 0 5.014581802242901e-06
human O 0 2.9423450541798957e-05
PAX6 O 0 0.3353792726993561
gene O 0 5.149836579221301e-05
result O 0 6.2483509282174055e-06
in O 0 7.350635655711812e-07
various O 0 9.46417799241317e-07
phenotypes O 0 0.0010390289826318622
, O 0 7.2857683335314505e-06
including O 0 1.3070407476334367e-05
aniridia B-Disease 1 0.9950249791145325
, O 0 0.0004349550581537187
Peters B-Disease 1 0.9928273558616638
anomaly I-Disease 1 0.9957367181777954
, O 0 0.0002638275036588311
autosomal B-Disease 1 0.9962149262428284
dominant I-Disease 1 0.8428773880004883
keratitis I-Disease 1 0.9980575442314148
, O 0 0.0002249221142847091
and O 0 0.0001693790836725384
familial B-Disease 1 0.9978713989257812
foveal I-Disease 1 0.9985026121139526
dysplasia I-Disease 1 0.9997761845588684
. O 0 0.008485142141580582

It O 0 1.3559463695855811e-05
is O 0 5.6842013691493776e-06
believed O 0 8.324299415107816e-06
that O 0 2.202986593147216e-07
the O 0 9.06914635834255e-07
mutated O 0 2.9702583560720086e-05
allele O 0 7.001800895523047e-06
of O 0 2.178584963985486e-06
PAX6 O 0 0.04161863401532173
produces O 0 4.2263407522113994e-05
an O 0 5.516290002560709e-06
inactive O 0 0.00020169935305602849
protein O 0 3.1958334147930145e-05
and O 0 8.893504855223e-06
aniridia B-Disease 1 0.9874697923660278
is O 0 4.147529398323968e-05
caused O 0 0.014115137979388237
due O 0 0.00011292491399217397
to O 0 7.213809567474527e-06
genetic O 0 0.0017124980222433805
haploinsufficiency O 0 0.36288681626319885
. O 0 0.0001903202064568177

However O 0 2.5980905775213614e-05
, O 0 2.814493200276047e-06
several O 0 1.418331066815881e-06
truncation O 0 0.0009189809206873178
mutations O 0 0.00011894370254594833
have O 0 1.294095341108914e-06
been O 0 9.616537681722548e-07
found O 0 8.038167607082869e-07
to O 0 8.96505412129045e-08
occur O 0 4.425269537478016e-07
in O 0 2.6531967023402103e-07
the O 0 1.599178744982055e-06
C O 0 0.001445185043849051
- O 0 0.00018902837473433465
terminal O 0 9.49262102949433e-05
half O 0 1.4770774896533112e-06
of O 0 2.49126219387108e-06
PAX6 O 1 0.7879523038864136
in O 0 4.5542394218500704e-05
patients O 0 0.26665300130844116
with O 0 3.2540501706535e-05
Aniridia B-Disease 1 0.9190436005592346
resulting O 0 6.501298048533499e-05
in O 0 9.042873330145085e-07
mutant O 0 9.724654773890506e-06
proteins O 0 4.574982597205235e-07
that O 0 8.016306907165927e-08
retain O 0 8.960093964560656e-07
the O 0 5.57595399186539e-07
DNA O 0 2.3507069272454828e-05
- O 0 2.4448403564747423e-05
binding O 0 8.510313023180061e-07
domains O 0 2.500137497918331e-06
but O 0 2.6319770540794707e-07
have O 0 6.422757792279299e-08
lost O 0 6.367818627950328e-07
most O 0 2.3108990276909935e-08
of O 0 6.929639084773953e-08
the O 0 2.654674744917429e-06
transactivation O 0 0.001307163154706359
domain O 0 7.273285882547498e-05
. O 0 5.646162753691897e-05

It O 0 1.2433923075150233e-05
is O 0 3.065042619709857e-06
not O 0 4.02973824975561e-07
clear O 0 1.9107085336145246e-06
whether O 0 1.029803570418153e-06
such O 0 7.534350743299001e-07
mutants O 0 0.00018423126311972737
really O 0 2.0244604456820525e-05
behave O 0 2.7705798856914043e-05
as O 0 2.110578407155117e-06
loss O 0 0.000493402301799506
- O 0 3.310225292807445e-05
of O 0 2.8651314210037526e-07
- O 0 6.8575594923459e-05
function O 0 1.3099718216835754e-06
mutants O 0 4.412051566760056e-05
as O 0 2.9547095437010285e-06
predicted O 0 0.00012934597907587886
by O 0 1.6994479665299878e-05
haploinsufficiency O 0 0.018475225195288658
. O 0 9.751899051479995e-05

Contrary O 0 2.5531064238748513e-05
to O 0 3.18389055564694e-07
this O 0 2.4281479227283853e-07
theory O 0 7.156048695833306e-07
, O 0 2.724999319525523e-07
our O 0 2.6589515300656785e-07
data O 0 7.138340265555598e-07
showed O 0 3.063908479816746e-06
that O 0 9.987610383177525e-08
these O 0 6.083241999021993e-08
mutants O 0 7.266506145242602e-06
are O 0 1.327911718362884e-07
dominant O 0 1.9262843125034124e-05
- O 0 4.155070928391069e-05
negative O 0 1.7326318584309774e-06
in O 0 7.817862410774978e-07
transient O 0 0.00024139523156918585
transfection O 0 0.0012094542616978288
assays O 0 1.2866631550423335e-05
when O 0 2.4927430786192417e-06
they O 0 1.329678269712531e-07
are O 0 9.623585839335647e-08
coexpressed O 0 0.0001779333542799577
with O 0 4.360038474260364e-06
wild O 0 0.0002515589876566082
- O 0 0.020516591146588326
type O 0 0.006167402025312185
PAX6 O 1 0.8742849230766296
. O 0 0.00019036304729525

We O 0 4.381359303806676e-06
found O 0 3.579672920750454e-06
that O 0 3.0999078148852277e-07
the O 0 1.8246111039843527e-06
dominant O 0 0.00025113747688010335
- O 0 0.0010974089382216334
negative O 0 1.2400138075463474e-05
effects O 0 0.00011900951358256862
result O 0 4.827327302336926e-06
from O 0 9.55222503762343e-07
the O 0 1.0319595276087057e-06
enhanced O 0 1.029457871482009e-05
DNA O 0 5.028536634199554e-06
binding O 0 1.1462776683401898e-06
ability O 0 9.61791329245898e-07
of O 0 2.63673285871846e-07
these O 0 2.3973047973413486e-06
mutants O 0 0.0005442443070933223
. O 0 6.502035830635577e-05

Kinetic O 0 2.6979771064361557e-05
studies O 0 4.61768604509416e-06
of O 0 4.420477921485144e-07
binding O 0 3.8405373743444216e-06
and O 0 1.8877943830375443e-06
dissociation O 0 0.00035836335155181587
revealed O 0 3.873812238452956e-05
that O 0 2.2121572840205772e-07
various O 0 1.242421205915889e-07
truncation O 0 9.747259900905192e-05
mutants O 0 3.979451867053285e-05
have O 0 6.987346523601445e-07
3 O 0 5.732232239097357e-06
- O 0 3.4075244911946356e-05
5 O 0 3.6232540878700092e-06
- O 0 1.2115942809032276e-05
fold O 0 2.7713767849490978e-06
higher O 0 3.754066426608915e-07
affinity O 0 2.791084057207627e-07
to O 0 1.4334173847885268e-08
various O 0 4.211007365029218e-08
DNA O 0 7.244315384014044e-06
- O 0 7.990453013917431e-06
binding O 0 4.842635235036141e-07
sites O 0 3.907686050297343e-07
when O 0 9.819344768402516e-07
compared O 0 1.650261538088671e-06
with O 0 5.279792389956128e-07
the O 0 3.926834779122146e-06
wild O 0 0.0001369318488286808
- O 0 0.003334630513563752
type O 0 0.0021318295039236546
PAX6 O 0 0.4233570396900177
. O 0 0.00015499818255193532

These O 0 2.7314829367242055e-06
results O 0 3.719978167282534e-06
provide O 0 4.5443178464665834e-07
a O 0 6.914692676218692e-07
new O 0 4.6904480655030056e-07
insight O 0 1.5114866300791618e-06
into O 0 7.818341174470333e-08
the O 0 1.3840741530657397e-07
role O 0 6.035994033481984e-07
of O 0 1.0930748430837411e-06
mutant O 0 0.001177777536213398
PAX6 O 1 0.9691205620765686
in O 0 0.00015292910393327475
causing O 1 0.9599320292472839
aniridia B-Disease 1 0.9951903820037842
. O 0 5.164501999388449e-05
. O 0 7.294220995390788e-05

Reversal O 0 0.2038850039243698
of O 0 0.012331673875451088
severe O 1 0.9998212456703186
hypertrophic B-Disease 1 0.9999397993087769
cardiomyopathy I-Disease 1 0.9999591112136841
and O 0 0.00022978390916250646
excellent O 0 0.0014908440643921494
neuropsychologic O 0 0.08185599744319916
outcome O 0 4.1594237700337544e-05
in O 0 8.50646938488353e-06
very B-Disease 0 4.598043960868381e-05
- I-Disease 0 0.0021724922116845846
long I-Disease 0 0.00039931549690663815
- I-Disease 0 0.0005427953437902033
chain I-Disease 0 0.0002765404642559588
acyl I-Disease 0 0.0024364511482417583
- I-Disease 0 0.001356806023977697
coenzyme I-Disease 0 0.0018132188124582171
A I-Disease 0 0.02727990597486496
dehydrogenase I-Disease 1 0.9915661811828613
deficiency I-Disease 1 0.9993809461593628
. O 0 0.00048005921416915953

Very B-Disease 0 0.0003155749582219869
- I-Disease 0 0.004691814538091421
long I-Disease 0 0.0005365926190279424
- I-Disease 0 0.0005326718674041331
chain I-Disease 0 0.00017686246428638697
acyl I-Disease 0 0.0006108911475166678
- I-Disease 0 0.00019123792299069464
coenzyme I-Disease 0 0.0001231332862516865
A I-Disease 0 9.18864825507626e-05
dehydrogenase I-Disease 0 0.013317443430423737
( I-Disease 0 0.00022770173382014036
VLCAD I-Disease 1 0.986909806728363
) I-Disease 0 0.0032127394806593657
deficiency I-Disease 1 0.9997217059135437
is O 0 2.5533472580718808e-05
a O 0 0.00046833694796077907
disorder O 1 0.9982840418815613
of O 0 8.274767424154561e-06
fatty O 0 0.03582090511918068
acid O 0 0.008077182807028294
beta O 0 0.0008095376542769372
oxidation O 0 0.0004902560031041503
that O 0 9.301466889155563e-06
reportedly O 0 0.00021864943846594542
has O 0 3.7824956962140277e-06
high O 0 3.0222379791666754e-05
rates O 0 1.7402295270585455e-05
of O 0 3.852503596135648e-06
morbidity O 1 0.9479717016220093
and O 0 6.984765059314668e-05
mortality O 1 0.6904004216194153
. O 0 9.015280375024304e-05

We O 0 1.7674418586466345e-06
describe O 0 2.8848114652646473e-06
the O 0 3.1291406799027754e-07
outcome O 0 6.245249437597522e-07
of O 0 1.3565711753926735e-07
a O 0 6.045671398169361e-06
5 O 0 2.665068495844025e-05
- O 0 0.0003733328194357455
year O 0 2.5124585590674542e-05
- O 0 0.00043652887688949704
old O 0 0.00028008705703541636
girl O 0 0.002128450432792306
with O 0 0.0003831622889265418
VLCAD B-Disease 1 0.9993857145309448
deficiency I-Disease 1 0.9999405145645142
who O 0 4.093230745638721e-05
was O 0 1.4373042176885065e-05
first O 0 1.310104266849521e-06
seen O 0 3.6943604300176958e-06
at O 0 1.22635549359984e-06
5 O 0 1.1210235015823855e-06
months O 0 2.147875420632772e-06
of O 0 7.338139766943641e-07
age O 0 0.022725403308868408
with O 0 0.08674918115139008
severe O 1 0.9998894929885864
hypertrophic B-Disease 1 0.9999490976333618
cardiomyopathy I-Disease 1 0.9999891519546509
, O 1 0.9970929622650146
hepatomegaly B-Disease 1 0.9999101161956787
, O 1 0.9896425604820251
encephalopathy B-Disease 1 0.9998577833175659
, O 0 0.0004204339056741446
and O 0 0.0002095787349389866
hypotonia B-Disease 1 0.9923134446144104
. O 0 0.0005953451618552208

Biochemical O 0 0.012334292754530907
studies O 0 0.004326026886701584
indicated O 1 0.9884631037712097
VLCAD B-Disease 1 0.9995711445808411
deficiency I-Disease 1 0.9999685287475586
caused O 1 0.9494080543518066
by O 0 2.6348770916229114e-05
a O 0 0.00012619761400856078
stable O 0 0.0025678472593426704
yet O 0 7.481967622879893e-05
inactive O 0 0.0008471543551422656
enzyme O 0 0.0005817522178404033
. O 0 7.702210132265463e-05

Molecular O 0 0.00021069009380880743
genetic O 0 3.946485958294943e-05
analysis O 0 2.3483485165343154e-06
of O 0 2.0259990378690418e-06
her O 0 0.0002743314253166318
VLCAD O 0 0.397277295589447
gene O 0 0.000205036616534926
revealed O 0 0.00027555247652344406
a O 0 3.942212788388133e-05
T1372C O 0 0.0009297002688981593
( O 0 1.9803279428742826e-05
F458L O 0 0.0003967179509345442
) O 0 8.885197530617006e-06
missense O 0 0.0002799266076181084
mutation O 0 5.842605241923593e-05
and O 0 3.98355314246146e-06
a O 0 0.0001459822233300656
1668 O 1 0.9258757829666138
ACAG O 1 0.9144856333732605
1669 O 0 0.426484078168869
splice O 0 0.002022574655711651
site O 0 0.0004069599381182343
mutation O 0 0.0006965388893149793
. O 0 9.604616207070649e-05

After O 0 0.0004946987028233707
initial O 0 0.0006686959532089531
treatment O 0 0.057330526411533356
with O 0 3.074306732742116e-05
intravenous O 1 0.5328236222267151
glucose O 0 0.016239508986473083
and O 0 1.8785465726978146e-05
carnitine O 1 0.9398075938224792
, O 0 4.682252438215073e-06
the O 0 1.2472899470594712e-05
patient O 0 0.008041707798838615
has O 0 7.082450792950112e-06
thrived O 0 0.0001395644503645599
on O 0 2.1575265236606356e-06
a O 0 2.6288756998837925e-05
low O 0 0.0007872513378970325
- O 0 0.0010024852817878127
fat O 0 0.00026318561867810786
diet O 0 9.145212970906869e-05
supplemented O 0 2.470212166372221e-05
with O 0 3.8836587918922305e-06
medium O 0 9.327541920356452e-05
- O 0 0.0003033797547686845
chain O 0 0.00013468880206346512
triglyceride O 0 0.0005613235989585519
oil O 0 3.0054878152441233e-05
and O 0 4.449536390893627e-06
carnitine O 0 0.01811210624873638
and O 0 2.520587713661371e-06
avoidance O 0 0.0006828880286775529
of O 0 1.033563785313163e-05
fasting O 0 0.0017421874217689037
. O 0 0.0001555896014906466

Her O 0 0.02775404416024685
ventricular O 1 0.995084822177887
hypertrophy O 1 0.9951311349868774
resolved O 0 0.0009998449822887778
significantly O 0 0.00015751388855278492
over O 0 2.7721380320144817e-06
1 O 0 5.720086846849881e-06
year O 0 8.040215107030235e-06
, O 0 1.0013530982178054e-06
and O 0 9.68449512583902e-07
cognitively O 0 0.000959605211392045
, O 0 1.6399443438785966e-06
she O 0 2.9707528028666275e-06
is O 0 1.9246996885158296e-07
in O 0 1.5671101039060886e-07
the O 0 3.753235944259359e-07
superior O 0 4.9772639613365754e-05
range O 0 3.4759634672809625e-06
for O 0 1.64966979809833e-06
age O 0 0.00029187052859924734
. O 0 6.382111314451322e-05

Clinical O 0 0.00471781799569726
recognition O 0 0.00024942224263213575
of O 0 0.0009431145153939724
VLCAD B-Disease 1 0.9998202919960022
deficiency I-Disease 1 0.9999819993972778
is O 0 2.2807891582488082e-05
important O 0 1.9631115719676018e-06
because O 0 3.491731604299275e-06
it O 0 1.278539087934405e-07
is O 0 6.608613745129333e-08
one O 0 4.3941742688957675e-08
of O 0 9.041832527145743e-08
the O 0 2.4396802018600283e-06
few O 0 1.548713589727413e-05
directly O 0 0.00026118732057511806
treatable O 1 0.9996483325958252
causes O 1 0.9522775411605835
of O 0 0.0017383667873218656
cardiomyopathy B-Disease 1 0.9999754428863525
in O 0 0.001374053186737001
children O 0 0.0022022840566933155
. O 0 7.663811993552372e-05
. O 0 0.00011163838644279167

Cloning O 0 4.640279075829312e-05
of O 0 6.442659241656656e-07
a O 0 3.84561008104356e-06
novel O 0 3.912211923307041e-06
member O 0 4.6010342202862375e-07
of O 0 1.2591422660079843e-07
the O 0 2.0052925719937775e-06
low O 0 0.00017612503143027425
- O 0 0.0002788597485050559
density O 0 3.824311352218501e-05
lipoprotein O 0 0.35391807556152344
receptor O 0 0.00034557192702777684
family O 0 0.00013613561168313026
. O 0 4.7400968469446525e-05

A O 0 2.397224488959182e-05
gene O 0 8.188274478015956e-06
encoding O 0 2.343583219044376e-06
a O 0 4.374211584945442e-06
novel O 0 1.465427158109378e-05
transmembrane O 0 0.00023015009355731308
protein O 0 9.846325156104285e-06
was O 0 4.4561352297023404e-06
identified O 0 5.44313195405266e-07
by O 0 4.238954431912134e-08
DNA O 0 5.094483981338271e-07
sequence O 0 1.5989331814125762e-07
analysis O 0 2.0474668360748183e-07
within O 0 5.36210905011103e-07
the O 0 2.4754141122684814e-05
insulin B-Disease 1 0.9269401431083679
- I-Disease 1 0.9435103535652161
dependent I-Disease 0 0.3109831213951111
diabetes I-Disease 1 0.9999617338180542
mellitus I-Disease 1 0.9997410178184509
( O 0 0.0012872343650087714
IDDM B-Disease 0 0.4214703142642975
) O 0 2.0532053895294666e-05
locus O 0 0.00024853937793523073
IDDM4 O 0 0.018982267007231712
on O 0 1.9035198420169763e-05
chromosome O 0 0.0011593044036999345
11q13 O 0 0.003992938436567783
. O 0 0.00010063018999062479

Based O 0 5.1940346565970685e-06
on O 0 1.1722842145900358e-06
its O 0 1.1334884675306967e-06
chromosomal O 0 0.0001869972620625049
position O 0 1.1065906164731132e-06
, O 0 1.5643580297819426e-07
this O 0 9.08399400145754e-08
gene O 0 1.0577493867458543e-06
is O 0 9.583708759919318e-08
a O 0 7.815909270902921e-07
candidate O 0 1.8255250324727967e-06
for O 0 1.38657003390108e-06
conferring O 0 0.0016190152382478118
susceptibility O 1 0.721284806728363
to O 0 0.0007263573352247477
diabetes B-Disease 1 0.9997037053108215
. O 0 0.001373789389617741

The O 0 2.788759047689382e-05
gene O 0 6.143194332253188e-05
, O 0 8.303461981995497e-06
termed O 0 0.0002555800892878324
low O 0 0.00031287583988159895
- O 0 0.0001504353858763352
density O 0 1.4081746485317126e-05
lipoprotein O 0 0.006293121725320816
receptor O 0 2.6742158297565766e-05
related O 0 3.674605750347837e-06
protein O 0 3.958482921007089e-06
5 O 0 3.0489873097394593e-06
( O 0 4.701403213402955e-06
LRP5 O 0 0.0007607446168549359
) O 0 2.955714251129393e-07
, O 0 4.539648301715715e-08
encodes O 0 1.707207246681719e-07
a O 0 1.5086007465470175e-07
protein O 0 2.2712137592861836e-07
of O 0 7.089128928328137e-08
1615 O 0 7.953887688927352e-05
amino O 0 6.441295568038186e-07
acids O 0 7.007714089013461e-07
that O 0 3.5355153471527956e-08
contains O 0 6.933684915111371e-08
conserved O 0 5.476001092574734e-07
modules O 0 7.017370649009536e-07
which O 0 5.408381298366294e-08
are O 0 1.0856819443461063e-08
characteristic O 0 5.183304097045038e-07
of O 0 1.4352728783251223e-07
the O 0 2.803686584229581e-06
low O 0 0.00020970107289031148
- O 0 0.0001772507675923407
density O 0 2.956047683255747e-05
lipoprotein O 1 0.8127351999282837
( O 0 8.685920329298824e-05
LDL O 1 0.9191291928291321
) O 0 1.123086713050725e-05
receptor O 0 0.00012637693725991994
family O 0 4.916058969683945e-05
. O 0 2.178717841161415e-05

These O 0 1.1978659131273162e-06
modules O 0 5.828506346006179e-06
include O 0 1.414511075381597e-06
a O 0 2.4584112452430418e-06
putative O 0 3.443162131588906e-05
signal O 0 3.855727300106082e-06
peptide O 0 6.714356459269766e-06
for O 0 1.235709419233899e-07
protein O 0 1.7602357047508121e-06
export O 0 1.988659050766728e-06
, O 0 7.597614626320137e-07
four O 0 1.6277379017992644e-06
epidermal O 0 0.02279464714229107
growth O 0 0.00011548188922461122
factor O 0 1.5904737665550783e-05
( O 0 2.5673185518826358e-05
EGF O 0 0.028570422902703285
) O 0 2.5789934170461493e-06
repeats O 0 1.7493579434813e-05
with O 0 7.874355674175604e-07
associated O 0 6.470727839769097e-06
spacer O 0 0.0002292130229761824
domains O 0 1.1480192370072473e-05
, O 0 1.8181599443778396e-06
three O 0 4.453501333046006e-06
LDL O 1 0.9926058053970337
- O 0 0.00029676518170163035
receptor O 0 2.747394682955928e-05
( O 0 3.5538180327421287e-06
LDLR O 0 0.0007630347972735763
) O 0 7.051731927276705e-07
repeats O 0 6.4625874074408785e-06
, O 0 2.1335428357360797e-07
a O 0 4.7342646780634823e-07
single O 0 6.30948477464699e-07
transmembrane O 0 4.462167271412909e-05
spanning O 0 1.0704795386118349e-05
domain O 0 4.081579845660599e-06
, O 0 6.897622029100603e-07
and O 0 4.471740169265104e-07
a O 0 5.290127319312887e-06
cytoplasmic O 0 0.00012501368473749608
domain O 0 4.6349185140570626e-05
. O 0 4.415966759552248e-05

The O 0 1.2976571497347322e-06
encoded O 0 1.3911978840042138e-06
protein O 0 5.650702860293677e-06
has O 0 8.420449830737198e-07
a O 0 1.5945111044857185e-06
unique O 0 1.2386655043883366e-06
organization O 0 2.400180392214679e-06
of O 0 1.9924025309592253e-06
EGF O 1 0.5414083003997803
and O 0 7.736449333606288e-06
LDLR O 0 0.0615270733833313
repeats O 0 0.00030067309853620827
; O 0 3.6924477626598673e-06
therefore O 0 1.4231872000891599e-06
, O 0 3.5810730878438335e-06
LRP5 O 0 0.008334745652973652
likely O 0 6.128345376055222e-06
represents O 0 1.94255517271813e-06
a O 0 9.546688488626387e-07
new O 0 7.697113346694096e-07
category O 0 1.64112725542509e-06
of O 0 2.7327024554324453e-07
the O 0 9.733979823067784e-06
LDLR O 0 0.2679401934146881
family O 0 0.0004455066518858075
. O 0 0.00010057061444967985

Both O 0 4.305956463213079e-05
human O 0 5.1719041948672384e-05
and O 0 3.060225208173506e-05
mouse O 0 0.01416053343564272
LRP5 O 1 0.961089015007019
cDNAs O 0 0.05737832561135292
have O 0 3.0442051865975372e-06
been O 0 1.480549599364167e-06
isolated O 0 4.969146630173782e-06
and O 0 6.197038260324916e-08
the O 0 1.0358171920188397e-07
encoded O 0 4.5144051341594604e-07
mature O 0 3.3343135328323115e-06
proteins O 0 1.9160370356985368e-07
are O 0 2.4330383041615278e-08
95 O 0 8.103220920929743e-07
% O 0 2.33928631132585e-07
identical O 0 2.0622478587029036e-06
, O 0 5.942550842519267e-07
indicating O 0 9.130386388278566e-06
a O 0 1.7527278259876766e-06
high O 0 6.147772637632443e-06
degree O 0 2.607115447972319e-06
of O 0 6.109113996899396e-07
evolutionary O 0 5.119214620208368e-05
conservation O 0 7.349868974415585e-05
. O 0 9.596632480679546e-06
. O 0 5.380873699323274e-05

The O 0 0.00010616065992508084
APC B-Disease 0 0.0074669248424470425
variants O 0 0.00019225261348765343
I1307K O 0 0.0009356304653920233
and O 0 1.377961234538816e-05
E1317Q O 0 0.0012072909157723188
are O 0 4.03958711103769e-06
associated O 0 0.003021018346771598
with O 1 0.9878250956535339
colorectal B-Disease 1 0.9999980926513672
tumors I-Disease 1 0.9999926090240479
, O 0 9.322519326815382e-05
but O 0 4.1241382859880105e-06
not O 0 2.6335035840929777e-07
always O 0 7.662192729185335e-07
with O 0 5.175766659704095e-07
a O 0 7.505637768190354e-06
family O 0 8.000023080967367e-05
history O 0 7.037745672278106e-05
. O 0 0.00010034665319835767

Classical O 0 0.11328764259815216
familial B-Disease 1 0.9981521964073181
adenomatous I-Disease 1 0.999108612537384
polyposis I-Disease 1 0.9996523857116699
( O 0 0.02968575246632099
FAP B-Disease 1 0.9906101822853088
) O 0 1.837461968534626e-05
is O 0 3.3144099234050373e-06
a O 0 5.509946640813723e-05
high O 0 0.021713336929678917
- O 1 0.8512150049209595
penetrance O 1 0.9951732754707336
autosomal B-Disease 1 0.9991258978843689
dominant I-Disease 1 0.9982308745384216
disease I-Disease 1 0.9998993873596191
that O 0 6.883884634589776e-05
predisposes O 0 0.07470538467168808
to O 0 1.9069474319621804e-06
hundreds O 0 1.0003336683439557e-05
or O 0 7.2400953285978176e-06
thousands O 0 5.724062430090271e-05
of O 0 0.0016424652421846986
colorectal B-Disease 1 0.9999936819076538
adenomas I-Disease 1 0.9998840093612671
and I-Disease 1 0.7267873287200928
carcinoma I-Disease 1 0.9999887943267822
and O 0 8.000838533916976e-06
that O 0 8.892503728930023e-07
results O 0 3.8107848467916483e-06
from O 0 3.3883138712553773e-06
truncating O 0 0.0006791292107664049
mutations O 0 1.9868881281581707e-05
in O 0 1.4973032875786885e-06
the O 0 5.761493412137497e-06
APC B-Disease 0 0.016533182933926582
gene O 0 0.0001724069006741047
. O 0 4.2957806726917624e-05

A O 0 0.0005537858232855797
variant O 0 0.006300521083176136
of O 0 6.64388935547322e-05
FAP B-Disease 1 0.9932708144187927
is O 0 0.003821820951998234
attenuated B-Disease 1 0.9954181909561157
adenomatous I-Disease 1 0.9996767044067383
polyposis I-Disease 1 0.999778687953949
coli I-Disease 1 0.9988946318626404
, O 0 9.491398486716207e-06
which O 0 1.0075228829009575e-06
results O 0 1.2611106285476126e-05
from O 0 1.6719654013286345e-05
germ O 1 0.9246593713760376
- O 0 0.000195432105101645
line O 0 8.913577403291129e-06
mutations O 0 2.8062947876605904e-06
in O 0 8.547502261535556e-08
the O 0 1.398936859686728e-07
5 O 0 3.418488176976098e-07
and O 0 8.160704823012566e-08
3 O 0 1.6519322798558278e-07
regions O 0 5.885519627213398e-08
of O 0 1.085601724071239e-07
the O 0 5.655112545355223e-06
APC B-Disease 0 0.00876876711845398
gene O 0 0.00029952696058899164
. O 0 7.652178464923054e-05

Attenuated B-Disease 1 0.9905699491500854
adenomatous I-Disease 1 0.9996002316474915
polyposis I-Disease 1 0.9998899698257446
coli I-Disease 1 0.9998456239700317
patients O 1 0.9974714517593384
have O 0 4.325752524891868e-05
" O 0 9.00822487892583e-05
multiple O 0 0.0039355214685201645
" O 0 0.4393185079097748
colorectal B-Disease 1 0.9999690055847168
adenomas I-Disease 1 0.9996050000190735
( O 0 8.863589755492285e-05
typically O 0 6.8885169639543165e-06
fewer O 0 3.3988512768701185e-06
than O 0 2.683883053578029e-07
100 O 0 6.906066118972376e-07
) O 0 3.3650144359853584e-07
without O 0 2.5971641548494517e-07
the O 0 1.0689540204111836e-06
florid O 0 0.00302001996897161
phenotype O 0 0.00018049567006528378
of O 0 3.047219934160239e-06
classical O 0 0.0009202001383528113
FAP B-Disease 1 0.9813127517700195
. O 0 0.00035710164229385555

Another O 0 5.725782102672383e-05
group O 0 2.1319887309800833e-05
of O 0 9.844127816904802e-06
patients O 0 0.4384188652038574
with O 0 1.87033128895564e-05
multiple O 0 0.001291795400902629
adenomas B-Disease 1 0.9976720213890076
has O 0 9.321955076302402e-06
no O 0 3.508167083055014e-06
mutations O 0 7.293735961866332e-06
in O 0 4.295335997994698e-07
the O 0 3.036391262867255e-06
APC B-Disease 0 0.0030405395664274693
gene O 0 1.135321053880034e-05
, O 0 3.456726460626669e-07
and O 0 7.460754858357177e-08
their O 0 1.901670287907109e-07
phenotype O 0 0.0002154531393898651
probably O 0 4.937041012453847e-06
results O 0 6.525307867377705e-07
from O 0 4.4744021465703554e-07
variation O 0 1.967020580195822e-06
at O 0 2.0339830371085554e-06
a O 0 2.585361471574288e-06
locus O 0 1.9263248759671114e-05
, O 0 6.453223591051938e-07
or O 0 1.1693521173583576e-06
loci O 0 1.2504879123298451e-05
, O 0 1.1556923027455923e-06
elsewhere O 0 1.33493756493408e-06
in O 0 5.956639483883919e-07
the O 0 2.764774762908928e-06
genome O 0 0.00014255358837544918
. O 0 3.8570509786950424e-05

Recently O 0 0.000796185340732336
, O 0 5.7586366892792284e-06
however O 0 2.6803584205481457e-06
, O 0 1.2294012776692398e-06
a O 0 3.628818376455456e-06
missense O 0 0.00017440775991417468
variant O 0 0.00048775479081086814
of O 0 4.3347858991182875e-06
APC B-Disease 0 0.05906534194946289
( O 0 2.2333932065521367e-05
I1307K O 0 0.0007420816109515727
) O 0 3.0148371479299385e-06
was O 0 1.0627692063280847e-05
described O 0 9.892708476400003e-06
that O 0 6.292958687481587e-07
confers O 0 0.00011345063830958679
an O 0 5.2150348892610054e-06
increased O 0 0.0003654324682429433
risk O 0 0.3320976197719574
of O 0 0.02288738824427128
colorectal B-Disease 1 0.9999966621398926
tumors I-Disease 1 0.9999758005142212
, O 0 6.06920184509363e-05
including O 0 2.9784245271002874e-05
multiple O 0 0.003581578843295574
adenomas B-Disease 1 0.9976778626441956
, O 0 8.677061850903556e-05
in O 0 4.2371684685349464e-05
Ashkenazim O 0 0.03441687673330307
. O 0 0.00014984126028139144

We O 0 2.8107112939323997e-06
have O 0 1.7659377249401587e-07
studied O 0 4.858525244344492e-07
a O 0 3.2510556025044934e-07
set O 0 2.946376298496034e-07
of O 0 8.719093784748111e-07
164 O 0 0.0020915421191602945
patients O 1 0.536482572555542
with O 0 0.00048418837832286954
multiple O 1 0.9876649975776672
colorectal B-Disease 1 0.9999769926071167
adenomas I-Disease 1 0.9996782541275024
and I-Disease 0 0.007160150445997715
/ I-Disease 1 0.997012734413147
or I-Disease 0 0.012365410104393959
carcinoma I-Disease 1 0.9999048709869385
and O 0 5.774243163614301e-06
analyzed O 0 5.1231112593086436e-05
codons O 0 0.00028362852754071355
1263 O 0 0.09835419058799744
- O 0 0.001826571417041123
1377 O 0 0.00990197155624628
( O 0 6.039845175109804e-06
exon O 0 8.824896940495819e-05
15G O 0 8.305665687657893e-05
) O 0 1.6629334709250543e-07
of O 0 4.37943974418431e-08
the O 0 1.2742983699354227e-06
APC B-Disease 0 0.0005758784827776253
gene O 0 2.1488349375431426e-05
for O 0 5.290263288770802e-06
germ O 1 0.9806984066963196
- O 0 0.002231415593996644
line O 0 8.145910396706313e-05
variants O 0 0.00010968509741360322
. O 0 5.553180380957201e-05

Three O 0 6.711905734846368e-05
patients O 0 0.01006370596587658
with O 0 1.5962364159349818e-06
the O 0 3.067311581617105e-06
I1307K O 0 0.0005677167791873217
allele O 0 2.4265989850391634e-05
were O 0 8.703250955477415e-07
detected O 0 1.4554952031176072e-05
, O 0 1.1419902534726134e-07
each O 0 5.7409632603366845e-08
of O 0 7.107975079634343e-07
Ashkenazi O 0 0.0008212245884351432
descent O 0 0.0002544818271417171
. O 0 8.241444447776303e-05

Four O 0 0.000257970008533448
patients O 0 0.49728769063949585
had O 0 0.0001264636084670201
a O 0 0.0003373179060872644
germ O 1 0.9806708097457886
- O 0 0.000995272770524025
line O 0 4.619302126229741e-05
E1317Q O 0 0.0003674719773698598
missense O 0 0.0002387474087299779
variant O 0 0.00047826694208197296
of O 0 2.484256356183323e-06
APC O 0 0.06322944909334183
that O 0 1.5867926776991226e-06
was O 0 4.762258868140634e-06
not O 0 1.0191011057258947e-07
present O 0 3.429302921631461e-07
in O 0 2.499970435110299e-07
controls O 0 3.1976248919818318e-06
; O 0 3.350923805101047e-07
one O 0 3.2328077992360704e-08
of O 0 3.08677954308223e-08
these O 0 8.964045861148406e-08
individuals O 0 5.105573563923826e-07
had O 0 3.7604979752359213e-06
an O 0 8.674091986904386e-07
unusually O 0 0.00011190323857590556
large O 0 1.6128557263073162e-06
number O 0 2.4409968091276824e-07
of O 0 1.3116556374370703e-06
metaplastic B-Disease 0 0.4321669340133667
polyps I-Disease 0 0.1296646147966385
of I-Disease 0 2.8075769478164148e-06
the I-Disease 0 8.357187471119687e-05
colorectum I-Disease 0 0.06144719198346138
. O 0 0.00011609499779297039

There O 0 1.553681431687437e-05
is O 0 3.5855669011652935e-06
increasing O 0 8.604877621110063e-06
evidence O 0 4.0258037188323215e-06
that O 0 7.262296435328608e-07
there O 0 1.5939090189931449e-06
exist O 0 6.1627533796126954e-06
germ O 1 0.7227842807769775
- O 0 0.00017170589126180857
line O 0 2.275071210533497e-06
variants O 0 1.1600042171266978e-06
of O 0 1.1333906257959825e-07
the O 0 2.458202516208985e-06
APC B-Disease 0 0.0018548698863014579
gene O 0 1.4791207831876818e-05
that O 0 3.9507636984126293e-07
predispose O 0 1.4290204489952885e-05
to O 0 6.852905443111013e-08
the O 0 3.865432631755539e-07
development O 0 1.961494717761525e-06
of O 0 8.111765055218711e-06
multiple O 1 0.9932090640068054
colorectal B-Disease 1 0.9999905824661255
adenomas I-Disease 1 0.9999109506607056
and I-Disease 1 0.9658300876617432
carcinoma I-Disease 1 0.9999921321868896
, O 0 3.4173393942182884e-05
but O 0 1.3981781421534833e-06
without O 0 1.341716256320069e-06
the O 0 1.971813617274165e-06
florid O 0 0.007174422964453697
phenotype O 0 0.00011968493345193565
of O 0 1.1698986099872855e-06
classical O 0 0.000437736016465351
FAP B-Disease 1 0.9817958474159241
, O 0 1.7374535445924266e-06
and O 0 3.5956881561105547e-07
possibly O 0 4.1046137084777e-06
with O 0 1.7203720972247538e-06
importance O 0 0.0001679717970546335
for O 0 0.3128882944583893
colorectal B-Disease 1 0.9999970197677612
cancer I-Disease 1 0.999985933303833
risk O 0 0.4430668354034424
in O 0 3.35321396960353e-06
the O 0 3.7586801227007527e-06
general O 0 1.5811878256499767e-05
population O 0 5.51674202142749e-06
. O 0 5.273238457448315e-06
. O 0 3.107377779087983e-05

Genomic O 0 0.0002889178285840899
structure O 0 0.00010123819811269641
of O 0 1.2973865523235872e-05
the O 0 0.0010517662158235908
human O 1 0.793226957321167
congenital B-Disease 1 0.9999641180038452
chloride I-Disease 1 0.9996778964996338
diarrhea I-Disease 1 0.999963641166687
( O 1 0.6272335648536682
CLD B-Disease 1 0.997900128364563
) O 0 0.0004109966102987528
gene O 0 0.0007411225815303624
. O 0 0.00017317601304966956

Congenital B-Disease 1 0.9998176693916321
chloride I-Disease 1 0.9989583492279053
diarrhea I-Disease 1 0.9999333620071411
( O 1 0.775187075138092
CLD B-Disease 1 0.9987446069717407
) O 0 0.00010024957737186924
is O 0 1.2866312317783013e-05
caused O 0 0.0011416923953220248
by O 0 1.0523060609557433e-06
mutations O 0 5.920664079894777e-06
in O 0 3.6594664720723813e-07
a O 0 2.075923930533463e-06
gene O 0 6.163847046991577e-06
which O 0 7.662587790946418e-07
encodes O 0 1.61174320965074e-05
an O 0 0.00010427415691083297
intestinal O 1 0.9985881447792053
anion O 1 0.9324727654457092
transporter O 1 0.9138122200965881
. O 0 0.00018462375737726688

We O 0 6.499578830698738e-06
report O 0 5.782884272775846e-06
here O 0 3.0300424214146915e-07
the O 0 2.0504231201812217e-07
complete O 0 2.351064495087485e-06
genomic O 0 6.0095094340795185e-06
organization O 0 6.306109980869223e-07
of O 0 1.1086677176308513e-07
the O 0 3.2322643619409064e-06
human O 0 4.7666821046732366e-05
CLD B-Disease 1 0.9892472624778748
gene O 0 4.083028034074232e-05
which O 0 8.490321761200903e-07
spans O 0 5.69560652365908e-05
approximately O 0 6.4889704844972584e-06
39kb O 0 0.0018394372891634703
, O 0 1.0091663398270612e-06
and O 0 4.1334567413287004e-07
comprises O 0 3.0518472158291843e-06
21 O 0 1.5389055988634937e-05
exons O 0 0.00011040053504984826
. O 0 4.3461957830004394e-05

All O 0 5.466059064929141e-06
exon O 0 0.0009093739790841937
/ O 0 0.0008706896333023906
intron O 0 0.0003454576653894037
boundaries O 0 1.619552904230659e-06
conform O 0 1.7737636881065555e-05
to O 0 8.421180837103748e-07
the O 0 2.493653300916776e-05
GT O 1 0.7484476566314697
/ O 0 0.2286645770072937
AG O 1 0.7524912357330322
rule O 0 0.00011865394480992109
. O 0 7.144047413021326e-05

An O 0 2.1210144041106105e-06
analysis O 0 9.305000503445626e-07
of O 0 2.0169909475953318e-07
the O 0 1.8267510313307866e-06
putative O 0 0.0001608272868907079
promoter O 0 0.00025166719569824636
region O 0 2.061278564724489e-06
sequence O 0 1.6403604377046577e-06
shows O 0 3.0460837479040492e-06
a O 0 1.787803012121003e-05
putative O 0 0.000889720453415066
TATA O 0 0.23948341608047485
box O 0 0.00028737555840052664
and O 0 2.5001588710438227e-06
predicts O 0 0.00011381439253455028
multiple O 0 1.1117303074570373e-05
transcription O 0 0.00011167299089720473
factor O 0 1.9957586118835025e-05
binding O 0 2.1260257199173793e-05
sites O 0 2.2776763216825202e-05
. O 0 5.023686389904469e-05

The O 0 1.967868593055755e-05
genomic O 0 0.00013390369713306427
structure O 0 8.77789716469124e-05
was O 0 1.4654914593847934e-05
determined O 0 1.24932853395876e-06
using O 0 1.931101536456481e-07
DNA O 0 3.4306742691114778e-06
from O 0 2.1777549363832804e-07
several O 0 9.37149238211532e-08
sources O 0 4.5086869704391574e-07
including O 0 6.74878435802384e-07
multiple O 0 1.9620632883743383e-05
large O 0 9.8466407507658e-05
- O 0 0.0011739390902221203
insert O 0 0.00034171435981988907
libaries O 0 0.00028939780895598233
and O 0 6.165560080262367e-07
genomic O 0 3.5115794162265956e-05
DNA O 0 0.00010501586803002283
from O 0 7.820792234269902e-05
Finnish O 1 0.9672967195510864
CLD B-Disease 1 0.9989190101623535
patients O 1 0.9914047718048096
and O 0 3.274227128713392e-05
controls O 0 0.000408294697990641
. O 0 0.00012392719509080052

Exon O 0 0.0051093013025820255
- O 0 0.00032998781534843147
specific O 0 2.8049862521584146e-06
primers O 0 5.6239798141177744e-05
developed O 0 1.1671801075863186e-05
in O 0 2.621500811983424e-07
this O 0 1.815491827983351e-07
study O 0 6.763654596397828e-07
will O 0 1.0406113659655603e-07
facilitate O 0 1.7488107459939783e-06
mutation O 0 1.9614944903878495e-05
screening O 0 1.3574446711572818e-05
studies O 0 2.3768959636072395e-06
of O 0 5.278737717162585e-06
patients O 1 0.944532573223114
with O 0 0.00028806927730329335
the O 0 0.017865940928459167
disease O 1 0.9995842576026917
. O 0 0.0007652834756299853

Genomic O 0 4.1657796828076243e-05
sequencing O 0 6.919865427335026e-06
of O 0 1.5026948858576361e-06
a O 0 0.0001768626389093697
BAC O 1 0.6086553335189819
clone O 1 0.5898577570915222
H O 1 0.9704408645629883
_ O 0 8.433979382971302e-05
RG364P16 O 0 0.0004082625964656472
revealed O 0 2.2937083485885523e-05
the O 0 3.854381702694809e-07
presence O 0 4.868395535595482e-07
of O 0 3.5408671550385407e-08
another O 0 6.115794235483918e-07
, O 0 1.9080758306699863e-07
highly O 0 4.938402184961888e-07
homologous O 0 3.906526217178907e-06
gene O 0 2.4444402697554324e-06
3 O 0 4.800104420610296e-07
of O 0 2.4307311718985147e-07
the O 0 9.704810508992523e-06
CLD B-Disease 1 0.988923192024231
gene O 0 1.5524105037911795e-05
, O 0 4.814839940081583e-07
with O 0 4.1868051425808517e-07
a O 0 1.4482416190730873e-06
similar O 0 1.722200750009506e-06
genomic O 0 3.166274109389633e-05
structure O 0 0.00021685399406123906
, O 0 6.850305453554029e-06
recently O 0 0.00014026944700162858
identified O 0 1.529804285382852e-05
as O 0 7.347100108745508e-06
the O 0 0.0005022502737119794
Pendred B-Disease 1 0.9990057349205017
syndrome I-Disease 1 0.9999561309814453
gene O 0 0.020909052342176437
( O 0 0.0011985255405306816
PDS B-Disease 1 0.9903246164321899
) O 0 3.38226200256031e-05
. O 0 1.7033289623213932e-05
. O 0 7.54399734432809e-05

The O 0 0.00022728419571649283
APCI1307K O 0 0.39985817670822144
allele O 0 0.003935274202376604
and O 0 0.0012909815413877368
cancer B-Disease 1 0.9995325803756714
risk O 0 0.005675682332366705
in O 0 3.359426727911341e-06
a O 0 1.2353844795143232e-05
community O 0 7.71977829572279e-06
- O 0 4.497257395996712e-05
based O 0 3.713243472702743e-07
study O 0 1.2692311202044948e-06
of O 0 1.5251365539370454e-06
Ashkenazi O 0 0.002112331800162792
Jews O 0 5.9784699260490015e-05
. O 0 9.784677968127653e-05

Mutations O 0 0.0011037340154871345
in O 0 4.370751412352547e-05
APC O 0 0.08384531736373901
are O 0 1.3641697478306014e-05
classically O 0 0.1747337132692337
associated O 0 0.0022007315419614315
with O 0 0.007558660581707954
familial B-Disease 1 0.9995349645614624
adenomatous I-Disease 1 0.9997268319129944
polyposis I-Disease 1 0.9998761415481567
( O 0 0.1069883406162262
FAP B-Disease 1 0.9959600567817688
) O 0 4.114850526093505e-05
, O 0 7.918109076854307e-06
a O 0 0.00018506756168790162
highly O 0 0.0207880400121212
penetrant O 1 0.9978463649749756
autosomal B-Disease 1 0.9998111128807068
dominant I-Disease 1 0.9991469383239746
disorder I-Disease 1 0.9999791383743286
characterized O 1 0.9982370138168335
by O 0 0.01672959513962269
multiple O 1 0.9975423812866211
intestinal O 1 0.999945878982544
polyps B-Disease 1 0.9993498921394348
and O 0 2.644505730131641e-05
, O 0 1.8222744984086603e-05
without O 0 5.382695235311985e-05
surgical O 1 0.7251916527748108
intervention O 0 0.00015879298734944314
, O 0 2.278345164086204e-06
the O 0 3.244277422709274e-06
development O 0 6.977495650062338e-05
of O 0 0.0024186105001717806
colorectal B-Disease 1 0.999984860420227
cancer I-Disease 1 0.9999349117279053
( O 0 0.011810332536697388
CRC B-Disease 1 0.9881302118301392
) O 0 0.0001035472669173032
. O 0 7.079721399350092e-05

APC B-Disease 0 0.016670823097229004
is O 0 8.08832046459429e-05
a O 0 0.0012034910032525659
tumour O 1 0.9994509816169739
- O 0 0.01202339306473732
suppressor O 0 0.0012609607074409723
gene O 0 1.546633939142339e-05
, O 0 9.532877811579965e-07
and O 0 1.3868900623492664e-06
somatic O 0 0.0003430955111980438
loss O 0 0.012390399351716042
occurs O 0 0.0011316162999719381
in O 0 0.0009623977239243686
tumours B-Disease 1 0.9987286925315857
. O 0 0.00043747745803557336

The O 0 0.0002767818223219365
germline O 0 0.41060778498649597
T O 1 0.9852712154388428
- O 0 0.00021364580607041717
to O 0 1.5085187214936013e-06
- O 0 5.416603380581364e-05
A O 0 1.0684560038498603e-05
transversion O 0 0.00019943797087762505
responsible O 0 1.5705796840848052e-06
for O 0 1.33803823132439e-07
the O 0 1.228988708135148e-06
APC O 0 0.0003753995697479695
I1307K O 0 5.636344576487318e-05
allele O 0 3.4325887554587098e-06
converts O 0 1.2125246939831413e-06
the O 0 6.941438073226891e-07
wild O 0 8.024114322324749e-06
- O 0 2.744519224506803e-05
type O 0 3.6887768146698363e-06
sequence O 0 3.651260556125635e-07
to O 0 1.780952914032241e-07
a O 0 2.8540496714413166e-05
homopolymer O 1 0.6555692553520203
tract O 1 0.9974474906921387
( O 0 0.00027353514451533556
A8 O 1 0.9877749681472778
) O 0 6.065693924028892e-06
that O 0 1.8153391465602908e-06
is O 0 6.092274816182908e-06
genetically O 0 0.0003041365125682205
unstable O 0 0.08005262166261673
and O 0 6.693508112221025e-06
prone O 0 0.0041335937567055225
to O 0 2.738540842983639e-06
somatic O 0 0.0006944176275283098
mutation O 0 0.0010558727663010359
. O 0 6.857624975964427e-05

The O 0 4.9227910494664684e-05
I1307K O 0 0.0007044616504572332
allele O 0 6.921048043295741e-05
was O 0 3.7367793993325904e-05
found O 0 8.23004938865779e-06
in O 0 4.576598257699516e-06
6 O 0 7.194988575065508e-05
. O 0 3.247038694098592e-05

1 O 0 3.2624175219098106e-05
% O 0 5.790808700112393e-06
of O 0 4.93433435622137e-06
unselected O 0 0.13699255883693695
Ashkenazi O 0 0.0022030575200915337
Jews O 0 1.0168591870751698e-05
and O 0 1.9462765976641094e-06
higher O 0 1.1765125236706808e-05
proportions O 0 0.00010398303129477426
of O 0 1.2283793466849602e-06
Ashkenazim O 0 0.00464765727519989
with O 0 8.216161404561717e-06
family O 0 9.31856338866055e-05
or O 0 4.843715487368172e-06
personal O 0 7.334274414461106e-06
histories O 0 6.35995966149494e-05
of O 0 1.0069628842757083e-05
CRC B-Disease 1 0.9865206480026245
( O 0 0.00017352956638205796
ref O 0 0.17416347563266754
. O 0 2.8713620849885046e-06
2 O 0 5.976759894110728e-06
) O 0 3.994409325969173e-06
. O 0 1.7638922145124525e-05

To O 0 3.0857841011311393e-06
evaluate O 0 6.881550689286087e-06
the O 0 9.385898920299951e-07
role O 0 1.6795647752587683e-06
of O 0 1.6479417581649614e-06
I1307K O 0 0.0075953127816319466
in O 0 0.0003926885256078094
cancer B-Disease 1 0.9992819428443909
, O 0 3.5117757306579733e-06
we O 0 1.2572622836160008e-06
genotyped O 0 0.0005641109892167151
5 O 0 1.0499279596842825e-05
, O 0 5.720463377656415e-06
081 O 0 0.008035708218812943
Ashkenazi O 0 0.00019865376816596836
volunteers O 0 7.366407771769445e-06
in O 0 6.903326834617474e-07
a O 0 4.447466380952392e-06
community O 0 7.646755875612143e-06
survey O 0 5.967368633719161e-05
. O 0 4.217966124997474e-05

Risk O 0 0.014499396085739136
of O 0 0.00014030742750037462
developing O 1 0.9605579972267151
colorectal B-Disease 1 0.999913215637207
, I-Disease 0 0.09324732422828674
breast I-Disease 1 0.9994003772735596
and I-Disease 0 1.6355214029317722e-05
other I-Disease 0 1.793727460608352e-05
cancers I-Disease 1 0.9959205389022827
were O 0 1.42106603107095e-06
compared O 0 2.0260751625755802e-05
between O 0 1.048133253789274e-05
genotyped O 0 0.13576984405517578
I1307K O 0 0.004396865610033274
carriers O 0 0.00016165612032637
and O 0 2.2698070551996352e-06
non O 0 2.925970511569176e-05
- O 0 0.00028872533584944904
carriers O 0 4.943683961755596e-06
and O 0 5.277305348272421e-08
their O 0 1.0338276723587114e-07
first O 0 3.611679858295247e-06
- O 0 0.00016916621825657785
degree O 0 1.7809317796491086e-05
relatives O 0 6.974515417823568e-05
. O 0 6.031042357790284e-05

Sperm O 0 0.00010668380855349824
DNA O 0 4.910759162157774e-05
analysis O 0 1.0972642485285178e-05
in O 0 1.1105710655101575e-05
a O 0 0.00071597786154598
Friedreich B-Disease 1 0.9936962723731995
ataxia I-Disease 1 0.998325765132904
premutation O 1 0.9845870733261108
carrier O 0 0.011101159267127514
suggests O 0 2.9637787520186976e-05
both O 0 1.3476419553626329e-06
meiotic O 0 0.0021865416783839464
and O 0 2.0682334707089467e-06
mitotic O 0 0.00047603374696336687
expansion O 0 3.146060407743789e-05
in O 0 2.376467364229029e-06
the O 0 2.012040204135701e-05
FRDA B-Disease 0 0.05557263642549515
gene O 0 0.000433296401752159
. O 0 6.801471317885444e-05

Friedreich B-Disease 1 0.9908627271652222
ataxia I-Disease 1 0.9976876974105835
is O 0 0.00023850463912822306
usually O 0 0.00020598599803633988
caused O 0 0.008771784603595734
by O 0 1.0016597116191406e-06
an O 0 7.163211535043956e-07
expansion O 0 3.500163529679412e-06
of O 0 4.2646701103876694e-07
a O 0 4.9225043767364696e-05
GAA O 0 0.00950348936021328
trinucleotide O 0 0.3770088255405426
repeat O 0 0.00012415548553690314
in O 0 2.2095985059422674e-06
intron O 0 0.0005523383151739836
1 O 0 9.993810863306862e-07
of O 0 2.959002642910491e-07
the O 0 8.224949851864949e-06
FRDA B-Disease 0 0.04742148146033287
gene O 0 0.0003005544131156057
. O 0 5.612643144559115e-05

Occasionally O 0 0.00013879381003789604
, O 0 7.403551535389852e-06
a O 0 8.523051292286254e-06
fully O 0 1.7781960195861757e-05
expanded O 0 9.545919965603389e-06
allele O 0 1.0993160685757175e-05
has O 0 2.433067493257113e-06
been O 0 6.257226345951494e-07
found O 0 1.2257813750693458e-06
to O 0 3.0607085932388145e-07
arise O 0 3.515408025123179e-06
from O 0 5.388374120229855e-07
a O 0 2.0152481283730594e-06
premutation O 0 8.692168194102123e-05
of O 0 2.5523186764075945e-07
100 O 0 2.0407601368788164e-06
or O 0 2.4386845325352624e-06
less O 0 9.492105164099485e-06
triplet O 0 0.005862053018063307
repeats O 0 0.0015806450974196196
. O 0 8.342416549567133e-05

We O 0 5.990363206365146e-06
have O 0 1.1698406297000474e-06
examined O 0 9.049059372046031e-06
the O 0 3.727367356987088e-07
sperm O 0 5.263621460471768e-06
DNA O 0 4.403203547553858e-06
of O 0 8.546978165213659e-07
a O 0 0.00011152124352520332
premutation O 0 0.12712997198104858
carrier O 0 0.009261897765100002
. O 0 0.0001087483178707771

This O 0 7.6075716606283095e-06
mans O 0 0.00016346767370123416
leucocyte O 0 0.0010010420810431242
DNA O 0 2.7348785806680098e-05
showed O 0 8.673234333400615e-06
one O 0 2.575729354248324e-07
normal O 0 1.3070567774775554e-06
allele O 0 9.18351759082725e-07
and O 0 4.2858633975129123e-08
one O 0 5.176615047730593e-08
allele O 0 5.361443982110359e-07
of O 0 8.580956034620613e-08
approximately O 0 2.6493128189031268e-06
100 O 0 6.455122274928726e-06
repeats O 0 0.00038644822780042887
. O 0 5.653167318087071e-05

His O 0 4.589204036165029e-05
sperm O 0 7.76257729739882e-05
showed O 0 1.9382103346288204e-05
an O 0 9.060440220309829e-07
expanded O 0 3.193772499798797e-06
allele O 0 4.381739472592017e-06
in O 0 2.195620396605591e-07
a O 0 9.102419085138536e-07
tight O 0 4.878978415945312e-06
range O 0 5.67018389574514e-07
centering O 0 1.2419513950590044e-06
on O 0 1.33704077143193e-07
a O 0 4.6344058546310407e-07
size O 0 1.68368626418669e-06
of O 0 2.5431538119846664e-07
approximately O 0 1.458815222576959e-05
320 O 0 0.0005059812683612108
trinucleotide O 1 0.5876481533050537
repeats O 0 0.0020315544679760933
. O 0 0.00010982587264152244

His O 0 0.0005154700484126806
affected O 0 0.0011603826424106956
son O 0 0.0032797171734273434
has O 0 7.161542725953041e-06
repeat O 0 4.598850864567794e-05
sizes O 0 2.683714001250337e-06
of O 0 1.2059880418746616e-06
1040 O 0 0.01676291972398758
and O 0 8.595405233791098e-06
540 O 0 0.0003210203431081027
. O 0 4.629617615137249e-05

These O 0 1.7845858337750542e-06
data O 0 3.6262340472603682e-06
suggest O 0 6.726784249622142e-06
that O 0 4.272376088465535e-07
expansion O 0 2.660004156496143e-06
occurs O 0 1.1517016673678881e-06
in O 0 1.0687382712148974e-07
two O 0 6.1395191153224e-08
stages O 0 5.507091373146977e-06
, O 0 1.0930752836202373e-07
the O 0 6.404127361747669e-08
first O 0 1.5796420882452367e-07
during O 0 1.6833008658068138e-06
meiosis O 0 1.1419719157856889e-05
followed O 0 1.1100628398708068e-06
by O 0 2.1397330840500217e-07
a O 0 1.7354614101350307e-06
second O 0 7.5168272815062664e-06
mitotic O 0 0.001137172686867416
expansion O 0 0.0002111584908561781
. O 0 3.9482027204940096e-05

We O 0 5.278309799905401e-06
also O 0 1.3038073802817962e-06
show O 0 1.1858675179610145e-06
that O 0 1.3712146085254062e-07
in O 0 6.552046727392735e-08
all O 0 8.740025947417962e-08
informative O 0 8.752102985454258e-06
carrier O 0 0.00046521463082171977
father O 0 6.246251723496243e-05
to O 0 1.5153503909459687e-06
affected O 0 5.2580922783818096e-05
child O 0 6.796777597628534e-05
transmissions O 0 1.8091959645971656e-05
, O 0 3.025684804924822e-07
with O 0 1.1018354229008764e-07
the O 0 1.735253221113453e-07
notable O 0 7.175470955189667e-07
exception O 0 7.385368689938332e-07
of O 0 1.1244075182048618e-07
the O 0 4.809819074580446e-06
premutation O 0 0.01570713520050049
carrier O 0 0.00030266534304246306
, O 0 5.032260332882288e-07
the O 0 4.978008405487344e-07
expansion O 0 1.6018320820876397e-05
size O 0 2.654587478900794e-05
decreases O 0 0.00014020137314219028
. O 0 6.164528713270556e-06
. O 0 2.4719631255720742e-05

The O 0 4.065125176566653e-05
R496H O 0 0.00059469323605299
mutation O 0 5.154268001206219e-05
of O 0 3.846314484690083e-06
arylsulfatase O 0 0.05954088643193245
A O 0 0.0007861366029828787
does O 0 7.536390330642462e-05
not O 0 4.0754108340479434e-05
cause O 1 0.6788521409034729
metachromatic B-Disease 1 0.994988739490509
leukodystrophy I-Disease 1 0.9969999194145203
. O 0 0.0015342225087806582

Deficiency B-Disease 1 0.9984176158905029
of I-Disease 0 1.2030935067741666e-05
arylsulfatase I-Disease 0 0.06561897695064545
A I-Disease 0 0.0007282127626240253
( O 0 0.00014028347504790872
ARSA O 1 0.5474120378494263
) O 0 1.2991148651053663e-05
enzyme O 0 0.00017297880549449474
activity O 0 0.00017293657583650202
causes O 0 0.39794695377349854
metachromatic B-Disease 1 0.9966614246368408
leukodystrophy I-Disease 1 0.999221682548523
( O 0 0.014798777177929878
MLD B-Disease 1 0.9976189732551575
) O 0 0.0002035418146988377
. O 0 0.0001277406554436311

A O 0 4.205310688121244e-05
number O 0 1.2259123423064011e-06
of O 0 6.6388734012434725e-06
ARSA O 1 0.8905901312828064
gene O 0 0.00023078689991962165
mutations O 0 0.00017548134201206267
responsible O 0 4.406387233757414e-05
for O 0 7.079362694639713e-05
MLD B-Disease 1 0.998957633972168
have O 0 1.1324930710543413e-05
been O 0 2.0160719941486605e-05
identified O 0 9.874143870547414e-05
. O 0 4.70491977466736e-05

Recently O 0 0.000274629273917526
, O 0 5.131643320055446e-06
the O 0 3.997110979980789e-06
R496H O 0 0.00025390405789949
mutation O 0 4.040054773213342e-05
of O 0 3.3129499570350163e-06
ARSA O 1 0.9761606454849243
was O 0 3.3452473871875554e-05
proposed O 0 3.919135451724287e-06
to O 0 2.2633258822679636e-07
be O 0 2.0060602423654927e-07
a O 0 4.184408680885099e-06
cause O 0 0.00021639109763782471
of O 0 6.03124544795719e-06
MLD B-Disease 1 0.9982501864433289
( O 0 0.0001167202863143757
Draghia O 0 0.010454824194312096
et O 0 0.000998673029243946
al O 0 8.020983659662306e-05
. O 0 1.7982669078264735e-06
, O 0 2.9652192097273655e-06
1997 O 0 9.631029388401657e-05
) O 0 1.1260294741077814e-05
. O 0 1.8760118109639734e-05

We O 0 1.4002362149767578e-05
have O 0 2.034002363870968e-06
investigated O 0 3.0228346076910384e-05
the O 0 2.621956127768499e-06
R496H O 0 0.0002732502471189946
mutation O 0 1.884306220745202e-05
and O 0 2.236934051325079e-07
found O 0 7.779775046401483e-07
this O 0 2.258340856542418e-07
mutation O 0 3.3600804272282403e-06
at O 0 5.42800535185961e-07
a O 0 9.432118872609863e-07
relatively O 0 1.2415606533977552e-06
high O 0 1.478568606216868e-06
frequency O 0 2.1341084277537448e-07
in O 0 8.458061984129017e-08
an O 0 1.8187773775935057e-07
African O 0 7.282971523636661e-07
American O 0 5.71451380437793e-07
population O 0 2.0024017999276111e-07
( O 0 4.7154838966889656e-07
f O 0 4.914234523312189e-06
= O 0 3.6711660413857317e-06
0 O 0 3.3805434895839426e-07
. O 0 2.3251271841218113e-07
09 O 0 1.1997707588307094e-05
, O 0 3.5206710435886635e-07
n O 0 5.8005921346193645e-06
= O 0 1.672643338679336e-05
61 O 0 1.0600431778584607e-05
subjects O 0 5.592006345978007e-06
) O 0 1.088174212782178e-05
. O 0 1.9958766642957926e-05

The O 0 0.00011476733925519511
ARSA O 0 0.16480398178100586
enzyme O 0 8.196940325433388e-05
activity O 0 4.871135388384573e-06
in O 0 7.155011303439096e-07
subjects O 0 1.1866300155816134e-06
with O 0 3.138773365662928e-07
and O 0 3.3641094887570944e-07
without O 0 8.285919079753512e-07
the O 0 1.9805054307653336e-06
R496H O 0 0.0008067152230069041
mutation O 0 9.392260835738853e-05
was O 0 1.1527123206178658e-05
determined O 0 1.8984263761012699e-06
and O 0 2.8342725499896915e-07
found O 0 1.3674343790626153e-06
to O 0 2.9013054358983936e-07
be O 0 7.63411890147836e-07
normal O 0 3.065088458242826e-05
. O 0 3.830216883216053e-05

It O 0 1.1429776350269094e-05
is O 0 3.422856934776064e-06
therefore O 0 2.5219196686521173e-06
concluded O 0 1.2700031220447272e-05
that O 0 3.292924759534799e-07
the O 0 9.633206445869291e-07
R496H O 0 0.0001485879038227722
mutation O 0 2.75457241514232e-05
of O 0 3.0853457246848848e-06
ARSA O 1 0.990669846534729
does O 0 6.955885055504041e-06
not O 0 3.2788733506095014e-07
negatively O 0 2.339019147257204e-06
influence O 0 6.192389605530479e-07
the O 0 3.463342181930784e-07
activity O 0 1.5130658539419528e-06
of O 0 1.2739193380184588e-06
ARSA O 1 0.9893940091133118
and O 0 1.1088427527283784e-06
is O 0 9.76276965047873e-07
not O 0 7.506716315219819e-07
a O 0 2.4627319362480193e-05
cause O 0 0.0019035979639738798
of O 0 9.559642057865858e-05
MLD B-Disease 1 0.9948952794075012

Down O 0 0.0009316584910266101
- O 0 0.00011832152085844427
regulation O 0 1.3565672816184815e-05
of O 0 2.678791815924342e-06
transmembrane O 0 0.0076742107048630714
carbonic O 1 0.8261870741844177
anhydrases O 1 0.6961976885795593
in O 0 0.005437851883471012
renal B-Disease 1 0.9998841285705566
cell I-Disease 1 0.9988505840301514
carcinoma I-Disease 1 0.9999558925628662
cell O 0 0.021433889865875244
lines O 0 0.0001025203600875102
by O 0 1.3757450687990058e-05
wild O 0 0.0002869254385586828
- O 0 0.010519959032535553
type O 0 0.008314787410199642
von B-Disease 1 0.6293068528175354
Hippel I-Disease 1 0.9766896963119507
- I-Disease 0 0.22888527810573578
Lindau I-Disease 1 0.8854679465293884
transgenes O 0 0.0450248196721077
. O 0 0.00039502952131442726

To O 0 1.3200812645663973e-05
discover O 0 0.00012918893480673432
genes O 0 1.109210916183656e-05
involved O 0 2.2873191483085975e-05
in O 0 4.823925701202825e-05
von B-Disease 1 0.6760664582252502
Hippel I-Disease 1 0.9836992025375366
- I-Disease 0 0.4420621395111084
Lindau I-Disease 1 0.9338311553001404
( O 0 0.0003929416125174612
VHL B-Disease 1 0.9895589351654053
) O 0 9.388285980094224e-05
- O 0 0.00241002906113863
mediated O 0 0.002063792198896408
carcinogenesis O 1 0.5060187578201294
, O 0 1.080328001989983e-05
we O 0 1.0971585652441718e-05
used O 0 0.00048019146197475493
renal B-Disease 1 0.9998325109481812
cell I-Disease 1 0.998600423336029
carcinoma I-Disease 1 0.9999552965164185
cell O 0 0.396391898393631
lines O 0 0.0010800723684951663
stably O 0 0.004965650383383036
transfected O 0 0.0043619368225336075
with O 0 2.6306512154405937e-05
wild O 0 0.0006953636766411364
- O 0 0.1433255672454834
type O 0 0.16522029042243958
VHL O 1 0.9936814308166504
- O 0 0.011598465032875538
expressing O 0 0.0005390296573750675
transgenes O 0 0.02047743648290634
. O 0 0.00016360504378098994

Large O 0 0.0001392945705447346
- O 0 0.00014966289745643735
scale O 0 2.079786099784542e-05
RNA O 0 1.295266247325344e-05
differential O 0 1.5001553038018756e-05
display O 0 6.030331405781908e-06
technology O 0 5.095643246022519e-06
applied O 0 7.762396307953168e-07
to O 0 1.3398259568475623e-07
these O 0 1.9728808808849863e-07
cell O 0 6.6038039221894e-05
lines O 0 8.309109944093507e-06
identified O 0 2.2794406504544895e-06
several O 0 4.2569863012431597e-07
differentially O 0 2.429585947538726e-05
expressed O 0 2.0802008293685503e-06
genes O 0 1.293510536015674e-06
, O 0 2.2489962248073425e-07
including O 0 3.823941767677752e-07
an O 0 2.2780063773097936e-06
alpha O 0 7.374694541795179e-05
carbonic O 0 0.014717400074005127
anhydrase O 0 0.06722075492143631
gene O 0 0.0001545146369608119
, O 0 2.4504326574970037e-05
termed O 0 0.007820593193173409
CA12 O 1 0.7735493779182434
. O 0 0.0003176789323333651

The O 0 2.650101350809564e-06
deduced O 0 8.699128557054792e-06
protein O 0 3.5266837130620843e-06
sequence O 0 3.483948376015178e-06
was O 0 1.2879656424047425e-05
classified O 0 1.2564014468807727e-05
as O 0 2.6567312261249754e-07
a O 0 1.4834951116426964e-06
one O 0 1.5572981055811397e-06
- O 0 5.2771509217564017e-05
pass O 0 5.234072887105867e-06
transmembrane O 0 0.0006786542944610119
CA O 0 0.00013801277964375913
possessing O 0 7.258595815073932e-06
an O 0 1.0750533192549483e-06
apparently O 0 1.4254992493079044e-05
intact O 0 2.034179306065198e-05
catalytic O 0 1.2068961041222792e-05
domain O 0 2.033110149568529e-06
in O 0 4.3729960452765226e-07
the O 0 2.411772356936126e-06
extracellular O 0 0.0002716423769015819
CA O 0 0.0018211586866527796
module O 0 0.0007436606683768332
. O 0 7.311310764634982e-05

Reintroduced O 0 0.001903204945847392
wild O 0 0.0005453452467918396
- O 0 0.01427090261131525
type O 0 0.0038969211746007204
VHL B-Disease 1 0.9610483050346375
strongly O 0 3.459236540948041e-05
inhibited O 0 4.962686216458678e-05
the O 0 6.926936180207122e-07
overexpression O 0 1.6904801668715663e-05
of O 0 2.5914783918778994e-07
the O 0 2.7474873149913037e-06
CA12 O 0 0.008585387840867043
gene O 0 1.6341462469426915e-05
in O 0 2.190071427321527e-06
the O 0 4.0634156903252006e-05
parental O 1 0.6059053540229797
renal B-Disease 1 0.9999345541000366
cell I-Disease 1 0.9994681477546692
carcinoma I-Disease 1 0.9999737739562988
cell O 1 0.9763578772544861
lines O 0 0.006452013738453388
. O 0 0.00041922187665477395

Similar O 0 4.680017082137056e-05
results O 0 9.36493779590819e-06
were O 0 6.665147225248802e-07
obtained O 0 2.7995506570732687e-06
with O 0 6.470363587141037e-06
CA9 O 0 0.44468188285827637
, O 0 7.817936875653686e-07
encoding O 0 1.2319751476752572e-06
another O 0 7.959802132972982e-06
transmembrane O 0 0.0022675408981740475
CA O 0 4.435748269315809e-05
with O 0 2.093913167300343e-07
an O 0 1.0741647429313161e-06
intact O 0 9.963553748093545e-05
catalytic O 0 0.00011209389049327001
domain O 0 6.31333386991173e-05
. O 0 8.454957423964515e-05

Although O 0 8.463978701911401e-06
both O 0 4.286125090402493e-07
domains O 0 3.2821942568261875e-06
of O 0 5.807815455227683e-07
the O 0 1.1553073818504345e-05
VHL B-Disease 1 0.7765982747077942
protein O 0 1.1462775546533521e-05
contribute O 0 3.1623428640159545e-06
to O 0 2.3707738705525117e-07
regulation O 0 4.389522928249789e-06
of O 0 6.919468660271377e-07
CA12 O 0 0.00987339299172163
expression O 0 5.644234079227317e-06
, O 0 5.6146194538087e-07
the O 0 1.1195353408766096e-06
elongin O 0 0.00020124463480897248
binding O 0 6.688390385534149e-06
domain O 0 1.6383221009164117e-05
alone O 0 5.2473573305178434e-05
could O 0 6.997648597462103e-06
effectively O 0 8.02659269538708e-05
regulate O 0 0.0013007598463445902
CA9 O 1 0.9515394568443298
expression O 0 0.00032208437914960086
. O 0 0.0001342231553280726

We O 0 5.545147359953262e-05
mapped O 0 0.0005396668566390872
CA12 O 0 0.020871484652161598
and O 0 5.6108077842509374e-05
CA9 O 1 0.6730042695999146
loci O 0 7.697018736507744e-05
to O 0 2.9337468276935397e-06
chromosome O 0 0.0001177461672341451
bands O 0 5.650935781886801e-05
15q22 O 0 0.001446596346795559
and O 0 1.503492512711091e-05
17q21 O 0 0.0030788215808570385
. O 0 0.00014969860785640776

2 O 0 9.159752517007291e-05
respectively O 0 3.551575355231762e-05
, O 0 7.566417480120435e-06
regions O 0 7.189538791863015e-06
prone O 0 0.0012207498075440526
to O 0 1.0995917136824573e-06
amplification O 0 8.300740591948852e-05
in O 0 3.5001069136342267e-06
some O 0 6.099209713283926e-06
human O 0 0.0012624686351045966
cancers B-Disease 1 0.9964216947555542
. O 0 0.00018664136587176472

Additional O 0 1.5239098502206616e-05
experiments O 0 8.332304787472822e-06
are O 0 1.2351486589068372e-07
needed O 0 7.476965038222261e-07
to O 0 5.8052794571494815e-08
define O 0 6.51525965622568e-07
the O 0 4.1990330146290944e-07
role O 0 2.2114957118901657e-06
of O 0 2.8306951662671054e-06
CA O 0 0.25120165944099426
IX O 1 0.6558176279067993
and O 0 1.6222198610194027e-05
CA O 0 0.0015914395917207003
XII O 0 0.008312389254570007
enzymes O 0 1.6376562825826113e-06
in O 0 7.151914616088106e-08
the O 0 8.369094928184495e-08
regulation O 0 8.504916877427604e-07
of O 0 1.1980459646565578e-07
pH O 0 0.00014598584675695747
in O 0 1.3092657979996147e-07
the O 0 4.482773761083081e-07
extracellular O 0 1.7999338524532504e-05
microenvironment O 0 0.0001900572533486411
and O 0 3.8655502976325806e-07
its O 0 7.144265623537649e-07
potential O 0 9.028268323163502e-06
impact O 0 0.00015581333718728274
on O 0 0.00027095817495137453
cancer B-Disease 1 0.9989953637123108
cell O 0 0.13494786620140076
growth O 0 0.00306700705550611
. O 0 0.00010728938650572672

A O 0 1.835538751038257e-05
gene O 0 5.5898044593050145e-06
encoding O 0 1.9808926481346134e-06
a O 0 5.302982572175097e-06
transmembrane O 0 0.00019296500249765813
protein O 0 2.7891259378520772e-05
is O 0 8.769112355366815e-06
mutated O 0 0.0025139087811112404
in O 0 0.00024506321642547846
patients O 1 0.9981997013092041
with O 1 0.992484986782074
diabetes B-Disease 1 0.9999902248382568
mellitus I-Disease 1 0.9999452829360962
and O 1 0.9540305137634277
optic B-Disease 1 0.9998806715011597
atrophy I-Disease 1 0.999729335308075
( O 1 0.9951468110084534
Wolfram B-Disease 1 0.999637246131897
syndrome I-Disease 1 0.9999871253967285
) O 0 0.0031581365037709475
. O 0 0.00026079866802319884

Wolfram B-Disease 1 0.9954758286476135
syndrome I-Disease 1 0.9999148845672607
( O 0 0.36239391565322876
WFS B-Disease 1 0.9926382303237915
; O 0 0.004561878740787506
OMIM O 1 0.9925975799560547
222300 O 0 0.03187987953424454
) O 0 2.954745286842808e-05
is O 0 1.5738103684270754e-05
an O 0 0.000601039151661098
autosomal B-Disease 1 0.9991959929466248
recessive I-Disease 1 0.9998202919960022
neurodegenerative I-Disease 1 0.9999667406082153
disorder I-Disease 1 0.999925971031189
defined O 0 0.002928654197603464
by O 0 0.0006048064096830785
young O 0 0.15456193685531616
- O 1 0.9742487668991089
onset O 1 0.9986461997032166
non O 0 0.15791642665863037
- O 1 0.9940674304962158
immune O 1 0.9976890087127686
insulin B-Disease 1 0.9942948222160339
- I-Disease 1 0.9941516518592834
dependent I-Disease 1 0.9294916391372681
diabetes I-Disease 1 0.9999576807022095
mellitus I-Disease 1 0.9998123049736023
and O 0 0.0361638143658638
progressive O 1 0.9955602884292603
optic B-Disease 1 0.9995893836021423
atrophy I-Disease 1 0.9982283711433411
. O 0 0.0028761918656527996

Linkage O 0 0.0005088634788990021
to O 0 6.183334789966466e-06
markers O 0 0.0002177743735956028
on O 0 2.1680643840227276e-05
chromosome O 0 0.002270008437335491
4p O 1 0.9803783297538757
was O 0 7.22696422599256e-05
confirmed O 0 1.8672515579964966e-05
in O 0 8.621869937996962e-07
five O 0 3.301652213849593e-06
families O 0 1.2866692486568354e-05
. O 0 3.726516297319904e-05

On O 0 3.744130253835465e-06
the O 0 7.584121135550959e-07
basis O 0 1.0010312507802155e-06
of O 0 1.1110403647762723e-05
meiotic O 1 0.9115660190582275
recombinants O 1 0.9866312146186829
and O 0 0.009973922744393349
disease O 1 0.9997656941413879
- O 0 0.3244616389274597
associated O 0 0.00021731307788286358
haplotypes O 0 0.0006218120106495917
, O 0 7.86669352237368e-06
the O 0 2.572813355072867e-05
WFS B-Disease 1 0.9552160501480103
gene O 0 4.3411921069491655e-05
was O 0 2.1458205083035864e-05
localized O 0 5.8388126490172e-05
to O 0 7.598477509418444e-07
a O 0 3.092841507168487e-05
BAC O 0 0.049034152179956436
/ O 0 0.0022480557672679424
P1 O 0 0.0035754747223109007
contig O 0 0.00010900828056037426
of O 0 2.514117340979283e-07
less O 0 2.3349653019977268e-06
than O 0 1.6181326145670027e-06
250 O 0 2.2909607650944963e-05
kb O 0 0.0012899447465315461
. O 0 5.7804962125374004e-05

Mutations O 0 0.00010812139953486621
in O 0 1.9506026092130924e-06
a O 0 5.103945113660302e-06
novel O 0 1.7382129954057746e-05
gene O 0 2.93433949991595e-05
( O 0 5.657976998918457e-06
WFS1 O 0 0.0004476393514778465
) O 0 3.256877221247123e-07
encoding O 0 3.414916704969073e-07
a O 0 1.2403889968481963e-06
putative O 0 1.833168244047556e-05
transmembrane O 0 6.183554069139063e-05
protein O 0 5.203980890655657e-06
were O 0 2.7573469196795486e-07
found O 0 7.216701192191977e-07
in O 0 1.8773188514842332e-07
all O 0 1.1306744340799924e-07
affected O 0 5.793549007648835e-06
individuals O 0 7.375845143542392e-07
in O 0 2.7990754460915923e-06
six O 0 7.374089182121679e-05
WFS B-Disease 1 0.9974168539047241
families O 0 1.0811741958605126e-05
, O 0 1.0685870392990182e-06
and O 0 1.915149283604478e-07
these O 0 1.598818926140666e-07
mutations O 0 1.0753028618637472e-05
were O 0 4.63585593024618e-07
associated O 0 1.4307836863736156e-05
with O 0 3.214763637515716e-05
the O 0 0.006848322693258524
disease O 1 0.9996821880340576
phenotype O 1 0.8280156254768372
. O 0 0.00040183388045988977

WFS1 O 0 0.15208005905151367
appears O 0 7.276158430613577e-05
to O 0 7.212827313196613e-07
function O 0 1.8130640455638058e-06
in O 0 1.745764734550903e-06
survival O 0 0.00011296690354356542
of O 0 1.8670558574740426e-06
islet O 0 0.003397957421839237
beta O 0 0.005939070135354996
- O 0 0.0030169577803462744
cells O 0 4.332470052759163e-05
and O 0 1.6495816907990957e-06
neurons O 0 0.00024331216991413385
. O 0 7.674848347960506e-06
. O 0 2.7010686608264223e-05

Stable O 0 0.00019049012917093933
interaction O 0 3.5473910884320503e-06
between O 0 1.1510692274896428e-06
the O 0 6.063763180463866e-07
products O 0 1.1750410067179473e-06
of O 0 1.226195962544807e-07
the O 0 5.919196155446116e-06
BRCA1 O 0 0.013966619968414307
and O 0 1.7870153897092678e-05
BRCA2 O 1 0.6485788226127625
tumor B-Disease 1 0.9913808703422546
suppressor O 0 0.0007374563138000667
genes O 0 6.461983502958901e-06
in O 0 1.9511849131959025e-06
mitotic O 0 0.0009881382575258613
and O 0 1.204489581141388e-05
meiotic O 0 0.3843105435371399
cells O 0 0.0022558083292096853
. O 0 9.935592970578e-05

BRCA1 O 0 0.08343694359064102
and O 0 3.384378942428157e-05
BRCA2 O 0 0.004484002012759447
account O 0 3.818766344920732e-06
for O 0 7.6109591873319e-07
most O 0 1.3529629541153554e-06
cases O 0 1.0222222954325844e-05
of O 0 3.1646056868339656e-06
familial O 1 0.9793809056282043
, O 0 0.0002038131351582706
early O 0 0.03304196521639824
onset O 1 0.999626636505127
breast B-Disease 1 0.999764621257782
and I-Disease 0 0.019629567861557007
/ I-Disease 1 0.9989944100379944
or I-Disease 1 0.9949995279312134
ovarian I-Disease 1 0.9999895095825195
cancer I-Disease 1 0.9998829364776611
and O 0 1.6012281776056625e-06
encode O 0 2.418571511952905e-06
products O 0 5.0253538574907e-06
that O 0 1.21618029425008e-07
each O 0 8.784598293232193e-08
interact O 0 2.6953175620292313e-06
with O 0 9.081670214072801e-06
hRAD51 O 0 0.009037494659423828
. O 0 8.600606088293716e-05

Results O 0 8.449830784229562e-05
presented O 0 1.7429452782380395e-05
here O 0 3.543688762874808e-06
show O 0 4.281551809981465e-06
that O 0 1.6972736602838268e-06
BRCA1 O 0 0.002179559553042054
and O 0 5.312902885634685e-06
BRCA2 O 0 0.003876361297443509
coexist O 0 1.3460618902172428e-05
in O 0 1.0108597052749246e-06
a O 0 5.903963483433472e-06
biochemical O 0 0.00011783636000473052
complex O 0 3.166884198435582e-05
and O 0 3.443891046117642e-06
colocalize O 0 0.002346830442547798
in O 0 4.150922904955223e-06
subnuclear O 0 0.0020173033699393272
foci O 0 0.0001802659098757431
in O 0 4.5230640353111085e-06
somatic O 0 0.00013708746701013297
cells O 0 1.625791446713265e-05
and O 0 1.7268108365442458e-07
on O 0 1.674124661121823e-07
the O 0 2.3556759742859867e-07
axial O 0 8.11789414001396e-06
elements O 0 6.593498937945697e-07
of O 0 2.2547847038367763e-06
developing O 0 0.0003269901790190488
synaptonemal O 0 0.10797856003046036
complexes O 0 0.005235759075731039
. O 0 0.00015673601592425257

Like O 0 0.0006554257706739008
BRCA1 O 0 0.03851662948727608
and O 0 4.0679326048120856e-05
RAD51 O 1 0.8340741991996765
, O 0 3.201387880835682e-05
BRCA2 O 0 0.0013728431658819318
relocates O 0 0.0002381415106356144
to O 0 5.309605967340758e-06
PCNA O 0 0.014051725156605244
+ O 0 4.769756196765229e-05
replication O 0 1.5873021766310558e-05
sites O 0 1.3735352695221081e-06
following O 0 6.071354164305376e-06
exposure O 0 0.00014430635201279074
of O 0 1.6889933931452106e-06
S O 0 0.023043286055326462
phase O 0 0.00021191302221268415
cells O 0 5.565294122789055e-05
to O 0 3.2930895486060763e-06
hydroxyurea O 0 0.022393425926566124
or O 0 0.00013096634938847274
UV O 0 0.4386138916015625
irradiation O 0 0.003361012786626816
. O 0 0.0002552112564444542

Thus O 0 9.410156053490937e-05
, O 0 2.8657854272751138e-05
BRCA1 O 0 0.003912488929927349
and O 0 4.784300472238101e-06
BRCA2 O 0 0.0004623450222425163
participate O 0 4.4778769847653166e-07
, O 0 2.642903496052895e-07
together O 0 1.768914472677352e-07
, O 0 2.1219480572653993e-07
in O 0 1.1488129558756555e-07
a O 0 1.8545503053246648e-06
pathway O 0 3.899461080436595e-05
( O 0 8.398127647524234e-06
s O 0 0.00021747431310359389
) O 0 5.164829985915276e-07
associated O 0 3.852680094951211e-07
with O 0 6.370600402760829e-08
the O 0 1.4945898385576584e-07
activation O 0 5.876994237041799e-06
of O 0 5.494933361660514e-07
double O 0 0.00023065402638167143
- O 0 0.0005804484244436026
strand O 0 7.977838686201721e-05
break O 0 0.00014937407104298472
repair O 0 0.181242898106575
and O 0 6.3549600781698246e-06
/ O 0 0.0005541793070733547
or O 0 5.059809609520016e-06
homologous O 0 0.00012160808546468616
recombination O 0 0.0004903235821984708
. O 0 0.00011308945977361873

Dysfunction O 1 0.9704992175102234
of O 0 2.2780216113460483e-06
this O 0 4.235129836160922e-06
pathway O 0 0.0002748175757005811
may O 0 1.0038725122285541e-05
be O 0 1.2596058240887942e-07
a O 0 1.2472286243792041e-06
general O 0 3.2100786029332085e-06
phenomenon O 0 5.224109372647945e-06
in O 0 1.2237089208610996e-07
the O 0 1.8027745340987167e-07
majority O 0 3.3312960567855043e-07
of O 0 3.0276305551524274e-07
cases O 0 4.311696829972789e-05
of O 0 4.427022213349119e-05
hereditary B-Disease 1 0.9995371103286743
breast I-Disease 1 0.9998075366020203
and I-Disease 0 0.01450227852910757
/ I-Disease 1 0.9987524747848511
or I-Disease 1 0.9938127994537354
ovarian I-Disease 1 0.9999909400939941
cancer I-Disease 1 0.9999430179595947
. O 0 0.00039004257996566594
. O 0 0.0001667424221523106

A O 0 0.0001187740417663008
novel O 0 0.00012136620352976024
Arg362Ser O 0 0.001967653864994645
mutation O 0 3.11222393065691e-05
in O 0 1.2045788935211021e-06
the O 0 2.9997686397109646e-06
sterol O 0 0.0012665004469454288
27 O 0 7.724799070274457e-05
- O 0 0.00015470568905584514
hydroxylase O 0 0.0001659898553043604
gene O 0 3.2677078706910834e-05
( O 0 8.627614988654386e-06
CYP27 O 0 0.0022801109589636326
) O 0 1.5665438013456878e-06
: O 0 3.591185304685496e-07
its O 0 1.2100093726985506e-07
effects O 0 7.4465619945840444e-06
on O 0 3.917723745416879e-07
pre O 0 2.478451824572403e-05
- O 0 4.655869815906044e-06
mRNA O 0 6.394381557583984e-07
splicing O 0 3.235564236092614e-06
and O 0 4.3056013510067714e-07
enzyme O 0 2.592581404314842e-05
activity O 0 2.583404966571834e-05
. O 0 4.8891666665440425e-05

A O 0 6.337256490951404e-05
novel O 0 3.3917032851604745e-05
C O 0 8.178967982530594e-05
to O 0 5.187359306546568e-07
A O 0 7.900722266640514e-06
mutation O 0 7.202110737125622e-06
in O 0 6.567097443621606e-07
the O 0 2.759364178928081e-06
sterol O 0 0.001559522352181375
27 O 0 0.00011264270870015025
- O 0 0.0001828700042096898
hydroxylase O 0 0.00015798574895597994
gene O 0 2.041681182163302e-05
( O 0 1.1703601558110677e-05
CYP27 O 0 0.003982332535088062
) O 0 2.5821607323450735e-06
was O 0 2.840828528860584e-06
identified O 0 6.707027182528691e-07
by O 0 2.0965107694337348e-07
sequencing O 0 5.25371160620125e-06
amplified O 0 8.20692876004614e-05
CYP27 O 0 0.003652453888207674
gene O 0 3.598764669732191e-05
products O 0 1.153944140241947e-05
from O 0 2.7342819066689117e-06
a O 0 7.022553472779691e-05
patient O 0 0.034492604434490204
with O 0 9.229061106452718e-05
cerebrotendinous B-Disease 1 0.992624819278717
xanthomatosis I-Disease 1 0.9915920495986938
( O 0 0.0013048476539552212
CTX B-Disease 1 0.9890562295913696
) O 0 0.00013031023263465613
. O 0 7.373737753368914e-05

The O 0 3.048806502192747e-05
mutation O 0 0.00010399850725661963
changed O 0 1.913369669637177e-05
the O 0 3.671026206575334e-06
adrenodoxin O 0 0.0004936614423058927
cofactor O 0 8.058480307227e-05
binding O 0 1.712474477244541e-05
residue O 0 0.0001720034924801439
362Arg O 0 0.0003655478067230433
to O 0 3.6164190078125102e-06
362Ser O 0 0.0013859556056559086
( O 0 4.0812337829265743e-05
CGT O 0 0.013535510748624802
362Arg O 0 0.0007277330150827765
to O 0 1.5162152521952521e-05
AGT O 1 0.9791532754898071
362Ser O 0 0.0019318013219162822
) O 0 4.264525614416925e-06
, O 0 1.2024314628433785e-06
and O 0 4.932913384436688e-07
was O 0 2.0422110537765548e-05
responsible O 0 1.9077197066508234e-05
for O 0 2.5926801754394546e-05
deficiency O 1 0.9995632767677307
in O 0 3.623776137828827e-06
the O 0 5.35883873453713e-06
sterol O 0 0.0058260769583284855
27 O 0 0.00012919670552946627
- O 0 0.00014758677571080625
hydroxylase O 0 6.478862633230165e-05
activity O 0 1.145355440712592e-06
, O 0 2.1047542020369292e-07
as O 0 1.4553302207787056e-07
confirmed O 0 8.672139415466518e-07
by O 0 3.731087261371613e-08
expression O 0 2.014376576653376e-07
of O 0 1.0200773914448291e-07
mutant O 0 1.5201938367681578e-05
cDNA O 0 3.247317363275215e-05
into O 0 2.5078483304241672e-05
COS O 1 0.6254447102546692
- O 0 0.0016236503142863512
1 O 0 5.469390089274384e-05
cells O 0 0.00018099545559380203
. O 0 2.1716361516155303e-05

Quantitative O 0 5.3759547881782055e-05
analysis O 0 6.320894499367569e-06
showed O 0 1.2968150258529931e-05
that O 0 1.2075194888439e-07
the O 0 1.554183910457141e-07
expression O 0 3.3921051567631366e-07
of O 0 1.3861611591892142e-07
CYP27 O 0 0.0004830493126064539
gene O 0 2.464608769514598e-06
mRNA O 0 1.0934647889371263e-06
in O 0 7.698970989622467e-07
the O 0 2.79632718047651e-06
patient O 0 0.001297792186960578
represented O 0 1.5052039998408873e-05
52 O 0 0.00015770987374708056
. O 0 3.856804687529802e-05

5 O 0 1.367152071907185e-05
% O 0 1.122058961300354e-06
of O 0 2.591868906165473e-07
the O 0 2.592328883110895e-06
normal O 0 5.654655251419172e-05
level O 0 0.00013505661627277732
. O 0 4.263375740265474e-05

As O 0 3.859821845253464e-06
the O 0 2.6681598228606163e-06
mutation O 0 1.7044925698428415e-05
occurred O 0 6.962243332964135e-06
at O 0 5.911958851356758e-07
the O 0 1.8354334940795525e-07
penultimate O 0 1.1253380762354936e-05
nucleotide O 0 8.028216598177096e-07
of O 0 2.5335916120639013e-07
exon O 0 8.994311065180227e-05
6 O 0 9.87672228802694e-06
( O 0 3.756014166356181e-06
- O 0 3.3570825053175213e-06
2 O 0 1.1498543273091855e-07
position O 0 4.2998728133625264e-08
of O 0 6.75848355058406e-08
exon O 0 7.303679012693465e-05
6 O 0 2.5925122827175073e-05
- O 0 9.42381375352852e-05
intron O 0 0.00028885199571959674
6 O 0 5.684277311956976e-06
splice O 0 2.7303205570206046e-05
site O 0 1.6809491398817045e-06
) O 0 1.2076853295184264e-07
of O 0 2.6209702852497685e-08
the O 0 3.759089111099456e-07
gene O 0 5.933427019044757e-06
, O 0 3.124899876638665e-07
we O 0 1.3725411918130703e-07
hypothesized O 0 4.090702532266732e-06
that O 0 1.0209591039256338e-07
the O 0 1.013188580145652e-06
mutation O 0 0.00010268433834426105
may O 0 1.9409682863624766e-05
partially O 0 4.763515244121663e-05
affect O 0 4.989291255697026e-07
the O 0 1.2774275148785819e-07
normal O 0 1.0155071095141466e-06
splicing O 0 6.3698203121020924e-06
efficiency O 0 4.502569481701357e-06
in O 0 8.200467505048437e-07
exon O 0 8.881984831532463e-05
6 O 0 9.004132152767852e-06
and O 0 8.275360983134306e-07
cause O 0 1.5285937479347922e-05
alternative O 0 1.3629490922539844e-06
splicing O 0 8.599750799476169e-06
elsewhere O 0 1.907189357552852e-06
, O 0 4.0660643207957037e-07
which O 0 2.895986881412682e-07
resulted O 0 7.232780262711458e-06
in O 0 2.3846564545237925e-06
decreased O 0 0.0003580756310839206
transcript O 0 0.0003609776613302529
in O 0 4.29855481343111e-06
the O 0 2.6947396690957248e-05
patient O 0 0.1729222536087036
. O 0 9.275646152673289e-05

Transfection O 0 0.0020491378381848335
of O 0 8.613572390459012e-06
constructed O 0 0.0013531643198803067
minigenes O 0 0.010046619921922684
, O 0 1.1961192285525613e-06
with O 0 3.565155850537849e-07
or O 0 6.53393897209753e-07
without O 0 3.5795187613985036e-07
the O 0 5.666221341016353e-07
mutation O 0 8.453032023680862e-06
, O 0 8.86735278982087e-07
into O 0 4.242774139129324e-06
COS O 0 0.45619359612464905
- O 0 0.0002960970741696656
1 O 0 7.751848897896707e-06
cells O 0 7.0687601692043245e-06
confirmed O 0 1.5859017139518983e-06
that O 0 8.273421769899869e-08
the O 0 4.782430096383905e-07
mutant O 0 2.5096182071138173e-05
minigene O 0 0.00042319431668147445
was O 0 2.2557590000360506e-06
responsible O 0 5.298001042319811e-07
for O 0 4.504079598177668e-08
a O 0 3.198626643552416e-07
mRNA O 0 7.213625394797418e-07
species O 0 2.3991955799829157e-07
alternatively O 0 4.6483582991641015e-06
spliced O 0 2.0579767806339078e-05
at O 0 2.9856751098122913e-06
an O 0 3.3635622003203025e-06
activated O 0 0.00015673512825742364
cryptic O 0 0.00011207293573534116
5 O 0 6.111606126069091e-06
splice O 0 4.44452598458156e-05
site O 0 8.282094313472044e-06
88 O 0 9.884343853627797e-06
bp O 0 3.6482953873928636e-05
upstream O 0 1.6911321836232673e-06
from O 0 1.5726885749245412e-07
the O 0 2.0857160620835202e-07
3 O 0 6.111153538768122e-07
end O 0 1.3706592199014267e-06
of O 0 9.021485993798706e-07
exon O 0 0.0007119776564650238
6 O 0 0.00015114912821445614
. O 0 6.296751234913245e-05

Our O 0 5.1892761803173926e-06
data O 0 3.70865700460854e-06
suggest O 0 4.337655809649732e-06
that O 0 1.6207566488901648e-07
the O 0 3.4051606689899927e-07
C O 0 7.4336408033559565e-06
to O 0 3.103285095562569e-08
A O 0 9.293231642004685e-07
mutation O 0 7.956280114740366e-07
at O 0 1.2397865134516906e-07
the O 0 4.3444387642921356e-08
penultimate O 0 3.863983693008777e-06
nucleotide O 0 1.445876023353776e-07
of O 0 4.017703858494315e-08
exon O 0 8.577160770073533e-06
6 O 0 5.820102160214446e-07
of O 0 7.140887703371845e-08
the O 0 1.8317524563826737e-06
CYP27 O 0 0.0027425128500908613
gene O 0 8.763227015151642e-06
not O 0 2.0883851448161295e-07
only O 0 5.131591365170607e-07
causes O 0 0.0028476202860474586
the O 0 0.00013052861322648823
deficiency B-Disease 1 0.9997019171714783
in I-Disease 0 3.0858077479933854e-06
the I-Disease 0 5.420275556389242e-06
sterol I-Disease 0 0.007896008901298046
27 I-Disease 0 0.0002137904812116176
- I-Disease 0 0.00025515767629258335
hydroxylase I-Disease 0 0.00013096959446556866
activity I-Disease 0 3.0152912131597986e-06
, O 0 8.878894277586369e-07
but O 0 6.206809644027089e-07
also O 0 7.494655847040121e-07
partially O 0 1.5690924556110986e-05
leads O 0 1.1834047199954512e-06
to O 0 4.9034397875402647e-08
alternative O 0 5.079909897176549e-07
pre O 0 7.783754881529603e-06
- O 0 1.3596477401733864e-06
mRNA O 0 1.0754290258319088e-07
splicing O 0 3.2161352692128276e-07
of O 0 9.777428289226009e-08
the O 0 3.3829378480731975e-06
gene O 0 0.00010525066318223253
. O 0 6.529735401272774e-05

To O 0 1.7775910237105563e-06
our O 0 7.228204594866838e-07
knowledge O 0 9.413365091859305e-07
, O 0 4.998997837901697e-07
this O 0 7.787622280375217e-08
is O 0 1.538042795345973e-07
the O 0 1.5594009994401858e-07
first O 0 5.193754759602598e-07
report O 0 1.64532866619993e-06
regarding O 0 1.4887162933518994e-06
effects O 0 1.8899969290941954e-05
on O 0 5.574901251748088e-07
pre O 0 1.962383248610422e-05
- O 0 1.467669676458172e-06
mRNA O 0 7.900549547912306e-08
splicing O 0 1.521395915915491e-07
of O 0 2.7839483607294824e-08
a O 0 1.0817896054504672e-06
mutation O 0 4.1122661968984175e-06
at O 0 1.235411787092744e-06
the O 0 4.7088244059523277e-07
- O 0 5.090626018500188e-06
2 O 0 1.2566877671815746e-07
position O 0 3.922643188047914e-08
of O 0 2.7695479687395164e-08
a O 0 2.3803484054951696e-06
5 O 0 9.39034634939162e-06
splice O 0 0.0002596227277535945
site O 0 7.708388875471428e-05
. O 0 3.0387167498702183e-05

ATM O 0 0.010681365616619587
germline O 0 0.014905720017850399
mutations O 0 0.00035175838274881244
in O 0 6.361560372170061e-05
classical O 0 0.1387804001569748
ataxia B-Disease 1 0.9998986721038818
- I-Disease 1 0.9995760321617126
telangiectasia I-Disease 1 0.9996054768562317
patients O 1 0.9577130079269409
in O 0 5.894315108889714e-06
the O 0 1.3496430256054737e-05
Dutch O 0 0.00024703043163754046
population O 0 1.271520432055695e-05
. O 0 3.0356148272403516e-05

Germline O 0 0.008928438648581505
mutations O 0 6.46174667053856e-05
in O 0 1.5354809193013352e-06
the O 0 2.2253786937653786e-06
ATM O 0 0.00021206280507612973
gene O 0 6.255959306145087e-06
are O 0 1.7319268863502657e-07
responsible O 0 1.054192125593545e-05
for O 0 9.133234925684519e-06
the O 0 0.00979391485452652
autosomal B-Disease 1 0.9999121427536011
recessive I-Disease 1 0.9999754428863525
disorder I-Disease 1 0.9999973773956299
ataxia B-Disease 1 0.9999700784683228
- I-Disease 1 0.9995266199111938
telangiectasia I-Disease 1 0.9990679621696472
( O 0 0.0311253871768713
A B-Disease 1 0.9971449971199036
- I-Disease 1 0.9973430037498474
T I-Disease 1 0.9982931017875671
) O 0 4.8321908252546564e-05
. O 0 5.233345291344449e-05

In O 0 1.2163755854999181e-05
our O 0 2.016959342654445e-06
study O 0 6.409605248336447e-06
, O 0 6.004772217238497e-07
we O 0 1.2279946304261102e-07
have O 0 4.411423049077712e-08
determined O 0 1.5758925542286306e-07
the O 0 2.413911488474696e-07
ATM O 0 3.1183826649794355e-05
mutation O 0 3.5624166230263654e-06
spectrum O 0 3.260032826801762e-06
in O 0 5.402235956353252e-07
19 O 0 9.279919140681159e-06
classical O 0 0.00024443434085696936
A B-Disease 1 0.9978047013282776
- I-Disease 1 0.9992832541465759
T I-Disease 1 0.9998086094856262
patients O 0 0.43101686239242554
, O 0 6.526515221594309e-07
including O 0 1.9456201982848143e-07
some O 0 2.756789285740524e-07
immigrant O 0 1.1321109013806563e-05
populations O 0 2.4477994884364307e-06
, O 0 4.0136066559171013e-07
as O 0 1.6236683109127625e-07
well O 0 1.0424390239904824e-07
as O 0 1.275881373885568e-07
12 O 0 2.3931923465170257e-07
of O 0 1.1810376321363947e-07
Dutch O 0 1.0612964615575038e-05
ethnic O 0 2.125197624991415e-06
origin O 0 1.2290753147681244e-05
. O 0 7.406098302453756e-05

Both O 0 1.232107933901716e-06
the O 0 9.085836722988461e-07
protein O 0 9.348662388219964e-06
truncation O 0 9.417318506166339e-05
test O 0 1.5690866348450072e-05
( O 0 5.039934876549523e-06
PTT O 0 3.24737629853189e-05
) O 0 4.803062552127813e-07
and O 0 1.3439748158816656e-07
the O 0 5.778373974862916e-07
restriction O 0 1.7816673789639026e-05
endonuclease O 0 0.0009012208902277052
fingerprinting O 0 0.00017339526675641537
( O 0 1.2102615983167198e-05
REF O 0 0.014193153008818626
) O 0 2.2888700357270864e-07
method O 0 1.1513531461559978e-07
were O 0 6.202300539825956e-08
used O 0 1.5649757756364124e-07
and O 0 1.1370846664249257e-07
compared O 0 8.785165732660971e-07
for O 0 3.774074741613731e-08
their O 0 4.593335134472909e-08
detection O 0 6.83594771544449e-06
efficiency O 0 2.8191755063744495e-06
, O 0 3.3942475852200005e-07
identifying O 0 2.549552846176084e-06
76 O 0 1.3318016499397345e-05
% O 0 3.096314742379036e-07
and O 0 5.560491800338241e-08
60 O 0 1.712043058432755e-07
% O 0 6.437537081183109e-08
of O 0 3.3836005997045504e-08
the O 0 1.1388376606191741e-06
mutations O 0 4.599205931299366e-05
, O 0 3.2801726774778217e-06
respectively O 0 3.4651598980417475e-05
. O 0 4.337070640758611e-05

Most O 0 0.0003596351307351142
patients O 0 0.2998379170894623
were O 0 2.8518165891000535e-06
found O 0 3.484194166958332e-06
to O 0 4.853375230595702e-07
be O 0 1.7890453136715223e-06
compound O 0 0.00022307322069536895
heterozygote O 0 0.0037862416356801987
. O 0 0.0001635186345083639

Seventeen O 0 0.00011878298391820863
mutations O 0 3.467076749075204e-05
were O 0 4.038494409996929e-07
distinct O 0 1.0190344710281352e-06
, O 0 2.310520699211338e-07
of O 0 7.059861673042178e-08
which O 0 7.082465458552178e-07
10 O 0 1.961109546755324e-06
were O 0 7.568543196612154e-07
not O 0 1.7814502371038543e-06
reported O 0 6.134201248642057e-05
previously O 0 5.266744119580835e-05
. O 0 7.046334212645888e-05

Mutations O 0 0.0002513537765480578
are O 0 9.271853400605323e-07
small O 0 7.563264261989389e-06
deletions O 0 4.434796574059874e-05
or O 0 5.193975084694102e-06
point O 0 1.747657370287925e-05
mutations O 0 7.883840589784086e-05
frequently O 0 3.842919977614656e-05
affecting O 0 0.00017247450887225568
splice O 0 0.0011591148795560002
sites O 0 5.168827556190081e-05
. O 0 0.00010135855700355023

Moreover O 0 0.00048596994020044804
, O 0 1.89329275599448e-05
a O 0 4.981709207640961e-05
16 O 0 0.00011771034769481048
. O 0 6.873245001770556e-05

7 O 0 0.0002085923042614013
- O 0 0.00015764596173539758
kb O 0 0.00010268013284076005
genomic O 0 1.2829014849558007e-05
deletion O 0 1.3266932000988163e-05
of O 0 1.1275409406152903e-07
the O 0 3.6756884469468787e-07
3 O 0 5.996771506033838e-07
end O 0 4.0103623177856207e-07
of O 0 2.6786761253561053e-08
the O 0 5.390821229411813e-07
gene O 0 7.171870493039023e-06
, O 0 2.475788676292723e-07
most O 0 1.7031028676228743e-07
likely O 0 1.0292801562172826e-06
a O 0 4.3184400055906735e-07
result O 0 5.012536234971776e-07
of O 0 5.886799314680502e-08
recombination O 0 4.614600129571045e-06
between O 0 4.261409856098908e-07
two O 0 3.2805374416966515e-07
LINE O 0 3.139023465337232e-05
elements O 0 2.206869112342247e-06
, O 0 4.170297870587092e-06
was O 0 5.111696737003513e-05
identified O 0 9.098788723349571e-05
. O 0 3.338131864438765e-05

The O 0 9.657502232585102e-06
most O 0 2.5283782179030823e-06
frequently O 0 1.1589136192924343e-05
found O 0 7.435207862727111e-06
mutation O 0 3.1392839446198195e-05
, O 0 7.913343438303855e-07
identified O 0 1.2603187542481464e-06
in O 0 3.002683115482796e-07
three O 0 8.257214290097181e-07
unrelated O 0 0.00024965990451164544
Turkish O 0 0.0009237221674993634
A B-Disease 1 0.9934796094894409
- I-Disease 1 0.997200608253479
T I-Disease 1 0.9984666109085083
individuals O 0 2.028887820415548e-06
, O 0 1.4815043414273532e-06
was O 0 1.1246836038480978e-05
previously O 0 5.285452971293125e-06
described O 0 5.536760454560863e-06
to O 0 1.3420152811249864e-07
be O 0 1.3891043693092797e-07
a O 0 4.160926437180024e-06
Turkish O 0 8.027342846617103e-05
A B-Disease 1 0.52994704246521
- I-Disease 1 0.9696741104125977
T I-Disease 1 0.9967267513275146
founder O 0 0.0010979506187140942
mutation O 0 0.0006203477969393134
. O 0 6.415256211766973e-05

The O 0 5.310036158334697e-06
presence O 0 3.175779738739948e-06
of O 0 4.1931187411137216e-07
a O 0 2.2419504603021778e-05
founder O 0 0.0004321813175920397
mutation O 0 7.440856279572472e-05
among O 0 1.3365439599510864e-06
relatively O 0 5.3661674428440165e-06
small O 0 1.0565355523795006e-06
ethnic O 0 7.732893436696031e-07
population O 0 3.2396474125562236e-07
groups O 0 1.5936156216866948e-07
in O 0 6.748591090399714e-07
Western O 0 5.832243004988413e-06
Europe O 0 3.836057203443488e-06
could O 0 9.416040143150894e-07
indicate O 0 1.797507479750493e-06
a O 0 2.0285801838326734e-06
high O 0 1.1885897038155235e-05
carrier O 0 3.439775173319504e-05
frequency O 0 8.44337534999795e-07
in O 0 4.432771163465077e-07
such O 0 8.121270411720616e-07
communities O 0 9.176241292152554e-06
. O 0 3.4023421903839335e-05

In O 0 0.0001554577611386776
patients O 0 0.003010410815477371
of O 0 6.330060386972036e-07
Dutch O 0 3.776533776544966e-05
ethnic O 0 9.206966637975711e-07
origin O 0 1.7285947251366451e-06
, O 0 2.0082493392692413e-06
however O 0 1.899014819173317e-06
, O 0 7.004132385191042e-07
no O 0 1.6859904690136318e-06
significant O 0 5.0077956075256225e-06
founder O 0 0.00015958640142343938
effect O 0 2.4648161343066022e-05
could O 0 3.513259571263916e-06
be O 0 1.2687313528658706e-06
identified O 0 2.9116741643520072e-05
. O 0 3.8466154364869e-05

The O 0 1.0917560757661704e-05
observed O 0 2.7049612981500104e-05
genetic O 0 6.471977394539863e-05
heterogeneity O 0 4.9911624955711886e-05
including O 0 7.922601525933715e-07
the O 0 7.068470608828648e-07
relative O 0 5.194277036935091e-06
high O 0 1.07234436654835e-05
percentage O 0 2.4079113245534245e-06
of O 0 5.189269245420292e-07
splice O 0 0.0005760146304965019
- O 0 0.0004158182709943503
site O 0 8.825642908050213e-06
mutations O 0 1.0631290933815762e-05
had O 0 1.2537421980596264e-06
no O 0 6.57337636766897e-07
reflection O 0 2.793762860164861e-06
on O 0 1.152564209405682e-06
the O 0 1.1384249773982447e-05
phenotype O 0 0.006212460342794657
. O 0 9.784827852854505e-05

All O 0 7.180095417425036e-05
patients O 0 0.16628259420394897
manifested O 0 0.0016849410021677613
classical O 0 0.000811354664620012
A B-Disease 1 0.9964107871055603
- I-Disease 1 0.9944180250167847
T I-Disease 1 0.9957279562950134
and O 0 1.3613240525955916e-06
increased O 0 8.135152711474802e-06
cellular O 0 7.768767682136968e-05
radioresistant O 0 0.0007561607053503394
DNA O 0 6.38722485746257e-05
synthesis O 0 9.86726299743168e-05
. O 0 6.90309316269122e-05

Determination O 0 8.391250958084129e-06
of O 0 2.4338234538845427e-07
the O 0 9.409891958966909e-07
genomic O 0 1.148700357589405e-05
structure O 0 4.8932556637737434e-06
of O 0 2.549199962231796e-07
the O 0 6.600717370019993e-06
COL4A4 O 0 0.02263994887471199
gene O 0 1.6592390238656662e-05
and O 0 6.138313892734004e-07
of O 0 2.3451525521522854e-06
novel O 0 0.0016208559973165393
mutations O 0 0.3699180483818054
causing O 1 0.9968363046646118
autosomal B-Disease 1 0.999496579170227
recessive I-Disease 1 0.9997265934944153
Alport I-Disease 1 0.9999072551727295
syndrome I-Disease 1 0.9999644756317139
. O 0 0.04308846965432167

Autosomal B-Disease 1 0.9977256655693054
recessive I-Disease 1 0.9995531439781189
Alport I-Disease 1 0.9998830556869507
syndrome I-Disease 1 0.9999607801437378
is O 0 0.0010215055663138628
a O 0 0.004474727436900139
progressive O 1 0.988671064376831
hematuric B-Disease 1 0.9975646734237671
glomerulonephritis I-Disease 1 0.9996500015258789
characterized O 1 0.9930184483528137
by O 0 0.005952638108283281
glomerular B-Disease 1 0.9994112253189087
basement I-Disease 1 0.9978604912757874
membrane I-Disease 1 0.77507084608078
abnormalities I-Disease 1 0.997890293598175
and O 0 2.5762501536519267e-06
associated O 0 2.0231442249496467e-05
with O 0 2.4783023491181666e-06
mutations O 0 1.1254615856159944e-05
in O 0 2.796087414935755e-07
either O 0 7.473478831343527e-07
the O 0 1.4010746554049547e-06
COL4A3 O 0 0.004573399666696787
or O 0 1.851531919783156e-06
the O 0 1.9226647509640316e-06
COL4A4 O 0 0.004228215664625168
gene O 0 4.044351499032928e-06
, O 0 1.2207004829178913e-07
which O 0 2.9475668128498e-08
encode O 0 2.1572640207523364e-07
the O 0 1.2051568774040788e-06
alpha3 O 0 0.00048416166100651026
and O 0 6.038497303961776e-06
alpha4 O 0 0.07864699512720108
type O 1 0.8157901763916016
IV O 1 0.9981948733329773
collagen O 1 0.9971626400947571
chains O 0 0.005333591252565384
, O 0 1.6530082575627603e-05
respectively O 0 8.430748130194843e-05
. O 0 6.294799823081121e-05

To O 0 2.2918040940567153e-06
date O 0 6.193521585373674e-06
, O 0 1.6975293419818627e-06
mutation O 0 9.592635251465254e-06
screening O 0 3.88085254598991e-06
in O 0 1.5388218344014604e-07
the O 0 1.8556775671640935e-07
two O 0 2.764708995073306e-07
genes O 0 3.7848267311346717e-06
has O 0 2.2748997707822127e-06
been O 0 3.2223381367657566e-06
hampered O 0 0.0009712239261716604
by O 0 3.5457267699712247e-07
the O 0 4.2931122834488633e-07
lack O 0 4.101730155525729e-06
of O 0 6.386806035152404e-07
genomic O 0 0.00011553895456017926
structure O 0 0.00030855363002046943
information O 0 2.8741824280587025e-05
. O 0 8.571123180445284e-05

We O 0 1.173200780613115e-05
report O 0 1.032976433634758e-05
here O 0 7.465280305041233e-07
the O 0 1.909186124748885e-07
complete O 0 1.2326062233114499e-06
characterization O 0 3.604196308515384e-06
of O 0 8.911693072377602e-08
the O 0 2.554281195443764e-07
48 O 0 7.822128509360482e-07
exons O 0 1.0810894082169398e-06
of O 0 8.03432342877386e-08
the O 0 1.956584810614004e-06
COL4A4 O 0 0.004463851917535067
gene O 0 5.179319941817084e-06
, O 0 3.1397047450809623e-07
a O 0 1.2456428066798253e-06
comprehensive O 0 1.4975851627241354e-05
gene O 0 1.7532178389956243e-05
screen O 0 8.53556048241444e-06
, O 0 2.0332367967057507e-07
and O 0 3.475057042123808e-08
the O 0 1.63140413178553e-07
subsequent O 0 1.6960277662292356e-06
detection O 0 3.527860826579854e-06
of O 0 6.942048713654003e-08
10 O 0 1.106634840652987e-06
novel O 0 8.367501322936732e-06
mutations O 0 3.308117811684497e-05
in O 0 1.4419460967474151e-05
eight O 0 0.021069621667265892
patients O 1 0.999488353729248
diagnosed O 1 0.9998856782913208
with O 1 0.9114521145820618
autosomal B-Disease 1 0.9997956156730652
recessive I-Disease 1 0.9998538494110107
Alport I-Disease 1 0.999931812286377
syndrome I-Disease 1 0.9999806880950928
. O 0 0.1488846242427826

Furthermore O 0 0.00020928139565512538
, O 0 5.119574325362919e-06
we O 0 5.582519975178002e-07
identified O 0 1.2150132988608675e-06
a O 0 5.651116339322471e-07
glycine O 0 7.238286343635991e-06
to O 0 1.707477537138402e-07
alanine O 0 1.0956194273603614e-05
substitution O 0 1.56844680532231e-06
in O 0 5.024309643886227e-07
the O 0 2.437270950395032e-06
collagenous O 0 0.048472169786691666
domain O 0 8.13266342447605e-06
that O 0 1.1758772870962275e-06
is O 0 1.659870690673415e-06
apparently O 0 2.2733274818165228e-05
silent O 0 6.112438859418035e-05
in O 0 4.795812174052116e-07
the O 0 1.1299538300590939e-06
heterozygous O 0 3.234370524296537e-05
carriers O 0 8.13301739981398e-05
, O 0 1.0018650300480658e-06
in O 0 2.8878171178803314e-06
11 O 0 3.682596798171289e-05
. O 0 2.719149961194489e-05

5 O 0 1.6379986846004613e-05
% O 0 1.601402345841052e-06
of O 0 1.1770728747251269e-07
all O 0 2.2601682303502457e-07
control O 0 3.2650675620971015e-06
individuals O 0 4.801945010513009e-07
, O 0 3.709565987719543e-07
and O 0 1.1642453046079027e-07
in O 0 9.298438641280882e-08
one O 0 1.2975590379937785e-07
control O 0 8.567085387767293e-07
individual O 0 1.0452961163309737e-07
homozygous O 0 2.247444626846118e-06
for O 0 1.937853681965862e-07
this O 0 5.68677648971061e-07
glycine O 0 8.84789988049306e-05
substitution O 0 5.639221490127966e-05
. O 0 2.901324478443712e-05

There O 0 3.0222869099816307e-05
has O 0 7.953412932693027e-06
been O 0 1.026758695843455e-06
no O 0 3.22857772516727e-07
previous O 0 3.6500384226201277e-07
finding O 0 3.243530102281511e-07
of O 0 5.1273936207962834e-08
a O 0 1.03560137176828e-06
glycine O 0 1.9956349206040613e-05
substitution O 0 4.215204626234481e-06
that O 0 4.86309147618158e-07
is O 0 3.518006224112469e-07
not O 0 2.112659558406449e-07
associated O 0 9.514912449049007e-07
with O 0 3.5310614521222305e-07
any O 0 1.5314009260691819e-06
obvious O 0 0.00015253384481184185
phenotype O 0 0.001933887368068099
in O 0 8.103877917164937e-06
homozygous O 0 0.00035541909164749086
individuals O 0 3.673322862596251e-05
. O 0 0.00015036380500532687

Founder O 0 0.00920634251087904
BRCA1 O 0 0.028779806569218636
and O 0 3.383697912795469e-05
BRCA2 O 0 0.008729042485356331
mutations O 0 0.00011102319695055485
in O 0 2.7315551051287912e-05
French O 0 0.0067639220505952835
Canadian O 1 0.8372543454170227
breast B-Disease 1 0.9996515512466431
and I-Disease 1 0.9896751046180725
ovarian I-Disease 1 0.9999911785125732
cancer I-Disease 1 0.9999428987503052
families O 0 0.00629336666315794
. O 0 0.0007103571551851928

We O 0 2.869199533961364e-06
have O 0 3.406570385777741e-07
identified O 0 6.481731134044821e-07
four O 0 1.5549429122074798e-07
mutations O 0 1.5419155943163787e-06
in O 0 7.393748546746792e-08
each O 0 6.49856630730028e-08
of O 0 1.530980284769612e-06
the O 0 0.0033458152320235968
breast B-Disease 1 0.9997805953025818
cancer I-Disease 1 0.9996440410614014
- O 0 0.04946063458919525
susceptibility O 0 0.0014232586836442351
genes O 0 1.462157797504915e-05
, O 0 8.26741597848013e-06
BRCA1 O 0 0.0028589796274900436
and O 0 3.976098923885729e-06
BRCA2 O 0 0.003869560081511736
, O 0 2.7382195639802376e-06
in O 0 8.57305531098973e-06
French O 0 0.002103580394759774
Canadian O 0 0.4016563594341278
breast B-Disease 1 0.9998045563697815
cancer I-Disease 1 0.9998078942298889
and O 1 0.9134292602539062
breast B-Disease 1 0.9999314546585083
/ I-Disease 1 0.9998107552528381
ovarian I-Disease 1 0.9999912977218628
cancer I-Disease 1 0.9999350309371948
families O 0 0.0007382205803878605
from O 0 0.0003171424032188952
Quebec O 0 0.006536099128425121
. O 0 0.00025530834682285786

To O 0 3.8515270716743544e-05
identify O 0 0.00014186149928718805
founder O 0 0.002509927609935403
effects O 0 0.0015553797129541636
, O 0 5.208772563491948e-06
we O 0 1.223076992573624e-06
examined O 0 3.655361433629878e-05
independently O 0 3.2452460345666623e-06
ascertained O 0 0.000299677747534588
French O 0 0.0009109496022574604
Canadian O 0 0.010079831816256046
cancer B-Disease 1 0.9990847110748291
families O 0 1.258730776498851e-06
for O 0 1.0196279731644609e-07
the O 0 8.243006277552922e-08
distribution O 0 1.681313364088055e-07
of O 0 7.614684705004038e-08
these O 0 2.728020547237975e-07
eight O 0 1.5057797099871095e-05
mutations O 0 0.0002208795485785231
. O 0 4.003195135737769e-05

Mutations O 0 0.00022188553703017533
were O 0 1.5621114926034352e-06
found O 0 2.3640327526663896e-06
in O 0 8.704853371455101e-07
41 O 0 6.337022114166757e-06
of O 0 1.6221775922531378e-06
97 O 0 0.00025153212482109666
families O 0 2.94400942948414e-05
. O 0 6.17934565525502e-05

Six O 0 4.1957614484999795e-06
of O 0 4.0721721461522975e-07
eight O 0 3.6237347558198962e-06
mutations O 0 1.4561603165930137e-05
were O 0 4.814049816559418e-07
observed O 0 2.516530685170437e-06
at O 0 3.967076736444142e-06
least O 0 2.726293359955889e-06
twice O 0 4.464750600163825e-05
. O 0 2.3718173906672746e-05

The O 0 0.00011289400572422892
BRCA1 O 0 0.012343772687017918
C4446T O 0 0.001509485999122262
mutation O 0 0.00012694712495431304
was O 0 7.31597310732468e-06
the O 0 7.244366315717343e-07
most O 0 3.7919988926660153e-07
common O 0 6.9159855229372624e-06
mutation O 0 2.9685792469535954e-05
found O 0 3.366331611687201e-06
, O 0 5.872836368325807e-07
followed O 0 2.2911988253326854e-06
by O 0 1.9396338757360354e-06
the O 0 2.5647417714935727e-05
BRCA2 O 0 0.028120994567871094
8765delAG O 0 0.008143605664372444
mutation O 0 0.0009329382446594536
. O 0 6.104027852416039e-05

Together O 0 6.733793270541355e-06
, O 0 2.4605385533504887e-06
these O 0 2.866979116333823e-07
mutations O 0 7.813629053998739e-06
were O 0 2.4386608288295974e-07
found O 0 8.611080488662992e-07
in O 0 1.559444058329973e-07
28 O 0 7.939430020087457e-07
of O 0 1.0860034649340378e-07
41 O 0 5.921770934946835e-06
families O 0 1.3052306258032331e-06
identified O 0 1.941029040608555e-06
to O 0 1.1292669910289987e-07
have O 0 3.629907894264761e-07
a O 0 1.3620117897517048e-05
mutation O 0 0.00034021001192741096
. O 0 5.375755063141696e-05

The O 0 1.4091955563344527e-05
odds O 0 5.246081855148077e-05
of O 0 3.0334976486301457e-07
detection O 0 5.038324616180034e-06
of O 0 4.0455017114027214e-08
any O 0 4.473804438021034e-08
of O 0 4.680706666704282e-08
the O 0 5.948708690084459e-07
four O 0 2.670069079613313e-06
BRCA1 O 0 0.012115214951336384
mutations O 0 9.183165821013972e-05
was O 0 5.398271241574548e-05
18 O 0 5.86598580412101e-05
. O 0 4.233037179801613e-05

7x O 0 0.08831039816141129
greater O 0 1.3781097550236154e-05
if O 0 3.135215138172498e-06
one O 0 7.363215672739898e-07
or O 0 1.9053242112931912e-06
more O 0 8.627808369965351e-07
cases O 0 0.00033748161513358355
of O 0 0.04646104946732521
ovarian B-Disease 1 0.999997615814209
cancer I-Disease 1 0.9999793767929077
were O 0 6.061408839741489e-06
also O 0 1.2750289215546218e-06
present O 0 1.752179628056183e-06
in O 0 1.3978620927446173e-06
the O 0 5.025382506573806e-06
family O 0 0.00011698235903168097
. O 0 5.1652506954269484e-05

The O 0 1.0139868209080305e-05
odds O 0 4.0248880395665765e-05
of O 0 2.4310674007210764e-07
detection O 0 3.2748532703408273e-06
of O 0 3.585066465916498e-08
any O 0 5.170743833105007e-08
of O 0 3.886123067786684e-08
the O 0 9.387572958985402e-07
four O 0 5.431088993645972e-06
BRCA2 O 0 0.01163473166525364
mutations O 0 0.00013149868755135685
was O 0 5.149556454853155e-05
5 O 0 5.00152054883074e-05
. O 0 4.5077944378135726e-05

3x O 0 0.002895437180995941
greater O 0 1.595684625499416e-05
if O 0 3.729109948835685e-06
there O 0 3.6541169379233907e-07
were O 0 1.597815924014867e-07
at O 0 6.813089044044318e-07
least O 0 3.265782027028763e-07
five O 0 6.873600568724214e-07
cases O 0 2.8435601052478887e-05
of O 0 0.00017954339273273945
breast B-Disease 1 0.9998980760574341
cancer I-Disease 1 0.9997530579566956
in O 0 1.0359745829191525e-05
the O 0 1.6651292753522284e-05
family O 0 0.00040845817420631647
. O 0 8.046002767514437e-05

Interestingly O 0 0.0004261280409991741
, O 0 2.2115634692454478e-06
the O 0 7.289482937267167e-07
presence O 0 2.0908571514155483e-06
of O 0 2.76858736469876e-06
a O 0 0.14247441291809082
breast B-Disease 1 0.9998250603675842
cancer I-Disease 1 0.9996342658996582
case O 0 0.000633222225587815
< O 0 0.002265365095809102
36 O 0 3.761516609301907e-06
years O 0 6.768610205654113e-07
of O 0 1.1130620691801596e-07
age O 0 2.732571192609612e-05
was O 0 2.3158424937719246e-06
strongly O 0 6.42956081264856e-07
predictive O 0 4.3191897702854476e-07
of O 0 2.3040902519255724e-08
the O 0 7.773272159283806e-08
presence O 0 1.209504034704878e-07
of O 0 1.72135141696117e-08
any O 0 3.4987536423614074e-08
of O 0 5.368514877091002e-08
the O 0 1.2527668786788126e-06
eight O 0 9.722485629026778e-06
mutations O 0 0.0003040431474801153
screened O 0 0.0004253422957845032
. O 0 4.37540584243834e-05

Carriers O 0 0.00010008213575929403
of O 0 2.2449417258485482e-07
the O 0 8.406144047512498e-07
same O 0 1.4106460639595753e-06
mutation O 0 2.6288355002179742e-05
, O 0 3.7453909840223787e-07
from O 0 2.0182993409889605e-07
different O 0 4.441682577294159e-08
families O 0 7.36369258902414e-07
, O 0 3.709863278800185e-07
shared O 0 8.61827686549077e-07
similar O 0 5.504760338226333e-06
haplotypes O 0 0.0004055812896694988
, O 0 2.2458978037320776e-06
indicating O 0 1.679508204688318e-05
that O 0 2.197558188754556e-07
the O 0 6.645953476436262e-07
mutant O 0 2.4227445464930497e-05
alleles O 0 6.102229235693812e-06
were O 0 4.06162257604592e-07
likely O 0 8.553240036235366e-07
to O 0 4.422703980822007e-08
be O 0 4.464104463863805e-08
identical O 0 3.319213419672451e-07
by O 0 1.0369221570272202e-07
descent O 0 1.2031495089104283e-06
for O 0 1.2934572168887826e-07
a O 0 1.3858614238415612e-06
mutation O 0 1.1695033208525274e-05
in O 0 8.055357625380566e-07
the O 0 3.4098052310582716e-06
founder O 0 0.00017748144455254078
population O 0 6.712352387694409e-06
. O 0 3.024665784323588e-05

The O 0 5.876836894458393e-06
identification O 0 2.380666273893439e-06
of O 0 8.980908887679107e-07
common O 0 0.00011412631283747032
BRCA1 O 0 0.018788518384099007
and O 0 1.0692561772884801e-05
BRCA2 O 0 0.005581491626799107
mutations O 0 1.6821339158923365e-05
will O 0 3.557785248631262e-07
facilitate O 0 3.1625208976038266e-06
carrier O 0 0.00028600639780052006
detection O 0 0.00011324949446134269
in O 0 1.4202980310074054e-05
French O 0 0.0019123252714052796
Canadian O 0 0.47389790415763855
breast B-Disease 1 0.9997255206108093
cancer I-Disease 1 0.9998096823692322
and O 1 0.8649064302444458
breast B-Disease 1 0.9999526739120483
/ I-Disease 1 0.9998307228088379
ovarian I-Disease 1 0.9999890327453613
cancer I-Disease 1 0.9999319314956665
families O 0 0.0020603048615157604
. O 0 0.00046738170203752816

Are O 0 4.4348133087623864e-05
Dp71 O 0 0.009766507893800735
and O 0 5.041370968683623e-05
Dp140 O 0 0.03285640478134155
brain O 1 0.9470723271369934
dystrophin O 0 0.0417691245675087
isoforms O 0 0.00011110219202237204
related O 0 0.00013360333105083555
to O 0 3.531180482241325e-05
cognitive B-Disease 1 0.6947143077850342
impairment I-Disease 1 0.9986520409584045
in O 1 0.7701678276062012
Duchenne B-Disease 1 0.9996612071990967
muscular I-Disease 1 0.9997528195381165
dystrophy I-Disease 1 0.9996954202651978
? O 1 0.940593957901001

Molecular O 0 0.0003709459269884974
study O 0 4.516520493780263e-05
and O 0 6.201795713423053e-06
neuropsychological O 0 0.0008413529139943421
analysis O 0 3.0936605526221683e-06
were O 0 1.0534618013480213e-06
performed O 0 3.367660838193842e-06
concurrently O 0 5.96580321143847e-06
on O 0 1.2221604265505448e-05
49 O 0 0.0038981763646006584
patients O 1 0.9817010760307312
with O 0 0.0776299461722374
Duchenne B-Disease 1 0.9998210072517395
muscular I-Disease 1 0.9998970031738281
dystrophy I-Disease 1 0.9999334812164307
( O 1 0.9235818982124329
DMD B-Disease 1 0.9998416900634766
) O 0 1.2302186405577231e-05
in O 0 2.6164730115851853e-07
order O 0 1.7246713923668722e-07
to O 0 3.273042992191222e-08
find O 0 1.2199487287034572e-07
a O 0 3.7565516208815097e-07
molecular O 0 3.1705810670246137e-06
explanation O 0 2.5209528757841326e-06
for O 0 4.276354559351603e-07
the O 0 5.678881279891357e-06
cognitive B-Disease 0 0.00451652379706502
impairment I-Disease 1 0.9948784112930298
observed O 0 0.00040202008676715195
in O 0 0.00013267378380987793
most O 0 0.0036247221287339926
DMD B-Disease 1 0.9996862411499023
patients O 1 0.9953641891479492
. O 0 0.0009255126933567226

Complete O 0 1.595062349224463e-05
analysis O 0 1.165773369393719e-06
of O 0 6.485849439741287e-07
the O 0 8.401580998906866e-06
dystrophin O 0 0.13722537457942963
gene O 0 3.920793460565619e-05
was O 0 8.315634659084026e-06
performed O 0 1.1613968808887876e-06
to O 0 5.296050531455876e-08
define O 0 2.988279561577656e-07
the O 0 1.9995793820726249e-07
localization O 0 5.187628630665131e-06
of O 0 1.896244725685392e-07
deletions O 0 2.0538789613055997e-05
and O 0 5.797411972707778e-07
duplications O 0 2.38246975641232e-05
in O 0 5.073567876934248e-07
relation O 0 2.2169542717165314e-06
to O 0 3.0205157486307144e-07
the O 0 2.9644359074154636e-06
different O 0 1.155155314336298e-05
DMD B-Disease 1 0.9988552331924438
promoters O 0 0.024872494861483574
. O 0 0.00022438254381995648

Qualitative O 0 1.6326586774084717e-05
analysis O 0 2.055334562101052e-06
of O 0 6.673053007943963e-07
the O 0 4.96458505949704e-06
Dp71 O 0 0.002594868652522564
transcript O 0 0.0001722260203678161
and O 0 3.488549111807515e-07
testing O 0 1.0436580168970977e-06
for O 0 2.67602580095172e-08
the O 0 6.389328177647258e-08
specific O 0 1.0725611332418339e-07
first O 0 3.4500834544815007e-07
exon O 0 1.5831734344828874e-05
of O 0 5.818864678985847e-07
Dp140 O 0 0.00025556088075973094
were O 0 1.0175535862799734e-06
also O 0 1.2330507388469414e-06
carried O 0 4.02154000767041e-06
out O 0 3.7987852010701317e-06
. O 0 2.5211713364114985e-05

Neuropsychological O 0 0.006733316462486982
analysis O 0 4.932508818455972e-05
assessed O 0 0.00017948501044884324
verbal O 0 0.00013162764662411064
and O 0 1.0556427696428727e-05
visuospatial O 0 0.021651383489370346
intelligence O 0 6.556216249009594e-05
, O 0 2.95753170576063e-06
verbal O 0 0.00010009234392782673
memory O 0 0.0013479538029059768
, O 0 2.591152224340476e-06
and O 0 1.8366889662502217e-06
reading O 0 0.0001545041595818475
skills O 0 0.00015420536510646343
. O 0 8.784828969510272e-05

Comparison O 0 3.3994852856267244e-05
of O 0 1.7130521428043721e-06
molecular O 0 7.924655801616609e-05
and O 0 5.666357537847944e-06
psychometric O 0 0.002570574404671788
findings O 0 5.4936033848207444e-05
demonstrated O 0 3.0359913580468856e-05
that O 0 1.7245016579181538e-06
deletions O 0 4.567178257275373e-05
and O 0 1.3985074929223629e-06
duplications O 0 3.2112431654240936e-05
that O 0 4.663463641918497e-07
were O 0 5.85139105169219e-07
localized O 0 2.8364534955471754e-05
in O 0 4.2098832864212454e-07
the O 0 4.716509636182309e-07
distal O 0 0.0002080710546579212
part O 0 7.481216357518861e-07
of O 0 2.4193181502596417e-07
the O 0 2.510123749743798e-06
gene O 0 3.080590249737725e-05
seemed O 0 8.16851115814643e-06
to O 0 1.2211802413730766e-07
be O 0 3.019470398157864e-07
preferentially O 0 1.1237241778871976e-05
associated O 0 2.2069971237215213e-05
with O 0 2.5991612346842885e-05
cognitive B-Disease 0 0.31507307291030884
impairment I-Disease 1 0.9961110949516296
. O 0 0.0008365843677893281

Two O 0 1.8233315131510608e-05
altered O 0 0.0004182863631285727
Dp71 O 0 0.0013384718913584948
transcripts O 0 2.015864447457716e-05
and O 0 2.7497628707351396e-07
two O 0 2.0141345657975762e-07
deleted O 0 1.642493953113444e-05
Dp140 O 0 3.5839078918797895e-05
DNA O 0 2.600477728265105e-06
sequences O 0 6.490701025541057e-07
were O 0 2.3870606469245104e-07
found O 0 1.3850791447111988e-06
in O 0 1.4508751746689086e-06
four O 0 4.484751480049454e-05
patients O 1 0.9961692690849304
with O 0 0.4538952112197876
severe O 1 0.9998716115951538
cerebral B-Disease 1 0.9998881816864014
dysfunction I-Disease 1 0.999674916267395
. O 0 0.012531307525932789

These O 0 7.633232598891482e-06
findings O 0 5.263575440039858e-05
suggest O 0 9.1308656919864e-06
that O 0 1.574289711925303e-07
some O 0 5.333659913731026e-08
sequences O 0 6.136112915555714e-07
located O 0 1.2153934676462086e-06
in O 0 2.976192661208188e-07
the O 0 4.943311751048896e-07
distal O 0 0.00013899656187277287
part O 0 7.033101496745076e-07
of O 0 1.3070351201349695e-07
the O 0 1.310210450355953e-06
gene O 0 8.19867545942543e-06
and O 0 5.055464953329647e-07
, O 0 3.649081463663606e-07
in O 0 3.345737695781281e-07
particular O 0 5.618861678158282e-07
, O 0 8.673173965689784e-07
some O 0 1.1991231758656795e-06
DMD B-Disease 1 0.9979693293571472
isoforms O 0 9.130456419370603e-06
expressed O 0 7.002395250310656e-06
in O 0 4.213773536321241e-06
the O 0 0.00014845296391285956
brain O 1 0.9984319806098938
may O 0 5.8251145674148574e-05
be O 0 4.5626430278389307e-07
related O 0 1.8717106513577164e-06
to O 0 3.648399058420182e-07
the O 0 8.67518610903062e-06
cognitive B-Disease 0 0.057541925460100174
impairment I-Disease 1 0.998561441898346
associated O 0 0.011450424790382385
with O 0 0.005460530519485474
DMD B-Disease 1 0.9995566010475159
. O 0 0.00016985699767246842
. O 0 0.00011397817434044555

I1307K O 0 0.010668312199413776
APC O 0 0.006079053971916437
and O 0 1.4625748008256778e-05
hMLH1 O 0 0.0010525373509153724
mutations O 0 2.2929583792574704e-05
in O 0 1.3057609749012045e-06
a O 0 1.1892428119608667e-05
non O 0 4.1136456275125965e-05
- O 0 0.00015643457300029695
Jewish O 0 4.450686446944019e-06
family O 0 2.935926750069484e-05
with O 0 6.747072620783001e-05
hereditary B-Disease 1 0.99736088514328
non I-Disease 1 0.9917102456092834
- I-Disease 1 0.9991850256919861
polyposis I-Disease 1 0.9997442364692688
colorectal I-Disease 1 0.9999904632568359
cancer I-Disease 1 0.9999228715896606
. O 0 0.0036113811656832695

We O 0 1.1317373719066381e-05
describe O 0 4.4051605073036626e-05
a O 0 3.501734317978844e-05
French O 0 0.00033630646066740155
Canadian O 0 0.0018144878558814526
hereditary B-Disease 1 0.9944596290588379
non I-Disease 1 0.9858006834983826
- I-Disease 1 0.9989001750946045
polyposis I-Disease 1 0.9998103976249695
colorectal I-Disease 1 0.9999912977218628
cancer I-Disease 1 0.9999558925628662
( O 1 0.6088851690292358
HNPCC B-Disease 1 0.9991716146469116
) O 0 0.00010679077240638435
kindred O 0 0.0013866176595911384
which O 0 1.1576083807085524e-06
carries O 0 4.545931460597785e-06
a O 0 6.964434760448057e-06
novel O 0 2.8995375032536685e-05
truncating O 0 0.002757889684289694
mutation O 0 0.0003644100797828287
in O 0 3.131859193672426e-05
hMLH1 O 0 0.02413533627986908
. O 0 0.00013799882435705513

Interestingly O 0 0.0004893210716545582
, O 0 6.75338196742814e-06
the O 0 8.554304258723278e-06
I1307K O 0 0.0006583764334209263
APC O 0 0.0017751236446201801
polymorphism O 0 3.753318378585391e-05
, O 0 1.4252680102799786e-06
associated O 0 3.191565156157594e-06
with O 0 6.415601774278912e-07
an O 0 3.6873170756734908e-06
increased O 0 0.0002874887431971729
risk O 0 0.22940778732299805
of O 0 0.02401302009820938
colorectal B-Disease 1 0.9999979734420776
cancer I-Disease 1 0.9999803304672241
, O 0 2.1039480998297222e-05
is O 0 1.1212950994377024e-06
also O 0 7.252136242641427e-07
present O 0 1.0787916835397482e-06
in O 0 9.6626308732084e-07
this O 0 2.11164956454013e-06
family O 0 0.0001393920974805951
. O 0 7.230286428239197e-05

The O 0 2.793830026348587e-05
I1307K O 0 0.0007390955579467118
polymorphism O 0 0.00012668591807596385
has O 0 6.958578978810692e-06
previously O 0 3.5205305266572395e-06
only O 0 1.6239718547694793e-07
been O 0 4.719487947113521e-07
identified O 0 1.4040628002476296e-06
in O 0 1.96620533188252e-07
individuals O 0 2.7946370551035216e-07
of O 0 1.1176673524460057e-06
self O 0 0.0005620120791718364
- O 0 0.018974939361214638
reported O 0 0.00023712670372333378
Ashkenazi O 0 0.0003554158902261406
Jewish O 0 3.0133280233712867e-05
origins O 0 0.00012184755178168416
. O 0 6.830324127804488e-05

In O 0 1.1199635082448367e-05
addition O 0 6.320605280052405e-06
, O 0 1.0526905498409178e-06
in O 0 5.396478854891029e-07
this O 0 6.113181711953075e-07
family O 0 2.072814095299691e-05
, O 0 9.772112434802693e-07
there O 0 4.295393125630653e-07
appears O 0 5.770279585703975e-06
to O 0 1.3782167229692277e-07
be O 0 1.393578514807814e-07
no O 0 4.930618615617277e-07
relationship O 0 1.4645210058006342e-06
between O 0 4.678644813793653e-07
the O 0 1.3744551097261137e-06
I1307K O 0 6.769738683942705e-05
polymorphism O 0 5.712313395633828e-06
and O 0 1.5737252567760152e-07
the O 0 3.873277591992519e-07
presence O 0 2.461705207679188e-06
or O 0 3.927984835172538e-06
absence O 0 0.00033723172964528203
of O 0 0.00010439504694659263
cancer B-Disease 1 0.9995997548103333
. O 0 4.982184327673167e-05
. O 0 7.629561878275126e-05

Identification O 0 3.6931064641976263e-06
of O 0 4.94393475491961e-07
a O 0 4.9038694669434335e-06
novel O 0 7.253849162225379e-06
mutation O 0 5.927443908149144e-06
of O 0 2.6208209646938485e-07
the O 0 3.987346644862555e-06
CPO O 0 0.0003867835912387818
gene O 0 1.6719095583539456e-05
in O 0 2.1009550437156577e-06
a O 0 4.447205355972983e-05
Japanese O 0 0.0018707250710576773
hereditary B-Disease 1 0.9766873121261597
coproporphyria I-Disease 1 0.8382891416549683
family O 0 0.0031433571130037308
. O 0 0.0003193926240783185

Hereditary B-Disease 1 0.9759798049926758
coproporphyria I-Disease 1 0.9456734657287598
( O 0 0.002015132224187255
HCP B-Disease 1 0.9906339645385742
) O 0 3.450617441558279e-05
is O 0 1.0977718375215773e-05
an O 0 0.00010826387733686715
autosomal B-Disease 1 0.9988501071929932
dominant I-Disease 1 0.9976128339767456
disease I-Disease 1 0.999882698059082
characterized O 1 0.9366063475608826
by O 0 0.00014424858090933412
a O 0 0.1627405881881714
deficiency B-Disease 1 0.9998587369918823
of I-Disease 0 1.1369733329047449e-05
coproporphyrinogen I-Disease 0 0.3611088693141937
oxidase I-Disease 0 0.0019744704477488995
( O 0 2.6780462576425634e-05
CPO O 0 0.0010422797640785575
) O 0 3.144413994959905e-06
caused O 0 8.29618948046118e-05
by O 0 3.929630452148558e-07
a O 0 3.4512891033955384e-06
mutation O 0 1.3927064173913095e-05
in O 0 6.901477718201932e-07
the O 0 5.687140401278157e-06
CPO O 0 0.0011679850285872817
gene O 0 0.00014756523887626827
. O 0 5.5596981837879866e-05

Only O 0 3.415259470784804e-06
11 O 0 6.0072748055972625e-06
mutations O 0 2.1226474018476438e-06
of O 0 1.1013395351255895e-07
the O 0 1.6137173588504083e-06
gene O 0 2.7421228878665715e-05
have O 0 1.5275631994882133e-06
been O 0 9.53971357375849e-06
reported O 0 0.00042344292160123587
in O 0 0.00012047856580466032
HCP B-Disease 1 0.9986327290534973
patients O 1 0.9901553392410278
. O 0 0.00044847052777186036

We O 0 7.113262654456776e-06
report O 0 1.2197851901873946e-05
another O 0 4.159327545494307e-06
mutation O 0 2.3503615011577494e-05
in O 0 1.2139987575210398e-06
a O 0 1.9579512809286825e-05
Japanese O 0 0.0003492740506771952
family O 0 0.0002556649560574442
. O 0 9.498452709522098e-05

Polymerase O 0 0.001661677029915154
chain O 0 0.0011436804197728634
reaction O 0 0.00017997308168560266
- O 0 0.00010421034676255658
single O 0 1.6274894960588426e-06
strand O 0 1.8179576727561653e-05
conformational O 0 7.353822184086312e-06
polymorphism O 0 3.698142791108694e-06
and O 0 4.7467061392580945e-08
direct O 0 7.588991479678953e-08
sequence O 0 3.092546307925659e-07
analyses O 0 1.3384318435782916e-06
demonstrated O 0 1.8630341855896404e-06
a O 0 2.534457053116057e-06
C O 0 6.437182310037315e-05
to O 0 5.753634582106315e-07
T O 0 0.0006730653694830835
substitution O 0 7.91871173078107e-07
in O 0 7.949843450205663e-08
exon O 0 7.163284408306936e-06
1 O 0 1.8233293985758792e-07
of O 0 3.380929669560828e-08
the O 0 4.794568440047442e-07
CPO O 0 2.9484068363672122e-05
gene O 0 8.234110282501206e-07
at O 0 5.477270406117896e-07
nucleotide O 0 8.904860351321986e-07
position O 0 6.550710054398223e-07
85 O 0 2.8559481961565325e-06
, O 0 1.3937406606601144e-07
which O 0 1.360068750955179e-07
lies O 0 1.1570145943551324e-06
in O 0 1.3884660177154728e-07
the O 0 4.517829097494541e-07
putative O 0 5.3117812058189884e-05
presequence O 0 0.00014779223420191556
for O 0 3.1677592460255255e-07
targeting O 0 1.8758349824565812e-06
to O 0 1.1734833833543235e-06
mitochondria O 0 0.00010742482845671475
. O 0 5.1197854190832004e-05

This O 0 5.282574875309365e-06
mutation O 0 1.543188227515202e-05
changes O 0 6.271067718444101e-07
the O 0 1.6667311797391449e-07
codon O 0 1.69872453170683e-06
for O 0 9.138230439020845e-08
glutamine O 0 4.119401637581177e-06
to O 0 8.940924800526773e-08
a O 0 7.660352139282622e-07
termination O 0 3.567583917174488e-05
codon O 0 4.268936663720524e-06
at O 0 1.1949438203373575e-06
amino O 0 4.432281912158942e-06
acid O 0 0.0002982091100420803
position O 0 2.346594374103006e-05
29 O 0 0.0001453348813811317
. O 0 4.302660090615973e-05

MaeI O 0 0.002941984450444579
restriction O 0 5.439274900709279e-05
analysis O 0 9.09801838133717e-06
showed O 0 1.4029214071342722e-05
two O 0 3.9816814023652114e-07
other O 0 6.142929009911313e-07
carriers O 0 5.110444180900231e-05
in O 0 1.1846625511680031e-06
the O 0 2.9315203846635995e-06
family O 0 0.0001093096288968809
. O 0 4.2318257328588516e-05

The O 0 0.00015567982336506248
C O 0 0.24201850593090057
- O 0 0.39934247732162476
T O 1 0.7402494549751282
mutation O 0 9.878257515083533e-06
is O 0 3.104155723576696e-07
located O 0 5.39910445240821e-07
within O 0 1.472468369456692e-07
a O 0 1.6667296449668356e-06
recently O 0 6.664272405032534e-06
proposed O 0 2.4946596113295527e-06
putative O 0 9.457390660827514e-06
alternative O 0 1.0697096968215192e-06
translation O 0 2.02064256882295e-06
initiation O 0 1.9849903765134513e-05
codon O 0 7.388744415948167e-05
( O 0 4.320640800870024e-05
TIC O 1 0.7314992547035217
- O 0 7.267094770213589e-05
1 O 0 2.3292361674975837e-06
) O 0 5.788081125501776e-07
, O 0 3.6018522564518207e-07
supporting O 0 3.3009282560669817e-06
that O 0 5.805025011795806e-06
TIC O 1 0.8346461653709412
- O 0 2.315998608537484e-05
1 O 0 7.562785526715743e-07
is O 0 1.759083261276828e-07
the O 0 5.590788987319684e-07
real O 0 1.5358706150436774e-05
TIC O 0 0.07484956085681915
rather O 0 4.130893103138078e-06
than O 0 1.1185619769094046e-05
TIC O 1 0.991575300693512
- O 0 0.00038879504427313805
2 O 0 1.0542031304794364e-05
. O 0 4.333086963015376e-06
. O 0 2.1140709577593952e-05

Human B-Disease 0 0.00027036157553084195
complement I-Disease 0 0.0013350816443562508
factor I-Disease 0 0.051980409771203995
H I-Disease 1 0.9988560676574707
deficiency I-Disease 1 0.9998576641082764
associated O 1 0.9778478741645813
with O 1 0.9954063892364502
hemolytic B-Disease 1 0.9999759197235107
uremic I-Disease 1 0.9999792575836182
syndrome I-Disease 1 0.9999626874923706
. O 0 0.1732320934534073

This O 0 1.1121300303784665e-05
study O 0 3.0159992093103938e-05
reports O 0 1.1433864528953563e-05
on O 0 2.5426231786696007e-06
six O 0 6.7754185693047475e-06
cases O 0 3.92813999496866e-05
of O 0 4.3352676584618166e-05
deficiency B-Disease 1 0.9998670816421509
in I-Disease 0 1.7471571709393174e-06
the I-Disease 0 6.418851512535184e-07
human I-Disease 0 9.881401865641237e-07
complement I-Disease 0 2.853157866411493e-06
regulatory I-Disease 0 5.456705184769817e-05
protein I-Disease 0 3.6687302781501785e-05
Factor I-Disease 0 6.545957876369357e-05
H I-Disease 0 0.13306520879268646
( O 0 3.380053385626525e-05
FH O 0 0.03816024214029312
) O 0 3.696887347359734e-07
in O 0 5.123014545915794e-08
the O 0 9.813131640612482e-08
context O 0 1.0201099485129816e-06
of O 0 7.616914899699623e-06
an O 1 0.6180453300476074
acute B-Disease 1 0.9999585151672363
renal I-Disease 1 0.9999984502792358
disease I-Disease 1 0.9999850988388062
. O 0 0.06718354672193527

Five O 0 3.339742761454545e-06
of O 0 7.204392886706046e-07
the O 0 2.7354349185770843e-06
cases O 0 1.4184841347741894e-05
were O 0 6.646143901889445e-07
observed O 0 1.011182575894054e-05
in O 0 4.414017439557938e-06
children O 0 7.254832598846406e-05
presenting O 0 0.004159033764153719
with O 1 0.9455190300941467
idiopathic O 1 0.9999595880508423
hemolytic B-Disease 1 0.9999938011169434
uremic I-Disease 1 0.9999960660934448
syndrome I-Disease 1 0.9999945163726807
( O 1 0.9953043460845947
HUS B-Disease 1 0.9995786547660828
) O 0 0.00182436965405941
. O 0 0.0003698224318213761

Two O 0 1.441423819414922e-06
of O 0 1.04687183011265e-06
the O 0 7.314939921343466e-06
children O 0 7.613005436724052e-05
exhibited O 0 0.0013093063607811928
a O 0 0.0038770223036408424
homozygous O 1 0.9761261940002441
deficiency O 1 0.9999237060546875
characterized O 0 0.012964782305061817
by O 0 1.4387649116542889e-06
the O 0 6.978050350880949e-07
absence O 0 4.315325440984452e-06
of O 0 1.1294199708800079e-07
the O 0 8.479883035761304e-07
150 O 0 7.4710019362100866e-06
- O 0 6.90279048285447e-05
kD O 0 9.012263762997463e-05
form O 0 3.504565029288642e-07
of O 0 2.447710301112238e-07
Factor O 0 1.2624848750419915e-05
H O 0 0.013513993471860886
and O 0 2.404239296538435e-07
the O 0 2.683171658190986e-07
presence O 0 1.0131026328963344e-06
, O 0 2.7025168947147904e-07
upon O 0 6.310555704658327e-07
immunoblotting O 0 4.1508097638143227e-05
, O 0 9.633355801952348e-08
of O 0 3.789742208937241e-08
the O 0 1.491919761065219e-06
42 O 0 4.477196489460766e-05
- O 0 0.00019175554916728288
kD O 0 0.0011233745608478785
Factor O 0 1.015036650642287e-05
H O 0 0.001974403625354171
- O 0 7.634484973095823e-06
like O 0 2.5036874262696074e-07
protein O 0 1.310856532654725e-06
1 O 0 2.305331463503535e-06
( O 0 4.2196529648208525e-06
FHL O 0 0.02571258507668972
- O 0 1.9767107005463913e-05
1 O 0 4.2048597492794215e-07
) O 0 2.7008576353182434e-07
and O 0 1.8622334607698576e-07
other O 0 1.2670360547417658e-06
FH O 1 0.6002970337867737
- O 0 0.00015327318396884948
related O 0 1.2076122402504552e-05
protein O 0 2.1196283341851085e-05
( O 0 2.240373032691423e-05
FHR O 0 0.010219376534223557
) O 0 1.0206996194028761e-05
bands O 0 5.355952453101054e-05
. O 0 5.456991493701935e-05

Southern O 0 0.0001411413832101971
blot O 0 0.00026476263883523643
and O 0 1.1387161293896497e-06
PCR O 0 8.28621705295518e-06
analysis O 0 2.855221907793748e-07
of O 0 1.2515758385234221e-07
DNA O 0 4.360845196060836e-06
of O 0 5.200942041483358e-07
one O 0 8.27516214485513e-06
patient O 0 0.0717506930232048
with O 0 0.00021494449174497277
homozygous O 1 0.9667220711708069
deficiency O 1 0.9999463558197021
ruled O 0 0.0001705080212559551
out O 0 3.2803683325255406e-07
the O 0 1.6396646174143825e-07
presence O 0 2.1301393360317888e-07
of O 0 4.7068393627114347e-08
a O 0 6.552790523528529e-07
large O 0 5.705283570023312e-07
deletion O 0 9.511823009233922e-06
of O 0 1.993473262018597e-07
the O 0 8.880343557393644e-06
FH O 1 0.688764214515686
gene O 0 1.929662175825797e-05
as O 0 1.4149495655146893e-06
the O 0 6.530066002596868e-06
underlying O 0 0.033933740109205246
defect O 1 0.9950826168060303
for O 0 9.261848754249513e-05
the O 0 0.04229997470974922
deficiency O 1 0.9998974800109863
. O 0 0.000814158353023231

The O 0 4.1178659557772335e-06
other O 0 6.131000986897561e-07
four O 0 1.5345616475315182e-06
children O 0 1.0408577509224415e-05
presented O 0 1.918094312713947e-05
with O 0 6.267289427341893e-05
heterozygous O 1 0.5279619097709656
deficiency O 1 0.9999079704284668
and O 0 7.1732110882294364e-06
exhibited O 0 0.0001918991474667564
a O 0 1.3242623026599176e-05
normal O 0 5.5525921197840944e-05
immunoblotting O 0 0.0014452043687924743
pattern O 0 1.153336779680103e-05
of O 0 1.6884283127183153e-07
proteins O 0 1.0627371693772147e-06
of O 0 8.159278195307706e-07
the O 0 9.937554568750784e-05
FH O 1 0.9916360378265381
family O 0 0.0003801910497713834
. O 0 0.0001272109366254881

Factor B-Disease 0 0.394999623298645
H I-Disease 1 0.9986955523490906
deficiency I-Disease 1 0.9995704293251038
is O 0 1.1639908734650817e-05
the O 0 1.0523178389121313e-05
only O 0 3.855414979625493e-05
complement B-Disease 1 0.9356973171234131
deficiency I-Disease 1 0.9999538660049438
associated O 0 0.014695635065436363
with O 0 0.004545255098491907
HUS B-Disease 1 0.999005138874054
. O 0 0.0008503914577886462

These O 0 1.489699002377165e-06
observations O 0 2.8856586595793488e-06
suggest O 0 4.957450073561631e-06
a O 0 2.0999495973228477e-06
role O 0 3.937684141419595e-06
for O 0 3.880682470480679e-06
FH O 1 0.9846394062042236
and O 0 7.847278538974933e-06
/ O 0 0.003861756529659033
or O 0 1.1048864507756662e-05
FH O 0 0.29536643624305725
receptors O 0 3.441225635469891e-05
in O 0 1.964538796528359e-06
the O 0 1.5334615454776213e-05
pathogenesis O 1 0.9348568320274353
of O 0 0.000954611983615905
idiopathic O 1 0.9997994303703308
HUS B-Disease 1 0.9995226860046387
. O 0 0.0008199422154575586
. O 0 0.0003065760829485953

Further O 0 2.3818562112865038e-05
evidence O 0 8.153428098012228e-06
for O 0 1.6471135495521594e-06
a O 0 1.3200346074881963e-05
major O 0 4.198975511826575e-05
ancient O 0 0.00029300415189936757
mutation O 0 0.3997516930103302
underlying O 1 0.9947130084037781
myotonic B-Disease 1 0.9998760223388672
dystrophy I-Disease 1 0.9999197721481323
from O 0 0.0008004042319953442
linkage O 0 0.028766149654984474
disequilibrium O 0 0.40526026487350464
studies O 0 1.237005471921293e-05
in O 0 1.1611487025220413e-06
the O 0 3.709314796651597e-06
Japanese O 0 0.0002970703353639692
population O 0 1.8785682186717167e-05
. O 0 5.482644337462261e-05

The O 0 0.03915422037243843
myotonic B-Disease 1 0.9993318915367126
dystrophy I-Disease 1 0.9998722076416016
( O 0 0.39398136734962463
DM B-Disease 1 0.999366819858551
) O 0 3.695966370287351e-05
mutation O 0 9.009256609715521e-05
is O 0 1.57771785325167e-06
an O 0 4.009737040178152e-06
unstable O 0 0.019358966499567032
( O 0 1.6875806977623142e-05
CTG O 0 0.0038723123725503683
) O 0 2.3585000690218294e-06
n O 0 8.917488230508752e-06
repeat O 0 2.0570034394040704e-05
, O 0 1.7023218390477268e-07
present O 0 2.4441368395855534e-07
at O 0 5.794206003884028e-07
a O 0 4.346668731614045e-07
copy O 0 7.97448819866986e-07
number O 0 1.9757910862949757e-08
of O 0 5.8456464557821164e-08
5 O 0 3.000942115249927e-06
- O 0 1.0131158887816127e-05
37 O 0 6.508813044092676e-07
repeats O 0 2.42448118115135e-06
on O 0 9.965403791056815e-08
normal O 0 1.4377854995473172e-06
chromosomes O 0 1.5701318716310197e-06
but O 0 3.9255476735888806e-07
amplified O 0 3.7293909826985328e-06
to O 0 1.321226790196306e-07
50 O 0 2.3730408429400995e-06
- O 0 2.9729535526712425e-05
3000 O 0 1.8195465600001626e-05
copies O 0 4.060339961142745e-06
on O 0 1.5452922525582835e-05
DM B-Disease 1 0.9956989288330078
chromosomes O 0 0.00021077027486171573
. O 0 8.199083822546527e-05

Previous O 0 0.0001298179995501414
findings O 0 6.193804438225925e-05
in O 0 6.479262083303183e-06
Caucasian O 0 0.0010383541230112314
populations O 0 4.744642865261994e-06
of O 0 1.8697088535191142e-06
a O 0 0.0019103121012449265
DM B-Disease 1 0.9994617104530334
founder O 0 0.0017503167036920786
chromosome O 0 0.0001572761539136991
raise O 0 4.952450581185985e-06
a O 0 7.511277999583399e-07
question O 0 3.1642358067074383e-07
about O 0 1.1127649912623383e-07
the O 0 1.4135451920083142e-07
molecular O 0 2.74438684755296e-06
events O 0 5.410010999185033e-07
involved O 0 1.069735048986331e-06
in O 0 4.4276248445385136e-07
the O 0 1.5533273654000368e-06
expansion O 0 8.089446782832965e-05
mutation O 0 0.00028592327726073563
. O 0 4.5036777009954676e-05

To O 0 4.341409294283949e-06
investigate O 0 1.9484388758428395e-05
whether O 0 3.125793000435806e-06
a O 0 5.918665465287631e-06
founder O 0 8.729065302759409e-05
chromosome O 0 2.730187952693086e-05
for O 0 1.3777082585875178e-06
the O 0 8.051376062212512e-05
DM B-Disease 1 0.9996377229690552
mutation O 0 0.00021731536253355443
exists O 0 4.290036940801656e-06
in O 0 4.286304999823187e-07
the O 0 1.1511790489748819e-06
Japanese O 0 2.4245056920335628e-05
population O 0 6.483301717707945e-07
, O 0 7.401437756016094e-07
we O 0 3.845694322990312e-07
genotyped O 0 7.036228635115549e-05
families O 0 3.075291203913366e-07
using O 0 7.362435781033128e-07
polymorphic O 0 7.940905197756365e-05
markers O 0 9.063785546459258e-05
near O 0 2.7111904273624532e-05
the O 0 3.71210694538604e-06
( O 0 1.4015359738550615e-05
CTG O 0 0.003722606925293803
) O 0 7.035891485429602e-06
n O 0 4.803837509825826e-05
repeat O 0 0.00012010943464701995
region O 0 6.699082859995542e-06
and O 0 1.9422179775574477e-06
constructed O 0 0.00030641508055850863
haplotypes O 0 0.002968815853819251
. O 0 0.00010965894762193784

Six O 0 1.4804007150814869e-05
different O 0 1.319090756624064e-06
haplotypes O 0 0.00035512124304659665
were O 0 4.9033646973839495e-06
found O 0 2.3633503587916493e-05
and O 0 4.0264392737299204e-05
DM B-Disease 1 0.9988234639167786
alleles O 0 4.6388766349991783e-05
were O 0 2.0990405573684257e-06
always O 0 1.7496216969448142e-05
haplotype O 0 0.0020057999063283205
A O 0 0.0003253877512179315
. O 0 6.940770981600508e-05

To O 0 1.7090119399654213e-06
find O 0 1.2442799288692186e-06
an O 0 1.4292736238985526e-07
origin O 0 1.3095279882691102e-07
of O 0 9.520761068415595e-08
the O 0 1.3782985206489684e-06
( O 0 1.102583519241307e-05
CTG O 0 0.00134839559905231
) O 0 1.6138727687575738e-06
n O 0 1.5689400242990814e-05
repeat O 0 4.634237848222256e-05
mutation O 0 7.133520739444066e-06
and O 0 1.1510458364227816e-07
to O 0 6.372642502583403e-08
investigate O 0 6.243415100470884e-07
the O 0 1.0227249447325448e-07
mechanism O 0 5.048430580245622e-07
of O 0 5.7299359923490556e-08
the O 0 7.662266057195666e-07
expansion O 0 9.5998921096907e-06
mutation O 0 8.51650293043349e-06
in O 0 3.031132109754253e-07
the O 0 7.976162237355311e-07
Japanese O 0 1.686144241830334e-05
population O 0 5.097978146295645e-07
we O 0 1.0078125001200533e-07
have O 0 1.0215239854005631e-07
studied O 0 3.2410089261247776e-06
90 O 0 1.4541938071488403e-05
Japanese O 0 0.0010438567260280252
DM B-Disease 1 0.9984184503555298
families O 0 7.812258445483167e-06
comprising O 0 5.403903287515277e-06
190 O 0 4.0808445191942155e-05
affected O 0 2.6756470106192864e-05
and O 0 2.391219823039137e-06
130 O 0 6.362203566823155e-05
unaffected O 0 0.0011943841818720102
members O 0 1.0631310942699201e-05
. O 0 4.2405434214742854e-05

The O 0 3.0177110602380708e-05
results O 0 1.924731259350665e-05
suggest O 0 9.098373993765563e-06
that O 0 2.835983821114496e-07
a O 0 2.105078692693496e-06
few O 0 1.6763817711762385e-06
common O 0 8.044694368436467e-06
ancestral O 0 0.00011328070831950754
mutations O 0 3.591773929656483e-05
in O 0 2.125606897607213e-06
both O 0 1.8043859881800017e-06
Caucasian O 0 0.0024026231840252876
and O 0 2.492726252967259e-06
Japanese O 0 7.644767902093008e-05
populations O 0 2.2248927962209564e-06
have O 0 1.3033532297868078e-07
originated O 0 1.0341841516492423e-06
by O 0 1.0089433288840155e-07
expansion O 0 6.296993433352327e-07
of O 0 7.591553696784104e-08
an O 0 7.443007916663191e-07
ancestral O 0 2.4692983060958795e-05
n O 0 1.3341458725335542e-05
= O 0 1.0426500921312254e-05
5 O 0 9.567897905071732e-07
repeat O 0 2.7674257125909207e-06
to O 0 1.2688727224485774e-07
n O 0 5.423910351964878e-06
= O 0 1.488924135628622e-05
19 O 0 5.622508524538716e-06
- O 0 2.4603470592410304e-05
37 O 0 6.424690582207404e-06
copies O 0 6.490022315119859e-06
. O 0 1.1480323337309528e-05

These O 0 9.193087180392467e-07
data O 0 1.7387264961143956e-06
support O 0 1.390468469253392e-06
multistep O 0 5.737052561016753e-05
models O 0 2.3353838969342178e-06
of O 0 6.286312554948381e-07
triplet O 0 0.009288736619055271
repeat O 0 0.0017658628057688475
expansion O 0 4.346610512584448e-05
that O 0 3.8001513757990324e-07
have O 0 1.915828704568412e-07
been O 0 2.662575298018055e-07
proposed O 0 1.5890703934928752e-06
for O 0 7.839632871764479e-07
both O 0 1.6018626411096193e-05
DM B-Disease 1 0.9990516304969788
and O 0 0.0001231579517479986
Friedreichs B-Disease 1 0.9770846962928772
ataxia I-Disease 1 0.9972395896911621
. O 0 0.00013868017413187772
. O 0 0.00014053411723580211

The O 0 9.47178796195658e-06
molecular O 0 2.7801343094324693e-05
basis O 0 6.638290415139636e-06
of O 0 0.00022457883460447192
C6 B-Disease 1 0.9998167157173157
deficiency I-Disease 1 0.9999417066574097
in O 0 7.585671482956968e-06
the O 0 4.823369636142161e-06
western O 0 1.6087948097265325e-05
Cape O 0 0.00024422022397629917
, O 0 2.912457375714439e-06
South O 0 2.1123136320966296e-05
Africa O 0 2.178875911340583e-05
. O 0 2.129686254193075e-05

Deficiency B-Disease 1 0.9972307085990906
of I-Disease 0 2.0290153770474717e-06
the I-Disease 0 2.7277887966192793e-06
sixth I-Disease 0 1.737864840833936e-05
component I-Disease 0 4.393933068058686e-06
of I-Disease 0 2.460963060002541e-07
human I-Disease 0 3.6432986689760583e-06
complement I-Disease 0 1.5897034245426767e-05
( O 0 4.387263470562175e-05
C6 O 1 0.9091619253158569
) O 0 2.9642803838214604e-06
has O 0 1.3789400554742315e-06
been O 0 5.34369519300526e-07
reported O 0 2.7123360268888064e-06
in O 0 8.473046619883462e-08
a O 0 1.7676818231393554e-07
number O 0 1.922824033329107e-08
of O 0 4.193766045545999e-08
families O 0 3.5571338230511174e-07
from O 0 4.049123276672617e-07
the O 0 8.085706326710351e-07
western O 0 5.02505645272322e-06
Cape O 0 0.00013454350118990988
, O 0 3.5551772725739283e-06
South O 0 2.374059840803966e-05
Africa O 0 3.8589423638768494e-05
. O 0 3.6968329368392006e-05

Meningococcal B-Disease 1 0.9984468817710876
disease I-Disease 1 0.9997218251228333
is O 0 0.00036905461456626654
endemic O 0 0.016520529985427856
in O 0 1.7494097619419335e-06
the O 0 2.3534332740382524e-06
Cape O 0 4.52961576229427e-05
and O 0 1.6627906518351665e-07
almost O 0 1.6660351320751943e-07
all O 0 6.801313645610207e-08
pedigrees O 0 2.5017139705596492e-05
of O 0 1.8532559806772042e-06
total O 0 0.0015339244855567813
C6 B-Disease 1 0.9998705387115479
deficiency I-Disease 1 0.9999681711196899
( O 0 0.000759285525418818
C6Q0 O 1 0.6848627924919128
) O 0 9.143456736637745e-06
have O 0 9.037916584020422e-07
been O 0 2.4082005438685883e-06
ascertained O 0 9.124941425397992e-05
because O 0 1.121629884437425e-05
of O 0 4.985454143024981e-05
recurrent O 1 0.9994681477546692
disease O 1 0.9998524188995361
. O 0 0.003343764692544937

We O 0 3.7541058190981857e-06
have O 0 5.335837727216131e-07
sequenced O 0 1.6118946177812177e-06
the O 0 2.2599698468184215e-07
expressed O 0 6.813414188400202e-07
exons O 0 2.8284366635489278e-06
of O 0 3.207503596058814e-07
the O 0 7.0863156906852964e-06
C6 O 1 0.7845278382301331
gene O 0 1.3447288438328542e-05
from O 0 8.291895596812537e-07
selected O 0 9.002852152661944e-07
cases O 0 4.9320105972583406e-06
and O 0 4.0016132629716594e-07
have O 0 2.4509057539034984e-07
found O 0 6.71484826852975e-07
three O 0 7.484013622161001e-07
molecular O 0 0.0013774893013760448
defects O 1 0.997168242931366
leading O 0 5.908648745389655e-05
to O 0 4.091350092494395e-06
total O 0 0.00030966525082476437
deficiency O 1 0.9999059438705444
879delG O 0 0.07381173968315125
, O 0 1.3796187658954295e-06
which O 0 2.656680635482189e-07
is O 0 4.77715161650849e-07
the O 0 2.0650563783419784e-06
common O 0 4.6027078496990725e-05
defect O 1 0.7508856058120728
in O 0 2.7593614504439756e-06
the O 0 6.6925886130775325e-06
Cape O 0 0.00021337180805858225
and O 0 2.7428588964539813e-06
hitherto O 0 0.00013308049528859556
unreported O 0 7.550863665528595e-05
, O 0 2.0089732970518526e-06
and O 0 1.3716085049964022e-06
1195delC O 0 0.00040103806531988084
and O 0 1.8819271190295694e-06
1936delG O 0 0.0013138607610017061
, O 0 1.3356137742448482e-06
which O 0 5.523789354811015e-07
have O 0 2.470005995292013e-07
been O 0 1.271444489248097e-06
previously O 0 1.0249827937514056e-05
reported O 0 4.527849523583427e-05
in O 0 5.7409688452025875e-06
African O 0 0.0001994706690311432
- O 0 0.0026859319768846035
Americans O 0 2.9541341064032167e-05
. O 0 4.030173295177519e-05

We O 0 9.060354386747349e-06
also O 0 1.9223364233766915e-06
show O 0 1.7862272443380789e-06
that O 0 3.9726654676996986e-07
the O 0 2.390469489910174e-06
879delG O 0 0.002238841261714697
and O 0 2.3371741917799227e-05
1195delC O 1 0.9459518194198608
defects O 1 0.9980925917625427
are O 0 8.529454476047249e-07
associated O 0 4.01603574573528e-05
with O 0 1.3980400581203867e-05
characteristic O 0 0.008761134929955006
C6 O 1 0.9980751276016235
/ O 0 0.47345253825187683
C7 O 1 0.7001234889030457
region O 0 1.5903795429039747e-05
DNA O 0 9.613083966542035e-05
marker O 0 0.0003987327218055725
haplotypes O 0 0.0006277313223108649
, O 0 2.284230276927701e-06
although O 0 2.8831582312704995e-06
small O 0 1.5485572930629132e-06
variations O 0 1.1099780749646015e-05
were O 0 2.6569491637928877e-06
observed O 0 5.133033846504986e-05
. O 0 6.0154077800689265e-05

The O 0 0.00020212230447214097
1936delG O 0 0.31480860710144043
defect O 1 0.959711492061615
was O 0 3.3367599826306105e-05
observed O 0 2.8731974452966824e-06
only O 0 3.9981497934604704e-07
once O 0 2.2414171780837933e-06
in O 0 2.5708109774313925e-07
the O 0 1.1581207672861638e-06
Cape O 0 4.724928658106364e-05
, O 0 6.650492991866486e-07
but O 0 3.440614193550573e-07
its O 0 1.106945205719967e-06
associated O 0 4.601259570335969e-05
haplotype O 0 0.0025018954183906317
could O 0 5.720627086702734e-06
be O 0 1.6967848068816238e-06
deduced O 0 8.281448390334845e-05
. O 0 4.411622285260819e-05

The O 0 4.723320216726279e-06
data O 0 1.9663436887640273e-06
from O 0 1.3123476492182817e-06
the O 0 1.779942181201477e-06
haplotypes O 0 0.00015184540825430304
indicate O 0 4.7383214223373216e-06
that O 0 1.1089363738392422e-07
these O 0 6.030769128528846e-08
three O 0 1.0985131666529924e-06
molecular O 0 0.0008107017492875457
defects O 1 0.9949606657028198
account O 0 3.770099965549889e-06
for O 0 2.1100570393173257e-06
the O 0 6.689541623927653e-05
defects O 1 0.9972347617149353
in O 0 7.100684911165445e-07
all O 0 1.2547309324872913e-07
the O 0 1.8440532585373148e-06
38 O 0 3.767932503251359e-05
unrelated O 0 0.0007923223893158138
C6Q0 O 0 0.13675908744335175
individuals O 0 1.6348335520888213e-06
we O 0 2.79596491736811e-07
have O 0 1.1312654635275976e-07
studied O 0 1.6190432461371529e-06
from O 0 1.0089353281728108e-06
the O 0 5.920336207054788e-06
Cape O 0 0.0005793916643597186
. O 0 5.614848487311974e-05

We O 0 7.01944418324274e-06
have O 0 8.531130788469454e-07
also O 0 5.970601932858699e-07
observed O 0 6.0329084590193816e-06
the O 0 5.170806616661139e-06
879delG O 0 0.006793342065066099
defect O 0 0.21293379366397858
in O 0 3.8034286262700334e-06
two O 0 9.610929737391416e-06
Dutch O 0 0.06284492462873459
C6 B-Disease 1 0.9993888139724731
- I-Disease 1 0.9927167296409607
deficient I-Disease 1 0.9977203011512756
kindreds O 0 0.0013071333523839712
, O 0 2.026010861300165e-06
but O 0 6.34870559679257e-07
the O 0 2.968334229080938e-06
879delG O 0 0.006975431926548481
defect O 0 0.31162744760513306
in O 0 1.897729589472874e-06
the O 0 5.594369667960564e-06
Cape O 0 0.0005580721190199256
probably O 0 2.0932171537424438e-05
did O 0 1.0721659009504947e-06
not O 0 6.637795735287e-08
come O 0 1.511325251613016e-07
from O 0 3.084472837144858e-07
The O 0 1.3373855836107396e-06
Netherlands O 0 1.0962956366711296e-05
. O 0 3.4869731280195992e-06
. O 0 1.7812630176194943e-05

Complement B-Disease 0 0.4167189300060272
C7 I-Disease 1 0.9990718364715576
deficiency I-Disease 1 0.9998748302459717
: O 0 5.132573642185889e-05
seven O 0 1.1776228348026052e-05
further O 0 2.814928302541375e-05
molecular O 0 0.010208813473582268
defects O 1 0.998282790184021
and O 0 4.0882141547626816e-06
their O 0 2.730362893998972e-06
associated O 0 0.00015941970923449844
marker O 0 0.005529592279344797
haplotypes O 0 0.014002400450408459
. O 0 0.00027823273558169603

Seven O 0 1.3446274351736065e-05
further O 0 6.3096322264755145e-06
molecular O 0 4.7368208470288664e-05
bases O 0 3.2476546039106324e-05
of O 0 0.000493353814817965
C7 B-Disease 1 0.999886155128479
deficiency I-Disease 1 0.9999665021896362
are O 0 2.8028953238390386e-05
described O 0 0.002002835739403963
. O 0 0.00013440949260257185

All O 0 8.878141102286463e-07
these O 0 1.2585063586811884e-06
new O 0 1.0638349522196222e-05
molecular O 0 0.0009398866095580161
defects O 1 0.9828412532806396
involve O 0 6.877259693283122e-06
single O 0 5.26547955814749e-06
- O 0 2.8547872716444544e-05
nucleotide O 0 1.4563731838279637e-06
events O 0 3.7401579788820527e-07
, O 0 2.504977203443559e-07
deletions O 0 3.3316148346784757e-06
and O 0 2.576095141648693e-07
substitutions O 0 1.023034656100208e-06
, O 0 2.009556681059621e-07
some O 0 3.5721591018500476e-08
of O 0 6.787149686715566e-08
which O 0 9.950017556548119e-07
alter O 0 4.505473407334648e-05
splice O 0 5.932666317676194e-05
sites O 0 2.1600524178211344e-06
, O 0 8.742256909499702e-07
and O 0 7.404783559650241e-07
others O 0 4.109412202524254e-06
codons O 0 0.00013294213567860425
. O 0 4.695064126281068e-05

They O 0 3.7722470551670995e-06
are O 0 2.3996992126740224e-07
distributed O 0 9.50928779275273e-07
along O 0 1.4134564025880536e-06
the O 0 5.321873686625622e-06
C7 O 0 0.33017435669898987
gene O 0 1.4010015547682997e-05
, O 0 3.891338167250069e-07
but O 0 1.6365900989967486e-07
predominantly O 0 2.1388721904713748e-07
towards O 0 6.120088187344663e-07
the O 0 2.031581061601173e-06
3 O 0 1.1781147804867942e-05
end O 0 5.9863432397833094e-05
. O 0 3.4299220715183765e-05

All O 0 7.391363965325581e-07
were O 0 1.0299812629455118e-06
found O 0 1.6367413309126277e-06
in O 0 1.3850052482666797e-06
compound O 0 0.00016595443594269454
heterozygous O 0 0.0001213176001328975
individuals O 0 1.64077846420696e-05
. O 0 9.75188086158596e-05

The O 0 0.0005941349663771689
C6 O 1 0.9867159128189087
/ O 0 0.4141574203968048
C7 O 1 0.941130518913269
marker O 0 0.0014487545704469085
haplotypes O 0 0.0026776804588735104
associated O 0 0.00013056110765319318
with O 0 3.698695218190551e-05
most O 0 0.000377058720914647
C7 B-Disease 1 0.999380350112915
defects I-Disease 1 0.9986717700958252
are O 0 4.3515560719242785e-06
tabulated O 0 0.0006623077788390219
. O 0 3.0744799005333334e-05
. O 0 6.96110655553639e-05

A O 0 0.00019999478536192328
genome O 0 0.00014534998626913875
- O 0 6.089696034905501e-05
wide O 0 4.9138507165480405e-06
search O 0 2.0510542526608333e-06
for O 0 2.5897293198795523e-06
chromosomal O 0 0.003436076920479536
loci O 0 0.0008771372376941144
linked O 0 0.015567240305244923
to O 0 0.00014101492706686258
mental O 1 0.9987626075744629
health O 1 0.9748997688293457
wellness O 0 0.3937757909297943
in O 0 1.8120690583600663e-05
relatives O 0 0.0001017228132695891
at O 0 0.00023401530052069575
high O 0 0.0289976354688406
risk O 1 0.71515291929245
for O 0 0.010615876875817776
bipolar B-Disease 1 0.9999675750732422
affective I-Disease 1 0.9997084736824036
disorder I-Disease 1 0.9999176263809204
among O 0 4.26297374360729e-05
the O 0 2.6503126719035208e-05
Old O 0 0.0015017598634585738
Order O 0 2.3762911951052956e-05
Amish O 0 0.001345067285001278
. O 0 0.00010982566163875163

Bipolar B-Disease 1 0.9996563196182251
affective I-Disease 1 0.9983652234077454
disorder I-Disease 1 0.9998132586479187
( O 1 0.9401719570159912
BPAD B-Disease 1 0.9992713332176208
; O 1 0.9882996082305908
manic B-Disease 1 0.999890923500061
- I-Disease 1 0.9997550845146179
depressive I-Disease 1 0.9999334812164307
illness I-Disease 1 0.999880313873291
) O 0 0.00011771068966481835
is O 0 1.0333902537240647e-05
characterized O 0 0.0007806129870004952
by O 0 2.064243062704918e-06
episodes O 0 2.579869942564983e-05
of O 0 2.0637175111914985e-05
mania B-Disease 1 0.998775064945221
and O 0 6.0998961998848245e-05
/ O 0 0.11994558572769165
or O 0 6.632519944105297e-05
hypomania B-Disease 1 0.9946889877319336
interspersed O 0 0.00026849997811950743
with O 0 1.072345366992522e-05
periods O 0 0.0007978509529493749
of O 0 0.00014947180170565844
depression B-Disease 1 0.9989080429077148
. O 0 0.0010512137087062001

Compelling O 0 7.440345507347956e-05
evidence O 0 2.0589524865499698e-05
supports O 0 1.4661597560916562e-05
a O 0 4.54891960544046e-06
significant O 0 8.251992767327465e-06
genetic O 0 3.7528068787651137e-05
component O 0 1.686904943198897e-05
in O 0 2.308541297679767e-06
the O 0 7.278782049979782e-06
susceptibility O 0 0.002544841030612588
to O 0 1.1455037565610837e-05
develop O 0 0.0026852383743971586
BPAD B-Disease 1 0.9935372471809387
. O 0 0.0002900781692005694

To O 0 7.66544781072298e-06
date O 0 1.6278267139568925e-05
, O 0 3.1127694910537684e-06
however O 0 2.278590955029358e-06
, O 0 1.4394291838470963e-06
linkage O 0 4.007462121080607e-05
studies O 0 1.3297864143169136e-06
have O 0 1.0499878300151977e-07
attempted O 0 1.991526687561418e-06
only O 0 8.062307443879035e-08
to O 0 1.7209220004588133e-07
identify O 0 3.7891643387411023e-06
chromosomal O 0 0.0005197401624172926
loci O 0 0.00011528484174050391
that O 0 3.526104819684406e-06
cause O 0 0.0028440169990062714
or O 0 6.616119662794517e-06
increase O 0 1.5040919606690295e-05
the O 0 7.634848770976532e-06
risk O 0 0.000355531316017732
of O 0 5.433337264548754e-06
developing O 0 0.003405192866921425
BPAD B-Disease 1 0.9938524961471558
. O 0 0.0003979146422352642

To O 0 5.405104275268968e-06
determine O 0 1.0866973752854392e-05
whether O 0 4.216177330818027e-06
there O 0 1.486174255660444e-06
could O 0 1.920434442581609e-06
be O 0 1.0222192941000685e-06
protective O 0 0.001758806174620986
alleles O 0 9.936790775100235e-06
that O 0 1.1862000519613503e-06
prevent O 0 9.705116099212319e-05
or O 0 4.6258405745902564e-06
reduce O 0 8.292843267554417e-05
the O 0 2.3587090254295617e-06
risk O 0 0.00010738569835666567
of O 0 1.0474320788489422e-06
developing O 0 0.0006531522376462817
BPAD B-Disease 1 0.9978159666061401
, O 0 2.7148773824592354e-06
similar O 0 1.4558537486664136e-06
to O 0 1.3753819416706392e-07
what O 0 3.7197398228272505e-07
is O 0 3.915732804671279e-07
observed O 0 2.54468250204809e-06
in O 0 2.650857140906737e-06
other O 0 4.368785084807314e-05
genetic B-Disease 1 0.9993832111358643
disorders I-Disease 1 0.999974250793457
, O 0 0.00010415322321932763
we O 0 1.0457459211465903e-05
used O 0 0.0002509402111172676
mental O 1 0.9992677569389343
health O 1 0.9913086891174316
wellness O 0 0.418069988489151
( O 0 3.498293153825216e-05
absence O 0 0.0001324634358752519
of O 0 5.1311390052433126e-06
any O 0 0.0019118202617391944
psychiatric B-Disease 1 0.9998584985733032
disorder I-Disease 1 0.999866247177124
) O 0 1.8855575035559013e-05
as O 0 1.3241802889751852e-06
the O 0 2.116827545250999e-06
phenotype O 0 0.00010259634291287512
in O 0 3.4111803870473523e-07
our O 0 6.293799401646538e-07
genome O 0 3.8348360249074176e-05
- O 0 5.134429011377506e-05
wide O 0 3.508073405100731e-06
linkage O 0 3.8229951314860955e-05
scan O 0 2.2925583834876306e-05
of O 0 1.1249760234477435e-07
several O 0 3.8985740502539556e-07
large O 0 9.243474778486416e-06
multigeneration O 0 0.0032554450444877148
Old O 0 0.00010313939128536731
Order O 0 4.897854068985907e-06
Amish O 0 0.00019337335834279656
pedigrees O 0 0.00029758087475784123
exhibiting O 0 0.00027782877441495657
an O 0 1.6090096323750913e-05
extremely O 0 0.0009279418736696243
high O 0 0.0022029862739145756
incidence O 1 0.8020237684249878
of O 0 4.415111834532581e-05
BPAD B-Disease 1 0.9956250786781311
. O 0 0.0003930326784029603

We O 0 1.5891773728071712e-05
have O 0 1.0758009238998056e-06
found O 0 2.2135805011203047e-06
strong O 0 1.3192668575356947e-06
evidence O 0 9.771171107786358e-07
for O 0 1.9460877354049444e-07
a O 0 2.2441936380346306e-06
locus O 0 2.0565777958836406e-05
on O 0 4.670086582336808e-06
chromosome O 0 0.0003654572064988315
4p O 0 0.3098739683628082
at O 0 1.1994389751635026e-05
D4S2949 O 0 0.000125427424791269
( O 0 4.7300545702455565e-06
maximum O 0 6.604646841879003e-06
GENEHUNTER O 0 0.0033920523710548878
- O 0 4.1062929085455835e-05
PLUS O 0 7.727297997917049e-06
nonparametric O 0 1.7030561139108613e-05
linkage O 0 1.4666225979453884e-05
score O 0 8.833034712552035e-07
= O 0 1.1061853911087383e-05
4 O 0 2.1889793515583733e-06
. O 0 7.704721838308615e-07
05 O 0 5.665417847922072e-05
, O 0 6.208608738234034e-07
P O 0 4.6266650315374136e-05
= O 0 5.950228569417959e-06
5 O 0 3.616473520651198e-07
. O 0 9.06528327959677e-08
22 O 0 8.692210826666269e-07
x O 0 2.7130554371979088e-06
10 O 0 3.861482582578901e-07
( O 0 1.1445790732977912e-06
- O 0 5.012535439163912e-06
4 O 0 5.023461540076823e-07
) O 0 2.7354818143976445e-07
; O 0 4.856556188315153e-07
SIBPAL O 0 0.00010711222421377897
Pempirical O 0 3.932908293791115e-05
value O 0 4.150897154886479e-07
< O 0 3.8823403883725405e-05
3 O 0 1.4787208328925772e-06
x O 0 4.5984202188265044e-06
10 O 0 1.06409413547226e-06
( O 0 8.316636694871704e-07
- O 0 6.514845154015347e-06
5 O 0 5.059434329268697e-07
) O 0 1.3280890698297299e-07
) O 0 8.401866580243222e-08
and O 0 4.8518064232894176e-08
suggestive O 0 4.880681899521733e-06
evidence O 0 3.720882659763447e-07
for O 0 8.958780739476424e-08
a O 0 1.0474830105522415e-06
locus O 0 1.227757275046315e-05
on O 0 2.9638422347488813e-06
chromosome O 0 0.0005544846644625068
4q O 1 0.7024555206298828
at O 0 9.744484486873262e-06
D4S397 O 0 0.0001702771696727723
( O 0 2.110123432430555e-06
maximum O 0 6.231022780411877e-06
GENEHUNTER O 0 0.0036981517914682627
- O 0 3.058745642192662e-05
PLUS O 0 5.991614216327434e-06
nonparametric O 0 1.516105385235278e-05
linkage O 0 1.3508560186892282e-05
score O 0 1.1780964541685535e-06
= O 0 9.490674528933596e-06
3 O 0 6.266475907068525e-07
. O 0 2.58114397411191e-07
29 O 0 3.0722824249096448e-06
, O 0 3.5771572015619313e-07
P O 0 3.3397333027096465e-05
= O 0 5.896862148802029e-06
2 O 0 5.986646556266351e-07
. O 0 1.9371184123428975e-07
57 O 0 2.8671452128037345e-06
x O 0 3.0089433948887745e-06
10 O 0 9.226172323906212e-07
( O 0 1.693414333203691e-06
- O 0 6.432004283851711e-06
3 O 0 6.841927415734972e-07
) O 0 3.627669116212928e-07
; O 0 9.16997976219136e-07
SIBPAL O 0 0.00029662714223377407
Pempirical O 0 6.336809019558132e-05
value O 0 7.092002078934456e-07
< O 0 4.116872150916606e-05
1 O 0 1.3479672134053544e-06
x O 0 4.1930734369088896e-06
10 O 0 8.501243655700819e-07
( O 0 1.0124545042344835e-06
- O 0 6.000861503707711e-06
3 O 0 6.035142519067449e-07
) O 0 3.2667443861100764e-07
) O 0 2.1310090403403592e-07
that O 0 9.15604374540635e-08
are O 0 2.818721611674846e-07
linked O 0 0.00048132683150470257
to O 0 3.485941488179378e-05
mental O 1 0.9979591369628906
health O 1 0.9861251711845398
wellness O 1 0.9595240354537964
. O 0 0.0003612520231399685

These O 0 3.846688287012512e-06
findings O 0 1.2650447388296016e-05
are O 0 8.757212555110527e-08
consistent O 0 1.0606423757053562e-06
with O 0 2.0638775310999335e-07
the O 0 4.812920337826654e-07
hypothesis O 0 5.048491857451154e-06
that O 0 2.1591823440303415e-07
certain O 0 6.02146542405535e-07
alleles O 0 1.1602362064877525e-05
could O 0 3.1416441288456554e-06
prevent O 0 3.272884714533575e-05
or O 0 3.1132979074754985e-06
modify O 0 3.761957850656472e-05
the O 0 4.101444574189372e-06
clinical O 0 0.000976930488832295
manifestations O 0 0.0005239342572167516
of O 0 1.3943636986368801e-05
BPAD B-Disease 1 0.9986494183540344
and O 0 1.944603536685463e-05
perhaps O 0 7.670231570955366e-05
other O 0 1.636568413232453e-05
related O 0 0.10717421770095825
affective B-Disease 1 0.9989159107208252
disorders I-Disease 1 0.9997795224189758
. O 0 0.008044115267693996

Segregation O 0 0.3703506588935852
distortion O 1 0.8404254913330078
in O 0 0.1330418586730957
myotonic B-Disease 1 0.9995278120040894
dystrophy I-Disease 1 0.9996837377548218
. O 0 0.010814055800437927

Myotonic B-Disease 1 0.998435914516449
dystrophy I-Disease 1 0.9996732473373413
( O 1 0.811615526676178
DM B-Disease 1 0.9993981122970581
) O 0 9.275991033064201e-05
is O 0 2.3416941985487938e-05
an O 0 0.0001947002310771495
autosomal B-Disease 1 0.999308705329895
dominant I-Disease 1 0.9981514811515808
disease I-Disease 1 0.9999103546142578
which O 0 4.038582119392231e-06
, O 0 7.250905014188902e-07
in O 0 2.932371216957108e-07
the O 0 2.0022196167701622e-06
typical O 0 0.00015979364980012178
pedigree O 0 0.0006012018420733511
, O 0 6.263489353841578e-07
shows O 0 5.55348492525809e-07
a O 0 1.2498469459387707e-06
three O 0 2.472360620231484e-06
generation O 0 0.00011499805987114087
anticipation O 0 0.0003910324885509908
cascade O 0 0.007812007330358028
. O 0 7.203927816590294e-05

This O 0 6.885486072860658e-05
results O 0 0.000616171455476433
in O 0 0.0013582708779722452
infertility B-Disease 1 0.9989743232727051
and O 1 0.8693462610244751
congenital B-Disease 1 0.9999817609786987
myotonic I-Disease 1 0.9999699592590332
dystrophy I-Disease 1 0.9999678134918213
( O 0 0.06230883300304413
CDM B-Disease 1 0.968357264995575
) O 0 6.7524802034313325e-06
with O 0 1.0818164355441695e-06
the O 0 2.0874879282928305e-06
disappearance O 0 0.00012459502613637596
of O 0 1.215434167534113e-05
DM B-Disease 1 0.9995185136795044
in O 0 1.874692134151701e-05
that O 0 1.0495916285435669e-05
pedigree O 0 0.009441589936614037
. O 0 0.00011320587509544566

The O 0 4.89658850710839e-06
concept O 0 9.674150533101056e-06
of O 0 3.754735871552839e-06
segregation O 0 0.005149207077920437
distortion O 0 0.0022548381239175797
, O 0 2.2170072497829096e-06
where O 0 7.503023198296432e-07
there O 0 2.2577812330837332e-07
is O 0 2.6104763151124644e-07
preferential O 0 1.5511823221459053e-06
transmission O 0 4.193141194264172e-06
of O 0 2.189355541304394e-08
the O 0 2.051925491741713e-07
larger O 0 9.337392725683458e-07
allele O 0 4.993478796677664e-06
at O 0 5.7292095334560145e-06
the O 0 4.287214687792584e-05
DM B-Disease 1 0.9991797804832458
locus O 0 0.00021510211809072644
, O 0 2.3729437543806853e-06
has O 0 1.6549895462958375e-06
been O 0 3.695195402997342e-07
put O 0 5.231585191722843e-07
forward O 0 3.7206979186521494e-07
to O 0 2.2602111471314856e-07
explain O 0 1.1298006029392127e-05
partially O 0 7.360194285865873e-05
the O 0 4.180938503850484e-06
maintenance O 0 0.0015500327572226524
of O 0 1.3159923582861666e-05
DM B-Disease 1 0.9993483424186707
in O 0 4.404757419251837e-06
the O 0 4.755011104862206e-06
population O 0 8.12120833870722e-06
. O 0 2.7127885914524086e-05

In O 0 9.375724403071217e-06
a O 0 1.2425246495695319e-05
survey O 0 3.072735489695333e-05
of O 0 8.46841066959314e-06
DM B-Disease 1 0.9982845187187195
in O 0 6.400454367394559e-06
Northern O 0 5.5332975534838624e-06
Ireland O 0 8.230442290368956e-06
, O 0 1.9466331195872044e-06
59 O 0 5.657556539517827e-05
pedigrees O 0 0.00021874350204598159
were O 0 6.4340533754148055e-06
ascertained O 0 0.00039462113636545837
. O 0 7.302028825506568e-05

Sibships O 0 0.004998166114091873
where O 0 3.8836069506942295e-06
the O 0 5.370009148464305e-07
status O 0 6.123649995970482e-07
of O 0 5.3389626941680035e-08
all O 0 2.91592261447704e-08
the O 0 3.8325433138197695e-07
members O 0 3.830555499462207e-07
had O 0 5.034583409724291e-06
been O 0 1.1643135167105356e-06
identified O 0 2.246236135761137e-06
were O 0 2.0206721274007577e-07
examined O 0 2.9524674118874827e-06
to O 0 3.7793693508092474e-08
determine O 0 1.5331031022469688e-07
the O 0 2.647996950599918e-07
transmission O 0 1.162914759333944e-05
of O 0 3.602525566748227e-07
the O 0 4.1646435420261696e-05
DM B-Disease 1 0.9993937015533447
expansion O 0 7.423597708111629e-05
from O 0 5.083868018118665e-06
affected O 0 1.627565870876424e-05
parents O 0 1.4534011825162452e-06
to O 0 2.8912376137668616e-07
their O 0 1.1868970659634215e-06
offspring O 0 0.00025570220896042883
. O 0 6.614896119572222e-05

Where O 0 2.1400859623099677e-05
the O 0 1.256644736713497e-05
transmitting O 0 0.0010929134441539645
parent O 0 0.0005608315696008503
was O 0 8.290645928354934e-05
male O 0 5.051327752880752e-05
, O 0 1.1080224794568494e-05
58 O 0 0.0001607972226338461
. O 0 4.2484163714107126e-05

3 O 0 1.1583423656702507e-05
% O 0 1.4406665513888584e-06
of O 0 4.1188064869857044e-07
the O 0 2.4407297587458743e-06
offspring O 0 4.998469739803113e-05
were O 0 1.0945436770271044e-06
affected O 0 6.599225798709085e-06
, O 0 3.0467097644759633e-07
and O 0 6.183754663879881e-08
in O 0 8.582151167502161e-08
the O 0 1.5019226395907026e-07
case O 0 7.794427006047044e-07
of O 0 1.0424071916759203e-07
a O 0 8.084780347417109e-06
female O 0 7.892010034993291e-05
transmitting O 0 0.002814726671203971
parent O 0 0.0006281101959757507
, O 0 1.9586832422646694e-05
68 O 0 0.0002530212514102459
. O 0 3.920823291991837e-05

7 O 0 0.00016044650692492723
% O 0 4.85793971165549e-05
were O 0 9.435445463168435e-06
affected O 0 0.00028360795113258064
. O 0 8.231359242927283e-05

Studies O 0 3.699718217831105e-05
on O 0 1.197054280055454e-05
meiotic O 0 0.007703220937401056
drive O 0 0.0001872368884505704
in O 0 7.460722554242238e-05
DM B-Disease 1 0.9993021488189697
have O 0 8.142542355926707e-07
shown O 0 1.355602876174089e-06
increased O 0 6.313131848401099e-07
transmission O 0 2.7235648758505704e-06
of O 0 1.8967902803979086e-08
the O 0 8.518401983792501e-08
larger O 0 9.284975703849341e-07
allele O 0 5.8132850426773075e-06
at O 0 3.858077434415463e-06
the O 0 1.380249705107417e-05
DM B-Disease 1 0.9976303577423096
locus O 0 0.0001267943298444152
in O 0 1.1708737474691588e-05
non O 0 0.000753285305108875
- O 1 0.6377236247062683
DM O 1 0.9973980188369751
heterozygotes O 0 0.004022745415568352
for O 0 2.96723756036954e-05
CTGn O 0 0.03749224171042442
. O 0 0.00023946232977323234

This O 0 3.4138008686568355e-06
study O 0 5.128761586092878e-06
provides O 0 3.581783403205918e-06
further O 0 1.0790365649882006e-06
evidence O 0 3.335732117193402e-06
that O 0 1.4038271274330327e-06
the O 0 4.17067640228197e-05
DM B-Disease 1 0.9990757703781128
expansion O 0 0.00018662144429981709
tends O 0 4.056609395775013e-05
to O 0 8.292568054457661e-07
be O 0 2.2808519588579657e-06
transmitted O 0 0.00022446087677963078
preferentially O 0 0.00010009243851527572
. O 0 4.868764881393872e-05

Diagnosis O 1 0.9898874163627625
of O 0 0.0037007280625402927
hemochromatosis B-Disease 1 0.9994638562202454
. O 0 0.0056289066560566425

If O 0 0.03553561866283417
untreated O 1 0.9985675811767578
, O 0 0.14981627464294434
hemochromatosis B-Disease 1 0.9999263286590576
can O 0 0.024934211745858192
cause O 1 0.9984436631202698
serious O 1 0.9985973238945007
illness O 1 0.9996408224105835
and O 0 1.6842397599248216e-05
early B-Disease 0 0.00021712064335588366
death I-Disease 0 0.011145065538585186
, O 0 7.941103831399232e-06
but O 0 9.015095201903023e-06
the O 0 0.00037253217305988073
disease O 1 0.9998130202293396
is O 0 5.374391548684798e-05
still O 0 0.0003120182373095304
substantially O 0 0.0493800975382328
under O 0 0.07732100039720535
- O 1 0.9970629811286926
diagnosed O 1 0.9993144273757935
. O 0 0.00029621427529491484

The O 0 1.9680564946611412e-05
cornerstone O 0 0.0001914201711770147
of O 0 1.5949582348184776e-06
screening O 0 5.281959238345735e-05
and O 0 1.3050090501565137e-06
case O 0 5.1450456339807715e-06
detection O 0 8.534307198715396e-06
is O 0 2.3878553179201845e-07
the O 0 2.0090661223548523e-07
measurement O 0 3.283465275671915e-06
of O 0 1.8329058093513595e-06
serum O 0 0.022382045164704323
transferrin O 0 0.004059190861880779
saturation O 0 6.973118433961645e-05
and O 0 1.6938698763624416e-06
the O 0 1.0993706382578239e-05
serum O 0 0.019202368333935738
ferritin O 0 0.015540162101387978
level O 0 0.0002013885969063267
. O 0 0.00010734883835539222

Once O 0 0.00072929059388116
the O 0 0.00015155176515690982
diagnosis O 1 0.9959498643875122
is O 0 4.2785195546457544e-05
suspected O 0 0.0008149569621309638
, O 0 1.2549728126032278e-05
physicians O 0 0.0002135407121386379
must O 0 2.061357008642517e-06
use O 0 6.4141909206227865e-06
serum O 0 0.2215539515018463
ferritin O 0 0.27409422397613525
levels O 0 0.00032551094773225486
and O 0 4.699167038779706e-05
hepatic O 1 0.9974759221076965
iron O 1 0.9909667372703552
stores O 0 0.0001758523576427251
on O 0 0.0005224326741881669
liver O 1 0.9994514584541321
biopsy O 1 0.944611668586731
specimens O 0 0.00014659613952971995
to O 0 4.215566605125787e-06
assess O 0 0.0008578405831940472
patients O 0 0.007289443165063858
for O 0 4.2095618368875876e-07
the O 0 2.5167539661197225e-06
presence O 0 1.0899741027969867e-05
of O 0 1.147886723629199e-05
iron B-Disease 1 0.998591959476471
overload I-Disease 1 0.996956467628479
. O 0 0.00037469129892997444

Liver O 1 0.9990904331207275
biopsy O 1 0.9766110181808472
is O 0 6.240877610252937e-06
also O 0 5.777145588581334e-07
used O 0 1.7642359750880132e-07
to O 0 4.5551995953019286e-08
establish O 0 2.7962954618487856e-07
the O 0 2.748871565927402e-07
presence O 0 1.9673993847391102e-06
or O 0 1.4440614677369012e-06
absence O 0 5.697106462321244e-05
of O 0 2.2279175027506426e-05
cirrhosis B-Disease 1 0.999919056892395
, O 0 1.7459133232478052e-05
which O 0 5.009821052226471e-06
can O 0 1.216369855683297e-05
affect O 0 0.000725619844160974
prognosis O 1 0.9986473917961121
and O 0 3.752985503524542e-05
management O 0 0.0031078483443707228
. O 0 0.00012946838978677988

A O 0 6.875500548630953e-05
DNA O 0 9.410729398950934e-05
- O 0 4.59901311842259e-05
based O 0 2.8549141006806167e-07
test O 0 7.523407816734107e-07
for O 0 1.4956705740587495e-07
the O 0 1.284025870518235e-06
HFE O 0 0.08441978693008423
gene O 0 7.51575180402142e-06
is O 0 4.0697651115806366e-07
commercially O 0 8.373986588594562e-07
available O 0 8.349388025408189e-08
, O 0 5.662564817043858e-08
but O 0 2.4973816792339676e-08
its O 0 2.508208574170112e-08
place O 0 8.734909329177754e-08
in O 0 4.0224509234576544e-07
the O 0 8.63591230881866e-06
diagnosis O 1 0.996184766292572
of O 0 0.00025620032101869583
hemochromatosis B-Disease 1 0.9999366998672485
is O 0 0.00012459229037631303
still O 0 4.478776463656686e-05
being O 0 1.9136652554152533e-05
evaluated O 0 0.00013282240252010524
. O 0 3.496351928333752e-05

Currently O 0 1.2303135918045882e-05
, O 0 9.359645787299087e-07
the O 0 1.6058115193118283e-07
most O 0 8.21737131673217e-08
useful O 0 1.5322291346819839e-07
role O 0 2.2399245835913462e-07
for O 0 5.695612870226796e-08
this O 0 7.34128988710836e-08
test O 0 4.856019586441107e-07
is O 0 9.015295887593311e-08
in O 0 5.508828238021124e-08
the O 0 2.1744946820945188e-07
detection O 0 2.3151174900704063e-05
of O 0 3.5369866964174435e-06
hemochromatosis B-Disease 1 0.9998038411140442
in O 0 3.5618083984445548e-06
the O 0 1.9040944607695565e-06
family O 0 4.93042534799315e-06
members O 0 6.856644176878035e-07
of O 0 1.3428260672299075e-06
patients O 0 0.05817575752735138
with O 0 3.1180907171801664e-06
a O 0 3.626609031925909e-05
proven O 0 0.00023595892707817256
case O 0 2.1260782887111418e-05
of O 0 3.980093879363267e-06
the O 0 0.001600996358320117
disease O 1 0.9991294741630554
. O 0 0.0005081499693915248

It O 0 5.781108939117985e-06
is O 0 4.273551894584671e-06
crucial O 0 4.069973874720745e-05
to O 0 0.00014178630954120308
diagnose O 1 0.9989770650863647
hemochromatosis B-Disease 1 0.9998657703399658
before O 1 0.9916648268699646
hepatic B-Disease 1 0.9998133778572083
cirrhosis I-Disease 1 0.9999027252197266
develops O 1 0.9948379397392273
because O 0 0.07935881614685059
phlebotomy O 1 0.9979619979858398
therapy O 1 0.9961644411087036
can O 0 0.017255177721381187
avert O 1 0.9988967180252075
serious O 1 0.9998331069946289
chronic O 1 0.9999963045120239
disease O 1 0.9999736547470093
and O 0 2.548885458963923e-05
can O 0 2.339492084502126e-06
even O 0 1.360672513328609e-06
lead O 0 2.876553253372549e-06
to O 0 3.7237185779304127e-07
normal O 0 2.2623149561695755e-05
life O 0 4.573397745843977e-05
expectancy O 0 0.005999866873025894
. O 0 1.0345242117182352e-05
. O 0 4.486214675125666e-05

Prevalence O 0 0.004561861045658588
of O 0 2.2501083094539354e-06
the O 0 9.68079621088691e-06
I1307K O 0 0.0024883481673896313
APC B-Disease 0 0.014550464227795601
gene O 0 8.777962648309767e-05
variant O 0 0.001164223882369697
in O 0 8.37996196878521e-07
Israeli O 0 3.0510320812027203e-06
Jews O 0 3.0012057550266036e-07
of O 0 4.049755730761717e-08
differing O 0 1.7068016404664377e-06
ethnic O 0 1.4138461210677633e-06
origin O 0 8.462743608106393e-06
and O 0 0.00011555866512935609
risk O 1 0.9918251037597656
for O 1 0.7418667078018188
colorectal B-Disease 1 0.999993085861206
cancer I-Disease 1 0.99993896484375
. O 0 0.004429879132658243

BACKGROUND O 0 0.0013437847374007106
& O 0 0.0007307716878131032
AIMS O 0 6.560300244018435e-05
Israeli O 0 1.0515614121686667e-05
Jews O 0 1.7730823174133548e-06
of O 0 4.2932023802677577e-07
European O 0 1.3939236851001624e-05
birth O 0 0.0006211997824721038
, O 0 6.048745035514003e-06
i O 0 1.3279438462632243e-05
. O 0 7.359241749327339e-07
e O 0 8.14553914096905e-06
. O 0 6.640732408413896e-07
, O 0 1.1218288591408054e-06
Ashkenazim O 0 0.000136287315399386
, O 0 1.3204072502048803e-06
have O 0 6.849814440101909e-07
the O 0 4.910483039566316e-05
highest O 1 0.987818717956543
colorectal B-Disease 1 0.9999904632568359
cancer I-Disease 1 0.9999723434448242
incidence O 1 0.9422284364700317
of O 0 4.1527343341840606e-07
any O 0 1.7303465256190975e-06
Israeli O 0 1.2870950740762055e-05
ethnic O 0 3.2355117127735866e-06
group O 0 2.9496808565454558e-05
. O 0 4.749721847474575e-05

The O 0 0.00014739055768586695
I1307K O 0 0.004837566055357456
APC B-Disease 0 0.02505321428179741
gene O 0 0.0004847788077313453
variant O 0 0.007966410368680954
was O 0 9.539972234051675e-05
found O 0 1.4894069863657933e-05
in O 0 7.565212854387937e-06
6 O 0 0.00010631910845404491
. O 0 4.95950662298128e-05

1 O 0 2.1408370230346918e-05
% O 0 2.358812707825564e-06
of O 0 3.930192917778186e-07
American O 0 3.637417648860719e-06
Jews O 0 1.223489903168229e-06
, O 0 4.871205305789772e-07
28 O 0 1.6201971675400273e-06
% O 0 6.953205229365267e-07
of O 0 7.97809434516239e-07
their O 0 0.00016157397476490587
familial O 1 0.9996970891952515
colorectal B-Disease 1 0.9999983310699463
cancer I-Disease 1 0.9999908208847046
cases O 0 0.0966913253068924
, O 0 2.031068470387254e-05
but O 0 1.6673575373715721e-06
not O 0 5.028974214837945e-07
in O 0 2.888161588998628e-06
non O 0 5.841714300913736e-05
- O 0 0.00043598824413493276
Jews O 0 1.826356128731277e-05
. O 0 2.2688791432301514e-05

We O 0 1.6848887753440067e-05
assessed O 0 8.796389010967687e-05
the O 0 1.925854667206295e-05
I1307K O 0 0.0057757399044930935
prevalence O 0 0.03232108801603317
in O 0 1.5405178146465914e-06
Israeli O 0 4.203626758680912e-06
Jews O 0 5.454293727780168e-07
of O 0 4.9711569971577774e-08
differing O 0 2.001379698413075e-06
ethnic O 0 1.7386221315973671e-06
origin O 0 8.540201633877587e-06
and O 0 7.51286861486733e-05
risk O 1 0.9793137907981873
for O 1 0.7521994709968567
colorectal B-Disease 1 0.9999940395355225
cancer I-Disease 1 0.9999527931213379
. O 0 0.004030589945614338

METHODS O 0 1.7446949641453102e-05
DNA O 0 3.532308983267285e-05
samples O 0 3.96958967030514e-06
from O 0 3.445343281782698e-06
500 O 0 1.0541780284256674e-05
unrelated O 0 1.5023315427242778e-05
Jews O 0 8.574302796660049e-07
of O 0 3.712921170517802e-07
European O 0 5.814537871629e-06
or O 0 9.494386176811531e-06
non O 0 1.979330954782199e-05
- O 0 6.376562669174746e-05
European O 0 3.5436616485640116e-07
origin O 0 1.1795766141631248e-07
, O 0 1.1309397507375252e-07
with O 0 1.4887784516304237e-07
or O 0 5.607074626823305e-07
without O 0 4.6065045467003074e-07
a O 0 2.4449716420349432e-06
personal O 0 9.135699656326324e-06
and O 0 2.6382322175777517e-06
/ O 0 0.0011341144563630223
or O 0 1.292219621973345e-06
family O 0 3.3383353184035514e-06
history O 0 2.0163324734312482e-06
of O 0 2.5225256194971735e-06
neoplasia B-Disease 1 0.9985528588294983
, O 0 3.0708911253896076e-06
were O 0 4.0248067989523406e-07
examined O 0 9.669640348874964e-06
for O 0 2.965172143376549e-07
the O 0 1.5383742493213504e-06
I1307K O 0 0.0004145628190599382
variant O 0 0.00015114695997908711
by O 0 5.356793053579167e-07
the O 0 1.0169831057282863e-06
allele O 0 1.9810000594588928e-05
- O 0 1.5933610484353267e-05
specific O 0 5.073393367638346e-07
oligonucleotide O 0 0.0001939625944942236
( O 0 2.511821367079392e-05
ASO O 0 0.4664115309715271
) O 0 4.726776296593016e-06
method O 0 8.138543307723012e-06
. O 0 3.106207441305742e-05

RESULTS O 0 0.00015251421427819878
In O 0 7.077373993524816e-06
persons O 0 8.438138138444629e-06
at O 0 4.677113247453235e-05
average O 0 0.0031677582301199436
risk O 1 0.7262415289878845
for O 0 0.10750570893287659
colorectal B-Disease 1 0.9999934434890747
cancer I-Disease 1 0.9999454021453857
, O 0 0.00011840189836220816
I1307K O 0 0.004321760963648558
was O 0 8.019614324439317e-05
found O 0 9.144189789367374e-06
in O 0 2.995920795001439e-06
5 O 0 3.4720735129667446e-05
. O 0 3.094617204624228e-05

0 O 0 1.4189414287102409e-05
% O 0 1.105242631638248e-06
of O 0 2.1666657801233669e-07
120 O 0 3.631061645137379e-06
European O 0 2.8230360840098e-06
and O 0 1.380066123601864e-06
1 O 0 1.980824708880391e-05
. O 0 2.531987411202863e-05

6 O 0 3.7194578908383846e-05
% O 0 2.6544214506429853e-06
of O 0 7.994522661647352e-07
188 O 0 5.051101470598951e-05
non O 0 2.344084896321874e-05
- O 0 3.528720117174089e-05
European O 0 7.834393613848079e-07
Jews O 0 1.2585074955495656e-06
( O 0 2.3090919967216905e-06
P O 0 0.0003078871523030102
= O 0 2.5915531296050176e-05
0 O 0 1.7193797248182818e-06
. O 0 1.125288804360025e-06
08 O 0 6.459158612415195e-05
) O 0 3.5470529837766662e-06
. O 0 7.91308866610052e-06

It O 0 3.354614455020055e-05
occurred O 0 0.00013105366087984294
in O 0 1.3558171303884592e-05
15 O 0 8.334188169101253e-05
. O 0 4.8640449676895514e-05

4 O 0 2.022096850851085e-05
% O 0 2.751515012278105e-06
of O 0 1.5279347280738875e-06
52 O 0 0.00011815354082500562
Ashkenazi O 0 0.000572230143006891
Israelis O 0 3.877234848914668e-05
with O 0 8.965667802840471e-05
familial O 1 0.9975894689559937
cancer B-Disease 1 0.999519944190979
( O 0 0.00013192003825679421
P O 0 0.013348087668418884
= O 0 0.0001189236281788908
0 O 0 4.16258171753725e-06
. O 0 1.592859007359948e-06
02 O 0 0.0003895758418366313
) O 0 3.4067068099830067e-07
and O 0 1.620546470348927e-07
was O 0 1.1145656344524468e-06
not O 0 2.2772779573188018e-07
detected O 0 7.09985033608973e-06
in O 0 4.3561965412663994e-07
51 O 0 9.51846504904097e-06
non O 0 1.5669513231841847e-05
- O 0 6.990003021201119e-05
European O 0 1.8048679066851037e-06
Jews O 0 4.887789600616088e-06
at O 0 0.00011682651529554278
increased O 0 0.023078810423612595
cancer B-Disease 1 0.999337375164032
risk O 0 0.4280511140823364
. O 0 0.0003055417037103325

Colorectal B-Disease 1 0.9987469911575317
neoplasia I-Disease 1 0.9975320100784302
occurred O 0 0.009647897444665432
personally O 0 0.0006887892377562821
or O 0 4.082413397554774e-06
in O 0 5.73248257751402e-07
the O 0 3.287176753019594e-07
families O 0 2.530858012050885e-07
of O 0 8.457674738338028e-08
13 O 0 1.382396362714644e-06
of O 0 4.613143005371967e-07
20 O 0 1.7212785678566433e-05
Ashkenazi O 0 0.0006951973191462457
I1307K O 0 0.0006941927131265402
carriers O 0 5.948852049186826e-05
, O 0 5.922410082348506e-07
8 O 0 1.137060053224559e-06
of O 0 1.473909918559002e-07
whom O 0 5.4559504860662855e-06
also O 0 1.5306386558222584e-06
had O 0 2.7466176106827334e-06
a O 0 2.362872010053252e-06
personal O 0 5.454254278447479e-06
or O 0 4.453764631762169e-06
family O 0 1.0318392924091313e-05
history O 0 1.0444314284541178e-05
of O 0 1.8269536667503417e-05
noncolonic O 1 0.9788789749145508
neoplasia B-Disease 1 0.9936330318450928
. O 0 0.0005756376194767654

CONCLUSIONS O 0 0.0002460409014020115
The O 0 5.5385567975463346e-05
I1307K O 0 0.010718110017478466
APC O 0 0.37963026762008667
variant O 0 0.010981793515384197
may O 0 1.0040859706350602e-05
represent O 0 9.50780133734952e-07
a O 0 1.2551953659567516e-05
susceptibility O 0 0.0029179269913583994
gene O 0 0.0004897268954664469
for O 0 0.00019670711481012404
colorectal B-Disease 1 0.9999275207519531
, I-Disease 0 1.5042698578326963e-05
or I-Disease 0 5.946512828813866e-06
other I-Disease 0 1.32617697090609e-06
, I-Disease 0 8.225121564464644e-05
cancers I-Disease 1 0.9975705742835999
in O 0 1.018328475765884e-05
Ashkenazi O 0 0.003222046187147498
Jews O 0 5.454041001939913e-06
, O 0 1.4867497384329909e-06
and O 0 1.5349304476330872e-06
partially O 0 0.00021646477398462594
explains O 0 3.07395494019147e-05
the O 0 5.4618903959635645e-06
higher O 0 0.0006884584436193109
incidence O 1 0.9964698553085327
of O 0 0.21037857234477997
colorectal B-Disease 1 0.9999945163726807
cancer I-Disease 1 0.9999440908432007
in O 0 8.712946873856708e-05
European O 0 0.00015031937800813466
Israelis O 0 0.00024135265266522765
. O 0 8.282380440505221e-05

Systematic O 0 3.7339083064580336e-05
analysis O 0 8.67100061441306e-06
of O 0 8.625080226920545e-06
coproporphyrinogen O 0 0.093071848154068
oxidase O 0 0.036752548068761826
gene O 0 0.013696781359612942
defects O 1 0.9962194561958313
in O 0 0.00011210595403099433
hereditary B-Disease 1 0.9918204545974731
coproporphyria I-Disease 1 0.7915789484977722
and O 0 5.216364297666587e-05
mutation O 0 0.003047352423891425
update O 0 0.005131084471940994
. O 0 0.00010660276166163385

Hereditary B-Disease 1 0.9677770137786865
coproporphyria I-Disease 1 0.8662075996398926
( O 0 0.004190666601061821
HC B-Disease 1 0.9972636699676514
) O 0 0.00020131758356001228
is O 0 0.00010837790614459664
an O 0 0.003191140480339527
acute O 1 0.9995736479759216
hepatic B-Disease 1 0.9996988773345947
porphyria I-Disease 1 0.9997023940086365
with O 0 0.018682582303881645
autosomal O 1 0.9992996454238892
dominant O 1 0.9556459784507751
inheritance O 1 0.993233859539032
caused O 1 0.996880292892456
by O 0 0.00028729636687785387
deficient B-Disease 1 0.9856762886047363
activity I-Disease 0 7.432641268678708e-06
of I-Disease 0 4.3017862481065094e-06
coproporphyrinogen I-Disease 0 0.10065683722496033
III I-Disease 1 0.7133961319923401
oxidase I-Disease 0 0.003730056108906865
( O 0 5.5437092669308186e-05
CPO O 0 0.0010421257466077805
) O 0 2.5525438104523346e-05
. O 0 3.914102853741497e-05

Clinical O 0 0.014238351956009865
manifestations O 0 0.0017087057931348681
of O 0 2.831296660588123e-05
the O 0 0.04986247047781944
disease O 1 0.9998218417167664
are O 0 2.3920905732666142e-05
characterized O 1 0.860736072063446
by O 0 0.0029955448117107153
acute O 1 0.9996034502983093
attacks O 0 0.018105152994394302
of O 0 0.015188928693532944
neurological B-Disease 1 0.9999464750289917
dysfunction I-Disease 1 0.9997822642326355
often O 0 0.0088491914793849
precipitated O 1 0.9872860312461853
by O 0 8.468901069136336e-05
drugs O 0 0.004678148776292801
, O 0 1.0494165508134756e-05
fasting O 0 0.0004472094587981701
, O 0 3.497272336971946e-05
cyclical O 0 0.38721051812171936
hormonal O 1 0.8291009664535522
changes O 0 0.0003903187462128699
, O 0 0.0004617343656718731
or O 0 0.13975772261619568
infectious B-Disease 1 0.9997105002403259
diseases I-Disease 1 0.9995182752609253
. O 0 0.0024514379911124706

Skin O 1 0.9990474581718445
photosensitivity O 1 0.9975641965866089
may O 0 0.0032782494090497494
also O 0 1.3407938240561634e-05
be O 0 2.3021764263830846e-06
present O 0 2.3541211703559384e-05
. O 0 5.448099909699522e-05

The O 0 5.199883162276819e-06
seven O 0 3.97122585127363e-06
exons O 0 2.8590424335561693e-05
, O 0 1.4920307194188354e-06
the O 0 2.0189897895761533e-06
exon O 0 0.0004731840454041958
/ O 0 0.0003590837586671114
intron O 0 0.00015027968038339168
boundaries O 0 1.480107556517396e-07
and O 0 4.337723780167835e-08
part O 0 5.736475472417624e-08
of O 0 2.6839231281883258e-08
3 O 0 5.312218149811088e-07
noncoding O 0 1.0270719940308481e-05
sequence O 0 9.807668277517223e-08
of O 0 4.709731271645978e-08
the O 0 1.3611734175356105e-06
CPO O 0 0.0001261509460164234
gene O 0 4.253266979503678e-06
were O 0 3.50625668943394e-07
systematically O 0 3.1537117592961295e-06
analyzed O 0 1.1592301234486513e-06
by O 0 1.8307800075945124e-07
an O 0 1.2095126749045448e-06
exon O 0 0.0004023076326120645
- O 0 9.238676284439862e-05
by O 0 1.83256497621187e-06
- O 0 6.271916936384514e-05
exon O 0 0.0001313704706262797
denaturing O 0 0.0018108158838003874
gradient O 0 0.0006191697320900857
gel O 0 0.007355582434684038
electrophoresis O 0 0.0010339426808059216
( O 0 3.4548713301774114e-05
DGGE O 0 0.005231210961937904
) O 0 3.341511046528467e-06
strategy O 0 3.844348611892201e-06
followed O 0 5.817649935124791e-07
by O 0 8.252555261378802e-08
direct O 0 1.4137933135316416e-07
sequencing O 0 9.773957572178915e-07
in O 0 5.346432203623408e-07
seven O 0 4.016572802356677e-06
unrelated O 0 0.0020350513514131308
heterozygous O 0 0.012904694303870201
HC B-Disease 1 0.9994857311248779
patients O 1 0.992120623588562
from O 0 6.010195647832006e-05
France O 0 0.00010165444109588861
, O 0 5.759262876381399e-06
Holland O 0 6.388010660884902e-05
, O 0 1.3090639185975306e-06
and O 0 9.916066119330935e-07
Czech O 0 6.235550972633064e-05
Republic O 0 2.0754270735778846e-05
. O 0 4.703788727056235e-05

Seven O 0 1.976742896658834e-05
novel O 0 5.191017407923937e-05
mutations O 0 1.7102307538152672e-05
and O 0 4.278618632724829e-07
two O 0 3.2392583193541213e-07
new O 0 7.060655207169475e-06
polymorphisms O 0 0.00019405582861509174
were O 0 5.58878127776552e-06
detected O 0 0.0010976592311635613
. O 0 4.4711505324812606e-05

Among O 0 7.51823972677812e-06
these O 0 4.783406097885745e-07
mutations O 0 5.825483185617486e-06
two O 0 1.3592466530099045e-07
are O 0 1.861152156834578e-07
missense O 0 6.759115058230236e-05
( O 0 5.101385340822162e-06
G197W O 0 0.00013961998047307134
, O 0 1.7183208456117427e-06
W427R O 0 7.340693264268339e-05
) O 0 6.131094210104493e-07
, O 0 1.228942352327067e-07
two O 0 6.75519729043117e-08
are O 0 1.3672904231043503e-07
nonsense O 0 4.621888729161583e-05
( O 0 4.0604095374874305e-06
Q306X O 0 0.00014682093751616776
, O 0 1.596549964233418e-06
Q385X O 0 8.019606320885941e-05
) O 0 5.85697364385851e-07
, O 0 9.291737512739928e-08
two O 0 2.2775815011755185e-08
are O 0 1.8914290578209147e-08
small O 0 4.12587525033814e-07
deletions O 0 1.2620370398508385e-05
( O 0 4.449841981113423e-06
662de14bp O 0 0.0001421938359271735
; O 0 1.5116955864868942e-06
1168del3bp O 0 0.0001532103487988934
removing O 0 1.2492244422901422e-05
a O 0 1.7066536202037241e-06
glycine O 0 2.1721662051277235e-05
at O 0 2.2355122837325325e-06
position O 0 1.1041850029869238e-06
390 O 0 7.4419476732145995e-06
) O 0 3.6620568266698683e-07
, O 0 6.288124154707475e-08
and O 0 1.5325674951327528e-08
one O 0 2.4184133806670616e-08
is O 0 5.42735421049656e-08
a O 0 5.69745964185131e-07
splicing O 0 8.394075848627836e-06
mutation O 0 6.082186519051902e-05
( O 0 1.8428738258080557e-05
IVS1 O 0 0.02156709134578705
- O 0 0.0011984833981841803
15c O 0 0.0027572575490921736
- O 0 0.0012533600674942136
- O 0 0.0002269390388391912
> O 0 8.819999493425712e-05
g O 0 1.5138153685256839e-05
) O 0 2.565971044532489e-07
which O 0 7.714178451578846e-08
creates O 0 1.3554335964727215e-06
a O 0 8.845224215292546e-07
new O 0 1.96895371118444e-06
acceptor O 0 0.000104819584521465
splice O 0 0.0004768430080730468
site O 0 0.00013987567217554897
. O 0 4.487250043894164e-05

The O 0 3.727077637449838e-05
pathological O 0 0.001645564683713019
significance O 0 2.7413918815000216e-06
of O 0 3.0913579962543736e-07
the O 0 2.0039351511513814e-06
point O 0 9.235942343366332e-06
mutations O 0 6.6183420130983e-05
G197W O 0 0.0002597311686258763
, O 0 2.6225513920508092e-06
W427R O 0 9.131086699198931e-05
, O 0 4.001945512754901e-07
and O 0 1.0668320982176738e-07
the O 0 6.311518632173829e-07
in O 0 1.8820455807144754e-06
- O 0 0.0002373911556787789
frame O 0 0.0002797259949147701
deletion O 0 0.00047574067139066756
390delGly O 0 0.0008999962592497468
were O 0 7.088905249474919e-07
assessed O 0 4.306424671085551e-06
by O 0 1.0242749937106055e-07
their O 0 2.9203198081972914e-08
respective O 0 2.942043693110463e-07
expression O 0 5.270535439194646e-07
in O 0 1.6170974959095474e-07
a O 0 1.8132974446416483e-06
prokaryotic O 0 2.682243393792305e-05
system O 0 1.1457922482804861e-05
using O 0 2.965532985399477e-06
site O 0 5.244436033535749e-05
- O 0 0.00012728251749649644
directed O 0 2.026233596552629e-05
mutagenesis O 0 0.0011199495056644082
. O 0 0.00011511061165947467

These O 0 6.700764060951769e-06
mutations O 0 5.247472654446028e-05
resulted O 0 2.5160983568639494e-05
in O 0 9.423038136446849e-07
the O 0 1.553511083329795e-06
absence O 0 3.720848690136336e-05
or O 0 1.9313938537379727e-06
a O 0 6.115156793384813e-06
dramatic O 0 6.135137664387003e-05
decrease O 0 8.722374332137406e-05
of O 0 4.465766778594116e-06
CPO O 0 0.0030880444683134556
activity O 0 9.499449515715241e-05
. O 0 5.6008804676821455e-05

The O 0 4.350917606643634e-06
two O 0 1.5484407640542486e-06
polymorphisms O 0 3.601679782150313e-05
were O 0 1.2265883242434938e-06
localized O 0 5.114627492730506e-05
in O 0 8.291721655950823e-07
noncoding O 0 5.900039468542673e-05
part O 0 2.598080470761488e-07
of O 0 5.1212268203926214e-08
the O 0 4.566578581943759e-07
gene O 0 3.280432338215178e-06
1 O 0 1.1137517503811978e-06
) O 0 4.708586232027301e-07
a O 0 4.763840024679666e-06
C O 0 0.00018864918092731386
/ O 0 0.00010463313810760155
G O 0 2.8273927455302328e-05
polymorphism O 0 3.87654336009291e-06
in O 0 3.1352104201687325e-07
the O 0 1.7851508573585306e-06
promotor O 0 0.0042866854928433895
region O 0 5.669227448379388e-06
, O 0 8.334509402629919e-07
142 O 0 1.3158844012650661e-05
bp O 0 3.311580076115206e-05
upstream O 0 2.6425807391206035e-06
from O 0 1.4746241561169882e-07
the O 0 1.3566152290422906e-07
transcriptional O 0 5.8749151321535464e-06
initiation O 0 1.1358072697476018e-05
site O 0 1.3452200619212817e-05
( O 0 9.844410669757053e-06
- O 0 0.00015077530406415462
142C O 0 0.00025725478189997375
/ O 0 0.00023414430324919522
G O 0 0.00010610075696604326
) O 0 5.959952318335127e-07
, O 0 1.9912273785394063e-07
and O 0 7.46472608170734e-08
2 O 0 2.8023771392327035e-07
) O 0 1.2596117926477746e-07
a O 0 4.5168897599978663e-07
6 O 0 2.173473603761522e-06
bp O 0 1.9863007764797658e-05
deletion O 0 1.3530800970329437e-05
polymorphism O 0 4.538775101536885e-06
in O 0 2.6712788780969277e-07
the O 0 3.339547447467339e-07
3 O 0 1.64784103162674e-06
noncoding O 0 3.1061274057719857e-05
part O 0 3.5356578109713155e-07
of O 0 1.2682023964316613e-07
the O 0 2.653728188306559e-06
CPO O 0 0.00020172528456896544
gene O 0 1.115508894145023e-05
, O 0 1.4084885151532944e-06
574 O 0 0.000139917028718628
bp O 0 4.454505324247293e-05
downstream O 0 3.8845037124701776e-06
of O 0 1.162722895742263e-07
the O 0 4.136390714393201e-07
last O 0 1.1486534958748962e-06
base O 0 1.7793063022963906e-07
of O 0 1.991728204586707e-08
the O 0 2.341388665172417e-07
normal O 0 3.989837750850711e-06
termination O 0 0.00015337039076257497
codon O 0 2.4198005121434107e-05
( O 0 1.4856647794658784e-05
+ O 0 0.0002390938752796501
574 O 0 0.0008604986942373216
delATTCTT O 0 0.0024393664207309484
) O 0 2.254690662084613e-05
. O 0 3.024207217094954e-05

Five O 0 0.00013659879914484918
intragenic O 0 0.06607475131750107
dimorphisms O 0 0.009996925480663776
are O 0 1.6676772247592453e-06
now O 0 5.7979209486802574e-06
well O 0 1.2594199461091193e-06
characterized O 0 6.694525654893368e-05
and O 0 3.138518991363526e-07
the O 0 8.243271736319002e-07
high O 0 8.435411473328713e-06
degree O 0 2.9025666208326584e-06
of O 0 8.546929279873439e-07
allelic O 0 0.0014147075125947595
heterogeneity O 0 0.0011471988400444388
in O 0 5.686294025508687e-05
HC B-Disease 1 0.9986414313316345
is O 0 8.709771464054938e-06
demonstrated O 0 3.896376711054472e-06
with O 0 2.947033692635159e-07
seven O 0 2.5457160290898173e-07
new O 0 2.2007165512150095e-07
different O 0 1.907987901006436e-08
mutations O 0 1.0684260587368044e-06
making O 0 1.2145298455834563e-07
a O 0 3.4759924005811627e-07
total O 0 1.0167072161948454e-07
of O 0 3.849517895559984e-07
nineteen O 0 0.00013943930389359593
CPO O 0 0.05463866889476776
gene B-Disease 0 0.011866950429975986
defects I-Disease 1 0.9990276098251343
reported O 0 0.0019009796669706702
so O 0 1.0961462066916283e-05
far O 0 1.1502942470542621e-05
. O 0 7.75368152972078e-06
. O 0 3.142114292131737e-05

Coincidence O 0 2.7342344765202142e-05
of O 0 3.5691732591658365e-07
two O 0 7.428471349157917e-07
novel O 0 1.5777086446178146e-05
arylsulfatase O 0 0.00047185798757709563
A O 0 8.462323421554174e-06
alleles O 0 6.4048022068163846e-06
and O 0 1.17797287657595e-06
mutation O 0 8.638094004709274e-05
459 O 0 0.001472744857892394
+ O 0 0.0009716756758280098
1G O 0 0.0042609707452356815
> O 0 6.52505477773957e-05
A O 0 2.2863835056341486e-06
within O 0 3.095736076375033e-07
a O 0 6.387022040144075e-06
family O 0 2.8384476536302827e-05
with O 0 7.587132131448016e-05
metachromatic B-Disease 1 0.997721254825592
leukodystrophy I-Disease 1 0.9987812638282776
: O 0 5.050817890150938e-06
molecular O 0 4.544539933704073e-06
basis O 0 2.478120109117299e-07
of O 0 1.6350797977793263e-06
phenotypic O 0 0.0008257361478172243
heterogeneity O 0 0.009553048759698868
. O 0 0.00029530716710723937

In O 0 1.5952206013025716e-05
a O 0 1.5187840290309396e-05
family O 0 1.6043148207245395e-05
with O 0 1.132819420490705e-06
three O 0 1.4213100030247006e-06
siblings O 0 6.123967614257708e-05
, O 0 9.108688914238883e-07
one O 0 7.402425694635895e-07
developed O 0 4.933929449180141e-05
classical O 0 0.00011661526514217257
late O 0 0.018227320164442062
infantile O 1 0.9976342916488647
metachromatic B-Disease 1 0.9974496960639954
leukodystrophy I-Disease 1 0.9991781115531921
( O 0 0.00896918959915638
MLD B-Disease 1 0.9979402422904968
) O 0 0.00010671351628843695
, O 0 4.2566123738652095e-05
fatal O 1 0.943679928779602
at O 0 3.341804040246643e-05
age O 0 0.00010576377826509997
5 O 0 9.049785148818046e-06
years O 0 7.389598977169953e-06
, O 0 2.3082111511030234e-06
with O 0 1.666676689637825e-05
deficient O 1 0.9750967621803284
arylsulfatase O 0 0.005811930634081364
A O 0 0.00018606815137900412
( O 0 4.4301548768999055e-05
ARSA O 0 0.1664304882287979
) O 0 2.9763223210466094e-06
activity O 0 2.459888719386072e-06
and O 0 1.0225390951745794e-06
increased O 0 2.181845047743991e-05
galactosylsulfatide O 0 0.0055924514308571815
( O 0 0.00010894240404013544
GS O 1 0.9679522514343262
) O 0 2.6229357899865136e-05
excretion O 0 0.0008475148351863027
. O 0 0.00011039590026484802

The O 0 5.086578767077299e-06
two O 0 7.413630100927548e-07
other O 0 9.261628406420641e-07
siblings O 0 0.0002216330758528784
, O 0 5.371461611503037e-06
apparently O 0 7.348699000431225e-05
healthy O 0 4.8315963795175776e-05
at O 0 3.1987779038900044e-06
12 O 0 2.2011270175426034e-06
( O 0 1.928441861309693e-06
1 O 0 1.830573751249176e-06
/ O 0 1.5424775483552366e-05
2 O 0 5.10000575104641e-07
) O 0 1.5892841531695012e-07
and O 0 8.375545945682461e-08
15 O 0 4.6321969193741097e-07
years O 0 8.748445452511078e-07
, O 0 2.523439661672455e-07
respectively O 0 8.702463105692004e-07
, O 0 1.7741214719535492e-07
and O 0 1.478774436236563e-07
their O 0 2.754345587163698e-07
father O 0 8.721109770704061e-05
, O 0 5.3862859203945845e-06
apparently O 0 0.00013602843682747334
healthy O 0 8.192065433831885e-05
as O 0 8.457801641270635e-07
well O 0 5.876376576452458e-07
, O 0 1.0757845529951737e-06
presented O 0 2.664801650098525e-05
ARSA O 1 0.6739583015441895
and O 0 5.840803623868851e-06
GS O 0 0.05185015872120857
values O 0 1.9783901450409758e-07
within O 0 2.1850007669854676e-07
the O 0 9.097238375943562e-07
range O 0 9.810044502955861e-06
of O 0 4.714778333436698e-05
MLD B-Disease 1 0.9991123080253601
patients O 1 0.9921844601631165
. O 0 0.0003793742216657847

Mutation O 0 0.0002813752507790923
screening O 0 2.155737456632778e-05
and O 0 3.118159952464339e-07
sequence O 0 2.2707079097017413e-06
analysis O 0 3.353063675604062e-06
disclosed O 0 9.580804908182472e-05
the O 0 5.893601837669848e-07
involvement O 0 2.668752813406172e-06
of O 0 5.066362973593641e-08
three O 0 4.0094826658787497e-07
different O 0 8.251018925875542e-07
ARSA O 1 0.9320584535598755
mutations O 0 2.8057515010004863e-05
being O 0 6.039967956894543e-07
the O 0 2.1785152171105437e-07
molecular O 0 2.2837707547296304e-06
basis O 0 2.2159875356919656e-07
of O 0 1.0676284318833495e-06
intrafamilial O 0 0.004507836420089006
phenotypic O 0 0.0009939376031979918
heterogeneity O 0 0.008203801698982716
. O 0 0.0002767232363112271

The O 0 0.0003377649118192494
late O 0 0.07086265832185745
infantile O 1 0.9984732270240784
patient O 1 0.9971816539764404
inherited O 1 0.9921431541442871
from O 0 1.9116681869491003e-05
his O 0 2.7338406653143466e-05
mother O 0 0.00010234561341349036
the O 0 1.894405841085245e-06
frequent O 0 2.759751987468917e-05
0 O 0 2.0004041289212182e-05
- O 0 0.00011636588169494644
type O 0 5.062211857875809e-05
mutation O 0 4.4797507143812254e-05
459 O 0 0.0007591299945488572
+ O 0 0.0004498065682128072
1G O 0 0.0026458343490958214
> O 0 0.00014495053619612008
A O 0 9.473015779803973e-06
, O 0 4.186549347195978e-07
and O 0 1.1974256608482392e-07
from O 0 3.834115318568365e-07
his O 0 1.7927720818988746e-06
father O 0 1.7876496713142842e-05
a O 0 1.7496448663223418e-06
novel O 0 3.5810660392598948e-06
, O 0 4.5023361394669337e-07
single O 0 1.2095149486412993e-06
basepair O 0 0.00011113462824141607
microdeletion O 0 2.0649322323151864e-05
of O 0 6.245082317946071e-08
guanine O 0 2.312236347279395e-06
at O 0 3.7009016295996844e-07
nucleotide O 0 7.514036610700714e-07
7 O 0 1.0774324437079486e-06
in O 0 4.39477815916689e-07
exon O 0 4.797922520083375e-05
1 O 0 7.690166057727765e-06
( O 0 9.59823501034407e-06
7delG O 0 0.0004581482207868248
) O 0 1.0451755770191085e-05
. O 0 2.0615281755453907e-05

The O 0 2.8114456654293463e-05
two O 0 1.3359384865907487e-05
clinically O 0 0.034056469798088074
unaffected O 0 0.00202134414575994
siblings O 0 8.647885988466442e-05
carried O 0 3.2281054700433742e-06
the O 0 3.2452337563881883e-06
maternal O 0 0.0005552287911996245
mutation O 0 0.0001833162095863372
459 O 0 0.002718512201681733
+ O 0 0.0012273722095414996
1G O 0 0.007043589372187853
> O 0 0.00024830017355270684
A O 0 7.93314120528521e-06
and O 0 1.9462082434529293e-07
, O 0 7.711383176456366e-08
on O 0 5.482267084744308e-08
their O 0 5.771198985371484e-08
paternal O 0 2.5634970370447263e-05
allele O 0 5.124068138684379e-06
, O 0 2.6208610393041454e-07
a O 0 5.758597012572864e-07
novel O 0 1.9848032479785616e-06
cytosine O 0 2.6974182674166514e-06
to O 0 1.6667408431203512e-07
thymidine O 0 1.2815662557841279e-05
transition O 0 2.4905664304242237e-06
at O 0 2.139669049938675e-06
nucleotide O 0 1.0330838449590374e-05
2435 O 0 0.0008818149217404425
in O 0 8.378564189115423e-07
exon O 0 6.068548100301996e-05
8 O 0 2.895511215683655e-06
, O 0 2.483140235653991e-07
resulting O 0 1.586155804034206e-06
in O 0 8.759634795296734e-08
substitution O 0 1.0063562285722583e-06
of O 0 6.338227649393957e-07
alanine O 0 0.0004135027411393821
464 O 0 0.0006264135590754449
by O 0 1.1974527296843007e-05
valine O 0 0.001465108711272478
( O 0 3.1159634090727195e-05
A464V O 0 0.0012565875658765435
) O 0 3.154264413751662e-05
. O 0 5.2271599997766316e-05

The O 0 3.753150303964503e-05
fathers O 0 9.980879258364439e-05
genotype O 0 0.00030939726275391877
thus O 0 4.01316792704165e-05
was O 0 0.00033798490767367184
7delG O 0 0.06751426309347153
/ O 0 0.015157860703766346
A464V O 0 0.0031175268813967705
. O 0 0.00012723034888040274

Mutation O 0 0.0015323756961151958
A464V O 0 0.0018938493449240923
was O 0 6.143317295936868e-05
not O 0 9.362663604406407e-07
found O 0 4.365789209259674e-06
in O 0 3.3460871691204375e-06
18 O 0 0.00022313791851047426
unrelated O 1 0.5905243754386902
MLD B-Disease 1 0.9995728135108948
patients O 1 0.961249053478241
and O 0 1.0914687663898803e-05
50 O 0 2.6685524062486365e-05
controls O 0 0.00017357079195789993
. O 0 8.798058843240142e-05

A464V O 0 0.009402582421898842
, O 0 2.7441528800409287e-05
although O 0 1.9423183402977884e-05
clearly O 0 7.764480687910691e-05
modifying O 0 0.0014121674466878176
ARSA O 1 0.978933572769165
and O 0 0.00016557128401473165
GS O 1 0.9973726272583008
levels O 0 0.0006105274078436196
, O 0 8.914682439353783e-06
apparently O 0 6.988349923631176e-05
bears O 0 4.586591967381537e-05
little O 0 4.417592663230607e-06
significance O 0 3.506862640278996e-06
for O 0 2.9950351745355874e-06
clinical O 0 0.0018469326896592975
manifestation O 0 0.006228577811270952
of O 0 7.030279084574431e-05
MLD B-Disease 1 0.9983071088790894
, O 0 4.015285230707377e-05
mimicking O 0 0.0013339719735085964
the O 0 3.133113932562992e-05
frequent O 0 0.0015803107526153326
ARSA O 1 0.9816014766693115
pseudodeficiency O 0 0.14578168094158173
allele O 0 0.0014958654064685106
. O 0 0.00020338004105724394

Our O 0 1.2975102436030284e-05
results O 0 1.1338451258779969e-05
demonstrate O 0 6.643857432209188e-06
that O 0 5.291022944220458e-07
in O 0 7.606974463669758e-07
certain O 0 3.653249450508156e-06
genetic O 0 0.004017254803329706
conditions O 1 0.5687146186828613
MLD B-Disease 1 0.9992665648460388
- O 0 0.1932542473077774
like O 0 0.00010375977581134066
ARSA O 1 0.9405825734138489
and O 0 9.145323929260485e-06
GS O 1 0.9315481781959534
values O 0 8.975334253591427e-07
need O 0 1.0785262247736682e-06
not O 0 1.540606007210954e-07
be O 0 3.6800062730435457e-07
paralleled O 0 0.00011371589789632708
by O 0 5.484824941959232e-05
clinical O 1 0.9939483404159546
disease O 1 0.999735414981842
, O 0 3.3930996323761065e-06
a O 0 7.785135494486894e-06
finding O 0 1.62525029736571e-05
with O 0 2.5372710297233425e-05
serious O 1 0.798711359500885
diagnostic O 0 0.39311322569847107
and O 0 6.554440187755972e-05
prognostic O 1 0.8040125370025635
implications O 0 0.006281964480876923
. O 0 0.0003077058063354343

Moreover O 0 0.0005625876365229487
, O 0 1.4773924704059027e-05
further O 0 3.4887943911598995e-05
ARSA O 1 0.9026284217834473
alleles O 0 9.160879562841728e-05
functionally O 0 0.0005378338391892612
similar O 0 8.886587238521315e-06
to O 0 3.248717348469654e-06
A464V O 0 0.0022318146657198668
might O 0 3.875544734910363e-06
exist O 0 3.723118595644337e-07
which O 0 8.41501730519667e-08
, O 0 7.917490307818298e-08
together O 0 5.421456705789751e-08
with O 0 4.291892139463016e-07
0 O 0 1.5180585251073353e-05
- O 0 0.0010221408447250724
type O 0 0.0003857634146697819
mutations O 0 8.75073455972597e-05
, O 0 1.0968405149469618e-05
may O 0 0.0003016749396920204
cause O 0 0.028584400191903114
pathological O 1 0.9845885634422302
ARSA O 1 0.9962171912193298
and O 0 0.00024533161194995046
GS O 1 0.9983226656913757
levels O 0 0.00019375814008526504
, O 0 1.7219166466020397e-06
but O 0 1.0022797596320743e-06
not O 0 1.3876202729079523e-06
clinical O 0 0.0027153571136295795
outbreak O 1 0.6914481520652771
of O 0 1.4988281691330485e-05
the O 0 0.029490401968359947
disease O 1 0.9998206496238708
. O 0 0.00011715258733602241
. O 0 0.000108565334812738

Human O 0 0.2441343367099762
MLH1 O 1 0.9951261281967163
deficiency O 1 0.9997130036354065
predisposes O 1 0.9854356646537781
to O 0 0.0009956378489732742
hematological B-Disease 1 0.9984046816825867
malignancy I-Disease 1 0.999514102935791
and O 0 0.0395667627453804
neurofibromatosis B-Disease 1 0.9996262788772583
type I-Disease 1 0.5478892922401428
1 I-Disease 0 0.00058937311405316
. O 0 0.00012959203741047531

Heterozygous O 0 0.007700264919549227
germ O 1 0.9799756407737732
- O 0 0.002761868992820382
line O 0 4.2223888158332556e-05
mutations O 0 1.536595846118871e-05
in O 0 1.2854729902755935e-06
the O 0 6.449226930271834e-06
DNA O 0 0.0009951513493433595
mismatch O 1 0.9376254677772522
repair O 1 0.9475321173667908
genes O 0 4.6392040530918166e-05
lead O 0 0.00015792793419677764
to O 0 8.462119876639917e-05
hereditary B-Disease 1 0.9976849555969238
nonpolyposis I-Disease 1 0.9990492463111877
colorectal I-Disease 1 0.999982476234436
cancer I-Disease 1 0.9999042749404907
. O 0 0.006093038246035576

The O 0 0.018491970375180244
disease O 1 0.9993450045585632
susceptibility O 0 0.012801987119019032
of O 0 3.5683976875588996e-06
individuals O 0 9.419854904990643e-06
who O 0 1.4691213436890393e-05
constitutionally O 0 6.393581134034321e-05
lack O 0 1.8158196326112375e-05
both O 0 1.111566007239162e-06
wild O 0 0.00011265087232459337
- O 0 0.004034312907606363
type O 0 0.00032327277585864067
alleles O 0 2.3933573174872436e-05
is O 0 5.2201107791916e-06
unknown O 0 3.6775814805878326e-05
. O 0 4.306937989895232e-05

We O 0 5.962020622973796e-06
have O 0 9.901003750201198e-07
identified O 0 3.339972181493067e-06
three O 0 4.811369649360131e-07
offspring O 0 2.727960054471623e-05
in O 0 8.1479247455718e-06
a O 0 0.0036948409397155046
hereditary B-Disease 1 0.998521625995636
nonpolyposis I-Disease 1 0.999447762966156
colorectal I-Disease 1 0.999993085861206
cancer I-Disease 1 0.9999680519104004
family O 1 0.5181766748428345
who O 0 0.0041978247463703156
developed O 0 0.45377224683761597
hematological B-Disease 1 0.9984124898910522
malignancy I-Disease 1 0.998940646648407
at O 0 3.6030090996064246e-05
a O 0 6.913710876688128e-06
very O 0 2.5396591354365228e-06
early O 0 1.0325903531338554e-05
age O 0 4.7946148697519675e-05
, O 0 2.7488923137752863e-07
and O 0 6.835725940845805e-08
at O 0 1.7066896873529913e-07
least O 0 1.7112459005375058e-08
two O 0 7.023353898460982e-09
of O 0 1.9983987797900227e-08
them O 0 1.6089630605620187e-07
displayed O 0 3.0083581805229187e-05
signs O 0 0.00038310454692691565
of O 0 1.4536253729602322e-05
neurofibromatosis B-Disease 1 0.9996191263198853
type I-Disease 0 0.018952980637550354
1 I-Disease 0 0.0001238368422491476
( O 0 9.628806583350524e-05
NF1 B-Disease 1 0.8870587944984436
) O 0 2.4785511413938366e-05
. O 0 2.620260784169659e-05

DNA O 0 1.127969426306663e-05
sequence O 0 1.8373335706201033e-06
analysis O 0 1.2385060017550131e-06
and O 0 7.057975608404377e-07
allele O 0 1.6541611330467276e-05
- O 0 1.1862264727824368e-05
specific O 0 3.004247162152751e-07
amplification O 0 1.251870889973361e-05
in O 0 2.178909994654532e-07
two O 0 5.078752565168543e-07
siblings O 0 0.0001000402553472668
revealed O 0 0.00015885841276030988
a O 0 3.519306847010739e-05
homozygous O 0 0.0008529216866008937
MLH1 O 0 0.3420366644859314
mutation O 0 0.0006970136892050505
( O 0 0.00012270911247469485
C676T O 0 0.015328915789723396
- O 0 0.04379500076174736
- O 0 0.002888874616473913
> O 0 0.0013184812851250172
Arg226Stop O 0 0.003600597847253084
) O 0 3.375222149770707e-05
. O 0 3.364116491866298e-05

Thus O 0 3.531062975525856e-05
, O 0 1.1225041816942394e-05
a O 0 8.56577098602429e-05
homozygous O 0 0.002975691808387637
germ O 1 0.985180139541626
- O 0 0.010084440000355244
line O 0 0.00042648811358958483
MLH1 O 1 0.6285511255264282
mutation O 0 0.0006152642308734357
and O 0 5.6143988331314176e-05
consequent O 1 0.9853065013885498
mismatch O 1 0.998627781867981
repair O 1 0.9996634721755981
deficiency O 1 0.9998831748962402
results O 0 0.00024705991381779313
in O 0 1.2690660696534906e-05
a O 0 0.0005838001961819828
mutator O 1 0.9889467358589172
phenotype O 1 0.7901507019996643
characterized O 1 0.964301347732544
by O 0 0.018802400678396225
leukemia B-Disease 1 0.9999303817749023
and O 0 0.009513993747532368
/ O 1 0.9981972575187683
or O 1 0.7066484689712524
lymphoma B-Disease 1 0.9999860525131226
associated O 0 0.05761450529098511
with O 0 0.03259426727890968
neurofibromatosis B-Disease 1 0.99983811378479
type I-Disease 1 0.5139186978340149
1 I-Disease 0 0.00018767766596283764
. O 0 1.1897838703589514e-05
. O 0 2.2329437342705205e-05

Missense O 0 0.0037946864031255245
mutations O 0 8.340857311850414e-05
in O 0 1.0178282536799088e-06
the O 0 7.167823810050322e-07
most O 0 2.121701072610449e-07
ancient O 0 1.2720679478661623e-06
residues O 0 2.8771182769560255e-06
of O 0 5.515724978977232e-07
the O 0 1.1517080565681681e-05
PAX6 O 0 0.18401148915290833
paired O 0 0.0001366476499242708
domain O 0 2.318562110303901e-05
underlie O 0 0.0002871528558898717
a O 0 3.0567432986572385e-05
spectrum O 0 0.00033433304633945227
of O 0 0.00014347188698593527
human O 1 0.9904047250747681
congenital B-Disease 1 0.9999841451644897
eye I-Disease 1 0.999612033367157
malformations I-Disease 1 0.9993923902511597
. O 0 0.0065263970755040646

Mutations O 0 6.135535659268498e-05
of O 0 1.6065021100075683e-06
the O 0 1.4913201084709726e-05
human O 0 0.00016664246504660696
PAX6 O 1 0.9684523344039917
gene O 0 0.005996560212224722
underlie O 1 0.9510198831558228
aniridia B-Disease 1 0.9990460276603699
( O 1 0.7272042632102966
congenital B-Disease 1 0.9999202489852905
absence I-Disease 0 0.0006556831649504602
of I-Disease 0 2.6214408990199445e-06
the I-Disease 0 5.248378874966875e-05
iris I-Disease 0 0.23209704458713531
) O 0 6.044881502020871e-06
, O 0 1.902165081446583e-06
a O 0 1.7873784599942155e-05
rare O 0 0.0019999993965029716
dominant O 0 0.011184705421328545
malformation B-Disease 1 0.998291552066803
of I-Disease 0 3.372191349626519e-05
the I-Disease 0 0.001292349654249847
eye I-Disease 1 0.9783346056938171
. O 0 0.0002934651856776327

The O 0 8.281849659397267e-06
spectrum O 0 4.3607597035588697e-05
of O 0 1.4928283235349227e-05
PAX6 O 1 0.9711166024208069
mutations O 0 0.005018044263124466
in O 0 0.0004455538000911474
aniridia B-Disease 1 0.9990395903587341
patients O 1 0.9549635648727417
is O 0 6.593469606741564e-06
highly O 0 1.2448742381820921e-05
biased O 0 8.901684850570746e-06
, O 0 3.855911074879259e-07
with O 0 1.7853693634606316e-07
92 O 0 4.382198767416412e-06
% O 0 8.992180511313563e-08
of O 0 2.165169732393224e-08
all O 0 1.27850739772839e-07
reported O 0 2.6369860279373825e-05
mutations O 0 1.1076168448198587e-05
leading O 0 4.483706561586587e-06
to O 0 8.010358669707784e-07
premature O 0 0.0005902301054447889
truncation O 0 1.820903707994148e-05
of O 0 1.5093979754965403e-07
the O 0 9.811183190322481e-07
protein O 0 9.405312994203996e-06
( O 0 2.7669270821206737e-06
nonsense O 0 1.843605059548281e-05
, O 0 1.742353816780451e-07
splicing O 0 2.4835906060616253e-06
, O 0 3.828747594525339e-07
insertions O 0 3.780822453336441e-06
and O 0 1.8385834721357242e-07
deletions O 0 4.124421593587613e-06
) O 0 3.434958557591017e-07
and O 0 7.268117485637049e-08
just O 0 2.0056891969488788e-07
2 O 0 2.451625960020465e-07
% O 0 8.361531200762329e-08
leading O 0 9.299945702423429e-08
to O 0 7.905581078659907e-09
substitution O 0 9.469633965863977e-08
of O 0 1.0658187221679327e-08
one O 0 6.177813105523455e-08
amino O 0 1.509708908997709e-06
acid O 0 4.100880687474273e-05
by O 0 1.2753099554174696e-06
another O 0 8.972366231319029e-06
( O 0 2.1398695025709458e-05
missense O 0 0.00043001974700018764
) O 0 1.6565700207138434e-05
. O 0 2.9116019504726864e-05

The O 0 7.531163646490313e-06
extraordinary O 0 1.6830997992656194e-05
conservation O 0 4.68088637717301e-06
of O 0 1.6806303904104425e-07
the O 0 2.368433342780918e-06
PAX6 O 0 0.0032531730830669403
protein O 0 3.7387210340966703e-06
at O 0 1.2382791965137585e-06
the O 0 5.884105007680773e-07
amino O 0 4.87450415675994e-06
acid O 0 0.000311708397930488
level O 0 1.7595139070181176e-05
amongst O 0 1.2114185665268451e-05
vertebrates O 0 0.00014047208242118359
predicts O 0 0.0010982591193169355
that O 0 4.9505197239341214e-06
pathological O 0 0.14634576439857483
missense O 0 0.007378722541034222
mutations O 0 0.0004442225908860564
should O 0 1.7291835092692054e-06
in O 0 1.6213516573770903e-06
fact O 0 5.524308107851539e-06
be O 0 8.104689754873107e-07
common O 0 1.086218617274426e-05
even O 0 5.486935151566286e-06
though O 0 1.9189753857062897e-06
they O 0 2.713337607929134e-07
are O 0 1.7751334269178187e-07
hardly O 0 3.6870947951683775e-05
ever O 0 2.8215448764967732e-05
seen O 0 0.00010884002404054627
in O 0 0.00011162456212332472
aniridia B-Disease 1 0.9968007802963257
patients O 1 0.9824108481407166
. O 0 0.0004043145745526999

This O 0 1.3275576748128515e-05
indicates O 0 2.911979754571803e-05
that O 0 5.350385663405177e-07
there O 0 3.7989408951943915e-07
is O 0 5.743503379562753e-07
a O 0 5.182749191590119e-06
heavy O 0 0.0014050109311938286
ascertainment O 0 0.013386952690780163
bias O 0 4.109359724679962e-05
in O 0 2.9935563361505046e-07
the O 0 1.7901172100209806e-07
selection O 0 1.0878916327783372e-06
of O 0 1.7848869902081788e-06
patients O 0 0.028273433446884155
for O 0 3.79852781406953e-06
PAX6 O 1 0.6047408580780029
mutation O 0 3.6997251299908385e-05
analysis O 0 1.0651297088770662e-06
and O 0 4.1535184891472454e-07
that O 0 7.52020866912062e-07
the O 0 4.0925519897427876e-06
missing O 0 0.0005478493985719979
PAX6 O 1 0.8644104599952698
missense O 0 0.010194201022386551
mutations O 0 0.0008216073038056493
frequently O 0 0.00013627677981276065
may O 0 0.0002661620092112571
underlie O 0 0.007528395392000675
phenotypes O 0 0.002764187753200531
distinct O 0 8.88911890797317e-05
from O 0 0.00012584995420183986
textbook O 1 0.6030970811843872
aniridia B-Disease 1 0.9915591478347778
. O 0 0.0004708331834990531

Here O 0 1.4547889804816805e-05
we O 0 5.688756345989532e-07
present O 0 1.375430656480603e-06
four O 0 1.744817723192682e-06
novel O 0 6.666564877377823e-05
PAX6 O 0 0.22570806741714478
missense O 0 0.0011503443820402026
mutations O 0 7.623692363267764e-05
, O 0 1.4686777376482496e-06
two O 0 1.0431365353724686e-06
in O 0 4.4942894419364166e-06
association O 0 0.0004131902242079377
with O 0 4.4924734538653865e-05
atypical O 1 0.9892459511756897
phenotypes O 0 0.4490908980369568
ectopia B-Disease 1 0.9422833919525146
pupillae I-Disease 1 0.6845110058784485
( O 0 0.000143767028930597
displaced B-Disease 0 0.0003694846236612648
pupils I-Disease 0 0.0002663006307557225
) O 0 9.862165461527184e-05
and O 0 0.00044648023322224617
congenital B-Disease 1 0.9999226331710815
nystagmus I-Disease 1 0.9826592206954956
( O 0 6.401866266969591e-05
searching B-Disease 0 4.5824519474990666e-05
gaze I-Disease 0 0.000450528139481321
) O 0 2.2006231574778212e-06
, O 0 4.791158403349982e-07
and O 0 1.1760786833292514e-07
two O 0 1.3460862646752503e-07
in O 0 1.8222322069050279e-06
association O 0 5.259611862129532e-05
with O 0 2.1465957615873776e-06
more O 0 4.200801413389854e-06
recognizable O 0 0.007827168330550194
aniridia B-Disease 1 0.9817845821380615
phenotypes O 0 0.041416849941015244
. O 0 0.00025217924849130213

Strikingly O 0 0.0005379825015552342
, O 0 1.811945821827976e-06
all O 0 1.1456619830596537e-07
four O 0 7.614029868818761e-07
mutations O 0 5.8412383623362985e-06
are O 0 3.135915704888248e-08
located O 0 5.561381613006233e-07
within O 0 3.003404742685234e-07
the O 0 2.0126190065639094e-06
PAX6 O 0 0.021581778302788734
paired O 0 3.170528725604527e-05
domain O 0 2.6188047286268556e-06
and O 0 1.7029356058628764e-07
affect O 0 1.3852205711373244e-06
amino O 0 1.0187799261984765e-06
acids O 0 1.404735257892753e-06
which O 0 1.471668156227679e-07
are O 0 1.8270746693360707e-08
highly O 0 3.9184709521578043e-07
conserved O 0 5.599577548309753e-07
in O 0 1.2001947879980435e-07
all O 0 5.8442751083020994e-08
known O 0 3.126263891317649e-06
paired O 0 2.223807678092271e-05
domain O 0 1.2220963071740698e-05
proteins O 0 2.0358231267891824e-05
. O 0 3.605060919653624e-05

Our O 0 4.769044608110562e-06
results O 0 3.8387834138120525e-06
support O 0 8.539628879589145e-07
the O 0 4.784428142556862e-07
hypothesis O 0 3.7229128793114796e-06
that O 0 1.8949141633584077e-07
the O 0 3.7718371004302753e-07
under O 0 2.756157982730656e-06
- O 0 3.8069415495556314e-06
representation O 0 7.183194128401738e-08
of O 0 4.259398451722518e-07
missense O 0 0.0007866964442655444
mutations O 0 0.00024992352700792253
is O 0 1.9169896404491737e-05
caused O 0 0.005003748927265406
by O 0 1.2470698493416421e-05
ascertainment O 0 0.17619192600250244
bias O 0 0.0003993490245193243
and O 0 1.6750793747632997e-06
suggest O 0 6.31239481663215e-06
that O 0 2.743732920862385e-07
a O 0 3.247025915698032e-06
substantial O 0 4.280107168597169e-05
burden O 0 0.0012386880116537213
of O 0 4.039700434077531e-05
PAX6 B-Disease 1 0.9987552165985107
- I-Disease 1 0.9983693957328796
related I-Disease 1 0.8617958426475525
disease I-Disease 1 0.9998469352722168
remains O 0 0.00028858965379185975
to O 0 1.3771737030765507e-06
be O 0 2.3388006411551032e-06
uncovered O 0 0.00040240082307718694
. O 0 7.864037797844503e-06
. O 0 2.9163316867197864e-05

The O 0 1.1485644790809602e-05
chromosomal O 0 9.737654181662947e-05
order O 0 5.769365998276044e-07
of O 0 2.898528634887043e-07
genes O 0 5.449870968732284e-06
controlling O 0 3.860709330183454e-05
the O 0 6.283667062234599e-06
major O 0 0.00015290678129531443
histocompatibility O 1 0.9869792461395264
complex O 0 9.412668441655114e-05
, O 0 7.119676411093678e-06
properdin O 0 0.003269252832978964
factor O 0 5.8261251979274675e-05
B O 0 0.0017236571293324232
, O 0 3.3254789286729647e-06
and O 0 8.560277819924522e-06
deficiency B-Disease 1 0.999036431312561
of I-Disease 0 1.0570691699740564e-07
the I-Disease 0 5.363817194847798e-07
second I-Disease 0 1.6458543541375548e-06
component I-Disease 0 5.132788828632329e-06
of I-Disease 0 6.818822271270619e-07
complement I-Disease 0 4.9860103899845853e-05
. O 0 4.387724038679153e-05

The O 0 4.541667749435874e-06
relationship O 0 4.911194082524162e-06
of O 0 1.0216779600114023e-07
the O 0 7.450116754625924e-07
genes O 0 1.8866891196012148e-06
coding O 0 2.629645496199373e-05
for O 0 2.8637975901801838e-06
HLA O 0 0.015926796942949295
to O 0 1.0791666937848277e-07
those O 0 1.4690473904011014e-07
coding O 0 1.4038837434782181e-05
for O 0 8.039471026677347e-07
properdin O 0 0.0007396155269816518
Factor O 0 2.230545214843005e-05
B O 0 0.00027212867280468345
allotypes O 0 0.000581363623496145
and O 0 1.1661270491458708e-06
for O 0 5.229547696217196e-06
deficiency B-Disease 1 0.9992061257362366
of I-Disease 0 7.401240509352647e-08
the I-Disease 0 1.800649016558964e-07
second I-Disease 0 5.151734967512311e-07
component I-Disease 0 1.5101855979082757e-06
of I-Disease 0 2.066299913394687e-07
complement I-Disease 0 1.2871171747974586e-05
( O 0 2.419578959234059e-05
C2 O 0 0.22001585364341736
) O 0 2.2734293452231213e-06
was O 0 3.0037194846954662e-06
studied O 0 2.905626843130449e-06
in O 0 7.025251989034587e-07
families O 0 2.90645857603522e-06
of O 0 1.0248225407849532e-05
patients O 1 0.9972938895225525
with O 0 0.10420063883066177
connective O 1 0.9997461438179016
tissue O 1 0.9997320771217346
disorders O 1 0.9998503923416138
. O 0 0.01506687980145216

Patients O 1 0.7318926453590393
were O 0 3.7209890706435544e-06
selected O 0 2.2654473923466867e-06
because O 0 1.5247410374286119e-06
they O 0 1.0009122064502662e-07
were O 0 3.7338284641919017e-07
heterozygous O 0 1.2909292308904696e-05
or O 0 1.3800484339299146e-05
homozygous O 0 0.0022900565527379513
for O 0 0.005422790534794331
C2 B-Disease 1 0.9998399019241333
deficiency I-Disease 1 0.9999518394470215
. O 0 0.0016147177666425705

12 O 0 4.7132863983279094e-05
families O 0 6.592771569557954e-06
with O 0 2.261654572066618e-06
15 O 0 1.6448297174065374e-05
matings O 0 0.0004103909304831177
informative O 0 0.0002538904664106667
for O 0 0.0025152317248284817
C2 B-Disease 1 0.9998506307601929
deficiency I-Disease 1 0.9999556541442871
were O 0 7.185916911112145e-05
found O 0 0.00021299616491887718
. O 0 8.694017014931887e-05

Of O 0 3.502170329738874e-06
57 O 0 9.400719864061102e-05
informative O 0 4.261031426722184e-05
meioses O 0 0.0006610510172322392
, O 0 1.19411788546131e-06
two O 0 2.3630178702660487e-07
crossovers O 0 8.1564921856625e-06
were O 0 5.472790576277475e-07
noted O 0 3.578792529879138e-06
between O 0 3.358904450578848e-06
the O 0 0.0006500224699266255
C2 B-Disease 1 0.9998045563697815
deficiency I-Disease 1 0.99988853931427
gene O 0 4.1211649659089744e-05
and O 0 1.990947566810064e-06
the O 0 2.3916572899906896e-05
HLA O 1 0.9932389259338379
- O 0 0.001082696719095111
B O 0 7.872415153542534e-05
gene O 0 2.223372121079592e-06
, O 0 5.67505296089621e-08
with O 0 6.056417589661578e-08
a O 0 5.042829798185267e-07
recombinant O 0 5.248904017207678e-06
fraction O 0 1.0680714694899507e-06
of O 0 8.608198527326749e-07
0 O 0 1.972438440134283e-05
. O 0 2.9720295060542412e-05

035 O 1 0.7736661434173584
. O 0 0.0016048988327383995

A O 0 9.287355351261795e-05
lod O 0 0.0003475622506812215
score O 0 2.9152676006560796e-07
of O 0 2.4178282842513e-07
13 O 0 2.605037707326119e-06
was O 0 2.048016767730587e-06
calculated O 0 1.2462594440876273e-06
for O 0 8.356539638043614e-07
linkage O 0 0.0006304119597189128
between O 0 0.0013732054503634572
C2 B-Disease 1 0.9998419284820557
deficiency I-Disease 1 0.9999393224716187
and O 0 0.00014783466758672148
HLA O 1 0.9949151277542114
- O 0 0.0006638168706558645
B O 0 2.7018648324883543e-05
at O 0 5.725117944166414e-07
a O 0 2.5177234874718124e-07
maximum O 0 1.8885312158545275e-07
likelihood O 0 5.239504048404342e-07
value O 0 1.8175024152355945e-08
of O 0 2.7069141594893154e-08
the O 0 3.1795087807040545e-07
recombinant O 0 1.0108190508617554e-05
fraction O 0 3.1551046504318947e-06
of O 0 1.2560735740407836e-06
0 O 0 3.597766044549644e-05
. O 0 3.472424214123748e-05

04 O 0 0.1637234091758728
. O 0 0.0010135347256436944

18 O 0 3.6829129385296255e-05
families O 0 2.5657193418737734e-06
with O 0 6.010994866301189e-07
21 O 0 2.201893266828847e-06
informative O 0 1.7700715488899732e-06
matings O 0 2.411948844383005e-05
for O 0 2.633202029755921e-07
both O 0 1.4223215885067475e-06
properdin O 0 0.000986931612715125
Factor O 0 3.2655025279382244e-05
B O 0 0.0005096073728054762
allotype O 0 0.00186585308983922
and O 0 1.8778231606120244e-05
HLA O 1 0.9937387704849243
- O 0 0.004504132084548473
B O 0 0.00026739866007119417
were O 0 1.6896860870474484e-06
found O 0 1.724511821521446e-05
. O 0 2.1423975340439938e-05

Of O 0 1.2264162251085509e-05
72 O 0 0.00019088356930296868
informative O 0 6.510231469292194e-05
meioses O 0 0.0017193870153278112
, O 0 3.075290123888408e-06
three O 0 1.7375811012243503e-06
recombinants O 0 0.0011679934104904532
were O 0 4.994180358153244e-07
found O 0 1.2670916476054117e-06
, O 0 2.0895424768241355e-07
giving O 0 2.4908936779866053e-07
a O 0 6.186551786413474e-07
recombinant O 0 6.303341251623351e-06
fraction O 0 2.2261599497142015e-06
of O 0 7.4936190230801e-07
0 O 0 2.799708272505086e-05
. O 0 2.17825872823596e-05

042 O 0 0.11794079095125198
. O 0 0.0010297705885022879

A O 0 4.702336445916444e-05
lod O 0 0.00023609551135450602
score O 0 3.6597248254111037e-07
of O 0 1.6568073135658778e-07
16 O 0 6.447997293435037e-06
between O 0 1.7356271200696938e-05
HLA O 1 0.9770547151565552
- O 0 0.00034192210296168923
B O 0 2.69322390522575e-05
and O 0 3.129815127067559e-07
Factor O 0 2.330758434254676e-06
B O 0 6.765659782104194e-05
allotypes O 0 9.110613609664142e-05
was O 0 1.3080891676509054e-06
calculated O 0 1.891279879373542e-07
at O 0 3.165512509895052e-07
a O 0 2.923793260833918e-07
maximum O 0 2.2045544767479441e-07
likelihood O 0 5.952374522166792e-07
value O 0 1.3943810550642866e-08
of O 0 1.1721055237501332e-08
the O 0 1.3501127682502556e-07
recombinant O 0 2.198596803282271e-06
fraction O 0 6.198859523465217e-07
of O 0 4.137230860123964e-07
0 O 0 1.0403427040728275e-05
. O 0 1.7504862626083195e-05

04 O 0 0.1642056405544281
. O 0 0.0006617216859012842

A O 0 8.14243103377521e-05
crossover O 0 6.119455792941153e-05
was O 0 1.597869959368836e-05
shown O 0 2.024114337473293e-06
to O 0 8.486502878213287e-08
have O 0 7.44362722571168e-08
occurred O 0 5.496002586369286e-07
between O 0 6.896767246189484e-08
genes O 0 2.865836563614721e-07
for O 0 9.517855659169072e-08
Factor O 0 3.029362687811954e-06
B O 0 8.80435254657641e-05
and O 0 5.0639177970879246e-06
HLA O 1 0.9429371953010559
- O 0 0.0012241983786225319
D O 0 0.0007606250583194196
, O 0 2.9125885703251697e-07
in O 0 5.033911634200194e-07
which O 0 5.36186007593642e-06
HLA O 1 0.9706730842590332
- O 0 0.003194779623299837
D O 0 0.003580404445528984
segregared O 0 0.0004743324243463576
with O 0 1.8160690160584636e-05
HLA O 1 0.9806594252586365
- O 0 0.0003696613130159676
A O 0 1.4752762581338175e-05
and O 0 3.8114826566015836e-06
B O 0 0.0007578629883937538
. O 0 2.4463630325044505e-05

These O 0 3.1772278816788457e-06
studies O 0 5.469761617860058e-06
suggest O 0 4.415356215758948e-06
that O 0 9.86780648304375e-08
the O 0 1.6818940196117182e-07
genes O 0 7.136284807529591e-07
for O 0 6.894399007251195e-07
Factor O 0 4.703174272435717e-05
B O 0 0.02101588062942028
and O 0 0.0005860950332134962
C2 B-Disease 1 0.9998607635498047
deficiency I-Disease 1 0.9999583959579468
are O 0 2.27689582743551e-07
located O 0 1.3406149719230598e-06
outside O 0 5.713173436561192e-07
those O 0 1.9335932677222445e-07
for O 0 2.4680803107912652e-06
HLA O 1 0.9456759095191956
, O 0 3.0871981948621396e-07
that O 0 2.7584874828789907e-08
the O 0 4.744814674495501e-08
order O 0 6.99782987112485e-08
of O 0 1.8635267906574882e-07
genese O 0 0.0007161996327340603
is O 0 6.5485010054544546e-06
HLA O 0 0.3140706717967987
- O 0 2.5246596123906784e-05
A O 0 4.40442545368569e-06
, O 0 1.1272361462033587e-06
- O 0 4.830804027733393e-05
B O 0 2.1838935936102644e-05
, O 0 1.026367044687504e-06
- O 0 6.275124178500846e-05
D O 0 0.0002098422555718571
, O 0 6.754823971277801e-07
Factor O 0 6.270425728871487e-06
B O 0 0.0003692439349833876
allotype O 0 0.03364395350217819
, O 0 0.0011230011004954576
C2 B-Disease 1 0.9997624754905701
deficiency I-Disease 1 0.9999436140060425
, O 0 1.7597068335817312e-06
that O 0 1.6104921485293744e-07
the O 0 5.080792107037269e-07
genes O 0 9.287249667977449e-06
coding O 0 0.0006523721385747194
for O 0 0.00043808005284518003
C2 B-Disease 1 0.9997623562812805
deficiency I-Disease 1 0.9999067783355713
and O 0 9.537975529383402e-06
Factor O 0 2.958887671411503e-05
B O 0 0.0001631772320251912
allotypes O 0 6.956726429052651e-05
are O 0 4.2689098478376764e-08
approximately O 0 5.36431855380215e-07
3 O 0 6.610374839510769e-06
- O 0 5.549215347855352e-05
- O 0 7.181959063018439e-06
5 O 0 5.099942654851475e-07
centimorgans O 0 2.226239666924812e-05
from O 0 5.599710561909887e-07
the O 0 2.36946561926743e-06
HLA O 0 0.11300716549158096
- O 0 5.8930447266902775e-05
A O 0 9.472790225117933e-06
and O 0 3.561176981747849e-06
HLA O 1 0.9266477227210999
- O 0 0.0003379932895768434
B O 0 3.791505878325552e-05
loci O 0 4.347441517893458e-06
, O 0 2.0819501855839917e-07
and O 0 1.22127687518514e-07
that O 0 2.3660034287331655e-07
the O 0 7.573329980914423e-07
apparent O 0 8.552549115847796e-05
lack O 0 4.89544936499442e-06
of O 0 3.004166728715063e-07
recombinants O 0 0.0002950415073428303
between O 0 1.0826080369952251e-06
the O 0 1.6382842886741855e-06
Factor O 0 2.5569292120053433e-05
B O 0 0.0007254753145389259
gene O 0 0.00018389605975244194
and O 0 0.0005232554394751787
C2 B-Disease 1 0.9998076558113098
deficiency I-Disease 1 0.9999560117721558
gene O 0 0.0006636776961386204
suggests O 0 4.219455149723217e-05
that O 0 1.4269747339312744e-07
these O 0 4.749396254055682e-08
two O 0 1.4098766598635848e-07
genes O 0 1.4695268646391924e-06
lie O 0 4.851468474953435e-06
in O 0 3.031814514997677e-07
close O 0 1.3942102441433235e-06
proximity O 0 2.1627097339660395e-06
to O 0 3.0692555696987256e-07
one O 0 1.3508691836250364e-06
another O 0 1.3551036317949183e-05
. O 0 3.8106772990431637e-05

Distribution O 0 1.546303610666655e-05
of O 0 7.0375826908275485e-06
emerin O 0 0.007225748151540756
and O 0 2.024126297328621e-05
lamins O 0 0.03306768089532852
in O 0 7.735815415799152e-06
the O 0 2.620865598146338e-05
heart O 1 0.7323328256607056
and O 0 6.465780643338803e-06
implications O 0 0.00028966719401068985
for O 0 7.514430035371333e-05
Emery B-Disease 1 0.9752500057220459
- I-Disease 1 0.9945833086967468
Dreifuss I-Disease 1 0.9963986873626709
muscular I-Disease 1 0.9991071820259094
dystrophy I-Disease 1 0.9994533658027649
. O 0 0.005864482372999191

Emerin O 0 0.0037670149467885494
is O 0 4.97867176818545e-06
a O 0 7.29078010408557e-06
nuclear O 0 2.4185337679227814e-05
membrane O 0 1.8234322851640172e-05
protein O 0 6.633595148741733e-06
which O 0 5.108933578412689e-07
is O 0 2.356559662075597e-06
missing O 0 4.5477681851480156e-05
or O 0 3.2877127523534e-05
defective O 0 0.401665061712265
in O 0 0.00028699522954411805
Emery B-Disease 1 0.9722693562507629
- I-Disease 1 0.9933063387870789
Dreifuss I-Disease 1 0.99580979347229
muscular I-Disease 1 0.9993465542793274
dystrophy I-Disease 1 0.9997240900993347
( O 0 0.04282240942120552
EDMD B-Disease 1 0.9957593083381653
) O 0 0.0003325100988149643
. O 0 0.00016227635205723345

It O 0 7.282857950485777e-06
is O 0 8.706530252311495e-07
one O 0 2.438358421841258e-07
member O 0 2.7794447987616877e-07
of O 0 8.025470776829025e-08
a O 0 2.1343089429137763e-06
family O 0 7.128080596885411e-06
of O 0 2.7338437575963326e-06
lamina O 1 0.9947957396507263
- O 0 0.0015322215622290969
associated O 0 4.616990736394655e-06
proteins O 0 6.652211936852837e-07
which O 0 3.4308141039218754e-07
includes O 0 3.717222398336162e-06
LAP1 O 0 0.02731294371187687
, O 0 9.390919331053738e-06
LAP2 O 0 0.0036174666602164507
and O 0 7.664848453714512e-06
lamin O 0 0.022235766053199768
B O 0 0.004418483003973961
receptor O 0 0.0027459817938506603
( O 0 0.0003651640145108104
LBR O 1 0.9924176931381226
) O 0 5.203665205044672e-05
. O 0 9.939658775692806e-05

A O 0 6.619995838264003e-05
panel O 0 3.807557368418202e-05
of O 0 1.6813243064461858e-06
16 O 0 6.23586674919352e-05
monoclonal O 0 0.0008278724271804094
antibodies O 0 0.000486532662762329
( O 0 2.9290637030499056e-05
mAbs O 0 0.001821270678192377
) O 0 1.5826896060389117e-06
has O 0 4.122225618630182e-07
been O 0 1.1360505425273004e-07
mapped O 0 6.594863179998356e-07
to O 0 2.752805805528169e-08
six O 0 8.758615877013654e-08
specific O 0 9.775098419595452e-08
sites O 0 1.7559774789788207e-07
throughout O 0 1.555373074779709e-07
the O 0 4.929598276248726e-07
emerin O 0 0.00020920857787132263
molecule O 0 1.0833293345058337e-05
using O 0 5.165202765056165e-06
phage O 0 0.0028823274187743664
- O 0 0.00012639752821996808
displayed O 0 1.554886512167286e-05
peptide O 0 1.7915768694365397e-05
libraries O 0 1.823254365262983e-06
and O 0 3.9070377511052357e-07
has O 0 5.555593247663637e-07
been O 0 1.8214036856534221e-07
used O 0 2.427689480555273e-07
to O 0 5.321222715792828e-07
localize O 0 0.0002494362706784159
emerin O 0 0.003605758771300316
in O 0 5.808740752399899e-06
human O 0 7.292342343134806e-05
and O 0 0.00015015075041446835
rabbit O 1 0.9831668734550476
heart O 1 0.9954778552055359
. O 0 0.00027702865190804005

Several O 0 6.514001142932102e-05
mAbs O 0 0.003537652315571904
against O 0 1.0413245036033913e-05
different O 0 2.802515382427373e-06
emerin O 0 0.02638643980026245
epitopes O 0 0.006188246421515942
did O 0 1.2008582416456193e-05
not O 0 8.387477805626986e-07
recognize O 0 1.588547274877783e-05
intercalated O 0 0.0008611196535639465
discs O 0 0.0001733202370814979
in O 0 4.901344709651312e-06
the O 0 5.285476436256431e-05
heart O 1 0.9952889680862427
, O 0 3.565105089364806e-06
though O 0 2.583680497991736e-06
they O 0 3.636085637026554e-07
recognized O 0 6.089469479775289e-06
cardiomyocyte O 0 0.0007979330257512629
nuclei O 0 3.472623211564496e-05
strongly O 0 1.2539583622128703e-05
, O 0 4.956118573318236e-07
both O 0 2.050720553370411e-07
at O 0 3.2975394788081758e-06
the O 0 2.0230759218975436e-06
rim O 0 0.00031487864907830954
and O 0 9.891942909234785e-07
in O 0 3.0723822419531643e-06
intranuclear O 0 0.002091724192723632
spots O 0 4.3699263187590986e-05
or O 0 9.936079550243448e-06
channels O 0 2.996904368046671e-05
. O 0 5.2991930715506896e-05

A O 0 0.0018818615935742855
polyclonal O 0 0.1738967001438141
rabbit O 0 0.14131678640842438
antiserum O 0 0.024357903748750687
against O 0 0.00017307448433712125
emerin O 0 0.0603245310485363
did O 0 1.714368409011513e-05
recognize O 0 5.991460511722835e-06
both O 0 8.538830797988339e-07
nuclear O 0 3.93500886275433e-05
membrane O 0 2.8465172363212332e-05
and O 0 1.8937321328849066e-06
intercalated O 0 0.0015238993801176548
discs O 0 0.0001049753263941966
but O 0 6.242860877136991e-07
, O 0 2.4869771664270957e-07
after O 0 1.2158456001998275e-06
affinity O 0 4.316757440392394e-06
purification O 0 1.8926539269159548e-05
against O 0 1.3925530311098555e-06
a O 0 5.419644367066212e-06
pure O 0 3.113129423581995e-05
- O 0 0.00024011824280023575
emerin O 0 0.00016873735876288265
band O 0 5.33887305209646e-06
on O 0 4.1365836978002335e-07
a O 0 3.0919113669369835e-06
western O 0 7.211567663034657e-06
blot O 0 0.0009448606870137155
, O 0 2.246077656309353e-06
it O 0 2.1985317744110944e-06
stained O 0 0.009357484988868237
only O 0 2.5122906777141907e-07
the O 0 2.254739456475363e-06
nuclear O 0 8.658505976200104e-05
membrane O 0 0.00016331263759639114
. O 0 3.329601895529777e-05

These O 0 4.211150553601328e-06
results O 0 2.0265466446289793e-05
would O 0 1.0709702564781765e-06
not O 0 1.5043194423469686e-07
be O 0 1.2725953979497717e-07
expected O 0 1.3198898614064092e-06
if O 0 1.0255832876282511e-06
immunostaining O 0 0.00024401565315201879
at O 0 9.409279300598428e-06
intercalated O 0 0.0014619503635913134
discs O 0 0.00010441285849083215
were O 0 3.437652651427925e-07
due O 0 1.3854729559170664e-06
to O 0 3.412103311006831e-08
a O 0 2.2968029611547536e-07
product O 0 3.13871339585603e-07
of O 0 6.52520881772034e-08
the O 0 1.955062771230587e-06
emerin O 0 0.0017292504198849201
gene O 0 1.8923976313089952e-05
and O 0 6.346708119053801e-07
, O 0 7.098403216332372e-07
therefore O 0 5.424973323897575e-07
, O 0 2.41973140191476e-07
cast O 0 6.541271204696386e-07
some O 0 1.6475112829539285e-07
doubt O 0 4.439863459992921e-06
upon O 0 1.0854065521925804e-06
the O 0 2.796882199618267e-06
hypothesis O 0 0.00023615045938640833
that O 0 0.0004057510814163834
cardiac B-Disease 1 0.9995927214622498
defects I-Disease 1 0.9995375871658325
in O 0 0.0007282092701643705
EDMD B-Disease 1 0.9985737800598145
are O 0 4.4701773731503636e-06
caused O 0 0.0021576702129095793
by O 0 1.9388089640415274e-06
absence O 0 3.22206542477943e-05
of O 0 2.434436737530632e-06
emerin O 0 0.014825303107500076
from O 0 4.585109491017647e-05
intercalated O 0 0.19999147951602936
discs O 0 0.012932983227074146
. O 0 0.00015927826461847872

Although O 0 0.00014372561417985708
emerin O 0 0.0030425582081079483
was O 0 1.761589192028623e-05
abundant O 0 5.948237230768427e-06
in O 0 4.903299668512773e-07
the O 0 5.568397796196223e-07
membranes O 0 2.0811807189602405e-05
of O 0 7.538555450992135e-07
cardiomyocyte O 0 0.002480503637343645
nuclei O 0 5.9526999393710867e-05
, O 0 1.9481356048345333e-06
it O 0 9.736595529830083e-07
was O 0 8.405226253671572e-06
absent O 0 1.886948120954912e-05
from O 0 8.23588493403804e-07
many O 0 1.1102374628535472e-06
non O 0 5.429195880424231e-05
- O 0 0.0037385534960776567
myocyte O 0 0.04255883768200874
cells O 0 6.183795630931854e-05
in O 0 5.173272256797645e-06
the O 0 4.695516327046789e-05
heart O 1 0.9865582585334778
. O 0 0.00027502753073349595

This O 0 1.0920244903900311e-06
distribution O 0 8.88093552475766e-07
of O 0 1.3494437780536828e-06
emerin O 0 0.005584572907537222
was O 0 1.1279403224762063e-05
similar O 0 6.758289714525745e-07
to O 0 6.71992239631436e-08
that O 0 5.176170958520743e-08
of O 0 2.2904049501448753e-07
lamin O 0 0.0016885421937331557
A O 0 5.103283001517411e-06
, O 0 5.764685511167045e-07
a O 0 1.5908869954728289e-06
candidate O 0 1.3441353985399473e-06
gene O 0 2.7262622097623535e-06
for O 0 3.3312036862298555e-07
an O 0 7.0163787313504145e-06
autosomal O 1 0.6018999814987183
form O 0 0.00011939596879528835
of O 0 0.00013931874127592891
EDMD B-Disease 1 0.9976370334625244
. O 0 0.000652081856969744

In O 0 3.8646139728371054e-05
contrast O 0 0.00024285489052999765
, O 0 0.00010075857426272705
lamin O 1 0.9748286008834839
B1 O 1 0.9979133009910583
was O 0 0.00018752741743810475
absent O 0 0.00012318415974732488
from O 0 9.92497916740831e-06
cardiomyocyte O 0 0.00133976258803159
nuclei O 0 6.959380698390305e-05
, O 0 5.857337328052381e-06
showing O 0 6.870389188406989e-05
that O 0 9.902440069708973e-06
lamin O 1 0.9436052441596985
B1 O 1 0.9982411861419678
is O 0 1.063217723640264e-06
not O 0 4.767093741975259e-08
essential O 0 1.1073342420786503e-07
for O 0 6.365620208725886e-08
localization O 0 6.668366040685214e-06
of O 0 4.823635890716105e-07
emerin O 0 0.0004710607754532248
to O 0 7.57685540975217e-07
the O 0 9.072217835637275e-06
nuclear O 0 0.0009256936027668417
lamina O 1 0.5703088641166687
. O 0 0.00010797446157084778

Lamin O 1 0.9738364815711975
B1 O 1 0.9969724416732788
is O 0 1.9110848370473832e-05
also O 0 3.7185345718171448e-06
almost O 0 7.486064532713499e-06
completely O 0 0.00010416026634629816
absent O 0 0.0006803886499255896
from O 0 0.00021716910123359412
skeletal O 1 0.9975300431251526
muscle O 1 0.9889557957649231
nuclei O 0 0.007774413097649813
. O 0 0.0003623236552812159

In O 0 0.00015048372733872384
EDMD B-Disease 1 0.8001630902290344
, O 0 3.4161976145696826e-06
the O 0 7.200072218438436e-07
additional O 0 2.803098141157534e-06
absence O 0 3.2811600249260664e-05
of O 0 2.7466900064609945e-05
lamin O 1 0.9876010417938232
B1 O 1 0.9977586269378662
from O 0 0.0007803172920830548
heart O 1 0.9966946840286255
and O 0 0.0003114351420663297
skeletal O 1 0.9987884163856506
muscle O 1 0.9926592707633972
nuclei O 0 0.0010403413325548172
which O 0 1.5288314898498356e-05
already O 0 0.00020852030138485134
lack O 0 0.0005020332173444331
emerin O 0 0.06623642891645432
may O 0 4.851098310609814e-06
offer O 0 8.046358743740711e-07
an O 0 3.034487008335418e-07
alternative O 0 1.0277108231093735e-06
explanation O 0 2.1120079054526286e-06
of O 0 5.164761205378454e-07
why O 0 1.818167402234394e-05
these O 0 9.952561867976328e-07
tissues O 0 0.0007760007865726948
are O 0 1.62393439495645e-06
particularly O 0 7.706456381129101e-05
affected O 0 0.00022249568428378552
. O 0 1.19032183647505e-05
. O 0 7.468651892850175e-05

Genetic O 0 0.00013949687127023935
mapping O 0 3.27118432323914e-05
of O 0 2.1800542526762e-06
the O 0 6.034580655978061e-05
copper B-Disease 1 0.8012253046035767
toxicosis I-Disease 1 0.9836965203285217
locus O 0 0.0005996007239446044
in O 0 4.166609141975641e-05
Bedlington O 0 0.055446524173021317
terriers O 0 0.0009653769084252417
to O 0 5.821284958074102e-06
dog O 0 0.000705389422364533
chromosome O 0 3.362455026945099e-05
10 O 0 1.5619178839187953e-06
, O 0 3.3012889844030724e-07
in O 0 3.4928999070871214e-07
a O 0 3.7007428090873873e-06
region O 0 6.556736934726359e-06
syntenic O 0 0.0004047985712531954
to O 0 8.837905056680029e-07
human O 0 7.5426492003316525e-06
chromosome O 0 0.0003516805882100016
region O 0 0.00019473308930173516
2p13 O 0 0.02746228687465191
- O 0 0.01130627654492855
p16 O 0 0.0037641797680407763
. O 0 0.000117622381367255

Abnormal O 1 0.9774078726768494
hepatic B-Disease 1 0.9964595437049866
copper I-Disease 1 0.9912614822387695
accumulation I-Disease 0 0.29223883152008057
is O 0 1.6270136256935075e-05
recognized O 0 2.2074897060520016e-05
as O 0 1.979125227080658e-05
an O 0 0.004632206168025732
inherited B-Disease 1 0.9999186992645264
disorder I-Disease 1 0.9999649524688721
in O 0 0.00034682813566178083
man O 0 0.02110128477215767
, O 0 4.3553736759349704e-05
mouse O 0 0.0034242901019752026
, O 0 3.366170494700782e-05
rat O 0 0.06775221228599548
and O 0 1.627156416361686e-05
dog O 0 0.009535761550068855
. O 0 9.952386608347297e-05

The O 0 8.439233351964504e-05
major O 0 0.0004975237534381449
cause O 0 0.004156884737312794
of O 0 6.210188439581543e-05
hepatic B-Disease 1 0.9989606142044067
copper I-Disease 1 0.9942193031311035
accumulation I-Disease 1 0.660088837146759
in O 0 1.306426383962389e-05
man O 0 0.00026274510310031474
is O 0 5.033671186538413e-06
a O 0 3.2692787499399856e-05
dysfunctional O 0 0.11743580549955368
ATP7B O 1 0.8910157084465027
gene O 0 0.0016151054296642542
, O 0 0.00023172044893726707
causing O 1 0.9866589307785034
Wilson B-Disease 1 0.9953939914703369
disease I-Disease 1 0.9996904134750366
( O 0 0.010538440197706223
WD B-Disease 1 0.9953651428222656
) O 0 0.00010581672540865839
. O 0 0.00010396716970717534

Mutations O 0 0.00024445459712296724
in O 0 9.782456800166983e-06
the O 0 1.362324837828055e-05
ATP7B O 0 0.03446616977453232
genes O 0 1.2293401596252806e-05
have O 0 5.446397608466214e-07
also O 0 8.81333619418001e-07
been O 0 1.3523334700948908e-06
demonstrated O 0 8.99132191989338e-06
in O 0 4.490669198276009e-06
mouse O 0 0.0006559100584127009
and O 0 2.8488853786257096e-05
rat O 0 0.22188761830329895
. O 0 5.446676368592307e-05

The O 0 0.00014652179379481822
ATP7B O 0 0.07359109818935394
gene O 0 0.00017846755508799106
has O 0 9.12730502022896e-06
been O 0 2.2691101548844017e-06
excluded O 0 4.861904017161578e-06
in O 0 6.769371907466848e-07
the O 0 1.8158827970182756e-06
much O 0 2.0440405933186412e-05
rarer O 0 0.145164355635643
human O 0 0.0023702564649283886
copper B-Disease 1 0.9980787038803101
overload I-Disease 1 0.9996716976165771
disease O 1 0.9996787309646606
non B-Disease 0 0.012060771696269512
- I-Disease 0 0.3355500400066376
Indian I-Disease 0 0.0007798087899573147
childhood I-Disease 1 0.9948157668113708
cirrhosis I-Disease 1 0.9996552467346191
, O 0 0.0001377380103804171
indicating O 0 0.0037470755632966757
genetic O 0 0.00414082920178771
heterogeneity O 0 0.013263697735965252
. O 0 0.00024775127531029284

By O 0 4.2644780478440225e-05
investigating O 0 0.0002111194480676204
the O 0 3.774618016905151e-05
common O 0 0.0019590912852436304
autosomal O 1 0.997369647026062
recessive O 1 0.9983692765235901
copper B-Disease 1 0.9983170032501221
toxicosis I-Disease 1 0.9982023239135742
( O 0 0.0026018312200903893
CT B-Disease 1 0.9830980896949768
) O 0 1.936143235070631e-05
in O 0 1.130360942624975e-05
Bedlington O 0 0.11415651440620422
terriers O 0 0.0011258164886385202
, O 0 1.0476499028300168e-06
we O 0 1.995873901705636e-07
have O 0 1.04334404227302e-07
identified O 0 1.0377210628575995e-06
a O 0 1.1034701401513303e-06
new O 0 2.8384617962728953e-06
locus O 0 0.00010648195893736556
involved O 0 8.553242514608428e-05
in O 0 0.0015219822525978088
progressive O 1 0.9988160133361816
liver B-Disease 1 0.9999685287475586
disease I-Disease 1 0.9999376535415649
. O 0 0.00890262983739376

We O 0 2.229392521257978e-05
examined O 0 0.00011064788850490004
whether O 0 9.935652997228317e-06
the O 0 1.6500380297657102e-05
WD B-Disease 1 0.9622131586074829
gene O 0 0.0002181621821364388
ATP7B O 0 0.018579822033643723
was O 0 3.648639903985895e-05
also O 0 3.205459506716579e-06
causative O 0 0.000160160954692401
for O 0 5.080242317490047e-06
CT B-Disease 0 0.13701070845127106
by O 0 1.6134418956426089e-06
investigating O 0 2.667608714546077e-05
the O 0 5.874523139937082e-06
chromosomal O 0 0.006758016999810934
co O 0 0.0010732930386438966
- O 0 0.000103093268990051
localization O 0 1.1305679436190985e-05
of O 0 1.224414404532581e-06
ATP7B O 0 0.004194837529212236
and O 0 1.3851584981239284e-06
C04107 O 0 5.286444502416998e-05
, O 0 2.0256925381545443e-07
using O 0 3.0520925520249875e-07
fluorescence O 0 9.418758963875007e-06
in O 0 8.450569453088974e-07
situ O 0 0.0001835131406551227
hybridization O 0 2.9677950806217268e-05
( O 0 1.5664403690607287e-05
FISH O 0 5.682753908331506e-05
) O 0 1.2597402928804513e-05
. O 0 2.0602152289939113e-05

C04107 O 0 0.002632073126733303
is O 0 9.749951459525619e-06
an O 0 5.702684575226158e-06
anonymous O 0 0.00010228200699202716
microsatellite O 0 0.00643082894384861
marker O 0 0.0010329836513847113
closely O 0 5.9434536524349824e-05
linked O 0 0.0014229213120415807
to O 0 3.062271571252495e-05
CT B-Disease 1 0.9787015914916992
. O 0 0.00010545429540798068

However O 0 0.0001442087086616084
, O 0 7.0009300543461e-05
BAC O 0 0.014345988631248474
clones O 0 0.0006092102266848087
containing O 0 9.655030589783564e-05
ATP7B O 0 0.028795385733246803
and O 0 5.126081759954104e-06
C04107 O 0 0.00020166838658042252
mapped O 0 1.164761579275364e-05
to O 0 7.823717282917642e-07
the O 0 6.012329777149716e-06
canine O 0 0.006885743234306574
chromosome O 0 0.00014700305473525077
regions O 0 1.0341237612010445e-05
CFA22q11 O 0 0.002598213031888008
and O 0 4.236668701196322e-06
CFA10q26 O 0 0.0030831776093691587
, O 0 2.759524704742944e-06
respectively O 0 4.7817552513151895e-06
, O 0 2.1587716219073627e-06
demonstrating O 0 2.4660223061800934e-05
that O 0 1.1101114978373516e-05
WD B-Disease 1 0.941741943359375
cannot O 0 4.677815923059825e-06
be O 0 3.8543672076229996e-07
homologous O 0 4.025256566819735e-05
to O 0 1.631522536627017e-05
CT B-Disease 1 0.8964363932609558
. O 0 9.298840450355783e-05

The O 0 9.416222746949643e-05
copper O 0 0.01915735751390457
transport O 0 0.00039317284245043993
genes O 0 6.620715430472046e-05
CTR1 O 0 0.026691105216741562
and O 0 7.187152732512914e-06
CTR2 O 0 0.014664886519312859
were O 0 7.132243240448588e-07
also O 0 5.15615852236806e-07
excluded O 0 1.78479012902244e-06
as O 0 1.7481158920418238e-07
candidate O 0 1.1423370551710832e-06
genes O 0 2.519602276152e-06
for O 0 3.1487829801335465e-06
CT B-Disease 1 0.9068583250045776
since O 0 5.505337867361959e-06
they O 0 1.309036150587417e-07
both O 0 7.507790655836288e-08
mapped O 0 8.579008863307536e-06
to O 0 2.3608290575793944e-06
canine O 0 0.04806133732199669
chromosome O 0 0.001309291343204677
region O 0 0.00024682373623363674
CFA11q22 O 0 0.12697286903858185
. O 0 0.00016238809621427208

2 O 0 0.0012163665378466249
- O 0 0.003229534486308694
22 O 0 0.00013292502262629569
. O 0 5.8316065405961126e-05

5 O 0 0.0007762057357467711
. O 0 0.00034383093588985503

A O 0 3.5007793485419825e-05
transcribed O 0 3.133729478577152e-05
sequence O 0 6.78844480717089e-06
identified O 0 5.136103936820291e-06
from O 0 9.356853070130455e-07
the O 0 2.0024660898343427e-06
C04107 O 0 0.0008857372449710965
- O 0 0.0001734966499498114
containing O 0 1.2618493201443925e-05
BAC O 0 0.007468868046998978
was O 0 5.549304205487715e-06
found O 0 4.2223638274663244e-07
to O 0 2.5092948163774054e-08
be O 0 2.3158984063798016e-08
homologous O 0 5.874068733646709e-07
to O 0 6.018198916990514e-08
a O 0 1.4146783087198855e-06
gene O 0 4.459434421733022e-06
expressed O 0 1.371146709061577e-06
from O 0 1.5227415133267641e-06
human O 0 7.823001396900509e-06
chromosome O 0 0.0003106060903519392
2p13 O 0 0.005084039177745581
- O 0 0.0008607323979958892
p16 O 0 0.00013301098078954965
, O 0 7.769224339426728e-07
a O 0 9.883174243441317e-07
region O 0 1.166416154774197e-06
devoid O 0 4.522252766037127e-06
of O 0 1.0697785057800502e-07
any O 0 9.486643648415338e-07
positional O 0 4.972956594428979e-05
candidate O 0 3.5851138818543404e-05
genes O 0 5.7247398217441514e-05
. O 0 6.675668555544689e-05

Molecular O 0 3.0850525945425034e-05
analysis O 0 2.0342661173344823e-06
of O 0 4.6832116140649305e-07
the O 0 6.536770797538338e-06
APC B-Disease 0 0.0017347116954624653
gene O 0 1.541996607556939e-05
in O 0 1.7831636114351568e-06
205 O 0 3.8881433283677325e-05
families O 0 1.9846272607537685e-06
: O 0 2.567616093074321e-06
extended O 0 1.0083754204970319e-05
genotype O 0 0.0004357285506557673
- O 0 0.000690668763127178
phenotype O 0 0.00024812290212139487
correlations O 0 5.8622837968869135e-05
in O 0 1.1680385796353221e-05
FAP B-Disease 1 0.6547641754150391
and O 0 3.761391269563319e-07
evidence O 0 6.261273597374384e-07
for O 0 4.705636769131161e-08
the O 0 7.766706744405383e-08
role O 0 2.820657698521245e-07
of O 0 4.040536225602409e-07
APC B-Disease 0 0.0015717885689809918
amino O 0 2.572062840044964e-05
acid O 0 0.00774986669421196
changes O 0 0.002401880221441388
in O 0 0.38486289978027344
colorectal B-Disease 1 0.9999841451644897
cancer I-Disease 1 0.999950647354126
predisposition O 1 0.9968814849853516
. O 0 0.0026349110994488

BACKGROUND O 0 0.00147879752330482
/ O 0 0.0018227890832349658
AIMS O 0 5.4157972044777125e-05
The O 0 7.75267653807532e-06
development O 0 8.756743773119524e-05
of O 0 0.003397854045033455
colorectal B-Disease 1 0.9999943971633911
cancer I-Disease 1 0.9999046325683594
and O 0 1.8052654695566162e-06
a O 0 2.290104475832777e-06
variable O 0 3.912125976057723e-06
range O 0 2.028599510595086e-06
of O 0 2.4775795282039326e-06
extracolonic O 0 0.23320242762565613
manifestations O 0 0.05577981472015381
in O 0 0.00395524175837636
familial B-Disease 1 0.9994519352912903
adenomatous I-Disease 1 0.9997605681419373
polyposis I-Disease 1 0.999842643737793
( O 0 0.05792701244354248
FAP B-Disease 1 0.9939409494400024
) O 0 7.678676411160268e-06
is O 0 6.264313014980871e-07
the O 0 2.9762381359432766e-07
result O 0 7.681617830712639e-07
of O 0 1.6461402196910058e-07
the O 0 4.722747689811513e-06
dominant O 0 0.00011387692939024419
inheritance O 0 0.0026017993222922087
of O 0 0.0013509637210518122
adenomatous B-Disease 1 0.9998176693916321
polyposis I-Disease 1 0.9997459053993225
coli I-Disease 1 0.9990678429603577
( O 0 0.0011282998602837324
APC B-Disease 0 0.21488413214683533
) O 0 3.150803968310356e-05
gene O 0 0.0002101011195918545
mutations O 0 0.00029830553103238344
. O 0 4.9881604354595765e-05

In O 0 4.505271135712974e-06
this O 0 7.221768782983418e-07
study O 0 1.6284986941172974e-06
, O 0 1.4735753950390063e-07
direct O 0 1.1340998895548182e-07
mutation O 0 8.859026365826139e-07
analysis O 0 8.621280045417734e-08
of O 0 5.028767802173206e-08
the O 0 2.132579538738355e-06
APC B-Disease 0 0.0022883727215230465
gene O 0 9.035908078658395e-06
was O 0 2.6003017410403118e-06
performed O 0 5.105173954689235e-07
to O 0 1.2558695061670733e-07
determine O 0 2.079768137264182e-06
genotype O 0 0.00035337373265065253
- O 0 0.0002915918012149632
phenotype O 0 6.501992174889892e-05
correlations O 0 1.2058824722771533e-05
for O 0 1.2852400459451019e-06
nine O 0 1.2864814380009193e-05
extracolonic O 0 0.00926512386649847
manifestations O 0 0.00010140921222046018
and O 0 3.667222472358844e-07
to O 0 2.602301094611903e-07
investigate O 0 8.403087122133002e-06
the O 0 2.278167130498332e-06
incidence O 0 0.006687926594167948
of O 0 4.176542915956816e-06
APC B-Disease 0 0.04758705571293831
mutations O 0 0.0002450228203088045
in O 0 9.760280954651535e-05
non O 0 0.08169325441122055
- O 1 0.9967859983444214
FAP O 1 0.998323380947113
colorectal B-Disease 1 0.9999717473983765
cancer I-Disease 1 0.999887228012085
. O 0 0.003242481965571642

METHODS O 0 3.783534702961333e-05
The O 0 4.193392305751331e-05
APC B-Disease 0 0.0061918566934764385
gene O 0 5.879067975911312e-05
was O 0 1.6384985428885557e-05
analysed O 0 1.553508081997279e-05
in O 0 2.7485671125759836e-06
190 O 0 2.8721600756398402e-05
unrelated O 0 0.0006763447308912873
FAP B-Disease 0 0.4647718369960785
and O 0 1.1528331924637314e-05
15 O 0 0.00019019284809473902
non O 0 0.015446653589606285
- O 1 0.9964261651039124
FAP O 1 0.9989877343177795
colorectal B-Disease 1 0.9999840259552002
cancer I-Disease 1 0.9999532699584961
patients O 1 0.9494640827178955
using O 0 3.2104500860441476e-05
denaturing O 0 0.06750267744064331
gradient O 0 0.0027933830861002207
gel O 0 0.00974045880138874
electrophoresis O 0 0.0002876850194297731
, O 0 6.663851195298776e-07
the O 0 5.896856691833818e-07
protein O 0 6.3553966356266756e-06
truncation O 0 0.00011561685823835433
test O 0 5.003394107916392e-06
, O 0 2.940941215001658e-07
and O 0 2.3026676387871703e-07
direct O 0 1.6162356359927799e-06
sequencing O 0 2.618007783894427e-05
. O 0 3.817712786258198e-05

RESULTS O 0 0.0012030435027554631
Chain O 0 0.0007508732378482819
terminating O 0 0.00022412296675611287
signals O 0 2.5670246031950228e-05
were O 0 8.227218586398521e-07
only O 0 4.6750366777814634e-07
identified O 0 1.820780562411528e-05
in O 0 8.50072865432594e-06
patients O 0 0.008174561895430088
belonging O 0 4.106125288672047e-06
to O 0 3.7267705010890495e-07
the O 0 5.5658883866271935e-06
FAP B-Disease 0 0.3370334506034851
group O 0 1.210963455378078e-05
( O 0 2.9227019695099443e-05
105 O 0 0.0004331889795139432
patients O 0 0.18435971438884735
) O 0 3.2389631087426096e-05
. O 0 4.3945830839220434e-05

Amino O 0 9.043167665367946e-05
acid O 0 0.0007690500351600349
changes O 0 1.4506354091281537e-05
were O 0 1.7139607280114433e-06
identified O 0 6.751623914169613e-06
in O 0 1.1408737918827683e-06
four O 0 8.001326932571828e-06
patients O 0 0.023043934255838394
, O 0 2.8967050980099884e-07
three O 0 7.583623329310285e-08
of O 0 2.1134736982730828e-07
whom O 0 6.928502443770412e-06
belonged O 0 1.0120373190147802e-05
to O 0 3.3086703865592426e-07
the O 0 1.8577152331999969e-06
non O 0 0.00011625431216089055
- O 0 0.0070210411213338375
FAP O 1 0.5524468421936035
group O 0 0.0001583172270329669
of O 0 0.009080231189727783
colorectal B-Disease 1 0.9999935626983643
cancer I-Disease 1 0.9999804496765137
patients O 1 0.9980807304382324
. O 0 0.0016758185811340809

Genotype O 0 0.026604244485497475
- O 0 0.011007282882928848
phenotype O 0 0.0013115422334522009
correlations O 0 8.847005665302277e-05
identified O 0 1.9388849977985956e-05
significant O 0 5.14327484779642e-06
differences O 0 5.136819254403235e-06
in O 0 5.726968765884521e-07
the O 0 5.454043616737181e-07
nature O 0 1.7218543462149682e-06
of O 0 3.640940064997267e-07
certain O 0 8.306456038553733e-06
extracolonic O 0 0.4142096936702728
manifestations O 0 0.031469907611608505
in O 0 0.0010808875085785985
FAP B-Disease 1 0.9984915256500244
patients O 1 0.6275792121887207
belonging O 0 1.5778994566062465e-05
to O 0 5.205313300393755e-07
three O 0 2.902954292949289e-06
mutation O 0 0.00017675088020041585
subgroups O 0 0.00012470556248445064
. O 0 0.00011407472629798576

CONCLUSIONS O 0 0.00036035323864780366
Extended O 0 0.00029454234754666686
genotype O 0 0.002987115876749158
- O 0 0.0013645379804074764
phenotype O 0 0.00030214470461942255
correlations O 0 1.2533258995972574e-05
made O 0 1.4334564184537157e-06
in O 0 2.840033062057046e-07
this O 0 6.321711225609761e-07
study O 0 5.205256456974894e-06
may O 0 2.946136191894766e-06
have O 0 5.9525003592852954e-08
the O 0 1.612445430509979e-07
potential O 0 3.1420708523910434e-07
to O 0 3.1758961682726294e-08
determine O 0 2.94030741088136e-07
the O 0 1.9357038638645463e-07
most O 0 2.3008414018477197e-07
appropriate O 0 1.7050365386239719e-06
surveillance O 0 3.8211939681787044e-05
and O 0 1.1512259334267583e-05
prophylactic O 1 0.7682369351387024
treatment O 1 0.9629224538803101
regimens O 0 0.13465829193592072
for O 0 5.083557425678009e-06
those O 0 2.354897696932312e-05
patients O 1 0.7794974446296692
with O 0 2.0528568711597472e-05
mutations O 0 0.0010989487636834383
associated O 0 0.0001373171980958432
with O 0 5.5857006373116747e-05
life O 0 0.0054809898138046265
threatening O 1 0.9806489944458008
conditions O 0 0.3302871584892273
. O 0 0.0003639760834630579

This O 0 6.780796866223682e-06
study O 0 1.1655493835860398e-05
also O 0 2.73844148068747e-06
provided O 0 2.4728983589739073e-06
evidence O 0 1.541424580864259e-06
for O 0 3.7399155417006114e-07
the O 0 1.1477259249659255e-06
pathological O 0 0.0003850598295684904
nature O 0 1.2218074516567867e-06
of O 0 1.5401901976019872e-07
amino O 0 5.237154255155474e-06
acid O 0 0.0006909146904945374
changes O 0 1.4187155102263205e-05
in O 0 8.590659490437247e-06
APC O 0 0.008554556407034397
associated O 0 1.1059607459174003e-05
with O 0 2.4428884444205323e-06
both O 0 6.138353455753531e-06
FAP B-Disease 1 0.9218878746032715
and O 0 5.44115828233771e-05
non O 0 0.0877719596028328
- O 1 0.9980114698410034
FAP O 1 0.9996556043624878
colorectal B-Disease 1 0.9999963045120239
cancer I-Disease 1 0.9999912977218628
patients O 1 0.9992037415504456
. O 0 0.00025218454538844526
. O 0 0.00019980895740445703

Inherited B-Disease 1 0.9991244673728943
colorectal I-Disease 1 0.9999396800994873
polyposis I-Disease 1 0.9995909333229065
and O 1 0.8880897164344788
cancer B-Disease 1 0.999769389629364
risk O 0 0.004996320698410273
of O 0 2.1017526705691125e-06
the O 0 3.737064980668947e-05
APC O 0 0.061501629650592804
I1307K O 0 0.003751854645088315
polymorphism O 0 0.0006586217205040157
. O 0 9.268519352190197e-05

Germ O 1 0.9624671936035156
- O 0 0.0015347952721640468
line O 0 2.427962317597121e-05
and O 0 1.5279449598892825e-06
somatic O 0 3.6550616641761735e-05
truncating O 0 0.0003114494029432535
mutations O 0 1.0213364475930575e-05
of O 0 4.0099911302604596e-07
the O 0 7.329479103646008e-06
APC B-Disease 0 0.00927644595503807
gene O 0 1.4063318303669803e-05
are O 0 2.3525889503162034e-07
thought O 0 8.732301466807257e-06
to O 0 4.279290351405507e-06
initiate O 0 0.014393526129424572
colorectal B-Disease 1 0.9998393058776855
tumor I-Disease 1 0.9990280866622925
formation O 1 0.7608189582824707
in O 0 0.06542357057332993
familial B-Disease 1 0.999818742275238
adenomatous I-Disease 1 0.999935507774353
polyposis I-Disease 1 0.9999772310256958
syndrome I-Disease 1 0.9999802112579346
and O 0 0.0642872229218483
sporadic O 1 0.9952375888824463
colorectal O 1 0.9999421834945679
carcinogenesis O 1 0.9988455772399902
, O 0 0.0002603507018648088
respectively O 0 0.0004513979656621814
. O 0 0.0002165250334655866

Recently O 0 0.00037763177533634007
, O 0 6.262566785153467e-06
an O 0 9.815350495046005e-06
isoleucine O 0 0.031908974051475525
- O 0 0.003553793765604496
- O 0 0.00013409342500381172
> O 0 5.3884836233919486e-05
lysine O 0 3.663056486402638e-05
polymorphism O 0 5.145477643964114e-06
at O 0 3.513292995194206e-06
codon O 0 1.8702206943999045e-05
1307 O 0 0.0007406799122691154
( O 0 4.3670006562024355e-06
I1307K O 0 3.2627129257889464e-05
) O 0 2.646050916155218e-07
of O 0 6.245070238719563e-08
the O 0 1.5960005157467094e-06
APC B-Disease 0 0.0017179118003696203
gene O 0 1.7074991774279624e-05
has O 0 8.882256565811986e-07
been O 0 5.624684149552195e-07
identified O 0 7.177674206104712e-07
in O 0 1.2468058230297174e-07
6 O 0 1.676428155406029e-06
% O 0 1.060685804077366e-06
- O 0 5.106087428430328e-06
7 O 0 2.2088327966685029e-07
% O 0 5.806830216670278e-08
of O 0 5.4787552272728135e-08
the O 0 1.258087536371022e-06
Ashkenazi O 0 0.00013170071179047227
Jewish O 0 6.768947059754282e-06
population O 0 5.584289738180814e-06
. O 0 2.8867081709904596e-05

To O 0 8.143946615746245e-06
assess O 0 4.928634371026419e-05
the O 0 5.816379143652739e-06
risk O 0 5.278031312627718e-05
of O 0 3.4308533258808893e-07
this O 0 2.7699290967575507e-06
common O 0 6.063191176508553e-05
APC B-Disease 0 0.3017924129962921
allelic O 0 0.1704237163066864
variant O 1 0.9766344428062439
in O 0 0.015649767592549324
colorectal O 1 0.9999418258666992
carcinogenesis O 1 0.9986901879310608
, O 0 6.4648556872271e-06
we O 0 3.647000710316206e-07
have O 0 1.012328283422903e-07
analyzed O 0 1.1343956884957151e-06
a O 0 1.6617998426227132e-06
large O 0 4.030920536024496e-06
cohort O 0 0.00014093643403612077
of O 0 2.3277837044588523e-06
unselected O 0 0.018194027245044708
Ashkenazi O 0 0.0010213765781372786
Jewish O 0 1.3053851944277994e-05
subjects O 0 6.0345115343807265e-05
with O 0 0.000593906850554049
adenomatous B-Disease 1 0.998974084854126
polyps I-Disease 1 0.9974005222320557
and O 0 8.997647819342092e-05
. O 0 0.0007400964386761189
or O 1 0.9797319769859314
colorectal B-Disease 1 0.9999934434890747
cancer I-Disease 1 0.9999402761459351
, I-Disease 0 6.682996627205284e-06
for O 0 1.7911740997078596e-06
the O 0 1.7811815268942155e-05
APC O 0 0.020598016679286957
I1307K O 0 0.00235996232368052
polymorphism O 0 0.0005278314929455519
. O 0 9.14209958864376e-05

The O 0 7.396373257506639e-05
APC O 0 0.003452364820986986
I1307K O 0 0.0004971137968823314
allele O 0 5.053558561485261e-05
was O 0 9.754908205650281e-06
identified O 0 2.614512823129189e-06
in O 0 3.3133088095382845e-07
48 O 0 2.218354438809911e-06
( O 0 5.877273565602081e-07
10 O 0 1.5827016852654197e-07
. O 0 7.455932404809573e-08
1 O 0 3.517231448313396e-07
% O 0 3.749937036445772e-07
) O 0 5.675101419910789e-07
of O 0 1.7872222315418185e-06
476 O 0 0.26416876912117004
patients O 1 0.7987787127494812
. O 0 8.62883243826218e-05

Compared O 0 2.6721765607362613e-05
with O 0 3.4896103784376464e-07
the O 0 2.6093189831044583e-07
frequency O 0 5.41742451787286e-07
in O 0 1.0466526845220869e-07
two O 0 4.5918199020889006e-08
separate O 0 3.4520090252954105e-07
population O 0 4.2338075445513823e-07
control O 0 2.2465039819508092e-06
groups O 0 2.1052099441476457e-07
, O 0 4.611810311416775e-07
the O 0 1.1438686442488688e-06
APC O 0 0.0013186277355998755
I1307K O 0 0.0002274370490340516
allele O 0 1.2969177078048233e-05
is O 0 6.242414656298934e-07
associated O 0 2.214186451965361e-06
with O 0 2.9026449510638486e-07
an O 0 1.2863436040788656e-06
estimated O 0 6.1180617194622755e-06
relative O 0 2.159572977689095e-05
risk O 0 0.0001366484211757779
of O 0 1.4750335139979143e-06
1 O 0 6.979664613027126e-05
. O 0 6.471174856415018e-05

5 O 0 0.0010338469874113798
- O 0 0.0020963428542017937
1 O 0 0.00010623195703374222
. O 0 5.921887714066543e-05

7 O 0 0.0008924747817218304
for O 0 0.0006538379820995033
colorectal B-Disease 1 0.9996528625488281
neoplasia I-Disease 1 0.9973598122596741
( O 0 4.026408714707941e-05
both O 0 7.736714906059206e-06
P O 0 0.013894273899495602
= O 0 0.00036678180913440883
. O 0 6.986972493905341e-06
01 O 0 0.009140041656792164
) O 0 1.0718238627305254e-05
. O 0 1.9294779121992178e-05

Furthermore O 0 0.00023036764468997717
, O 0 9.007095286506228e-06
compared O 0 3.710332021000795e-05
with O 0 6.698361175949685e-06
noncarriers O 0 0.01154722087085247
, O 0 1.789578891475685e-05
APC O 0 0.0197890717536211
I1307K O 0 0.0032319820020347834
carriers O 0 0.00020134291844442487
had O 0 5.062971013103379e-06
increased O 0 2.1674400159099605e-06
numbers O 0 1.0372164069849532e-06
of O 0 3.672146476674243e-06
adenomas B-Disease 1 0.9942994117736816
and O 0 0.0020380245987325907
colorectal B-Disease 1 0.9999372959136963
cancers I-Disease 1 0.9990501999855042
per O 0 5.911246262257919e-05
patient O 0 0.0456325002014637
( O 0 2.9428616471705027e-05
P O 0 0.0032935473136603832
= O 0 7.81112612457946e-05
. O 0 1.6258078403552645e-06
03 O 0 0.0005308446707203984
) O 0 3.478277221802273e-07
, O 0 5.090083732284256e-08
as O 0 2.623225903164439e-08
well O 0 3.637031653624945e-08
as O 0 1.352605210058755e-07
a O 0 3.722710516740335e-06
younger O 0 5.202003740123473e-05
age O 0 0.0003576601156964898
at O 0 0.0005095080123282969
diagnosis O 1 0.9964403510093689
. O 0 0.00020334706641733646

We O 0 9.180994311464019e-06
conclude O 0 2.6997247914550826e-05
that O 0 1.2869277270510793e-06
the O 0 6.5991443989332765e-06
APC O 0 0.002804271876811981
I1307K O 0 0.0011606982443481684
variant O 0 0.0009584027575328946
leads O 0 4.739857104141265e-05
to O 0 5.608815172308823e-06
increased O 0 0.0009356536320410669
adenoma B-Disease 1 0.9994621872901917
formation O 0 0.00032167843892239034
and O 0 6.973220365580346e-07
directly O 0 4.426721318395721e-07
contributes O 0 3.485510433165473e-06
to O 0 1.1082639161941188e-07
3 O 0 7.850002248233068e-07
% O 0 7.024226533758338e-07
- O 0 3.26648773807392e-06
4 O 0 2.2199853333404462e-07
% O 0 1.269281710847281e-07
of O 0 1.313077149234232e-07
all O 0 2.6355589852755656e-06
Ashkenazi O 0 0.026742683723568916
Jewish O 0 0.0664629265666008
colorectal B-Disease 1 0.9999462366104126
cancer I-Disease 1 0.9998237490653992
. O 0 0.0020540133118629456

The O 0 2.912679519795347e-05
estimated O 0 9.987106022890657e-05
relative O 0 0.00025216001085937023
risk O 0 0.0034842451568692923
for O 0 4.372689545562025e-06
carriers O 0 0.0025370880030095577
may O 0 2.01292714336887e-05
justify O 0 2.6523355700192042e-05
specific O 0 1.476946522416256e-06
clinical O 0 0.00026089217863045633
screening O 0 1.7253640180570073e-05
for O 0 2.4351561478397343e-07
the O 0 8.409166980527516e-07
360 O 0 8.213176442950498e-06
, O 0 1.0531834959692787e-06
000 O 0 5.7262054724560585e-06
Americans O 0 1.206192905556236e-06
expected O 0 6.623636750191508e-07
to O 0 2.697423724384862e-07
harbor O 0 4.0695977077120915e-05
this O 0 1.5007715603587712e-07
allele O 0 2.0034078715980286e-06
, O 0 2.2151296263928089e-07
and O 0 1.54625965365085e-07
genetic O 0 5.4223537517827936e-06
testing O 0 1.8122947267329437e-06
in O 0 5.720304940837195e-08
the O 0 6.383225326089814e-08
setting O 0 6.35757544387161e-07
of O 0 9.769764801603742e-07
long O 0 0.0009416102548129857
- O 0 0.0012488074135035276
term O 0 4.216172601445578e-05
- O 0 6.991456029936671e-05
outcome O 0 5.915195288253017e-06
studies O 0 5.460973625304177e-06
may O 0 3.090135214733891e-05
impact O 0 0.00035446995752863586
significantly O 0 0.09783511608839035
on O 0 0.4322103261947632
colorectal B-Disease 1 0.9999934434890747
cancer I-Disease 1 0.999975323677063
prevention O 1 0.9915423393249512
in O 0 1.023593813442858e-05
this O 0 4.6814661800453905e-06
population O 0 1.965936644410249e-05
. O 0 4.62243115180172e-05

Localization O 0 0.0001502795348642394
of O 0 3.3646015253907535e-06
human O 0 4.17651936004404e-05
BRCA1 O 0 0.0015102631878107786
and O 0 1.0881905154747074e-06
its O 0 1.4538572941091843e-06
loss O 0 0.00045676506124436855
in O 0 4.153322606725851e-06
high O 0 0.0004981877282261848
- O 0 0.0011869710870087147
grade O 0 0.0008491925545968115
, O 0 1.2246560800122097e-05
non B-Disease 0 0.0012617608299478889
- I-Disease 1 0.9915660619735718
inherited I-Disease 1 0.9977461695671082
breast I-Disease 1 0.9994730353355408
carcinomas I-Disease 1 0.9986818432807922
. O 0 0.001445720554329455

Although O 0 2.0035064153489657e-05
the O 0 3.861946424876805e-06
link O 0 2.9120852559572086e-05
between O 0 7.6175765570951626e-06
the O 0 0.00027926312759518623
BRCA1 O 1 0.9923129677772522
tumour B-Disease 1 0.9991506338119507
- O 0 0.023921484127640724
suppressor O 0 0.0030460753478109837
gene O 0 0.000209745456231758
and O 0 0.00011870235903188586
hereditary B-Disease 1 0.9986746311187744
breast I-Disease 1 0.9998800754547119
and I-Disease 1 0.9971292614936829
ovarian I-Disease 1 0.9999951124191284
cancer I-Disease 1 0.9999700784683228
is O 0 1.3687750652024988e-05
established O 0 3.952190581912873e-06
, O 0 3.0174206244737434e-07
the O 0 3.6796237168346124e-07
role O 0 1.219024625243037e-06
, O 0 3.1050853976921644e-07
if O 0 1.1656561582640279e-07
any O 0 8.145216412458467e-08
, O 0 1.4093429001604818e-07
of O 0 5.170547296984296e-07
BRCA1 O 0 0.01082188356667757
in O 0 2.1988273147144355e-05
non B-Disease 0 0.003768753260374069
- I-Disease 1 0.9888028502464294
familial I-Disease 1 0.9983195662498474
cancers I-Disease 1 0.999087929725647
is O 0 7.26660291547887e-05
unclear O 0 0.00042943519656546414
. O 0 9.522575419396162e-05

BRCA1 O 0 0.19384326040744781
mutations O 0 0.00017656305863056332
are O 0 9.307307777817186e-07
rare O 0 0.00018336395442020148
in O 0 2.34015842579538e-05
sporadic B-Disease 0 0.31462594866752625
cancers I-Disease 1 0.9993809461593628
, O 0 9.370199222757947e-06
but O 0 2.5760068638192024e-06
loss O 0 0.00013830815441906452
of O 0 2.2482508938992396e-06
BRCA1 O 0 0.19313518702983856
resulting O 0 0.000102032812719699
from O 0 5.940300980000757e-06
reduced O 0 4.672877548728138e-05
expression O 0 2.7487008082971442e-06
or O 0 1.214119151882187e-06
incorrect O 0 1.026375775836641e-05
subcellular O 0 2.348040470678825e-05
localization O 0 3.2267143978970125e-05
is O 0 9.234931326318474e-07
postulated O 0 7.430558071064297e-06
to O 0 1.065016448364986e-07
be O 0 9.131539968620928e-08
important O 0 1.7458535239711637e-07
in O 0 4.577000254357699e-06
non B-Disease 0 0.0008027663570828736
- I-Disease 1 0.9581251740455627
familial I-Disease 1 0.9978970289230347
breast I-Disease 1 0.9997982382774353
and I-Disease 1 0.9632622599601746
ovarian I-Disease 1 0.9999806880950928
cancers I-Disease 1 0.9997286200523376
. O 0 0.0046610478311777115

Epigenetic O 0 0.016081275418400764
loss O 0 0.3250266909599304
, O 0 1.7044047126546502e-05
however O 0 6.2237058955361135e-06
, O 0 1.308550849898893e-06
has O 0 4.220149776301696e-07
not O 0 8.501586279408002e-08
received O 0 1.5061352769407677e-06
general O 0 1.5517106248807977e-06
acceptance O 0 1.358089593850309e-05
due O 0 1.0328248208679724e-05
to O 0 2.0775827636043687e-07
controversy O 0 4.891342996415915e-06
regarding O 0 4.070491002039489e-07
the O 0 2.879193914395728e-07
subcellular O 0 1.5989689927664585e-05
localization O 0 1.6141535525093786e-05
of O 0 1.0691262559703318e-06
BRCA1 O 0 0.0021325426641851664
proteins O 0 3.85698831451009e-06
, O 0 6.137037757980579e-07
reports O 0 6.85793281718361e-07
of O 0 1.2036770158374566e-07
which O 0 3.8803688084954047e-07
have O 0 3.0550978635801584e-07
ranged O 0 1.2535732821561396e-05
from O 0 7.191021040853229e-07
exclusively O 0 1.9852141122100875e-06
nuclear O 0 1.7004142137011513e-05
, O 0 4.529252350948809e-07
to O 0 2.874795654861373e-07
conditionally O 0 4.570794408209622e-05
nuclear O 0 7.719469067524187e-06
, O 0 2.3767910306560225e-07
to O 0 1.728306671111568e-07
the O 0 4.190019353700336e-06
ER O 1 0.5857760906219482
/ O 0 0.0009579722536727786
golgi O 0 0.0008734542061574757
, O 0 4.647515936540003e-07
to O 0 2.720304621561809e-07
cytoplasmic O 0 3.169663978042081e-05
invaginations O 0 9.610150300431997e-05
into O 0 1.0317125997971743e-06
the O 0 6.631058568018489e-06
nucleus O 0 0.00019932466966565698
. O 0 6.941895844647661e-05

In O 0 1.0397942787676584e-05
an O 0 2.4851235593814636e-06
attempt O 0 8.658176739118062e-06
to O 0 6.12179235304211e-07
resolve O 0 2.8120972274336964e-05
this O 0 8.786003604654979e-07
issue O 0 2.825317324095522e-06
, O 0 6.540098524965288e-07
we O 0 1.6360750976218696e-07
have O 0 4.1785759208323725e-07
comprehensively O 0 0.00017192462109960616
characterized O 0 0.0017303440254181623
19 O 0 0.000673435628414154
anti O 1 0.5558863878250122
- O 0 0.42769530415534973
BRCA1 O 0 0.13746139407157898
antibodies O 0 0.0010320048313587904
. O 0 6.157821189844981e-05

These O 0 7.291468136827461e-06
reagents O 0 0.00019595364574342966
detect O 0 0.00013758325076196343
a O 0 1.349891499557998e-05
220 O 0 3.8187794416444376e-05
- O 0 0.0002272941783303395
kD O 0 0.0003814194933511317
protein O 0 2.6531561161391437e-06
localized O 0 1.1145603821205441e-05
in O 0 2.1783385761864338e-07
discrete O 0 3.09233018924715e-06
nuclear O 0 3.533407289069146e-05
foci O 0 5.377272464102134e-05
in O 0 1.3729105603488279e-06
all O 0 1.350075876871415e-06
epithelial O 0 0.32049188017845154
cell O 0 0.0018134060082957149
lines O 0 3.811934948316775e-05
, O 0 4.004423033165949e-07
including O 0 6.56588269976055e-07
those O 0 9.64872583608667e-07
derived O 0 4.27570084866602e-05
from O 0 0.0015042395098134875
breast B-Disease 1 0.9990221261978149
malignancies I-Disease 1 0.9870725870132446
. O 0 0.0004336331330705434

Immunohistochemical O 0 0.033810537308454514
staining O 0 0.0027995610143989325
of O 0 2.6587551474221982e-05
human O 0 0.0032440172508358955
breast O 1 0.9979884624481201
specimens O 0 0.000921320344787091
also O 0 3.402384390938096e-05
revealed O 0 0.004604472778737545
BRCA1 O 0 0.16235888004302979
nuclear O 0 0.0009080527233891189
foci O 0 0.006728467997163534
in O 0 0.0015219837659969926
benign O 1 0.9988425374031067
breast O 1 0.9994625449180603
, O 0 0.01770971156656742
invasive B-Disease 1 0.997026264667511
lobular I-Disease 1 0.9995483756065369
cancers I-Disease 1 0.9991893172264099
and O 0 0.00036231192643754184
low B-Disease 1 0.9451887607574463
- I-Disease 1 0.9848601222038269
grade I-Disease 1 0.9891552329063416
ductal I-Disease 1 0.998348593711853
carcinomas I-Disease 1 0.9984627962112427
. O 0 0.0009348760941065848

Conversely O 0 0.0010261036222800612
, O 0 4.7529108996968716e-05
BRCA1 O 0 0.00785993691533804
expression O 0 2.1885489331907593e-05
was O 0 8.423071994911879e-05
reduced O 0 0.00014073189231567085
or O 0 6.9662678470194805e-06
undetectable O 0 0.0009208119008690119
in O 0 1.2248074199305847e-07
the O 0 1.4687040561511822e-07
majority O 0 2.2226078044695896e-07
of O 0 4.4250205633034057e-07
high O 0 0.0006693551549687982
- O 0 0.005491349380463362
grade O 0 0.007826128043234348
, O 0 0.0001132598627009429
ductal B-Disease 1 0.9989074468612671
carcinomas I-Disease 1 0.9995321035385132
, O 0 1.05220942714368e-05
suggesting O 0 6.676533666905016e-05
that O 0 5.18674596605706e-07
absence O 0 3.8737791328458115e-05
of O 0 3.860506240016548e-06
BRCA1 O 1 0.6669775247573853
may O 0 1.3898736142436974e-05
contribute O 0 2.324657998542534e-06
to O 0 1.0183686072195997e-07
the O 0 6.373918495228281e-07
pathogenesis O 0 0.0004352503165137023
of O 0 1.3698604561795946e-07
a O 0 2.7249495815340197e-06
significant O 0 3.4415206755511463e-06
percentage O 0 8.993757546704728e-06
of O 0 8.560677997593302e-06
sporadic B-Disease 1 0.9937989115715027
breast I-Disease 1 0.9998714923858643
cancers I-Disease 1 0.9993842840194702
. O 0 0.00014120680862106383
. O 0 0.00013181165559217334

